0000950170-24-12561310-Q Arcadia Biosciences, Inc. 20241112202411121700091700091700009 0 0000950170-24-125613 10-Q 75 20240930 20241112 20241112 Arcadia Biosciences, Inc. 0001469443 0100 810571538 DE 1231 10-Q 34 001-37383 241449567 202 COUSTEAU PLACE SUITE 105 DAVIS X1 95618 530-756-7077 202 COUSTEAU PLACE SUITE 105 DAVIS CA 95618 10-Q 1 rkda-20240930.htm 10-Q 10-Q false--12-310001469443Q3http://fasb.org/us-gaap/2024#ShortTermInvestmentsMemberhttp://fasb.org/us-gaap/2024#ShortTermInvestmentsMemberhttp://fasb.org/us-gaap/2024#ShortTermInvestmentsMemberhttp://fasb.org/us-gaap/2024#ShortTermInvestmentsMemberhttp://fasb.org/us-gaap/2024#ShortTermInvestmentsMemberhttp://fasb.org/us-gaap/2024#ShortTermInvestmentsMemberhttp://fasb.org/us-gaap/2024#ShortTermInvestmentsMember0P1YP0YP1Y2005-06-30P1Y0001469443rkda:DecemberTwoThousandTwentyWarrantsPrivatePlacementOfferingMember2023-12-310001469443us-gaap:RetainedEarningsMember2024-01-012024-03-310001469443rkda:CollaborativeArrangementsCopromotionMember2024-01-012024-09-300001469443rkda:PreferredInvestmentOptionsMember2023-07-012023-09-300001469443us-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMember2024-05-162024-05-160001469443us-gaap:FairValueInputsLevel3Memberrkda:AugustTwoThousandTwentyTwoPlacementAgentOptionsMember2024-01-012024-09-300001469443us-gaap:FairValueInputsLevel3Memberrkda:ContingentLiabilitiesMember2023-12-310001469443rkda:July2020PlacementAgentWarrantsMember2024-01-012024-09-300001469443rkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:OptionAmendmentAgreementsMemberrkda:MarchTwoThousandTwentyThreePlacementAgentOptionsMember2024-01-012024-09-300001469443us-gaap:SegmentDiscontinuedOperationsMemberrkda:CoPackingBusinessSaavyNaturalsProvaultAndSoulSpringBodyCareBrandsMember2024-07-012024-09-300001469443rkda:AugustTwoThousandTwentyTwoPlacementAgentOptionsMember2024-01-012024-09-300001469443rkda:DecemberTwoThousandTwentyWarrantsPrivatePlacementOfferingMember2024-09-300001469443rkda:OctoberTwoThousandAndTwentyTwoServiceAndPerformanceWarrantsMember2024-09-300001469443rkda:September2019PlacementAgentWarrantsMember2024-01-012024-09-300001469443us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedDividendRateMemberrkda:AugustTwoThousandTwentyTwoOptionsAndAugustTwoThousandTwentyTwoPlacementAgentOptionsMember2024-09-300001469443rkda:MarchTwoThousandTwentyThreeOptionsAndMarchTwoThousandTwentyThreePlacementAgentOptionsMember2023-03-060001469443rkda:June2019PlacementAgentWarrantsMember2023-12-310001469443rkda:BodyCareMember2024-01-012024-09-300001469443rkda:DecemberTwoThousandTwentyPlacementAgentWarrantsMember2024-01-012024-09-300001469443rkda:CollaborativeArrangementsCopromotionMember2017-08-012017-08-310001469443us-gaap:FairValueInputsLevel1Member2024-09-300001469443rkda:July2020PlacementAgentWarrantsMember2023-12-310001469443us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2023-12-310001469443rkda:DecemberTwoThousandTwentyWarrantsMember2024-01-012024-09-300001469443rkda:MarchTwoThousandTwentyThreeOptionsSeriesBMember2024-01-012024-09-300001469443rkda:DecemberTwoThousandTwentyPlacementAgentWarrantsMember2023-01-012023-09-300001469443srt:MaximumMember2024-01-012024-09-300001469443rkda:SeptemberTwoThousandNineteenWarrantsPrivatePlacementOfferingMember2024-09-300001469443us-gaap:FurnitureAndFixturesMember2023-12-310001469443us-gaap:WarrantMemberrkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:OptionAmendmentAgreementsMember2019-09-300001469443rkda:SoftwareAndComputerEquipmentMember2023-12-310001469443us-gaap:RetainedEarningsMember2022-12-310001469443us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2023-12-310001469443us-gaap:NoncontrollingInterestMember2023-04-012023-06-300001469443us-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMemberus-gaap:ProductMember2024-07-012024-09-300001469443rkda:JuneTwoThousandNineteenWarrantsMember2024-09-300001469443us-gaap:WarrantMember2024-01-012024-09-300001469443us-gaap:FairValueInputsLevel3Memberrkda:AugustTwoThousandTwentyTwoOptionsMember2024-09-300001469443rkda:AugustTwoThousandTwentyTwoOptionsMember2023-01-012023-09-300001469443rkda:MarchTwoThousandTwentyThreePreFundedWarrantsMember2023-01-012023-09-300001469443us-gaap:RetainedEarningsMember2023-12-310001469443us-gaap:LicenseMember2024-07-012024-09-300001469443rkda:JanuaryTwoThousandTwentyOneWarrantsMember2024-01-012024-09-300001469443rkda:DecemberTwoThousandTwentyWarrantsPrivatePlacementOfferingMember2024-01-012024-09-300001469443us-gaap:RetainedEarningsMember2023-07-012023-09-300001469443us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001469443rkda:July2020WarrantsMember2023-01-012023-09-300001469443us-gaap:EmployeeStockMember2015-05-132015-05-140001469443us-gaap:CommonStockMember2023-09-300001469443rkda:BodyCareMember2023-01-012023-09-300001469443694432024-04-012024-06-300001469443rkda:VerdecaLLCMember2022-01-012022-12-310001469443rkda:JuneTwoThousandNineteenWarrantsMember2023-01-012023-09-300001469443us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001469443rkda:TwoThousandFifteenOmnibusEquityIncentivePlanMembersrt:MaximumMember2015-05-202015-05-200001469443rkda:TwoThousandFifteenOmnibusEquityIncentivePlanMember2024-06-252024-06-250001469443us-gaap:FairValueInputsLevel3Memberrkda:AugustTwoThousandTwentyTwoPlacementAgentOptionsMember2024-09-300001469443us-gaap:EmployeeStockMember2024-09-300001469443rkda:MarchTwoThousandAndTwentyThreePIPEMember2024-01-012024-09-300001469443rkda:SeptemberTwoThousandNineteenWarrantsMember2024-09-300001469443rkda:GoodwheatMember2024-07-012024-09-300001469443rkda:July2020WarrantsMember2024-01-012024-09-3000014694432023-09-300001469443rkda:JanuaryTwoThousandTwentyOneWarrantsMember2024-09-300001469443us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2023-12-310001469443rkda:May2020WarrantsPrivatePlacementOfferingMember2023-12-310001469443rkda:DecemberTwoThousandTwentyPlacementAgentWarrantsMember2023-12-310001469443us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2023-12-310001469443us-gaap:AdditionalPaidInCapitalMember2024-06-300001469443rkda:MarchTwoThousandTwentyThreePreFundedWarrantsMember2024-01-012024-09-300001469443rkda:SeptemberTwoThousandNineteenWarrantsPrivatePlacementOfferingMember2023-12-310001469443us-gaap:MoneyMarketFundsMemberus-gaap:CashEquivalentsMember2024-09-300001469443rkda:OctoberTwoThousandAndTwentyTwoServiceAndPerformanceWarrantsMember2023-12-310001469443us-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMember2023-07-012023-09-300001469443rkda:SeptemberTwoThousandNineteenWarrantsMember2024-01-012024-09-300001469443us-gaap:MachineryAndEquipmentMember2023-12-310001469443rkda:AnawahIncMember2024-01-012024-09-300001469443us-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMemberus-gaap:ProductMember2023-07-012023-09-300001469443us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreePlacementAgentOptionsMember2023-12-310001469443us-gaap:ShortTermInvestmentsMemberus-gaap:USTreasurySecuritiesMember2024-09-300001469443us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedDividendRateMemberrkda:MarchTwoThousandTwentyThreeOptionsSeriesAAndMarchTwoThousandTwentyThreePlacementAgentOptionsMember2024-09-300001469443rkda:May2020WarrantsPrivatePlacementOfferingMember2023-01-012023-09-300001469443rkda:BioceresCropSolutionsMemberrkda:VerdecaLLCMember2023-01-012023-12-310001469443rkda:MarchTwoThousandTwentyThreePreFundedWarrantsMemberus-gaap:CommonStockMember2024-01-012024-03-310001469443us-gaap:WarrantMember2023-07-012023-09-300001469443rkda:March2023AndAugust2022OptionsAndPlacementAgentOptionsMember2023-12-3100014694432022-12-310001469443us-gaap:CommonStockMember2023-07-012023-09-300001469443us-gaap:RelatedPartyMember2023-12-310001469443us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-07-012024-09-300001469443us-gaap:FairValueInputsLevel3Memberrkda:AugustTwoThousandTwentyTwoOptionsMember2023-12-310001469443us-gaap:SegmentDiscontinuedOperationsMemberrkda:CoPackingBusinessSaavyNaturalsProvaultAndSoulSpringBodyCareBrandsMemberus-gaap:ProductMember2024-01-012024-09-3000014694432024-07-012024-09-300001469443rkda:September2019PlacementAgentWarrantsMember2023-01-012023-09-300001469443rkda:PreferredInvestmentOptionsMember2024-07-012024-09-300001469443rkda:SeptemberTwoThousandNineteenWarrantsPrivatePlacementOfferingMember2024-01-012024-09-300001469443us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001469443rkda:ArcadiaBiosciencesIncorporationMemberrkda:ArchipelagoVenturesHawaiiLLCMember2019-08-092019-08-0900014694432023-04-012023-06-300001469443rkda:MarchTwoThousandTwentyThreePlacementAgentOptionsMember2023-03-062023-03-060001469443us-gaap:CommonStockMemberrkda:AugustTwoThousandTwentyTwoPreFundedWarrantsMember2023-01-012023-03-310001469443us-gaap:SegmentDiscontinuedOperationsMemberrkda:CoPackingBusinessSaavyNaturalsProvaultAndSoulSpringBodyCareBrandsMember2023-12-310001469443rkda:April2019ServiceAndPerformanceWarrantsMember2023-12-310001469443rkda:May2020PlacementAgentWarrantsMember2023-12-310001469443rkda:April2019ServiceAndPerformanceWarrantsMember2024-09-300001469443us-gaap:FairValueInputsLevel3Memberrkda:NoteReceivableBifurcatedDerivativesMember2024-01-012024-09-300001469443us-gaap:FairValueInputsLevel3Memberrkda:ContingentLiabilitiesMember2024-09-300001469443us-gaap:WarrantMember2024-07-012024-09-300001469443rkda:OctoberTwoThousandAndTwentyTwoServiceAndPerformanceWarrantsMember2023-01-012023-09-300001469443us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesAAndMarchTwoThousandTwentyThreePlacementAgentOptionsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2023-12-310001469443us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2023-12-310001469443us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2024-09-300001469443rkda:GoodwheatMember2024-01-012024-09-300001469443us-gaap:SegmentDiscontinuedOperationsMemberrkda:CoPackingBusinessSaavyNaturalsProvaultAndSoulSpringBodyCareBrandsMember2024-09-300001469443us-gaap:CommonStockMember2024-03-310001469443us-gaap:RetainedEarningsMember2023-04-012023-06-3000014694432023-06-300001469443us-gaap:FairValueInputsLevel3Member2023-12-310001469443us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001469443rkda:TwoThousandSixStockIncentivePlanMember2023-12-310001469443us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedDividendRateMemberrkda:MarchTwoThousandTwentyThreeOptionsSeriesBMember2023-12-310001469443rkda:June2019PlacementAgentWarrantsMember2024-01-012024-09-300001469443us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001469443rkda:May2020PlacementAgentWarrantsMember2024-09-300001469443rkda:April2019ServiceAndPerformanceWarrantsMember2024-01-012024-09-300001469443us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001469443rkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:MarchTwoThousandTwentyThreePlacementAgentOptionsMemberrkda:PreferredInvestmentOptionsMember2023-03-012023-03-310001469443rkda:MarchTwoThousandTwentyThreePreFundedWarrantsMemberus-gaap:CommonStockMember2023-04-012023-06-300001469443us-gaap:FairValueInputsLevel1Member2023-12-310001469443us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMemberrkda:MarchTwoThousandTwentyThreeOptionsSeriesBMember2023-12-310001469443rkda:MarchTwoThousandTwentyThreeOptionsSeriesBMember2024-09-300001469443rkda:DecemberTwoThousandAndTwentyTwoServiceAndPerformanceWarrantsMember2024-01-012024-09-3000014694432023-01-012023-09-300001469443us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001469443rkda:May2020WarrantsPrivatePlacementOfferingMember2024-09-300001469443us-gaap:RetainedEarningsMember2023-01-012023-03-310001469443us-gaap:NoncontrollingInterestMember2023-12-310001469443rkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:SeriesAAndBPreferredInvestmentOptionsMemberrkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePurchaseAgreementMember2024-01-012024-09-300001469443rkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:OptionAmendmentAgreementsMemberrkda:MarchTwoThousandTwentyThreePlacementAgentOptionsMember2024-09-300001469443srt:MaximumMemberrkda:IndustrialSeedInnovationsMember2024-09-300001469443us-gaap:NonrelatedPartyMember2023-12-310001469443rkda:MarchTwoThousandTwentyThreeOptionsMember2023-03-060001469443us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedDividendRateMemberrkda:MarchTwoThousandTwentyThreeOptionsSeriesBMember2024-09-300001469443rkda:TwoThousandFifteenOmnibusEquityIncentivePlanMember2024-09-300001469443us-gaap:CommonStockMember2023-03-310001469443us-gaap:USTreasurySecuritiesMember2024-09-300001469443us-gaap:FairValueInputsLevel2Member2023-12-310001469443us-gaap:RetainedEarningsMember2024-06-300001469443rkda:DecemberTwoThousandTwentyWarrantsPrivatePlacementOfferingMember2023-01-012023-09-300001469443rkda:April2019ServiceAndPerformanceWarrantsMember2023-01-012023-09-300001469443us-gaap:WarrantMemberrkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:OptionAmendmentAgreementsMember2022-08-310001469443rkda:MarchTwoThousandTwentyThreePlacementAgentOptionsMember2023-12-310001469443us-gaap:LeaseholdImprovementsMember2024-09-300001469443rkda:July2020WarrantsMember2024-09-300001469443rkda:MarchTwoThousandTwentyThreePlacementAgentOptionsMember2024-01-012024-09-300001469443us-gaap:AdditionalPaidInCapitalMember2024-09-300001469443us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001469443us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMemberrkda:AugustTwoThousandTwentyTwoOptionsAndAugustTwoThousandTwentyTwoPlacementAgentOptionsMember2023-12-310001469443us-gaap:EmployeeStockMember2023-01-012023-09-300001469443rkda:DecemberTwoThousandTwentyWarrantsMember2023-12-310001469443us-gaap:AdditionalPaidInCapitalMember2023-03-310001469443us-gaap:AdditionalPaidInCapitalMember2023-06-300001469443rkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePurchaseAgreementMember2023-03-012023-03-310001469443us-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMember2024-09-300001469443us-gaap:CommonStockMember2023-04-012023-06-300001469443rkda:May2020PlacementAgentWarrantsMember2024-01-012024-09-300001469443rkda:MarchTwoThousandTwentyThreeOptionsAndMarchTwoThousandTwentyThreePlacementAgentOptionsMember2023-03-062023-03-060001469443us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001469443rkda:PreferredInvestmentOptionsMember2024-01-012024-09-300001469443us-gaap:RetainedEarningsMember2023-03-310001469443rkda:JanuaryTwoThousandTwentyOneWarrantsPrivatePlacementOfferingMember2024-09-300001469443rkda:MarchTwoThousandTwentyThreeOptionsSeriesAMember2023-01-012023-09-300001469443us-gaap:MeasurementInputExpectedDividendRateMemberus-gaap:FairValueInputsLevel3Memberrkda:AugustTwoThousandTwentyTwoOptionsAndAugustTwoThousandTwentyTwoPlacementAgentOptionsMember2023-12-310001469443us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001469443us-gaap:RelatedPartyMember2024-09-300001469443us-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMember2023-12-310001469443us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001469443us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-3100014694432024-01-012024-09-300001469443us-gaap:CommonStockMember2024-06-300001469443us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesBMember2024-01-012024-09-300001469443rkda:AugustTwoThousandTwentyTwoPreFundedWarrantsMember2023-01-012023-09-300001469443us-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMember2024-05-140001469443rkda:MarchTwoThousandTwentyThreePlacementAgentOptionsMember2024-09-300001469443us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2024-09-300001469443us-gaap:AdditionalPaidInCapitalMember2023-12-310001469443us-

gaap:ShortTermInvestmentsMemberus-gaap:USTreasurySecuritiesMember2023-12-310001469443us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001469443rkda:June2019PlacementAgentWarrantsMember2023-01-012023-09-300001469443rkda:MarchTwoThousandTwentyThreePreFundedWarrantsMember2024-09-300001469443us-gaap:WarrantMemberrkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:OptionAmendmentAgreementsMember2023-03-310001469443us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesAAndMarchTwoThousandTwentyThreePlacementAgentOptionsMemberus-gaap:MeasurementInputPriceVolatilityMember2024-09-300001469443srt:MinimumMemberrkda:IndustrialSeedInnovationsMember2024-09-300001469443us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001469443us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMemberrkda:MarchTwoThousandTwentyThreeOptionsSeriesAAndMarchTwoThousandTwentyThreePlacementAgentOptionsMember2023-12-310001469443rkda:JuneTwoThousandNineteenWarrantsMember2023-12-310001469443us-gaap:FairValueInputsLevel3Memberrkda:NoteReceivableBifurcatedDerivativesMember2023-12-310001469443us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001469443us-gaap:WarrantMemberrkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:OptionAmendmentAgreementsMember2021-01-310001469443us-gaap:RetainedEarningsMember2024-09-300001469443rkda:DecemberTwoThousandTwentyWarrantsMember2024-09-3000014694432023-01-012023-03-310001469443us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMemberrkda:MarchTwoThousandTwentyThreeOptionsSeriesBMember2023-12-310001469443rkda:OctoberTwoThousandAndTwentyTwoServiceAndPerformanceWarrantsMember2024-01-012024-09-300001469443us-gaap:SegmentDiscontinuedOperationsMemberrkda:CoPackingBusinessSaavyNaturalsProvaultAndSoulSpringBodyCareBrandsMemberus-gaap:ProductMember2023-07-012023-09-300001469443us-gaap:NoncontrollingInterestMember2023-06-300001469443rkda:May2020WarrantsMember2024-09-300001469443rkda:ArcadiaBiosciencesIncorporationMemberrkda:ArchipelagoVenturesHawaiiLLCMember2024-09-300001469443us-gaap:NoncontrollingInterestMember2024-03-310001469443us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesAAndMarchTwoThousandTwentyThreePlacementAgentOptionsMemberus-gaap:MeasurementInputExpectedTermMember2023-12-310001469443us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2024-09-3000014694432023-01-012023-12-310001469443rkda:TwoThousandFifteenOmnibusEquityIncentivePlanMember2015-05-202015-05-200001469443rkda:TwoThousandFifteenOmnibusEquityIncentivePlanMember2023-12-310001469443rkda:September2019PlacementAgentWarrantsMember2024-09-300001469443rkda:AnawahIncMember2010-12-310001469443us-gaap:CommonStockMember2023-06-300001469443rkda:JuneTwoThousandNineteenWarrantsMember2024-01-012024-09-300001469443us-gaap:CommonStockMember2024-09-300001469443us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesAMember2024-09-300001469443us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2024-09-300001469443rkda:TwoThousandFifteenOmnibusEquityIncentivePlanMember2015-05-2000014694432024-06-300001469443rkda:BioceresCropSolutionsMemberrkda:VerdecaLLCMember2020-11-012020-11-300001469443us-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMember2024-05-142024-05-140001469443us-gaap:SegmentDiscontinuedOperationsMemberrkda:CoPackingBusinessSaavyNaturalsProvaultAndSoulSpringBodyCareBrandsMemberus-gaap:ProductMember2024-07-012024-09-300001469443rkda:AnawahIncMember2024-09-300001469443rkda:SeptemberTwoThousandNineteenWarrantsPrivatePlacementOfferingMember2023-01-012023-09-300001469443rkda:JanuaryTwoThousandTwentyOneWarrantsPrivatePlacementOfferingMember2023-01-012023-09-300001469443us-gaap:CommonStockMember2024-01-012024-03-310001469443us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMemberrkda:AugustTwoThousandTwentyTwoOptionsAndAugustTwoThousandTwentyTwoPlacementAgentOptionsMember2023-12-310001469443rkda:PreferredInvestmentOptionsMember2023-01-012023-09-300001469443us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesAAndMarchTwoThousandTwentyThreePlacementAgentOptionsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2024-09-300001469443rkda:DecemberTwoThousandAndTwentyTwoServiceAndPerformanceWarrantsMember2023-12-310001469443us-gaap:FairValueInputsLevel3Memberrkda:NoteReceivableBifurcatedDerivativesMember2024-09-300001469443us-gaap:WarrantMember2023-01-012023-09-300001469443us-gaap:WarrantMemberrkda:AugustTwoThousandTwentyTwoPlacementAgentOptionsMemberrkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:AugustTwoThousandAndTwenty1 01-012024-09-300001469443us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesAMember2024-01-012024-09-300001469443rkda:July2020WarrantsMember2023-12-310001469443rkda:MarchTwoThousandTwentyThreeOptionsSeriesAMember2023-12-310001469443us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001469443us-gaap:SegmentDiscontinuedOperationsMemberrkda:CoPackingBusinessSaavyNaturalsProvaultAndSoulSpringBodyCareBrandsMember2023-01-012023-09-300001469443us-gaap:FairValueInputsLevel3Memberrkda:AugustTwoThousandTwentyTwoOptionsAndAugustTwoThousandTwentyTwoPlacementAgentOptionsMemberus-gaap:MeasurementInputExpectedTermMember2024-09-300001469443rkda:September2019PlacementAgentWarrantsMember2023-12-310001469443rkda:JanuaryTwoThousandTwentyOnePlacementAgentWarrantsMember2024-09-300001469443us-gaap:FairValueInputsLevel3Memberrkda:AugustTwoThousandTwentyTwoOptionsMember2024-01-012024-09-300001469443us-gaap:AdditionalPaidInCapitalMember2023-09-300001469443us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesBMember2024-09-300001469443rkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:MarchTwoThousandTwentyThreeOptionsMemberrkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePu 03-060001469443us-gaap:USTreasurySecuritiesMember2023-12-310001469443rkda:SeriesBPreferredInvestmentOptionsMemberrkda:MarchTwoThousandTwentyThreeOptionsAndMarchTwoThousandTwentyThreePlacementAgentOptionsMember2023-03-062023-03-060001469443rkda:July2020PlacementAgentWarrantsMember2024-09-300001469443us-gaap:WarrantMemberrkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePurchaseAgreementMemberrkda:MarchTwoThous 01-012024-09-300001469443rkda:July2020PlacementAgentWarrantsMember2023-01-012023-09-300001469443us-gaap:EmployeeStockMember2015-05-140001469443us-gaap:MoneyMarketFundsMemberus-gaap:CashEquivalentsMember2023-12-310001469443us-gaap:AdditionalPaidInCapitalMember2022-12-310001469443us-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMember2023-01-012023-09-300001469443us-gaap:FairValueInputsLevel3Member2024-09-300001469443us-gaap:EmployeeStockMember2024-07-012024-09-300001469443rkda:GoodwheatMember2023-07-012023-09-300001469443us-gaap:SegmentDiscontinuedOperationsMemberrkda:CoPackingBusinessSaavyNaturalsProvaultAndSoulSpringBodyCareBrandsMember2023-07-012023-09-3000014694432024-03-310001469443us-gaap:CommonStockMember2023-01-012023-03-310001469443rkda:LegacyVenturesHawaiiLLCMemberrkda:ArchipelagoVenturesHawaiiLLCMember2024-09-300001469443us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2024-09-300001469443rkda:SoftwareAndComputerEquipmentMember2024-09-300001469443rkda:DecemberTwoThousandTwentyWarrantsMember2023-01-012023-09-300001469443rkda:JanuaryTwoThousandTwentyOneWarrantsPrivatePlacementOfferingMember2023-12-310001469443us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedDividendRateMemberrkda:MarchTwoThousandTwentyThreeOptionsSeriesAAndMarchTwoThousandTwentyThreePlacementAgentOptionsMember2023-12-3100014694432024-11-050001469443us-gaap:MoneyMarketFundsMember2024-09-300001469443rkda:MarchTwoThousandTwentyThreeOptionsSeriesAMember2024-09-300001469443rkda:MarchTwoThousandTwentyThreePlacementAgentOptionsMember2023-01-012023-09-300001469443us-gaap:NoncontrollingInterestMember2023-09-300001469443us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001469443rkda:SellingGeneralAndAdministrativeAndResearchAndDevelopmentExpensesMember2024-01-012024-09-300001469443rkda:May2020WarrantsMember2024-01-012024-09-300001469443rkda:JanuaryTwoThousandTwentyOnePlacementAgentWarrantsMember2024-01-012024-09-300001469443us-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMemberus-gaap:ProductMember2024-01-012024-09-300001469443rkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:SeriesAAndBPreferredInvestmentOptionsMemberrkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePu 03-3100014694432024-01-310001469443rkda:SellingGeneralAndAdministrativeAndResearchAndDevelopmentExpensesMember2023-01-012023-09-300001469443rkda:June2019PlacementAgentWarrantsMember2024-09-300001469443rkda:MarchTwoThousandTwentyThreePlacementAgentOptionsMemberus-gaap:FairValueInputsLevel3Member2024-01-012024-09-300001469443us-gaap:RetainedEarningsMember2023-09-300001469443rkda:MarchTwoThousandTwentyThreeOptionsSeriesAMember2024-01-012024-09-300001469443rkda:May2020WarrantsMember2023-12-310001469443us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesAAndMarchTwoThousandTwentyThreePlacementAgentOptionsMemberus-gaap:MeasurementInputExpectedTermMember2024-09-300001469443us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesBMemberus-gaap:MeasurementInputExpectedTermMember2024-09-3000014694432023-03-310001469443rkda:TwoThousandSixStockIncentivePlanMember2024-09-3000014694432024-09-300001469443us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMemberrkda:AugustTwoThousandTwentyTwoOptionsAndAugustTwoThousandTwentyTwoPlacementAgentOptionsMember2024-09-300001469443srt:MinimumMember2024-01-012024-09-3000014694432023-07-012023-09-3000014694432024-01-012024-03-310001469443us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-12-310001469443rkda:AugustTwoThousandTwentyTwoPreFundedWarrantsMember2024-09-300001469443us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesBMember2023-12-310001469443us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001469443rkda:InducementStockOptionMember2023-12-310001469443us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2024-09-300001469443us-gaap:LicenseMember2023-01-012023-09-300001469443us-gaap:WarrantMemberrkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:OptionAmendmentAgreementsMember2020-12-310001469443us-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMember2024-05-160001469443rkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePurchaseAgreementMember2024-01-012024-09-300001469443rkda:TwoThousandFifteenOmnibusEquityIncentivePlanMember2024-01-012024-09-300001469443us-gaap:ProductMember2024-07-012024-09-300001469443us-gaap:EmployeeStockMember2024-01-012024-09-300001469443us-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMemberus-gaap:ProductMember2023-01-012023-09-300001469443srt:MaximumMember2024-09-300001469443rkda:MarchTwoThousandAndTwentyThreePIPEMember2023-01-012023-03-310001469443rkda:May2020WarrantsPrivatePlacementOfferingMember2024-01-012024-09-300001469443us-gaap:FurnitureAndFixturesMember2024-09-300001469443rkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePurchaseAgreementMemberrkda:SeriesAAndBPreferredI 03-012023-03-310001469443rkda:JanuaryTwoThousandTwentyOnePlacementAgentWarrantsMember2023-12-310001469443us-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMember2024-07-012024-09-300001469443us-gaap:FairValueInputsLevel3Memberrkda:ContingentLiabilitiesMember2024-01-012024-09-300001469443rkda:JanuaryTwoThousandTwentyOneWarrantsMember2023-12-310001469443rkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePurchaseAgreementMemberrkda:CommonStockAndPreF 03-060001469443rkda:JanuaryTwoThousandTwentyOnePlacementAgentWarrantsMember2023-01-012023-09-300001469443rkda:AugustTwoThousandTwentyTwoPreFundedWarrantsMember2024-01-012024-09-300001469443rkda:SeptemberTwoThousandNineteenWarrantsMember2023-12-310001469443us-gaap:CommonStockMemberrkda:MarchTwoThousandAndTwentyThreePIPEMember2023-01-012023-03-310001469443us-gaap:RetainedEarningsMember2024-04-012024-06-300001469443rkda:AnawahIncMember2005-06-300001469443us-gaap:SegmentDiscontinuedOperationsMemberrkda:CoPackingBusinessSaavyNaturalsProvaultAndSoulSpringBodyCareBrandsMember2024-01-012024-09-300001469443srt:MinimumMember2024-09-300001469443us-gaap:MachineryAndEquipmentMember2024-09-300001469443rkda:InducementStockOptionMemberrkda:PresidentAndChiefExecutiveOfficerMember2022-02-022022-02-020001469443rkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:SeriesAPreferredInvestmentOptionsMemberrkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePurchas 03-310001469443us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMemberrkda:MarchTwoThousandTwentyThreeOptionsSeriesBMember2024-09-300001469443rkda:CommonStockAndPreFundedWarrantsMember2023-03-062023-03-060001469443us-gaap:ProductMember2023-07-012023-09-300001469443rkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:SeriesAPreferredInvestmentOptionsMemberrkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePurchas 03-012023-03-310001469443us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001469443rkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:PreFundedWarrantsMemberrkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePurchaseAgreementMe 03-310001469443us-gaap:SegmentDiscontinuedOperationsMemberrkda:CoPackingBusinessSaavyNaturalsProvaultAndSoulSpringBodyCareBrandsMemberus-gaap:ProductMember2023-01-012023-09-300001469443rkda:DecemberTwoThousandTwentyPlacementAgentWarrantsMember2024-09-300001469443rkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:OptionAmendmentAgreementsMemberrkda:PreferredInvestmentOptionsMember2023-03-310001469443rkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePurchaseAgreementMemberrkda:MarchTwoThousandTw 01-012024-09-300001469443rkda:AugustTwoThousandTwentyTwoPlacementAgentOptionsMember2024-09-300001469443rkda:JohnSperlingFoundationMember2024-09-300001469443us-gaap:FairValueInputsLevel3Member2024-01-012024-09-300001469443rkda:JanuaryTwoThousandTwentyOneWarrantsPrivatePlacementOfferingMember2024-01-012024-09-300001469443rkda:SellingGeneralAndAdministrativeAndResearchAndDevelopmentExpensesMember2023-07-012023-09-300001469443us-gaap:LicenseMember2023-07-012023-09-300001469443us-gaap:NoncontrollingInterestMember2023-03-310001469443us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001469443rkda:AugustTwoThousandTwentyTwoOptionsMember2024-09-300001469443rkda:AugustTwoThousandTwentyTwoPlacementAgentOptionsMember2023-01-012023-09-300001469443us-gaap:CommonStockMember2023-12-310001469443us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001469443rkda:TwoThousandSixStockIncentivePlanMember2015-05-200001469443us-gaap:CommonStockMember2024-07-012024-09-300001469443us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001469443us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-300001469443us-gaap:FairValueInputsLevel3Memberrkda:AugustTwoThousandTwentyTwoPlacementAgentOptionsMember2023-12-310001469443rkda:MarchTwoThousandTwentyThreeOptionsSeriesBMember2023-12-310001469443rkda:MarchTwoThousandTwentyThreePreFundedWarrantsMember2023-12-310001469443rkda:AugustTwoThousandTwentyTwoPlacementAgentOptionsMember2023-12-310001469443rkda:MarchTwoThousandAndTwentyThreePIPEMemberus-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001469443us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001469443rkda:BioceresCropSolutionsMember2022-01-012022-12-310001469443rkda:March2023AndAugust2022OptionsAndPlacementAgentOptionsMember2024-01-012024-09-300001469443rkda:BodyCareMember2023-07-012023-09-

300001469443us-gaap:RetainedEarningsMember2024-07-012024-09-3000014694432023-12-310001469443rkda:SeptemberTwoThousandNineteenWarrantsMember2023-01-012023-09-300001469443rkda:MarchTwoThousandTwentyThreeOptionsSeriesBMember2023-01-012023-09-300001469443rkda:March2023AndAugust2022OptionsAndPlacementAgentOptionsMember2023-01-012023-09-300001469443rkda:GoodwheatMember2023-01-012023-09-300001469443us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesAMember2023-12-310001469443us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreePlacementAgentOptionsMember2024-09-300001469443us-gaap:MoneyMarketFundsMember2023-12-310001469443us-gaap:WarrantMemberrkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:OptionAmendmentAgreementsMember2020-05-310001469443us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesBMemberus-gaap:MeasurementInputExpectedTermMember2023-12-310001469443us-gaap:ProductMember2023-01-012023-09-300001469443us-gaap:ProductMember2024-01-012024-09-300001469443us-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMember2024-01-012024-09-300001469443us-gaap:NonrelatedPartyMember2024-09-300001469443us-gaap:EmployeeStockMember2023-07-012023-09-300001469443us-gaap:FairValueInputsLevel2Member2024-09-300001469443us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001469443us-gaap:AdditionalPaidInCapitalMember2024-03-310001469443us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001469443rkda:May2020PlacementAgentWarrantsMember2023-01-012023-09-300001469443rkda:MarchTwoThousandAndTwentyThreePIPEMember2023-01-012023-09-300001469443us-gaap:WarrantMemberrkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:OptionAmendmentAgreementsMember2020-07-310001469443us-gaap:NoncontrollingInterestMember2022-12-310001469443rkda:JohnSperlingFoundationMember2023-12-310001469443rkda:LegacyVenturesHawaiiLLCMemberrkda:ArchipelagoVenturesHawaiiLLCMember2019-08-092019-08-090001469443us-gaap:FairValueInputsLevel3Memberrkda:AugustTwoThousandTwentyTwoOptionsAndAugustTwoThousandTwentyTwoPlacementAgentOptionsMemberus-gaap:MeasurementInputExpectedTermMember2023-12-310001469443us-gaap:NoncontrollingInterestMember2024-09-300001469443us-gaap:NoncontrollingInterestMember2024-06-300001469443us-gaap:RetainedEarningsMember2024-03-310001469443rkda:DecemberTwoThousandAndTwentyTwoServiceAndPerformanceWarrantsMember2023-01-012023-09-300001469443rkda:InducementStockOptionMember2024-09-300001469443rkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:SeriesBPreferredInvestmentOptionsMemberrkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePurchas
03-012023-03-310001469443rkda:JanuaryTwoThousandTwentyOneWarrantsMember2023-01-012023-09-300001469443rkda:March2023AndAugust2022OptionsAndPlacementAgentOptionsMember2024-09-300001469443us-gaap:CommonStockMember2022-12-310001469443rkda:AnawahIncMember2010-01-012010-12-310001469443rkda:SeriesBPreferredInvestmentOptionsMemberrkda:MarchTwoThousandTwentyThreeOptionsAndMarchTwoThousandTwentyThreePlacementAgentOptionsMember2023-03-060001469443rkda:May2020WarrantsMember2023-01-012023-09-300001469443us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001469443rkda:AugustTwoThousandTwentyTwoOptionsMember2023-12-310001469443us-gaap:LeaseholdImprovementsMember2023-12-310001469443us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMemberrkda:MarchTwoThousandTwentyThreeOptionsSeriesBMember2024-09-300001469443rkda:SellingGeneralAndAdministrativeAndResearchAndDevelopmentExpensesMember2024-07-012024-09-300001469443us-gaap:LicenseMember2024-01-012024-09-300001469443rkda:AugustTwoThousandTwentyTwoOptionsMember2024-01-012024-09-300001469443us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMemberrkda:AugustTwoThousandTwentyTwoOptionsAndAugustTwoThousandTwentyTwoPlacementAgentOptionsMember2024-09-300001469443us-gaap:RetainedEarningsMember2023-06-300001469443us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001469443rkda:BodyCareMember2024-07-012024-09-300001469443rkda:BioceresCropSolutionsMembersrt:MaximumMemberrkda:VerdecaLLCMember2020-11-012020-11-300001469443rkda:DecemberTwoThousandAndTwentyTwoServiceAndPerformanceWarrantsMember2024-09-300001469443rkda:AugustTwoThousandTwentyTwoPreFundedWarrantsMember2023-12-31rkda:Individualxbrliːpureiso4217:USDxbrliːsharesxbrliːsharesrkda:IncentivePlaniso4217:USDrkda:Program Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Â FORM 10-Q Â (Mark One) â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the transition period from to Â Commission File Number: 001-37383 Â Arcadia Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Â Â Delaware 81-0571538 (State or other jurisdiction ofincorporation or organization) (I.R.S. EmployerIdentification No.) 5950 Sherry Lane, Suite 215Dallas, TX 75225 (Address of Principal Executive Offices) (Zip Code) Registrantâ€™s telephone number, including area code: (214) 974-8921 Â Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Trading Symbol(s) Name of each exchange on which registered Common RKDA NASDAQÂ CAPITAL MARKET Â Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer â˜ Â Accelerated filer Â â˜ Â Â Â Â Â Â Â Non-accelerated filer â˜’ Smaller reporting company â˜’ Â Â Â Â Â Â Â Â Emerging growth company â˜ Â Â Â Â Â Â Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Â Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’ Â As of November 5, 2024, the registrant had 1,364,940 shares of common stock outstanding, $0.001 par value per share. Â Â Arcadia Biosciences, Inc. FORM 10-Q FOR THE QUARTER ENDED September 30, 2024 INDEX Â Â Page Part I â€” Financial Information (Unaudited) Â Â Â Â Â Â Â Â Item 1. Condensed Consolidated Financial Statements: Â 1 Â Â Â Â Â Â Â Â Condensed Consolidated Balance Sheets Â 1 Â Â Â Â Â Â Â Â Condensed Consolidated Statements of Operations and Comprehensive Loss Â 2 Â Â Â Â Â Â Â Â Â Â Â Â Condensed Consolidated Statements of Stockholdersâ€™ Equity Â 3 Â Â Â Â Â Â Â Â Â Â Condensed Consolidated Statements of Cash Flows Â 4 Â Â Â Â Â Â Â Â Notes to Condensed Consolidated Financial Statements Â 5 Â Â Â Â Â Â Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations Â 19 Â Â Â Â Â Â Item 3. Quantitative and Qualitative Disclosures About Market Risk Â 28 Â Â Â Â Â Â Item 4. Controls and Procedures Â 28 Â Â Â Â Â Part II â€” Other Information Â 29 Â Â Â Â Â Â Â Item 1. Legal Proceedings Â 29 Â Â Â Â Â Â Â Item 1A. Risk Factors Â 29 Â Â Â Â Â Â Â Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Â 29 Â Â Â Â Â Â Â Â Item 3. Defaults Upon Senior Securities Â 29 Â Â Â Â Â Â Â Â Item 4. Mine Safety Disclosures Â 29 Â Â Â Â Â Â Â Â Item 5. Other Information Â 29 Â Â Â Â Â Â Â Item 6. Exhibits Â 30 Â Â Â Â Â Â Â Â SIGNATURES Â 31 Â Â Â ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Arcadia Biosciences, Inc. Condensed Consolidated Balance Sheets (Unaudited) (In thousands, except share data) Â Â September 30, 2024 Â Â December 31, 2023 Â Assets Â Â Â Â Â Â Current assets: Â Â Â Â Â Â Cash and cash equivalents Â $ 3,936 Â Â $ 6,518 Â Short-term investments Â Â 2,640 Â Â Â 5,124 Â Accounts receivable and other receivables, net of allowance for doubtful accounts of Â Â Â $0Â as of September 30, 2024 and December 31, 2023 Â Â 882 Â Â Â 506 Â Inventories â€” current Â Â 835 Â Â Â 837 Â Assets held for sale Â Â Â€” Â Â Â 51 Â Note receivable â€” current Â Â 1,827 Â Â Â Â Â€” Â Prepaid expenses and other current assets Â Â 521 Â Â Â 807 Â Current assets of discontinued operations â€” GoodWheat Â Â 70 Â Â Â 1,129 Â Total current assets Â Â 10,711 Â Â Â 14,972 Â Property and equipment, net Â Â 55 Â Â Â 70 Â Right of use asset Â Â 306 Â Â Â 792 Â Inventories â€” noncurrent Â Â Â€” Â Â Â 196 Â Intangible assets, net Â Â 39 Â Â Â 39 Â Note receivable â€” noncurrent Â Â 3,966 Â Â Â Â€” Â Other noncurrent assets Â Â 164 Â Â Â 164 Â Noncurrent assets of discontinued operations â€” GoodWheat Â Â Â€” Â Â Â 3,472 Â Total assets Â $ 15,241 Â Â $ 19,705 Â Liabilities and stockholdersâ€™ equity Â Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Accounts payable and accrued expenses Â $ 1,692 Â Â $ 1,910 Â Amounts due to related parties Â Â 30 Â Â Â 58 Â Operating lease liability â€” current Â Â 346 Â Â Â 852 Â Other current liabilities Â Â 260 Â Â Â 270 Â Current liabilities of discontinued operations â€” GoodWheat Â Â Â€” Â Â Â 500 Â Total current liabilities Â Â 2,328 Â Â Â 3,590 Â Operating lease liability â€” noncurrent Â Â Â€” Â Â Â 155 Â Common stock warrant and option liabilities Â Â 764 Â Â Â 1,257 Â Other noncurrent liabilities Â Â 2,000 Â Â Â 2,000 Â Total liabilities Â Â 5,092 Â Â Â 7,002 Â Commitments and contingencies (Note 14) Â Â Â Â Â Â Stockholdersâ€™ equity: Â Â Â Â Â Â Common stock, $0.001Â par valueâ€”150,000,000Â shares authorized; 1,364,940Â and 1,285,337Â Â Â shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively Â Â 65 Â Â Â 65 Â Additional paid-in capital Â Â 284,919 Â Â Â 284,515 Â Accumulated other comprehensive income Â Â 117 Â Â Â 101 Â Accumulated deficit Â Â (274,814) Â Â (271,840) Total stockholdersâ€™ equity Â Â 10,287 Â Â Â 12,841 Â Non-controlling interest Â Â (138) Â Â (138) Total stockholders' equity Â Â 10,149 Â Â Â 12,703 Â Total liabilities and stockholdersâ€™ equity Â $ 15,241 Â Â $ 19,705 Â Â See accompanying notes to the unaudited condensed consolidated financial statements. 1 Â Arcadia Biosciences, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except share and per share data) Â Â Â Three Months Ended September 30, Â Â Â Nine Months Ended September 30, Â Â Â Â 2024 Â Â Â 2023 Â Â Â 2024 Â Â Â 2023 Â Revenues: Â Â Â Â Â Â Â Â Â Â Â Â Product Â $ 1,537 Â Â $ 1,298 Â Â $ 3,829 Â Â $ 3,667 Â License Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â 10 Â Total revenues Â Â 1,537 Â Â Â 1,298 Â Â Â 3,829 Â Â Â 3,677 Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Cost of revenues Â Â 1,032 Â Â Â 818 Â Â Â 2,136 Â Â Â 1,996 Â Research and development Â Â 24 Â Â Â 15 Â Â Â 40 Â Â Â 55 Â Gain on sale of intangible assets Â Â Â€” Â Â Â€” Â Â Â (4,000) Â Â Â€” Â Â Â Impairment of property and equipment Â Â Â€” Â Â Â€” Â Â Â 36 Â Â Â Â€” Â Selling, general and administrative Â Â 2,241 Â Â Â 1,862 Â Â Â 6,986 Â Â Â 6,535 Â Total operating expenses Â Â 3,297 Â Â Â 2,695 Â Â Â 5,198 Â Â Â 8,586 Â Loss from continuing operations Â Â (1,760) Â Â (1,397) Â Â (1,369) Â Â (4,909) Interest income Â Â 233 Â Â Â 133 Â Â Â 428 Â Â Â 538 Â Other income, net Â Â 15 Â Â Â 17 Â Â Â 168 Â Â Â 36 Â Valuation loss on March 2023 PIPE Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â (6,076) Change in fair value of common stock warrant and option liabilities Â Â 330 Â Â Â 608 Â Â Â 493 Â Â Â 5,965 Â Issuance and offering costs allocated to liability classified options Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â (430) Net loss from continuing operations before income taxes Â Â (1,182) Â Â (639) Â Â (280) Â Â (4,876) Income tax provision Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â (1) Net loss from continuing operations Â Â (1,182) Â Â (639) Â Â (280) Â Â (4,877) Net loss from discontinued operations â€” Body Care Â Â Â€” Â Â Â (83) Â Â Â€” Â Â Â (591) Net loss from discontinued operations â€” GoodWheat Â Â (430) Â Â (1,845) Â Â (2,694) Â Â (5,665) Net loss Â Â (1,612) Â Â (2,567) Â Â (2,974) Â Â (11,133) Net loss attributable to non-controlling interest Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â (5) Net loss attributable to common stockholders Â $ (1,612) Â $ (2,567) Â $ (2,974) Â $ (11,128) Net loss per share attributable to common stockholders: Â Â Â Â Â Â Â Â Â Â Â Â Basic and diluted from continuing operations Â $ (0.87) Â $ (0.47) Â $ (0.21) Â $ (4.08) Basic from discontinuing operations Â $ (0.32) Â $ (1.42) Â $ (1.98) Â $ (5.24) Net loss per basic and diluted share attributable to common stockholders Â $ (1.18) Â $ (1.89) Â $ (2.18) Â $ (9.31) Weighted-average number of shares used in per share Â Â Â calculations: Â Â Â Â Â Â Â Â Â Â Â Â Basic and diluted Â Â 1,363,753 Â Â Â 1,359,511 Â Â Â 1,362,754 Â Â Â 1,195,354 Â Other comprehensive income (loss), net of tax Â Â Â Â Â Â Â Â Â Â Â Â Unrealized gains on available-for-sale securities Â $ 36 Â Â $ 66 Â Â $ 117 Â Â $ 87 Â Reclassification adjustment for gains on available-for-sale securities included in net loss Â Â Â€” Â Â Â Â€” Â Â Â (111) Â Â Â€” Â Change in unrealized gains on available-for-sale securities Â $ 36 Â Â $ 66 Â Â $ 6 Â Â $ 87 Â Comprehensive loss Â $ (1,576) Â $ (2,501) Â $ (2,968) Â $ (11,041) Â See accompanying notes to the unaudited condensed consolidated financial statements. 2 Â Arcadia Biosciences, Inc. Condensed Consolidated Statements of Stockholdersâ€™ Equity (Unaudited) (In thousands, except share data) Â Â Â Common Stock Â Â AdditionalPaid-In Â Â Accumulated Â Â Accumulated Other Â Â Non-Controlling Â Â TotalStockholdersâ€™ Â Â Â Shares Â Â Amount Â Â Capital Â Â Deficit Â Â Comprehensive Income Â Â Interest Â Â Equity Â Balance at December 31, 2023 Â Â 1,285,337 Â Â Â $ 65 Â Â $ 284,515 Â Â $ (271,840) Â $ 101 Â Â $ (138) Â $ 12,703 Â Issuance of shares related to March 2023 pre-funded warrants exercise Â Â 75,000 Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Issuance of shares related to employee stockÂ Â Â purchase plan Â Â 2,503 Â Â Â Â€” Â Â Â 5 Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â 5 Â Stock-based compensation Â Â Â€” Â Â Â Â€” Â Â Â 138 Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â 138 Â Unrealized gains on available-for-sale securities Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â 60 Â Â Â Â€” Â Â Â 60 Â Net loss Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â (2,423) Â Â Â€” Â Â Â Â€” Â Â Â (2,423) Balance at March 31, 2024 Â Â 1,362,840 Â Â Â $ 65 Â Â $ 284,658 Â Â $ (274,263) Â $ 161 Â Â $ (138) Â $ 10,483 Â Stock-based compensation Â Â Â€” Â Â Â Â€” Â Â Â 102 Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â 102 Â Change in unrealized gains on available-for-sale securities Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â (80) Â Â Â Â€” Â Â Â (80) Net income Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â 1,061 Â Â Â Â€” Â Â Â 1,061 Â Balance at June 30, 2024 Â Â 1,362,840 Â Â Â $ 65 Â Â $ 284,760 Â Â $ (273,202) Â $ 81 Â Â $ (138) Â $ 11,566 Â Issuance of shares related to employee stockÂ Â Â purchase plan Â Â 2,100 Â Â Â Â€” Â Â Â 4 Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â 4 Â Stock-based compensation Â Â Â€” Â Â Â Â€” Â Â Â 155 Â Â Â Â€” Â Â Â Â€” Â Â Â 155 Â Change in unrealized gains on available-for-sale securities Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â 36 Â Â Â Â€” Â Â Â 36 Â Net loss Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â (1,612) Â Â Â€” Â Â Â (1,612) Balance at September 30, 2024 Â Â 1,364,940 Â Â Â $ 65 Â Â $ 284,919 Â Â $ (274,814) Â $ 117 Â Â $ (138) Â $ 10,149 Â Â Â Â Â Â Common Stock Â Â AdditionalPaid-In Â Â Accumulated Â Â Accumulated Other Â Â Non-Controlling Â Â TotalStockholdersâ€™ Â Â Â Shares Â Â Amount Â Â Capital Â Â Deficit Â Â Comprehensive Income Â Â Interest Â Â Equity Â Balance at December 31, 2022 Â Â 616,079 Â Â Â $ 65 Â Â $ 278,827 Â Â $ (257,859) Â $ â€” Â Â Â $ (133) Â $ 20,900 Â Issuance of shares related to March 2023 PIPE Â Â 165,500 Â Â Â Â€” Â Â Â 4,740 Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â 4,740 Â Modification of warrants related to March 2023 PIPE Â Â Â€” Â Â Â Â€” Â Â Â 219 Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â 219 Â Issuance of shares related to August 2022 pre-funded warrants exercise Â Â 56,813 Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Issuance of shares related to employee stockÂ Â Â purchase plan Â Â 88 Â Â Â Â€” Â Â Â 5 Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â 5 Â Issuance of shares related to reverse stock split Â Â 19,092 Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Stock-based compensation Â Â Â€” Â Â Â Â€” Â Â Â 212 Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â 212 Â Net loss Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â (9,384) Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â (9,384) Balance at March 31, 2023 Â Â 857,572 Â Â Â $ 65 Â Â $ 284,003 Â Â $ (267,243) Â $ â€” Â Â Â $ (133) Â $ 16,692 Â Issuance of shares related to March 2023 pre-funded warrants exercise Â Â 250,834 Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Issuance of shares related to reverse stock split Â Â 26 Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Stock-based compensation Â Â Â€” Â Â Â Â€” Â Â Â 199 Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â 199 Â Unrealized gains on available-for-sale securities Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â 21 Â Â Â Â€” Â Â Â 21 Â Net income Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â 823 Â Â Â Â€” Â Â Â (5) Â Â 818 Â Balance at June 30, 2023 Â Â 1,108,432 Â Â Â $ 65 Â Â $ 284,202 Â Â $ (266,420) Â $ 21 Â Â $ (138) Â $ 17,730 Â Issuance of shares related to employee stockÂ Â Â purchase plan Â Â 1,905 Â Â Â Â€” Â Â Â 7 Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â 7 Â Stock-based compensation Â Â Â€” Â Â Â Â€” Â Â Â 162 Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â 162 Â Unrealized gains on available-for-sale securities Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â 66 Â Â Â Â€” Â Â Â 66 Â Net loss Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â Â€” Â Â Â (2,567) Â Â Â€” Â Â Â Â€” Â Â Â (2,567) Balance at September 30, 2023 Â Â 1,110,337 Â Â Â $ 65 Â Â $ 284,371 Â Â $ (268,987) Â $ 87 Â Â $ (138) Â $ 15,398 Â Â See accompanying notes to the unaudited condensed consolidated financial statements. 3 Â Arcadia Biosciences, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) (In thousands) Â Â Â Nine Months Ended September 30, Â Â Â Â 2024 Â Â Â 2023 Â CASH FLOWS FROM OPERATING ACTIVITIES: Â Â Â Â Â Â Net loss Â $ (2,974) Â $ (11,133) Adjustments to reconcile net loss to cash used in operating activities: Â Â Â Â Â Â Change in fair value of common stock warrant and

option liabilities Â Â (493) Â Â (5,965) Issuance and offering costs allocated to liability classified options Â Â â€” Â Â Â 430 Â Valuation loss on March 2023 PIPE Â Â â€” Â Â Â 6,076 Â Depreciation Â Â 92 Â Â Â 227 Â Lease amortization Â Â 502 Â Â Â 535 Â Amortization of note receivable discount Â Â (90) Â Â â€” Â Gain on disposal of property and equipment Â Â (65) Â Â (36) Gain on sale of RS durum wheat trait Â Â (4,000) Â Â â€” Â Stock-based compensation Â Â 395 Â Â Â 573 Â Write-down of inventories Â Â 154 Â Â Â 444 Â Impairment of property and equipment Â Â 36 Â Â Â â€” Â Changes in operating assets and liabilities: Â Â Â Â Â Â Accounts receivable and other receivables Â Â (445) Â Â 249 Â Inventories Â Â 620 Â Â Â (1,388) Prepaid expenses and other current assets Â Â 287 Â Â Â (284) Other noncurrent assets Â Â â€” Â Â Â (13) Accounts payable and accrued expenses Â Â (719) Â Â (300) Amounts due to related parties Â Â (29) Â Â (2) Other current liabilities Â Â (11) Â Â 11 Â Operating lease liabilities Â Â (678) Â Â (573) Net cash used in operating activities Â Â (7,418) Â Â (11,149) CASH FLOWS FROM INVESTING ACTIVITIES: Â Â Â Â Â Â Proceeds from sale of property and equipment Â Â 342 Â Â Â 42 Â Proceeds from sale of Verdeca â€” earn-out received Â Â â€” Â Â Â 569 Â Proceeds from sale of investments Â Â 2,501 Â Â Â â€” Â Proceeds from sale of RS durum wheat trait Â Â 4,000 Â Â Â â€” Â Cash paid related to sale of GoodWheat Â Â (2,000) Â Â â€” Â Purchases of property and equipment Â Â (16) Â Â (5) Purchases of investments Â Â â€” Â Â Â (5,002) Net cash provided by (used in) investing activities Â Â 4,827 Â Â Â (4,396) CASH FLOWS FROM FINANCING ACTIVITIES: Â Â Â Â Â Â Proceeds from issuance of common stock, pre-funded warrants and Â Â Â preferred investment options from March 2023 PIPE Â Â â€” Â Â Â 5,997 Â Payments of offering costs relating to March 2023 PIPE Â Â â€” Â Â Â (497) Proceeds from ESPP purchases Â Â 9 Â Â Â 12 Â Net cash provided by financing activities Â Â 9 Â Â Â 5,512 Â Net decrease in cash and cash equivalents Â Â (2,582) Â Â (10,033) Cash and cash equivalents â€” beginning of period Â Â 6,518 Â Â Â 20,644 Â Cash and cash equivalents â€” end of period Â $ 3,936 Â Â $ 10,611 Â SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Â Â Â Â Â Â NONCASH INVESTING AND FINANCING ACTIVITIES: Â Â Â Â Â Â Common stock options issued to placement agent and included in offering Â Â Â Â costs related to March 2023 PIPE Â $ â€” Â Â $ 212 Â Warrant and option modifications included in Valuation loss on MarchÂ Â Â Â 2023 PIPE Â $ â€” Â Â $ 404 Â Right of use assets obtained in exchange for new operating lease liabilities Â $ 86 Â Â $ â€” Â Note receivable recognized from sale of GoodWheat Â $ 5,705 Â Â $ â€” Â Â See accompanying notes to the unaudited condensed consolidated financial statements. 4 Â Arcadia Biosciences, Inc. Notes to Condensed Consolidated Financial Statements (Unaudited) Â 1. Description of Business and Basis of PresentationOrganizationArcadia Biosciences, Inc. (the "Company," "Arcadia" or "management"), was incorporated in Arizona in 2002 and maintains its headquarters in Dallas, Texas, with additional office space in Davis and Sacramento, California. The Company was reincorporated in Delaware in March 2015.Since acquiring the assets of Live Zola, LLC ("Zola") in May 2021, the Company has provided consumers with a great tasting way to rehydrate, reset, and reenergize with Zola coconut water products. The company has leveraged its history as a leader in science-based approaches to develop high value products and drive innovation in the consumer goods industry. Previously, the Company developed products primarily in wheat, which it commercialized through the sales of seed, grain and food ingredients and products, and through trait licensing and royalty agreements.On May 16, 2024, the Company sold the GoodWheatâ„¢ brand to Above Food Ingredients Corp. ("Above Food") for net consideration of $3.7 million. Refer to Note 6 for details of the transaction.On May 14, 2024, the Company sold its non-GMO Resistant Starch ("RS") durum wheat trait to longtime partner Corteva AgriScience ("Corteva"). Under the terms of the agreement, Arcadia retained certain rights to use the RS durum wheat trait. The Company received $4.0 million in cash payment from Corteva during the nine months ended September 30, 2024 and recorded a gain of the same amount as the trait had no carrying value on the condensed consolidated statement of operations and comprehensive loss related to the transaction. Refer to Note 8 for details of the partnership and transaction.In May 2021, the Companyâ€™s wholly owned subsidiary Arcadia Wellness, LLC (â€œArcadia Wellnessâ€ or â€œAWâ€) acquired the businesses of Eko Holdings, LLC, Lief, LLC, and Zola. The acquisition included Saavy Naturalsâ„¢, a line of natural body care products, Soul Springâ„¢, a CBD-infused botanical therapy brand in the natural category, and ProVaultâ„¢, a THC-free CBD sports performance formula made with natural ingredients, providing effective support and recovery for athletes (collectively, "body care brands"). Also included in the purchase was Zola, a coconut water sourced exclusively with sustainably grown coconuts from Thailand. In July 2022, the Company entered into an agreement to license Saavy Naturals to Radiance Beauty and Wellness, Inc. ("Radiance Beauty"). In July 2023, management made the decision to exit the remaining body care brands, Soul Spring and ProVault, as a result of continued pressure on the CBD market due to regulatory uncertainty. Body care operations ceased during the third quarter of 2023. In August 2019, the Company entered into a joint venture agreement with Legacy Ventures Hawaii, LLC (â€œLegacy,â€ see Note 7) to grow, extract, and sell hemp products. The partnership Archipelago Ventures Hawaii, LLC (â€œArchipelagoâ€), combines the Companyâ€™s extensive genetic expertise and resources with Legacyâ€™s experience in hemp extraction and sales. In October 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to regulatory challenges and a saturated hemp market.In February 2012, the Company formed Verdeca, which was equally owned with Bioceres. Verdeca was formed to develop and deregulate soybean varieties using both partnersâ€™ agricultural technologies. In November 2020, Arcadia sold its membership interest in Verdeca to Bioceres in a transaction in which Arcadia received cash, shares of Bioceres stock and a royalty stream of up to $10.0 million on sales of Haab 4 soybeans (â€œHB4â€). An additional $2.0 million in cash was to be paid to Arcadia upon Verdeca achieving commercial plantings of at least 200,000 hectares of HB4 or China approving the HB4 soybean trait for â€œfood and feedâ€. During 2022, Bioceres received China's approval of the HB4 soybean trait and as a result, Arcadia recorded license revenue of $862,000 and a gain on sale of Verdeca of $1.1 million on the condensed consolidated statements of operations and comprehensive loss. The Company received the full payment of $2.0 million as of December 31, 2023. Basis of Presentation and Principles of ConsolidationThe accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (â€œGAAPâ€) for interim financial statements and are in the form prescribed by the Securities and Exchange Commission (the â€œSECâ€) in instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Companyâ€™s financial position, results of operations and cash flows for the periods indicated. All material intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company, Arcadia Wellness, and Archipelago. 5 Â The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities ("VIEs"). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIEâ€™s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE.For all periods presented, the Company has determined that it is the primary beneficiary of Archipelago, a joint venture, as it has a controlling interest in Archipelago. Accordingly, the Company consolidates Archipelago in the condensed consolidated financial statements after eliminating intercompany transactions. For consolidated joint ventures, the non-controlling partnerâ€™s share of the assets, liabilities and operations of the joint venture is included in non-controlling interests as equity of the Company. The non-controlling partnerâ€™s interest is generally computed as the joint venture partnerâ€™s ownership percentage of Archipelago. The non-controlling partnerâ€™s equity interests are presented as non-controlling interests on the condensed consolidated balance sheets.The information included in these condensed consolidated financial statements and notes thereto should be read in conjunction with Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations included herein and Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations and the condensed consolidated financial statements and notes thereto for the fiscal year ended December 31, 2023 included in the Companyâ€™s Annual Report on Form 10-K, filed with the SEC on March 28, 2024.ReclassificationsCertain previously reported financial information has been reclassified to conform to the current year presentation. For a discussion of the reclassification of the financial presentation of our former GoodWheat and body care brands reported as discontinued operations, see â€œDiscontinued Operationsâ€ section below. Unless otherwise noted, amounts and disclosures throughout these notes to condensed consolidated financial statements relate solely to continuing operations and exclude all discontinued operations.Reverse Stock SplitIn February 2023, the Companyâ€™s board of directors approved a reverse split of 40:1 on the Companyâ€™s issued and outstanding common stock. On February 15, 2023, the Companyâ€™s stockholders approved the certificate of amendment to the Companyâ€™s certificate of incorporation, which the Company filed on February 27, 2023 with the Secretary of State of Delaware to effect the reverse split on March 1, 2023. As a result of the reverse stock split, 19,118 additional shares of common stock were issued in lieu of fractional shares. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the condensed consolidated financial statements have been retroactively adjusted to reflect the reverse stock split for all periods presented.Liquidity, Capital Resources, and Going ConcernThe accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. Since inception, the Company has financed its operations primarily through equity financings. As of September 30, 2024, the Company had an accumulated deficit of $274.8 million, cash and cash equivalents of $3.9 million, short-term investments of $2.6 million and current note receivable of $1.8 million. For the nine months ended September 30, 2024, the Company had net loss of $3.0 million and net cash used in operations of $7.4 million. For the twelve months ended December 31, 2023, the Company had net losses of $14.0 million and net cash used in operations of $15.3 million.With cash and cash equivalents of $3.9 million, short-term investments of $2.6 million and current note receivable of $1.8 million as of September 30, 2024, the Company believes that its existing cash, cash equivalents and short-term investments will not be sufficient to meet its anticipated cash requirements for at least the next 12-18 months from the issuance date of these financial statements, and thus raises substantial doubt about the Companyâ€™s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.The Company may seek to raise additional funds through debt or equity financings. The Company may also consider entering into additional partner arrangements. The sale of additional equity would result in dilution to the Companyâ€™s stockholders. The incurrence of debt would result in debt service obligations, and the instruments governing such debt could provide for additional operating and financing covenants that would restrict operations. If the Company requires additional funds and is unable to secure adequate additional funding at terms agreeable to the Company, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned product launches. Any of these actions could materially harm the business, results of operations and financial condition.Discontinued OperationsOn May 16, 2024, the Company sold the GoodWheat brand to Above Food. GoodWheat operations ceased during the second quarter of 2024. In July 2023, management made the decision to exit its body care brands as a result of continued pressure on the CBD market due to regulatory uncertainty. Body care operations ceased during the third quarter of 2023. In accordance with the provisions of ASC 205-20, the Company has separately reported the assets and liabilities of the discontinued operations in the condensed consolidated balance sheets and the results of the discontinued operations as separate components on the condensed consolidated statements of operations and comprehensive loss for all periods presented.Â 6Â Major classes of line items constituting the balance sheet of discontinued operations:Â Â Â GoodWheat Â Â Body Care Â (In thousands) Â September 30, 2024 Â Â December 31, 2023 Â Â September 30, 2024 Â Â December 31, 2023 Â Assets Â Â Â Â Â Â Â Â Â Â Â Â Accounts receivable and other receivables Â $ 70 Â Â $ 8 Â Â $ â€” Â Â $ â€” Â Inventories, net â€” current Â Â â€” Â Â Â 1,121 Â Â Â â€” Â Â Â â€” Â Property and equipment, net Â Â â€” Â Â Â 314 Â Â Â â€” Â Â Â â€” Â noncurrent Â Â â€” Â Â Â 3,158 Â Â Â â€” Â Â Â â€” Â Total assets Â $ 70 Â Â $ 4,601 Â Â $ â€” Â Â $ â€” Â Â Â Â Â Â Â Â Â Â Â Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Â Accounts payable and accrued expenses Â $ â€” Â Â $ 500 Â Â $ â€” Â Â $ â€” Â Total liabilities Â $ â€” Â Â $ 500 Â Â $ â€” Â Â $ â€” Â Â Major classes of line items constituting net loss from discontinued operations:Â Â Â GoodWheat Â Â Body Care Â Three Months Ended September 30, Â Nine Months Ended September 30, Â Three Months Ended September 30, Â Nine Months Ended September 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â (In thousands) Â Product revenue Â $ (76) Â $ 300 Â Â $ 372 Â Â $ 484 Â Â $ â€” Â Â $ 37 Â Â $ â€” Â Â $ 373 Â Cost of revenues Â Â â€” Â Â Â (285) Â Â (691) Â Â (634) Â Â â€” Â Â Â (34) Â Â â€” Â Â Â (313) Research and development Â Â â€” Â Â Â (291) Â Â (400) Â Â (1,000) Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â (Loss) Gain on sale of property and equipment Â Â (24) Â Â 11 Â Â Â 65 Â Â Â 36 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Selling, general and administrative Â Â (330) Â Â (1,580) Â Â (2,040) Â Â (4,551) Â Â â€” Â Â Â (86) Â Â â€” Â Â Â (651) Net loss from discontinued operations Â $ (430) Â $ (1,845) Â $ (2,694) Â $ (5,665) Â $ â€” Â Â $ (83) Â $ â€” Â Â $ (591) The following table presents non-cash items of discontinued operations:Â Â Â GoodWheat Â Â Body Care Â Nine Months Ended September 30, Â Nine Months Ended September 30, Â (In thousands) Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Depreciation Â $ 37 Â Â $ 109 Â Â $ â€” Â Â $ 24 Â Gain on disposal of property and equipment Â $ (65) Â $ (36) Â $ â€” Â Â $ â€” Â Write-down of inventories Â $ â€” Â Â $ 275 Â Â $ â€” Â Â $ â€” Â Accounts receivable and other receivables Â $ (78) Â $ â€” Â Â $ â€” Â Â $ (99) Inventories Â $ 575 Â Â $ (1,975) Â $ â€” Â Â $ 250 Â Prepaid expenses and other current assets Â $ â€” Â Â $ â€” Â Â $ â€” Â Â $ 14 Â Accounts payable and accrued expenses Â $ (500) Â $ 144 Â Â $ â€” Â Â $ 5 Â Proceeds from sale of property and equipment Â $ 342 Â Â $ 37 Â Â $ â€” Â Â $ â€” Â There were no other operating or investing non-cash items for the nine months ended September 30, 2024 and 2023. 7 Â 2. Recent Accounting PronouncementsIn November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) â€” Improvements to Reportable Segment Disclosures. The amendments in this update improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The new guidance is effective retrospectively for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this update on our segment disclosures. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) â€” Improvements to Income Tax Disclosures. The amendments in this update require additional income tax disclosures primarily related to the rate reconciliation and income taxes paid. The new guidance is effective either prospectively or retrospectively, for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this update on our income tax disclosures. 3. InventoryInventory costs are tracked on a lot-identified basis and are included as cost of revenues when sold. Inventories are stated at the lower of cost or net realizable value. The Company makes adjustments to inventory when conditions indicate that the net realizable value may be less than cost due to physical deterioration, obsolescence, changes in price levels, or other factors. Additional adjustments to inventory are made for excess and slow-moving inventory on hand that is not expected to be sold within a reasonable timeframe to reduce the carrying amount to its estimated net realizable value. The write-downs to inventory are included in cost of revenues and are based upon estimates about future demand from the Companyâ€™s customers and distributors and market conditions. The Company recorded a write-down of $154,000 related to hemp and GoodWheat seed during the three and nine months ended September 30, 2024. The Company recorded inventory write-downs of $252,000 and $444,000 related to packaging materials, hemp seed and GoodWheat during the three and nine months ended September 30, 2023, respectively. If there are significant changes in demand and market conditions, substantial future write-downs of inventory may be required, which would materially increase the Companyâ€™s expenses in the period the write down is taken and materially affect the Companyâ€™s operating results.Inventories, net consist of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Raw materials Â $ 450 Â Â $ 373 Â Finished goods Â Â 385 Â Â Â 660 Â Inventories Â $ 835 Â Â $ 1,033 Â Â 4. Property and Equipment, NetProperty and equipment, net consisted of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Software and computer equipment Â $ 291 Â Â $ 349 Â Machinery and equipment Â Â â€” Â Â Â 34 Â Furniture and fixtures Â Â 32 Â Â Â 39 Â Leasehold improvements Â Â 1,584 Â Â Â 1,590 Â Property and equipment, gross Â Â 1,907 Â Â Â 2,012 Â Less: accumulated depreciation and amortization Â Â (1,852) Â Â (1,942) Property and equipment, net Â $ 55 Â Â $ 70 Â Â Depreciation expense was $7,000 and $92,000 for the three and nine months ended September 30, 2024, respectively. Depreciation expense was $89,000 and $227,000 for the three and nine months ended September 30, 2023, respectively.During the three and nine months ended September 30, 2024 and 2023, there were no sales of property and equipment from continuing operations.Property and equipment are considered assets held for sale when management approves and commits to a plan to dispose of a property or group of properties. The property and equipment held for sale prior to the sale date is separately presented, within current assets, on the condensed consolidated balance sheet as assets held for sale. Property and equipment related to Archipelago of $51,000 were classified as assets held for sale as of December 31, 2023. During the first quarter of 2024, the Company recorded an impairment of $36,000 related to these assets. During the second quarter of 2024, all Archipelago property and equipment previously held for sale were sold. 8 Â 5. Investments and Fair Value Instruments Available-for-Sale InvestmentsThe Company classified short-term investments as â€œavailable-for-sale.â€ These short-term investments are free of trading restrictions. The investments are carried at fair value, based on quoted market prices or other readily available market information. Unrealized gains and losses are included in accumulated other comprehensive income, which is reflected as a separate component of stockholderâ€™s

equity in the condensed consolidated balance sheets. Gains and losses are recognized when realized in the condensed consolidated statements of operations and comprehensive loss.The following tables summarize the amortized cost and fair value of the investment securities portfolio at September 30, 2024 and December 31, 2023 and the corresponding amounts of unrealized gains and losses recognized in accumulated other comprehensive income:Â (Dollars in thousands) Â AmortizedCost Â Â UnrealizedGains Â Â UnrealizedLosses Â Â EstimatedFair Value Â September 30, 2024 Â Â Â

$ 245.20 Â Â Â â€” Â Â Â 1,741 Â Â Â â€” Â Â Â 1,741 Â September 2019 Placement Agent Warrants (3) Â September 2019 Â 5Â years Â $ 379.20 Â Â Â â€” Â Â Â 1,649 Â Â Â â€” Â Â Â â€” Â June 2019 Placement Agent Warrants (3) Â June 2019 Â 5Â years Â $ 251.60 Â Â Â â€” Â Â Â 1,862 Â Â Â â€” Â Â Â â€” Â April 2019 Service and Performance Warrants (1)(3) Â April 2019 Â 5Â years Â $ 247.20 Â Â Â â€” Â Â Â 3,629 Â Â Â â€” Â Â Â â€” Â January 2021 Warrants (2) Â January 2021 Â 5.5Â years Â $ 9.00 Â Â Â â€” Â Â Â 7,831 Â Â Â â€” Â Â Â 7,831 Â January 2021 Warrants Â January 2021 Â 5.5Â years Â $ 125.20 Â Â Â â€” Â Â Â 90,629 Â Â Â â€” Â Â Â 90,629 Â September 2019 Warrants (2) Â September 2019 Â 5.5Â years Â $ 9.00 Â Â Â â€” Â Â Â 9,892 Â Â Â â€” Â Â Â 9,892 Â September 2019 Warrants Â September 2019 Â 5.5Â years Â $ 300.80 Â Â Â â€” Â Â Â 6,594 Â Â Â â€” Â Â Â 6,594 Â June 2019 Warrants Â June 2019 Â 5.5Â years Â $ 200.00 Â Â Â â€” Â Â Â 10,896 Â Â Â â€” Â Â Â 10,896 Â Total Â Â Â Â Â Â Â Â Â (482,647) Â Â 341,957 Â Â Â (75,000) Â Â 259,817 Â (1) The Company issued service and performance warrants (â€œService and Performance Warrantsâ€) in connection with professional services agreements with non-affiliated third party entities.(2) These warrants were repriced as part of the March 2023 Private Placement offering.(3) These warrants expired during the nine months ended September 30, 2024. 14 Â Liability Classified Preferred Investment OptionsThe preferred investment options issued in connection with the March 2023 Private Placement and August 2022 Registered Direct offerings contain certain early settlement provisions that preclude them from equity classification and therefore were accounted for as liabilities at the date of issuance and are adjusted to fair value at each balance sheet date. The change in fair value of the options liabilities is recorded as change in fair value of common stock warrant and option liabilities in the condensed consolidated statements of operations and comprehensive loss. The key terms and activity of the liability classified preferred investment options are summarized as follows: Â Â Â Issuance Date Â Term Â ExercisePrice PerShare Â Â Exercisedduring theYear EndedDecember 31,2023 Â Â Outstanding atDecember 31,2023 Â Â Exercisedduring theNineMonths EndedSeptember 30, 2024 Â Â Outstanding atSeptember 30, 2024 Â March 2023 Options - Series A Â March 2023 Â 5Â years Â $ 9.00 Â Â Â â€” Â Â Â 666,334 Â Â Â â€” Â Â Â 666,334 Â March 2023 Options - Series B (2) Â March 2023 Â 1.5Â years Â $ 9.00 Â Â Â â€” Â Â Â 666,334 Â Â Â â€” Â Â Â â€” Â March 2023 Placement Agent Options Â March 2023 Â 5Â years Â $ 11.25 Â Â Â â€” Â Â Â 33,317 Â Â Â â€” Â Â Â 33,317 Â August 2022 Options (1) Â August 2022 Â 5 years Â $ 9.00 Â Â Â â€” Â Â Â 118,063 Â Â Â â€” Â Â Â 118,063 Â August 2022 Placement Agent Options Â August 2022 Â 5 years Â $ 52.80 Â Â Â â€” Â Â Â 5,904 Â Â Â â€” Â Â Â 5,904 Â Total Â Â Â Â Â Â Â Â Â â€” Â Â Â 1,489,952 Â Â Â â€” Â Â Â 823,618 Â (1) These options were repriced as part of the March 2023 Private Placement offering.(2) These warrants expired during the nine months ended September 30, 2024. 12. Stock-Based Compensation and Employee Stock Purchase ProgramStock Incentive PlansThe Company has two equity incentive plans: the 2006 Stock Plan (â€œ2006 Planâ€) and the 2015 Omnibus Equity Incentive Plan (â€œ2015 Planâ€).In 2006, the Company adopted the 2006 Plan, which provided for the granting of stock options to executives, employees, and other service providers under terms and provisions established by the Board of Directors. The Company granted non-statutory stock options (â€œNSOsâ€) under the 2006 Plan until May 2015, when it was terminated as to future awards, although it continues to govern the terms of options that remain outstanding and were issued under the 2006 Plan. The 2015 Plan became effective upon the Companyâ€™s IPO in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 3,860 shares of common stock reserved for future issuance, which included 259 that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan. The maximum number of shares that may be awarded to any individual employee, including our directors and officers, during any calendar year was 9,375 shares. The 2015 Plan provides for the grant of incentive stock options (â€œISOsâ€), NSOs, restricted stock awards, stock units, stock appreciation rights, and other forms of equity compensation, all of which may be granted to employees, officers, non-employee directors, and consultants. The exercise price for ISOs and NSOs will be granted at a price per share not less than the fair value of our common stock at the date of grant. Options granted generally vest over a four-year period; however, there might be alternative vesting schedules, as approved by the Board. Options granted, once vested, are generally exercisable for up to 10 years, after grant to the extent vested.On June 25, 2024, the shareholders approved an amendment to the Companyâ€™s 2015 Plan that increased the number of shares of common stock that may be issued under the 2015 Plan by 200,000 shares and increased the maximum number of shares of common stock issuable to employees, including our officers and directors, in any fiscal year from 9,375 shares to 50,000 shares. On February 2, 2022, former president and chief executive officer of the Company, Stanley Jacot, Jr. was hired. The Company granted Mr. Jacot an inducement stock option to purchase 7,902 shares of the Companyâ€™s common stock pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The Company filed a registration statement on Form S-8 to register the issuance of shares upon exercise of this inducement stock option. The inducement options grants were issued outside of the 2015 Plan, but are subject to the terms and conditions of the 2015 Plan. As of September 30, 2024, a total of 338,248 shares of common stock were reserved for issuance under the 2015 Plan, of which 127,725 shares of common stock are available for future grant. As of September 30, 2024, a total of 102 and 210,523 options are outstanding under the 2006 and 2015 Plans, respectively. As of December 31, 2023, a total of 102 and 71,609 options were outstanding under the 2006 and 2015 Plans, respectively. A total of 6,949 and 8,366 inducement options were outstanding as of September 30, 2024 and December 31, 2023, respectively. 15 Â The following is a summary of stock option information and weighted average exercise prices under the Companyâ€™s stock incentive plans (in thousands, except share data and price per share):Â Â Â SharesSubject toOutstandingOptions Â Weighted-AverageExercisePrice PerShare Â Â AggregateIntrinsicValue Â Outstanding â€” Balance at December 31, 2023 Â Â 80,078 Â Â $ 85.30 Â Â $ â€” Â Options granted Â Â 158,000 Â Â Â 2.71 Â Â Â â€” Â Options forfeited Â Â (7,927) Â Â 19.08 Â Â $ 397 Â Options expired Â Â (12,576) Â Â 170.08 Â Â Â â€” Â Outstanding â€” Balance at September 30, 2024 Â Â 217,575 Â Â $ 22.83 Â Â $ 3,140 Â Vested and expected to vest â€” September 30, 2024 Â Â 198,542 Â Â $ 24.68 Â Â $ 2,778 Â Exercisable â€” September 30, 2024 Â Â 50,515 Â Â $ 84.37 Â Â $ â€” Â Â Aggregate intrinsic value represents the difference between the exercise price of the options and the estimated fair value of the Companyâ€™s common stock determined by its Board of Directors for each of the respective periods.As of September 30, 2024, there was $524,000 of unrecognized compensation cost related to unvested stock-based compensation grants that will be recognized over the weighted-average remaining recognition period of 1.4 years.In determining the fair value of the stock-based awards, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine.Expected Termâ€”The expected term is the estimated period of time outstanding for stock options granted and was estimated based on a simplified method allowed by the SEC, and defines the term as the average of the contractual term of the options and the weighted-average vesting period for all open employee awards.Expected Volatilityâ€”The historical volatility data was computed using the daily closing prices for the Companyâ€™s shares during the equivalent period of the calculated expected term of the stock-based awards.Risk-Free Interest Rateâ€”The risk-free interest rate is based on the interest rate of U.S. Treasuries of comparable maturities on the date the options were granted.Expected Dividendâ€”The expected dividend yield is based on the Companyâ€™s expectation of future dividend payouts to common stockholders.The fair value of stock option awards was estimated at the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumption:Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Expected term (years) Â Â 8.04 Â Â Â â€” Â Â Â 8.04 Â Â Â 7.06 Â Expected volatility Â Â 101.31 % Â Â â€” Â Â 101.31 % Â Â 124 % Risk-free interest rate Â Â 3.77 % Â Â â€” Â Â 3.77 % Â Â 3.61 % Dividend yield Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â The Company recognized $155,000 and $395,000 of compensation expense for stock options awards during the three and nine months ended September 30, 2024, respectively. The Company recognized $162,000 and $573,000 of compensation expense for stock options awards during the three and nine months ended September 30, 2023, respectively. 16 Â Employee Stock Purchase PlanThe Companyâ€™s 2015 Employee Stock Purchase Plan (â€œESPPâ€) became effective on May 14, 2015. The ESPP allows eligible employees to purchase shares of the Companyâ€™s common stock at a discount of up to 15% of their eligible compensation through payroll deductions, subject to any plan limitations. After the first offering period, which began on May 14, 2015 and ended on February 1, 2016, the ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Companyâ€™s common stock on the first trading day of the offering period or on the last day of the offering period. As of September 30, 2024, the number of shares of common stock reserved for future issuance under the ESPP is 3,209. The ESPP provides for automatic annual increases in the shares available for purchase beginning on January 1, 2016. As of September 30, 2024, 8,073 shares had been issued under the ESPP. The Company recorded $2,000 and $6,000 of ESPP related compensation expense during the three and nine months ended September 30, 2024, respectively. The Company recorded $7,000 and $12,000 of ESPP related compensation expense during the three and nine months ended September 30, 2023, respectively. 13. Income TaxesIncome tax expense during interim periods is based on applying an estimated annual effective income tax rate to year-to-date income, plus any significant unusual or infrequently occurring items that are recorded in the interim period. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in various jurisdictions, permanent and temporary differences, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, additional information becomes known, or as the tax environment changes.The interim financial statement provision for income taxes is different from the amounts computed by applying the United States federal statutory income tax rate of 21%. The Companyâ€™s effective tax rate was 0.00% for each of the three and nine months ended September 30, 2024 and 2023. The difference between the effective tax rate and the federal statutory rate of 21% was primarily due to the full valuation allowance recorded on the Companyâ€™s net deferred tax assets.During the nine months ended September 30, 2024, there were no material changes to the Companyâ€™s uncertain tax positions.In February 2023, the Company received notification from the Internal Revenue Service ("IRS") that our Archipelago joint venture was selected for audit for the 2021 tax year. The Company received the IRS Notice of Proposed Partnership Adjustment during the third quarter of 2024 and accepted the adjustments. The Company is now awaiting the IRS Final Partnership Adjustment ("FPA"). Reception of the FPA will start a 45-day clock on making the push out election, to push the audit adjustments to the partners. Upon conclusion of the audit, Arcadia expects to adjust their balance of available tax net operating losses and have no penalties or interest due. The Company is currently not under audit for state purposes. 14. Commitments and ContingenciesLeasesThe Company leases office and warehouse space and equipment under operating lease agreements having initial lease terms ranging from one to five years, including certain renewal options available to the Company at market rates. The Company also leases land for field trials on a short-term basis. See Note 9.Legal MattersFrom time to time, in the ordinary course of business, the Company may become involved in certain legal proceedings. The Company currently is not a party to any material litigation or other material legal proceedings.Contingent Liability Related to the Anawah Acquisition In June 2005, the Company completed its agreement and plan of merger and reorganization with Anawah, to purchase the Anawahâ€™s food and agricultural research company through a non-cash stock purchase. Pursuant to the merger with Anawah, and in accordance with the ASC 805 - Business Combinations, the Company incurred a contingent liability not to exceed $5.0 million. This liability represents amounts to be paid to Anawahâ€™s previous stockholders for cash collected on revenue recognized by the Company upon commercial sale of certain specific products developed using technology acquired in the purchase. During 2010, the Company ceased activities relating to three of the six Anawah product programs thus, the contingent liability was reduced to $3.0 million. During 2016, one of the programs previously accrued for was abandoned and another program previously abandoned was reactivated. During 2019, the Company determined that one of the technologies was no longer active and decided to abandon the previously accrued program. As of September 30, 2024, the Company continues to pursue or are otherwise liable for a total of two development programs using this technology and believes that the contingent liability is probable. As a result, $2.0 million remains on the condensed consolidated balance sheet as an other noncurrent liability.ContractsThe Company has entered into contract research agreements with unrelated parties that require the Company to pay certain funding commitments. The initial terms of these agreements range from one to three years in duration and in certain cases are cancelable. 17 Â The Company licenses certain technologies via executed agreements (â€œIn-Licensing Agreementsâ€) that are used to develop and advance the Companyâ€™s own technologies. The Company has entered into various In-Licensing Agreements with related and unrelated parties that require the Company to pay certain license fees, royalties, and/or milestone fees. In addition, certain royalty payments ranging from 2% to 15% of net revenue amounts as defined in the In-Licensing Agreements are or will be due.The Company could be adversely affected by certain actions by the government as it relates to government contract revenue received in prior years. Government agencies, such as the Defense Contract Audit Agency routinely audit and investigate government contractors. These agencies review a contractorâ€™s performance under its agreements; cost structure; and compliance with applicable laws, regulations and standards. The agencies also review the adequacy of, and a contractorâ€™s compliance with, its internal control systems and policies, including the contractorâ€™s purchasing, property, estimating, compensation and management information systems. While the Companyâ€™s management anticipates no adverse result from an audit, should any costs be found to be improperly allocated to a government agreement, such costs will not be reimbursed, or if already reimbursed, may need to be refunded. If an audit uncovers improper or illegal activities, civil and criminal penalties and administrative sanctions, including termination of contracts, forfeiture of profits, suspension of payments or fines, and suspension or prohibition from doing business with the government could occur. In addition, serious reputational harm or significant adverse financial effects could occur if allegations of impropriety were made against the Company. 15. Net Loss per ShareBasic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per share attributable to common stockholders is computed giving effect to all potentially dilutive common shares, including common stock issuable upon exercise of stock options and warrants. Dilutive securities are not included in the computation of net loss per share when the impact would be anti-dilutive. Securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows (in shares):Â Â Â Three Months Ended September 30, Â Â For the Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Options to purchase common stock Â Â 217,575 Â Â Â 84,058 Â Â Â 217,575 Â Â Â 84,058 Â Warrants to purchase common stock Â Â 259,817 Â Â Â 266,957 Â Â Â 259,817 Â Â Â 266,957 Â Preferred investment options Â Â 823,618 Â Â Â 1,489,952 Â Â Â 823,618 Â Â Â 1,489,952 Â Total Â Â 1,301,010 Â Â Â 1,840,967 Â Â Â 1,301,010 Â Â Â 1,840,967 Â Â 16. Related-Party TransactionsThe Companyâ€™s related parties include Moral Compass Corporation (â€œMCCâ€) and the John Sperling Foundation (â€œJSFâ€). The rights to the intellectual property owned by Blue Horse Labs, Inc. (â€œBHLâ€) were assigned to its sole shareholder, the John Sperling Revocable Trust (â€œJSRTâ€) due to BHLâ€™s dissolution and then subsequently to the JSF. The JSF is deemed a related party of the Company because MCC, one of the Companyâ€™s largest stockholder, and the JSF share common officers and directors.JSF receives a single digit royalty from the Company when revenue has been collected on product sales or for license payments from third parties that involve certain intellectual property developed under research funding originally from BHL. Royalty fees due to JSF were $30,000 and $58,000 as of September 30, 2024 and December 31, 2023, respectively, and are included in the condensed consolidated balance sheets as amounts due to related parties. 18 Â ITEM 2. MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Special Note Regarding Forward-Looking Statements The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and the related notes to those statements included herein. In addition to historical financial information, this report contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed in the forward-looking statements. The statements contained in this report that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements are often identified by the use of words such as, but not limited to, â€œanticipate,â€ â€œbelieve,â€ â€œcan,â€ â€œcontinue,â€ â€œcould,â€ â€œestimate,â€ â€œexpect,â€ â€œintend,â€ â€œmay,â€ â€œplan,â€ â€œproject,â€ â€œseek,â€ â€œshould,â€ â€œstrategy,â€ â€œtarget,â€ â€œwill,â€ â€œwouldâ€ and similar expressions or variations intended to identify forward-looking statements. These statements are based on the beliefs and assumptions of our management based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section titled â€œRisk Factorsâ€ included in the most recent Annual Report on Form 10-K filed by the Company. Furthermore, such forward-looking statements speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements. Solely for convenience, the trademarks, service marks and trade names referred to in this report may appear

without the Â®, TM, or SM symbols, but such references do not constitute a waiver of any rights that might be associated with the respective trademarks, service marks, or trade names. Overview Since acquiring the assets of Live Zola, LLC ("Zola") in May 2021, the Company has provided consumers with a great tasting way to rehydrate, reset, and reenergize with Zola coconut water products. The company has leveraged its history as a leader in science-based approaches to develop high value products and drive innovation in the consumer goods industry. Previously, the Company developed products primarily in wheat, which it commercialized through the sales of seed, grain and food ingredients and products, and through trait licensing and royalty agreements. On May 16, 2024, the Company sold the GoodWheatâ„¢ brand to Above Food Ingredients Corp. ("Above Food") for net consideration of $3.7 million. Refer to Note 6 to the condensed consolidated financial statements for further details of the transaction. On May 14, 2024, the Company sold its non-GMO Resistant Starch ("RS") durum wheat trait to longtime partner Corteva AgriScience ("Corteva"). Under the terms of the agreement, Arcadia retained certain rights to use the RS durum wheat trait. The Company received $4.0 million in cash payment from Corteva during the nine months ended September 30, 2024 and recorded a gain of the same amount as the trait had no carrying value on the condensed consolidated statement of operations and comprehensive loss related to the transaction. Refer to Note 8 to the condensed consolidated financial statements for further details of the partnership and transaction. In May 2021, the Companyâ€™s wholly owned subsidiary Arcadia Wellness, LLC (â€œArcadia Wellnessâ€ or â€œAWâ€) acquired the businesses of Eko Holdings, LLC, Lief, LLC, and Zola. The acquisition included Saavy Naturalsâ„¢, a line of natural body care products, Soul Springâ„¢, a CBD-infused botanical therapy brand in the natural category, and ProVaultâ„¢, a THC-free CBD sports performance formula made with natural ingredients, providing effective support and recovery for athletes (collectively, "body care brands"). Also included in the purchase was Zola, a coconut water sourced exclusively with sustainably grown coconuts from Thailand. In July 2022, the Company entered into an agreement to license Saavy Naturals to Radiance Beauty and Wellness, Inc. ("Radiance Beauty"). In July 2023, management made the decision to exit the remaining body care brands, Soul Spring and ProVault, as a result of continued pressure on the CBD market due to regulatory uncertainty. Body care operations ceased during the third quarter of 2023. 19 Â Our Growth Strategy We believe there are significant opportunities to grow our business by executing the following elements of our strategy: â€¢Scale Zola through retail expansion. Based on our research, consumers prefer the clean, crisp taste of Zola to that of other leading coconut water brands. As a result, we plan to continue to invest in trial-driving activities and expand distribution of our Zola coconut water brand through mass market retailers and grocery store chains. â€¢Monetization of our wheat trait portfolio. Our proprietary intellectual property ("IP") with multiple non-GMO wheat traits have clear functional benefits, which we utilized to launch the GoodWheat brand into multiple categories. We believe our wheat provides a compelling point of difference and we will continue to evaluate ways to extract value from our proprietary technology. â€¢Evaluate M&A opportunities. We intend to evaluate potential asset sales, mergers, acquisitions and other strategic opportunities. Our Product Portfolio Zola Coconut Water Founded in 2002, Zola became part of the Arcadia family of brands in May 2021. Sourced from Thailand, Zola is a pure, natural, 100% coconut water with a crisp, clean taste thatâ€™s slightly sweet and refreshing. Naturally hydrating and rich in electrolytes, Zola is Non-GMO Project Verified and only contains 60 calories per serving. In taste tests, Zola beat competitors 2 to 1 and is the best tasting way to rehydrate, reset and reenergize. Zola flavors include original, original with pulp, and espresso, and in May 2024, we added lime and pineapple. Wheat Traits RG Wheat Many consumers are interested in reducing levels of gluten in their diet. Critically, for some, this is due to having Celiac disease ("CD"), an autoimmune disease that impacts many people worldwide with estimates from 1% of the population in Europe to 3.5% in Mexico. Furthermore, non-celiac gluten sensitivity ("NCGS") impacts an estimated additional 6% of the population. Both CD and NCGS are characterized by sensitivity to dietary gluten. The only effective treatment of CD and NCGS requires removal of gluten sources from the diet. Since required adherence to a gluten-free diet is extremely difficult to accomplish for average consumers, efforts to develop alternative approaches are needed. Our proprietary, non-GMO wheat variety developed using advanced screening and plant breeding techniques have reduced allergenic glutens and increased essential amino acids such as lysine, along with all the other health benefits of high protein wheat. Importantly, this variety also delivers impressively high fiber content at approximately 14 grams per serving compared to 2-3 grams per serving of traditional wheat, providing additional value to health-conscious consumers. Improved Shelf Life of Whole Grain Flour The United States Department of Agriculture recommends that â€œeat least one serving of grains per day must be whole grain-richâ€ due to evidence that a diet containing whole grains provides a multitude of benefits, including lower risk of obesity, cardiovascular disease, and type-2 diabetes. Despite these health benefits, consumption of whole grain products is negatively affected by the bitter and rancid flavors and odors that accumulate in whole wheat flour after milling. Our improved stability and flavor wheat lines greatly reduced the production of rancid and bitter compounds in milled whole grain flour as it progresses through the supply chain. 20 Â Discontinued Operations As mentioned above, the Company exited the GoodWheat and body care brands. In accordance with the provisions of ASC 205-20, the Company has separately reported the assets and liabilities of the discontinued operations in the condensed consolidated balance sheets and the results of the discontinued operations as separate components on the condensed consolidated statements of operations and comprehensive loss for all periods presented. See Note 1 to the condensed consolidated financial statements for further information on discontinued operations. Components of Our Statements of Operations Data Revenues Product revenues Product revenues consist primarily of sales of Zola and GLA products. We recognize revenue from product sales when control of the product is transferred to third-party distributors and manufacturers, collectively â€œour customers,â€ which generally occurs upon delivery. Revenues fluctuate depending on the timing of shipments of product to our customers and are reported net of estimated chargebacks, returns and losses. License revenues License revenues consist of up-front, nonrefundable license fees, annual license fees, and subsequent milestone payments that we receive under our license agreements. Revenue generated from up-front license fees are recognized upon execution of the agreement. We recognize annual license fees when it is probable that a material reversal will not occur. Operating Expenses Cost of revenues Cost of revenues primarily relates to the sale of Zola products and consists primarily of product and freight costs. Adjustments or write-downs to inventory are also included in cost of revenues. Research and development expenses ("R&D") Research and development expenses consist of costs incurred in the development and testing of our products and other products in development incorporating our traits. These expenses currently consist primarily of fees paid to product formulation consultants and are expensed as incurred. Additionally, the Company is required from time to time to make certain milestone payments in connection with the development of technologies in-licensed from third parties. The Company's research and development expenses may fluctuate from period to period. Gain on sale of intangible assets Gain on sale of intangible assets consists of the gain on sale of our RS durum wheat trait to Corteva. Impairment of property and equipment Impairment of property and equipment includes losses from tangible assets due to impairment or recoverability test charges to write down fixed assets to their fair value or recoverability value. Â Selling, general and administrative expenses Selling, general and administrative expenses consist primarily of employee costs, professional service fees, broker and sales commission fees, and overhead costs. Our selling, general, and administrative expenses may fluctuate from period to period. 21 Â Interest income Interest income consists of interest income on our cash and cash equivalents, investments and note receivable. Other income, net Other income, net consists of miscellaneous income net of miscellaneous losses. Valuation loss on March 2023 PIPE Valuation loss on March 2023 PIPE includes the fair value in excess of gross proceeds and the increase in fair value related to the re-pricing of existing warrants. Change in the estimated fair value of common stock warrant and option liabilities Change in the estimated fair value of common stock warrant and option liabilities is comprised of the fair value remeasurement of the liabilities associated with our financing transactions. Issuance and offering costs allocated to liability classified options Issuance and offering costs generally include placement agent, legal, advisory, accounting and filing fees related to financing transactions. Net loss from discontinued operations Net loss from discontinued operations represents results of operations related to the discontinued GoodWheat and body care brands. See Note 1 to the condensed consolidated financial statements for further information on discontinued operations. Results of Operations Comparison of the Three Months Ended September 30, 2024 and 2023 Â Â Â Three Months Ended September 30, Â Â $ Change Â Â % Change Â Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â (In thousands except percentage) Â Revenues: Â Â Â Â Â Â Â Â Â Â Â Â Product Â $ 1,537 Â Â $ 1,298 Â Â $ 239 Â Â Â 18 % License Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 0 % Total revenues Â Â 1,537 Â Â Â 1,298 Â Â Â 239 Â Â Â 18 % Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Cost of revenues Â Â 1,032 Â Â Â 818 Â Â Â 214 Â Â Â 26 % Research and development Â Â 24 Â Â Â 15 Â Â Â 9 Â Â Â 60 % Selling, general and administrative Â Â 2,241 Â Â Â 1,862 Â Â Â 379 Â Â Â 20 % Total operating expenses Â Â 3,297 Â Â Â 2,695 Â Â Â 602 Â Â Â 22 % Loss from continuing operations Â Â (1,760) Â Â (1,397) Â Â (363) Â Â (26)% Interest income Â Â 233 Â Â Â 133 Â Â Â 100 Â Â Â 75 % Other income, net Â Â 15 Â Â Â 17 Â Â Â (2) Â Â (12)% Change in fair value of common stock warrant and option liabilities Â Â 330 Â Â Â 608 Â Â Â (278) Â Â (46)% Net loss from continuing operations before income taxes Â Â (1,182) Â Â (639) Â Â (543) Â Â 85 % Income tax provision Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 0 % Net loss from continuing operations Â Â (1,182) Â Â (639) Â Â (543) Â Â 85 % Net loss from discontinued operations â€” Body Care Â Â â€” Â Â Â (83) Â Â 83 Â Â Â (100)% Net loss from discontinued operations â€” GoodWheat Â Â (430) Â Â (1,845) Â Â 1,415 Â Â Â (77)% Net loss Â Â (1,612) Â Â (2,567) Â Â 955 Â Â Â (37)% Net loss attributable to non-controlling interest Â Â â€” Â Â Â â€” Â Â Â 0 % Net loss attributable to common stockholders Â $ (1,612) Â $ (2,567) Â $ 955 Â Â Â (37)% Â 22 Â Revenues Product revenues accounted for 100% of total revenues during the three months ended September 30, 2024. Product revenues increased $239,000, or 18%, during the three months ended September 30, 2024 compared to the same period in 2023 driven by an increase in Zola sales. Cost of revenues Cost of revenues increased by $214,000, or 26%, during the three months ended September 30, 2024 compared to the same period in 2023 driven by higher revenues and input costs. Research and development Research and development expenses increased by $9,000, or 60%, during the three months ended September 30, 2024 compared to the same period in 2023. Selling, general, and administrative Selling, general, and administrative expenses increased by $379,000, or 20%, during the three months ended September 30, 2024 compared to the same period in 2023 primarily driven by employee severance expenses related to the change in management. Interest income During the three months ended September 30, 2024, the Company recognized interest income of $233,000, of which $186,000 was related to discount amortization and accrued interest on the promissory note from Above Food. The remaining difference was related to interest from investments. During the three months ended September 30, 2023, the Company recognized interest income of $133,000 from investments. Other income, net During the three months ended September 30, 2024 and 2023, the Company recognized other income of $15,000 and $17,000, respectively. Change in the estimated fair value of common stock warrant and option liabilities The change in the estimated fair value of common stock warrant and option liabilities resulted in a gain of $330,000 and $608,000 during the three months ended September 30, 2024 and 2023, respectively, related to the change in the estimated fair value of the liability classified preferred investment options issued in connection with the March 2023 PIPE and August 2022 Registered Direct Offering financing transactions. Net loss from discontinued operations Net loss from discontinued operations for Body Care was $83,000 during the three months ended September 30, 2023. Net loss from discontinued operations for GoodWheat was $430,000 and $1.8 million during the three months ended September 30, 2024 and 2023, respectively. See Note 1 to the condensed consolidated financial statements for further information on discontinued operations. 23 Â Comparison of the Nine Months Ended September 30, 2024 and 2023 Â Â Â Nine Months Ended September 30, Â Â $ Change Â Â % Change Â Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â (In thousands except percentage) Â Revenues: Â Â Â Â Â Â Â Â Â Â Â Â Product Â $ 3,829 Â Â $ 3,667 Â Â $ 162 Â Â Â 4 % License Â Â â€” Â Â Â 10 Â Â Â (10) Â Â (100)% Total revenues Â Â 3,829 Â Â Â 3,677 Â Â Â 152 Â Â Â 4 % Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Cost of revenues Â Â 2,136 Â Â Â 1,996 Â Â Â 140 Â Â Â 7 % Research and development Â Â 40 Â Â Â 55 Â Â Â (15) Â Â (27)% Gain on sale of intangible assets Â Â (4,000) Â Â â€” Â Â Â (4,000) Â Â 100 % Impairment of property and equipment Â Â 36 Â Â Â â€” Â Â Â 36 Â Â Â (100)% Selling, general and administrative Â Â 6,986 Â Â Â 6,535 Â Â Â 451 Â Â Â 7 % Total operating expenses Â Â 5,198 Â Â Â 8,586 Â Â Â (3,388) Â Â (39)% Loss from continuing operations Â Â (1,369) Â Â (4,909) Â Â 3,540 Â Â Â (72)% Interest income Â Â 428 Â Â Â 538 Â Â Â (110) Â Â (20)% Other income, net Â Â 168 Â Â Â 36 Â Â Â 132 Â Â Â 367 % Valuation loss on March 2023 PIPE Â Â â€” Â Â Â (6,076) Â Â 6,076 Â Â Â (100)% Change in fair value of common stock warrant and option liabilities Â Â 493 Â Â Â 5,965 Â Â Â (5,472) Â Â (92)% Issuance and offering costs allocated to liability classified options Â Â â€” Â Â Â (430) Â Â 430 Â Â Â (100)% Net loss from continuing operations before income taxes Â Â (280) Â Â (4,876) Â Â 4,596 Â Â Â (94)% Income tax provision Â Â â€” Â Â Â (1) Â Â 1 Â Â Â (100)% Net loss from continuing operations Â Â (280) Â Â (4,877) Â Â 4,597 Â Â Â (94)% Net loss from discontinued operations â€” Body Care Â Â â€” Â Â Â (591) Â Â 591 Â Â Â (100)% Net loss from discontinued operations â€” GoodWheat Â Â (2,694) Â Â (5,665) Â Â 2,971 Â Â Â (52)% Net loss Â Â (2,974) Â Â (11,133) Â Â 8,159 Â Â Â (73)% Net loss attributable to non-controlling interest Â Â â€” Â Â Â (5) Â Â 5 Â Â Â (100)% Net loss attributable to common stockholders Â $ (2,974) Â $ (11,128) Â $ 8,154 Â Â Â (73)% Revenues Product revenues accounted for 100% of total revenues during the nine months ended September 30, 2024. Product revenues increased $162,000, or 4%, during the nine months ended September 30, 2024 compared to the same period in 2023 driven by an increase in Zola sales. Cost of revenues Cost of revenues increased by $140,000, or 7%, during the nine months ended September 30, 2024 compared to the same period in 2023 driven by higher revenues and input costs. Research and development Research and development expenses decreased by $15,000, or 27%, during the nine months ended September 30, 2024 compared to the same period in 2023. Gain on sale of intangible assets During the nine months ended September 30, 2024, the Company realized a gain of $4.0 million related to the sale of its RS durum wheat trait to Corteva. There was no such gain recorded during the nine months ended September 30, 2023. Impairment of property and equipment During the nine months ended September 30, 2024, the Company recognized impairment of property and equipment held for sale of $36,000. There was no such impairment of property and equipment during the nine months ended September 30, 2023. 24 Â Selling, general, and administrative Selling, general, and administrative expenses increased by $451,000, or 7%, during the nine months ended September 30, 2024 compared to the same period in 2023 primarily driven by employee severance expenses related to the change in management as well as higher consulting and legal expenses. Interest income During the nine months ended September 30, 2024, the Company recognized interest income of $428,000, of which $282,000 was related to discount amortization and accrued interest on the promissory note from Above Food. The remaining difference was related to interest from investments. During the nine months ended September 30, 2023, the Company recognized interest income of $538,000 from investments. Other income, net During the nine months ended September 30, 2024, the Company recognized other income of $168,000, of which $117,000 was related to realized gains on investments. During the nine months ended September 30, 2023, the Company recognized other income of $36,000. Valuation loss on March 2023 PIPE During the nine months ended September 30, 2023, the Company recognized a $6.1 million valuation loss related to the March 2023 PIPE financing transaction. The valuation loss includes the fair value in excess of gross proceeds and the increase in fair value related to the re-pricing of existing warrants. There was no such valuation loss during the nine months ended September 30, 2024. Change in the estimated fair value of common stock warrant and option liabilities The change in the estimated fair value of common stock warrant and option liabilities resulted in a gain of $493,000 and $6.0 million during the nine months ended September 30, 2024 and 2023, respectively, related to the change in the estimated fair value of the liability classified preferred investment options issued in connection with the March 2023 PIPE and August 2022 Registered Direct Offering financing transactions. Issuance and offering costs allocated to liability classified options Issuance and offering costs were $430,000 during the nine months ended September 30, 2023 and were related to the liability classified options issued in the March 2023 PIPE financing transaction. There were no such issuance and offering costs during the nine months ended September 30, 2024. Net loss from discontinued operations Net loss from discontinued operations for Body Care was $591,000 during the nine months ended September 30, 2023. Net loss from discontinued operations for GoodWheat was $2.7 million and $5.7 million during the nine months ended September 30, 2024 and 2023, respectively. See Note 1 to the condensed consolidated financial statements for further information on discontinued operations. Seasonality The coconut water category, similar to other beverages, is seasonal. Generally, sales volumes are highest during our second and third fiscal quarters when the weather is warmer. 25 Â Liquidity & Capital Resources We have funded our operations primarily with the net proceeds from our private and public offerings of our equity securities as well as proceeds from the sale of our products and payments under license agreements. Our principal use of cash is to fund our operations, which are primarily focused on commercializing our products. Our contractual obligations are primarily related to our operating leases for facilities, land and equipment. As of September 30, 2024, we had cash and cash equivalents of $3.9 million, short-term investments of $2.6 million and current note receivable of $1.8 million. For the nine months ended September 30, 2024, the Company had net losses of $3.0 million and net cash used in operations of $7.4 million. For the twelve months ended December 31, 2023, the Company had net losses of $14.0 million and net cash used in operations of $15.3 million. Going Concern We believe that our existing cash and cash equivalents, short-term investments and current note receivable will not be sufficient to meet our anticipated cash requirements for at least the next 12-18 months from the issuance date of these financial statements, and thus raises substantial doubt about the Companyâ€™s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. We may seek to raise additional funds through debt or equity financings, if necessary. We may also consider entering into additional partner

arrangements. Any sale of additional equity would result in dilution to our stockholders. Our incurrence of debt would result in debt service obligations, and the instruments governing our debt could provide for additional operating and financing covenants that would restrict our operations. If we require additional funds and are not able to secure adequate additional funding, we may be forced to reduce our spending, extend payment terms with our suppliers, liquidate assets, or suspend or curtail planned product launches. Any of these actions could materially harm our business, results of operations and financial condition. Liquidity The following table summarizes total current assets, current liabilities and working capital for the dates indicated (in thousands): Â Â Â As ofSeptember 30, Â Â As ofDecember 31, Â Â Â 2024 Â Â 2023 Â Current assets Â $ 10,711 Â Â $ 14,972 Â Current liabilities Â Â 2,328 Â Â Â 3,590 Â Working capital surplus Â $ 8,383 Â Â $ 11,382 Â Cash Flows The following table summarizes our cash flows for the periods indicated (in thousands): Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Net cash (used in) provided by: Â Â Â Â Â Â Operating activities Â $ (7,418) Â $ (11,149) Investing activities Â Â 4,827 Â Â Â (4,396) Financing activities Â Â 9 Â Â Â 5,512 Â Net decrease in cash Â $ (2,582) Â $ (10,033) Â Cash flows from operating activities Cash used in operating activities for the nine months ended September 30, 2024, was $7.4 million. With respect to our net loss of $3.0 million, non-cash charges including $92,000 of depreciation, $502,000 of lease amortization, $395,000 of stock-based compensation, $154,000 of write-downs of inventory, and $36,000 of impairment of property and equipment, were offset by the change in fair value of common stock warrant and option liabilities of $493,000, amortization of note receivable discount of $90,000, a gain on disposal of property and equipment of $65,000, gain on sale of RS durum wheat trait of $4.0 million, adjustments in our working capital accounts of $297,000, and operating lease payments of $678,000. Cash used in operating activities for the nine months ended September 30, 2023, was $11.1 million. With respect to our net loss of $11.1 million, non-cash charges, including $430,000 of issuance and offering costs, $6.1 million of valuation loss recognized for the March 2023 PIPE, $573,000 of stock-based compensation, $535,000 of lease amortization, $227,000 of depreciation and $444,000 of write-downs of inventory, were offset by the change in fair value of common stock warrant and option liabilities of $6.0 million, adjustments in our working capital accounts of $1.7 million, a gain on disposal of property and equipment of $36,000, and operating lease payments of $573,000. 26 Â Cash flows from investing activities Cash provided by investing activities for the nine months ended September 30, 2024 consisted of proceeds of $342,000 from the sale of property and equipment, proceeds from the sale of investments of $2.5 million, proceeds from the sale of our RS durum wheat trait of $4.0 million, offset by cash paid related to the GoodWheat sale of $2.0 million and $16,000 of purchases of property and equipment. Cash used in investing activities for the nine months ended September 30, 2023 consisted of proceeds of $42,000 from the sale of property and equipment as well as proceeds of $569,000 from the sale of Verdeca, offset by $5,000 of purchases of property and equipment and $5.0 million of purchases of investments. Â Cash flows from financing activities Â Cash provided by financing activities for the nine months ended September 30, 2024 consisted of proceeds from the purchase of ESPP shares of $9,000. Â Cash provided by financing activities for the nine months ended September 30, 2023 consisted of gross proceeds of $6.0 million from the March 2023 PIPE financing transaction and proceeds from the purchase of ESPP shares of $12,000, which were offset by payments of transaction costs related to the March 2023 PIPE financing transaction of $497,000. Â Off-Balance Sheet Arrangements Since our inception, we have not engaged in any off-balance sheet arrangements, including the use of structured finance, special purpose entities, or variable interest entities other than Verdeca, which was disposed of in November 2020. Critical Accounting Policies and Estimates Our managementâ€™s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated, and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We consider our critical accounting policies and estimates to be revenue recognition, determination of the provision for income taxes, and net realizable value of inventory. 27 Â ITEM 3: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Not Required. ITEM 4: CONTROLS AND PROCEDURES Evaluation of Disclosure Controls and Procedures We maintain â€œdisclosure controls and procedures,â€ as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, or Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our President and Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Our disclosure controls and procedures have been designed to meet reasonable assurance standards. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Based on their evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, our President and Chief Executive Officer and our Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level. Changes in Internal Control over Financial Reporting There were no changes in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) identified in connection with the evaluation identified above that occurred during the quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 28 Â PART II. OTHER INFORMATION ITEM 1. LEGAL PROCEEDINGS Â We currently are not a party to any material litigation or other material legal proceedings. From time to time, we may be subject to legal proceedings and claims in the ordinary course of business. ITEM 1A. RISK FACTORS In addition to the other information set forth in this Quarterly Report, you should carefully consider the factors discussed in Part I, â€œItem 1A. Risk Factorsâ€ in our Annual Report on Form 10-K for the year ended December 31, 2023, which could materially affect our business, financial condition, liquidity or future results. The risks described in our Annual Report on Form 10-K are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, liquidity or future results. ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS None. ITEM 3. DEFAULTS UPON SENIOR SECURITIES None. ITEM 4. MINE SAFETY DISCLOSURES Not applicable. ITEM 5. OTHER INFORMATION During the quarter ended September 30, 2024, no director or â€œofficerâ€ (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated a â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangement,â€ as each term is defined in Item 408(a) of Regulation S-K. 29 Â ITEM 6. EXHIBITS The following exhibits are attached hereto or are incorporated herein by reference. Â Â Â Â Â Incorporated by Reference Â Â ExhibitNumber Exhibit Description Â Form Â File No. Â Exhibit Â Filing Date Â Filed Herewith Â Â Â Â Â Â Â Â Â Â Â Â Â Â 10.1+ Â Employment Letter and Severance and Change In Control Agreement for Thomas J. Schaefer Â 8-K/A Â 001-37383 Â 10.1 Â 8/23/2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â 10.2+ Â Employment Letter and Severance and Change In Control Agreement for Mark Kawakami Â 8-K/A Â 001-37383 Â 10.2 Â 8/23/2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â 10.3+ Â Separation Agreement for Stanley Jacot, Jr. Â 8-K Â 001-37383 Â 10.1 Â 7/8/2024 Â 31.1 Principal Executive Officerâ€™s Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

link:calculationLink link:definitionLink 100080 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100090 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Description of Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Property and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Investments and Fair Value Instruments link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Note Receivable link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Consolidated Joint Venture link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Collaborative Arrangements link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Equity Financing link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Warrants and Options link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Stock-Based Compensation and Employee Stock Purchase Program link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Commitment and Contingencies link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Related-Party Transactions link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Description of Business and Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Description of Business and Basis of Presentation (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Investments and Fair Value Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Warrants and Options (Tables) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Stock-Based Compensation and Employee Stock Purchase Program (Tables) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Description of Business - Summary of Major Classes of Line Items Constituting the Balance Sheet on Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Description of Business and Basis of Presentation - Summary of Major Classes of Line Items Constituting Net Loss from Discontinued Operations (Detail) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Description of Business and Basis of Presentation - Non-cash Items of Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Inventory - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Inventory - Summary of Inventories (Detail) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Detail) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Property and Equipment, Net - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Investments and Fair Value Instruments - Summary of Amortized Cost and Fair Value of Investment Securities Portfolio (Detail) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Investments and Fair Value Instruments - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Investments and Fair Value Instruments - Summary of Fair Value of Investments Securities (Detail) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Investments and Fair Value Instruments - Summary of Preferred Investment Option Liabilities Measured and Recorded on Recurring Basis using Black-Scholes Model (Detail) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Investments and Fair Value Instruments - Summary of Changes in Fair Value and Other Adjustments of Assets and Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Note Receivable - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Consolidated Joint Venture - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Collaborative Arrangements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Leases - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Leases - Schedule of Leases (Detail) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Intangible Assets, Net - Schedule of Future Amortization of Intellectual Property and Customer Lists (Detail) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Equity Financing - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Warrants and Options - Summary of Warrants Issued to Purchase Common Stock (Detail) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - Warrants and Options - Summary of Warrants Issued to Purchase Common Stock (Parenthetical) (Detail) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - Warrants and Options - Summary of Key Terms and Activity of Liability Classified Preferred Investment Options (Detail) link:presentationLink link:calculationLink link:definitionLink 995945 - Disclosure - Stock-Based Compensation and Employee Stock Purchase Program - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995955 - Disclosure - Stock-Based Compensation and Employee Stock Purchase Program - Summary of Activity Under Stock Incentive Plans (Detail) link:presentationLink link:calculationLink link:definitionLink 995965 - Disclosure - Stock-Based Compensation and Employee Stock Purchase Program - Weighted-Average Fair Value Assumption of Stock Option Awards (Detail) link:presentationLink link:calculationLink link:definitionLink 995975 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995985 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995995 - Disclosure - Net Loss per Share - Summary of Securities Not Included in Diluted Per Share Calculations (Detail) link:presentationLink link:calculationLink link:definitionLink 996005 - Disclosure - Related-Party Transactions - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink Statement [Line Items] Statement [Line Items] Inventory, Current [Table] Reclassification adjustment for gains on available-for-sale securities included in net loss OCI, Debt Securities, Available-for-Sale, Transfer from Held-to-Maturity, Gain (Loss), before Adjustment, after Tax Raw materials Inventory Raw Materials Current And Non Current Inventory raw materials current and non-current. First offering period, end date First Offering Period End Date First offering period end date. Increase (Decrease) in Accounts Receivable Accounts receivable and other receivables Plan Name Plan Name [Domain] Proceeds from sale of property and equipment in accounts receivable and other receivables Proceeds From Sale Of Property And Equipment In Accounts Receivable And Other Receivables Proceeds from sale of property and equipment in accounts receivable and other receivables. Date of reincorporation Entity Reincorporation Date Of Reincorporation Entity reincorporation date of reincorporation. Office Space [Member] Office Building [Member] Discontinued Operations [Member] Initial recognition Fair Value Measurement Initial Recognition Fair Value Measurement Initial Recognition. Summary of Warrants Issued to Purchase Common Stock Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Disposal Group Name [Axis] Change in fair value of common stock warrant and option liabilities Change in fair value of common stock warrant and option liabilities Change in Fair Value of Common Stock Warrant and Option Liabilities Change in fair value of common stock warrant and option liabilities. May 2020 Placement Agent Warrants [Member] May2020 Placement Agent Warrants [Member] May 2020 placement agent warrants. Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Proceeds from Sale of Intangible Assets Proceeds from sale of RS durum wheat trait Revenues: Revenues [Abstract] March 2018 Offering [Member] March Two Thousand Eighteen Offering [Member] March two thousand eighteen offering. 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Four Weighted Average Exercise Price Per Share, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Percentage in payroll deductions to acquire shares of common stock Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Business acquisition activities, description Business Acquisition, Description of Acquired Entity Stockholders' Equity, Reverse Stock Split Reverse stock split Stockholders Equity, Beginning Balance, Shares Stockholders Equity, Ending Balance, Shares Shares, Outstanding Gain (Loss) on Disposition of Intangible Assets Gain on sale of intangible assets Gain on sale of collaborative arrangements Gain on sale of RS durum wheat trait Investment Income, Amortization of Discount Amortization of discount Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Laboratory equipment [Member] Laboratory Equipment [Member] Laboratory equipment. Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Payment for sale of disposal group, including discontinued operation. Payment For Sale Of Disposal Group, Including Discontinued Operation Cash paid related to sale of GoodWheat Warrant liabilities Warrant Liabilities Warrant liabilities. Leases Lessee, Operating Leases [Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Receivable with Imputed Interest, Discount Loan receivable, discount Lease Term and Discount Rate Operating Lease Term And Discount Rate [Abstract] Operating lease term and discount rate. Adjustments to additional paid in capital modification of warrants. Adjustments To Additional Paid In Capital Modification of Warrants Modification of warrants related to March 2023 PIPE Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Summary of Changes in Fair Value and Other Adjustments of Assets and Liabilities Product and Service Product and Service [Axis] Finite-Lived Intangible Assets by Major Class Finite-Lived Intangible Assets by Major Class [Axis] Investment, Name [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] NONCASH INVESTING AND FINANCING ACTIVITIES: Noncash Investing and Financing Items [Abstract] August 2022 Purchase Agreement [Member] August Two Thousand And Twenty Two Purchase Agreement [Member] August two thousand and twenty two purchase agreement. 2015 Employee Stock Purchase Plan [Member] Employee Stock [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Equity Financing Equity [Text Block] Title of Individual Title and Position [Axis] July 2020 Placement Agent Warrants [Member] July2020 Placement Agent Warrants [Member] July 2020 placement agent warrants. Class of Warrant or Right Class of Warrant or Right [Axis] Sale of Stock Sale of Stock [Domain] Disposal Group, Including Discontinued Operation, Assets [Abstract] Assets Share-based compensation arrangement by share-based payment award, forfeiture, intrinsic value. Share-based Compensation Arrangement by Share-based Payment Award, Forfeiture, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Options Forfeited December 2020 Placement Agent Warrants [Member] December Two Thousand Twenty Placement Agent Warrants [Member] December 2020 placement agent warrants. December Two Thousand and Twenty Two Service And Performance Warrants [Member] December Two Thousand and Twenty Two Service And Performance Warrants [Member] December 2022 Service and Performance Warrants [Member] October Two Thousand and Twenty Two Service And Performance Warrants [Member] October Two Thousand and Twenty Two Service And Performance Warrants [Member] October 2022 Service and Performance Warrants [Member] Fair value of promissory note receivable. Fair Value of Promissory Note Receivable Fair value of promissory note receivable Goods in process Inventory Goods In Process Current And Non Current Inventory goods ion process current and non current. Promissory note term. Promissory Note Term Promissory note term Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Entity Central Index Key Entity Central Index Key Schedule Of Available For Sale Securities [Line Items] Debt Securities, Available-for-Sale [Line Items] Warrants to Purchase Common Stock [Member] Warrants [Member] Warrant [Member] Promissory note principal receviable each year. Promissory Note Principal Receviable Each Year Promissory note principal receviable each year Shares Subject to Outstanding, Options Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Short term lease cost Short term lease cost Short Term Lease Cost And Cost Reclassifications Short term lease cost and cost (reclassifications). Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Proceeds from Divestiture of Businesses Net consideration from sale of brand Common Stock, Shares, Issued, Total Common stock, issued Common Stock, Shares, Issued Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Expected Dividend Yield [Member] Measurement Input, Expected Dividend Rate [Member] Increase (Decrease) in Prepaid Expense and Other Assets, Total Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Net loss from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Description of Business and Basis of Presentation Business Description and Basis of Presentation [Text Block] Preferred Investment Options Liability [Member] Preferred Investment Options Liability [Member] Preferred investment options liability. Income Statement [Abstract] Entity Address, State or Province Entity Address, State or Province Issuance of shares related to employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Net loss from continuing operations before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Revision of Prior Period [Axis] Class Of Warrant Or Right [Table] Class of Warrant or Right [Table] March two thousand twenty three options series A and march two thousand twenty three placement agent options. March Two Thousand Twenty Three Options Series A and March Two Thousand Twenty Three Placement Agent Options [Member] March 2023 Options - Series A & March 2023 Placement Agent Options [Member] Summary of Key Terms and Activity of Liability Classified Preferred Investment Options Schedule Of Key Terms And Activity Of Preferred Investment Options [Table Text Block] Schedule of key terms and activity of preferred investment options. Diluted net loss per share attributable to common stockholders from discontinued operations Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share, Total Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share First offering period, start date First Offering Period Start Date First offering period start date. Additional shares authorized for issuance under the plan Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized March 2023 Offering [Member] March Two Thousand And Twenty Three Offering Member March two thousand and twenty three offering member Software and computer equipment [Member] Software And Computer Equipment [Member] Software and computer equipment. Number of additional properties under lease agreement Additional Properties Under Lease Agreement Additional properties under lease agreement. Consolidated Joint Venture Equity Method Investments and Joint Ventures Disclosure [Text Block] Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Net loss from discontinued operations 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Three Business combination remaining contingent liability written-down. Business Combination Remaining Contingent Liability Written-down Business combination remaining contingent liability written-down Lease Cost Lease, Cost [Abstract] Aggregate Intrinsic Value, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Liability Class Liability Class [Axis] Proceeds from sale of Verdeca - earn-out received Proceeds from Sale of Equity Method Investments Issuance Date Class Of Warrants Or Rights Issuance Month And Year Class of warrants or rights issuance month and year. August 2022 Options [Member] August Two Thousand Twenty Two Options [Member] August two thousand twenty two options. Unrealized Losses Debt And Equity Securities Accumulated Gross Unrealized Loss Before Tax Debt and equity securities accumulated gross unrealized loss before tax. Cover [Abstract] May 2020 Warrants [Member] May Two Thousand Twenty Warrants [Member] May two thousand twenty warrants. Net loss per basic share attributable to common stockholders Basic Net income (loss) per share attributable to common stockholders: Earnings Per Share, Basic Earnings Per Share, Basic, Total Lease option to extend, description Lessee, Operating Lease, Option to Extend Amendment [Member] Amendment [Member] Amendment. Co-packing business, saavy naturals, provault and soul spring body care brands. Co-packing business, Saavy Naturals, ProVault and Soul Spring Body Care Brands [Member] Co-packing business, Saavy Naturals, ProVault and Soul Spring Body Care Brands [Member] Payments Of Offering Costs Payments of offering costs. Payments of offering costs relating to March 2023 PIPE Inventories Inventory Current And Non Current Net Inventory current and non current net. Investments, Debt and Equity Securities [Abstract] License License [Member] Place of incorporation Entity Place Of Incorporation Entity place of incorporation. Pre Funded Warrants [Member] Pre-funded warrants. Disposal Group, Including Discontinued Operation, Inventory, Noncurrent Inventories, net - noncurrent Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Total Accumulated deficit Retained Earnings (Accumulated Deficit) Plan Name Plan Name [Axis] Total number of options outstanding Shares

Subject to Outstanding, Beginning Balance Shares Subject to Outstanding, Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Current assets: Assets, Current [Abstract] Total number of shares reserved for issuance under plan Common Stock, Capital Shares Reserved for Future Issuance January 2021 Offering [Member] January Two Thousand And Twenty One Offering [Member] January two thousand and twenty one offering. Preferred Investment Options Liability Exercise Price Per Share Preferred investment options liability exercise price per share. Exercise Price Per Share Nonrelated Party [Member] Investment Type Investment Type [Axis] March two thousand twenty three options series A. March Two Thousand Twenty Three Options Series A [Member] March 2023 Options - Series A [Member] Net cash used in operating activities Net cash used in operations Net Cash Provided by (Used in) Operating Activities Net cash used in operations Investments and Fair Value Instruments Investments And Fair Value Of Instruments Disclosure [Text Block] Investments and fair value of instruments disclosure. March two thousand twenty three securities purchase purchase agreement. March Two Thousand Twenty Three Securities Purchase Purchase Agreement [Member] March 2023 Purchase Agreement [Member] Product and Service Product and Service [Domain] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Operating leases, term of contract Lessee, Operating Lease, Term of Contract Remaining contingent liability Remaining Contingent Liability Remaining contingent Debt Instrument, Term Promissory note, term Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Beginning Balance Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Operating activities Thereafter Finite Lived Intangible Assets Amortization Expense After Year Four Finite lived intangible assets amortization expense after year four. Common stock, par value Common Stock, Par or Stated Value Per Share Option to Purchase Common Stock [Member] Unrealized gains on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Measurement Input Type Measurement Input Type [Domain] Disposal Groups, Including Discontinued Operations [Table] Statement of Cash Flows [Abstract] Counterparty Name Counterparty Name [Axis] Real Estate Real Estate [Domain] Promissory note interest description. Promissory Note Interest Description Promissory note interest description Antidilutive Securities, Name [Domain] Capital contributions Equity Method Investments Change in fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) Accounts, Notes, Loans and Financing Receivable [Line Items] Note receivable recognized from sale of good wheat. Note Receivable Recognized From Sale Of Good Wheat Note receivable recognized from sale of GoodWheat SG&A and R&D Expenses [Member] Selling General And Administrative And Research And Development Expenses [Member] Selling, general and administrative and research and development expenses. Warrant issued, shares of common stock called by warrant Class of Warrant or Right, Number of Securities Called by Warrants or Rights SG&A Expenses [Member] Selling, General and Administrative Expenses [Member] Selling, General and Administrative Expenses [Member] Embedded Derivative, Fair Value of Embedded Derivative Asset Fair value of embedded derivative note receivable Additional Paid-In Capital [Member] Equity Components [Axis] Restructuring activities, description Restructuring and Related Activities, Description Entity Address, Address Line One Entity Address, Address Line One Schedule Of Related Party Transactions By Related Party [Table] Related Party Transaction [Table] Schedule Of Finite Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Disposal group including discontinued operation selling general and administrative expense. Disposal Group, Including Discontinued Operation Selling, General and Administrative Expense Selling, general and administrative June 2019 Offering [Member] June Two Thousand And Nineteen Offering [Member] June two thousand and nineteen offering. Option amendment agreements. Option Amendment Agreements [Member] Option Amendment Agreements [Member] Property Plant And Equipment [Line Items] Property, Plant and Equipment [Line Items] Subsequent Event Type [Axis] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Securities Not Included in Diluted per Share Calculations Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Anawah, Inc [Member] Anawah Inc [Member] Anawah Inc. Recent Accounting Pronouncements Accounting Standards Update and Change in Accounting Principle [Text Block] Year of incorporation Entity Incorporation Year Of Incorporation Entity incorporation year of incorporation. March 2018 Placement Agent Warrants [Member] March2018 Placement Agent Warrants [Member] March 2018 placement agent warrants. Proceeds from Issuance of Common Stock Pre-funded Warrants and Preferred Investment Options Proceeds from issuance of common stock pre-funded warrants and preferred investment options. Proceeds from issuance of common stock, pre-funded warrants and preferred investment options from March 2023 PIPE 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Two Amendment Flag Amendment Flag ASU 2016-02 Accounting Standards Update 2016-02 [Member] Net loss attributable to noncontrolling interest Net loss attributable to non-controlling interest Net Income (Loss) Attributable to Noncontrolling Interest, Total Net Income (Loss) Attributable to Noncontrolling Interest Operating lease liabilities Increase (Decrease) in Operating Lease Liability Issuance costs allocated to liability preferred options. Issuance Costs Allocated to Liability Preferred Options Issuance costs allocated to liability preferred options Operating lease liability â€” noncurrent Noncurrent - Operating Operating Lease, Liability, Noncurrent Corporate Securities [Member] Corporate Debt Securities [Member] Additional Paid in Capital, Common Stock, Ending Balance Additional Paid in Capital, Common Stock, Beginning Balance Additional paid-in capital Additional Paid in Capital, Common Stock January two thousand twenty one warrants private placement offering. January Two Thousand Twenty One Warrants Private Placement Offering [Member] January 2021 Warrants [Member] Receivables [Abstract] Property, plant and equipment, net including discontinued operations. Property, Plant and Equipment, Net Including Discontinued Operations Property and equipment, net Disposal Group, Including Discontinued Operation, Depreciation and Amortization Depreciation Amortization expense Net loss attributable to common stockholders Net loss attributable to common stockholders Lessee Lease Description [Table] Lessee, Lease, Description [Table] Inventories - noncurrent Inventory, Noncurrent, Total Inventory, Noncurrent Shares Subject to Outstanding, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number R&D Expenses [Member] Research and Development Expense [Member] Gain on sale of property and equipment Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Gain on disposal of property and equipment Equity Component Equity Component [Domain] Statistical Measurement Statistical Measurement [Domain] Proceeds from sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment, Total Proceeds from Sale of Property, Plant, and Equipment Number of technology development programs. Number Of Technology Development Programs Number of development programs Other income , net Other Nonoperating Income (Expense), Total Other Nonoperating Income (Expense) Other (expense) income, net Options exercisable period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period John Sperling Foundation [Member] John Sperling Foundation [Member] John sperling foundation. Furniture and fixtures [Member] Furniture and Fixtures [Member] Series A preferred investment options. Series A Preferred Investment Options [Member] Series A Preferred Investment Options [Member] Summary of Inventories Schedule Of Inventory Current And Non Current Table [Text Block] Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. Includes current and non-current inventory balances. Net loss Net losses Net (loss) income Net loss Lease payments Operating Lease, Payments Fair value of common stock and pre-funded warrants. Fair Value of Common Stock and Pre-funded Warrants Fair value of common stock and pre-funded warrants Issuance of shares related to employee stock purchase plan, Shares Issuance of common stock pursuant to employee stock purchase plan Stock Issued During Period, Shares, Employee Stock Purchase Plans Short-term investments Short-Term Investments Short-Term Investments, Total Fair value assumptions, value Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Value Share-based compensation arrangement by share-based payment award, fair value assumptions, value. Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Weighted-Average Exercise Price Per Share, Options forfeited Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current Prepaid expenses and other current assets Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Class of Stock [Domain] Other comprehensive income Other comprehensive income Other Comprehensive Income (Loss), Net of Tax Collaborative Arrangements Collaborative Arrangement Disclosure [Text Block] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Common stock, outstanding Common Stock, Shares, Outstanding July 2020 Warrants [Member] July2020 Warrants [Member] July 2020 warrants. Payments to Acquire Investments, Total Payments to Acquire Investments Purchases of investments Finite-Lived Intangible Assets, Major Class Name Finite-Lived Intangible Assets, Major Class Name [Domain] Interest income Interest Income (Expense), Net, Total Interest Income (Expense), Operating Accrued interest Industrial Seed Innovations [Member] Industrial Seed Innovations [Member] Industrial seed innovations. Antidilutive Securities [Axis] March Two Thousand Twenty Three Placement Agent Options. March Two Thousand Twenty Three Placement Agent Options [Member] March 2023 Placement Agent Options [Member] March 2023 and August 2022 Options And Placement Agent Options. March 2023 and August 2022 Options And Placement Agent Options [Member] March 2023, August 2022 Options and Placement Agent Options [Member] Finite Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Discontinued Operations and Disposal Groups [Abstract] Entity Interactive Data Current Entity Interactive Data Current Product Product [Member] Gain (Loss) on Disposition of Business Loss on sale of brand Disposal group including discontinued operation write-down of inventories. Disposal Group Including Discontinued Operation Write-down of Inventories Write-down of inventories Number of equity incentive plans Number Of Equity Incentive Plans Number of equity incentive plans. Accounting Standards Update [Domain] Document Quarterly Report Document Quarterly Report Related-Party Transactions Related Party Transactions Disclosure [Text Block] Statistical Measurement Statistical Measurement [Axis] Schedule Of Equity Method Investments [Table] Equity Method Investment [Table] Liabilities Operating Lease Liabilities [Abstract] Operating lease liabilities. Cost of Goods and Services Sold, Total Cost of Goods and Services Sold Cost of revenues Operating lease cost Operating lease cost Operating Lease, Cost Total Assets at Fair Value Assets, Fair Value Disclosure Related Party Related and Nonrelated Parties [Domain] Net lease cost Net lease cost Lease, Cost Inducement Stock Option [Member] Inducement Stock Option [Member] Inducement stock option. Place of reincorporation Entity Reincorporation State Country Name State or Country Name where an entity is re-incorporated. Bioceres Crop Solutions [Member] Bioceres Crop Solutions [Member] Bioceres Crop Solutions. Common stock available for future grant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant August 2019 Service and Performance Warrants [Member] August2019 Service And Performance Warrants [Member] August 2019 service and performance warrants. Weighted-average remaining recognition period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Basis of Presentation and Principles of Consolidation Basis Of Presentation And Principles Of Consolidation Policy Policy [Text Block] Basis of presentation and principles of consolidation. Machinery and equipment [Member] Machinery and Equipment [Member] Income Statement Location Statement of Income Location, Balance [Axis] Total assets Assets Expected term Expected term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Disposal group including discontinued operation research and development. Disposal Group Including Discontinued Operation Research and Development Research and development Stock Issued During Period Shares Related To Exercise Of Options Stock issued during period shares related to exercise of options. Exercised during the period Entity Address, City or Town Entity Address, City or Town Accumulated Other Comprehensive Income [Member] AOCI Attributable to Parent [Member] Equity [Abstract] Segments [Axis] January 2021 Warrants [Member] January Two Thousand Twenty One Warrants [Member] January two thousand twenty one warrants. Assets at Fair Value Assets, Fair Value Disclosure [Abstract] Offering costs Additional offering costs Payments of Stock Issuance Costs March Two Thousand Twenty Three Pre Funded Warrants. March Two Thousand Twenty Three Pre Funded Warrants [Member] March 2023 Pre-Funded Warrants [Member] (Loss) Gain on sale of property and equipment Disposal group including discontinued operation gain on sale of property and equipment. Disposal Group Including Discontinued Operation Gain on Sale of Property and Equipment Gain on sale of property and equipment Debt Instrument, Face Amount Promissory note, principal ASU 2020-06 [Member] Accounting Standards Update 2020-06 [Member] Depreciation expense Depreciation, Total Depreciation Depreciation Stock price Share Price Revision of Prior Period [Domain] Disposal Group, Including Discontinued Operation, Assets, Current, Total Disposal Group, Including Discontinued Operation, Assets, Current Current assets of discontinued operations - GoodWheat Purchase Agreement [Member] Private Placement [Member] Proceeds from issuance of common stock and warrants gross Proceeds From Issuance Of Common Stock And Warrants Gross Proceeds from issuance of common stock and warrants gross. Stock-Based Compensation and Employee Stock Purchase Program Share-Based Payment Arrangement [Text Block] Construction in Progress [Member] Construction in Progress [Member] Shares Subject to Outstanding, Options Expired Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent January 2021 Placement Agent Warrants [Member] January Two Thousand Twenty One Placement Agent Warrants [Member] January two thousand twenty one placement agent warrants. Fair Value Disclosures [Abstract] Common stock and Pre-funded warrants. Common Stock and Pre-Funded Warrants [Member] Assets held for sale Asset, Held-for-Sale, Not Part of Disposal Group, Current Assets Held-for-sale, Not Part of Disposal Group, Current, Total December two thousand twenty warrants private placement offering. December Two Thousand Twenty Warrants Private Placement Offering [Member] December 2020 Warrants [Member] Issuance of shares Stock Issued During Period, Value, New Issues August 2022 Offering [Member] August Two Thousand And Twenty Two Offering [Member] August two thousand and twenty two offering. Chief Executive Officer [Member] Chief Executive Officer [Member] Lessee Lease Description [Line Items] Lessee, Lease, Description [Line Items] Current liabilities: Liabilities, Current [Abstract] Archipelago Ventures Hawaii, LLC [Member] Archipelago Ventures Hawaii L L C [Member] Archipelago Ventures Hawaii, LLC. Document Type Document Type Accounting Standards Update [Axis] Legacy Ventures Hawaii, LLC [Member] Legacy Ventures Hawaii L L C [Member] Legacy Ventures Hawaii, LLC. Asset Impairment Charges, Total Asset Impairment Charges Impairment charges Title of 12(b) Security Title of 12(b) Security Gain (loss) on private placement. Gain (Loss) on Private Placement Valuation loss on March 2023 PIPE Valuation loss on March 2023 PIPE Disposal group, including discontinued operation, accrued interest expense. Disposal Group, Including Discontinued Operation, Accrued Interest Expense Accrued interest expense Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Disposal Group, Including Discontinued Operation, Other Liabilities, Current Other current liabilities Statement of Stockholders' Equity [Abstract] Number of annual installment of common stock shares payable Number of annual installment of common stock shares payable Number Of Annual Installment Of Common Stock Shares Payable Number of annual installment of common stock, shares payable. Inventory [Line Items] Beginning Balance Ending Balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Document Fiscal Period Focus Document Fiscal Period Focus Research and Development Expense, Total Research and development Research and Development Expense Shares Subject to Outstanding, Options Granted Shares Subject to Outstanding, Options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Date of merger and reorganization Business Acquisition, Effective Date of Acquisition Asset Class Asset Class [Domain] Property, Plant and Equipment, Gross, Ending Balance Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Total Property and equipment, gross Property, Plant and Equipment, Gross Common Stock Warrant Liability [Member] Common stock warrant liability. Common Stock Warrant Liability [Member] Total leased assets Operating Lease Assets Operating lease assets. Subsequent Event Type [Domain] Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Note Receivable Organization Organization Policy Policy [Text Block] Organization policy. Remaining Term [Member] Measurement Input, Expected Term [Member] Weighted-Average Fair Value Assumption of Stock Option Awards Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Rent payments Payments for Rent Accounting Changes and Error Corrections [Abstract] Exercise Price Per Share Warrants issued, exercise price Class of Warrant or Right, Exercise Price of Warrants or Rights Financial Instruments Financial Instruments [Domain] Disposal Group, Including Discontinued Operation, Assets, Noncurrent, Total Disposal Group, Including Discontinued Operation, Assets, Noncurrent Noncurrent assets of discontinued operations - GoodWheat Note Receivable Bifurcated Derivatives. Note Receivable Bifurcated Derivatives [Member] Note Receivable Bifurcated Derivatives [Member] Class Of Warrant Or Right [Line Items] Class of Warrant or Right [Line Items] Sale of Stock Sale of Stock [Axis] CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Investments Investments [Domain] Collaborative Arrangements [Member] Collaborative Arrangements Copromotion [Member] Collaborative arrangements, copromotion. Revenue from Contract with Customer, Excluding Assessed Tax, Total Total revenues Revenue from Contract with Customer, Excluding Assessed Tax License revenue Disposal Groups, Including Discontinued Operations [Table Text Block] Summary of Major Classes of Line Items Constituting Discontinued Operations Income Taxes Income Tax Disclosure [Text Block] Purchase plan offering period Employee

Stock Purchase Plan Offering Period Employee stock purchase plan offering period. September 2019 Placement Agent Warrants [Member] September2019 Placement Agent Warrants [Member] September 2019 placement agent warrants. Revenue Milestone in 2022 [Member] Achievement Of Revenue Milestone In2022 [Member] Achievement of Revenue Milestone in 2022. Warrants and Rights Note Disclosure [Abstract] Discontinued operations, assets Disposal Group, Including Discontinued Operation, Assets Total assets Vehicles [Member] Vehicles [Member] Selling, General and Administrative Expense, Total Selling, general and administrative Selling, General and Administrative Expense Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies table. Issuance Date Preferred Investment Options Liability Issuance Month And Year Preferred investment options liability issuance month and year Finite-Lived Intangible Assets, Net, Total Finite-Lived Intangible Assets, Net, Ending Balance Finite-Lived Intangible Assets, Net, Beginning Balance Finite-Lived Intangible Assets, Net Debt Securities, Available-for-Sale [Table] Entity Address, Address Line Two Entity Address, Address Line Two Liabilities and stockholdersâ€™ equity Liabilities and Equity [Abstract] Contractual agreement month and year Contractual Agreement Month And Year Contractual agreement month and year. Document Period End Date Document Period End Date Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Securities Financing Transaction [Axis] Effective Income Tax Rate Reconciliation, Percent, Total Effective tax rate Effective Income Tax Rate Reconciliation, Percent 2015 Omnibus Equity Incentive Plan [Member] Two Thousand Fifteen Omnibus Equity Incentive Plan [Member] Two thousand fifteen omnibus equity incentive plan. May 2020 warrants private placement offering. May 2020 Warrants Private Placement Offering [Member] May 2020 Warrants [Member] Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Net loss from discontinued operations Net loss from discontinued operations Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities not included in the diluted per share calculations, amount Remaining amount paid in multiple installments Business Combination Consideration Transferred Remaining Amount Business combination consideration transferred remaining amount. APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Joint venture interest percentage Equity Method Investment, Ownership Percentage Number of installment become due within 12 months as full amount contingent consideration included in other noncurrent liabilities Number Of Installment Become Due Within Twelve Months As Full Amount Contingent Consideration Included In Other Noncurrent Liabilities Number of installment become due within twelve months as full amount contingent consideration included in other noncurrent liabilities. Income Tax Expense (Benefit), Total Income Tax Expense (Benefit) Income tax provision Gain on sale of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Gain (Loss) on Disposition of Property Plant Equipment, Total Trading Symbol Trading Symbol Stockholders' Equity Attributable to Parent, Ending Balance Stockholders' Equity Attributable to Parent, Beginning Balance Equity, Attributable to Parent Total stockholders' equity Discontinued operations, liabilities Disposal Group, Including Discontinued Operation, Liabilities Total liabilities Unrealized Gains Debt And Equity Securities Accumulated Gross Unrealized Gain Before Tax Debt and equity securities accumulated gross unrealized gain before tax. March two thousand twenty three options and march two thousand twenty three placement agent options. March Two Thousand Twenty Three Options And March Two Thousand Twenty Three Placement Agent Options [Member] March 2023 Options and March 2023 Placement Agent Options [Member] Long-Lived Tangible Asset Long-Lived Tangible Asset [Axis] Outstanding Class of Warrant or Right, Outstanding Other Liabilities, Noncurrent, Total Other noncurrent liability Other noncurrent liabilities Other Liabilities, Noncurrent Finished goods Inventory Finished Goods Current And Non Current Inventory finished goods current and non-current. Related Party Transactions [Abstract] Basic net loss per share attributable to common stockholders from discontinued operations Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share, Total Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Body Care [Member] Body Care [Member] Body Care Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment [Table] Revenue Milestone in 2021 [Member] Achievement Of Revenue Milestone In2021 [Member] Achievement of Revenue Milestone in 2021. Operating lease term expiration month and year. Operating Lease Term Expiration Month and Year Operating lease term, expiration Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Unrecognized compensation cost related to unvested stock-based compensation grants Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Remaining term (in years) Term Preferred Investment Options Liability Term Preferred investment options liability term. Disposal Group Classification [Axis] Measurement Input Type Measurement Input Type [Axis] Geographical Geographical [Axis] Number of technology development programs ceased. Number Of Technology Development Programs Ceased Number of development programs ceased Outstanding Preferred Investment Options Liability Outstanding Preferred investment options liability outstanding. Acres of land Area of Land Disclosure Of Compensation Related Costs Share Based Payments And Warrants [Abstract] Disclosure of compensation related costs share based payments and warrants. Chesterfield, MO And Chatsworth, CA [Member] Chesterfield And Chatsworth [Member] Chesterfield and Chatsworth. Related Party [Member] December 2020 Warrants [Member] December Two Thousand Twenty Warrants [Member] December 2020 warrants. Expected Volatility [Member] Expected Volatility [Member] Measurement Input, Price Volatility [Member] Lessee Disclosure [Abstract] Disposal Group, Including Discontinued Operation, Inventory, Current Inventories, net - current Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Security Exchange Name Security Exchange Name July 2020 Warrants Transaction [Member] July Two Thousand And Twenty Warrants Transaction Member July two thousand and twenty warrants transaction. Basic net loss per share attributable to common stockholders from continuing operations Income (Loss) from Continuing Operations, Per Basic Share Counterparty Name Counterparty Name [Domain] Fair Value by Liability Class Fair Value by Liability Class [Domain] Business Acquisition, Acquiree Business Acquisition, Acquiree [Domain] Warrant modification included in valuation loss. Warrant Modification Included In Valuation Loss Warrant modification included in valuation loss Warrant and option modifications included in Valuation loss on March 2023 PIPE Series A and B preferred investment options. Series A and B Preferred Investment Options [Member] Series A and B Preferred Investment Options [Member] Risk-Free Interest Rate [Member] Risk-Free Interest Rate [Member] Measurement Input, Risk Free Interest Rate [Member] Warrant expiration month and year Warrant Expiration Month and Year Warrant expiration month and year. Long-Lived Tangible Asset Long-Lived Tangible Asset [Domain] Class of Stock [Axis] Option Indexed to Issuer's Equity [Table] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Less accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Subsequent Event [Member] Maximum [Member] Maximum [Member] Maximum [Member] Total liabilities and stockholdersâ€™ equity Liabilities and Equity Operating expenses : Operating Income (Loss) [Abstract] Business Combination, remaining contingent liability. Business Combination, remaining Contingent Liability Remaining contingent liability Right of use asset Operating lease assets Operating Lease, Right-of-Use Asset June 2019 Placement Agent Warrants [Member] June2019 Placement Agent Warrants [Member] June 2019 placement agent warrants. Net loss per diluted share attributable to common stockholders Diluted Net income (loss) per share attributable to common stockholders: Earnings Per Share, Diluted Earnings Per Share, Diluted, Total Leasehold improvements [Member] Leasehold Improvements [Member] Stock Issued During Period, Shares, Reverse Stock Splits Issuance of shares related to reverse stock split Additional shares of common stock of reverse stock split Total liabilities Liabilities Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Financing Receivable, after Allowance for Credit Loss, Current, Total Financing Receivable, after Allowance for Credit Loss, Current Note receivable - current Current note receivable Total current assets Assets, Current Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) investing activities Arcadia Biosciences, Inc [Member] Arcadia Biosciences Incorporation [Member] Arcadia Biosciences incorporation. Shares of common stock issued Issuance of shares, Shares Stock Issued During Period, Shares, New Issues Unrecognized Tax Benefits, Ending Balance Unrecognized Tax Benefits, Beginning Balance Uncertain tax positions Unrecognized Tax Benefits Options vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Existence of option to extend Lessee, Operating Lease, Existence of Option to Extend [true false] Disposal Group, Including Discontinued Operation, Costs of Goods Sold Cost of revenues Cost of lease amendments Number Of Lease Amendments Number of lease amendments. Entity Filer Category Entity Filer Category June 2018 Warrants [Member] June Two Thousand Eighteen Warrants [Member] June two thousand eighteen warrants. Property, Plant and Equipment [Abstract] Estimated fair value options exceeded gross proceeds. Estimated Fair Value Options Exceeded Gross Proceeds Estimated fair value, loss May 2020 Warrant Transaction [Member] May Two Thousand And Twenty Warrant Transaction [Member] May two thousand and twenty warrant transaction. Total stockholders' equity Stockholders Equity, Beginning Balance Stockholders Equity, Ending Balance Equity, Including Portion Attributable to Noncontrolling Interest Separation agreement. Separation Agreement [Member] Separation Agreement [Member] Current Fiscal Year End Date Current Fiscal Year End Date Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Non-Controlling Interest [Member] Noncontrolling Interest [Member] Gain on sale of Verdeca Equity Method Investment, Realized Gain (Loss) on Disposal Gain on sale of Verdeca Gain on sale of Verdeca Share-based Payment Arrangement, Noncash Expense, Total Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Aggregate Intrinsic Value, Ending Balance Aggregate Intrinsic Value, Beginning Balance Aggregate Intrinsic Value, Outstanding Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Related Party Related and Nonrelated Parties [Axis] September 2019 Warrants [Member] September Two Thousand Nineteen Warrants [Member] September 2019 warrants. Disposal Group, Including Discontinued Operation, Revenue Revenue Disposal Group, Including Discontinued Operation, Revenue, Total Entity Registrant Name Entity Registrant Name Other Income Other income other income Business Combination, Contingent Consideration, Liability, Total Contingent liability Business Combination, Contingent Consideration, Liability March two thousand twenty three options series B. March Two Thousand Twenty Three Options Series B [Member] March 2023 Options - Series B [Member] Warrants expiration period Warrants Expiration Period Warrants expiration period. Warrants and Options Warrants And Options Disclosure [Text Block] Warrants and options disclosure. Promissory note, current and non current. Promissory Note, Current And Non Current Promissory note, current and non current. Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Net Loss per Share Earnings Per Share [Text Block] Entity Emerging Growth Company Entity Emerging Growth Company Real Estate, Type of Property Real Estate, Type of Property [Axis] Schedule of Leases Schedule Of Operating Lease Table [Text Block] Schedule of operating lease. Investment, Type [Extensible Enumeration] Equity Method Investments and Joint Ventures [Abstract] Money Market Funds [Member] Money Market Funds [Member] Other current liabilities Amounts due to related parties Royalty fees due Other Liabilities, Current, Total Weighted average number of common shares outstanding Weighted Average Number of Shares Outstanding, Basic, Total Weighted average shares - Basic Weighted average shares - Basic Estimated Fair Value Debt And Equity Securities Debt and equity securities. Number of individuals appointed Number Of Individuals Appointed Number of individuals appointed. Proceeds from sale of Verdeca in accounts receivable and other receivables Payment received on accounts and other receivable Proceeds From Sale Of Equity Method Investments In Accounts And Other Receivable Proceeds from sale of equity method investments in accounts and other receivable. Schedule Of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Increase (Decrease) in Due to Related Parties, Total Amounts due to related parties Increase (Decrease) in Due to Related Parties Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Summary of Amortized Cost and Fair Value of Investment Securities Portfolio Summary Of Amortized Cost And Fair Value Of Investment Securities Table [Text Block] Summary of amortized cost and fair value of investment securities. Increase (Decrease) in Other Current Liabilities Other current liabilities Common stock, authorized Common Stock, Shares Authorized Sublease Income Sublease income March 2020 Service and Performance Warrants [Member] March2020 Service And Performance Warrants [Member] March 2020 service and performance warrants. Royalty Royalty [Member] Short-term investments Debt And Equity Securities Current Debt and equity securities current. Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Issuance and offering costs allocated to liability classified options. Issuance and Offering Costs Allocated to Liability Classified Options Issuance and offering costs allocated to liability classified options Issuance and offering costs allocated to liability classified options Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Weighted Average Exercise Price Per Share, Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Weighted-Average Exercise Price Per Share, Options granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Financial Instrument Financial Instrument [Axis] Impairment of property and equipment Impairment, Long-Lived Asset, Held-for-Use Impairment, Long-Lived Asset, Held-for-Use, Total Share-Based Payment Arrangement [Abstract] Promissory note received from asset sale. Promissory note received from asset sale Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] August 2022 Pre-Funded Warrants [Member] August Two Thousand Twenty Two Pre Funded Warrants [Member] August two thousand twenty two pre funded warrants. Offering closing period Offering Closing Period Offering closing period. August 2022 Options and August 2022 Placement Agent Options [Member] August Two Thousand Twenty Two Options and August Two Thousand Twenty Two Placement Agent Options [Member] August 2022 options and August 2022 placement agent options. August 2022 Options & August 2022 Placement Agent Options [Member] Accounting Policies [Abstract] September two thousand nineteen warrants private placement offering. September Two Thousand Nineteen Warrants Private Placement Offering [Member] September 2019 Warrants [Member] Summary of Activity Under Stock Incentive Plans Share-Based Payment Arrangement, Option, Activity [Table Text Block] Options expiration period. Options expiration period Income Tax Disclosure [Abstract] Stockholdersâ€™ equity: Equity, Attributable to Parent [Abstract] February 3, 2020 Service and Performance Warrants [Member] February32020 Service And Performance Warrants [Member] February 3, 2020 service and performance warrants. Disposal Group Name [Domain] Statement [Table] Statement [Table] 2006 Stock Incentive Plan [Member] Two Thousand Six Stock Incentive Plan [Member] Two thousand six stock incentive plan. Inventory Write-down Inventories written down Write-down of inventories Disposal Group Classification [Domain] Entity File Number Securities Act File Number cash shares and royalty receivable from sale of interest in joint venture cash shares and royalty receivable from sale of interest in joint venture Cash shares and royalty receivable Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net decrease in cash and cash equivalents March two thousand twenty three private placement. March Two Thousand Twenty Three Private Placement [Member] March 2023 Private Placement [Member] Net loss per share attributable to common stockholders: Earnings Per Share [Abstract] Earnings Per Share [Abstract] Option Indexed to Issuer's Equity [Line Items] Cash Equivalents [Member] Cash Equivalents [Member] Term Remaining term (in years) Warrants and Rights Outstanding, Term Assets Operating Lease Assets [Abstract] Operating lease assets. Common stock warrant and option liabilities Common Stock Warrant and Option Liabilities Common stock warrant and option liabilities. Inventory Disclosure [Abstract] Statement of Financial Position [Abstract] Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent Property and equipment, net Property and equipment, net Loss from continuing operations Operating Income (Loss) March two thousand twenty three options. March Two Thousand Twenty Three Options [Member] March 2023 Options [Member] Exercise price Shares Issued, Price Per Share Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Contingent Liabilities [Member] Contingent Liabilities [Member] Contingent liabilities. Entity Shell Company Entity Shell Company Discontinued Operations, Policy [Policy Text Block] Discontinued Operations Summary of Preferred Investment Option Liabilities Measured and Recorded on Recurring Basis using Black-Scholes Model Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number Assets Assets [Abstract] Class of Warrant or Right Class of Warrant or Right [Domain] Entity Current Reporting Status Entity Current Reporting Status Preferred investment options liability, measurement input Preferred Investment Options Liability Outstanding Measurement Input Preferred investment options liability outstanding measurement input. Investments And Fair Value Instruments [Abstract] Investments and fair value instruments. Payment for asset sale transaction. Payment for asset sale transaction Amortized Cost Debt And Equity Securities Amortized Cost Basis Debt and equity securities amortized cost basis. Property and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Subsequent Events [Abstract] Inventory Inventory Disclosure [Text Block] March two thousand and twenty three P I P E. March Two Thousand And Twenty Three P I P E [Member] March 2023 PIPE [Member] Geographical Geographical [Domain] Document Fiscal Year Focus Document Fiscal Year Focus March 2018 PIPE [Member] March Two Thousand Eighteen P I P E Member March two thousand eighteen P I P E. May 2020 Warrants [Member] May2020 Warrants [Member] May 2020 warrants. Warrant, exercisable term Class Of Warrant Or Right Exercisable Term Class of warrant or right exercisable term. Payments for termination fees. Payments for Termination Fees Early termination fees GoodWheat [Member] GoodWheat [Member] GoodWheat Disposal Group, Including

Discontinued Operation, Accounts Payable and Accrued Liabilities, Current, Total Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued expenses Loans Receivable, Fair Value Disclosure Estimated fair value of loan receivable Cash and cash equivalents - end of period Cash and cash equivalents - beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Proceeds from issuance, aggregate offering prices Proceeds from Issuance Initial Public Offering Business Acquisition Business Acquisition [Axis] City Area Code City Area Code Disposal Group, Including Discontinued Operation, Consideration Sale of net consideration Reclassification, Comparability Adjustment [Policy Text Block] Reclassifications Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax, Total OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax Change in unrealized gains on available-for-sale securities Total current liabilities Liabilities, Current July 2020 Warrants [Member] July Two Thousand Twenty Warrants [Member] July two thousand twenty warrants. Inventories - current Inventory, Net, Total Inventory, Net Federal statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Aggregate Intrinsic Value, Options Granted Share Based Compensation Arrangement By Share Based Payment Award Grants Outstanding Intrinsic Value Share based compensation arrangement by share based payment award grants outstanding intrinsic value. Organization, Consolidation and Presentation of Financial Statements [Abstract] Local Phone Number Local Phone Number Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] March 2018 Warrants [Member] March Two Thousand Eighteen Warrants [Member] March 2018 warrants. Commitments and Contingencies Disclosure [Abstract] Warrants expiration date. Warrants Expiration Date Warrants expiration date Operating lease liability â€" current Current - Operating Operating Lease, Liability, Current Accumulated Deficit [Member] Retained Earnings [Member] Payments to Acquire Property, Plant, and Equipment, Total Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Mr. Kevin Comcowich [Member] Board of Directors Chairman [Member] Summary of Fair Value of Investment Securities Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Document Transition Report Document Transition Report Securities Financing Transaction [Domain] Employees are able to purchase company's common stock on first trading day of offering period, percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent September 2019 Offering [Member] September Two Thousand And Nineteen Offering [Member] September two thousand and nineteen offering. Proceeds from Sale of Other Investments Proceeds from sale of investments Antidilutive Security, Excluded EPS Calculation [Table] Additional cash receivable from sale of interest in joint venture Additional Cash Receivable From Sale Of Interest In Joint Venture Additional cash receivable from sale of interest in joint venture. Estimated fair value of liability options. Estimated Fair Value of Liability Options Estimated fair value of liability options Proceeds from ESPP purchases Proceeds from Stock Plans Property and equipment classified as assets held for sale, fair value Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] 2022 (excluding the nine months ended September 30, 2022) Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Minimum [Member] Minimum [Member] Liquidity, Capital Resources, and Going Concern Liquidity Capital Resources And Going Concern Policy Policy [Text Block] Liquidity capital resources and going concern. Net loss per share attributable to common stockholders: Earnings Per Share Reconciliation [Abstract] Common Stock [Member] Common Stock [Member] Exercised during the period Issuance of shares related to Pre-Funded Warrants exercise Stock Issued During Period Shares Related To Exercise Of Warrants Stock issued during period shares related to exercise of warrants. Aggregate Intrinsic Value, Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Investment, Name [Axis] Reverse stock split policy policy text block. Reverse Stock Split Policy [Policy Text Block] Reverse Stock Split Increase (Decrease) in Other Noncurrent Assets Other noncurrent assets Other noncurrent assets Lease amortization Operating Lease, Right-of-Use Asset, Periodic Reduction Additional Paid-In Capital [Member] Additional Paid-in Capital [Member] Financing Receivable, after Allowance for Credit Loss, Noncurrent, Total Financing Receivable, after Allowance for Credit Loss, Noncurrent Note receivable - noncurrent Adjustments to reconcile net loss to cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Short-term Investments [Member] Short-Term Investments [Member] July 2019 Service and Performance Warrants [Member] July2019 Service And Performance Warrants [Member] July 2019 service and performance warrants. Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax [Abstract] Income Statement Location Statement of Income Location, Balance [Domain] Other Assets, Noncurrent, Total Other noncurrent assets Other Assets, Noncurrent February 12, 2020 Service and Performance Warrants [Member] February122020 Service And Performance Warrants [Member] February 12, 2020 service and performance warrants. Intellectual Property and Customer Lists [Member] Intellectual Property And Customer Lists [Member] Intellectual property and customer lists. Segments [Domain] Goodwill and Intangible Assets Disclosure [Abstract] Radiance beauty licensing agreement. Radiance Beauty Licensing Agreement [Member] Radiance Beauty Licensing Agreement [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Reclassification upon Adoption [Member] Revision of Prior Period, Accounting Standards Update, Adjustment [Member] Diluted net loss per share attributable to common stockholders from continuing operations Income (Loss) from Continuing Operations, Per Diluted Share Accounts and Financing Receivables [Table] Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance Stockholders' Equity Attributable to Noncontrolling Interest, Total Non-controlling interest Equity, Attributable to Noncontrolling Interest June 2018 Placement Agent Warrants [Member] June Two Thousand Eighteen Placement Agent Warrants [Member] June two thousand eighteen placement agent warrants. 2023 Finite-Lived Intangible Asset, Expected Amortization, Year One Amortization of note receivable discount. Amortization Of Note Receivable Discount Amortization of note receivable discount Title of Individual Title and Position [Domain] Offering costs Remaining offering costs allocated to common stock and offset to additional paid in capital Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Series B preferred investment options. Series B Preferred Investment Options [Member] Series B Preferred Investment Options [Member] Business combination, equity interest issuable upon achievement of revenue milestone Business Combination Equity Interest Issuable Upon Achievement Of Revenue Milestone Share Business combination, equity interest issuable upon achievement of revenue milestone share. Increase (Decrease) in Accounts and Other Receivables Accounts receivable and other receivables Common stock, $0.001 par value - 150,000,000 shares authorized; 1,364,940 and 1,285,337 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Total Common Stock, Value, Issued Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Verdeca LLC [Member] Verdeca L L C [Member] Verdeca LLC. Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Discounted promissory note. Discounted Promissory Note Discounted promissory note January 2021 PIPE [Member] January Two Thousand And Twenty One P I P E [Member] January two thousand and twenty one PIPE. April 2019 Service and Performance Warrants [Member] April2019 Service And Performance Warrants [Member] April 2019 service and performance warrants. Share based compensation arrangement by share based payment award expired outstanding intrinsic value. Share Based Compensation Arrangement By Share Based Payment Award Expired Outstanding Intrinsic Value Aggregate Intrinsic Value, Options Expired Decrease in operating lease liability Total leased liabilities Operating Lease, Liability Commitments and Contingencies Commitments and contingencies (Note 14) June 2019 Warrants [Member] June Two Thousand Nineteen Warrants [Member] June 2019 warrants. Investment in continuous unrealized loss position for more than twelve months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Weighted average number of common shares outstanding - diluted Weighted average shares - Diluted Weighted average shares - Diluted Common Stock Options Issued to Placement Agent and Included in Offering Costs Common stock options issued to placement agent and included in offering costs. Common stock options issued to placement agent and included in offering costs Common stock options issued to placement agent and included in offering costs Option to extend lease, term Lessee, Operating Lease, Renewal Term Shares Subject to Outstanding, Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Increase (Decrease) in Inventories, Total Inventories Increase (Decrease) in Inventories Summary of Property and Equipment, Net Schedule Of Property Plant And Equipment Table [Text Block] Schedule of property plant and equipment. Payment to aquire promissory note. Payment To Aquire Promissory Note Payment to aquire promissory note Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted-average number of shares used in per share calculations: Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies line items. Entity Small Business Entity Small Business Terms under the plan Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award Remaining term (in years) Preferred Investment Options Liability Measured Remaining Term Preferred investment options liability measured remaining term. March 2018 Purchase Agreement [Member] March Two Thousand And Eighteen Purchase Agreement [Member] March 2018 purchase agreement. Preferred Investment Options [Member] Preferred Investment Options [Member] Preferred investment options. January 2021 Service and Performance Warrants [Member] January Two Thousand Twenty One Service And Performance Warrants [Member] January two thousand twenty one service and performance warrants. Treasury Bills [Member] US Treasury Securities [Member] August 2022 Options and Placement Agent Options [Member] August Two Thousand Twenty Two Options And Placement Agent Options [Member] August two thousand twenty two options and placement agent options. August 2022 Options & August 2022 Placement Agent Options [Member] Short-term investments Investments, Fair Value Disclosure Investments, Fair Value Disclosure, Total Disposal Group, Including Discontinued Operation, Liabilities, Current, Total Disposal Group, Including Discontinued Operation, Liabilities, Current Current liabilities of discontinued operations - GoodWheat Accounts receivable and other receivables, net of allowance for doubtful accounts of $0 as of September 30, 2024 and December 31, 2023 Remaining accounts receivable and other receivables Accounts receivable and other receivables Weighted-Average Exercise Price Per Share, Options expired Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Stanley Jacot, Jr. [Member] President and Chief Executive Officer [Member] President and Chief Executive Officer [Member] CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Weighted-Average Exercise Price Per Share, Outstanding Beginning Balance Weighted Average Exercise Price Per Share, Outstanding Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Asset Class Asset Class [Axis] Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Accounts receivable and other receivables August 2022 Placement Agent Options [Member] August Two Thousand Twenty Two Placement Agent Options [Member] August two thousand twenty two placement agent options. Lessor, Operating Lease, Assumptions and Judgments, Value of Underlying Asset, Amount Recognition of additional right-of-use asset and lease liability Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Total intangible asset, Net Carrying Amount Right of use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee Number of shares awarded o individual employee Disposal group including discontinued operation impairment of property and equipment. Disposal Group Including Discontinued Operation Impairment of Property And Equipment Impairment of property and equipment Impairment of property and equipment Depreciation continuing and discontinued operations. Depreciation Continuing and Discontinued Operations Depreciation Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Weighted-average remaining lease term (years) Operating Lease, Weighted Average Remaining Lease Term Subsequent Events Subsequent Events [Text Block] OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total Change in unrealized gains on available-for-sale securities Disposal group including discontinued operation assets held for sale. Disposal Group Including Discontinued Operation Assets Held for Sale Assets held for sale Total operating expenses Costs and Expenses Term Warrant and Rights Outstanding Term Warrant and rights outstanding term. Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Disposal Group, Including Discontinued Operation, Liabilities [Abstract] Liabilities Short term lease cost Short term lease cost Short-Term Lease, Cost Accounts Payable and Accrued Liabilities, Current, Total Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Royalty payments due, percentage of net revenue as defined in the In-Licensing agreements Royalty Payments Due Percentage Of Net Revenue As Defined In Agreements Royalty Payments Due, Percentage Of Net Revenue As Defined In Agreements XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 05, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Amendment Flag false Â Document Period End Date Sep. 30, 2024 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Entity Registrant Name Arcadia Biosciences, Inc. Â Entity Central Index Key 0001469443 Â Entity Current Reporting Status Yes Â Current Fiscal Year End Date --12-31 Â Entity Filer Category Non-accelerated Filer Â Entity Common Stock, Shares Outstanding Â 1,364,940 Entity Shell Company false Â Entity Emerging Growth Company false Â Entity Small Business true Â Entity File Number 001-37383 Â Entity Tax Identification Number 81-0571538 Â Entity Address, Address Line One 5950 Sherry Lane Â Entity Address, Address Line Two Suite 215 Â Entity Address, City or Town Dallas Â Entity Address, State or Province TX Â Entity Address, Postal Zip Code 75225 Â City Area Code 214 Â Local Phone Number 974-8921 Â Entity Incorporation, State or Country Code DE Â Trading Symbol RKDA Â Title of 12(b) Security Common Â Security Exchange Name NASDAQ Â Entity Interactive Data Current Yes Â Document Quarterly Report true Â Document Transition Report false Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration

X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 9 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 3,936 $ 6,518 Short-term investments 2,640 5,124 Accounts receivable and other receivables, net of allowance for doubtful accounts of $0 as of September 30, 2024 and December 31, 2023 882 506 Inventories - current 835 837 Assets held for sale 0 51 Note receivable - current 1,827 0 Prepaid expenses and other current assets 521 807 Current assets of discontinued operations - GoodWheat 70 1,129 Total current assets 10,711 14,972 Property and equipment, net 55 70 Right of use asset 306 792 Inventories - noncurrent 0 196 Intangible assets, net 39 39 Note receivable - noncurrent 3,966 0 Other noncurrent assets 164 164 Noncurrent assets of discontinued operations - GoodWheat 0 3,472 Total assets 15,241 19,705 Current liabilities: Â Â Accounts payable and accrued expenses 1,692 1,910 Operating lease liability â€” current 346 852 Current liabilities of discontinued operations - GoodWheat 0 500 Total current liabilities 2,328 3,590 Operating lease liability â€” noncurrent 0 155 Common stock warrant and option liabilities 764 1,257 Other noncurrent liabilities 2,000 2,000 Total liabilities 5,092 7,002 Commitments and contingencies (Note 14) Stockholdersâ€™ equity: Â Â Common stock, $0.001 par value - 150,000,000 shares authorized; 1,364,940 and 1,285,337 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 65 65 Additional paid-in capital 284,919 284,515 Accumulated other comprehensive income 117 101 Accumulated deficit (274,814) (271,840) Total stockholders' equity 10,287 12,841 Non-controlling interest (138) (138) Total stockholders' equity 10,149 12,703 Total liabilities and stockholdersâ€™ equity 15,241 19,705 Related Party [Member] Â Â Current liabilities: Â Â Other current liabilities 30 58 Nonrelated Party [Member] Â Â Current liabilities: Â Â Other current liabilities $ 260 $ 270 X - DefinitionCommon stock warrant and option liabilities. + ReferencesNo definition available. + Details Name: rkda_CommonStockWarrantAndOptionLiabilities Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_AccountsAndOtherReceivablesNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -

Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 15 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482309/360-10-15-4 + Details Name: us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 11 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionInventories not expected to be converted to cash, sold or exchanged within the normal operating cycle. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_MinorityInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_NotesAndLoansReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of financing receivable, classified as noncurrent. + ReferencesNo definition available. + Details Name: us-gaap_NotesAndLoansReceivableNetNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data

Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember Namespace Prefix: Data Type: na

Balance Type: Period Type: XML 10 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â Allowance for doubtful accounts $ 0 $ 0 Common stock, par value $ 0.001 $ 0.001 Common stock, authorized 150,000,000 150,000,000 Common stock, issued 1,364,940 1,285,337 Common stock, outstanding 1,364,940 1,285,337 X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 11 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenues: Â Â Â Â Total revenues $ 1,537 $ 1,298 $ 3,829 $ 3,677 Operating expenses : Â Â Â Â Cost of revenues 1,032 818 2,136 1,996 Research and development 24 15 40 55 Gain on sale of intangible assets 0 0 (4,000) 0 Impairment of property and equipment 0 0 36 0 Selling, general and administrative 2,241 1,862 6,986 6,535 Total operating expenses 3,297 2,695 5,198 8,586 Loss from continuing operations (1,760) (1,397) (1,369) (4,909) Interest income 233 133 428 538 Other income , net 15 17 168 36 Valuation loss on March 2023 PIPE 0 0 0 (6,076) Change in fair value of common stock warrant and option liabilities 330 608 493 5,965 Issuance and offering costs allocated to liability classified options 0 0 0 (430) Net loss from continuing operations before income taxes (1,182) (639) (280) (4,876) Income tax provision 0 0 0 (1) Net loss from continuing operations (1,182) (639) (280) (4,877) Net loss (1,612) (2,567) (2,974) (11,133) Net loss attributable to non-controlling interest 0 0 0 (5) Net loss attributable to common stockholders $ (1,612) $ (2,567) $ (2,974) $ (11,128) Net loss per share attributable to common stockholders: Â Â Â Â Basic net loss per share attributable to common stockholders from continuing operations $ (0.87) $ (0.47) $ (0.21) $ (4.08) Diluted net loss per share attributable to common stockholders from continuing operations (0.87) (0.47) (0.21) (4.08) Basic net loss per share attributable to common stockholders from discontinued operations (0.32) (1.42) (1.98) (5.24) Net loss per basic share attributable to common stockholders (1.18) (1.89) (2.18) (9.31) Net loss per diluted share attributable to common stockholders $ (1.18) $ (1.89) $ (2.18) $ (9.31) Weighted-average number of shares used in per share calculations: Â Â Â Â Weighted average shares - Basic 1,363,753 1,359,511 1,362,754 1,195,354 Weighted average shares - Diluted 1,363,753 1,359,511 1,362,754 1,195,354 Other comprehensive income (loss), net of tax Â Â Â Â Unrealized gains on available-for-sale securities $ 36 $ 66 $ 117 $ 87 Reclassification adjustment for gains on available-for-sale securities included in net loss 0 0 (111) 0 Change in unrealized gains on available-for-sale securities 36 66 6 87 Comprehensive loss (1,576) (2,501) (2,968) (11,041) Body Care Â Â Â Â Operating expenses : Â Â Â Â Net loss from discontinued operations 0 (83) 0 (591) GoodWheat Â Â Â Â Operating expenses : Â Â Â Â Net loss from discontinued operations (430) (1,845) (2,694) (5,665) Product Â Â Â Â Revenues: Â Â Â Â Total revenues 1,537 1,298 3,829 3,667 License Â Â Â Â Revenues: Â Â Â Â Total revenues $ 0 $ 0 $ 0 $ 10 X - DefinitionChange in fair value of common stock warrant and option liabilities. + ReferencesNo definition available. + Details Name: rkda_ChangeInFairValueOfCommonStockWarrantAndOptionLiabilities Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGain (loss) on private placement. + ReferencesNo definition available. + Details Name: rkda_GainLossOnPrivatePlacement Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIssuance and offering costs allocated to liability classified options. + ReferencesNo definition available. + Details Name: rkda_IssuanceAndOfferingCostsAllocatedToLiabilityClassifiedOptions Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14:

http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section

50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPer basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income (expense) classified as operating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_InterestIncomeExpenseNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B + Details Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingIncomeLossAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A + Details Name: us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type:

xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=rkda_BodyCareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=rkda_GoodwheatMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_LicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 12 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands Total March 2023 PIPE [Member] Common Stock [Member] Common Stock [Member] August 2022 Pre-Funded Warrants [Member] Common Stock [Member] March 2023 Pre-Funded Warrants [Member] Common Stock [Member] March 2023 PIPE [Member] Additional Paid-In Capital [Member] Additional Paid-In Capital [Member] March 2023 PIPE [Member] Accumulated Deficit [Member] Accumulated Other Comprehensive Income [Member] Non-Controlling Interest [Member] Stockholders Equity, Beginning Balance at Dec. 31, 2022 $ 20,900 Â $ 65 Â Â Â $ 278,827 Â $ (257,859) Â $ (133) Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2022 Â Â 616,079 Â Â Â Â Â Â Â Â Â Â Issuance of shares Â $ 4,740 Â Â Â Â Â $ 4,740 Â Â Â Issuance of shares, Shares Â Â Â Â Â 165,500 Â Â Â Â Â Modification of warrants related to March 2023 PIPE Â $ 219 Â Â Â Â Â $ 219 Â Â Â Issuance of shares related to Pre-Funded Warrants exercise Â Â Â 56,813 Â Â Â Â Â Â Â Issuance of shares related to employee stock purchase plan 5 Â Â Â Â Â 5 Â Â Â Â Issuance of shares related to employee stock purchase plan, Shares Â Â 88 Â Â Â Â Â Â Â Â Issuance of shares related to reverse stock split Â Â 19,092 Â Â Â Â Â Â Â Â Stock-based compensation 212 Â Â Â Â Â 212 Â Â Â Â Net (loss) income (9,384) Â Â Â Â Â Â Â (9,384) Â Â Stockholders Equity, Ending Balance at Mar. 31, 2023 16,692 Â $ 65 Â Â Â 284,003 Â (267,243) Â (133) Stockholders Equity, Ending Balance, Shares at Mar. 31, 2023 Â Â 857,572 Â Â Â Â Â Â Â Â Stockholders Equity, Beginning Balance at Dec. 31, 2022 $ 20,900 Â $ 65 Â Â Â 278,827 Â (257,859) Â (133) Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2022 Â Â 616,079 Â Â Â Â Â Â Â Â Issuance of shares related to Pre-Funded Warrants exercise (482,647) Â Â Â Â Â Â Â Â Â Â Net (loss) income $ (11,133) Â Â Â Â Â Â Â Â Â Â Stockholders Equity, Ending Balance at Sep. 30, 2023 15,398 Â $ 65 Â Â Â 284,371 Â (268,987) $ 87 (138) Stockholders Equity, Ending Balance, Shares at Sep. 30, 2023 Â Â 1,110,337 Â Â Â Â Â Â Â Â Stockholders Equity, Beginning Balance at Dec. 31, 2022 20,900 Â $ 65 Â Â Â 278,827 Â (257,859) Â (133) Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2022 Â Â 616,079 Â Â Â Â Â Â Â Â Net (loss) income (14,000) Â Â Â Â Â Â Â Â Â Â Stockholders Equity, Ending Balance at Dec. 31, 2023 12,703 Â $ 65 Â Â Â 284,515 Â (271,840) 101 (138) Stockholders Equity, Ending Balance, Shares at Dec. 31, 2023 Â Â 1,285,337 Â Â Â Â Â Â Â Â Stockholders Equity, Beginning Balance at Mar. 31, 2023 16,692 Â $ 65 Â Â Â 284,003 Â (267,243) Â (133) Stockholders Equity, Beginning Balance, Shares at Mar. 31, 2023 Â Â 857,572 Â Â Â Â Â Â Â Â Issuance of shares related to Pre-Funded Warrants exercise Â Â Â 250,834 Â Â Â Â Â Â Issuance of shares related to reverse stock split Â Â 26 Â Â Â Â Â Â Â Â Stock-based compensation 199 Â Â Â Â Â 199 Â Â Â Â Change in unrealized gains on available-for-sale securities 21 Â Â Â Â Â Â Â Â 21 Â Net (loss) income 818 Â Â Â Â Â Â Â 823 Â (5) Stockholders Equity, Ending Balance at Jun. 30, 2023 17,730 Â $ 65 Â Â Â 284,202 Â (266,420) 21 (138) Stockholders Equity, Ending Balance, Shares at Jun. 30, 2023 Â Â 1,108,432 Â Â Â Â Â Â Â Â Issuance of shares related to employee stock purchase plan 7 Â Â Â Â Â 7 Â Â Â Â Issuance of shares related to employee stock purchase plan, Shares Â Â 1,905 Â Â Â Â Â Â Â Â Stock-based compensation 162 Â Â Â Â Â 162 Â Â Â Â Change in unrealized gains on available-for-sale securities 66 Â Â Â Â Â Â Â Â 66 Â Net (loss) income (2,567) Â Â Â Â Â Â Â (2,567) Â Â Stockholders Equity, Ending Balance at Sep. 30, 2023 15,398 Â $ 65 Â Â Â 284,371 Â (268,987) 87 (138) Stockholders Equity, Ending Balance, Shares at Sep. 30, 2023 Â Â 1,110,337 Â Â Â Â Â Â Â Â Stockholders Equity, Beginning Balance at Dec. 31, 2023 12,703 Â $ 65 Â Â Â 284,515 Â (271,840) 101 (138) Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2023 Â Â 1,285,337 Â Â Â Â Â Â Â Â Issuance of shares related to Pre-Funded Warrants exercise Â Â Â Â 75,000 Â Â Â Â Â Â Issuance of shares related to employee stock purchase plan 5 Â Â Â Â Â 5 Â Â Â Â Issuance of shares related to employee stock purchase plan, Shares Â Â 2,503 Â Â Â Â Â Â Â Â Stock-based compensation 138 Â Â Â Â Â 138 Â Â Â Â Change in unrealized gains on available-for-sale securities 60 Â Â Â Â Â Â Â Â 60 Â Net (loss) income (2,423) Â Â Â Â Â Â Â (2,423) Â Â Stockholders Equity, Ending Balance at Mar. 31, 2024 10,483 Â $ 65 Â Â Â 284,658 Â (274,263) 161 (138) Stockholders Equity, Ending Balance, Shares at Mar. 31, 2024 Â Â 1,362,840 Â Â Â Â Â Â Â Â Stockholders Equity, Beginning Balance at Dec. 31, 2023 $ 12,703 Â $ 65 Â Â Â 284,515 Â (271,840) 101 (138) Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2023 Â Â 1,285,337 Â Â Â Â Â Â Â Â Issuance of shares related to Pre-Funded Warrants exercise (75,000) Â Â Â Â Â Â Â Â Â Â Issuance of shares related to reverse stock split 19,118 Â Â Â Â Â Â Â Â Â Â Net (loss) income $ (2,974) Â Â Â Â Â Â Â Â Â Â Stockholders Equity, Ending Balance at Sep. 30, 2024 10,149 Â $ 65 Â Â Â 284,919 Â (274,814) 117 (138) Stockholders Equity, Ending Balance, Shares at Sep. 30, 2024 Â Â 1,364,940 Â Â Â Â Â Â Â Â Stockholders Equity, Beginning Balance at Mar. 31, 2024 10,483 Â $ 65 Â Â Â 284,658 Â (274,263) 161 (138) Stockholders Equity, Beginning Balance, Shares at Mar. 31, 2024 Â Â 1,362,840 Â Â Â Â Â Â Â Â Stock-based compensation 102 Â Â Â Â Â 102 Â Â Â Â Change in unrealized gains on available-for-sale securities (80) Â Â Â Â Â Â Â Â (80) Â Net (loss) income 1,061 Â Â Â Â Â Â Â 1,061 Â Â Stockholders Equity, Ending Balance at Jun. 30, 2024 11,566 Â $ 65 Â Â Â 284,760 Â (273,202) 81 (138) Stockholders Equity, Ending Balance, Shares at Jun. 30, 2024 Â Â 1,362,840 Â Â Â Â Â Â Â Â Issuance of shares related to employee stock purchase plan 4 Â Â Â Â Â 4 Â Â Â Â Issuance of shares related to employee stock purchase plan, Shares Â Â 2,100 Â Â Â Â Â Â Â Â Stock-based compensation 155 Â Â Â Â Â 155 Â Â Â Â Change in unrealized gains on available-for-sale securities 36 Â Â Â Â Â Â Â Â 36 Â Net (loss) income (1,612) Â Â Â Â Â Â Â (1,612) Â Â Stockholders Equity, Ending Balance at Sep. 30, 2024 $ 10,149 Â $ 65 Â Â Â $ 284,919 Â $ (274,814) $ 117 $ (138) Stockholders Equity, Ending Balance, Shares at Sep. 30, 2024 Â Â 1,364,940 Â Â Â Â Â Â Â Â X - DefinitionAdjustments to additional paid in capital modification of warrants. + ReferencesNo definition available. + Details Name: rkda_AdjustmentsToAdditionalPaidInCapitalModificationOfWarrants Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period shares related to exercise of warrants. + ReferencesNo definition available. + Details Name: rkda_StockIssuedDuringPeriodSharesRelatedToExerciseOfWarrants Namespace Prefix: rkda_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionReduction in the number of shares during the period as a result of a reverse stock split. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML

13 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 CASH FLOWS FROM OPERATING ACTIVITIES: Â Â Â Â Â Â Â Net loss $ (1,612,000) $ (2,423,000) $ (2,567,000) $ (9,384,000) $ (2,974,000) $ (11,133,000) $ (14,000,000) Adjustments to reconcile net loss to cash used in operating activities: Â Â Â Â Â Â Â Change in fair value of common stock warrant and option liabilities (330,000) Â (608,000) Â (493,000) (5,965,000) Â Issuance and offering costs allocated to liability classified options 0 Â 0 Â 0 430,000 Â Valuation loss on March 2023 PIPE 0 Â 0 Â 0 6,076,000 Â Depreciation Â Â Â Â Â 92,000 227,000 Â Lease amortization Â Â Â Â Â 502,000 535,000 Â Amortization of note receivable discount Â Â Â Â (90,000) 0 Â Gain on disposal of property and equipment Â Â Â Â (65,000) (36,000) Â Gain on sale of RS durum wheat trait 0 Â 0 Â (4,000,000) 0 Â Stock-based compensation 155,000 Â 162,000 Â 395,000 573,000 Â Write-down of inventories 154,000 Â 252,000 Â 154,000 444,000 Â Impairment of property and equipment Â 36,000 Â Â 36,000 0 Â Changes in operating assets and liabilities: Â Â Â Â Â Â Â Accounts receivable and other receivables Â Â Â Â (445,000) 249,000 Â Inventories Â Â Â Â Â 620,000 (1,388,000) Â Prepaid expenses and other current assets Â Â Â Â 287,000 (284,000) Â Other noncurrent assets Â Â Â Â Â 0 (13,000) Â Accounts payable and accrued expenses Â Â Â Â (719,000) (300,000) Â Amounts due to related parties Â Â Â Â (29,000) (2,000) Â Other current liabilities Â Â Â Â Â (11,000) 11,000 Â Operating lease liabilities Â Â Â Â (678,000) (573,000) Â Net cash used in operating activities Â Â Â Â (7,418,000) (11,149,000) (15,300,000) CASH FLOWS FROM INVESTING ACTIVITIES: Â Â Â Â Â Â Â Proceeds from sale of property and equipment Â Â Â Â Â 342,000 42,000 Â Proceeds from sale of Verdeca - earn-out received Â Â Â Â Â 0 569,000 Â Proceeds from sale of investments Â Â Â Â Â 2,501,000 0 Â Proceeds from sale of RS durum wheat trait Â Â Â Â Â 4,000,000 0 Â Cash paid related to sale of GoodWheat Â Â Â Â Â (2,000,000) 0 Â Purchases of property and equipment Â Â Â Â (16,000) (5,000) Â Purchases of investments Â Â Â Â 0 (5,002,000) Â Net cash provided by (used in) investing activities Â Â Â Â 4,827,000 (4,396,000) Â CASH FLOWS FROM FINANCING ACTIVITIES: Â Â Â Â Â Â Â Proceeds from ESPP purchases Â Â Â Â Â 9,000 12,000 Â Net cash provided by financing activities Â Â Â Â 9,000 5,512,000 Â Net decrease in cash and cash equivalents Â Â Â Â (2,582,000) (10,033,000) Â Cash and cash equivalents - beginning of period Â $ 6,518,000 Â $ 20,644,000 6,518,000 20,644,000 20,644,000 Cash and cash equivalents - end of period $ 3,936,000 Â $ 10,611,000 Â 3,936,000 10,611,000 $ 6,518,000 NONCASH INVESTING AND FINANCING ACTIVITIES: Â Â Â Â Â Â Â Right of use assets obtained in exchange for new operating lease liabilities Â Â Â Â 86,000 0 Â Note receivable recognized from sale of GoodWheat Â Â Â Â 5,705,000 0 Â March 2023 PIPE [Member] Â Â Â Â Â Â Â CASH FLOWS FROM FINANCING ACTIVITIES: Â Â Â Â Â Â Â Proceeds from issuance of common stock, pre-funded warrants and preferred investment options from March 2023 PIPE Â Â Â Â 0 5,997,000 Â Payments of offering costs relating to March 2023 PIPE Â Â Â Â 0 (497,000) Â NONCASH INVESTING AND FINANCING ACTIVITIES: Â Â Â Â Â Â Â Common stock options issued to placement agent and included in offering costs Â Â Â Â 0 212,000 Â Warrant and option modifications included in Valuation loss on March 2023 PIPE Â Â Â Â Â $ 0 $ 404,000 Â X - DefinitionAmortization of note receivable discount. + ReferencesNo definition available. + Details Name: rkda_AmortizationOfNoteReceivableDiscount Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionChange in fair value of common stock warrant and option liabilities. + ReferencesNo definition available. + Details Name: rkda_ChangeInFairValueOfCommonStockWarrantAndOptionLiabilities Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCommon stock options issued to placement agent and included in offering costs. + ReferencesNo definition available. + Details Name: rkda_CommonStockOptionsIssuedToPlacementAgentAndIncludedInOfferingCosts Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDepreciation continuing and discontinued operations. + ReferencesNo definition available. + Details Name: rkda_DepreciationContinuingAndDiscontinuedOperations Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDisposal group including discontinued operation impairment of property and equipment. + ReferencesNo definition available. + Details Name: rkda_DisposalGroupIncludingDiscontinuedOperationImpairmentOfPropertyAndEquipment Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGain (loss) on private placement. + ReferencesNo definition available. + Details Name: rkda_GainLossOnPrivatePlacement Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIssuance and offering costs allocated to liability classified options. + ReferencesNo definition available. + Details Name: rkda_IssuanceAndOfferingCostsAllocatedToLiabilityClassifiedOptions Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNote receivable recognized from sale of good wheat. + ReferencesNo definition available. + Details Name: rkda_NoteReceivableRecognizedFromSaleOfGoodWheat Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPayment for sale of disposal group, including discontinued operation. + ReferencesNo definition available. + Details Name: rkda_PaymentForSaleOfDisposalGroupIncludingDiscontinuedOperation Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPayments of offering costs. + ReferencesNo definition available. + Details Name: rkda_PaymentsOfOfferingCosts Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProceeds from issuance of common stock pre-funded warrants and preferred investment options. + ReferencesNo definition available. + Details Name: rkda_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndPreferredInvestmentOptions Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWarrant modification included in valuation loss. + ReferencesNo definition available. + Details Name: rkda_WarrantModificationIncludedInValuationLoss Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3 + Details Name: us-gaap_GainLossOnDispositionOfAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDueToRelatedParties Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in current liabilities classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherCurrentLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2 + Details Name: us-gaap_InventoryWriteDown Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow associated with the purchase of all investments (debt, security, other) during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from the sale of investments classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfOtherInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the stock plan during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromStockPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_SecuritiesFinancingTransactionAxis=rkda_MarchTwoThousandAndTwentyThreePIPEMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 14 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Net Income (Loss) $ (1,612) $ (2,567) $ (2,974) $ (11,128) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 15 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Basis of Presentation 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Description of Business and Basis of Presentation 1. Description of Business and Basis of PresentationOrganizationArcadia Biosciences, Inc. (the "Company," "Arcadia" or "management"), was incorporated in Arizona in 2002 and maintains its headquarters in Dallas, Texas, with additional office space in Davis and Sacramento, California. The Company was reincorporated in Delaware in March 2015.Since acquiring the assets of Live Zola, LLC ("Zola") in May 2021, the Company has provided consumers with a great tasting way to rehydrate, reset, and reenergize with Zola coconut water products. The company has leveraged its history as a leader in science-based approaches to develop high value products and drive innovation in the consumer goods industry. Previously, the Company developed products primarily in wheat, which it commercialized through the sales of seed, grain and food ingredients and products, and through trait licensing and royalty agreements.On May 16, 2024, the Company sold the GoodWheatâ„¢ brand to Above Food Ingredients Corp. ("Above Food") for net consideration of $3.7 million. Refer to Note 6 for details of the transaction.On May 14, 2024, the Company sold its non-GMO Resistant Starch ("RS") durum wheat trait to longtime partner Corteva AgriScience ("Corteva"). Under the terms of the agreement, Arcadia retained certain rights to use the RS durum wheat trait. The Company received $4.0 million in cash payment from Corteva during the nine months ended September 30, 2024 and recorded a gain of the same amount as the trait had no carrying value on the condensed consolidated statement of operations and comprehensive loss related to the transaction. Refer to Note 8 for details of the partnership and transaction.In May 2021, the Companyâ€™s wholly owned subsidiary Arcadia Wellness, LLC (â€œArcadia Wellnessâ€ or â€œAWâ€) acquired the businesses of Eko Holdings, LLC, Lief, LLC, and Zola. The acquisition included Saavy Naturalsâ„¢, a line of natural body care products, Soul Springâ„¢, a CBD-infused botanical therapy brand in the natural category, and ProVaultâ„¢, a THC-free CBD sports performance formula made with natural ingredients, providing effective support and recovery for athletes (collectively, "body care brands"). Also included in the purchase was Zola, a coconut water sourced exclusively with sustainably grown coconuts from Thailand. In July 2022, the Company entered into an agreement to license Saavy Naturals to Radiance Beauty and Wellness, Inc. ("Radiance Beauty"). In July 2023, management made the decision to exit the remaining body care brands, Soul Spring and ProVault, as a result of continued pressure on the CBD market due to regulatory uncertainty. Body care operations ceased during the third quarter of 2023. In August 2019, the Company entered into a joint venture agreement with Legacy Ventures Hawaii, LLC (â€œLegacy,â€ see Note 7) to grow, extract, and sell hemp products. The partnership Archipelago Ventures Hawaii, LLC (â€œArchipelagoâ€), combines the Companyâ€™s extensive genetic expertise and resources with Legacyâ€™s experience in hemp extraction and sales. In October 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to regulatory challenges and a saturated hemp market.In February 2012, the Company formed Verdeca, which was equally owned with Bioceres. Verdeca was formed to develop and deregulate soybean varieties using both partnersâ€™ agricultural technologies. In November 2020, Arcadia sold its membership interest in Verdeca to Bioceres in a transaction in which Arcadia received cash, shares of Bioceres stock and a royalty stream of up to $10.0 million on sales of Haab 4 soybeans (â€œHB4â€). An additional $2.0 million in cash was to be paid to Arcadia upon Verdeca achieving commercial plantings of at least 200,000 hectares of HB4 or China approving the HB4 soybean trait for â€œfood and feedâ€. During 2022, Bioceres received China's approval of the HB4 soybean trait and as a result, Arcadia recorded license revenue of $862,000 and a gain on sale of Verdeca of $1.1 million on the condensed consolidated statements of operations and comprehensive loss. The Company received the full payment of $2.0 million as of December 31, 2023. Basis of Presentation and Principles of ConsolidationThe accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (â€œGAAPâ€) for interim financial statements and are in the form prescribed by the Securities and Exchange Commission (the â€œSECâ€) in instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Companyâ€™s financial position, results of operations and cash flows for the periods indicated. All material intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company, Arcadia Wellness, and Archipelago.The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities ("VIEs"). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIEâ€™s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE.For all periods presented, the Company has determined that it is the primary beneficiary of Archipelago, a joint venture, as it has a controlling interest in Archipelago. Accordingly, the Company consolidates Archipelago in the condensed consolidated financial statements after eliminating intercompany transactions. For consolidated joint ventures, the non-controlling partnerâ€™s share of the assets, liabilities and operations of the joint venture is included in non-controlling interests as equity of the Company. The non-controlling partnerâ€™s interest is generally computed as the joint venture partnerâ€™s ownership percentage of Archipelago. The non-controlling partnerâ€™s equity interests are presented as non-controlling interests on the condensed consolidated balance sheets.The information included in these condensed consolidated financial statements and notes thereto should be read in conjunction with Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations included herein and Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations and the condensed consolidated financial statements and notes thereto for the fiscal year ended December 31, 2023 included in the Companyâ€™s Annual Report on Form 10-K, filed with the SEC on March 28, 2024.ReclassificationsCertain previously reported financial information has been reclassified to conform to the current year presentation. For a discussion of the reclassification of the financial presentation of our former GoodWheat and body care brands reported as discontinued operations, see â€œDiscontinued Operationsâ€ section below. Unless otherwise noted, amounts and disclosures throughout these notes to condensed consolidated financial statements relate solely to continuing operations and exclude all discontinued operations.Reverse Stock SplitIn February 2023, the Companyâ€™s board of directors approved a reverse split of 40:1 on the Companyâ€™s issued and outstanding common stock. On February 15, 2023, the Companyâ€™s stockholders approved the certificate of amendment to the Companyâ€™s certificate of incorporation, which the Company filed on February 27, 2023 with the Secretary of State of Delaware to effect the reverse split on March 1, 2023. As a result of the reverse stock split, 19,118 additional shares of common stock were issued in lieu of fractional shares. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the condensed consolidated financial statements have been retroactively adjusted to reflect the reverse stock split for all periods presented.Liquidity, Capital Resources, and Going ConcernThe accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. Since inception, the Company has financed its operations primarily through equity financings. As of September 30, 2024, the Company had an accumulated deficit of $274.8 million, cash and cash equivalents of $3.9 million, short-term investments of $2.6 million and current note receivable of $1.8 million. For the nine months ended September 30, 2024, the Company had net loss of $3.0 million and net cash used in operations of $7.4 million. For the twelve months ended December 31, 2023, the Company had net losses of $14.0 million and net cash used in operations of $15.3 million.With cash and cash equivalents of $3.9 million, short-term investments of $2.6 million and current note receivable of $1.8 million as of September 30, 2024, the Company believes that its existing cash, cash equivalents and short-term investments will not be sufficient to meet its anticipated cash requirements for at least the next 12-18 months from the issuance date of these financial statements, and thus raises substantial doubt about the Companyâ€™s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.The Company may seek to raise additional funds through debt or equity financings. The Company may also consider entering into additional partner arrangements. The sale of additional equity would result in dilution to the Companyâ€™s stockholders. The incurrence of debt would result in debt service obligations, and the instruments governing such debt could provide for additional operating and financing covenants that would restrict operations. If the Company requires additional funds and is unable to secure adequate additional funding at terms agreeable to the Company, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned product launches. Any of these actions could materially harm the business, results of operations and financial condition.Discontinued OperationsOn May 16, 2024, the Company sold the GoodWheat brand to Above Food. GoodWheat operations ceased during the second quarter of 2024. In July 2023, management made the decision to exit its body care brands as a result of continued pressure on the CBD market due to regulatory uncertainty. Body care operations ceased during the third quarter of 2023. In accordance with the provisions of ASC 205-20, the Company has separately reported the assets and liabilities of the discontinued operations in the condensed consolidated balance sheets and the results of the discontinued operations as separate components on the condensed consolidated statements of operations and comprehensive loss for all periods presented.Â Major classes of line items constituting the balance sheet of discontinued operations:Â Â Â GoodWheat Â Â Body Care Â (In thousands) Â September 30, 2024 Â Â December 31, 2023 Â Â September 30, 2024 Â Â December 31, 2023 Â Assets Â Â Â Â Â Â Â Â Â Â Â Â Accounts receivable and other receivables Â $ 70 Â Â $ 8 Â Â $ â€” Â Â $ â€” Â Inventories, net â€” current Â Â â€” Â Â Â 1,121 Â Â Â â€” Â Â Â â€” Â Property and equipment, net Â Â â€” Â Â Â 314 Â Â Â Â â€” Â Â Â â€” Â Inventories, net â€” noncurrent Â Â â€” Â Â Â 3,158 Â Â Â â€” Â Â Â â€” Â Total assets Â $ 70 Â Â $ 4,601 Â Â $ â€” Â Â $ â€” Â Â Â Â Â Â Â Â Â Â Â Â Â Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Â Accounts payable and accrued expenses Â $ â€” Â Â $ 500 Â Â $ â€” Â Â $ â€” Â Total liabilities Â $ â€” Â Â $ 500 Â Â $ â€” Â Â $ â€” Â Â Major classes of line items constituting net loss from discontinued operations:Â Â Â GoodWheat Â Â Body Care Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â (In thousands) Â Product revenue Â $ (76) Â $ 300 Â Â $ 372 Â Â $ 484 Â Â $ â€” Â Â $ 37 Â Â $ â€” Â Â $ 373 Â Cost of revenues Â Â â€” Â Â Â (285) Â Â Â (691) Â Â Â (634) Â Â â€” Â Â Â (34) Â Â â€” Â Â Â (313) Research and development Â Â â€” Â Â Â (291) Â Â Â (400) Â Â (1,000) Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â (Loss) Gain on sale of property and equipment Â Â (24) Â Â 11 Â Â Â 65 Â Â Â 36 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Selling, general and administrative Â Â (330) Â Â (1,580) Â Â (2,040) Â Â (4,551) Â Â â€” Â Â Â (86) Â Â â€” Â Â Â (651) Net loss from discontinued operations Â $ (430) Â $ (1,845) Â $ (2,694) Â $ (5,665) Â $ â€” Â Â $ (83) Â $ â€” Â Â $ (591) The following table presents non-cash items of discontinued operations:Â Â Â GoodWheat Â Â Body Care Â Nine Months Ended September 30, Â Â Nine Months Ended September 30, Â (In thousands) Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Depreciation Â $ 37 Â Â $ 109 Â Â $ â€” Â Â $ 24 Â Gain on disposal of property and equipment Â $ (65) Â $ (36) Â $ â€” Â Â $ â€” Â Write-down of inventories Â $ â€” Â Â $ 275 Â Â $ â€” Â Â $ â€” Â Accounts receivable and other receivables Â $ (78) Â $ â€” Â Â $ â€” Â Â $ (99) Inventories Â $ 575 Â Â $ (1,975) Â $ â€” Â Â $ 250 Â Prepaid expenses and other current assets Â $ â€” Â Â $ â€” Â Â $ â€” Â Â $ 14 Â Accounts payable and accrued expenses Â $ (500) Â $ 144 Â Â $ â€” Â Â $ 5 Â Proceeds from sale of property and equipment Â $ 342 Â Â $ 37 Â Â $ â€” Â Â $ â€” Â There were no other operating or investing non-cash items for the nine months ended September 30, 2024 and 2023. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 17 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Recent Accounting Pronouncements 9 Months Ended Sep. 30, 2024 Accounting Changes and Error Corrections [Abstract] Â Recent Accounting Pronouncements 2. Recent Accounting PronouncementsIn November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) â€”

Improvements to Reportable Segment Disclosures. The amendments in this update improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The new guidance is effective retrospectively for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this update on our segment disclosures. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) â€" Improvements to Income Tax Disclosures. The amendments in this update require additional income tax disclosures primarily related to the rate reconciliation and income taxes paid. The new guidance is effective either prospectively or retrospectively, for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this update on our income tax disclosures. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingChangesAndErrorCorrectionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 11.M.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 250 -Publisher FASB -URI https://asc.fasb.org/250/tableOfContentReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1 + Details Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 18 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Inventory 9 Months Ended Sep. 30, 2024 Inventory Disclosure [Abstract] Â Inventory 3. InventoryInventory costs are tracked on a lot-identified basis and are included as cost of revenues when sold. Inventories are stated at the lower of cost or net realizable value. The Company makes adjustments to inventory when conditions indicate that the net realizable value may be less than cost due to physical deterioration, obsolescence, changes in price levels, or other factors. Additional adjustments to inventory are made for excess and slow-moving inventory on hand that is not expected to be sold within a reasonable timeframe to reduce the carrying amount to its estimated net realizable value. The write-downs to inventory are included in cost of revenues and are based upon estimates about future demand from the Companyâ€™s customers and distributors and market conditions. The Company recorded a write-down of $154,000 related to hemp and GoodWheat seed during the three and nine months ended September 30, 2024. The Company recorded inventory write-downs of $252,000 and $444,000 related to packaging materials, hemp seed and GoodWheat during the three and nine months ended September 30, 2023, respectively. If there are significant changes in demand and market conditions, substantial future write-downs of inventory may be required, which would materially increase the Companyâ€™s expenses in the period the write down is taken and materially affect the Companyâ€™s operating results.Inventories, net consist of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Raw materials Â $ 450 Â Â $ 373 Â Finished goods Â Â 385 Â Â Â 660 Â Inventories Â $ 835 Â Â $ 1,033 Â X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details Name: us-gaap_InventoryDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment, Net 9 Months Ended Sep. 30, 2024 Property, Plant and Equipment [Abstract] Â Property and Equipment, Net 4. Property and Equipment, NetProperty and equipment, net consisted of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Software and computer equipment Â $ 291 Â Â $ 349 Â Machinery and equipment Â Â â€" Â Â Â 34 Â Furniture and fixtures Â Â 32 Â Â Â 39 Â Leasehold improvements Â Â 1,584 Â Â Â 1,590 Â Property and equipment, gross Â Â 1,907 Â Â Â 2,012 Â Less: accumulated depreciation and amortization Â Â (1,852) Â Â (1,942) Property and equipment, net Â $ 55 Â Â $ 70 Â Â Depreciation expense was $7,000 and $92,000 for the three and nine months ended September 30, 2024, respectively. Depreciation expense was $89,000 and $227,000 for the three and nine months ended September 30, 2023, respectively.During the three and nine months ended September 30, 2024 and 2023, there were no sales of property and equipment from continuing operations.Property and equipment are considered assets held for sale when management approves and commits to a plan to dispose of a property or group of properties. The property and equipment held for sale prior to the sale date is separately presented, within current assets, on the condensed consolidated balance sheet as assets held for sale. Property and equipment related to Archipelago of $51,000 were classified as assets held for sale as of December 31, 2023. During the first quarter of 2024, the Company recorded an impairment of $36,000 related to these assets. During the second quarter of 2024, all Archipelago property and equipment previously held for sale were sold. X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7 + Details Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Investments and Fair Value Instruments 9 Months Ended Sep. 30, 2024 Investments And Fair Value Instruments [Abstract] Â Investments and Fair Value Instruments 5. Investments and Fair Value Instruments Available-for-Sale InvestmentsThe Company classified short-term investments as â€œavailable-for-sale.â€ These short-term investments are free of trading restrictions. The investments are carried at fair value, based on quoted market prices or other readily available market information. Unrealized gains and losses are included in accumulated other comprehensive income, which is reflected as a separate component of stockholderâ€™s equity in the condensed consolidated balance sheets. Gains and losses are recognized when realized in the condensed consolidated statements of operations and comprehensive loss.The following tables summarize the amortized cost and fair value of the investment securities portfolio at September 30, 2024 and December 31, 2023 and the corresponding amounts of unrealized gains and losses recognized in accumulated other comprehensive income:Â (Dollars in thousands) Â AmortizedCost Â Â UnrealizedGains Â Â UnrealizedLosses Â Â EstimatedFair Value Â September 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 2,770 Â Â $ â€" Â Â $ â€" Â Â $ 2,770 Â Short-term investments: Â Â Â Â Â Â Â Â Â Â Â Treasury bills Â Â 2,523 Â Â Â 117 Â Â Â â€" Â Â Â 2,640 Â Total Assets at Fair Value Â $ 5,293 Â Â $ 117 Â Â $ â€" Â Â $ 5,410 Â Â (Dollars in thousands) Â AmortizedCost Â Â UnrealizedGains Â Â UnrealizedLosses Â Â EstimatedFair Value Â December 31, 2023 Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 4,925 Â Â $ â€" Â Â $ â€" Â Â $ 4,925 Â Short-term investments: Â Â Â Â Â Â Â Â Â Â Â Treasury bills Â Â 5,023 Â Â Â 101 Â Â Â â€" Â Â $ 5,124 Â Total Assets at Fair Value Â $ 9,948 Â Â $ 101 Â Â $ â€" Â Â $ 10,049 Â Â The Company did not have any investment categories that were in a continuous unrealized loss position for more than twelve months as of September 30, 2024. Fair Value MeasurementÂ The fair value of the investment securities at September 30, 2024 were as follows:Â Â Â Fair Value Measurements at September 30, 2024 Â (Dollars in thousands) Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Total Â Assets at Fair Value Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 2,770 Â Â $ â€" Â Â $ â€" Â Â $ 2,770 Â Short-term investments: Â Â Â Â Â Â Â Â Â Â Â Treasury bills Â Â 2,640 Â Â Â â€" Â Â Â 2,640 Â Total Assets at Fair Value Â $ 5,410 Â Â $ â€" Â Â $ â€" Â Â $ 5,410 Â Â The fair value of the investment securities at December 31, 2023 were as follows:Â Â Â Fair Value Measurements at December 31, 2023 Â (Dollars in thousands) Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Total Â Assets at Fair Value Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 4,925 Â Â $ â€" Â Â $ â€" Â Â $ 4,925 Â Short-term investments: Â Â Â Â Â Â Â Â Â Â Â Treasury bills Â Â 5,124 Â Â Â â€" Â Â Â 5,124 Â Total Assets at Fair Value Â $ 10,049 Â Â $ â€" Â Â $ â€" Â Â $ 10,049 Â Â The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2024 or 2023. The Companyâ€™s financial instruments consist primarily of cash and cash equivalents, short-term investments, accounts receivable and other receivables, note receivable, accounts payable and accrued liabilities. For short-term investments, accounts receivable and other receivables, accounts payable and accrued liabilities, the carrying amounts of these financial instruments as of September 30, 2024 and December 31, 2023 were considered representative of their fair values due to their short term to maturity or repayment. Cash equivalents are carried at cost, which approximates their fair value. The note receivable is recorded at amortized cost. The amortized cost of the note receivable is considered approximate fair value due to its variable interest rate.The Companyâ€™s Level 3 liabilities consist of a contingent liability resulting from the Anawah, Inc. ("Anawah") acquisition as described in Note 14, as well as preferred investment options related to the March 2023 Private Placement and August 2022 Registered Direct offerings described in Note 10.The contingent liability related to the Anawah acquisition was measured and recorded on a recurring basis as of September 30, 2024 and December 31, 2023, using unobservable inputs, namely the Companyâ€™s ability and intent to pursue certain specific products developed using technology acquired in the purchase. A significant deviation in the Companyâ€™s ability and/or intent to pursue the technology acquired in the purchase could result in a significantly lower (higher) fair value measurement.The preferred investment option liabilities were measured and recorded on a recurring basis using the Black-Scholes Model with the following assumptions as of September 30, 2024 and December 31, 2023: Â Â March 2023 Options - Series A & March 2023 Placement Agent Options Â Â March 2023 Options - Series B Â Â August 2022 Options & August 2022 Placement Agent Options Â Â September 30, 2024 Â Â December 31,2023 Â Â September 30, 2024 Â Â December 31,2023 Â Â September 30, 2024 Â Â December 31,2023 Â Remaining term (in years) Â Â 3.40 Â Â Â 4.16 Â Â Â â€" Â Â Â 0.61 Â Â Â 2.92 Â Â Â 3.67 Â Expected volatility Â Â 86.9 % Â Â 91.7 % Â Â â€" Â Â Â 78.7 % Â Â 91.8 % Â Â 90.5 % Risk-free interest rate Â Â 3.6 % Â Â 3.9 % Â Â â€" Â Â Â 5.2 % Â Â 3.6 % Â Â 4.0 % Expected dividend yield Â Â 0 % Â Â 0 % Â Â â€" Â Â Â 0 % Â Â 0 % Â Â 0 % Â The significant input used in the fair value measurement of the Companyâ€™s Level 3 options liabilities is volatility. A significant increase (decrease) in volatility could result in a significantly higher (lower) fair value measurement.The following table sets forth the establishment of the Companyâ€™s Level 3 assets and liabilities, as well as a summary of the changes in the fair value and other adjustments (in thousands):Â Â Â Â Â (Dollars in thousands) Â March 2023Options - Series A Â Â March 2023Options - Series B Â Â March 2023 Placement Agent Options Â Â August 2022Options Â Â August 2022Placement Agent Options Â Â Note Receivable Bifurcated Derivatives Â Â ContingentLiabilities Â Â Total Â Balance as of December 31, 2023 Â $ 1,008 Â Â $ 41 Â Â $ 46 Â Â $ 159 Â Â $ 3 Â Â $ â€" Â Â $ 2,000 Â Â $ 3,257 Â Initial recognition Â Â â€" Â Â Â â€" Â Â Â â€" Â Â Â â€" Â Â Â â€" Â Â Â 250 Â Â Â â€" Â Â Â 250 Â Change in fair value Â Â (378) Â Â (41) Â Â (19) Â Â (53) Â Â (2) Â Â â€" Â Â Â â€" Â Â Â (493) Balance as of September 30, 2024 Â $ 630 Â Â $ â€" Â Â $ 27 Â Â $ 106 Â Â $ 1 Â Â $ 250 Â Â $ 2,000 Â Â $ 3,014 Â Â X - DefinitionInvestments and fair value instruments. + ReferencesNo definition available. + Details Name: rkda_InvestmentsAndFairValueInstrumentsAbstract Namespace Prefix: rkda_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionInvestments and fair value of instruments disclosure. + ReferencesNo definition available. + Details Name: rkda_InvestmentsAndFairValueOfInstrumentsDisclosureTextBlock Namespace Prefix: rkda_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Note Receivable 9 Months Ended Sep. 30, 2024 Receivables [Abstract] Â Note Receivable 6. Note ReceivableOn May 16, 2024, the

Company sold the GoodWheat brand to Above Food for net consideration of $3.7 million. The assets sold consisted primarily of grain and finished goods inventories, formulations and trademarks. A loss of $1,500 was recognized in the condensed consolidated statements of operations and comprehensive loss during the nine months ended September 30, 2024, related to the sale. In connection with the transaction, Arcadia paid to Above Food $2.0 million and received a $6.0 million promissory note dated May 14, 2024. The promissory note has a term of three years and accrues interest at the Wall Street Journal prime rate. On each of the first, second and third anniversaries of the promissory note, accrued interest and $2.0 million of principal are payable to Arcadia. The promissory note contains contingent features, including an option that requires Above Food to cause its parent entity, Above Food Ingredients Inc. (â€œParent Companyâ€), to issue to the Company publicly traded stock of Parent Company in exchange for the cancellation of a portion of the principal of the promissory note, as well as default provisions. The Company accounted for the promissory note as a note receivable in accordance with ASC 310. The Company did not elect the fair value option and since the Company intends to and has the ability to hold the promissory note to maturity, it has been classified as held for investment and is reported on the condensed consolidated balance sheet at amortized cost. The first installment payment due in 2025 is classified as current and the remaining installment payments due in 2026 and 2027 are classified as noncurrent on the condensed consolidated balance sheet. The contingent features of the promissory note were evaluated for bifurcation in accordance with ASC 815. The contingent features requiring bifurcation had an estimated fair value of $250,000 as of the transaction date and as of September 30, 2024. The estimated fair value of the contingent features is reported in note receivable â€“ noncurrent on the condensed consolidated balance sheet as of September 30, 2024. The promissory note was recorded at a discount of $545,000, which is being amortized over the term of the promissory note using the effective interest method. The Company recognized discount amortization of $60,000 and $89,000 in the condensed consolidated statements of operations and comprehensive loss during the three and nine months ended September 30, 2024, respectively. The Company recognized accrued interest of $126,000 and $193,000 in the condensed consolidated statements of operations and comprehensive loss during the three and nine months ended September 30, 2024, respectively. X - DefinitionThe entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/310-10/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ReceivablesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 22 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Joint Venture 9 Months Ended Sep. 30, 2024 Equity Method Investments and Joint Ventures [Abstract] Â Consolidated Joint Venture 7. Consolidated Joint VentureIn 2019, the Company and Legacy Ventures Hawaii, LLC, a Nevada limited liability company (â€œLegacyâ€), formed Archipelago Ventures Hawaii, LLC, a Delaware limited liability company and entered into a Limited Liability Company Operating Agreement (the â€œOperating Agreementâ€). The Company and Legacy formed Archipelago to develop, extract and commercialize hemp-derived products from industrial hemp grown in Hawaii.Pursuant to the Operating Agreement, a joint operating committee consisting of two individuals appointed by the Company and two individuals appointed by Legacy will manage Archipelago. As of September 30, 2024, the Company and Legacy hold 50.75% and 49.25% interests in Archipelago, respectively, and have made capital contributions to Archipelago of $3.1 million and $3.0 million, respectively, as determined by the joint operating committee. The Operating Agreement includes indemnification rights, non-competition obligations, and certain rights and obligations in connection with the transfer of membership interests, including rights of first refusal.The Company consolidates Archipelago in the condensed consolidated financial statements after eliminating intercompany transactions. Legacyâ€™s equity interests are presented as non-controlling interests on the condensed consolidated balance sheets. Refer to Note 1 for basis of presentation.In October 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to regulatory challenges and a saturated hemp market. X - ReferencesNo definition available. + Details Name: us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group. + ReferencesReference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478156/740-323-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 323 -Publisher FASB -URI https://asc.fasb.org/323/tableOfContent + Details Name: us-gaap_EquityMethodInvestmentsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Collaborative Arrangements 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Collaborative Arrangements 8. Collaborative ArrangementsIn August 2017, the Company entered into a collaborative arrangement for the research, development and commercialization of our non-GMO RS durum wheat trait in North America. This collaborative arrangement was a contractual agreement with Corteva and involved a joint operating activity where both Arcadia and Corteva were active participants in the activities of the collaboration. Arcadia and Corteva participated in the research and development, and Arcadia had the primary responsibility for the intellectual property strategy while Corteva generally led the marketing and commercialization efforts. Both parties were exposed to significant risks and rewards of the collaboration and the agreement included both cost sharing and profit sharing. The activities were performed with no guarantee of either technological or commercial success.The Company accounted for research and development (â€œR&Dâ€) costs in accordance ASC 730, Research and Development, which states R&D costs must be charged to expense as incurred. Accordingly, internal R&D costs are expensed as incurred. Third-party R&D costs are expensed when the contracted work has been performed or as milestone results are achieved.On May 14, 2024, the Company sold its RS durum wheat trait to Corteva. Under the terms of the agreement, Arcadia retained certain rights to use the RS durum wheat trait. The Company received $4.0 million in cash payment from Corteva during the nine months ended September 30, 2024 and recorded a gain of the same amount as the trait had no carrying value on the condensed consolidated statement of operations and comprehensive loss related to the transaction. X - DefinitionThe entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 808 -Publisher FASB -URI https://asc.fasb.org/808/tableOfContent + Details Name: us-gaap_CollaborativeArrangementDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Leases 9 Months Ended Sep. 30, 2024 Lessee Disclosure [Abstract] Â Leases 9. LeasesOperating LeasesAs of September 30, 2024, the Company leases office space in Dallas, TX, Davis and Sacramento, CA, as well as additional buildings, land and equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these short-term leases on a straight-line basis. The Company subleases the Davis office to third parties.Some leases (the Dallas and Davis offices, a warehouse, and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years. The exercise of lease renewal options is at the Companyâ€™s sole discretion. In January 2024, the Company exercised it's option to renew the facility lease in American Falls, Idaho for one year through December 31, 2024. The lease renewal resulted in recognition of additional right-of-use asset and lease liability of $86,000 on the condensed consolidated balance sheet. The Company subsequently terminated the facility lease in American Falls, Idaho effective July 2024.The Companyâ€™s lease agreements do not contain any material variable lease payments, material residual value guarantees or material restrictive covenants. Leases consisted of the following (in thousands):Â Leases Â Classification Â September 30, 2024 Â Â December 31, 2023 Â Assets Â Â Â Â Â Â Â Â Â Operating lease assets Â Â Right of use asset Â $ 306 Â Â Â $ 792 Â Total leased assets Â Â Â Â $ 306 Â Â Â $ 792 Â Liabilities Â Â Â Â Â Â Â Â Â Current - Operating Â Â Operating lease liability- current Â $ 346 Â Â Â $ 852 Â Noncurrent - Operating Â Â Operating lease liability- noncurrent Â Â â€” Â Â Â 155 Â Total leased liabilities Â Â Â Â $ 346 Â Â Â $ 1,007 Â Â Lease Cost Â Classification Â ThreeMonths EndedSeptember 30, 2024 Â Â ThreeMonths EndedSeptember 30, 2023 Â Â NineMonths EndedÂ September 30, 2024 Â Â NineMonths EndedÂ September 30, 2023 Â Operating lease cost Â Â SG&A and R&D Expenses Â $ 172 Â Â Â $ 191 Â Â Â $ 678 Â Â Â $ 572 Â Short term lease cost Â Â SG&A Expenses Â Â Â 3 Â Â Â Â Â 3 Â Â Â 10 Â Â Â Â 10 Â Sublease income (1) Â Â SG&A and R&D Expenses Â Â (142) Â Â (111) Â Â (404) Â Â (329) Net lease cost Â Â Â Â $ 33 Â Â Â $ 83 Â Â Â $ 284 Â Â Â $ 253 Â Â (1)Sublease income is recorded as a reduction to lease expense.Â Lease Termand Discount Rate Â September 30, 2024 Â Â December 31, 2023 Â Weighted-average remainingÂ Â Â lease term (years) Â Â 0.7 Â Â Â 2.3 Â Weighted-average discount rate Â Â 6.5 % Â Â 6.0 % X - ReferencesNo definition available. + Details Name: us-gaap_LesseeDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Equity Financing 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Equity Financing 10. Equity FinancingMarch 2023 Private PlacementIn March 2023, the Company issued in a private placement offering (the â€œMarch 2023 Private Placementâ€) pursuant to a securities purchase agreement (â€œMarch 2023 Purchase Agreementâ€) (i) 165,500 shares of its common stock, (ii) pre-funded common stock purchase warrants (the â€œMarch 2023 Pre-Funded Warrantsâ€) to purchase up to 500,834 shares of common stock, at an exercise price of $0.0001 per share, (iii) Series A preferred investment options (the â€œMarch 2023 Options - Series A") to purchase up to a total of 666,334 shares of common stock, at an exercise price of $9.00 per share, and (iv) Series B preferred investment options (the â€œMarch 2023 Options - Series Bâ€, and together with the March 2023 Options - Series A, the "March 2023 Options") to purchase up to a total of 666,334 shares of common stock, at an exercise price of $9.00 per share, and raised total gross proceeds of $6.0 million. The March 2023 Private Placement closed on March 6, 2023. The March 2023 Pre-Funded Warrants became exercisable upon issuance and were fully exercised as of September 30, 2024. The March 2023 Options - Series A are exercisable at any time at the option of the holder and expire 5 years from the date of issuance. The March 2023 Options - Series B were exercisable at any time at the option of the holder and expire 1.5 years from the date of issuance. As of September 30, 2024, the March 2023 Options - Series B expired.In connection with the March 2023 Private Placement, the Company entered into preferred investment option amendment agreements (the â€œOption Amendment Agreementsâ€) with certain investors. Under the Option Amendment Agreements, the Company agreed to amend certain existing warrants and preferred investment options to purchase up to a total of 178,132 shares of common stock that were previously issued to the investors in September 2019, May 2020, July 2020, December 2020, January 2021 and August 2022, with exercise prices of $300.80, $191.00, $154.00, $120.00, $125.20 and $37.35 per share, respectively (the â€œExisting Warrantsâ€). Under the Option Amendment Agreements, the Company agreed to lower the exercise price of the Existing Warrants to $9.00 per share. In addition, the Company granted to a placement agent preferred investment options to purchase a total of 33,317 shares of Common Stock (the â€œMarch 2023 Placement Agent Optionsâ€) that have an exercise price per share equal to $11.25 and a term of 5 years from the date of issuance. The re-pricing of the Existing Warrants resulted in an increase in fair value of $404,000, of which $185,000 of the increase in fair value was related to the August 2022 liability classified options. The increase in fair value related to the re-pricing of Existing Warrants was recognized in Valuation Loss on March 2023 PIPE on the condensed consolidated statements of operations and comprehensive loss.The March 2023 Options and March 2023 Placement Agent Options are classified as liabilities within Level 3 due to certain early settlement provisions that preclude them from equity classification. The Company utilized the Black-Scholes Model on March 6, 2023 with the following assumptions for the Series A Investment Options: volatility of 128.55%, stock price of $7.61 and risk-free rate of 4.27%. The following assumptions were utilized for the Series B Investment Options: volatility of 103.33%, stock price of $7.61 and risk-free rate of 4.97%. The estimated fair value of the liability classified March 2023 Options issued was $6.6 million. The estimated fair value of the common stock option liabilities was subsequently remeasured at September 30, 2024 with the changes recorded on the Companyâ€™s condensed consolidated statements of operations and comprehensive loss. The estimated fair value of the common stock issued and March 2023 Pre-Funded Warrants was $5.1 million. The total estimated fair value of the common stock issued, March 2023 Pre-Funded Warrants and March 2023 Options as of March 6, 2023 exceeded the gross proceeds of the March 2023 Private Placement by $5.7 million and this amount was recognized in Valuation Loss on March 2023 PIPE on the condensed consolidated statements of operations and comprehensive loss.The March 2023 Placement Agent Options were issued for services performed by the placement agent as part of the March 2023 Private Placement and were treated as offering costs. The value of the March 2023 Placement Agent Options was determined to be $212,000, calculated using the Black-Scholes Model. The Company incurred additional offering costs totaling $548,000 that consist of direct incremental legal, advisory, accounting and filing fees relating to the March 2023 Private Placement. A total of $430,000 was allocated to the common stock option liabilities and expensed while the remaining $330,000 was allocated to the common stock and March 2023 Pre-Funded Warrants and offset to additional paid in capital. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards

Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Warrants and Options 9 Months Ended Sep. 30, 2024 Warrants and Rights Note Disclosure [Abstract] Â Warrants and Options 11. Warrants and OptionsEquity Classified Common Stock WarrantsThe Company issued the following warrants to purchase shares of its common stock, which are outstanding as of September 30, 2024 and December 31, 2023, respectively. These warrants are exercisable any time at the option of the holder until their expiration date.Â Â Â Issuance Date Â Term Â ExercisePrice PerShare Â Â Exercisedduring theYear EndedDecember 31,2023 Â Â Outstanding atDecember 31,2023 Â Â Exercisedduring theNine Months EndedSeptember 30,2024 Â Â Outstanding atSeptember 30, 2024 Â March 2023 Pre-Funded Warrants Â March 2023 Â perpetual Â $ â€” Â Â Â (425,834) Â Â 75,000 Â Â Â (75,000) Â Â â€” Â December 2022 Service and Performance Warrants (1) Â December 2022 Â 5Â years Â $ 11.20 Â Â Â â€” Â Â Â 1,000 Â Â Â â€” Â Â Â 1,000 Â October 2022 Service and Performance Warrants (1) Â October 2022 Â 5Â years Â $ 16.00 Â Â Â â€” Â Â Â 1,000 Â Â Â â€” Â Â Â 1,000 Â August 2022 Pre-Funded Warrants Â August 2022 Â perpetual Â $ â€” Â Â Â (56,813) Â Â â€” Â Â Â â€” Â Â Â â€” Â January 2021 Placement Agent Warrants Â January 2021 Â 5.5Â years Â $ 159.60 Â Â Â â€” Â Â Â 9,846 Â Â Â â€” Â Â Â 9,846 Â December 2020 Warrants (2) Â December 2020 Â 5.5Â years Â $ 9.00 Â Â Â â€” Â Â Â 16,367 Â Â Â â€” Â Â Â 16,367 Â December 2020 Warrants Â December 2020 Â 5.5Â years Â $ 120.00 Â Â Â â€” Â Â Â 49,100 Â Â Â â€” Â Â Â 49,100 Â December 2020 Placement Agent Warrants Â December 2020 Â 5Â years Â $ 152.80 Â Â Â â€” Â Â Â 3,274 Â Â Â â€” Â Â Â 3,274 Â July 2020 Warrants (2) Â July 2020 Â 5.5Â years Â $ 9.00 Â Â Â â€” Â Â Â 16,036 Â Â Â â€” Â Â Â 16,036 Â July 2020 Placement Agent Warrants Â July 2020 Â 5.5Â years Â $ 198.80 Â Â Â â€” Â Â Â 802 Â Â Â â€” Â Â Â 802 Â May 2020 Warrants (2) Â May 2020 Â 5Â years Â $ 9.00 Â Â Â â€” Â Â Â 9,946 Â Â Â â€” Â Â Â 9,946 Â May 2020 Warrants Â May 2020 Â 5Â years Â $ 191.20 Â Â Â â€” Â Â Â 24,863 Â Â Â â€” Â Â Â 24,863 Â May 2020 Placement Agent Warrants Â May 2020 Â 5Â years Â $ 245.20 Â Â Â â€” Â Â Â 1,741 Â Â Â â€” Â Â Â 1,741 Â September 2019 Placement Agent Warrants (3) Â September 2019 Â 5Â years Â $ 379.20 Â Â Â â€” Â Â Â 1,649 Â Â Â â€” Â Â Â â€” Â June 2019 Placement Agent Warrants (3) Â June 2019 Â 5Â years Â $ 251.60 Â Â Â â€” Â Â Â 1,862 Â Â Â â€” Â Â Â â€” Â April 2019 Service and Performance Warrants (1)(3) Â April 2019 Â 5Â years Â $ 247.20 Â Â Â â€” Â Â Â 3,629 Â Â Â â€” Â Â Â â€” Â January 2021 Warrants (2) Â January 2021 Â 5.5Â years Â $ 9.00 Â Â Â â€” Â Â Â 7,831 Â Â Â â€” Â Â Â 7,831 Â January 2021 Warrants Â January 2021 Â 5.5Â years Â $ 125.20 Â Â Â â€” Â Â Â 90,629 Â Â Â â€” Â Â Â 90,629 Â September 2019 Warrants (2) Â September 2019 Â 5.5Â years Â $ 9.00 Â Â Â â€” Â Â Â 9,892 Â Â Â â€” Â Â Â 9,892 Â September 2019 Warrants Â September 2019 Â 5.5Â years Â $ 300.80 Â Â Â â€” Â Â Â 6,594 Â Â Â â€” Â Â Â 6,594 Â June 2019 Warrants Â June 2019 Â 5.5Â years Â $ 200.00 Â Â Â â€” Â Â Â 10,896 Â Â Â â€” Â Â Â 10,896 Â Total Â Â Â Â Â Â Â Â Â Â Â (482,647) Â Â 341,957 Â Â Â (75,000) Â Â 259,817 Â (1) The Company issued service and performance warrants (â€œService and Performance Warrantsâ€) in connection with professional services agreements with non-affiliated third party entities.(2) These warrants were repriced as part of the March 2023 Private Placement offering.(3) These warrants expired during the nine months ended September 30, 2024.Liability Classified Preferred Investment OptionsThe preferred investment options issued in connection with the March 2023 Private Placement and August 2022 Registered Direct offerings contain certain early settlement provisions that preclude them from equity classification and therefore were accounted for as liabilities at the date of issuance and are adjusted to fair value at each balance sheet date. The change in fair value of the options liabilities is recorded as change in fair value of common stock warrant and option liabilities in the condensed consolidated statements of operations and comprehensive loss. The key terms and activity of the liability classified preferred investment options are summarized as follows: Â Â Â Issuance Date Â Term Â ExercisePrice PerShare Â Â Exercisedduring theYear EndedDecember 31,2023 Â Â Outstanding atDecember 31,2023 Â Â Exercisedduring theNineMonths EndedSeptember 30, 2024 Â Â Outstanding atSeptember 30, 2024 Â March 2023 Options - Series A Â March 2023 Â 5Â years Â $ 9.00 Â Â Â â€” Â Â Â 666,334 Â Â Â â€” Â Â Â 666,334 Â March 2023 Options - Series B (2) Â March 2023 Â 1.5Â years Â $ 9.00 Â Â Â â€” Â Â Â 666,334 Â Â Â â€” Â Â Â â€” Â March 2023 Placement Agent Options Â March 2023 Â 5Â years Â $ 11.25 Â Â Â â€” Â Â Â 33,317 Â Â Â â€” Â Â Â 33,317 Â August 2022 Options (1) Â August 2022 Â 5 years Â $ 9.00 Â Â Â â€” Â Â Â 118,063 Â Â Â â€” Â Â Â 118,063 Â August 2022 Placement Agent Options Â August 2022 Â 5 years Â $ 52.80 Â Â Â â€” Â Â Â 5,904 Â Â Â â€” Â Â Â 5,904 Â Total Â Â Â Â Â Â Â Â Â Â Â 1,489,952 Â Â Â â€” Â Â Â 823,618 Â (1) These options were repriced as part of the March 2023 Private Placement offering.(2) These warrants expired during the nine months ended September 30, 2024. X - DefinitionWarrants and options disclosure. + ReferencesNo definition available. + Details Name: rkda_WarrantsAndOptionsDisclosureTextBlock Namespace Prefix: rkda_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WarrantsAndRightsNoteDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 27 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation and Employee Stock Purchase Program 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Stock-Based Compensation and Employee Stock Purchase Program 12. Stock-Based Compensation and Employee Stock Purchase ProgramStock Incentive PlansThe Company has two equity incentive plans: the 2006 Stock Plan (â€œ2006 Planâ€) and the 2015 Omnibus Equity Incentive Plan (â€œ2015 Planâ€).In 2006, the Company adopted the 2006 Plan, which provided for the granting of stock options to executives, employees, and other service providers under terms and provisions established by the Board of Directors. The Company granted non-statutory stock options (â€œNSOsâ€) under the 2006 Plan until May 2015, when it was terminated as to future awards, although it continues to govern the terms of options that remain outstanding and were issued under the 2006 Plan. The 2015 Plan became effective upon the Companyâ€™s IPO in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 3,860 shares of common stock reserved for future issuance, which included 259 that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan. The maximum number of shares that may be awarded to any individual employee, including our directors and officers, during any calendar year was 9,375 shares. The 2015 Plan provides for the grant of incentive stock options (â€œISOsâ€), NSOs, restricted stock awards, stock units, stock appreciation rights, and other forms of equity compensation, all of which may be granted to employees, officers, non-employee directors, and consultants. The exercise price for ISOs and NSOs will be granted at a price per share not less than the fair value of our common stock at the date of grant. Options granted generally vest over a four-year period; however, there might be alternative vesting schedules, as approved by the Board. Options granted, once vested, are generally exercisable for up to 10 years, after grant to the extent vested.On June 25, 2024, the shareholders approved an amendment to the Companyâ€™s 2015 Plan that increased the number of shares of common stock that may be issued under the 2015 Plan by 200,000 shares and increased the maximum number of shares of common stock issuable to employees, including our officers and directors, in any fiscal year from 9,375 shares to 50,000 shares. On February 2, 2022, former president and chief executive officer of the Company, Stanley Jacot, Jr. was hired. The Company granted Mr. Jacot an inducement stock option to purchase 7,902 shares of the Companyâ€™s common stock pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The Company filed a registration statement on Form S-8 to register the issuance of shares upon exercise of this inducement stock option. The inducement options grants were issued outside of the 2015 Plan, but are subject to the terms and conditions of the 2015 Plan. As of September 30, 2024, a total of 338,248 shares of common stock were reserved for issuance under the 2015 Plan, of which 127,725 shares of common stock are available for future grant. As of September 30, 2024, a total of 102 and 210,523 options are outstanding under the 2006 and 2015 Plans, respectively. As of December 31, 2023, a total of 102 and 71,609 options were outstanding under the 2006 and 2015 Plans, respectively. A total of 6,949 and 8,366 inducement options were outstanding as of September 30, 2024 and December 31, 2023, respectively.The following is a summary of stock option information and weighted average exercise prices under the Companyâ€™s stock incentive plans (in thousands, except share data and price per share):Â Â Â SharesSubject toOutstandingOptions Â Â Weighted-AverageExercisePrice PerShare Â Â AggregateIntrinsicValue Â Outstanding â€” Balance at December 31, 2023 Â Â 80,078 Â Â $ 85.30 Â Â $ â€” Â Options granted Â Â 158,000 Â Â Â 2.71 Â Â Â â€” Â Options forfeited Â Â (7,927) Â Â 19.08 Â Â $ 397 Â Options expired Â Â (12,576) Â Â 170.08 Â Â Â â€” Â Outstanding â€” Balance at September 30, 2024 Â Â 217,575 Â Â $ 22.83 Â Â $ 3,140 Â Vested and expected to vest â€” September 30, 2024 Â Â 198,542 Â Â $ 24.68 Â Â $ 2,778 Â Exercisable â€” September 30, 2024 Â Â 50,515 Â Â $ 84.37 Â Â $ â€” Â Â Aggregate intrinsic value represents the difference between the exercise price of the options and the estimated fair value of the Companyâ€™s common stock determined by its Board of Directors for each of the respective periods.As of September 30, 2024, there was $524,000 of unrecognized compensation cost related to unvested stock-based compensation grants that will be recognized over the weighted-average remaining recognition period of 1.4 years.In determining the fair value of the stock-based awards, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine.Expected Termâ€”The expected term is the estimated period of time outstanding for stock options granted and was estimated based on a simplified method allowed by the SEC, and defines the term as the average of the contractual term of the options and the weighted-average vesting period for all open employee awards.Expected Volatilityâ€”The historical volatility data was computed using the daily closing prices for the Companyâ€™s shares during the equivalent period of the calculated expected term of the stock-based awards.Risk-Free Interest Rateâ€”The risk-free interest rate is based on the interest rate of U.S. Treasuries of comparable maturities on the date the options were granted.Expected Dividendâ€”The expected dividend yield is based on the Companyâ€™s expectation of future dividend payouts to common stockholders.The fair value of stock option awards was estimated at the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumption:Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Expected term (years) Â Â 8.04 Â Â Â â€” Â Â Â 8.04 Â Â Â 7.06 Â Expected volatility Â Â 101.31 % Â Â â€” Â Â Â 101.31 % Â Â 124 % Risk-free interest rate Â Â 3.77 % Â Â â€” Â Â Â 3.77 % Â Â 3.61 % Dividend yield Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â The Company recognized $155,000 and $395,000 of compensation expense for stock options awards during the three and nine months ended September 30, 2024, respectively. The Company recognized $162,000 and $573,000 of compensation expense for stock options awards during the three and nine months ended September 30, 2023, respectively. Employee Stock Purchase PlanThe Companyâ€™s 2015 Employee Stock Purchase Plan (â€œESPPâ€) became effective on May 14, 2015. The ESPP allows eligible employees to purchase shares of the Companyâ€™s common stock at a discount of up to 15% of their eligible compensation through payroll deductions, subject to any plan limitations. After the first offering period, which began on May 14, 2015 and ended on February 1, 2016, the ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Companyâ€™s common stock on the first trading day of the offering period or on the last day of the offering period. As of September 30, 2024, the number of shares of common stock reserved for future issuance under the ESPP is 3,209. The ESPP provides for automatic annual increases in the shares available for purchase beginning on January 1, 2016. As of September 30, 2024, 8,073 shares had been issued under the ESPP. The Company recorded $2,000 and $6,000 of ESPP related compensation expense during the three and nine months ended September 30, 2024, respectively. The Company recorded $7,000 and $12,000 of ESPP related compensation expense during the three and nine months ended September 30, 2023, respectively. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 28 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes 9 Months Ended Sep. 30, 2024 Income Tax Disclosure [Abstract] Â Income Taxes 13. Income TaxesIncome tax expense during interim periods is based on applying an estimated annual effective income tax rate to year-to-date income, plus any significant unusual or infrequently occurring items that are recorded in the interim period. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in various jurisdictions, permanent and temporary differences, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, additional information becomes known, or as the tax environment changes.The interim financial statement provision for income taxes is different from the amounts computed by applying the United States federal statutory income tax rate of 21%. The Companyâ€™s effective tax rate was 0.00% for each of the three and nine months ended September 30, 2024 and 2023. The difference between the effective tax rate and the federal statutory rate of 21% was primarily due to the full valuation allowance recorded on the Companyâ€™s net deferred tax assets.During the nine months ended September 30, 2024, there were no material changes to the Companyâ€™s uncertain tax positions.In February 2023, the Company received notification from the Internal Revenue Service ("IRS") that our Archipelago joint venture was selected for audit for the 2021 tax year. The Company received the IRS Notice of Proposed Partnership Adjustment during the third quarter of 2024 and accepted the adjustments. The Company is now awaiting the IRS Final Partnership Adjustment ("FPA"). Reception of the FPA will start a 45-day clock on making the push out election, to push the audit adjustments to the partners. Upon conclusion of the audit, Arcadia expects to adjust their balance of available tax net operating losses and have no penalties or interest due. The Company is currently not under audit for state purposes. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Commitment and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and Contingencies 14. Commitments and ContingenciesLeasesThe Company leases office and warehouse space and equipment under operating lease agreements having initial lease terms ranging from one to five years, including certain renewal options available to the Company at market rates. The Company also leases land for field trials on a short-term basis. See Note 9.Legal MattersFrom time to time, in the ordinary course of business, the Company may become involved in certain legal proceedings. The Company currently is not a party to any material litigation or other material legal proceedings.Contingent Liability Related to the Anawah Acquisition In June 2005, the Company completed its agreement and plan of merger and reorganization with Anawah, to purchase the Anawahâ€™s food and agricultural research company through a non-cash stock purchase. Pursuant to the merger with Anawah, and in accordance with the ASC 805 - Business Combinations, the Company incurred a contingent liability not to exceed $5.0 million. This liability represents amounts to be paid to Anawahâ€™s previous stockholders for cash collected on revenue recognized by the Company upon commercial sale of certain specific products developed using technology acquired in the purchase. During 2010, the Company ceased activities relating to three of the six Anawah product programs thus, the contingent liability was reduced to $3.0 million. During 2016, one of the programs previously accrued for was abandoned and another program previously abandoned was reactivated. During 2019, the Company determined that one of the technologies was no longer active and decided to abandon the previously accrued program. As of September 30, 2024, the Company continues to pursue or are otherwise liable for a total of two development programs using this technology and believes that the contingent liability is probable. As a result, $2.0 million remains on the condensed consolidated balance sheet as an other noncurrent liability.ContractsThe Company has entered into contract research agreements with unrelated parties that require the Company to pay certain funding commitments. The initial terms of these agreements range from one to three years in duration and in certain cases are cancelable.The Company licenses certain technologies via executed agreements (â€œIn-Licensing Agreementsâ€) that are used to develop and advance the Companyâ€™s own technologies. The Company has entered into various In-Licensing Agreements with related and unrelated parties that require the Company to pay certain license fees, royalties, and/or milestone fees. In addition, certain royalty payments ranging from 2% to 15% of net revenue amounts as defined in the In-Licensing Agreements are or will be due.The Company could be adversely affected by certain actions by the government as it relates to government contract revenue received in prior years. Government agencies, such as the Defense Contract Audit Agency routinely audit and investigate government contractors. These agencies review a contractorâ€™s performance under its agreements; cost structure; and compliance with applicable laws, regulations and standards. The agencies also review the adequacy of, and a contractorâ€™s compliance with, its internal control systems and policies, including the contractorâ€™s purchasing, property, estimating, compensation and management information systems. While the Companyâ€™s management anticipates no adverse result from an audit, should any costs be found to be improperly allocated to a government agreement, such costs will not be reimbursed, or if already reimbursed, may need to be refunded. If an audit uncovers improper or illegal activities, civil and criminal penalties and administrative sanctions, including termination of contracts, forfeiture of profits, suspension of payments or fines, and suspension or prohibition from doing business with the government could occur. In addition, serious reputational harm or significant adverse financial effects could occur if allegations of impropriety were made against the Company. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Net Loss per Share 15. Net Loss per ShareBasic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per share attributable to common stockholders is computed giving effect to all potentially dilutive common shares, including common stock issuable upon exercise of stock options and warrants. Dilutive securities are not included in the computation of net loss per share when the impact would be anti-dilutive. Securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows (in shares):Â Â Â Three Months Ended September 30, Â Â For the Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Options to purchase common stock Â Â 217,575 Â Â Â 84,058 Â Â Â 217,575 Â Â Â 84,058 Â Warrants to purchase common stock Â Â 259,817 Â Â Â 266,957 Â Â Â 259,817 Â Â Â 266,957 Â Preferred investment options Â Â 823,618 Â Â Â 1,489,952 Â Â Â 823,618 Â Â Â Â 1,489,952 Â Total Â Â 1,301,010 Â Â Â 1,840,967 Â Â Â 1,301,010 Â Â Â 1,840,967 Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Related-Party Transactions 9 Months Ended Sep. 30, 2024 Related Party Transactions [Abstract] Â Related-Party Transactions 16. Related-Party TransactionsThe Companyâ€™s related parties include Moral Compass Corporation (â€œMCCâ€) and the John Sperling Foundation (â€œJSFâ€). The rights to the intellectual property owned by Blue Horse Labs, Inc. (â€œBHLâ€) were assigned to its sole shareholder, the John Sperling Revocable Trust (â€œJSRTâ€) due to BHLâ€™s dissolution and then subsequently to the JSF. The JSF is deemed a related party of the Company because MCC, one of the Companyâ€™s largest stockholder, and the JSF share common officers and directors.JSF receives a single digit royalty from the Company when revenue has been collected on product sales or for license payments from third parties that involve certain intellectual property developed under research funding originally from BHL. Royalty fees due to JSF were $30,000 and $58,000 as of September 30, 2024 and December 31, 2023, respectively, and are included in the condensed consolidated balance sheets as amounts due to related parties. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Basis of Presentation (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Organization OrganizationArcadia Biosciences, Inc. (the "Company," "Arcadia" or "management"), was incorporated in Arizona in 2002 and maintains its headquarters in Dallas, Texas, with additional office space in Davis and Sacramento, California. The Company was reincorporated in Delaware in March 2015.Since acquiring the assets of Live Zola, LLC ("Zola") in May 2021, the Company has provided consumers with a great tasting way to rehydrate, reset, and reenergize with Zola coconut water products. The company has leveraged its history as a leader in science-based approaches to develop high value products and drive innovation in the consumer goods industry. Previously, the Company developed products primarily in wheat, which it commercialized through the sales of seed, grain and food ingredients and products, and through trait licensing and royalty agreements.On May 16, 2024, the Company sold the GoodWheatâ„¢ brand to Above Food Ingredients Corp. ("Above Food") for net consideration of $3.7 million. Refer to Note 6 for details of the transaction.On May 14, 2024, the Company sold its non-GMO Resistant Starch ("RS") durum wheat trait to longtime partner Corteva AgriScience ("Corteva"). Under the terms of the agreement, Arcadia retained certain rights to use the RS durum wheat trait. The Company received $4.0 million in cash payment from Corteva during the nine months ended September 30, 2024 and recorded a gain of the same amount as the trait had no carrying value on the condensed consolidated statement of operations and comprehensive loss related to the transaction. Refer to Note 8 for details of the partnership and transaction.In May 2021, the Companyâ€™s wholly owned subsidiary Arcadia Wellness, LLC (â€œArcadia Wellnessâ€ or â€œAWâ€) acquired the businesses of Eko Holdings, LLC, Lief, LLC, and Zola. The acquisition included Saavy Naturalsâ„¢, a line of natural body care products, Soul Springâ„¢, a CBD-infused botanical therapy brand in the natural category, and ProVaultâ„¢, a THC-free CBD sports performance formula made with natural ingredients, providing effective support and recovery for athletes (collectively, "body care brands"). Also included in the purchase was Zola, a coconut water sourced exclusively with sustainably grown coconuts from Thailand. In July 2022, the Company entered into an agreement to license Saavy Naturals to Radiance Beauty and Wellness, Inc. ("Radiance Beauty"). In July 2023, management made the decision to exit the remaining body care brands, Soul Spring and ProVault, as a result of continued pressure on the CBD market due to regulatory uncertainty. Body care operations ceased during the third quarter of 2023. In August 2019, the Company entered into a joint venture agreement with Legacy Ventures Hawaii, LLC (â€œLegacy,â€ see Note 7) to grow, extract, and sell hemp products. The partnership Archipelago Ventures Hawaii, LLC (â€œArchipelagoâ€), combines the Companyâ€™s extensive genetic expertise and resources with Legacyâ€™s experience in hemp extraction and sales. In October 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to regulatory challenges and a saturated hemp market.In February 2012, the Company formed Verdeca, which was equally owned with Bioceres. Verdeca was formed to develop and deregulate soybean varieties using both partnersâ€™ agricultural technologies. In November 2020, Arcadia sold its membership interest in Verdeca to Bioceres in a transaction in which Arcadia received cash, shares of Bioceres stock and a royalty stream of up to $10.0 million on sales of Haab 4 soybeans (â€œHB4â€). An additional $2.0 million in cash was to be paid to Arcadia upon Verdeca achieving commercial plantings of at least 200,000 hectares of HB4 or China approving the HB4 soybean trait for â€œfood and feedâ€. During 2022, Bioceres received China's approval of the HB4 soybean trait and as a result, Arcadia recorded license revenue of $862,000 and a gain on sale of Verdeca of $1.1 million on the condensed consolidated statements of operations and comprehensive loss. The Company received the full payment of $2.0 million as of December 31, 2023. Basis of Presentation and Principles of Consolidation Basis of Presentation and Principles of ConsolidationThe accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (â€œGAAPâ€) for interim financial statements and are in the form prescribed by the Securities and Exchange Commission (the â€œSECâ€) in instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Companyâ€™s financial position, results of operations and cash flows for the periods indicated. All material intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company, Arcadia Wellness, and Archipelago.The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities ("VIEs"). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIEâ€™s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE.For all periods presented, the Company has determined that it is the primary beneficiary of Archipelago, a joint venture,

as it has a controlling interest in Archipelago. Accordingly, the Company consolidates Archipelago in the condensed consolidated financial statements after eliminating intercompany transactions. For consolidated joint ventures, the non-controlling partnerâ€™s share of the assets, liabilities and operations of the joint venture is included in non-controlling interests as equity of the Company. The non-controlling partnerâ€™s interest is generally computed as the joint venture partnerâ€™s ownership percentage of Archipelago. The non-controlling partnerâ€™s equity interests are presented as non-controlling interests on the condensed consolidated balance sheets.The information included in these condensed consolidated financial statements and notes thereto should be read in conjunction with Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations included herein and Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations and the condensed consolidated financial statements and notes thereto for the fiscal year ended December 31, 2023 included in the Companyâ€™s Annual Report on Form 10-K, filed with the SEC on March 28, 2024. Reclassifications ReclassificationsCertain previously reported financial information has been reclassified to conform to the current year presentation. For a discussion of the reclassification of the financial presentation of our former GoodWheat and body care brands reported as discontinued operations, see â€œDiscontinued Operationsâ€ section below. Unless otherwise noted, amounts and disclosures throughout these notes to condensed consolidated financial statements relate solely to continuing operations and exclude all discontinued operations. Reverse Stock Split Reverse Stock SplitIn February 2023, the Companyâ€™s board of directors approved a reverse split of 40:1 on the Companyâ€™s issued and outstanding common stock. On February 15, 2023, the Companyâ€™s stockholders approved the certificate of amendment to the Companyâ€™s certificate of incorporation, which the Company filed on February 27, 2023 with the Secretary of State of Delaware to effect the reverse split on March 1, 2023. As a result of the reverse stock split, 19,118 additional shares of common stock were issued in lieu of fractional shares. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the condensed consolidated financial statements have been retroactively adjusted to reflect the reverse stock split for all periods presented. Liquidity, Capital Resources, and Going Concern Liquidity, Capital Resources, and Going ConcernThe accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. Since inception, the Company has financed its operations primarily through equity financings. As of September 30, 2024, the Company had an accumulated deficit of $274.8 million, cash and cash equivalents of $3.9 million, short-term investments of $2.6 million and current note receivable of $1.8 million. For the nine months ended September 30, 2024, the Company had net loss of $3.0 million and net cash used in operations of $7.4 million. For the twelve months ended December 31, 2023, the Company had net losses of $14.0 million and net cash used in operations of $15.3 million.With cash and cash equivalents of $3.9 million, short-term investments of $2.6 million and current note receivable of $1.8 million as of September 30, 2024, the Company believes that its existing cash, cash equivalents and short-term investments will not be sufficient to meet its anticipated cash requirements for at least the next 12-18 months from the issuance date of these financial statements, and thus raises substantial doubt about the Companyâ€™s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.The Company may seek to raise additional funds through debt or equity financings. The Company may also consider entering into additional partner arrangements. The sale of additional equity would result in dilution to the Companyâ€™s stockholders. The incurrence of debt would result in debt service obligations, and the instruments governing such debt could provide for additional operating and financing covenants that would restrict operations. If the Company requires additional funds and is unable to secure adequate additional funding at terms agreeable to the Company, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned product launches. Any of these actions could materially harm the business, results of operations and financial condition. Discontinued Operations Discontinued OperationsOn May 16, 2024, the Company sold the GoodWheat brand to Above Food. GoodWheat operations ceased during the second quarter of 2024. In July 2023, management made the decision to exit its body care brands as a result of continued pressure on the CBD market due to regulatory uncertainty. Body care operations ceased during the third quarter of 2023. In accordance with the provisions of ASC 205-20, the Company has separately reported the assets and liabilities of the discontinued operations in the condensed consolidated balance sheets and the results of the discontinued operations as separate components on the condensed consolidated statements of operations and comprehensive loss for all periods presented.Â Major classes of line items constituting the balance sheet of discontinued operations:Â Â Â GoodWheat Â Â Body Care Â (In thousands) Â September 30, 2024 Â Â December 31, 2023 Â Â September 30, 2024 Â Â December 31, 2023 Â Assets Â Â Â Â Â Â Â Â Â Â Â Â Â Accounts receivable and other receivables Â $ 70 Â Â $ 8 Â Â $ â€” Â Â $ â€” Â Inventories, net â€” current Â Â â€” Â Â Â 1,121 Â Â Â â€” Â Â Â â€” Â Property and equipment, net Â Â â€” Â Â Â 314 Â Â Â â€” Â Â Â â€” Â Inventories, net â€” noncurrent Â Â â€” Â Â Â 3,158 Â Â Â â€” Â Â Â â€” Â Total assets Â $ 70 Â Â $ 4,601 Â Â $ â€” Â Â $ â€” Â Â Â Â Â Â Â Â Â Â Â Â Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Â Â Accounts payable and accrued expenses Â $ â€” Â Â $ 500 Â Â $ â€” Â Â $ â€” Â Total liabilities Â $ â€” Â Â $ 500 Â Â $ â€” Â Â $ â€” Â Â Major classes of line items constituting net loss from discontinued operations:Â Â Â GoodWheat Â Â Body Care Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â (In thousands) Â Product revenue Â $ (76) Â $ 300 Â Â $ 372 Â Â $ 484 Â Â $ â€” Â Â $ 37 Â Â $ â€” Â Â $ 373 Â Cost of revenues Â Â â€” Â Â Â (285) Â Â (691) Â Â (634) Â Â â€” Â Â Â (34) Â Â â€” Â Â Â (313) Research and development Â Â â€” Â Â Â (291) Â Â (400) Â Â (1,000) Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â (Loss) Gain on sale of property and equipment Â Â (24) Â Â 11 Â Â Â 65 Â Â Â 36 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Selling, general and administrative Â Â (330) Â Â (1,580) Â Â (2,040) Â Â (4,551) Â Â â€” Â Â Â (86) Â Â â€” Â Â Â (651) Net loss from discontinued operations Â $ (430) Â $ (1,845) Â $ (2,694) Â $ (5,665) Â $ â€” Â Â $ (83) Â $ â€” Â Â $ (591) The following table presents non-cash items of discontinued operations:Â Â Â GoodWheat Â Â Body Care Â Nine Months Ended September 30, Â Â Nine Months Ended September 30, Â (In thousands) Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Depreciation Â $ 37 Â Â $ 109 Â Â $ â€” Â Â $ 24 Â Gain on disposal of property and equipment Â $ (65) Â $ (36) Â $ â€” Â Â $ â€” Â Write-down of inventories Â $ â€” Â Â $ 275 Â Â $ â€” Â Â $ â€” Â Accounts receivable and other receivables Â $ (78) Â $ â€” Â Â $ â€” Â Â $ (99) Inventories Â $ 575 Â Â $ (1,975) Â $ â€” Â Â $ 250 Â Prepaid expenses and other current assets Â $ â€” Â Â $ â€” Â Â $ â€” Â Â $ 14 Â Accounts payable and accrued expenses Â $ (500) Â $ 144 Â Â $ â€” Â Â $ 5 Â Proceeds from sale of property and equipment Â $ 342 Â Â $ 37 Â Â $ â€” Â Â $ â€” Â There were no other operating or investing non-cash items for the nine months ended September 30, 2024 and 2023. X - DefinitionBasis of presentation and principles of consolidation. + ReferencesNo definition available. + Details Name: rkda_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock Namespace Prefix: rkda_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionLiquidity capital resources and going concern. + ReferencesNo definition available. + Details Name: rkda_LiquidityCapitalResourcesAndGoingConcernPolicyPolicyTextBlock Namespace Prefix: rkda_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionOrganization policy. + ReferencesNo definition available. + Details Name: rkda_OrganizationPolicyPolicyTextBlock Namespace Prefix: rkda_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionReverse stock split policy policy text block. + ReferencesNo definition available. + Details Name: rkda_ReverseStockSplitPolicyPolicyTextBlock Namespace Prefix: rkda_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section S99 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480781/205-20-S99-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1 + Details Name: us-gaap_DiscontinuedOperationsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 205 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1 + Details Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Basis of Presentation (Tables) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Summary of Major Classes of Line Items Constituting Discontinued Operations Major classes of line items constituting the balance sheet of discontinued operations:Â Â Â GoodWheat Â Â Body Care Â (In thousands) Â September 30, 2024 Â Â December 31, 2023 Â Â September 30, 2024 Â Â December 31, 2023 Â Assets Â Â Â Â Â Â Â Â Â Â Â Â Â Accounts receivable and other receivables Â $ 70 Â Â $ 8 Â Â $ â€” Â Â $ â€” Â Inventories, net â€” current Â Â â€” Â Â Â 1,121 Â Â Â â€” Â Â Â â€” Â Property and equipment, net Â Â â€” Â Â Â 314 Â Â Â â€” Â Â Â â€” Â Inventories, net â€” noncurrent Â Â â€” Â Â Â 3,158 Â Â Â â€” Â Â Â â€” Â Total assets Â $ 70 Â Â $ 4,601 Â Â $ â€” Â Â $ â€” Â Â Â Â Â Â Â Â Â Â Â Â Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Â Â Accounts payable and accrued expenses Â $ â€” Â Â $ 500 Â Â $ â€” Â Â $ â€” Â Total liabilities Â $ â€” Â Â $ 500 Â Â $ â€” Â Â $ â€” Â Â Major classes of line items constituting net loss from discontinued operations:Â Â Â GoodWheat Â Â Body Care Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â (In thousands) Â Product revenue Â $ (76) Â $ 300 Â Â $ 372 Â Â $ 484 Â Â $ â€” Â Â $ 37 Â Â $ â€” Â Â $ 373 Â Cost of revenues Â Â â€” Â Â Â (285) Â Â (691) Â Â (634) Â Â â€” Â Â Â (34) Â Â â€” Â Â Â (313) Research and development Â Â â€” Â Â Â (291) Â Â (400) Â Â (1,000) Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â (Loss) Gain on sale of property and equipment Â Â (24) Â Â 11 Â Â Â 65 Â Â Â 36 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Selling, general and administrative Â Â (330) Â Â (1,580) Â Â (2,040) Â Â (4,551) Â Â â€” Â Â Â (86) Â Â â€” Â Â Â (651) Net loss from discontinued operations Â $ (430) Â $ (1,845) Â $ (2,694) Â $ (5,665) Â $ â€” Â Â $ (83) Â $ â€” Â Â $ (591) The following table presents non-cash items of discontinued operations:Â Â Â GoodWheat Â Â Body Care Â Nine Months Ended September 30, Â Â Nine Months Ended September 30, Â (In thousands) Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Depreciation Â $ 37 Â Â $ 109 Â Â $ â€” Â Â $ 24 Â Gain on disposal of property and equipment Â $ (65) Â $ (36) Â $ â€” Â Â $ â€” Â Write-down of inventories Â $ â€” Â Â $ 275 Â Â $ â€” Â Â $ â€” Â Accounts receivable and other receivables Â $ (78) Â $ â€” Â Â $ â€” Â Â $ (99) Inventories Â $ 575 Â Â $ (1,975) Â $ â€” Â Â $ 250 Â Prepaid expenses and other current assets Â $ â€” Â Â $ â€” Â Â $ â€” Â Â $ 14 Â Accounts payable and accrued expenses Â $ (500) Â $ 144 Â Â $ â€” Â Â $ 5 Â Proceeds from sale of property and equipment Â $ 342 Â Â $ 37 Â Â $ â€” Â Â $ â€” Â There were no other operating or investing non-cash items for the nine months ended September 30, 2024 and 2023. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3AReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5D -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5DReference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3AReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3 + Details Name: us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Inventory (Tables) 9 Months Ended Sep. 30, 2024 Inventory Disclosure [Abstract] Â Summary of Inventories Inventories, net consist of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Raw materials Â $ 450 Â Â $ 373 Â Finished goods Â Â 385 Â Â Â 660 Â Inventories Â $ 835 Â Â $ 1,033 Â X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. Includes current and non-current inventory balances. + ReferencesNo definition available. + Details Name: rkda_ScheduleOfInventoryCurrentAndNonCurrentTableTextBlock Namespace Prefix: rkda_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 35 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment, Net (Tables) 9 Months Ended Sep. 30, 2024 Property, Plant and Equipment [Abstract] Â Summary of Property and Equipment, Net Property and equipment, net consisted of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Software and computer equipment Â $ 291 Â Â $ 349 Â Machinery and equipment Â Â â€” Â Â Â 34 Â Furniture and fixtures Â Â 32 Â Â Â 39 Â Leasehold improvements Â Â 1,584 Â Â Â 1,590 Â Property and equipment, gross Â Â 1,907 Â Â Â 2,012 Â Less: accumulated depreciation and amortization Â Â (1,852) Â Â (1,942) Property and equipment, net Â $ 55 Â Â $ 70 Â X - DefinitionSchedule of property plant and equipment. + ReferencesNo definition available. + Details Name: rkda_ScheduleOfPropertyPlantAndEquipmentTableTextBlock Namespace Prefix: rkda_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 36 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Investments and Fair Value Instruments (Tables) 9 Months Ended Sep. 30, 2024 Investments And Fair Value Instruments [Abstract] Â Summary of Amortized Cost and Fair Value of Investment Securities Portfolio The following tables summarize the amortized cost and fair value of the investment securities portfolio at September 30, 2024 and December 31, 2023 and the corresponding amounts of unrealized gains and losses recognized in accumulated other comprehensive income:Â (Dollars in thousands) Â AmortizedCost Â Â UnrealizedGains Â Â UnrealizedLosses Â Â EstimatedFair Value Â September 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 2,770 Â Â $ â€” Â Â $ â€” Â Â $ 2,770 Â Short-term investments: Â Â Â Â Â Â Â Â Â Â Â Â Â Treasury bills Â Â 2,523 Â Â Â 117 Â Â Â â€” Â Â Â 2,640 Â Total Assets at Fair Value Â $ 5,293 Â Â $ 117 Â Â $ â€” Â Â $ 5,410 Â Â (Dollars in thousands) Â AmortizedCost Â Â UnrealizedGains Â Â UnrealizedLosses Â Â EstimatedFair Value Â December 31, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 4,925 Â Â $ â€” Â Â $ â€” Â Â $ 4,925 Â Short-term investments: Â Â Â Â Â Â Â Â Â Â Â Â Â Treasury bills Â Â 5,023 Â Â Â 101 Â Â Â â€” Â Â $ 5,124 Â

Total Assets at Fair Value Â $ 9,948 Â Â $ 101 Â Â $ â€” Â Â $ 10,049 Â Summary of Fair Value of Investment Securities The fair value of the investment securities at September 30, 2024 were as follows:Â Â Â Fair Value Measurements at September 30, 2024 Â (Dollars in thousands) Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Total Â Assets at Fair Value Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 2,770 Â Â $ â€” Â Â $ â€” Â Â $ 2,770 Â Short-term investments: Â Â Â Â Â Â Â Â Â Â Â Treasury bills Â Â 2,640 Â Â Â Â â€” Â Â Â â€” Â Â Â 2,640 Â Total Assets at Fair Value Â $ 5,410 Â Â $ â€” Â Â $ â€” Â Â $ 5,410 Â Â The fair value of the investment securities at December 31, 2023 were as follows:Â Â Â Fair Value Measurements at December 31, 2023 Â (Dollars in thousands) Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Total Â Assets at Fair Value Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 4,925 Â Â $ â€” Â Â $ â€” Â Â $ 4,925 Â Short-term investments: Â Â Â Â Â Â Â Â Â Â Â Treasury bills Â Â 5,124 Â Â Â Â â€” Â Â Â â€” Â Â Â 5,124 Â Total Assets at Fair Value Â $ 10,049 Â Â $ â€” Â Â $ â€” Â Â $ 10,049 Â Summary of Preferred Investment Option Liabilities Measured and Recorded on Recurring Basis using Black-Scholes Model The preferred investment option liabilities were measured and recorded on a recurring basis using the Black-Scholes Model with the following assumptions as of September 30, 2024 and December 31, 2023: Â Â March 2023 Options - Series A & March 2023 Placement Agent Options Â Â March 2023 Options - Series B Â Â August 2022 Options & August 2022 Placement Agent Options Â Â September 30, 2024 Â Â December 31,2023 Â Â September 30, 2024 Â Â December 31,2023 Â Â September 30, 2024 Â Â December 31,2023 Â Remaining term (in years) Â Â 3.40 Â Â Â 4.16 Â Â Â â€” Â Â Â 0.61 Â Â Â 2.92 Â Â Â 3.67 Â Expected volatility Â Â 86.9 % Â Â 91.7 % Â Â â€” Â Â Â 78.7 % Â Â 91.8 % Â Â 90.5 % Risk-free interest rate Â Â 3.6 % Â Â 3.9 % Â Â â€” Â Â Â 5.2 % Â Â 3.6 % Â Â 4.0 % Expected dividend yield Â Â 0 % Â Â 0 % Â Â â€” Â Â Â 0 % Â Â 0 % Â Â 0 % Â Summary of Changes in Fair Value and Other Adjustments of Assets and Liabilities The following table sets forth the establishment of the Companyâ€™s Level 3 assets and liabilities, as well as a summary of the changes in the fair value and other adjustments (in thousands):Â Â Â Â Â (Dollars in thousands) Â March 2023Options - Series A Â Â March 2023Options - Series B Â Â March 2023 Placement Agent Options Â Â August 2022Options Â Â August 2022Placement Agent Options Â Â Note Receivable Bifurcated Derivatives Â Â ContingentLiabilities Â Â Total Â Balance as of December 31, 2023 Â $ 1,008 Â Â $ 41 Â Â $ 46 Â Â $ 159 Â Â $ 3 Â Â $ â€” Â Â $ 2,000 Â Â $ 3,257 Â Initial recognition Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 250 Â Â Â â€” Â Â Â 250 Â Change in fair value Â Â (378) Â Â (41) Â Â (19) Â Â (53) Â Â (2) Â Â â€” Â Â Â â€” Â Â Â (493) Balance as of September 30, 2024 Â $ 630 Â Â $ â€” Â Â $ 27 Â Â $ 106 Â Â $ 1 Â Â $ 250 Â Â $ 2,000 Â Â $ 3,014 Â X - DefinitionInvestments and fair value instruments. + ReferencesNo definition available. + Details Name: rkda_InvestmentsAndFairValueInstrumentsAbstract Namespace Prefix: rkda_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSummary of amortized cost and fair value of investment securities. + ReferencesNo definition available. + Details Name: rkda_SummaryOfAmortizedCostAndFairValueOfInvestmentSecuritiesTableTextBlock Namespace Prefix: rkda_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Tables) 9 Months Ended Sep. 30, 2024 Lessee Disclosure [Abstract] Â Schedule of Leases Leases consisted of the following (in thousands):Â Leases Â Classification Â September 30, 2024 Â Â December 31, 2023 Â Assets Â Â Â Â Â Â Â Â Operating lease assets Â Â Right of use asset Â $ 306 Â Â $ 792 Â Total leased assets Â Â Â Â $ 306 Â Â $ 792 Â Liabilities Â Â Â Â Â Â Â Â Current - Operating Â Â Operating lease liability- current Â $ 346 Â Â $ 852 Â Noncurrent - Operating Â Â Operating lease liability- noncurrent Â Â â€” Â Â Â 155 Â Total leased liabilities Â Â Â $ 346 Â Â $ 1,007 Â Â Lease Cost Â Classification Â ThreeMonths EndedSeptember 30, 2024 Â Â ThreeMonths EndedSeptember 30, 2023 Â Â NineMonths EndedÂ September 30, 2024 Â Â NineMonths EndedÂ September 30, 2023 Â Operating lease cost Â Â SG&A and R&D Expenses Â $ 172 Â Â $ 191 Â Â $ 678 Â Â $ 572 Â Short term lease cost Â Â SG&A Expenses Â Â Â 3 Â Â Â 3 Â Â Â 10 Â Â Â 10 Â Sublease income (1) Â Â SG&A and R&D Expenses Â Â (142) Â Â (111) Â Â (404) Â Â (329) Net lease cost Â Â Â $ 33 Â Â $ 83 Â Â $ 284 Â Â $ 253 Â Â (1)Sublease income is recorded as a reduction to lease expense.Â Lease Termand Discount Rate Â September 30, 2024 Â Â December 31, 2023 Â Weighted-average remainingÂ Â Â lease term (years) Â Â 0.7 Â Â Â 2.3 Â Weighted-average discount rate Â Â 6.5 % Â Â 6.0 % X - DefinitionSchedule of operating lease. + ReferencesNo definition available. + Details Name: rkda_ScheduleOfOperatingLeaseTableTextBlock Namespace Prefix: rkda_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LesseeDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 38 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Warrants and Options (Tables) 9 Months Ended Sep. 30, 2024 Warrants and Rights Note Disclosure [Abstract] Â Summary of Warrants Issued to Purchase Common Stock The Company issued the following warrants to purchase shares of its common stock, which are outstanding as of September 30, 2024 and December 31, 2023, respectively. These warrants are exercisable any time at the option of the holder until their expiration date.Â Â Â Issuance Date Â Term Â ExercisePrice PerShare Â Â Exercisedduring theYear EndedDecember 31,2023 Â Â Outstanding atDecember 31,2023 Â Â Exercisedduring theNine Months EndedSeptember 30,2024 Â Â Outstanding atSeptember 30, 2024 Â March 2023 Pre-Funded Warrants Â March 2023 Â perpetual Â $ â€” Â Â Â (425,834) Â Â 75,000 Â Â Â (75,000) Â Â â€” Â December 2022 Service and Performance Warrants (1) Â December 2022 Â 5Â years Â $ 11.20 Â Â Â â€” Â Â Â 1,000 Â Â Â â€” Â Â Â 1,000 Â October 2022 Service and Performance Warrants (1) Â October 2022 Â 5Â years Â $ 16.00 Â Â Â â€” Â Â Â 1,000 Â Â Â â€” Â Â Â 1,000 Â August 2022 Pre-Funded Warrants Â August 2022 Â perpetual Â $ â€” Â Â Â (56,813) Â Â â€” Â Â Â â€” Â Â Â â€” Â January 2021 Placement Agent Warrants Â January 2021 Â 5.5Â years Â $ 159.60 Â Â Â â€” Â Â Â 9,846 Â Â Â â€” Â Â Â 9,846 Â December 2020 Warrants (2) Â December 2020 Â 5.5Â years Â $ 9.00 Â Â Â â€” Â Â Â 16,367 Â Â Â â€” Â Â Â 16,367 Â December 2020 Warrants Â December 2020 Â 5.5Â years Â $ 120.00 Â Â Â â€” Â Â Â 49,100 Â Â Â â€” Â Â Â 49,100 Â December 2020 Placement Agent Warrants Â December 2020 Â 5Â years Â $ 152.80 Â Â Â â€” Â Â Â 3,274 Â Â Â â€” Â Â Â 3,274 Â July 2020 Warrants (2) Â July 2020 Â 5.5Â years Â $ 9.00 Â Â Â â€” Â Â Â 16,036 Â Â Â â€” Â Â Â 16,036 Â July 2020 Placement Agent Warrants Â July 2020 Â 5.5Â years Â $ 198.80 Â Â Â â€” Â Â Â 802 Â Â Â â€” Â Â Â 802 Â May 2020 Warrants (2) Â May 2020 Â 5Â years Â $ 9.00 Â Â Â â€” Â Â Â 9,946 Â Â Â â€” Â Â Â 9,946 Â May 2020 Warrants Â May 2020 Â 5Â years Â $ 191.20 Â Â Â â€” Â Â Â 24,863 Â Â Â â€” Â Â Â 24,863 Â May 2020 Placement Agent Warrants Â May 2020 Â 5Â years Â $ 245.20 Â Â Â â€” Â Â Â 1,741 Â Â Â â€” Â Â Â 1,741 Â September 2019 Placement Agent Warrants (3) Â September 2019 Â 5Â years Â $ 379.20 Â Â Â â€” Â Â Â 1,649 Â Â Â â€” Â Â Â â€” Â June 2019 Placement Agent Warrants (3) Â June 2019 Â 5Â years Â $ 251.60 Â Â Â â€” Â Â Â 1,862 Â Â Â â€” Â Â Â â€” Â April 2019 Service and Performance Warrants (1)(3) Â April 2019 Â 5Â years Â $ 247.20 Â Â Â â€” Â Â Â 3,629 Â Â Â â€” Â Â Â â€” Â January 2021 Warrants (2) Â January 2021 Â 5.5Â years Â $ 9.00 Â Â Â â€” Â Â Â 7,831 Â Â Â â€” Â Â Â 7,831 Â January 2021 Warrants Â January 2021 Â 5.5Â years Â $ 125.20 Â Â Â â€” Â Â Â 90,629 Â Â Â â€” Â Â Â 90,629 Â September 2019 Warrants (2) Â September 2019 Â 5.5Â years Â $ 9.00 Â Â Â â€” Â Â Â 9,892 Â Â Â â€” Â Â Â 9,892 Â September 2019 Warrants Â September 2019 Â 5.5Â years Â $ 300.80 Â Â Â â€” Â Â Â 6,594 Â Â Â â€” Â Â Â 6,594 Â June 2019 Warrants Â June 2019 Â 5.5Â years Â $ 200.00 Â Â Â â€” Â Â Â 10,896 Â Â Â â€” Â Â Â 10,896 Â Total Â Â Â Â Â Â Â Â Â (482,647) Â Â 341,957 Â Â Â (75,000) Â Â 259,817 Â (1) The Company issued service and performance warrants (â€œService and Performance Warrantsâ€) in connection with professional services agreements with non-affiliated third party entities.(2) These warrants were repriced as part of the March 2023 Private Placement offering. (3) These warrants expired during the nine months ended September 30, 2024. Summary of Key Terms and Activity of Liability Classified Preferred Investment Options The key terms and activity of the liability classified preferred investment options are summarized as follows: Â Â Â Issuance Date Â Term Â ExercisePrice PerShare Â Â Exercisedduring theYear EndedDecember 31,2023 Â Â Outstanding atDecember 31,2023 Â Â Exercisedduring theNineMonths EndedSeptember 30, 2024 Â Â Outstanding atSeptember 30, 2024 Â March 2023 Options - Series A Â March 2023 Â 5Â years Â $ 9.00 Â Â Â â€” Â Â Â 666,334 Â Â Â â€” Â Â Â 666,334 Â March 2023 Options - Series B (2) Â March 2023 Â 1.5Â years Â $ 9.00 Â Â Â â€” Â Â Â 666,334 Â Â Â â€” Â Â Â â€” Â March 2023 Placement Agent Options Â March 2023 Â 5Â years Â $ 11.25 Â Â Â â€” Â Â Â 33,317 Â Â Â â€” Â Â Â 33,317 Â August 2022 Options (1) Â August 2022 Â 5 years Â $ 9.00 Â Â Â â€” Â Â Â 118,063 Â Â Â â€” Â Â Â 118,063 Â August 2022 Placement Agent Options Â August 2022 Â 5 years Â $ 52.80 Â Â Â â€” Â Â Â 5,904 Â Â Â â€” Â Â Â 5,904 Â Total Â Â Â Â Â Â Â Â Â â€” Â Â Â 1,489,952 Â Â Â â€” Â Â Â 823,618 Â (1) These options were repriced as part of the March 2023 Private Placement offering.(2) These warrants expired during the nine months ended September 30, 2024. X - DefinitionSchedule of key terms and activity of preferred investment options. + ReferencesNo definition available. + Details Name: rkda_ScheduleOfKeyTermsAndActivityOfPreferredInvestmentOptionsTableTextBlock Namespace Prefix: rkda_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 + Details Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WarrantsAndRightsNoteDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 39 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation and Employee Stock Purchase Program (Tables) 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Summary of Activity Under Stock Incentive Plans The following is a summary of stock option information and weighted average exercise prices under the Companyâ€™s stock incentive plans (in thousands, except share data and price per share):Â Â Â SharesSubject toOutstandingOptions Â Â Weighted-AverageExercisePrice PerShare Â Â AggregateIntrinsicValue Â Outstanding â€” Balance at December 31, 2023 Â Â 80,078 Â Â $ 85.30 Â Â $ â€” Â Options granted Â Â 158,000 Â Â Â 2.71 Â Â Â â€” Â Options forfeited Â Â (7,927) Â Â 19.08 Â Â $ 397 Â Options expired Â Â (12,576) Â Â 170.08 Â Â Â â€” Â Outstanding â€” Balance at September 30, 2024 Â Â 217,575 Â Â $ 22.83 Â Â $ 3,140 Â Vested and expected to vest â€” September 30, 2024 Â Â 198,542 Â Â $ 24.68 Â Â $ 2,778 Â Exercisable â€” September 30, 2024 Â Â 50,515 Â Â $ 84.37 Â Â $ â€” Â Weighted-Average Fair Value Assumption of Stock Option Awards The fair value of stock option awards was estimated at the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumption:Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Expected term (years) Â Â 8.04 Â Â Â â€” Â Â Â 8.04 Â Â Â 7.06 Â Expected volatility Â Â 101.31 % Â Â â€” Â Â Â 101.31 % Â Â 124 % Risk-free interest rate Â Â 3.77 % Â Â â€” Â Â Â 3.77 % Â Â 3.61 % Dividend yield Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share (Tables) 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Schedule of Securities Not Included in Diluted per Share Calculations Securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows (in shares):Â Â Â Three Months Ended September 30, Â Â For the Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Options to purchase common stock Â Â 217,575 Â Â 84,058 Â Â 217,575 Â Â 84,058 Â Warrants to purchase common stock Â Â 259,817 Â Â 266,957 Â Â 259,817 Â Â 266,957 Â Preferred investment options Â Â 823,618 Â Â 1,489,952 Â Â 823,618 Â Â 1,489,952 Â Total Â Â 1,301,010 Â Â 1,840,967 Â Â

1,301,010 Â Â Â 1,840,967 Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($) 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended Nov. 30, 2020 Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Dec. 31, 2022 May 16, 2024 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Place of incorporation Â Â Â Â Â Â Â Arizona Â Â Â Â Year of incorporation Â Â Â Â Â Â Â 2002 Â Â Â Â Place of reincorporation Â Â Â Â Â Â Â Delaware Â Â Â Â Date of reincorporation Â Â Â Â Â Â Â 2015-03 Â Â Â Â Gain on sale of collaborative arrangements Â $ 0 Â Â $ 0 Â Â $ 4,000,000 $ 0 Â Â Â Proceeds from sale of RS durum wheat trait Â Â Â Â Â Â 4,000,000 0 Â Â Â License revenue Â 1,537,000 Â Â 1,298,000 Â Â 3,829,000 3,677,000 Â Â Â Accumulated deficit Â (274,814,000) Â Â Â Â Â (274,814,000) Â $ (271,840,000) Â Â Cash and cash equivalents Â 3,936,000 Â Â Â Â 3,936,000 Â 6,518,000 Â Â Short-term investments Â 2,640,000 Â Â Â Â Â 2,640,000 Â 5,124,000 Â Â Current note receivable Â 1,827,000 Â Â Â Â Â 1,827,000 Â 0 Â Â Net losses Â $ (1,612,000) $ 1,061,000 $ (2,423,000) $ (2,567,000) $ 818,000 $ (9,384,000) (2,974,000) (11,133,000) (14,000,000) Â Â Net cash used in operations Â Â Â Â Â Â Â $ 7,418,000 $ 11,149,000 15,300,000 Â Â Reverse stock split Â Â Â Â Â Â Â In February 2023, the Companyâ€™s board of directors approved a reverse split of 40:1 on the Companyâ€™s issued and outstanding common stock. Â Â Â Â Additional shares of common stock of reverse stock split Â Â Â Â Â Â Â 19,118 Â Â Â Â Verdeca LLC [Member] Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Gain on sale of Verdeca Â Â Â Â Â Â Â Â Â Â $ 1,100,000 Â Discontinued Operations [Member] | GoodWheat [Member] Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Sale of net consideration Â Â Â Â Â Â Â Â Â Â Â $ 3,700,000 Collaborative Arrangements [Member] Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Gain on sale of collaborative arrangements Â Â Â Â Â Â Â $ 4,000,000 Â Â Â Â Proceeds from sale of RS durum wheat trait Â Â Â Â Â Â Â $ 4,000,000 Â Â Â Â Bioceres Crop Solutions [Member] Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â License revenue Â Â Â Â Â Â Â Â Â $ 862,000 Â Bioceres Crop Solutions [Member] | Verdeca LLC [Member] Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Additional cash receivable from sale of interest in joint venture $ 2,000,000 Â Â Â Â Â Â Â Â Â Â Payment received on accounts and other receivable Â Â Â Â Â Â Â Â Â $ 2,000,000 Â Â Bioceres Crop Solutions [Member] | Verdeca LLC [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Â Â Cash shares and royalty receivable $ 10,000,000 Â Â Â Â Â Â Â Â Â Â X - DefinitionAdditional cash receivable from sale of interest in joint venture. + ReferencesNo definition available. + Details Name: rkda_AdditionalCashReceivableFromSaleOfInterestInJointVenture Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definitioncash shares and royalty receivable from sale of interest in joint venture + ReferencesNo definition available. + Details Name: rkda_CashSharesAndRoyaltyReceivableFromSaleOfInterestInJointVenture Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEntity incorporation year of incorporation. + ReferencesNo definition available. + Details Name: rkda_EntityIncorporationYearOfIncorporation Namespace Prefix: rkda_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionEntity place of incorporation. + ReferencesNo definition available. + Details Name: rkda_EntityPlaceOfIncorporation Namespace Prefix: rkda_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEntity reincorporation date of reincorporation. + ReferencesNo definition available. + Details Name: rkda_EntityReincorporationDateOfReincorporation Namespace Prefix: rkda_ Data Type: xbrli:gYearMonthItemType Balance Type: na Period Type: duration X - DefinitionState or Country Name where an entity is re-incorporated. + ReferencesNo definition available. + Details Name: rkda_EntityReincorporationStateCountryName Namespace Prefix: rkda_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionProceeds from sale of equity method investments in accounts and other receivable. + ReferencesNo definition available. + Details Name: rkda_ProceedsFromSaleOfEquityMethodInvestmentsInAccountsAndOtherReceivable Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of gain (loss) on sale or disposal of an equity method investment. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionAmortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_NotesAndLoansReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35:

http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionReduction in the number of shares during the period as a result of a reverse stock split. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityReverseStockSplit Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rkda_VerdecaLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=rkda_GoodwheatMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=rkda_CollaborativeArrangementsCopromotionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=rkda_BioceresCropSolutionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business - Summary of Major Classes of Line Items Constituting the Balance Sheet on Discontinued Operations (Details) - Discontinued Operations [Member] - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Co-packing business, Saavy Naturals, ProVault and Soul Spring Body Care Brands [Member] Â Â Assets Â Â Accounts receivable and other receivables $ 0 $ 0 Inventories, net - current 0 0 Property and equipment, net 0 0 Inventories, net - noncurrent 0 0 Total assets 0 0 Liabilities Â Â Accounts payable and accrued expenses 0 0 Total liabilities 0 0 GoodWheat [Member] Â Â Assets Â Â Accounts receivable and other receivables 70 8 Inventories, net - current 0 1,121 Property and equipment, net 0 314 Inventories, net - noncurrent 0 3,158 Total assets 70 4,601 Liabilities Â Â Accounts payable and accrued expenses 0 500 Total liabilities $ 0 $ 500 X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as inventory attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 11 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-11Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 11 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-11Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=rkda_CoPackingBusinessSaavyNaturalsProvaultAndSoulSpringBodyCareBr Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=rkda_GoodwheatMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Basis of Presentation - Summary of Major Classes of Line Items Constituting Net Loss from Discontinued Operations (Detail) - Discontinued Operations [Member] - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Co-packing business, Saavy Naturals, ProVault and Soul Spring Body Care Brands [Member] Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Cost of revenues $ 0 $ (34) $ 0 $ (313) Research and development 0 0 0 0 (Loss) Gain on sale of property and equipment 0 0 0 0 Selling, general and administrative 0 (86) 0 (651) Net loss from discontinued operations 0 (83) 0 (591) Co-packing business, Saavy Naturals, ProVault and Soul Spring Body Care Brands [Member] | Product Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Revenue 0 37 0 373 GoodWheat [Member] Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Cost of revenues 0 (285) (691) (634) Research and development 0 (291) (400) (1,000) (Loss) Gain on sale of property and equipment (24) 11 65 36 Selling, general and administrative (330) (1,580) (2,040) (4,551) Net loss from discontinued operations (430) (1,845) (2,694) (5,665) GoodWheat [Member] | Product Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Revenue $ (76) $ 300 $ 372 $ 484 X - DefinitionDisposal group including discontinued operation gain on sale of property and equipment. + ReferencesNo definition available. + Details Name: rkda_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfPropertyAndEquipment Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDisposal group including discontinued operation research and development. + ReferencesNo definition available. + Details Name: rkda_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDisposal group including discontinued operation selling general and administrative expense. + ReferencesNo definition available. + Details Name: rkda_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=rkda_CoPackingBusinessSaavyNaturalsProvaultAndSoulSpringBodyCareBr Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=rkda_GoodwheatMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Basis of Presentation - Non-cash Items of Discontinued Operations (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Changes in operating assets and liabilities: Â Â Â Â Inventories Â Â $ 620 $ (1,388) Prepaid expenses and other current assets Â Â 287 (284) Accounts payable and accrued expenses Â Â (719) (300) Proceeds from sale of property and equipment Â Â 342 42 Co-packing business, Saavy Naturals, ProVault and Soul Spring Body Care Brands [Member] | Discontinued Operations [Member] Â Â Â Â Operating activities Â Â Â Â Depreciation Â Â 0 24 Gain on sale of property and equipment $ 0 $ 0 0 0 Write-down of inventories Â Â 0 0 Changes in operating assets and liabilities: Â Â Â Â Accounts receivable and other receivables Â Â 0 (99) Inventories Â Â 0 250 Prepaid expenses and other current assets Â Â 0 14 Accounts payable and accrued expenses Â Â 0 5 Proceeds from sale of property and equipment Â Â 0 0 GoodWheat [Member] | Discontinued Operations [Member] Â Â Â Â Operating activities Â Â Â Â Depreciation Â Â 37 109 Gain on sale of property and equipment $ 24 $ (11) (65) (36) Write-down of inventories Â Â 0 275 Changes in operating assets and liabilities: Â Â Â Â Accounts receivable and other receivables Â Â (78) 0 Inventories Â Â 575 (1,975) Prepaid expenses and other current assets Â Â 0 0 Accounts payable and accrued expenses Â Â (500) 144 Proceeds from sale of property and equipment Â Â $ 342 $ 37 X - DefinitionDisposal group including discontinued operation gain on sale of property and equipment. + ReferencesNo definition available. + Details Name: rkda_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfPropertyAndEquipment Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDisposal group including discontinued operation write-down of inventories. + ReferencesNo definition available. + Details Name: rkda_DisposalGroupIncludingDiscontinuedOperationWriteDownOfInventories Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=rkda_CoPackingBusinessSaavyNaturalsProvaultAndSoulSpringBodyCareBr Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=rkda_GoodwheatMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Inventory - Additional Information (Detail) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Inventory [Line Items] Â Â Â Â Write-down of inventories $ 154,000 $ 252,000 $ 154,000 $ 444,000 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_InventoryLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2 + Details Name: us-gaap_InventoryWriteDown Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 46 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Inventory - Summary of Inventories (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Inventory Disclosure [Abstract] Â Â Raw materials $ 450 $ 373 Finished goods 385 660 Inventories $ 835 $ 1,033 X - DefinitionInventory current and non current net. + ReferencesNo definition available. + Details Name: rkda_InventoryCurrentAndNonCurrentNet Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionInventory finished goods current and non-current. + ReferencesNo definition available. + Details Name: rkda_InventoryFinishedGoodsCurrentAndNonCurrent Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionInventory raw materials current and non-current. + ReferencesNo definition available. + Details Name: rkda_InventoryRawMaterialsCurrentAndNonCurrent Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 47 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment, Net - Summary of Property and Equipment, Net (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Property Plant And Equipment [Line Items] Â Â Property and equipment, gross $ 1,907 $ 2,012 Less accumulated depreciation and amortization (1,852) (1,942) Property and equipment, net 55 70 Software and computer equipment [Member] Â Â Property Plant And Equipment [Line Items] Â Â Property and equipment, gross 291 349 Machinery and equipment [Member] Â Â Property Plant And Equipment [Line Items] Â Â Property and equipment, gross 0 34 Furniture and fixtures [Member] Â Â Property Plant And Equipment [Line Items] Â Â Property and equipment, gross 32 39 Leasehold improvements [Member] Â Â Property Plant And Equipment [Line Items] Â Â Property and equipment, gross $ 1,584 $ 1,590 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=rkda_SoftwareAndComputerEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment, Net - Additional Information (Detail) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Property Plant And Equipment [Line Items] Â Â Â Â Â Â Depreciation expense $ 7,000 Â $ 89,000 $ 92,000 $ 227,000 Â Property and equipment classified as assets held for sale, fair value Â Â Â Â Â $ 51,000 Impairment of property and equipment Â $ 36,000 Â $ 36,000 $ 0 Â X - DefinitionDisposal group including discontinued operation impairment of property and equipment. + ReferencesNo definition available. + Details Name: rkda_DisposalGroupIncludingDiscontinuedOperationImpairmentOfPropertyAndEquipment Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair value portion of assets classified as held for sale. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 49 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Investments and Fair Value Instruments - Summary of Amortized Cost and Fair Value of Investment Securities Portfolio (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Schedule Of Available For Sale Securities [Line Items] Â Â Amortized Cost $ 5,293 $ 9,948 Unrealized Gains 117 101 Unrealized Losses 0 0 Estimated Fair Value 5,410 10,049 Cash Equivalents [Member] | Money Market Funds [Member] Â Â Schedule Of Available For Sale Securities [Line Items] Â Â Amortized Cost 2,770 4,925 Unrealized Gains 0 0 Unrealized Losses 0 0 Estimated Fair Value 2,770 4,925 Short-term Investments [Member] | Treasury Bills [Member] Â Â Schedule Of Available For Sale Securities [Line Items] Â Â Amortized Cost 2,523 5,023 Unrealized Gains 117 101 Unrealized Losses 0 0 Estimated Fair Value $ 2,640 $ 5,124 X - DefinitionDebt and equity securities. + ReferencesNo definition available. + Details Name: rkda_DebtAndEquitySecurities Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDebt and equity securities accumulated gross unrealized gain before tax. + ReferencesNo definition available. + Details Name: rkda_DebtAndEquitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDebt and equity securities accumulated gross unrealized loss before tax. + ReferencesNo definition available. + Details Name: rkda_DebtAndEquitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDebt and equity securities amortized cost basis. + ReferencesNo definition available. + Details Name: rkda_DebtAndEquitySecuritiesAmortizedCostBasis Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Investments and Fair Value Instruments - Additional Information (Detail) Sep. 30, 2024 USD ($) Investments, Debt and Equity Securities [Abstract] Â Investment in continuous unrealized loss position for more than twelve months $ 0 X - DefinitionAmount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 51 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Investments and Fair Value Instruments - Summary of Fair Value of Investments Securities (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Assets at Fair Value Â Â Total Assets at Fair Value $ 5,410 $ 10,049 Money Market Funds [Member] Â Â Assets at Fair Value Â Â Cash equivalents 2,770 4,925 Treasury Bills [Member] Â Â Assets at Fair Value Â Â Short-term investments $ 2,640 $ 5,124 Investment, Type [Extensible Enumeration] Short-Term Investments [Member] Short-Term Investments [Member] Level 1 [Member] Â Â Assets at Fair Value Â Â Total Assets at Fair Value $ 5,410 $ 10,049 Level 1 [Member] | Money Market Funds [Member] Â Â Assets at Fair Value Â Â Cash equivalents 2,770 4,925 Level 1 [Member] | Treasury Bills [Member] Â Â Assets at Fair Value Â Â Short-term investments $ 2,640 $ 5,124 Investment, Type [Extensible Enumeration] Short-Term Investments [Member] Short-Term Investments [Member] Level 2 [Member] Â Â Assets at Fair Value Â Â Total Assets at Fair Value $ 0 $ 0 Level 2 [Member] | Money Market Funds [Member] Â Â Assets at Fair Value Â Â Cash equivalents 0 0 Level 2 [Member] | Treasury Bills [Member] Â Â Assets at Fair Value Â Â Short-term investments $ 0 $ 0 Investment, Type [Extensible Enumeration] Short-Term Investments [Member] Short-Term Investments [Member] Level 3 [Member] Â Â Assets at Fair Value Â Â Total Assets at Fair Value $ 0 $ 0 Level 3 [Member] | Money Market Funds [Member] Â Â Assets at Fair Value Â Â Cash equivalents 0 0 Level 3 [Member] | Treasury Bills [Member] Â Â Assets at Fair Value Â Â Short-term investments $ 0 $ 0 Investment, Type [Extensible Enumeration] Short-Term Investments [Member] Short-Term Investments [Member] X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsFairValueDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIndicates type of investment. Includes, but is not limited to, common stock, preferred stock, convertible security, fixed income security, government security, option purchased, warrant, loan participation and assignment, commercial paper, bankers' acceptance, certificates of deposit, short-term security, repurchase agreement, and other investment company. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic

320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column C)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2 + Details Name: us-gaap_InvestmentTypeExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionFair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_InvestmentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Investments and Fair Value Instruments - Summary of Preferred Investment Option Liabilities Measured and Recorded on Recurring Basis using Black-Scholes Model (Detail) - Level 3 [Member] Sep. 30, 2024 Dec. 31, 2023 Remaining Term [Member] | March 2023 Options - Series A & March 2023 Placement Agent Options [Member] Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Â Â Remaining term (in years) 3 years 4 months 24 days 4 years 1 month 28 days Remaining Term [Member] | March 2023 Options - Series B [Member] Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Â Â Remaining term (in years) 0 years 7 months 9 days Remaining Term [Member] | August 2022 Options & August 2022 Placement Agent Options [Member] Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Â Â Remaining term (in years) 2 years 11 months 1 day 3 years 8 months 1 day Expected Volatility [Member] | March 2023 Options - Series A & March 2023 Placement Agent Options [Member] Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Â Â Preferred investment options liability, measurement input 86.9 91.7 Expected Volatility [Member] | March 2023 Options - Series B [Member] Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Â Â Preferred investment options liability, measurement input 0 78.7 Expected Volatility [Member] | August 2022 Options & August 2022 Placement Agent Options [Member] Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Â Â Preferred investment options liability, measurement input 91.8 90.5 Risk-Free Interest Rate [Member] | March 2023 Options - Series A & March 2023 Placement Agent Options [Member] Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Â Â Preferred investment options liability, measurement input 3.6 3.9 Risk-Free Interest Rate [Member] | March 2023 Options - Series B [Member] Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Â Â Preferred investment options liability, measurement input 0 5.2 Risk-Free Interest Rate [Member] | August 2022 Options & August 2022 Placement Agent Options [Member] Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Â Â Preferred investment options liability, measurement input 3.6 4 Expected Dividend Yield [Member] | March 2023 Options - Series A & March 2023 Placement Agent Options [Member] Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Â Â Preferred investment options liability, measurement input 0 0 Expected Dividend Yield [Member] | March 2023 Options - Series B [Member] Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Â Â Preferred investment options liability, measurement input 0 0 Expected Dividend Yield [Member] | August 2022 Options & August 2022 Placement Agent Options [Member] Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Â Â Preferred investment options liability, measurement input 0 0 X - DefinitionPreferred investment options liability measured remaining term. + ReferencesNo definition available. + Details Name: rkda_PreferredInvestmentOptionsLiabilityMeasuredRemainingTerm Namespace Prefix: rkda_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionPreferred investment options liability outstanding measurement input. + ReferencesNo definition available. + Details Name: rkda_PreferredInvestmentOptionsLiabilityOutstandingMeasurementInput Namespace Prefix: rkda_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByLiabilityClassAxis=rkda_MarchTwoThousandTwentyThreeOptionsSeriesAAndMarchTwoThousandTwentyThreePlacementAgentOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByLiabilityClassAxis=rkda_MarchTwoThousandTwentyThreeOptionsSeriesBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByLiabilityClassAxis=rkda_AugustTwoThousandTwentyTwoOptionsAndAugustTwoThousandTwentyTwoPlacementAgentOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Investments and Fair Value Instruments - Summary of Changes in Fair Value and Other Adjustments of Assets and Liabilities (Detail) - Level 3 [Member] $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Â Beginning Balance $ 3,257 Initial recognition 250 Change in fair value (493) Ending Balance 3,014 March 2023 Options - Series A [Member] Â Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Â Beginning Balance 1,008 Initial recognition 0 Change in fair value (378) Ending Balance 630 March 2023 Options - Series B [Member] Â Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Â Beginning Balance 41 Initial recognition 0 Change in fair value (41) Ending Balance 0 March 2023 Placement Agent Options [Member] Â Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Â Beginning Balance 46 Initial recognition 0 Change in fair value (19) Ending Balance 27 August 2022 Options [Member] Â Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Â Beginning Balance 159 Initial recognition 0 Change in fair value (53) Ending Balance 106 August 2022 Placement Agent Options [Member] Â Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Â Beginning Balance 3 Initial recognition 0 Change in fair value (2) Ending Balance 1 Note Receivable Bifurcated Derivatives [Member] Â Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Â Beginning Balance 0 Initial recognition 250 Change in fair value 0 Ending Balance 250 Contingent Liabilities [Member] Â Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Â Beginning Balance 2,000 Initial recognition 0 Change in fair value 0 Ending Balance $ 2,000 X - DefinitionFair Value Measurement Initial Recognition. + ReferencesNo definition available. + Details Name: rkda_FairValueMeasurementInitialRecognition Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByLiabilityClassAxis=rkda_MarchTwoThousandTwentyThreeOptionsSeriesAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByLiabilityClassAxis=rkda_MarchTwoThousandTwentyThreeOptionsSeriesBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByLiabilityClassAxis=rkda_MarchTwoThousandTwentyThreePlacementAgentOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByLiabilityClassAxis=rkda_AugustTwoThousandTwentyTwoOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByLiabilityClassAxis=rkda_AugustTwoThousandTwentyTwoPlacementAgentOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByLiabilityClassAxis=rkda_NoteReceivableBifurcatedDerivativesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByLiabilityClassAxis=rkda_ContingentLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Note Receivable - Additional Information (Details) - USD ($) 3 Months Ended 9 Months Ended May 16, 2024 May 14, 2024 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Accounts, Notes, Loans and Financing Receivable [Line Items] Â Â Â Â Â Â Accrued interest Â Â $ 233,000 $ 133,000 $ 428,000 $ 538,000 Discontinued Operations [Member] | GoodWheat [Member] Â Â Â Â Â Â Accounts, Notes, Loans and Financing Receivable [Line Items] Â Â Â Â Â Â Sale of net consideration $ 3,700,000 Â Â Â Â Â Â Loss on sale of brand $ 1,500 Â Â Â Â Â Â Payment to aquire promissory note Â $ 2,000,000 Â Â Â Â Promissory note, current and non current. Â $ 6,000,000 Â Â Â Â Promissory note term Â 3 years Â Â Â Â Promissory note interest description Â Wall Street Journal prime rate Â Â Â Â Â Promissory note principal receviable each year Â $ 2,000,000 Â Â Â Â Fair value of embedded derivative note receivable Â Â 250,000 Â 250,000 Â Discounted promissory note Â Â 545,000 Â 545,000 Â Amortization of discount Â Â 60,000 Â 89,000 Â Accrued interest Â Â $ 126,000 Â $ 193,000 Â X - DefinitionDiscounted promissory note. + ReferencesNo definition available. + Details Name: rkda_DiscountedPromissoryNote Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPayment to aquire promissory note. + ReferencesNo definition available. + Details Name: rkda_PaymentToAquirePromissoryNote Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPromissory note, current and non current. + ReferencesNo definition available. + Details Name: rkda_PromissoryNoteCurrentAndNonCurrent Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPromissory note interest description. + ReferencesNo definition available. + Details Name: rkda_PromissoryNoteInterestDescription Namespace Prefix: rkda_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPromissory note principal receviable each year. + ReferencesNo definition available. + Details Name: rkda_PromissoryNotePrincipalReceviableEachYear Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPromissory note term. + ReferencesNo definition available. + Details Name: rkda_PromissoryNoteTerm Namespace Prefix: rkda_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 40 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsNotesAndLoansReceivableLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as an asset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -

Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details Name: us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B + Details Name: us-gaap_GainLossOnSaleOfBusiness Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest income (expense) classified as operating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_InterestIncomeExpenseNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of accretion of purchase discount on nonoperating securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InvestmentIncomeAmortizationOfDiscount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=rkda_GoodwheatMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Joint Venture - Additional Information (Detail) - Archipelago Ventures Hawaii, LLC [Member] $ in Millions Aug. 09, 2019 Individual Sep. 30, 2024 USD ($) Arcadia Biosciences, Inc [Member] Â Â Schedule Of Equity Method Investments [Line Items] Â Â Number of individuals appointed | Individual 2 Â Joint venture interest percentage Â 50.75% Capital contributions | $ Â $ 3.1 Legacy Ventures Hawaii, LLC [Member] Â Â Schedule Of Equity Method Investments [Line Items] Â Â Number of individuals appointed | Individual 2 Â Joint venture interest percentage Â 49.25% Capital contributions | $ Â $ 3.0 X - DefinitionNumber of individuals appointed. + ReferencesNo definition available. + Details Name: rkda_NumberOfIndividualsAppointed Namespace Prefix: rkda_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details Name: us-gaap_EquityMethodInvestmentOwnershipPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThis item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 + Details Name: us-gaap_EquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details Name: us-gaap_ScheduleOfEquityMethodInvestmentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=rkda_ArchipelagoVenturesHawaiiLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=rkda_ArcadiaBiosciencesIncorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=rkda_LegacyVenturesHawaiiLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Collaborative Arrangements - Additional Information (Detail) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Aug. 31, 2017 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Proceeds from sale of RS durum wheat trait Â Â Â $ 4,000 $ 0 Gain on sale of collaborative arrangements Â $ 0 $ 0 4,000 $ 0 Collaborative Arrangements [Member] Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Contractual agreement month and year 2017-08 Â Â Â Â Proceeds from sale of RS durum wheat trait Â Â Â 4,000 Â Gain on sale of collaborative arrangements Â Â Â $ 4,000 Â X - DefinitionContractual agreement month and year. + ReferencesNo definition available. + Details Name: rkda_ContractualAgreementMonthAndYear Namespace Prefix: rkda_ Data Type: xbrli:gYearMonthItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=rkda_CollaborativeArrangementsCopromotionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Additional Information (Detail) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Jan. 31, 2024 Lessee Lease Description [Line Items] Â Â Recognition of additional right-of-use asset and lease liability $ 86,000 Â Existence of option to extend true Â Lease option to extend, description Some leases (the Dallas and Davis offices, a warehouse, and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years. The exercise of lease renewal options is at the Companyâ€™s sole discretion. In January 2024, the Company exercised it's option to renew the facility lease in American Falls, Idaho for one year through December 31, 2024. The lease renewal resulted in recognition of additional right-of-use asset and lease liability of $86,000 on the condensed consolidated balance sheet. The Company subsequently terminated the facility lease in American Falls, Idaho effective July 2024. Â Option to extend lease, term Â 1 year Minimum [Member] Â Â Lessee Lease Description [Line Items] Â Â Option to extend lease, term 1 year Â Maximum [Member] Â Â Lessee Lease Description [Line Items] Â Â Option to extend lease, term 6 years Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIndicates (true false) whether lessee has option to extend operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionDescription of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount lessor expects from underlying asset following end of operating lease term. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-3 + Details Name: us-gaap_LessorOperatingLeaseAssumptionsAndJudgmentsValueOfUnderlyingAssetAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Schedule of Leases (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Assets Â Â Â Â Â Operating lease assets $ 306 Â $ 306 Â $ 792 Total leased assets 306 Â 306 Â 792 Liabilities Â Â Â Â Â Current - Operating 346 Â 346 Â 852 Noncurrent - Operating 0 Â 0 Â 155 Total leased liabilities 346 Â 346 Â $ 1,007 Lease Cost Â Â Â Â Â Net lease cost $ 33 $ 83 $ 284 $ 253 Â Lease Term and Discount Rate Â Â Â Â Â Weighted-average remaining lease term (years) 8 months 12 days Â 8 months 12 days Â 2 years 3 months 18 days Weighted-average discount rate 6.50% Â 6.50% Â 6.00% SG&A and R&D Expenses [Member] Â Â Â Â Â Lease Cost Â Â Â Â Â Operating lease cost $ 172 191 $ 678 572 Â Sublease income (142) (111) (404) (329) Â SG&A Expenses [Member] Â Â Â Â Â Lease Cost Â Â Â Â Â Short term lease cost $ 3 $ 3 $ 10 $ 10 Â X - DefinitionOperating lease assets. + ReferencesNo definition available. + Details Name: rkda_OperatingLeaseAssets Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionOperating lease assets. + ReferencesNo definition available. + Details Name: rkda_OperatingLeaseAssetsAbstract Namespace Prefix: rkda_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionOperating lease liabilities. + ReferencesNo definition available. + Details Name: rkda_OperatingLeaseLiabilitiesAbstract Namespace Prefix: rkda_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionOperating lease term and discount rate. + ReferencesNo definition available. + Details Name: rkda_OperatingLeaseTermAndDiscountRateAbstract Namespace Prefix: rkda_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionShort term lease cost and cost (reclassifications). + ReferencesNo definition available. + Details Name: rkda_ShortTermLeaseCostAndCostReclassifications Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeaseCostAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-

gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of sublease income excluding finance and operating lease expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_SubleaseIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=rkda_SellingGeneralAndAdministrativeAndResearchAndDevelopmentExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Equity Financing - Additional Information (Detail) - USD ($) 1 Months Ended 9 Months Ended Mar. 06, 2023 Mar. 31, 2023 Sep. 30, 2024 Aug. 31, 2022 Jan. 31, 2021 Dec. 31, 2020 Jul. 31, 2020 May 31, 2020 Sep. 30, 2019 Common Stock and Pre-Funded Warrants [Member] Â Â Â Â Â Â Â Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Â Â Â Â Â Â Â Remaining offering costs allocated to common stock and offset to additional paid in capital $ 330,000 Â Â Â Â Â Â Â Â Â March 2023 Placement Agent Options [Member] Â Â Â Â Â Â Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Â Â Â Â Â Â Issuance costs allocated to liability preferred options $ 430,000 Â Â Â Â Â Â Â Â Â March 2023 Options and March 2023 Placement Agent Options [Member] Â Â Â Â Â Â Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Â Â Â Â Â Â Expected volatility 128.55% Â Â Â Â Â Â Â Â Â Â Stock price $ 7.61 Â Â Â Â Â Â Â Â Â Risk-free interest rate 4.27% Â Â Â Â Â Â Â Â Â March 2023 Options and March 2023 Placement Agent Options [Member] | Series B Preferred Investment Options [Member] Â Â Â Â Â Â Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Â Â Â Â Â Â Expected volatility 103.33% Â Â Â Â Â Â Â Â Â Stock price $ 7.61 Â Â Â Â Â Â Â Â Â Risk-free interest rate 4.97% Â Â Â Â Â Â Â Â Â March 2023 Options [Member] Â Â Â Â Â Â Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Â Â Â Â Â Â Estimated fair value of liability options $ 6,600,000 Â Â Â Â Â Â Â Â Â March 2023 Private Placement [Member] | March 2023 Purchase Agreement [Member] Â Â Â Â Â Â Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Â Â Â Â Â Â Shares of common stock issued Â 165,500 Â Â Â Â Â Â Â Offering costs Â Â $ 548,000 Â Â Â Â Â Â March 2023 Private Placement [Member] | March 2023 Purchase Agreement [Member] | Pre Funded Warrants [Member] Â Â Â Â Â Â Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Â Â Â Â Â Â Warrant issued, shares of common stock called by warrant Â 500,834 Â Â Â Â Â Â Â Warrants issued, exercise price Â $ 0.0001 Â Â Â Â Â Â Â March 2023 Private Placement [Member] | March 2023 Purchase Agreement [Member] | Common Stock and Pre-Funded Warrants [Member] Â Â Â Â Â Â Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Â Â Â Â Â Â Fair value of common stock and pre-funded warrants 5,100,000 Â Â Â Â Â Â Â Â Â March 2023 Private Placement [Member] | Series A Preferred Investment Options [Member] | March 2023 Purchase Agreement [Member] Â Â Â Â Â Â Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Â Â Â Â Â Â Shares of common stock issued Â 666,334 Â Â Â Â Â Â Â Exercise price Â $ 9 Â Â Â Â Â Â Â Â Â Options expiration period Â 5 years Â Â Â Â Â Â Â Â Â March 2023 Private Placement [Member] | Series A and B Preferred Investment Options [Member] | March 2023 Purchase Agreement [Member] Â Â Â Â Â Â Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Â Â Â Â Â Â Shares of common stock issued Â 666,334 Â Â Â Â Â Â Â Exercise price Â $ 9 Â Â Â Â Â Â Â Proceeds from issuance of common stock and warrants gross Â Â 6,000,000 Â Â Â Â Â Â Â March 2023 Private Placement [Member] | Series B Preferred Investment Options [Member] | March 2023 Purchase Agreement [Member] Â Â Â Â Â Â Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Â Â Â Â Â Â Options expiration period Â 1 year 6 months Â Â Â Â Â Â Â March 2023 Private Placement [Member] | March 2023 Placement Agent Options [Member] | Preferred Investment Options [Member] Â Â Â Â Â Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Â Â Â Â Â Shares of common stock issued Â 33,317 Â Â Â Â Â Â Â March 2023 Private Placement [Member] | March 2023 Placement Agent Options [Member] | March 2023 Purchase Agreement [Member] Â Â Â Â Â Â Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Â Â Â Â Â Â Common stock options issued to placement agent and included in offering costs Â Â 212,000 Â Â Â Â Â Â March 2023 Private Placement [Member] | March 2023 Placement Agent Options [Member] | March 2023 Purchase Agreement [Member] | Warrants [Member] Â Â Â Â Â Â Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Â Â Â Â Â Â Warrant modification included in valuation loss Â Â 404,000 Â Â Â Â Â Â Â March 2023 Private Placement [Member] | August 2022 Placement Agent Options [Member] | August 2022 Purchase Agreement [Member] | Warrants [Member] Â Â Â Â Â Â Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Â Â Â Â Â Â Warrant modification included in valuation loss Â Â $ 185,000 Â Â Â Â Â Â Â March 2023 Private Placement [Member] | March 2023 Options [Member] | March 2023 Purchase Agreement [Member] | Common Stock and Pre-Funded Warrants [Member] Â Â Â Â Â Â Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Â Â Â Â Â Â Estimated fair value, loss $ 5,700,000 Â Â Â Â Â Â Â Â Â March 2023 Private Placement [Member] | Option Amendment Agreements [Member] | Preferred Investment Options [Member] Â Â Â Â Â Â Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Â Â Â Â Â Â Warrant issued, shares of common stock called by warrant Â 178,132 Â Â Â Â Â Â Â March 2023 Private Placement [Member] | Option Amendment Agreements [Member] | Warrants [Member] Â Â Â Â Â Â Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Â Â Â Â Â Â Warrants issued, exercise price Â $ 9 Â $ 37.35 $ 125.2 $ 120 $ 154 $ 191 $ 300.8 March 2023 Private Placement [Member] | Option Amendment Agreements [Member] | March 2023 Placement Agent Options [Member] Â Â Â Â Â Â Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Â Â Â Â Â Â Exercise price Â Â $ 11.25 Â Â Â Â Â Â Â Warrant, exercisable term Â Â 5 years Â Â Â Â Â Â Â X - DefinitionClass of warrant or right exercisable term. + ReferencesNo definition available. + Details Name: rkda_ClassOfWarrantOrRightExercisableTerm Namespace Prefix: rkda_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionCommon stock options issued to placement agent and included in offering costs. + ReferencesNo definition available. + Details Name: rkda_CommonStockOptionsIssuedToPlacementAgentAndIncludedInOfferingCosts Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEstimated fair value of liability options. + ReferencesNo definition available. + Details Name: rkda_EstimatedFairValueOfLiabilityOptions Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEstimated fair value options exceeded gross proceeds. + ReferencesNo definition available. + Details Name: rkda_EstimatedFairValueOptionsExceededGrossProceeds Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of common stock and pre-funded warrants. + ReferencesNo definition available. + Details Name: rkda_FairValueOfCommonStockAndPreFundedWarrants Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIssuance costs allocated to liability preferred options. + ReferencesNo definition available. + Details Name: rkda_IssuanceCostsAllocatedToLiabilityPreferredOptions Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionOptions expiration period. + ReferencesNo definition available. + Details Name: rkda_OptionsExpirationPeriod Namespace Prefix: rkda_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionProceeds from issuance of common stock and warrants gross. + ReferencesNo definition available. + Details Name: rkda_ProceedsFromIssuanceOfCommonStockAndWarrantsGross Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWarrant modification included in valuation loss. + ReferencesNo definition available. + Details Name: rkda_WarrantModificationIncludedInValuationLoss Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementEquityComponentsAxis=rkda_CommonStockAndPreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=rkda_MarchTwoThousandTwentyThreePlacementAgentOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=rkda_MarchTwoThousandTwentyThreeOptionsAndMarchTwoThousandTwentyThreePlacementAgentOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=rkda_SeriesBPreferredInvestmentOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=rkda_MarchTwoThousandTwentyThreeOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=rkda_MarchTwoThousandTwentyThreePrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SecuritiesFinancingTransactionAxis=rkda_MarchTwoThousandTwentyThreeSecuritiesPurchasePurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=rkda_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=rkda_SeriesAPreferredInvestmentOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=rkda_SeriesAAndBPreferredInvestmentOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=rkda_PreferredInvestmentOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name:

srt_TitleOfIndividualAxis=rkda_AugustTwoThousandTwentyTwoPlacementAgentOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SecuritiesFinancingTransactionAxis=rkda_AugustTwoThousandAndTwentyTwoPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=rkda_OptionAmendmentAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Warrants and Options - Summary of Warrants Issued to Purchase Common Stock (Detail) - $ / shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Class Of Warrant Or Right [Line Items] Â Â Â Exercised during the period (75,000) (482,647) Â Outstanding 259,817 Â 341,957 March 2023 Pre-Funded Warrants [Member] Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Issuance Date 2023-03 Â Â Term perpetual Â Â Exercise Price Per Share $ 0 Â Â Exercised during the period (75,000) (425,834) Â Outstanding 0 Â 75,000 December 2022 Service and Performance Warrants [Member] Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Issuance Date 2022-12 Â Â Term 5 years Â Â Exercise Price Per Share $ 11.2 Â Â Exercised during the period 0 0 Â Outstanding 1,000 Â 1,000 October 2022 Service and Performance Warrants [Member] Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Issuance Date 2022-10 Â Â Term 5 years Â Â Exercise Price Per Share $ 16 Â Â Exercised during the period 0 0 Â Outstanding 1,000 Â 1,000 August 2022 Pre-Funded Warrants [Member] Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Issuance Date 2022-08 Â Â Term perpetual Â Â Exercise Price Per Share $ 0 Â Â Exercised during the period 0 (56,813) Â Outstanding 0 Â 0 January 2021 Placement Agent Warrants [Member] Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Issuance Date 2021-01 Â Â Term 5 years 6 months Â Â Exercise Price Per Share $ 159.60 Â Â Exercised during the period 0 0 Â Outstanding 9,846 Â 9,846 December 2020 Warrants [Member] Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Issuance Date 2020-12 Â Â Term 5 years 6 months Â Â Exercise Price Per Share $ 9 Â Â Exercised during the period 0 0 Â Outstanding 16,367 Â 16,367 December 2020 Warrants [Member] Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Issuance Date 2020-12 Â Â Term 5 years 6 months Â Â Exercise Price Per Share $ 120.00 Â Â Exercised during the period 0 0 Â Outstanding 49,100 Â 49,100 December 2020 Placement Agent Warrants [Member] Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Issuance Date 2020-12 Â Â Term 5 years Â Â Exercise Price Per Share $ 152.80 Â Â Exercised during the period 0 0 Â Outstanding 3,274 Â 3,274 July 2020 Warrants [Member] Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Issuance Date 2020-07 Â Â Term 5 years 6 months Â Â Exercise Price Per Share $ 9.00 Â Â Exercised during the period 0 0 Â Outstanding 16,036 Â 16,036 July 2020 Placement Agent Warrants [Member] Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Issuance Date 2020-07 Â Â Term 5 years 6 months Â Â Exercise Price Per Share $ 198.80 Â Â Exercised during the period 0 0 Â Outstanding 802 Â 802 May 2020 Warrants [Member] Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Issuance Date 2020-05 Â Â Term 5 years Â Â Exercise Price Per Share $ 9 Â Â Exercised during the period 0 0 Â Outstanding 9,946 Â 9,946 May 2020 Warrants [Member] Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Issuance Date 2020-05 Â Â Term 5 years Â Â Exercise Price Per Share $ 191.20 Â Â Exercised during the period 0 0 Â Outstanding 24,863 Â 24,863 May 2020 Placement Agent Warrants [Member] Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Issuance Date 2020-05 Â Â Term 5 years Â Â Exercise Price Per Share $ 245.20 Â Â Exercised during the period 0 0 Â Outstanding 1,741 Â 1,741 September 2019 Placement Agent Warrants [Member] Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Issuance Date 2019-09 Â Â Term 5 years Â Â Exercise Price Per Share $ 379.20 Â Â Exercised during the period 0 0 Â Outstanding 0 Â 1,649 June 2019 Placement Agent Warrants [Member] Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Issuance Date 2019-06 Â Â Term 5 years Â Â Exercise Price Per Share $ 251.60 Â Â Exercised during the period 0 0 Â Outstanding 0 Â 1,862 April 2019 Service and Performance Warrants [Member] Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Issuance Date 2019-04 Â Â Term 5 years Â Â Exercise Price Per Share $ 247.20 Â Â Exercised during the period 0 0 Â Outstanding 0 Â 3,629 January 2021 Warrants [Member] Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Issuance Date 2021-01 Â Â Term 5 years 6 months Â Â Exercise Price Per Share $ 125.2 Â Â Exercised during the period 0 0 Â Outstanding 90,629 Â 90,629 January 2021 Warrants [Member] Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Issuance Date 2021-01 Â Â Term 5 years 6 months Â Â Exercise Price Per Share $ 9 Â Â Exercised during the period 0 0 Â Outstanding 7,831 Â 7,831 September 2019 Warrants [Member] Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Issuance Date 2019-09 Â Â Term 5 years 6 months Â Â Exercise Price Per Share $ 300.8 Â Â Exercised during the period 0 0 Â Outstanding 6,594 Â 6,594 September 2019 Warrants [Member] Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Issuance Date 2019-09 Â Â Term 5 years 6 months Â Â Exercise Price Per Share $ 9 Â Â Exercised during the period 0 0 Â Outstanding 9,892 Â 9,892 June 2019 Warrants [Member] Â Â Â Class Of Warrant Or Right [Line Items] Â Â Â Issuance Date 2019-06 Â Â Term 5 years 6 months Â Â Exercise Price Per Share $ 200 Â Â Exercised during the period 0 0 Â Outstanding 10,896 Â 10,896 X - DefinitionClass of warrants or rights issuance month and year. + ReferencesNo definition available. + Details Name: rkda_ClassOfWarrantsOrRightsIssuanceMonthAndYear Namespace Prefix: rkda_ Data Type: xbrli:gYearMonthItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period shares related to exercise of warrants. + ReferencesNo definition available. + Details Name: rkda_StockIssuedDuringPeriodSharesRelatedToExerciseOfWarrants Namespace Prefix: rkda_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWarrant and rights outstanding term. + ReferencesNo definition available. + Details Name: rkda_WarrantAndRightsOutstandingTerm Namespace Prefix: rkda_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rkda_MarchTwoThousandTwentyThreePreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rkda_DecemberTwoThousandAndTwentyTwoServiceAndPerformanceWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rkda_OctoberTwoThousandAndTwentyTwoServiceAndPerformanceWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rkda_AugustTwoThousandTwentyTwoPreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rkda_JanuaryTwoThousandTwentyOnePlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rkda_DecemberTwoThousandTwentyWarrantsPrivatePlacementOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rkda_DecemberTwoThousandTwentyWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rkda_DecemberTwoThousandTwentyPlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rkda_July2020WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rkda_July2020PlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rkda_May2020WarrantsPrivatePlacementOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rkda_May2020WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rkda_May2020PlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rkda_September2019PlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rkda_June2019PlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rkda_April2019ServiceAndPerformanceWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rkda_JanuaryTwoThousandTwentyOneWarrantsPrivatePlacementOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rkda_JanuaryTwoThousandTwentyOneWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rkda_SeptemberTwoThousandNineteenWarrantsPrivatePlacementOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rkda_SeptemberTwoThousandNineteenWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rkda_JuneTwoThousandNineteenWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Warrants and Options - Summary of Key Terms and Activity of Liability Classified Preferred Investment Options (Detail) - $ / shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 March 2023 Options - Series A [Member] Â Â Â Option Indexed to Issuer's Equity [Line Items] Â Â Â Issuance Date 2023-03 Â Â Term 5 years Â Â Exercise Price Per Share $ 9 Â Â Exercised during the period 0 0 Â Outstanding 666,334 Â 666,334 March 2023 Options - Series B [Member] Â Â Â Option Indexed to Issuer's Equity [Line Items] Â Â Â Issuance Date 2023-03 Â Â Term 1 year 6 months Â Â Exercise Price Per Share $ 9 Â Â Exercised during the period 0 0 Â Outstanding 0 Â 666,334 March 2023 Placement Agent Options [Member] Â Â Â Option Indexed to Issuer's Equity [Line Items] Â Â Â Issuance Date 2023-03 Â Â Term 5 years Â Â Exercise Price Per Share $ 11.25 Â Â Exercised during the period 0 0 Â Outstanding 33,317 Â 33,317 August 2022 Options [Member] Â Â Â Option Indexed to Issuer's Equity [Line Items] Â Â Â Issuance Date 2022-08 Â Â Term 5 years Â Â Exercise Price Per Share $ 9 Â Â Exercised during the period 0 0 Â Outstanding 118,063 Â 118,063 August 2022 Placement Agent Options [Member] Â Â Â Option Indexed to Issuer's Equity [Line Items] Â Â Â Issuance Date 2022-08 Â Â Term 5 years Â Â Exercise Price Per Share $ 52.8 Â Â Exercised during the period 0 0 Â Outstanding 5,904 Â 5,904 March 2023, August 2022 Options and Placement Agent Options [Member] Â Â Â Option Indexed to Issuer's Equity [Line Items] Â Â Â Exercised during the period 0 0 Â Outstanding 823,618 Â 1,489,952 X - DefinitionPreferred investment options liability exercise price per share. + ReferencesNo definition available. + Details Name: rkda_PreferredInvestmentOptionsLiabilityExercisePricePerShare Namespace Prefix: rkda_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionPreferred investment options liability issuance month and year + ReferencesNo definition available. + Details Name: rkda_PreferredInvestmentOptionsLiabilityIssuanceMonthAndYear Namespace Prefix: rkda_ Data Type: xbrli:gYearMonthItemType Balance Type: na Period Type: duration X - DefinitionPreferred investment options liability outstanding. + ReferencesNo definition available. + Details Name: rkda_PreferredInvestmentOptionsLiabilityOutstanding Namespace Prefix: rkda_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPreferred investment options liability term. + ReferencesNo definition available. + Details Name: rkda_PreferredInvestmentOptionsLiabilityTerm Namespace Prefix: rkda_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionStock issued during period shares related to exercise of options. + ReferencesNo definition available. + Details Name: rkda_StockIssuedDuringPeriodSharesRelatedToExerciseOfOptions Namespace Prefix: rkda_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_OptionIndexedToIssuersEquityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=rkda_MarchTwoThousandTwentyThreeOptionsSeriesAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=rkda_MarchTwoThousandTwentyThreeOptionsSeriesBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=rkda_MarchTwoThousandTwentyThreePlacementAgentOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=rkda_AugustTwoThousandTwentyTwoOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=rkda_AugustTwoThousandTwentyTwoPlacementAgentOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=rkda_March2023AndAugust2022OptionsAndPlacementAgentOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation and Employee Stock Purchase Program - Additional Information (Detail) 3 Months Ended 9 Months Ended Jun. 25, 2024 shares Feb. 02, 2022 shares May 20, 2015 shares May 14, 2015 Sep. 30, 2024 USD ($) shares Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) IncentivePlan shares Sep. 30, 2023 USD ($) Dec. 31, 2023 shares Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Number of equity incentive plans | IncentivePlan Â Â Â Â Â Â 2 Â Â Shares Subject to Outstanding, Options granted Â Â Â Â Â 158,000 Â Â Total number of options outstanding Â Â Â 217,575 Â 217,575 Â 80,078 Unrecognized compensation cost related to unvested stock-based compensation grants | $ Â Â Â Â $ 524,000 Â $ 524,000 Â Â Weighted-average remaining recognition period Â Â Â Â Â Â 1 year 4 months 24 days Â Â Stock-based compensation | $ Â Â Â Â $ 155,000 $ 162,000 $ 395,000 $ 573,000 Â 2015 Employee Stock Purchase Plan [Member] Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Total number of shares reserved for issuance under plan Â Â Â 3,209 Â 3,209 Â Â Stock-based compensation | $ Â Â Â Â $ 2,000 $ 7,000 $ 6,000 $ 12,000 Â Percentage in payroll deductions to acquire shares of common stock Â Â Â 15.00% Â Â Â Â Â Purchase plan offering period Â Â Â 6 months Â Â Â Â Â Employees are able to purchase company's common stock on first trading day of offering period, percentage Â Â Â 85.00% Â Â Â Â Â Issuance of common stock pursuant to employee stock purchase plan Â Â Â Â Â 8,073 Â Â First offering period, start date Â Â Â May 14, 2015 Â Â Â Â Â First offering period, end date Â Â Â Feb. 01, 2016 Â Â Â Â Â Inducement Stock Option [Member] Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Total number of options outstanding Â Â Â Â 6,949 Â 6,949 Â 8,366 Inducement Stock Option [Member] | Stanley Jacot, Jr. [Member] Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Shares Subject to Outstanding, Options granted Â 7,902 Â Â Â Â Â Â Â 2015 Omnibus Equity Incentive Plan [Member] Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Terms under the plan Â Â Â Â Â The 2015 Plan became effective upon the Companyâ€™s IPO in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 3,860 shares of common stock reserved for future issuance, which included 259 that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan. Â Â Total number of shares reserved for issuance under plan Â Â 3,860 Â 338,248 Â 338,248 Â Â Number of shares awarded o individual employee 50,000 Â 9,375 Â Â Â Â Â Â Options vesting period Â Â 4 years Â Â Â Â Â Â Additional shares authorized for issuance under the plan 200,000 Â Â Â Â Â Â Â Common stock available for future grant Â Â Â 127,725 Â 127,725 Â Â Total number of options outstanding Â Â Â Â 210,523 Â 210,523 Â 71,609 2015 Omnibus Equity Incentive Plan [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Options exercisable period Â Â 10 years Â Â Â Â Â Â 2006 Stock Incentive Plan [Member] Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Total number of shares reserved for issuance under plan Â Â 259 Â Â Â Â Â Â Total number of options outstanding Â Â Â Â 102 Â 102 Â 102 X - DefinitionEmployee stock purchase plan offering period. + ReferencesNo definition

available. + Details Name: rkda_EmployeeStockPurchasePlanOfferingPeriod Namespace Prefix: rkda_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionFirst offering period end date. + ReferencesNo definition available. + Details Name: rkda_FirstOfferingPeriodEndDate Namespace Prefix: rkda_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionFirst offering period start date. + ReferencesNo definition available. + Details Name: rkda_FirstOfferingPeriodStartDate Namespace Prefix: rkda_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionNumber of equity incentive plans. + ReferencesNo definition available. + Details Name: rkda_NumberOfEquityIncentivePlans Namespace Prefix: rkda_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe highest percentage of annual salary that an employee is permitted to utilize with respect to the plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe highest quantity of shares an employee can purchase under the plan per period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionDescription of terms of award under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPurchase price of common stock expressed as a percentage of its fair value. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=rkda_InducementStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=rkda_PresidentAndChiefExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=rkda_TwoThousandFifteenOmnibusEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=rkda_TwoThousandSixStockIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation and Employee Stock Purchase Program - Summary of Activity Under Stock Incentive Plans (Detail) $ / shares in Units, $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) $ / shares shares Share-Based Payment Arrangement [Abstract] Â Shares Subject to Outstanding, Beginning Balance | shares 80,078 Shares Subject to Outstanding, Options Granted | shares 158,000 Shares Subject to Outstanding, Options Forfeited | shares (7,927) Shares Subject to Outstanding, Options Expired | shares (12,576) Shares Subject to Outstanding, Ending Balance | shares 217,575 Shares Subject to Outstanding, Vested and expected to vest | shares 198,542 Shares Subject to Outstanding, Exercisable | shares 50,515 Weighted-Average Exercise Price Per Share, Outstanding Beginning Balance | $ / shares $ 85.30 Weighted-Average Exercise Price Per Share, Options granted | $ / shares 2.71 Weighted-Average Exercise Price Per Share, Options forfeited | $ / shares 19.08 Weighted-Average Exercise Price Per Share, Options expired | $ / shares 170.08 Weighted Average Exercise Price Per Share, Outstanding Ending Balance | $ / shares 22.83 Weighted Average Exercise Price Per Share, Vested and expected to vest | $ / shares 24.68 Weighted Average Exercise Price Per Share, Exercisable | $ / shares $ 84.37 Aggregate Intrinsic Value, Beginning Balance | $ $ 0 Aggregate Intrinsic Value, Options Granted | $ 0 Aggregate Intrinsic Value, Options Forfeited | $ 397 Aggregate Intrinsic Value, Options Expired | $ 0 Aggregate Intrinsic Value, Ending Balance | $ 3,140 Aggregate Intrinsic Value, Vested and expected to vest | $ 2,778 Aggregate Intrinsic Value, Exercisable | $ $ 0 X - DefinitionShare based compensation arrangement by share based payment award expired outstanding intrinsic value. + ReferencesNo definition available. + Details Name: rkda_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiredOutstandingIntrinsicValue Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionShare-based compensation arrangement by share-based payment award, forfeiture, intrinsic value. + ReferencesNo definition available. + Details Name: rkda_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureOutstandingIntrinsicValue Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionShare based compensation arrangement by share based payment award

grants outstanding intrinsic value. + ReferencesNo definition available. + Details Name: rkda_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsOutstandingIntrinsicValue Namespace Prefix: rkda_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 64 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation and Employee Stock Purchase Program - Weighted-Average Fair Value Assumption of Stock Option Awards (Detail) - Employee Stock Option 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Expected term (years) 8 years 14 days 0 years 8 years 14 days 7 years 21 days Expected volatility 101.31% 0.00% 101.31% 124.00% Risk-free interest rate 3.77% 0.00% 3.77% 3.61% Dividend yield 0.00% 0.00% 0.00% 0.00% X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes - Additional Information (Detail) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Tax Disclosure [Abstract] Â Â Â Â Federal statutory tax rate Â Â 21.00% Â Effective tax rate 0.00% 0.00% 0.00% 0.00% Uncertain tax positions $ 0 Â $ 0 Â X - DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of domestic federal statutory tax rate applicable to pretax income (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.1.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of unrecognized tax benefits. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 217 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B + Details Name: us-gaap_UnrecognizedTaxBenefits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 66 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Additional Information (Detail) $ in Thousands 9 Months Ended 12 Months Ended Sep. 30, 2024 USD ($) Dec. 31, 2010 USD ($) Program Dec. 31, 2023 USD ($) Jun. 30, 2005 USD ($) Commitments And Contingencies [Line Items] Â Â Â Â Other noncurrent liability $ 2,000 Â $ 2,000 Â Anawah, Inc [Member] Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Contingent liability Â $ 3,000 Â $ 5,000 Date of merger and reorganization Jun. 30, 2005 Â Â Â Number of development programs ceased | Program Â 3 Â Â Number of development programs | Program Â 6 Â Â Other noncurrent liability $ 2,000 Â Â Â Minimum [Member] Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Operating leases, term of contract 1 year Â Â Â Royalty payments due, percentage of net revenue as defined in the In-Licensing agreements 2.00% Â Â Â Minimum [Member] | Industrial Seed Innovations [Member] Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Operating leases, term of contract 1 year Â Â Â Maximum [Member] Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Operating leases, term of contract 5 years Â Â Â Royalty payments due, percentage of net revenue as defined in the In-Licensing agreements 15.00% Â Â Â Maximum [Member] | Industrial Seed Innovations [Member] Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Operating leases, term of contract 3 years Â Â Â X - DefinitionCommitments and contingencies line items. + ReferencesNo definition available. + Details Name: rkda_CommitmentsAndContingenciesLineItems Namespace Prefix: rkda_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of technology development programs. + ReferencesNo definition available. + Details Name: rkda_NumberOfTechnologyDevelopmentPrograms Namespace Prefix: rkda_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of technology development programs ceased. + ReferencesNo definition available. + Details Name: rkda_NumberOfTechnologyDevelopmentProgramsCeased Namespace Prefix: rkda_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionRoyalty Payments Due, Percentage Of Net Revenue As Defined In Agreements + ReferencesNo definition available. + Details Name: rkda_RoyaltyPaymentsDuePercentageOfNetRevenueAsDefinedInAgreements Namespace Prefix: rkda_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionDate when the acquirer obtains control of the acquiree, in YYYY-MM-DD format. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 7 -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479405/805-10-25-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 6 -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479405/805-10-25-6 + Details Name: us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1 Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_BusinessAcquisitionAxis=rkda_AnawahIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=rkda_IndustrialSeedInnovationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share - Summary of Securities Not Included in Diluted Per Share Calculations (Detail) - shares 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Antidilutive securities not included in the diluted per share calculations, amount 1,301,010 1,840,967 1,301,010 1,840,967 Option to Purchase Common Stock [Member] Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Antidilutive securities not included in the diluted per share calculations, amount 217,575 84,058 217,575 84,058 Warrants to Purchase Common Stock [Member] Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Antidilutive securities not included in the diluted per share calculations, amount 259,817 266,957 259,817 266,957 Preferred Investment Options [Member] Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Antidilutive securities not included in the diluted per share calculations, amount 823,618 1,489,952 823,618 1,489,952 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rkda_PreferredInvestmentOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R61.htm IDEA: XBRL DOCUMENT v3.24.3 Related-Party Transactions - Additional Information (Detail) - USD ($) Sep. 30, 2024 Dec. 31, 2023 John Sperling Foundation [Member] Â Â Related Party Transaction [Line Items] Â Â Royalty fees due $ 30,000 $ 58,000 X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=rkda_JohnSperlingFoundationMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 69 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

:K${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}HS-WX18WER<4!L6HNM6DML61MN-NPK&>^21PP7] (\O>.O+@D9!JJC]M/ MVTD@.WXT,B-X?1G@FF4]A+IX1]#TQ@P?@>^8!% H]=;\5!,-! MI):$$,P/QK8C>$>;L,UEQD/%LS:%9P:K#U.L6HNM6DML61OA%H*]Q//,F<>.; M")[5K>%6K<56K26VK VCT)=.GKET.N-]!&##-O!" H "WD@ *BO@E02H_@I& MRB*0+XL\ /M\.OA-=@?NY< E=_OT/4] GZ/T76R>\FU-[]Y 8#K9YE&ZE@2W$] MJVHN)5]QKK[J#AF^X]S2?>-'S=?14U1\8J"1# 7W+>O![(§QQ>)E[\!5!+ M P04 " B&Q9!1D,$N81 !N_ & 'AL+W=OM@#IL??&EFSVKP;V\WEZ_*^]URL2[>;JSM_6J5; [XI5B6GUZ?V6=?_N%O MBYO;W?X?SB]?W>4WQ;MB]^O=VTWUV_D#Y7JQ*M;;1;FV-L6'UV<_VS]EH;-O M<'C$_RZ*3]M'/UO[I_*^+' ;_Q)?OSX;[WM4+(NKW1Z15W])+*;%3,NBX^Y/?+W=_*3[HX M/B% S[L]E]O#G]:GXV/'9]5_797KHZ-JQZL%NO/?>_'U^(1PUL]T0#Y]C M:35P_!,-W&,#M]W .=' S:P6@V"4UWRCPW\=H-3"L&Q0=!JX(4G&H3"!F&K M@1N<:# Y-IBTNV2?:'!Q;'#1?4Ñ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{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|(XE!9":1&*UI5?:U][;V1?>U#[M&DH+H#0&I7$H+832(A2MJ\76OO;ZV-?IRU;&>YM9_V+)Y((Y6CV=XV5CZ\W- MU_+5N2B*>H+WRM:Z@G#J4Q*(U[A_=0)D+\R8383Q55 MLZX.6TO<.['H._ZQ?<#-WA[:]?HF];;*CQ(3U!^'T@(HC4%IW#N\<3,1,O!(M,;V%.>ZUŸK@W>5-K!&J/0VD!E,:@- ZEÄ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{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

^$_3 MX7CF/\V&_FD(Y*+L\[7,WK]X*=OL5?6Z(PW>\C;7/9X%C[/AV=G M_GFC56Q[NO=HSC+G0L-DF=ER]&:W#G$_',Y08>5][‘LC^==T,L$AYS@ MA0*Q &,,]X,U3\:/.ZQ.9P^B@8#\PCA_%^@.(WG(6@G"/#WKB2V:QB<+D3SB M.WC<#*V#)X)>/'\-^WG3VG _N9"&/S_N6,)V/$2D4 M7_*J(W:S=B5!K, RM.#"7/ION!
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|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`Y`\$-D#\(B;O@'8%X=T[[.!WZ1B\=1\B MYW-K)#H%KŶ)9H;^\]3=5^#3D372!\UU# =WH["!##;'B@*%@), #T5+'GB9@/ MZC5/)U*$'><>(P]U@,+5;2I6=QV[!5)?H!WW5W28HZ-*:B44),X%MJ+5V=_" M=N@(#0*[3&@PTJLNMWL)S/[PGAGM*IX^A@/-84"/"/E6)96@0(!&O4<0AL1< MPY^"SMD4%M@A@V",9RH5 B6E Q@)9>D5%=LXVZ!:>F;=7:MDFLKAJ$=1B>6!FZ;S6 @V6H0JO*V@U'#%PU-FN6O.I]@]RD#80%/(!L$-2# M[T: JCPU(ESG/|19':93]J>K/4NZR9093>..8W)6>ES(A9QU<.E*NN*H'5[: MQT@A.+@ZE)$%|7*)U8^AO_PK&=H?=F@!]W1&(P4=:RAKJ2FWGHQ:7*#6F(ML_@L+4+#&?)%PEG@]B7#+9]I*+/&Y;2${=@1BWLUA5'LP@\;WB7[(E&[-0] M'O[:8_ZA&L'6#4L7L"0/1TC*FM290&Z@M)RC<+53K\5'AT45J(M" -(]^0] MUO.2(%_(7*%B^1VQ7JE/3"DU8!,LF)?6(7<293UN!,+-58*[<8) F+1,/#D' M*8(+45])Y4)K,C-=!I/M^FX%7JC-#KDV%D[C,@%&$F+ 0H+Z:B0=;I45 -Z6*&@DU@CY6\7B!.3< M58_%+S*?7XE#>^XV(+1:#G3-E37LQHR5;N>.R\VFEC^XWKI7|$X9"5]_1%" MOE1HRH[%H(N^<]CMG]8M2M0][8NX>Q%C[?2LJ?'[/'RI>#9 AN'6)Q:!C2EN=Q5.X'=, M;S=[C:6R:FN+K8ZFM&2J:_*E>?\8XVK@-[OX\T0+?[M<0^B-E#?2.93ZW[=--SI"8HB'U,?%!^.Z)P<7%.29^%&^,1Y% MS>?6>XX ^: A_"O.#L7OQBA%@W"]OY& OYB - FBZT76-VR>$>%>2=.!YM7 MS_B,+SAL.[V.H@V+H_Y0[/]RWFO\/I(K.^5?@:B_0LL&ULS5=M;]LV$/XK![%Q=]!:CUYQ0F@PCXR@ MZ.<.K] 8!B(U/NTP>WN1?+ [;M'?B.UDRU(%O'+F@RYB>=$[]4&!*]68^-YM M?L*=/5/&RYT)\A|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

MH)=.SEWI:U)?|"W%HTF"13Z?E)WVAZP]^XGV;^]S=VD=U>^NHNI[_0DB&<*9 M]>%\F#U]\(]:L9I/1VHVG1T^8F|\^I#<7>_-?I]<^F5A:'}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|7D MT6/U*1,EZ ROS&6Z ;\M?SBO&.'!@=\AIH_T?@"MZ_F%O3<^"D@C,[DZHT5H M>4*Y!*-]=('7.^&2H7 *HY7N*D,ZO&\.+^|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|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`0S.YN-596? M5UME:?KY94%_-U [!9+O%%5?WSB.NC\PRZ]02P,$% @ (AL6:RCEG/R M P LP@ !D !X;"]W;WK&ULE5;;;MLX$/T5 M0BV*72!KR9>DV<0V$+L;I$#*$FZ^[#8!TH<6T0H4B4IN_[('E*RZG03 WVQ M>)DY<^;&\71KF),KB3S[5BGM9DGI?7V1IJXH]>)N8&K2N%D96W&/K5VGKK;$M152J5#K*LK.TXE(G\VD\N[/SJ6F\DIKN+'--57&[6Y RVUDR3/8']W)=^G"0 MSJKO?HU]%W^))S1TNC_I'"E[/D M/&&"5KQ1_MYL;ZCSYS3@%4:Y^,NVK>P8PD7CO*DZ93"HI&Z__%L7AP.%|^P5MA5&G,(J\6T.1Y0?N^7QS]9;9(VTL(BN1FV0DSHDY<;W$KH^?D]*>Y) '" M< =>Q1\NUXS%>;IIZX >IM.BP%BW6Z!6L/]FMT;YT["\M2#$73\&K)S?:DUN, MC@(^4#U@K?R$C+1YC>N'=V'/&QYUE_W>6 7N5.V^Q^^\EOUO8R1/UI?9H8'1T ^.U MQ=L4G#!;#8;YCBU40^S&6$?L, |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{?QXNTXOT6A2;PIBE90S0:O3Y,VE _<:,; ^HEYG+C,>3BLL2 "K)! /576PB5% C#T !D !X;"]W M;W)K&ULE5;;;MLX$/T5 M0BV*72!KR9>DV<0V$+L;I$#*$FZ^[#8!TH<6T0H4B4IN_[('E*RZG03 WVQ M>)DY<^;&\71KF),KB3S[5BGM9DGI?7V1IJXH]>)N8&K2N%D96W&/K5VGKK;$M152J5#K*LK.TXE(G\VD\N[/SJ6F\DIKN+'--57&[6Y RVUDR3/8']W)=^G"0 MSJKO?HU]%W^))S1TNC_I'"E[/D M/&&"5KQ1_MYL;ZCSYS3@%4:Y^,NVK>P8PD7CO*DZ93"HI&Z__%L7AP.%|^P5MA5&G,(J\6T.1Y0?N^7QS]9;9(VTL(BN1FV0DSHDY<;W$KH^?D]*>Y) '"

5]\"./#>.*&M95+;S M>%F?)<DP73H:P\?/H0!WYT]QI< MWD94F8C@@I M_1NMWG>; P7$G]+$|(BON=Y$+B1_S\ARM,:N1&[@*A_'41P"?ZUZQG@\#[] MY?"UXM)*^4%_%(V-6.09N1:O.P!BCVXB:"@$E&'"&I&E('#CT%CL^T.O|XS* MUHI22&;I;*6()%K"CY1;Y#)O_'?=`P\# #=VQ"2#H1U'<>ZAK:%<0G/+-\BS!1U<=VVU.8U@>]LPVS/
M9'J6/IWF.NACS.ZLV=\IPZPMV#,JM=*-SJSL&W./9+PZDI&U&;CI/662+H/3D_NW6OU% ML7;L]^K.,@1I1]0!QRY"25?* 9E4EQ"[WK MLIU$KC=^$]Z)G$Z0W!QNON>[MH0\?
6 %VP2<;'WN/7+U0P82>[+# ^@??.U4 MRXH90%#B!R]L.0N8 I&B]O+;DEG8(N61Q(3O.;$E0K''QG@V^1X;6&', &H/.]2 -:,R,*,@&3EK_S MD32A+38SL%:."5H:!-
P3MHU;EE:!76C\Y*F'7)55;0]:!#$.TB3<3@<#R$;A/$P>Z;V?C"M_M]91C|<-)F"5C2$>C<#(CY,P3F*2LD$<3D;C@[9#31KM[9(*]<9O3$-E--*V:Z6S=DOY MK-U%C^[M1O_"](83<8%K"HU/QL,
=+LE6\6]VF^FE;*TY[Q8TH\%M7.@\[52 M]D%Q";I?U?P?4$L#!!0 ("(;%GDO:9W^@L $"6 9 >&PO=V]R M:W-H965T?;1R,XV& V^\[;$+Q.]GQMC/X#$/]N5S
MQK_D"\8$^.;I,TOR]MQ!.B==`OY[,%6]+\8[9B:?&7AXPD2>\L= ^ON*,S]N@ M9=+7!X-1?TGCM#>]K%Z[Y=/+;"V2,&6WG.3KY9+REVN69,]7;:WW^L+G^'$A MRA?ZT\L5?
61W3/RVNN7%L_Y6F<=+EN9QEA+.`JYZG[2+R)B4 =42O\?L.=]Y M3,I5N<^R+^43;W[5&Y0]8@F;B9*@O3]//(8E22D5_?BK1GO;-LO W<>ONEVM M?+$R]S1G-UGR1SP7BZO>I$?
F/(&N$_$Y>W99O4)GI3?+DKSZ/WFNEQWTR&R= MBVQ9!Q<]6,;IYE_ZM7XC=@(*1QZ@UP'ZL0%&'6"\#1CN"1C6 <-C \[J@+-C M_T9UP.C8@'$=,#XV8%('3-X$[-T.YW7 ^;$M:((7+3=X&S+:%
[+=V)VMO:>5 MU\VM=:,WL2_D=8-KU1;O:_;%:D@#?2[!0]3A=M*!*PDUUN+],E>&6.CRBO C7]H:,QW=> NX>WWE9N/=M[[S_;>L]_---E-V/CP^7)>$1X?
>NA>BC62KWLH!8SM(&15G M[.&*3^6$WF>>_B@7C1"OH2MI!?X;%23S!EOF _M9,/2|@-#>0?*HZ>+?$5G[*]W*L=" L1ZT^^_TT;#GV4IB<1,)&8A,1N).4C.
M16(>$O.16(#$0B06@;#6:#'P3C_]3'/ *$AS9BP")A4@L F&M!#[;)OB9|MW_M)ZA|/Q6J,?F-Q(SD9B%Q&PDYB O%XEYZCU,'PQD1[T^L@L!$@N16 3"6LD]
MVB:WZ+A/:\X,YK=2.C6_D9B)Q"PD9B,Q!XFY2,Q3[V0F2^@SY4R6X\AN!$@L M1&(1"&OE^'B;XV/UVT_%L2FNA$Y-<21F(C$+B=E(S$%B+A+SU/N8/M#./@QD MI[Y\9"\")!8BL0B$M3)\LLWPB?
+===VB7_:?=3$8V9R$Q^V#?'61S+A+SNGT?#]K_VFO@'US' -FM M$(E%(*R58N?:%#M7'RCS;..8/",."B(XC84LQ93V MJ2F&Q$PD9B$Q&XDY2,Q%8MX&,SN8N-WEWB8NLELA$HM
6"MQM4'SG?M F:IA M/&-ISHKCWR>6KF6SD&NU<&[']"UMKNMM+.C:%GFYK09BVH9LM60C^?=%;"@3;K M0C5/LA+&1# _O9I=LP=&XN\D";/\"|!:.AM':=2=V:.K3|+/9>KE.BMGFO"SF MBF?
RST*UJN5#-.V&+ ^=*6@UH;M5O6 M)L/NOVT(;3E":>W,U)O,U)69>4/S156\,2L?L+ 6|5-Q +MG,JBV3LY/O3NP MGALC27(BF[6@F@W5'*CF0C7OV,WE0YL-),V.SK3NP48(;39":>VT:,JL-&5A
MQO1ND7'Q03"^)"ZQ"*O]Q2-&CHY)XW.NZV)(.@"6W6@FHV5'.@F@O5O&.W MEP]M-I T>Z,IW0 I$-!LA-+:.=E4,VGJ6L:->=E;6.:B7+&,&/%1^5]I\T
M0@N:.;ITUWYKHLDDCM%H])ME0S8%]+E3SCMUV1 MIBX-^84)DF1YSN0?B]"2HUIK30^TD:9+4K"[I#88:9T%+1FI#W6CLZ0M7?)L MU-VA',F2$\FADBL3SXU)=P#WZB7:.
[+SL6P^)EE2TS2CNT*!=%'IJ8YN"&DU=[%#NL=4T:YVS.2F_EUNQS1?N!T86E4#U4RH9D$UZHY4,V% M;EZM[>;O>"A)>%^R8)&;P^[9S]!>\LT):FE]0]M@4%H[-9LZ&$U=I/"9/3&>
M,Y*+;(;%Y*MDSPE*:!4,5.#.AF@75;*CF0#47]GD'|C,O)3:[YVO*7ZH?A/U$ MQ(*1FVRYHNG+]I]-=&W\/9)8MEV552+F[?Y25YD#?E0"[MA5 M0FGMD:>IS]'4!3H[O^'-%[1H85.ETVR>37W>
<<,3M%X]IE0S8]J-E1S MH)+U:O;:WV\GVO:Y.WQ K+1 *]%4"U":>WL:T]'-'7MT. ^,S]F.DC"\(7]& M:'G/N/1 7L6KFY.R&U@E!-0NJV5#-@6HN5/,&/F@_5]@60K4(I;6O*=%4(.F;
MRHMW $6]#JU@=FHF5+.@F@W5'*CF0C4/JOE0+8!J(52+4%I[[&BIJG1U5=7; MVO[Z8$(Z!D KJZ":"=4LJ&9#-0>]N5#-@VH^5 N@6JAW:[TT37*&,T(UVT]O
MIC1+5Y=FF7$^RU(11^4)G% ^W7Q5LYPGD;^)DV?R/ZO<%JLF#NIV3DQ^IF5#- M@FHV5'.@F@O5/*CF0!4 JH50+4)I[1&BJ1+3W_UR7#JTO RJF5#-@FHV5'.@ MF@O5/*CF0[4
JH50+4)I[;&CJ6;3U=5L= _6D(2V+$HK#BGC.]O_X7VV=/ H@ M-1.]65#-AFH.5'.AF@25?*@60+40]D6UMCL9J7X.N#,9:2=X4Q^C]^OC]AX< MY.K) K1P#][94_V";C94%]!5 MDU#-
@FHV5'.@F@O5O%HI?(TB:+.!5 NA6H32VAG?E"?JZK+$:[NHD1H . >.A MA8AOS8)]-E1SH)H+U3S]V*N209I-H%H(U2*4UL[XIA115Y.IBS14)(MG;N#EQ#L]HH&]/RCV!]7.8,X1B;Q&*O4 MTI?]$&$S
+!Y67= 9[-L758N5M>QJ8X=U!?@5+=O\F$"M(H1JEE0S89]#E1S MH9H'U7RH%AC=ZS-*/]9":+,12FLG?E.@:*@OC_@_GF$H7H[HUWBY7]I/.D!K M$Z&:."=4LJ&9#-0>]N5#-@VH^5
N@6@C5(I36'C::VD1C ,XG': %C%#-A&H6 M5+,AF@/57*CF034?]@50+81]$4IKCOU-E:.AKG*L[ZDXEV]N=@'"UX]D(3\7)H M/%)[4[K]IH%ZXF>=W3+GS9ZX%V
M$5:0]YMFIYB^X,/XV(ZQ>/'O?:)R%97/:U'[C,ALF7U M<,'HG/%R@>+O#UDF7I^4#3OG_$NUFM/_ E!+ P04 " B&Q9>5I AAP$ M #$$@ &0
'AL+W=OT&:';#NI>'Q3[0\CAF(XDJ2=G)W^^05B0+ENATJ[[I8 M(G7F^,QPQ&-QM!7R0:T!-'E,XE2-O:76V:7QJV@-"5,G(H.4[ZR$3)C&H;SW M52:.!+6U0$OMA$ S]A/'4FXSLW)VP>Y]
_9W<21W)LN0)[(+E$A8C;TK>CD-;8!%?,&P57O7Q*2R M$.+1 #&Z68RPBB"&2!L*AE\;F$(<&R;4\;T@]^U,NO=^Z1\:Q8'NN/8OLG% D-#%\D8F4_R,: !AZ)FF6<.W4CE.
<;IR0Q4)'EF2RI6Y#I7"%'*G)#Y;F'-['W]B29ODPI4&;B X+(C89$ MD:E(E>&ZUSR])W)K%+(V S&T7(NV,ITBD>#^)?D[\G,KRGR9@::\5B] MQ1]KP_QS"\D"Y+\(^3R?D3>OWI)7A*?
DTUKDBJ5+-?(U5L'DXD=%QM>[C,.6 MC.>0G9)>\(Z$0=AO")^ZPV<083BUX;UZN(^U+Q<@+!<@M'S]%KZI,.E8]&"]_MMRB*_X[,&=L\D;^8SB6+<7PGQ1?3F 13)G.1QV2>21-R+99/9,HDEEV:Z
M<>E[7:;8$5DMQ7Z98M_9%E=1)/4*]P|(^ ;.MHC!+&I 1STSN339684<]M-1F M']],@I&_V4_-A:C!91Z!TZ]-^D&4BTD!VS7%! .$]R]L2YJH$K[H%H M1 M$S@L!0Z= O$1PFU%/]D|PO>
<9VA&VFIM4C@\JM"%["D*O6>_6@)4Y$ZJGAV M5*,+4=-X7FH!=VK\)#2+*6M]_LZ/2G(A:(N2DD7SLW@_V<+'G/-FY^%BRYW MA([:GG2H++JX&5[0L:>R@V!19$TI@F/^,]-=>@X'4MBQ-
2U[OWUX^^H%EB M]_H4'$YM+DA=6^6ZU&V[X582ET#TT!"=)\;=TO59/N3)-^G]=DW9]FUVO MU=.LC)/^ONR@'0\QYRWM6+DG[=(^Z7' ;(!0&M(6C96)TDY=E!ZW
MT09(C_9;=%962COV4GK<3!L@/3IH6_K*4>G/62H]=,S#ECS$](=!VVI7SDI_MREIII][:%5O]+:PRU_ 7F6MXW%P;((.@Q<+"RE[##NRUX'"]"S1 #M7Y>T<,
MYGSGELE[CB_H,:PP*C@]P^3D[LAD-] BLZ<.'Z&U2.PEVNT2['@_940^GE@ M#C+*@ZO)?U!+ P04 " B&Q9"]8.IL% #8'P &0 'AL+W=O7YE62SRX'K.4B1SN\P?Q= M?
DO%G56O1'&*,O:3#%"\O1Z]@%>]XT@#A7@?XWMV<@VDE#M"/LJ:5]'UR)8K M*@D.N:1 XM\!KW&22":OCD\EZ;B:4QI>7C^R_ZK$"%$WB.$U23[$$=!?C^8C
M$.$M*A+^EMS_ADM!$\D7DH2IO^"^Q-HC$!:,D[0T%BM(X^SX'WTN'7%B(CT M!DYIX+0-O#,&;FG@?ND,7FG@?>D,D]) 2;>.\I7C?2,31:85/+)#?]:4+!,$&-805|+<_"*XY2!-28F.0?
Y\P;G=YC^)2#O-CYX^N09> +B#/RQ M)P43]V8+BPN_2'566/I@=?2!<\8'+K@1, ^T9"+((1QI[O]_^LL?>$O&H@N(\ M!F7E]!)N7FKD[.?YL]^,;9&\YP]PQU%9]WAF]-QCD*
M^HDNBNS]\PI&H\@#>(%0OEXOZ6DO>RJB\W9 B 9N<2I,5B1[&E$,5E1F M1Y4_NC3I78@LV5=,+ 5?CW+0]M *#'BU__@E,[5!T,3)\)YILD"PRI1-:,+I5=`T M%+#M]]OLI"D&&O$.
<'B>\,O1)5)4!:*(?5=E/%[$46Q?-E1HJI 0E@A%@+N M'N1M3I@8?TE)D8NX"[DB&2@S]:+NB)I8^Z9C+E),M\D66"(K!'S217SR< ; MS+C\-E!\P"(\V@I]9)@]!KFY.2SMA74X]6T7,7:])L8?9 ET+-"M0
U]TTK? MM%??6 ^$O1,.]2MY(B$Q(+G-;1 /(-.G1.8CP!Q%!'Z(A<59)G/5*?"]_W<_ M2['S!&((%Y!+":.4[%CI?O!*<>?BOBL[MF@[D&$X@(^A -W?-*][Q7]T;L M8$5UN0 [G(F2DBBA*!
(;L9AQ066(.6*=V/IBVBQC/IRV]@RR!AF4Z@7K)EY7D MRU[)65#NUZ+2LDJ[LZD1?#HKN(L9SMR5ZD"70L$PNSXB&=KT/MO^(;0;X M1Q!%1:A]*_FX7,J+5?'Z-LOE&VP!1;,[HG70[\L;8=Y7I-
1=XDFV^4+3#%UHH\ M4T?>&?@XJTV'-@:.8,720-O9JV(-TP1:FC.[#E@W1K" ,WD2/1ACQ'O;6KZ M2;XZTXRV-4;9 E-LS7#4G0W\P5H::+2W.;2NM.!YIK=>!PKZ.!C)VV%E^'\NQ.C=6@
MH&V?:0!@W?G [)SZP&Y7,G:\MB>Z(-CQ0O=>Y]W7 MP)SII==V@]Y%F]I[D2O-7Z;I"?/VAL,Z.:E,_=VI(V(&0E)D_'@D5(U6Q] OU.%K:WP%K]90,^[#]^!X
MR%S3'|^\;O:#=O2)U$[P54]G/9Z(\TN,O\O&&DUR=D]X1SDF]+D6MBS"5 /%\ M2PA_O)$35(?YRW\!4$L#!!0 ("(;%FL-SP^,08 #_] 9 >&PO M=VIR:W-H965T3W@[$F+QAL4D4N|L&0^QO5)?
!OB=B3K")(5!#$G. MJ!'=B&G7FL^3>'9 /V%X&-")W'(A]&&+ ^N" !.]YV8.?IQF=ZOY/Z1F\^B_$] M61/Y);[CZ]J7]_@T))&@+ *<;&\|;`^\-"DUU0A+QE9*C.'D-]%_VC'W7%^_]
MVXZC>T0"XDDM@=6_ UF2(-!*]A|_,M%.WJ9./W]l/YG.G@UF T69.F";]27 MN!O.1 -\LL7[0'YFQ[|-[J"AUO-8(]*_X)C%.AW@[85D89:L>A#2*N/'S(C M3A*43GT"RA+0><*@(;&?)?
1_MH5!EC#XV1;&64(R|%XZ]L0X%TL\GW%V!%O' M*$7I(G$_R59^T4A/E+7DZEVI\N3<+C-$Z*QK9@L1KQ(>XP;>MP"U13.P%6D4 \FGS7 MG#\UY/>4>[F%Z,G"]3(*MDK@\O2=UP
Y:%#3G^7/I_?KAG-=ZZMGMUXRHY_/ MIWZBUV_06^YP=$^$KC%+YT%T#[01*9S*!X0P,I*1$W=;5/U0?UZGK5O!$Q M]LAM))9SDA](9_[;W#D_%%GO$TQUZ;8RI)8]42#O$0#D_K\?
710'V:&50GJ M*F!.;EL!FV)N*C9*Q/0#\# ?(6?6.YP:6XWIPOYDDD>5'!OFC@V-CJGU+\;4 M!^1!/9\%26!"2Q$WL>UT^/)X_KK#3*MK72II@[JMHTAM.S M+VN"^HY3[^4X]W)\86HRCQ!?
@"UG(1!8N:F>QS^7BZ]3)PE1/ 8T5GL[66>1 M4;VMI3;%W'"%K?X G3E;C3D)*?ZYR?V<&/UZ'78(WQX1%\ MQ'+/<;'NE>E?]4XTL7?-]@%8QURG+)C_"):8$[#@>G<# _OE P@WA_X+ &O=(
M3R%U3'VM6UU:(]Y-L56EL1*!9_F!9\;--RR?BEV*9I9D9U)7BJG-A M4L?9GP]/F'B\OA[A9B"GZ(]AP*S7O M:>-334W4S/Z9PHI^U=P&OUNH :MDII5-=>]VLJ66KE0!:U!,Z[ENV6U M.A)ZR#?,*7|4-
^LGOE6:LZKF9FK&B5\-Z4ZG#5._H#EHQKD+ &S.;NV9562# M51ZK>%:#=<,FY:) -FAFMJL0V*S=VE&KY ;K5%9QM!H"FO[:!;=!,[@]&X+- MN]W-M,ILL ID%3.K(<,&+PMF@V9HNO:"S?
*M+;4*6IF:T5)32-G2@HJ@<:<_ M?\>8_VU'L+P68[Y.)L)G#+5ZUNS>$2VJXE9W-#P??4U0?]0P^H+*D!$FVE&M6:OU!+**8)F;Z:%$X+& M#7L!5.
2&OQ2KD56BS9:&O6;>VE50Y#57|KO MYB<D(O MO9 L3H[@;9B4+$Q>*K;V"=0GO.=_P]02P,$% @ (AL M62WW^8N& @ PP< !D !X;"]W:W)K&ULK55M M:YLP$/XK%INF5EH+
=)M&4%]0]9%6]6]4=M$6;>R4()?4HT3]5SM@&$FN'A)^B*(BI'[9HSMP3-+4\RD!A0H^U^ MQ_4B0T=OCQ-?:6E#X,>MS,3)A" .(1.B",U5*:&,%%#WX;#_ ^OZLF\KT/NX@ZW
M<4 "O80+[$]1%+Q'81#&/?>9'@Z/^L+Y/_79/ZL_2D;4/8+(\D5_?00_ONDC M-%=0R9]]578|<3^/Z6DC6>, M%2/NBA'O8T]O!%%P4O"&(;Y$I"T- =E7#T=U9JG,2-
BD@V$+XD9N+V1 I2A6(E1T'$N5\S91[FYVUFSCGMM$^L4\&H^F@ MQYII">4&RAJZ-IXNL%@1)A&%I98*3C_HIBGO#) 3K]C#MP2078M6Q.IN0]M_/=D(4(&5[V OQQSW'YUS[7N**BV>9 RCT
M4E FITZN5#EO79GF4& YX"4PO;/AHL!*3\76E:4 G%WW1<]R*WP(0Y26S7 M%B*)^4Y1PF AD-P5!1:O]T!Y-76&SF%A2;:Y,@MN$I=X"RM03^5"Z)G:LF2D M "9)9TC
9NK<#2>ST.3;@.\$*MD9(^-DS?FSF3QF4\;H^NH&72'"T+><[R1FF8O=I948/C=M3KVO3_7?.'4%Y0 % MW@?D>_ZH!SZ[#)]#N%#"P^.X:[VWR:I;Y@6[[@KTF8$YE2+G<"T, ^[M51" M/[-???
Y]PE$_H2F]B2QQ"E-'UY8$L0?]N&'F?^]S^)|(CI'K;C$GBQQ MI= ^3 D$P[;W)&AY9N.D)^V04>K&|[QHXCPEN@S;F2->HU36ZJ.N!,**?=8:V MG/<_ L1H?
=@\=AR?"SF.BR.L7%K:"PHO"]J71IRH\2\4X.%5U'C/T@M-\N9VB M-@WU*Q9:PB2BL-$P:W"K643=I,JXJ6M\S57NFO88:[[,@@3H&/ULM5AKCYLX%/TK%CNJ6]DS8!YY3!.D=F:K5II91P9_RHB
(D>DS@5 M2R.2,KLV31%$D!!QQ3)(U9,-XPF1:LBWIL@XD+!(2F+3MJR)F1";&OZBN+?B M_H+E,J8IK#@2>9(0_OT=Q&R_-+#O=,.,3W492WS#]14:VL ;Y.5MQ-3)KE) F MD
K*4L1ALS3>XNL;/-4)1<0_%/:B=8UT*0^,?=6#C^'2L#0CB'&0&H*HKQW< M0!QK),7C6P5]U+^I$]O73^COB^)5,0]$P V+_Z6AC);&S$ A;$@>RT]L_P&J M@CR-%
[!8%)]H7\5:!@IR(5E2)2L&"4W+;_)8"=%*PXS"7:58/_?!*=*<(!" M2V9%6;=$$G_!V1YQ'-W0]$6A39&MJ]&IGL:UY.HI57G27W'E"'"Z_(Y*&Z,)O M.+% MPI2*I_Y%,ZAXO2MYV<_P6D-VA1SK-;
(MV^U)OQE.OX5 I>,BW>FFFTJA6B;[MELDN\)O?R;2*22K1VI8&Z,N=BD82)23BOlY*2VBW'UJOTVN1D0^6AEJ(O@. M#/_%'WABO>FK>R2PC@!,K8(SA-XU"S0>V'(F>N>XA)L4<'I#V2
EX;DT7YJY= MT7&0;6&[#NHP=6NF[B#3.O!";1%IGN0QD1"JE:WT""@1]PY%GR2,2 JCN-%' MO<3W6]PN\-X!S>.0]=7/<5)SG QR M7+.-W!,.!<>)5DN@3=DT9=[2!Z]ZZ'0>1 3U\-
(8!T1IK4(T_/M"M,Q51@) MK*/"K%9A-NZN,#MRHSW!]XX]CG'<>;]EYS7/^2#/>O)$ZA8_(#IHU4'$4R=I M)+!.\=A[7O36^U[57 MN-UH%?>T(,EAWL94Y68B2TKA)-.X.' M^YG3+7O[#1^P[/3X^,"-
W,/7=L7-3]L9\W6D5C _M'W%/^):F L6P46G6U52YA)=' '(@65:KYAC'Y- ' M[_J%O\G4$L#!!0 ("(;%GO@~:+2@, -X- 9 >&PO=VIR:W-H M965T7+!&+(5%, M)$3"8F2===@8SW]AG!C\9;-5.FYB9W
IQ9SH7T)C ^? N2'" M,.X+3JMT:8"[[2?V:39WG,LM57 N^"\6Z=7(.K9(! NZYOI*;+]!.9^>X0L% M5]D_V>:V?=2Q2UU(^$)A&9W*]9BC+3A^0';H(OY#2*F%$,Y>0BR65O]',0 M@*:.?T:+F^N
"S\/+0U!F.H(:!P?)8[=E]O[)%+D>B5(LD@]&@VG&GS3@ M;5R$9\UPP.(R[E[#:GP2E%Z&9_W/U'..4TT.=V5)OG]':W)A898 .F374[=&)6K*95*)>MQC]K*?
YGB>B5B>@U)N+9N0+EY@TY58HM&2*OPIT(JL@$<$ M3Q>B*(=#L]!.D@WEZ|K,-!IZ_9NDRQHDVS2)MFT3;)9KR*^7F=7>_DXI=R M\1OE
M.WOG.AF#7&:,5@B*A6"]CVF1>3>0=+=+L,GLK-%Z-L^8*"S"0Q@#?+X303QWCH"SI MQG\!4$L#!!0 ("(;%FEHD>XZ0,)40 9 >&PO=V]R:W-H965T M&&6Z%O%,K $WNXRA1 M(V>E]?
K4==5\!3%3)V(-"7Y9"ADSC4-YZZ]U!+;(0'"D^]I7=6/&$V<\S-Y= MR_%0I#KB"5Q+HM(X9O+7&41B.W*H\ #B"!=:?/"'0_7!:FH&_ 6UQ:!+LFR MX#$DBHN$2%B.G/?T=$+
[!I!9?.,P595G8ER9"7%G!1>+D>,911#!7:!L*AC\. MF$ 4&2;4\;.@=DY>OWI#7A&>D*\KD2]D4T-7HVI&H3LO ,#C+_? ? M)6,*ZO/2|=X2W ,#%OC$#C^'.<)I!N_4X2Y&M RK7X;5S ,@ZC\G!XI9((R!_
M8[@VZ"N;X0 W!D?R*A$Y?MGA))+#;'ZT>9V/D_0/H\IYY*=]S>8P>P:/1%:+2;^,2?|WI:7<,+4)+):2 9E2 8O3$N#QN[T>[W]+=PT"@9^ MV+Z#J;F H,JS:,25W\KOA2:R$[.#D5-$\L
M;8N596UWY9#:Z^%TA1OOG089DVH35LE27S'"*L6>ZXQ'D3U#V>=Z[GD\%EL] M,KMJ3(/?E*6HM>X _RO'8]N'9=<)4'LK\'2FHLTR[X?^?@?58A5Z%:NZO%U# M0.T=P4&YJ]72-[JH-
J/'VBBZZP:HO1TX+%_UGLY7-I.ZMEU5IM8*=WB^ZC>:.M7[\:-!0VK4]]+D4UD6[ESF@N[-@_W>*JD0B6"/-.>NBAS._ ^4"+=7:-G F- ME]+L<05L =(8X/>E$/IA8&ZFY7\BQO\#4$L#!!0 ("
(;%GME/R],P(M ($$ 9 >&PO=V]R:W-H965T*F5=I.H(FHNX]@5%=:"G9@&-7M6QM:"V+3KV#4611E M8K3 M)#F/:R%UE&=A[\[FF6E28UW%K=A[\[FFE2%GB%&

\HP0Q6(VMB3N:#U6\#OB>P9;O/2/E M9$GI@QI<)V/+40N"'&*A&+#\V\ ,\EP1R67\KCFM1E(!]Y]W|)?;N_2RQ!QF M-/^1)2(=6Y\ME, *5[FXH]LKJ/T,%%],V>OA?IN=_U.?_|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|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{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|=Q_:0T^FO8R*T>EOH^7%H5 J. MW&,EC'%BM/XU@LD/['X 4$L#!!0 ("(;%F2.S$JVP0)DH / M>&PO=V]R:V)O;VLN>&ULQ9K?3^- &$(#_E56>6JDT\:]PARXGP=%KJ1 ""'**/ MU6)OR I[-]U=PW%_?6?M&L8AC/HRY"GVVG$^3^SY9L?^]&C=_:VUJ^)!4QN_ MF*Q#V!Q-I[Y20!93.8S M..!*.Q^Z;KC2V|\4+!SO]8&^U770;E3&=3OSK8;;>[B8> LIN@TNC@.GWT0 MC]S_":-=K72I3FW9-LJ$/HY.U1'0^+7>^(DPLE+&R;"+D*82OYD 01)GIC\4 M[!O/%'[ZK.K/.@ NBJ$[TK#!G54=.!_D%VLJ9;RJ!"QY6^L*."IQ(FMI2B40 M9$I IGN$_#M%D!D!F>T%\D)?R M23QX<:E<[_5XLYQJ7];6MTXAQ$,"\9_7\DN8L78_"(M\ -!^(&7|%3YTNE- '!=V)4Y:KXWROLN8)QO)#?B0@/_)"7JDR9O'CLK0M9'$(M)*C1P'+9A1+G\1F5R&?<__8#[&#=$P8BS<*L%HC2!O3^U/OOGU9OXA=^$1=[M%#/**PFS6&+,?.ANB(IRJ]1.W,BZ56!J/*DS)(PJ^4"*C$1+T/](+M??L&B M7)+PR^0E,_JI-=PD-_"-PVNH"D]LQZ*&VCQ+7\/KK<4LH0*?ODHVET>)XC03Z) M>E5PZ8T9R:D'LR+ 5N+<0DT"+A/+M1PEMY2R0LIA:LXJ*]#2QDE"T4>7'CE M]JV14H)(F05!EG>CV49*62)EM@2-B><;*:6*E%D5SP6>^.DZE@'^9TQ&:2-E MU@91Z456C$E9)&6V'"%GMC2]'2B@ILU#ZDF#7GYQ1 LF8!;++P3LA*:-DS$8A M93SN%%%2R=Y=*CLC27:SF.U")\4<8U**R?:DF .Q:)L&IYZ,4DRV5|44&)-2 M3,:L&!ISCC$IWV3LC:W!A ?BN*ITW$'6S|UUC$GY)GL'WPR8W=4(2Q#581AC M4K[)F'U#V1O <>..:|D_.[!:|QAC4@;*F0U$%QFXF,PI ^7[['R-TGM.62AG MMA"-B?- F3CY58;80C8GS9DY9*&>V$(UYB#$1"^7,%MI]=VXG>8Q)62AGMM#; M[<^,&&-2%LJ9+?1V# 05)F6A_'UF/3N%GY:7E 6*I@M](RYA(-5+5R=8/1A MQG:*>T,%9:&"V4+;C=RMN&),RD(%LX5VSBE?BB6,25FH8+80B3E^:DY9J&"V M$#WYQ:5'03[=9[80C8E+CX*R4,%L(1H3EQX%9:&"?2[TTM??D3TQ)F6A@MU" M0ZO? O^[UBP.,25FH8+;0CL8,GKOA5T\H"|V9+?1VZW_;Z7/*0O/^K;CA5;A* MK6"Z7UW 3W@8+V5=7CH1/_H']7D1'[2MVKK^ F/?S+F5U?!FW?!6X.=_ 5!+ M P04 " B&Q9]4F2S $" !>) &@ 'AL+U]R96QS+W=O3ENT]"MW]IM3KI3_F=AO-OMU M_MVO_QSS:?K'X/3>CV]EE_/4+%ZZ<9NG59,^#M?=)5TVW"R>7E?-^/0J M3:H=I!"D]8,,@JQ^D$.0UP|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|#,! %T%^)LD6- MZU=YB+(!MM %/V"2"8V;Q)9MH/P]3@J50*6B*A)WTZBU/7?BD&^?:IC0QK;.7OOJ6,OE(*-+) M<4]8-BZK1U MW914V? *Y2T>*X#R9*BR)8M<6FZ(G^Y-CNF':?/*C\|3H\ M[G,DP^F)2X7(QV;_*VX34^FCWX^&:5=4_3(7>^K]:MQ'H&-C^/O^.N,M_4/ M[$.]"%!^E @?6B0/F8@?9R"]'$&TL&UL4$L! A0#% @ M (AL6?UUCOCO *P(!$ (!KP &1O8U!R;W!S+V-O M&UL4$L! A0#% @ (AL69E&PO=V]R:W-H965T&UL4$L! A0#% @ (AL6<)5DU6-!P SR. !@ M ("!'PX 'AL+W=O(5 !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% M @ (AL6049#!+F$0 ;OP !@ ("!^2('AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M (AL66[4|29)! = H !D ("!I&0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ (AL616'_$S9!P &PO=V]R:W-H M965T6"?PP .DC 9 M " @967 !X;"]W;W)K&UL4$L! M A0#% @ (AL6;O1Y=W"!0 (0T !D ("!2Z0 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ (AL M6:RCEG/R P LP@ !D ("!%[< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ (AL61O:GL)N @ 5 4 M !D ("!4]4 'AL+W=O$" !D!@ &0 @('XUP M>&PO=V]R:W-H965T&UL4$L! A0#% @ (AL60R RY-\ P]@< !D M ("!>>$ 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ (AL63EC:OH! P M@8 !D ("!&? 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ (AL61PJ MF#J;!0 V!\ !D ("!U0,! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ (AL60_BLF5D @ -08 !D M ("!S!(! 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ (AL6:6B1[CI P E1 !D ("! MQOP! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ (AL6?X#[W2S!0 6"P !D ("!CR@! 'AL+W=O&PO=V]R:W-H965TO);04 -HD 9 " @2,T 0!X M;"]W;W)K&UL4$L! A0#% @ (AL62_X;I8 M P XPP !D ("!QSD! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ (AL65H(_J92!0 DR, !D M ("! D8! 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ (AL66>Q=;95!@ +C$!D ("!D&H! M 'AL+W=O&PO=V]R:W-H965TQ::C 0 %\2 9 M " @:A] 0!X;"]W;W)K&UL4$L! A0#% @ M (AL6>7:/N%A P @ L !D ("!;X(! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ (AL60IZQ7(.! M718 !D ("!Q8X! 'AL+W=O&PO=V]R:W-H965T7!E&UL4$L%!@ !% $4 VA($VC $ 0 $! end XML 70 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent) {a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 71 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .num{ padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 73 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html4203251false1040false7 falsefalseR1.htm100000 - Document - Document and Entity InformationSheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformationDocument and Entity InformationCover1 falsefalseR2.htm100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedCondensed Consolidated Balance Sheets (Unaudited)Statements2 falsefalseR3.htm100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParentheticalUnauditedCondensed Consolidated Balance Sheets (Parenthetical) (Unaudited)Statements3 falsefalseR4.htm100060 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnauditedCondensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)Statements4 falsefalseR5.htm100080 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedCondensed Consolidated Statements of Stockholders' Equity (Unaudited)Statements5 falsefalseR6.htm100090 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnauditedCondensed Consolidated Statements of Cash Flows (Unaudited)Statements6 falsefalseR7.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes7 falsefalseR8.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes8 falsefalseR9.htm995455 - Disclosure - Description of Business and Basis of PresentationSheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationDescription of Business and Basis of PresentationNotes9 falsefalseR10.htm995465 - Disclosure - Recent Accounting PronouncementsSheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRecentAccountingPronouncementsRecent Accounting PronouncementsNotes10 falsefalseR11.htm995475 - Disclosure - InventorySheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInventoryInventoryNotes11 falsefalseR12.htm995485 - Disclosure - Property and Equipment, NetSheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetProperty and Equipment, NetNotes12 falsefalseR13.htm995495 - Disclosure - Investments and Fair Value InstrumentsSheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsInvestments and Fair Value InstrumentsNotes13 falsefalseR14.htm995505 - Disclosure - Note ReceivableSheethttp://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableNote ReceivableNotes14 falsefalseR15.htm995515 - Disclosure - Consolidated Joint VentureSheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureConsolidatedJointVentureConsolidated Joint VentureNotes15 falsefalseR16.htm995525 - Disclosure - Collaborative ArrangementsSheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCollaborativeArrangementsCollaborative ArrangementsNotes16 falsefalseR17.htm995535 - Disclosure - LeasesSheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesLeasesNotes17 falsefalseR18.htm995545 - Disclosure - Equity FinancingSheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingEquity FinancingNotes18 falsefalseR19.htm995555 - Disclosure - Warrants and OptionsSheethttp://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsWarrants and OptionsNotes19 falsefalseR20.htm995565 - Disclosure - Stock-Based Compensation and Employee Stock Purchase ProgramSheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramStock-Based Compensation and Employee Stock Purchase ProgramNotes20 falsefalseR21.htm995575 - Disclosure - Income TaxesSheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesIncome TaxesNotes21 falsefalseR22.htm995585 - Disclosure - Commitment and ContingenciesSheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentAndContingenciesCommitment and ContingenciesNotes22 falsefalseR23.htm995595 - Disclosure - Net Loss per ShareSheethttp://arcadiabio.com/20240930/taxonomy/role/DisclosureNetLossPerShareNet Loss per ShareNotes23 falsefalseR24.htm995605 - Disclosure - Related-Party TransactionsSheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsRelated-Party TransactionsNotes24 falsefalseR25.htm995625 - Disclosure - Description of Business and Basis of Presentation (Policies)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationPoliciesDescription of Business and Basis of Presentation (Policies)Policieshttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRecentAccountingPronouncements25 falsefalseR26.htm995635 - Disclosure -

Description of Business and Basis of Presentation
(Tables)Sheethttp://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationTablesDescription of Business and Basis of Presentation
(Tables)Tableshttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentation26 falsefalseR27.htm995645 - Disclosure - Inventory (Tables)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInventoryTablesInventory
(Tables)Tableshttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInventory27 falsefalseR28.htm995655 - Disclosure - Property and Equipment, Net
(Tables)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTablesProperty and Equipment, Net
(Tables)Tableshttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet28 falsefalseR29.htm995665 - Disclosure - Investments and Fair Value Instruments (Tables)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsTablesInvestments and Fair Value Instruments (Tables)Tableshttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstruments29 falsefalseR30.htm995675 - Disclosure - Leases (Tables)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesTablesLeases
(Tables)Tableshttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeases30 falsefalseR31.htm995685 - Disclosure - Warrants and Options
(Tables)Sheethttp://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsTablesWarrants and Options
(Tables)Tableshttp://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptions31 falsefalseR32.htm995695 - Disclosure - Stock-Based Compensation and Employee Stock Purchase Program
(Tables)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramTablesStock-Based Compensation and Employee Stock Purchase Program
(Tables)Tableshttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgram32 falsefalseR33.htm995705 - Disclosure - Net Loss per Share (Tables)Sheethttp://arcadiabio.com/20240930/taxonomy/role/DisclosureNetLossPerShareTablesNet Loss per Share
(Tables)Tableshttp://arcadiabio.com/20240930/taxonomy/role/DisclosureNetLossPerShare33 falsefalseR34.htm995715 - Disclosure - Description of Business and Basis of Presentation - Additional Information
(Detail)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetailDescription of Business and Basis of Presentation - Additional Information (Detail)Details34 falsefalseR35.htm995725 - Disclosure - Description of Business - Summary of Major Classes of Line Items Constituting the Balance Sheet on Discontinued Operations
(Details)Sheethttp://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessSummaryOfMajorClassesOfLineItemsConstitutingTheBalanceSheetOnDiscontinu of Business - Summary of Major Classes of Line Items Constituting the Balance Sheet on Discontinued Operations (Details)Details35 falsefalseR36.htm995735 - Disclosure - Description of Business and Basis of Presentation - Summary of Major Classes of Line Items Constituting Net Loss from Discontinued Operations
(Detail)Sheethttp://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationSummaryOfMajorClassesOfLineItemsConstitutingNetLoss of Business and Basis of Presentation - Summary of Major Classes of Line Items Constituting Net Loss from Discontinued Operations (Detail)Details36 falsefalseR37.htm995745 - Disclosure - Description of Business and Basis of Presentation - Non-cash Items of Discontinued Operations
(Details)Sheethttp://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationNoncashItemsOfDiscontinuedOperationsDetailsDescripti of Business and Basis of Presentation - Non-cash Items of Discontinued Operations (Details)Details37 falsefalseR38.htm995755 - Disclosure - Inventory - Additional Information (Detail)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInventoryAdditionalInformationDetailInventory - Additional Information (Detail)Details38 falsefalseR39.htm995765 - Disclosure - Inventory - Summary of Inventories
(Detail)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInventorySummaryOfInventoriesDetailInventory - Summary of Inventories (Detail)Details39 falsefalseR40.htm995775 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net
(Detail)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetailProperty and Equipment, Net - Summary of Property and Equipment, Net (Detail)Details40 falsefalseR41.htm995785 - Disclosure - Property and Equipment, Net - Additional Information
(Detail)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetailProperty and Equipment, Net - Additional Information (Detail)Details41 falsefalseR42.htm995795 - Disclosure - Investments and Fair Value Instruments - Summary of Amortized Cost and Fair Value of Investment Securities Portfolio
(Detail)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfAmortizedCostAndFairValueOfInvestmentSecuriti and Fair Value Instruments - Summary of Amortized Cost and Fair Value of Investment Securities Portfolio (Detail)Details42 falsefalseR43.htm995805 - Disclosure - Investments and Fair Value Instruments - Additional Information
(Detail)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsAdditionalInformationDetailInvestments and Fair Value Instruments - Additional Information (Detail)Details43 falsefalseR44.htm995815 - Disclosure - Investments and Fair Value Instruments - Summary of Fair Value of Investments Securities
(Detail)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfFairValueOfInvestmentsSecuritiesDetailInvestmer and Fair Value Instruments - Summary of Fair Value of Investments Securities (Detail)Details44 falsefalseR45.htm995825 - Disclosure - Investments and Fair Value Instruments - Summary of Preferred Investment Option Liabilities Measured and Recorded on Recurring Basis using Black-Scholes Model
(Detail)Sheethttp://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRec and Fair Value Instruments - Summary of Preferred Investment Option Liabilities Measured and Recorded on Recurring Basis using Black-Scholes Model (Detail)Details45 falsefalseR46.htm995835 - Disclosure - Investments and Fair Value Instruments - Summary of Changes in Fair Value and Other Adjustments of Assets and Liabilities
(Detail)Sheethttp://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAnd and Fair Value Instruments - Summary of Changes in Fair Value and Other Adjustments of Assets and Liabilities (Detail)Details46 falsefalseR47.htm995845 - Disclosure - Note Receivable - Additional Information (Details)Sheethttp://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableAdditionalInformationDetailsNote Receivable - Additional Information (Details)Details47 falsefalseR48.htm995855 - Disclosure - Consolidated Joint Venture - Additional Information
(Detail)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureConsolidatedJointVentureAdditionalInformationDetailConsolidated Joint Venture - Additional Information (Detail)Details48 falsefalseR49.htm995865 - Disclosure - Collaborative Arrangements - Additional Information
(Detail)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCollaborativeArrangementsAdditionalInformationDetailCollaborative Arrangements - Additional Information (Detail)Details49 falsefalseR50.htm995875 - Disclosure - Leases - Additional Information
(Detail)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetailLeases - Additional Information (Detail)Details50 falsefalseR51.htm995885 - Disclosure - Leases - Schedule of Leases
(Detail)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasesDetailLeases - Schedule of Leases (Detail)Details51 falsefalseR52.htm995905 - Disclosure - Equity Financing - Additional Information
(Detail)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetailEquity Financing - Additional Information (Detail)Details52 falsefalseR53.htm995915 - Disclosure - Warrants and Options - Summary of Warrants Issued to Purchase Common Stock
(Detail)Sheethttp://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetailWarrants and Options - Summary of Warrants Issued to Purchase Common Stock (Detail)Details53 falsefalseR54.htm995935 - Disclosure - Warrants and Options - Summary of Key Terms and Activity of Liability Classified Preferred Investment Options
(Detail)Sheethttp://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfKeyTermsAndActivityOfLiabilityClassifiedPreferredInvestmentOptionsDe and Options - Summary of Key Terms and Activity of Liability Classified Preferred Investment Options (Detail)Details54 falsefalseR55.htm995945 - Disclosure - Stock-Based Compensation and Employee Stock Purchase Program - Additional Information
(Detail)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetailStock-Based Compensation and Employee Stock Purchase Program - Additional Information (Detail)Details55 falsefalseR56.htm995955 - Disclosure - Stock-Based Compensation and Employee Stock Purchase Program - Summary of Activity Under Stock Incentive Plans
(Detail)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramSummaryOfActivityUnderStockIncen Based Compensation and Employee Stock Purchase Program - Summary of Activity Under Stock Incentive Plans (Detail)Details56 falsefalseR57.htm995965 - Disclosure - Stock-Based Compensation and Employee Stock Purchase Program - Weighted-Average Fair Value Assumption of Stock Option Awards
(Detail)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramWeightedAverageFairValueAssumptio Based Compensation and Employee Stock Purchase Program - Weighted-Average Fair Value Assumption of Stock Option Awards (Detail)Details57 falsefalseR58.htm995975 - Disclosure - Income Taxes - Additional Information
(Detail)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetailIncome Taxes - Additional Information (Detail)Details58 falsefalseR59.htm995985 - Disclosure - Commitments and Contingencies - Additional Information
(Detail)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetailCommitments and Contingencies - Additional Information (Detail)Details59 falsefalseR60.htm995995 - Disclosure - Net Loss per Share - Summary of Securities Not Included in Diluted Per Share Calculations
(Detail)Sheethttp://arcadiabio.com/20240930/taxonomy/role/DisclosureNetLossPerShareSummaryOfSecuritiesNotIncludedInDilutedPerShareCalculationsDetailNet Loss per Share - Summary of Securities Not Included in Diluted Per Share Calculations (Detail)Details60 falsefalseR61.htm996005 - Disclosure - Related-Party Transactions - Additional Information (Detail)Sheethttp://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetailRelated-Party Transactions - Additional Information (Detail)Details61 falsefalseAll ReportsBookAll Reports rkda-20240930.htmrkda-20240930.xsd http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024falsefalse JSON 76 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "rkda-20240930.htm": { "nsprefix": "rkda", "nsuri": "http://arcadiabio.com/20240930", "dts": { "inline": { "local": ["rkda-20240930.htm"] }, "schema": { "local": ["rkda-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] } }, "keyStandard": 244, "keyCustom": 81, "axisStandard": 25, "axisCustom": 0, "memberStandard": 30, "memberCustom": 62, "hidden": { "total": 20, "http://fasb.org/us-gaap/2024": 15, "http://xbrl.sec.gov/dei/2024": 4, "http://arcadiabio.com/20240930": 1 }, "contextCount": 420, "entityCount": 1, "segmentCount": 104, "elementCount": 773, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 815, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_3a6ed2b3-fdd8-456c-a36f-6b5343140499", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3a6ed2b3-fdd8-456c-a36f-6b5343140499", "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"

```
], "reportCount": 1, "baseRef": "rkda-20240930.htm", "unique": true } }, "R3": { "role":
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited", "longName": "100030 - Statement -
Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited)", "isDefault":
"false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_3a6ed2b3-fdd8-456c-a36f-
6b5343140499", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span",
"p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3a6ed2b3-fdd8-
456c-a36f-6b5343140499", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3",
"ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R4": { "role":
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "longName": "100060 -
Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations and
Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef":
"C_bc2d70ab-6711-421f-809b-99cfde23f1ad", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null,
"decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true }, "uniqueAnchor": {
"contextRef": "C_bc2d70ab-6711-421f-809b-99cfde23f1ad", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals":
"-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "unique": true } }, "R5": { "role":
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "longName": "100080 - Statement -
Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
"isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_b757298c-844e-423f-a3ed-
63af4018305c", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals":
"-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef":
"C_43d280e4-ebc0-44a9-8149-c232d9497b3e", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3",
"ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "unique": true } }, "R6": { "role":
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "longName": "100090 - Statement - Condensed
Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType":
"statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_bc2d70ab-6711-421f-809b-99cfde23f1ad", "name": "us-
gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef":
"rkda-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name":
"rkda:DepreciationContinuingAndDiscontinuedOperations", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table",
"body", "html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 -
Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat":
"Notes", "order": "7", "firstAnchor": { "contextRef": "C_bc2d70ab-6711-421f-809b-99cfde23f1ad", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false",
"lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true }, "uniqueAnchor":
null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider
Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_bc2d70ab-
6711-421f-809b-99cfde23f1ad", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body",
"html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bc2d70ab-6711-421f-809b-99cfde23f1ad",
"name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1,
"baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R9": { "role":
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentation", "longName": "995455 - Disclosure - Description of Business
and Basis of Presentation", "shortName": "Description of Business and Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat":
"Notes", "order": "9", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true,
"unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true,
"unique": true } }, "R10": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRecentAccountingPronouncements", "longName": "995465 - Disclosure -
Recent Accounting Pronouncements", "shortName": "Recent Accounting Pronouncements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat":
"Notes", "order": "10", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-
gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div",
"body", "html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-
e7c88b539004", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R11": { "role":
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInventory", "longName": "995475 - Disclosure - Inventory", "shortName": "Inventory", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-
gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef":
"rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-
gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef":
"rkda-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet",
"longName": "995485 - Disclosure - Property and Equipment, Net", "shortName": "Property and Equipment, Net", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-
gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount":
1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-
gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount":
1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R13": { "role":
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstruments", "longName": "995495 - Disclosure - Investments and Fair Value
Instruments", "shortName": "Investments and Fair Value Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13",
"firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "rkda:InvestmentsAndFairValueOfInstrumentsDisclosureTextBlock", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "rkda:InvestmentsAndFairValueOfInstrumentsDisclosureTextBlock", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } },
"R14": { "role": "http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivable", "longName": "995505 - Disclosure - Note Receivable", "shortName": "Note
Receivable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-
836e-e7c88b539004", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-
48bb-836e-e7c88b539004", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R15": { "role":
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureConsolidatedJointVenture", "longName": "995515 - Disclosure - Consolidated Joint Venture", "shortName":
"Consolidated Joint Venture", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef":
"C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals":
null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-
ac57-48bb-836e-e7c88b539004", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R16": { "role":
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCollaborativeArrangements", "longName": "995525 - Disclosure - Collaborative Arrangements", "shortName":
"Collaborative Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef":
"C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals":
null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-
ac57-48bb-836e-e7c88b539004", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R17": { "role":
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeases", "longName": "995535 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-
gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef":
"rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-
gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef":
"rkda-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancing", "longName": "995545
- Disclosure - Equity Financing", "shortName": "Equity Financing", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18",
"firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false",
"lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R19": { "role":
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptions", "longName": "995555 - Disclosure - Warrants and Options", "shortName": "Warrants and
Options", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-
e7c88b539004", "name": "rkda:WarrantsAndOptionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body",
"html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004",
"name": "rkda:WarrantsAndOptionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ],
"reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R20": { "role":
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgram", "longName": "995565 - Disclosure - Stock-
Based Compensation and Employee Stock Purchase Program", "shortName": "Stock-Based Compensation and Employee Stock Purchase Program", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-
gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body",
"html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004",
"name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [
"div", "body", "html" ], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R21": { "role":
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxes", "longName": "995575 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004",
"name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1,
```

"baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentAndContingencies", "longName": "995585 - Disclosure - Commitment and Contingencies", "shortName": "Commitment and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://arcadiabio.com/20240930/taxonomy/role/DisclosureNetLossPerShare", "longName": "995595 - Disclosure - Net Loss per Share", "shortName": "Net Loss per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactions", "longName": "995605 - Disclosure - Related-Party Transactions", "shortName": "Related-Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies", "longName": "995625 - Disclosure - Description of Business and Basis of Presentation (Policies)", "shortName": "Description of Business and Basis of Presentation (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "rkda:OrganizationPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "rkda:OrganizationPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationTables", "longName": "995635 - Disclosure - Description of Business and Basis of Presentation (Tables)", "shortName": "Description of Business and Basis of Presentation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInventoryTables", "longName": "995645 - Disclosure - Inventory (Tables)", "shortName": "Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "rkda:ScheduleOfInventoryCurrentAndNonCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "rkda:ScheduleOfInventoryCurrentAndNonCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables", "longName": "995655 - Disclosure - Property and Equipment, Net (Tables)", "shortName": "Property and Equipment, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "rkda:ScheduleOfPropertyPlantAndEquipmentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "rkda:ScheduleOfPropertyPlantAndEquipmentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsTables", "longName": "995665 - Disclosure - Investments and Fair Value Instruments (Tables)", "shortName": "Investments and Fair Value Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "rkda:SummaryOfAmortizedCostAndFairValueOfInvestmentSecuritiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "rkda:InvestmentsAndFairValueOfInstrumentsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "rkda:SummaryOfAmortizedCostAndFairValueOfInvestmentSecuritiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "rkda:InvestmentsAndFairValueOfInstrumentsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesTables", "longName": "995675 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "rkda:ScheduleOfOperatingLeaseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "rkda:ScheduleOfOperatingLeaseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsTables", "longName": "995685 - Disclosure - Warrants and Options (Tables)", "shortName": "Warrants and Options (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "rkda:WarrantsAndOptionsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "rkda:WarrantsAndOptionsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramTables", "longName": "995695 - Disclosure - Stock-Based Compensation and Employee Stock Purchase Program (Tables)", "shortName": "Stock-Based Compensation and Employee Stock Purchase Program (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://arcadiabio.com/20240930/taxonomy/role/DisclosureNetLossPerShareTables", "longName": "995705 - Disclosure - Net Loss per Share (Tables)", "shortName": "Net Loss per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "longName": "995715 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Detail)", "shortName": "Description of Business and Basis of Presentation - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "rkda:EntityPlaceOfIncorporation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "rkda:OrganizationPolicyPolicyTextBlock", "div", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "rkda:EntityPlaceOfIncorporation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "rkda:OrganizationPolicyPolicyTextBlock", "div", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessSummaryOfMajorClassesOfLineItemsConstitutingTheBalanceSheetOnDiscontinuedOperations", "longName": "995725 - Disclosure - Description of Business - Summary of Major Classes of Line Items Constituting the Balance Sheet on Discontinued Operations (Details)", "shortName": "Description of Business - Summary of Major Classes of Line Items Constituting the Balance Sheet on Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_cd4ac140-74ba-4669-bde0-86c2e3018caf", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cd4ac140-74ba-4669-bde0-86c2e3018caf", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationSummaryOfMajorClassesOfLineItemsConstitutingNetLossFromDiscon
"longName": "995735 - Disclosure - Description of Business and Basis of Presentation - Summary of Major Classes of Line Items Constituting Net Loss from Discontinued Operations (Detail)", "shortName": "Description of Business and Basis of Presentation - Summary of Major Classes of Line Items Constituting Net Loss from Discontinued Operations (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_88894626-d996-4475-b864-a984ca87fe5c", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-

gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_88894626-d996-4475-b864-a984ca87fe5c", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationNoncashItemsOfDiscontinuedOperationsDetails", "longName": "995745 - Disclosure - Description of Business and Basis of Presentation - Non-cash Items of Discontinued Operations (Details)", "shortName": "Description of Business and Basis of Presentation - Non-cash Items of Discontinued Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-gaap:IncreaseDecreaseInInventories", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_4d7ce3ad-faec-4598-87ad-e7b83cbe7248", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "div", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "unique": true } }, "R38": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInventoryAdditionalInformationDetail", "longName": "995755 - Disclosure - Inventory - Additional Information (Detail)", "shortName": "Inventory - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_bc2d70ab-6711-421f-809b-99cfde23f1ad", "name": "us-gaap:InventoryWriteDown", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true }, "uniqueAnchor": null }, "R39": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInventorySummaryOfInventoriesDetail", "longName": "995765 - Disclosure - Inventory - Summary of Inventories (Detail)", "shortName": "Inventory - Summary of Inventories (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_3a6ed2b3-fdd8-456c-a36f-6b5343140499", "name": "rkda:InventoryRawMaterialsCurrentAndNonCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "rkda:ScheduleOfInventoryCurrentAndNonCurrentTableTextBlock", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3a6ed2b3-fdd8-456c-a36f-6b5343140499", "name": "rkda:InventoryRawMaterialsCurrentAndNonCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "rkda:ScheduleOfInventoryCurrentAndNonCurrentTableTextBlock", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail", "longName": "995775 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Detail)", "shortName": "Property and Equipment, Net - Summary of Property and Equipment, Net (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_3a6ed2b3-fdd8-456c-a36f-6b5343140499", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "rkda:ScheduleOfPropertyPlantAndEquipmentTableTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3a6ed2b3-fdd8-456c-a36f-6b5343140499", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "rkda:ScheduleOfPropertyPlantAndEquipmentTableTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R41": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail", "longName": "995785 - Disclosure - Property and Equipment, Net - Additional Information (Detail)", "shortName": "Property and Equipment, Net - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_bc2d70ab-6711-421f-809b-99cfde23f1ad", "name": "us-gaap:Depreciation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bc2d70ab-6711-421f-809b-99cfde23f1ad", "name": "us-gaap:Depreciation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfAmortizedCostAndFairValueOfInvestmentSecuritiesPortfolioD "longName": "995795 - Disclosure - Investments and Fair Value Instruments - Summary of Amortized Cost and Fair Value of Investment Securities Portfolio (Detail)", "shortName": "Investments and Fair Value Instruments - Summary of Amortized Cost and Fair Value of Investment Securities Portfolio (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_3a6ed2b3-fdd8-456c-a36f-6b5343140499", "name": "rkda:DebtAndEquitySecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "rkda:SummaryOfAmortizedCostAndFairValueOfInvestmentSecuritiesTableTextBlock", "div", "rkda:InvestmentsAndFairValueOfInstrumentsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3a6ed2b3-fdd8-456c-a36f-6b5343140499", "name": "rkda:DebtAndEquitySecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "rkda:SummaryOfAmortizedCostAndFairValueOfInvestmentSecuritiesTableTextBlock", "div", "rkda:InvestmentsAndFairValueOfInstrumentsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R43": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsAdditionalInformationDetail", "longName": "995805 - Disclosure - Investments and Fair Value Instruments - Additional Information (Detail)", "shortName": "Investments and Fair Value Instruments - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_3a6ed2b3-fdd8-456c-a36f-6b5343140499", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "rkda:InvestmentsAndFairValueOfInstrumentsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3a6ed2b3-fdd8-456c-a36f-6b5343140499", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "rkda:InvestmentsAndFairValueOfInstrumentsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R44": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfFairValueOfInvestmentsSecuritiesDetail", "longName": "995815 - Disclosure - Investments and Fair Value Instruments - Summary of Fair Value of Investments Securities (Detail)", "shortName": "Investments and Fair Value Instruments - Summary of Fair Value of Investments Securities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_3a6ed2b3-fdd8-456c-a36f-6b5343140499", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "div", "rkda:InvestmentsAndFairValueOfInstrumentsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3a6ed2b3-fdd8-456c-a36f-6b5343140499", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "div", "rkda:InvestmentsAndFairValueOfInstrumentsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R45": { "role": "http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec "longName": "995825 - Disclosure - Investments and Fair Value Instruments - Summary of Preferred Investment Option Liabilities Measured and Recorded on Recurring Basis using Black-Scholes Model (Detail)", "shortName": "Investments and Fair Value Instruments - Summary of Preferred Investment Option Liabilities Measured and Recorded on Recurring Basis using Black-Scholes Model (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_37ccc15f-08ad-4023-931a-6604196b3773", "name": "rkda:PreferredInvestmentOptionsLiabilityMeasuredRemainingTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_37ccc15f-08ad-4023-931a-6604196b3773", "name": "rkda:PreferredInvestmentOptionsLiabilityMeasuredRemainingTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R46": { "role": "http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe "longName": "995835 - Disclosure - Investments and Fair Value Instruments - Summary of Changes in Fair Value and Other Adjustments of Assets and Liabilities (Detail)", "shortName": "Investments and Fair Value Instruments - Summary of Changes in Fair Value and Other Adjustments of Assets and Liabilities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_cfaa4344-5ebc-4a58-89c9-ce7b1c7f06cb", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cfaa4344-5ebc-4a58-89c9-ce7b1c7f06cb", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R47": { "role": "http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableAdditionalInformationDetails", "longName": "995845 - Disclosure - Note Receivable - Additional Information (Details)", "shortName": "Note Receivable - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_bc2d70ab-6711-421f-809b-99cfde23f1ad", "name": "us-gaap:InterestIncomeExpenseNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_81f6fc00-0a93-461b-b143-32683f177731", "name": "us-gaap:GainLossOnSaleOfBusiness", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "unique": true } }, "R48": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureConsolidatedJointVentureAdditionalInformationDetail", "longName": "995855 - Disclosure - Consolidated Joint Venture - Additional Information (Detail)", "shortName": "Consolidated Joint Venture - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_bea32059-eeb0-4854-8ac7-796df3675407", "name": "rkda:NumberOfIndividualsAppointed", "unitRef": "U_Individual", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bea32059-eeb0-4854-8ac7-796df3675407", "name": "rkda:NumberOfIndividualsAppointed", "unitRef": "U_Individual", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R49": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCollaborativeArrangementsAdditionalInformationDetail", "longName": "995865 - Disclosure - Collaborative Arrangements - Additional Information (Detail)", "shortName": "Collaborative Arrangements - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-

gaap:ProceedsFromSaleOfIntangibleAssets", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_90b1e349-70f5-43ef-b304-8154e974d67d", "name": "rkda:ContractualAgreementMonthAndYear", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "unique": true } }, "R50": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail", "longName": "995875 - Disclosure - Leases - Additional Information (Detail)", "shortName": "Leases - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_3a6ed2b3-fdd8-456c-a36f-6b5343140499", "name": "us-gaap:LessorOperatingLeaseAssumptionsAndJudgmentsValueOfUnderlyingAssetAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "us-gaap:LesseeOperatingLeaseOptionToExtend", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3a6ed2b3-fdd8-456c-a36f-6b5343140499", "name": "us-gaap:LessorOperatingLeaseAssumptionsAndJudgmentsValueOfUnderlyingAssetAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "us-gaap:LesseeOperatingLeaseOptionToExtend", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R51": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasesDetail", "longName": "995885 - Disclosure - Leases - Schedule of Leases (Detail)", "shortName": "Leases - Schedule of Leases (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_3a6ed2b3-fdd8-456c-a36f-6b5343140499", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_66fe3aaf-0369-4ac2-a833-8bbe0959b22b", "name": "rkda:OperatingLeaseAssets", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "unique": true } }, "R52": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail", "longName": "995905 - Disclosure - Equity Financing - Additional Information (Detail)", "shortName": "Equity Financing - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_51718bec-b476-4eb7-b250-e802a5b0343b", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_51718bec-b476-4eb7-b250-e802a5b0343b", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R53": { "role": "http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail", "longName": "995915 - Disclosure - Warrants and Options - Summary of Warrants Issued to Purchase Common Stock (Detail)", "shortName": "Warrants and Options - Summary of Warrants Issued to Purchase Common Stock (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "rkda:StockIssuedDuringPeriodSharesRelatedToExerciseOfWarrants", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "rkda:WarrantsAndOptionsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3a6ed2b3-fdd8-456c-a36f-6b5343140499", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "rkda:WarrantsAndOptionsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "unique": true } }, "R54": { "role": "http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfKeyTermsAndActivityOfLiabilityClassifiedPreferredInvestmentOptionsDetail", "longName": "995935 - Disclosure - Warrants and Options - Summary of Key Terms and Activity of Liability Classified Preferred Investment Options (Detail)", "shortName": "Warrants and Options - Summary of Key Terms and Activity of Liability Classified Preferred Investment Options (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_3795cad4-f8d7-47b9-9c62-29bcf622576b", "name": "rkda:PreferredInvestmentOptionsLiabilityIssuanceMonthAndYear", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3795cad4-f8d7-47b9-9c62-29bcf622576b", "name": "rkda:PreferredInvestmentOptionsLiabilityIssuanceMonthAndYear", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R55": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail", "longName": "995945 - Disclosure - Stock-Based Compensation and Employee Stock Purchase Program - Additional Information (Detail)", "shortName": "Stock-Based Compensation and Employee Stock Purchase Program - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "rkda:NumberOfEquityIncentivePlans", "unitRef": "U_IncentivePlan", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "rkda:NumberOfEquityIncentivePlans", "unitRef": "U_IncentivePlan", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R56": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramSummaryOfActivityUnderStockIncentivePlansDet "longName": "995955 - Disclosure - Stock-Based Compensation and Employee Stock Purchase Program - Summary of Activity Under Stock Incentive Plans (Detail)", "shortName": "Stock-Based Compensation and Employee Stock Purchase Program - Summary of Activity Under Stock Incentive Plans (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "C_66fe3aaf-0369-4ac2-a833-8bbe0959b22b", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "unique": true } }, "R57": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramWeightedAverageFairValueAssumptionOfStockOp "longName": "995965 - Disclosure - Stock-Based Compensation and Employee Stock Purchase Program - Weighted-Average Fair Value Assumption of Stock Option Awards (Detail)", "shortName": "Stock-Based Compensation and Employee Stock Purchase Program - Weighted-Average Fair Value Assumption of Stock Option Awards (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C_64e7146a-86c8-45df-9969-f7c57c8f15ee", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_64e7146a-86c8-45df-9969-f7c57c8f15ee", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R58": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "longName": "995975 - Disclosure - Income Taxes - Additional Information (Detail)", "shortName": "Income Taxes - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f0400279-ac57-48bb-836e-e7c88b539004", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R59": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "longName": "995985 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C_3a6ed2b3-fdd8-456c-a36f-6b5343140499", "name": "us-gaap:OtherLiabilitiesNoncurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_083affa8-810e-4d8c-868d-f1eee130d228", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "unique": true } }, "R60": { "role": "http://arcadiabio.com/20240930/taxonomy/role/DisclosureNetLossPerShareSummaryOfSecuritiesNotIncludedInDilutedPerShareCalculationsDetail", "longName": "995995 - Disclosure - Net Loss per Share - Summary of Securities Not Included in Diluted Per Share Calculations (Detail)", "shortName": "Net Loss per Share - Summary of Securities Not Included in Diluted Per Share Calculations (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "C_bc2d70ab-6711-421f-809b-99cfde23f1ad", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bc2d70ab-6711-421f-809b-99cfde23f1ad", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } }, "R61": { "role": "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail", "longName": "996005 - Disclosure - Related-Party Transactions - Additional Information (Detail)", "shortName": "Related-Party Transactions - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "C_550fd7ed-69b7-496d-935b-e3f3cf344c95", "name": "us-gaap:OtherLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_550fd7ed-69b7-496d-935b-e3f3cf344c95", "name": "us-gaap:OtherLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rkda-20240930.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingChangesAndErrorCorrectionsAbstract", "lang": { "en-us": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdate201602Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingStandardsUpdate201602Member", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "ASU 2016-02", "label": "Accounting Standards Update 2016-02 [Member]", "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842)." } } }, "auth_ref": ["r561"] }, "us-gaap_AccountingStandardsUpdate202006Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"AccountingStandardsUpdate202006Member", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
], "lang": { "en-us": { "role": { "terseLabel": "ASU 2020-06 [Member]", "label": "Accounting Standards Update 2020-06 [Member]", "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity." } } }, "auth_ref": ["r518", "r519", "r520", "r521", "r522", "r523", "r524", "r526", "r527", "r528", "r529"] }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsAndOtherReceivablesNetCurrent", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable and other receivables, net of allowance for doubtful accounts of $0 as of September 30, 2024 and December 31, 2023", "verboseLabel": "Remaining accounts receivable and other receivables", "label": "Accounts receivable and other receivables", "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r274", "r1088"] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Accounts Payable and Accrued Liabilities, Current, Total", "terseLabel": "Accounts payable and accrued expenses", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r74", "r75"] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"], "lang": { "en-us": { "role": { "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "negatedLabel": "Less accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r32", "r169", "r691"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r23", "r24", "r90", "r175", "r686", "r734", "r738"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income [Member]", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r4", "r13", "r24", "r509", "r512", "r588", "r729", "r730", "r1063", "r1064", "r1065", "r1074", "r1075", "r1076", "r1077"] }, "rkda_AchievementOfRevenueMilestoneIn2021Member": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "AchievementOfRevenueMilestoneIn2021Member", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Revenue Milestone in 2021 [Member]", "label": "Achievement Of Revenue Milestone In2021 [Member]", "documentation": "Achievement of Revenue Milestone in 2021." } } }, "auth_ref": [] }, "rkda_AchievementOfRevenueMilestoneIn2022Member": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "AchievementOfRevenueMilestoneIn2022Member", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Revenue Milestone in 2022 [Member]", "label": "Achievement Of Revenue Milestone In2022 [Member]", "documentation": "Achievement of Revenue Milestone in 2022." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r994"] }, "rkda_AdditionalCashReceivableFromSaleOfInterestInJointVenture": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "AdditionalCashReceivableFromSaleOfInterestInJointVenture", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Additional cash receivable from sale of interest in joint venture", "label": "Additional Cash Receivable From Sale Of Interest In Joint Venture", "documentation": "Additional cash receivable from sale of interest in joint venture." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r84"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital [Member]", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r753", "r1074", "r1075", "r1076", "r1077", "r1140", "r1201"] }, "rkda_AdditionalPropertiesUnderLeaseAgreement": { "xbrltype": "stringItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "AdditionalPropertiesUnderLeaseAgreement", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Number of additional properties under lease agreement", "label": "Additional Properties Under Lease Agreement", "documentation": "Additional properties under lease agreement." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r1007"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r1007"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r1007"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r1007"] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": ["r156", "r157", "r158", "r159", "r160", "r161", "r208", "r209", "r210", "r212", "r224", "r271", "r272", "r314", "r315", "r316", "r317", "r320", "r321", "r322", "r323", "r324", "r325", "r358", "r359", "r363", "r462", "r463", "r464", "r465", "r466", "r475", "r476", "r477", "r478", "r479", "r480", "r482", "r483", "r484", "r486", "r487", "r488", "r490", "r491", "r492", "r493", "r494", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r514", "r515", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r526", "r527", "r528", "r529", "r547", "r548", "r562", "r563", "r564", "r582", "r584", "r585", "r586", "r587", "r588", "r637", "r638", "r639", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738"] }, "rkda_AdjustmentsToAdditionalPaidInCapitalModificationOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "AdjustmentsToAdditionalPaidInCapitalModificationOfWarrants", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital modification of warrants.", "label": "Adjustments To Additional Paid In Capital Modification of Warrants", "terseLabel": "Modification of warrants related to March 2023 PIPE" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total", "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r38", "r39", "r417"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail"], "lang": { "en-us": { "role": { "negatedLabel": "Offering costs", "verboseLabel": "Remaining offering costs allocated to common stock and offset to additional paid in capital", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": ["r14", "r120"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r1040"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous

Compensation Amount" } } }, "auth_ref": ["r966", "r976", "r986", "r1018"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r969", "r979", "r989", "r1021"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r1041"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r1007"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r1014"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r970", "r980", "r990", "r1014", "r1022", "r1026", "r1034"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r1032"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": ["r176", "r275", "r326"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "rkda_AmendmentMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "AmendmentMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Amendment [Member]", "label": "Amendment [Member]", "documentation": "Amendment." } } }, "auth_ref": [] }, "rkda_AmortizationOfNoteReceivableDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "AmortizationOfNoteReceivableDiscount", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "documentation": "Amortization of note receivable discount.", "label": "Amortization Of Note Receivable Discount", "terseLabel": "Amortization of note receivable discount" } } }, "auth_ref": [] }, "rkda_AnawahIncMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "AnawahIncMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Anawah, Inc [Member]", "label": "Anawah Inc [Member]", "documentation": "Anawah Inc." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureNetLossPerShareSummaryOfSecuritiesNotIncludedInDilutedPerShareCalculationsDetail"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities not included in the diluted per share calculations, amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r235"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureNetLossPerShareSummaryOfSecuritiesNotIncludedInDilutedPerShareCalculationsDetail"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r29"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureNetLossPerShareSummaryOfSecuritiesNotIncludedInDilutedPerShareCalculationsDetail"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureNetLossPerShareSummaryOfSecuritiesNotIncludedInDilutedPerShareCalculationsDetail"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r29"] }, "rkda_April2019ServiceAndPerformanceWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "April2019ServiceAndPerformanceWarrantsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail"], "lang": { "en-us": { "role": { "terseLabel": "April 2019 Service and Performance Warrants [Member]", "label": "April2019 Service And Performance Warrants [Member]", "documentation": "April 2019 service and performance warrants." } } }, "auth_ref": [] }, "rkda_ArcadiaBiosciencesIncorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "ArcadiaBiosciencesIncorporationMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureConsolidatedJointVentureAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Arcadia Biosciences, Inc [Member]", "label": "Arcadia Biosciences Incorporation [Member]", "documentation": "Arcadia Biosciences incorporation." } } }, "auth_ref": [] }, "rkda_ArchipelagoVenturesHawaiiLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "ArchipelagoVenturesHawaiiLLCMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureConsolidatedJointVentureAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Archipelago Ventures Hawaii, LLC [Member]", "label": "Archipelago Ventures Hawaii L L C [Member]", "documentation": "Archipelago Ventures Hawaii, LLC." } } }, "auth_ref": [] }, "us-gaap_AreaOfLand": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AreaOfLand", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Acres of land", "label": "Area of Land", "documentation": "Area of land held." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCollaborativeArrangementsAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInventoryAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r495"] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "totalLabel": "Asset Impairment Charges, Total", "label": "Asset Impairment Charges", "terseLabel": "Impairment charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": ["r10", "r30"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r131", "r143", "r171", "r197", "r239", "r244", "r261", "r264", "r312", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r497", "r502", "r549", "r682", "r795", "r890", "r891", "r929", "r957", "r1104", "r1105", "r1157"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r165", "r178", "r197", "r312", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r497", "r502", "r549", "r929", "r1104", "r1105", "r1157"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfFairValueOfInvestmentsSecuritiesDetail"], "lang": { "en-us": { "role": { "totalLabel": "Total Assets at Fair Value", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r531", "r532", "r914"] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfFairValueOfInvestmentsSecuritiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Assets at Fair Value", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsHeldForSaleLongLivedFairValueDisclosure", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Property and equipment classified as assets held for sale, fair value", "documentation": "Fair value portion of assets classified as held for sale." } } }, "auth_ref": ["r913", "r914", "r916", "r1143"] }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Assets held for sale", "label": "Asset, Held-for-Sale, Not Part of Disposal Group, Current", "totalLabel": "Assets Held-for-sale, Not Part of Disposal Group, Current, Total", "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer." } } }, "auth_ref": ["r111",

```
"r929" ] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AssetsOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessSummaryOfMajorClassesOfLineItemsConstitutingTheBalanceSheetOnDiscontinuedOperations
], "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations, assets", "label": "Disposal Group, Including Discontinued Operation, Assets", "totalLabel": "Total
assets", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r3", "r53", "r69", "r115", "r163", "r164"
] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessSummaryOfMajorClassesOfLineItemsConstitutingTheBalanceSheetOnDiscontinuedOperations
], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-
gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Disposal Group,
Including Discontinued Operation, Assets, Current, Total", "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "terseLabel": "Current assets of
discontinued operations - GoodWheat", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of
within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r53", "r69", "r112", "r115", "r163", "r164" ] },
"rkda_August2019ServiceAndPerformanceWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"August2019ServiceAndPerformanceWarrantsMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "August 2019 Service and Performance Warrants [Member]", "label": "August2019 Service And Performance Warrants [Member]", "documentation": "August
2019 service and performance warrants." } } }, "auth_ref": [] }, "rkda_AugustTwoThousandAndTwentyTwoOfferingMember": { "xbrltype": "domainItemType", "nsuri":
"http://arcadiabio.com/20240930", "localname": "AugustTwoThousandAndTwentyTwoOfferingMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "August 2022 Offering [Member]", "label": "August Two Thousand And Twenty Two Offering [Member]", "documentation": "August two thousand and twenty two
offering." } } }, "auth_ref": [] }, "rkda_AugustTwoThousandAndTwentyTwoPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri":
"http://arcadiabio.com/20240930", "localname": "AugustTwoThousandAndTwentyTwoPurchaseAgreementMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "August 2022
Purchase Agreement [Member]", "label": "August Two Thousand And Twenty Two Purchase Agreement [Member]", "documentation": "August two thousand and twenty two
purchase agreement." } } }, "auth_ref": [] }, "rkda_AugustTwoThousandTwentyTwoOptionsAndAugustTwoThousandTwentyTwoPlacementAgentOptionsMember": { "xbrltype":
"domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"AugustTwoThousandTwentyTwoOptionsAndAugustTwoThousandTwentyTwoPlacementAgentOptionsMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "August 2022
Options and August 2022 Placement Agent Options [Member]", "label": "August Two Thousand Twenty Two Options and August Two Thousand Twenty Two Placement Agent
Options [Member]", "documentation": "August 2022 options and August 2022 placement agent options.", "verboseLabel": "August 2022 Options & August 2022 Placement
Agent Options [Member]" } } }, "auth_ref": [] }, "rkda_AugustTwoThousandTwentyTwoOptionsAndPlacementAgentOptionsMember": { "xbrltype": "domainItemType", "nsuri":
"http://arcadiabio.com/20240930", "localname": "AugustTwoThousandTwentyTwoOptionsAndPlacementAgentOptionsMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfKeyTermsAndActivityOfLiabilityClassifiedPreferredInvestmentOptionsDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "August 2022 Options and Placement Agent Options [Member]", "label": "August Two Thousand Twenty Two Options And Placement
Agent Options [Member]", "documentation": "August two thousand twenty two options and placement agent options.", "verboseLabel": "August 2022 Options & August 2022
Placement Agent Options [Member]" } } }, "auth_ref": [] }, "rkda_AugustTwoThousandTwentyTwoOptionsMember": { "xbrltype": "domainItemType", "nsuri":
"http://arcadiabio.com/20240930", "localname": "AugustTwoThousandTwentyTwoOptionsMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfKeyTermsAndActivityOfLiabilityClassifiedPreferredInvestmentOptionsDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "August 2022 Options [Member]", "label": "August Two Thousand Twenty Two Options [Member]", "documentation": "August two
thousand twenty two options." } } }, "auth_ref": [] }, "rkda_AugustTwoThousandTwentyTwoPlacementAgentOptionsMember": { "xbrltype": "domainItemType", "nsuri":
"http://arcadiabio.com/20240930", "localname": "AugustTwoThousandTwentyTwoPlacementAgentOptionsMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfKeyTermsAndActivityOfLiabilityClassifiedPreferredInvestmentOptionsDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "August 2022
Placement Agent Options [Member]", "label": "August Two Thousand Twenty Two Placement Agent Options [Member]", "documentation": "August two thousand twenty two
placement agent options." } } }, "auth_ref": [] }, "rkda_AugustTwoThousandTwentyTwoPreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri":
"http://arcadiabio.com/20240930", "localname": "AugustTwoThousandTwentyTwoPreFundedWarrantsMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "August 2022 Pre-Funded Warrants [Member]", "label": "August Two Thousand Twenty Two Pre Funded Warrants [Member]", "documentation": "August two
thousand twenty two pre funded warrants." } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price",
"terseLabel": "Exercise Price" } } }, "auth_ref": [ "r1029" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair
Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r1030" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award
Timing Disclosures" } } }, "auth_ref": [ "r1025" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award
Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r1025" ] }, "ecd_AwardTmgMethodTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } },
"auth_ref": [ "r1025" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award
Timing MNPI Considered" } } }, "auth_ref": [ "r1025" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing
MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r1025" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ],
"lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r1025" ] }, "us-
gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramWeightedAverageFairValueAssumptionOfStockOp
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by
type of award under share-based payment arrangement." } } }, "auth_ref": [ "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431",
"r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype":
"decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r1028" ] },
"ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
"terseLabel": "Name" } } }, "auth_ref": [ "r1027" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI
Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r1026" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel":
"Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r1026" ] }, "rkda_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock",
"presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "lang": { "en-us": { "role": {
"terseLabel": "Basis of Presentation and Principles of Consolidation", "label": "Basis Of Presentation And Principles Of Consolidation Policy Policy [Text Block]",
"documentation": "Basis of presentation and principles of consolidation." } } }, "auth_ref": [] }, "rkda_BioceresCropSolutionsMember": { "xbrltype": "domainItemType",
"nsuri": "http://arcadiabio.com/20240930", "localname": "BioceresCropSolutionsMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Bioceres Crop Solutions [Member]", "label": "Bioceres Crop Solutions [Member]", "documentation": "Bioceres Crop Solutions." } } }, "auth_ref": [] },
"srt_BoardOfDirectorsChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "BoardOfDirectorsChairmanMember",
"presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Mr. Kevin Comcowich [Member]", "label": "Board of Directors Chairman [Member]" } } }, "auth_ref": [ "r1086" ] }, "rkda_BodyCareMember": { "xbrltype":
"domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "BodyCareMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": {
"documentation": "Body Care [Member]", "label": "Body Care [Member]", "terseLabel": "Body Care" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Business Acquisition, Acquiree", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or
series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r348", "r349",
"r350", "r351", "r352", "r485", "r904", "r905" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessAcquisitionAxis", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "Business Acquisition", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of
individually immaterial business combinations." } } }, "auth_ref": [ "r40", "r42", "r348", "r349", "r350", "r351", "r352", "r485", "r904", "r905" ] }, "us-
gaap_BusinessAcquisitionDescriptionOfAcquiredEntity": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

```
"BusinessAcquisitionDescriptionOfAcquiredEntity", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Business acquisition activities, description", "label": "Business Acquisition, Description of Acquired Entity", "documentation": "With respect to a business combination
completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important
information." } } }, "auth_ref": [ "r41" ] }, "us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "BusinessAcquisitionEffectiveDateOfAcquisition1", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Date of merger and reorganization", "label": "Business Acquisition, Effective Date of Acquisition", "documentation": "Date when the acquirer obtains control of the acquiree,
in YYYY-MM-DD format." } } }, "auth_ref": [ "r0", "r1", "r15" ] }, "rkda_BusinessCombinationConsiderationTransferredRemainingAmount": { "xbrltype": "monetaryItemType",
"nsuri": "http://arcadiabio.com/20240930", "localname": "BusinessCombinationConsiderationTransferredRemainingAmount", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Remaining amount paid in multiple installments", "label": "Business Combination Consideration Transferred Remaining Amount", "documentation": "Business combination
consideration transferred remaining amount." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "totalLabel":
"Business Combination, Contingent Consideration, Liability, Total", "terseLabel": "Contingent liability", "label": "Business Combination, Contingent Consideration, Liability",
"documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r43", "r124", "r489", "r533", "r534",
"r535" ] }, "rkda_BusinessCombinationEquityInterestIssuableUponAchievementOfRevenueMilestoneShare": { "xbrltype": "sharesItemType", "nsuri":
"http://arcadiabio.com/20240930", "localname": "BusinessCombinationEquityInterestIssuableUponAchievementOfRevenueMilestoneShare", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Business combination, equity interest issuable upon achievement of revenue milestone", "label": "Business Combination Equity Interest Issuable Upon Achievement Of
Revenue Milestone Share", "documentation": "Business combination, equity interest issuable upon achievement of revenue milestone share." } } }, "auth_ref": [] },
"rkda_BusinessCombinationRemainingContingentLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"BusinessCombinationRemainingContingentLiability", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
"Business Combination, remaining contingent liability.", "label": "Business Combination, remaining Contingent Liability", "terseLabel": "Remaining contingent liability" } } },
"auth_ref": [] }, "rkda_BusinessCombinationRemainingContingentLiabilityWrittenDown": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930",
"localname": "BusinessCombinationRemainingContingentLiabilityWrittenDown", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
"Business combination remaining contingent liability written-down.", "label": "Business Combination Remaining Contingent Liability Written-down", "terseLabel": "Business
combination remaining contingent liability written-down" } } }, "auth_ref": [] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentation" ], "lang": { "en-us": { "role": { "terseLabel": "Description of
Business and Basis of Presentation", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business
description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as
may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about
significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally
Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r52", "r107", "r108" ] }, "us-
gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "periodEndLabel": "Cash and
Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "totalLabel": "Cash and Cash
Equivalents, at Carrying Value, Total", "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of
currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.
Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk
of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r28",
"r167", "r880" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfFairValueOfInvestmentsSecuritiesDetail" ], "lang": { "en-us":
{ "role": { "terseLabel": "Cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as
demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term,
highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value
because of changes in interest rates." } } }, "auth_ref": [ "r1142", "r1143" ] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr":
"debit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": {
"role": { "periodEndLabel": "Cash and cash equivalents - end of period", "periodStartLabel": "Cash and cash equivalents - beginning of period", "totalLabel": "Cash, Cash
Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "label": "Cash, Cash Equivalents, Restricted
Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash
equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand,
demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to,
short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in
value because of changes in interest rates." } } }, "auth_ref": [ "r28", "r104", "r195" ] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"crdr": "debit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-
us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel":
"Net decrease in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to
withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions,
and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both
readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } },
"auth_ref": [ "r2", "r104" ] }, "us-gaap_CashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashEquivalentsMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfAmortizedCostAndFairValueOfInvestmentSecuritiesPortfolioD
], "lang": { "en-us": { "role": { "terseLabel": "Cash Equivalents [Member]", "label": "Cash Equivalents [Member]", "documentation": "Short-term, highly liquid investments that
are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
} } }, "auth_ref": [ "r167" ] }, "rkda_CashSharesAndRoyaltyReceivableFromSaleOfInterestInJointVenture": { "xbrltype": "monetaryItemType", "nsuri":
"http://arcadiabio.com/20240930", "localname": "CashSharesAndRoyaltyReceivableFromSaleOfInterestInJointVenture", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "cash shares and royalty receivable from sale of interest in joint venture", "label": "cash shares and royalty receivable from sale of interest in joint venture",
"terseLabel": "Cash shares and royalty receivable" } } }, "auth_ref": [] }, "rkda_ChangeInFairValueOfCommonStockWarrantAndOptionLiabilities": { "xbrltype":
"monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "ChangeInFairValueOfCommonStockWarrantAndOptionLiabilities", "crdr": "credit",
"presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "Change in fair value of common stock warrant and option liabilities", "negatedLabel": "Change in fair value of common stock warrant and option liabilities",
"label": "Change in Fair Value of Common Stock Warrant and Option Liabilities", "documentation": "Change in fair value of common stock warrant and option liabilities." } }
}, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text
Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r1005" ] }, "rkda_ChesterfieldAndChatsworthMember": { "xbrltype": "domainItemType", "nsuri":
"http://arcadiabio.com/20240930", "localname": "ChesterfieldAndChatsworthMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Chesterfield, MO And
Chatsworth, CA [Member]", "label": "Chesterfield And Chatsworth [Member]", "documentation": "Chesterfield and Chatsworth." } } }, "auth_ref": [] },
"srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefExecutiveOfficerMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "Chief Executive Officer [Member]", "label": "Chief Executive Officer [Member]" } } }, "auth_ref": [ "r1086" ] },
"ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year
Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r1002" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are
Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } },
"auth_ref": [ "r1000" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City
Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ClassOfStockDomain", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Class of Stock
[Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable
preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r155", "r172", "r173", "r174", "r197", "r229", "r230", "r232", "r234", "r241",
"r242", "r312", "r373", "r375", "r376", "r377", "r380", "r381", "r387", "r388", "r391", "r394", "r401", "r549", "r742", "r743", "r744", "r745", "r753", "r754", "r755", "r756",
"r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r783", "r804", "r827", "r856", "r857", "r858", "r859", "r860", "r1044", "r1070", "r1078" ] }, "us-
gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail",
```

```
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockParentheticalDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r35" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail",
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockParentheticalDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "rkda_ClassOfWarrantOrRightExercisableTerm": { "xbrltype": "durationItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "ClassOfWarrantOrRightExercisableTerm", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant, exercisable term", "label": "Class Of Warrant Or Right Exercisable Term", "documentation": "Class of warrant or right exercisable term." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercise Price Per Share", "terseLabel": "Warrants issued, exercise price", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r402" ] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail",
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockParentheticalDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Class Of Warrant Or Right [Line Items]", "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant issued, shares of common stock called by warrant", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r402" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail",
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockParentheticalDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Class Of Warrant Or Right [Table]", "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": [ "r35" ] }, "rkda_ClassOfWarrantsOrRightsIssuanceMonthAndYear": { "xbrltype": "gYearMonthItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "ClassOfWarrantsOrRightsIssuanceMonthAndYear", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance Date", "label": "Class Of Warrants Or Rights Issuance Month And Year", "documentation": "Class of warrants or rights issuance month and year." } } }, "auth_ref": [] }, "rkda_CoPackingBusinessSaavyNaturalsProvaultAndSoulSpringBodyCareBrandsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "CoPackingBusinessSaavyNaturalsProvaultAndSoulSpringBodyCareBrandsMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationNoncashItemsOfDiscontinuedOperationsDetails",
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationSummaryOfMajorClassesOfLineItemsConstitutingNetLossFromDiscon
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessSummaryOfMajorClassesOfLineItemsConstitutingTheBalanceSheetOnDiscontinuedOperations
], "lang": { "en-us": { "role": { "documentation": "Co-packing business, saavy naturals, provault and soul spring body care brands.", "label": "Co-packing business, Saavy Naturals, ProVault and Soul Spring Body Care Brands [Member]", "terseLabel": "Co-packing business, Saavy Naturals, ProVault and Soul Spring Body Care Brands [Member]" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r1006" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r1006" ] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCollaborativeArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r146", "r147", "r154" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCollaborativeArrangementsAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r495" ] }, "rkda_CollaborativeArrangementsCopromotionMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "CollaborativeArrangementsCopromotionMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCollaborativeArrangementsAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements [Member]", "label": "Collaborative Arrangements Copromotion [Member]", "documentation": "Collaborative arrangements, copromotion." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 14)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r79", "r132", "r684", "r782" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentAndContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r118", "r367", "r368", "r864", "r1099", "r1101" ] }, "rkda_CommitmentsAndContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "CommitmentsAndContingenciesLineItems", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments And Contingencies [Line Items]", "label": "Commitments And Contingencies [Line Items]", "documentation": "Commitments and contingencies line items." } } }, "auth_ref": [] }, "rkda_CommitmentsAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "CommitmentsAndContingenciesTable", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments And Contingencies [Table]", "label": "Commitments And Contingencies [Table]", "documentation": "Commitments and contingencies table." } } }, "auth_ref": [] }, "rkda_CommonStockAndPreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "CommonStockAndPreFundedWarrantsMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Common stock and Pre-funded warrants.", "label": "Common Stock and Pre-Funded Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Total number of shares reserved for issuance under plan", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r82" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r947", "r948", "r949", "r951", "r952", "r953", "r954", "r1074", "r1075", "r1077", "r1140", "r1200", "r1201" ] }, "rkda_CommonStockOptionsIssuedToPlacementAgentAndIncludedInOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "CommonStockOptionsIssuedToPlacementAgentAndIncludedInOfferingCosts", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Common Stock Options Issued to Placement Agent and Included in Offering Costs", "documentation": "Common stock options issued to placement agent and included in offering costs.", "verboseLabel": "Common stock options issued to placement agent and included in offering costs", "terseLabel": "Common stock options issued to placement agent and included in offering costs" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-
```

gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited"], "lang": { "en-us": { "role": { "terseLabel":
"Common stock, par value", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } },
"auth_ref": ["r82"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockSharesAuthorized", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited"], "lang": { "en-us": { "role": { "terseLabel":
"Common stock, authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's
charter and bylaws." } } }, "auth_ref": ["r82", "r783"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommonStockSharesIssued", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited"], "lang": { "en-us": { "role": { "totalLabel":
"Common Stock, Shares, Issued, Total", "terseLabel": "Common stock, issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of
an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital
invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held
in the treasury." } } }, "auth_ref": ["r82"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockSharesOutstanding", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParentheticalUnaudited"], "lang": { "en-us": { "role": {
"periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel":
"Common stock, outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent
the ownership interest in a corporation." } } }, "auth_ref": ["r14", "r82", "r783", "r801", "r1201", "r1202"] }, "us-gaap_CommonStockValue": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Common stock,
$0.001 par value - 150,000,000 shares authorized; 1,364,940 and 1,285,337 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively",
"periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "totalLabel": "Common Stock,
Value, Issued, Total", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock
redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par
value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r82", "r685", "r929"] },
"rkda_CommonStockWarrantAndOptionLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"CommonStockWarrantAndOptionLiabilities", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Common stock
warrant and option liabilities", "label": "Common Stock Warrant and Option Liabilities", "documentation": "Common stock warrant and option liabilities." } } }, "auth_ref": [] },
"rkda_CommonStockWarrantLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"CommonStockWarrantLiabilityMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec
], "lang": { "en-us": { "role": { "terseLabel": "Common Stock Warrant Liability [Member]", "documentation": "Common stock warrant liability.", "label": "Common Stock
Warrant Liability [Member]" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-
us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" }
} }, "auth_ref": ["r1011"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid
vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r1010"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation
Actually Paid vs. Other Measure" } } }, "auth_ref": ["r1012"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-
us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } },
"auth_ref": ["r1009"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": {
"totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in
equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity
resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r25", "r184", "r186", "r191", "r677", "r700", "r701"] }, "us-
gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember",
"presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail"], "lang": { "en-us": { "role": {
"terseLabel": "Construction in Progress [Member]", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under
construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] },
"rkda_ContingentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "ContingentLiabilitiesMember", "presentation":
[
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
], "lang": { "en-us": { "role": { "terseLabel": "Contingent Liabilities [Member]", "label": "Contingent Liabilities [Member]", "documentation": "Contingent liabilities." } } },
"auth_ref": [] }, "rkda_ContractualAgreementMonthAndYear": { "xbrltype": "gYearMonthItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"ContractualAgreementMonthAndYear", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCollaborativeArrangementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel":
"Contractual agreement month and year", "label": "Contractual Agreement Month And Year", "documentation": "Contractual agreement month and year." } } }, "auth_ref": []
}, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember",
"presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfAmortizedCostAndFairValueOfInvestmentSecuritiesPortfolioD
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfFairValueOfInvestmentsSecuritiesDetail"], "lang": { "en-us":
{ "role": { "terseLabel": "Corporate Securities [Member]", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign
corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": ["r901", "r903", "r914", "r930", "r945", "r1197"] }, "us-
gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit",
"presentation": ["http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": {
"en-us": { "role": { "totalLabel": "Cost of Goods and Services Sold, Total", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of revenues", "documentation": "The
aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period
related to financial services rendered and other revenue generating activities." } } }, "auth_ref": ["r94", "r95", "r635"] }, "us-gaap_CostsAndExpenses": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": {
"totalLabel": "Total operating expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [
"r100"] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableAdditionalInformationDetails",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureConsolidatedJointVentureAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"], "lang": { "en-us": { "role": {
"terseLabel": "Counterparty Name", "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r201", "r202", "r383", "r389", "r597", "r618", "r681", "r882", "r884"] },
"dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover
[Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "CurrentFiscalYearEndDate", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-
us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-
DD." } } }, "auth_ref": [] }, "rkda_DebtAndEquitySecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"DebtAndEquitySecurities", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfAmortizedCostAndFairValueOfInvestmentSecuritiesPortfolioD
], "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value", "label": "Debt And Equity Securities", "documentation": "Debt and equity securities." } } }, "auth_ref": [] },
"rkda_DebtAndEquitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"DebtAndEquitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfAmortizedCostAndFairValueOfInvestmentSecuritiesPortfolioD
], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains", "label": "Debt And Equity Securities Accumulated Gross Unrealized Gain Before Tax", "documentation": "Debt
and equity securities accumulated gross unrealized gain before tax." } } }, "auth_ref": [] }, "rkda_DebtAndEquitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
"xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "DebtAndEquitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr":
"debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfAmortizedCostAndFairValueOfInvestmentSecuritiesPortfolioD
], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized Losses", "label": "Debt And Equity Securities Accumulated Gross Unrealized Loss Before Tax", "documentation":
"Debt and equity securities accumulated gross unrealized loss before tax." } } }, "auth_ref": [] }, "rkda_DebtAndEquitySecuritiesAmortizedCostBasis": { "xbrltype":
"monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "DebtAndEquitySecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfAmortizedCostAndFairValueOfInvestmentSecuritiesPortfolioD
], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Debt And Equity Securities Amortized Cost Basis", "documentation": "Debt and equity securities
amortized cost basis." } } }, "auth_ref": [] }, "rkda_DebtAndEquitySecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930",
"localname": "DebtAndEquitySecuritiesCurrent", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfFairValueOfInvestmentsSecuritiesDetail"], "lang": { "en-us":
{ "role": { "terseLabel": "Short-term investments", "label": "Debt And Equity Securities Current", "documentation": "Debt and equity securities current." } } }, "auth_ref": [] },
"us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr":
"credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"],
"lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Promissory note, principal", "documentation": "Face (par) amount of debt instrument at
time of issuance." } } }, "auth_ref": ["r382", "r559", "r560", "r896", "r897", "r926"] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"], "lang": { "en-us": { "role": {

```
"label": "Debt Instrument, Term", "terseLabel": "Promissory note, term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "crdr": "debit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in continuous unrealized loss position for more than twelve months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r144", "r333" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfAmortizedCostAndFairValueOfInvestmentSecuritiesPortfolioD
], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287" ] }, "rkda_DecemberTwoThousandAndTwentyTwoServiceAndPerformanceWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "DecemberTwoThousandAndTwentyTwoServiceAndPerformanceWarrantsMember", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail" ], "lang": { "en-us": { "role": { "documentation": "December Two Thousand and Twenty Two Service And Performance Warrants [Member]", "label": "December Two Thousand and Twenty Two Service And Performance Warrants [Member]", "terseLabel": "December 2022 Service and Performance Warrants [Member]" } } }, "auth_ref": [] }, "rkda_DecemberTwoThousandTwentyPlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "DecemberTwoThousandTwentyPlacementAgentWarrantsMember", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail" ], "lang": { "en-us": { "role": { "terseLabel": "December 2020 Placement Agent Warrants [Member]", "label": "December Two Thousand Twenty Placement Agent Warrants [Member]", "documentation": "December 2020 placement agent warrants." } } }, "auth_ref": [] }, "rkda_DecemberTwoThousandTwentyWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "DecemberTwoThousandTwentyWarrantsMember", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail" ], "lang": { "en-us": { "role": { "terseLabel": "December 2020 Warrants [Member]", "label": "December Two Thousand Twenty Warrants [Member]", "documentation": "December 2020 warrants." } } }, "auth_ref": [] }, "rkda_DecemberTwoThousandTwentyWarrantsPrivatePlacementOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "DecemberTwoThousandTwentyWarrantsPrivatePlacementOfferingMember", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail" ], "lang": { "en-us": { "role": { "documentation": "December two thousand twenty warrants private placement offering.", "label": "December Two Thousand Twenty Warrants Private Placement Offering [Member]", "terseLabel": "December 2020 Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation expense", "totalLabel": "Depreciation, Total", "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r10", "r31" ] }, "rkda_DepreciationContinuingAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "DepreciationContinuingAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Depreciation continuing and discontinued operations.", "label": "Depreciation Continuing and Discontinued Operations", "terseLabel": "Depreciation" } } }, "auth_ref": [] }, "rkda_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndWarrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndWarrantsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Share Based Payments And Warrants [Abstract]", "documentation": "Disclosure of compensation related costs share based payments and warrants." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgram" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation and Employee Stock Purchase Program", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r415", "r419", "r446", "r447", "r449", "r907" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsPolicyTextBlock", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations, Policy [Policy Text Block]", "terseLabel": "Discontinued Operations", "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation." } } }, "auth_ref": [ "r12", "r22" ] }, "rkda_DiscountedPromissoryNote": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "DiscountedPromissoryNote", "crdr": "debit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Discounted promissory note.", "label": "Discounted Promissory Note", "terseLabel": "Discounted promissory note" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationNoncashItemsOfDiscontinuedOperationsDetails",
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationSummaryOfMajorClassesOfLineItemsConstitutingNetLossFromDiscon
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessSummaryOfMajorClassesOfLineItemsConstitutingTheBalanceSheetOnDiscontinuedOperations
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableAdditionalInformationDetails",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r163" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationNoncashItemsOfDiscontinuedOperationsDetails",
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationSummaryOfMajorClassesOfLineItemsConstitutingNetLossFromDiscon
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessSummaryOfMajorClassesOfLineItemsConstitutingTheBalanceSheetOnDiscontinuedOperations
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableAdditionalInformationDetails",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessSummaryOfMajorClassesOfLineItemsConstitutingTheBalanceSheetOnDiscontinuedOperations
], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "terseLabel": "Accounts receivable and other receivables", "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [
"r3", "r53", "r69", "r115" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessSummaryOfMajorClassesOfLineItemsConstitutingTheBalanceSheetOnDiscontinuedOperations
], "lang": { "en-us": { "role": { "totalLabel": "Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities, Current, Total", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued expenses", "documentation": "Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r53", "r69", "r112", "r115" ] }, "rkda_DisposalGroupIncludingDiscontinuedOperationAccruedInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedInterestExpense", "crdr": "debit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Disposal group, including discontinued operation, accrued interest expense.", "label": "Disposal Group, Including Discontinued Operation, Accrued Interest Expense", "terseLabel": "Accrued interest expense" } } }, "auth_ref": [] }, "rkda_DisposalGroupIncludingDiscontinuedOperationAssetsHeldForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsHeldForSale", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessSummaryOfMajorClassesOfLineItemsConstitutingTheBalanceSheetOnDiscontinuedOperations
], "lang": { "en-us": { "role": { "documentation": "Disposal group including discontinued operation assets held for sale.", "label": "Disposal Group Including Discontinued Operation Assets Held for Sale", "terseLabel": "Assets held for sale" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "crdr": "debit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent, Total", "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent", "terseLabel": "Noncurrent assets of discontinued operations - GoodWheat", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r5", "r53", "r69", "r115", "r163", "r164" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableAdditionalInformationDetails",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Sale of net consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationSummaryOfMajorClassesOfLineItemsConstitutingNetLossFromDiscon
], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "terseLabel": "Cost of revenues", "negatedLabel": "Cost of revenues", "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r68", "r164" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization", "crdr": "debit", "presentation": [
```

```
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationNoncashItemsOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Depreciation and Amortization", "terseLabel": "Depreciation", "verboseLabel": "Amortization expense", "documentation": "Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r68" ] }, "rkda_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfPropertyAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfPropertyAndEquipment", "crdr": "credit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationNoncashItemsOfDiscontinuedOperationsDetails", "http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationSummaryOfMajorClassesOfLineItemsConstitutingNetLossFromDiscon
], "lang": { "en-us": { "role": { "terseLabel": "(Loss) Gain on sale of property and equipment", "documentation": "Disposal group including discontinued operation gain on sale of property and equipment.", "label": "Disposal Group Including Discontinued Operation Gain on Sale of Property and Equipment", "negatedLabel": "Gain on sale of property and equipment" } } }, "auth_ref": [] }, "rkda_DisposalGroupIncludingDiscontinuedOperationImpairmentOfPropertyAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationImpairmentOfPropertyAndEquipment", "crdr": "debit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Disposal group including discontinued operation impairment of property and equipment.", "label": "Disposal Group Including Discontinued Operation Impairment of Property And Equipment", "terseLabel": "Impairment of property and equipment", "negatedLabel": "Impairment of property and equipment" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "crdr": "debit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessSummaryOfMajorClassesOfLineItemsConstitutingTheBalanceSheetOnDiscontinuedOperations
], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Inventory, Current", "terseLabel": "Inventories, net - current", "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r53", "r69", "r112", "r115" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryNoncurrent", "crdr": "debit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessSummaryOfMajorClassesOfLineItemsConstitutingTheBalanceSheetOnDiscontinuedOperations
], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Inventory, Noncurrent", "terseLabel": "Inventories, net - noncurrent", "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r5", "r53", "r69", "r115" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities", "crdr": "credit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessSummaryOfMajorClassesOfLineItemsConstitutingTheBalanceSheetOnDiscontinuedOperations
], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Current", "terseLabel": "Other current liabilities", "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r53", "r69", "r112", "r115" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "crdr": "debit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessSummaryOfMajorClassesOfLineItemsConstitutingTheBalanceSheetOnDiscontinuedOperations
], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r53", "r69", "r112", "r115" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent", "crdr": "debit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessSummaryOfMajorClassesOfLineItemsConstitutingTheBalanceSheetOnDiscontinuedOperations
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r5", "r53", "r69", "r115" ] }, "rkda_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment", "crdr": "debit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationSummaryOfMajorClassesOfLineItemsConstitutingNetLossFromDiscon
], "lang": { "en-us": { "role": { "documentation": "Disposal group including discontinued operation research and development.", "label": "Disposal Group Including Discontinued Operation Research and Development", "terseLabel": "Research and development" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationSummaryOfMajorClassesOfLineItemsConstitutingNetLossFromDiscon
], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Revenue", "terseLabel": "Revenue", "totalLabel": "Disposal Group, Including Discontinued Operation, Revenue, Total", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r68", "r164" ] }, "rkda_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationSummaryOfMajorClassesOfLineItemsConstitutingNetLossFromDiscon
], "lang": { "en-us": { "role": { "documentation": "Disposal group including discontinued operation selling general and administrative expense.", "label": "Disposal Group, Including Discontinued Operation Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "auth_ref": [] }, "rkda_DisposalGroupIncludingDiscontinuedOperationWriteDownOfInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationWriteDownOfInventories", "crdr": "debit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationNoncashItemsOfDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Disposal group including discontinued operation write-down of inventories.", "label": "Disposal Group Including Discontinued Operation Write-down of Inventories", "terseLabel": "Write-down of inventories" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationNoncashItemsOfDiscontinuedOperationsDetails",
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationSummaryOfMajorClassesOfLineItemsConstitutingNetLossFromDiscon
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessSummaryOfMajorClassesOfLineItemsConstitutingTheBalanceSheetOnDiscontinuedOperations
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableAdditionalInformationDetails",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r904", "r905" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r961" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r993" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r1004" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Net loss per share attributable to common stockholders:", "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Net loss per basic share attributable to common stockholders", "terseLabel": "Basic Net income (loss) per share attributable to common stockholders:", "label": "Earnings Per Share, Basic", "totalLabel": "Earnings Per Share, Basic, Total", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r192", "r213", "r214", "r216", "r217", "r218", "r220", "r227", "r229", "r232", "r233", "r234", "r238", "r483", "r494", "r528", "r529", "r678", "r702", "r886" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Net loss per diluted share attributable to common stockholders", "terseLabel": "Diluted Net income (loss) per share attributable to common stockholders:", "label": "Earnings Per Share, Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r192", "r213", "r214", "r216", "r217",
```

```
"r218", "r220", "r229", "r232", "r233", "r234", "r238", "r483", "r494", "r528", "r529", "r678", "r702", "r886" ] }, "us-gaap_EarningsPerShareReconciliationAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareReconciliationAbstract", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "Net loss per share attributable to common stockholders:", "label": "Earnings Per Share Reconciliation [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureNetLossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss per Share", "label": "Earnings Per Share
[Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r226", "r235", "r236", "r237" ] }, "us-
gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ],
"lang": { "en-us": { "role": { "totalLabel": "Effective Income Tax Rate Reconciliation, Percent, Total", "terseLabel": "Effective tax rate", "label": "Effective Income Tax Rate
Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing
operations." } } }, "auth_ref": [ "r455", "r910" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Federal statutory
tax rate", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax
rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r198", "r455", "r467", "r910" ] }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset", "crdr": "debit",
"presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Embedded
Derivative, Fair Value of Embedded Derivative Asset", "terseLabel": "Fair value of embedded derivative note receivable", "documentation": "Fair value as of the balance sheet
date of the embedded derivative or group of embedded derivatives classified as an asset." } } }, "auth_ref": [ "r128", "r1144", "r1145", "r1146" ] }, "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total", "terseLabel": "Unrecognized compensation cost
related to unvested stock-based compensation grants", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation":
"Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r448" ] }, "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "Weighted-average remaining recognition period", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized,
Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment
arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r448" ] },
"us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "2015 Employee Stock Purchase Plan [Member]", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a
tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureNetLossPerShareSummaryOfSecuritiesNotIncludedInDilutedPerShareCalculationsDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramWeightedAverageFairValueAssumptionOfStockOp
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option",
"verboseLabel": "Option to Purchase Common Stock [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other
restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] },
"rkda_EmployeeStockPurchasePlanOfferingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"EmployeeStockPurchasePlanOfferingPeriod", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "Purchase plan offering period", "label": "Employee Stock Purchase Plan Offering Period", "documentation": "Employee stock purchase plan
offering period." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityAddressAddressLine1", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": {
"terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" }
} }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityAddressAddressLine2", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": {
"terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } },
"auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown",
"presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address,
City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip
Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype":
"stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or
Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype":
"centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key",
"label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly
abbreviated as CIK." } } }, "auth_ref": [ "r959" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ],
"lang": { "en-us": { "role": { "verboseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate
number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related
periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member]
or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype":
"yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting
Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or
15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been
subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
} } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityEmergingGrowthCompany", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": {
"role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth
company criteria." } } }, "auth_ref": [ "r959" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityFileNumber", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": {
"terseLabel": "Entity File Number", "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may
contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref":
[] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label":
"Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions
of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related
disclosure." } } }, "auth_ref": [ "r959" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ],
"lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-
character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "rkda_EntityIncorporationYearOfIncorporation": { "xbrltype":
"gYearItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "EntityIncorporationYearOfIncorporation", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Year of incorporation", "label": "Entity Incorporation Year Of Incorporation", "documentation": "Entity incorporation year of incorporation." } } }, "auth_ref": []
}, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current",
"label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to
be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } },
"auth_ref": [ "r1043" ] }, "rkda_EntityPlaceOfIncorporation": { "xbrltype": "stringItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"EntityPlaceOfIncorporation", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Place of incorporation", "label": "Entity Place Of Incorporation", "documentation": "Entity place of incorporation." } } }, "auth_ref": [] },
"dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name",
"label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." }
} }, "auth_ref": [ "r959" ] }, "rkda_EntityReincorporationDateOfReincorporation": { "xbrltype": "gYearMonthItemType", "nsuri": "http://arcadiabio.com/20240930",
"localname": "EntityReincorporationDateOfReincorporation", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Date of reincorporation", "label": "Entity Reincorporation Date Of Reincorporation", "documentation": "Entity reincorporation date of reincorporation." } } },
"auth_ref": [] }, "rkda_EntityReincorporationStateCountryName": { "xbrltype": "stringItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"EntityReincorporationStateCountryName", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Place of reincorporation", "label": "Entity Reincorporation State Country Name", "documentation": "State or Country Name where an entity is re-incorporated."
} } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [
```

```
"http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r959" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r959" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r959" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r998" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r1039" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r1039" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r1039" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r14", "r158", "r187", "r188", "r189", "r203", "r204", "r205", "r209", "r218", "r221", "r223", "r240", "r317", "r325", "r359", "r403", "r462", "r463", "r478", "r479", "r480", "r484", "r493", "r494", "r507", "r509", "r510", "r511", "r512", "r515", "r527", "r550", "r552", "r553", "r554", "r555", "r556", "r563", "r566", "r588", "r698", "r729", "r730", "r731", "r753", "r827" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureConsolidatedJointVentureAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r308", "r309", "r311", "r474", "r1045", "r1046", "r1047", "r1136", "r1137", "r1138", "r1139" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureConsolidatedJointVentureAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Joint venture interest percentage", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r308" ] }, "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal", "crdr": "credit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain on sale of Verdeca", "label": "Equity Method Investment, Realized Gain (Loss) on Disposal", "negatedLabel": "Gain on sale of Verdeca", "terseLabel": "Gain on sale of Verdeca", "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment." } } }, "auth_ref": [ "r1066", "r1067", "r1069" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureConsolidatedJointVentureAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Capital contributions", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r239", "r254", "r264", "r307", "r1058", "r1093" ] }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "lang": { "en-us": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsDisclosureTextBlock", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureConsolidatedJointVenture" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Joint Venture", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group." } } }, "auth_ref": [ "r153", "r310", "r313", "r1047" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r1008" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r966", "r976", "r986", "r1018" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r963", "r973", "r983", "r1015" ] }, "rkda_EstimatedFairValueOfLiabilityOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "EstimatedFairValueOfLiabilityOptions", "crdr": "credit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Estimated fair value of liability options.", "label": "Estimated Fair Value of Liability Options", "terseLabel": "Estimated fair value of liability options" } } }, "auth_ref": [] }, "rkda_EstimatedFairValueOptionsExceededGrossProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "EstimatedFairValueOptionsExceededGrossProceeds", "crdr": "debit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Estimated fair value options exceeded gross proceeds.", "label": "Estimated Fair Value Options Exceeded Gross Proceeds", "terseLabel": "Estimated fair value, loss" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r1014" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfFairValueOfInvestmentsSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r531", "r532", "r543", "r914" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfFairValueOfInvestmentsSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r531", "r532", "r543", "r914" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Fair Value of Investment Securities", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity." } } }, "auth_ref": [ "r914", "r1142", "r1143", "r1149" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec
], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r533", "r534", "r535", "r919" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec
], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r533", "r534", "r535", "r919" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Preferred Investment Option Liabilities Measured and Recorded on Recurring Basis using Black-Scholes Model", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r533", "r534", "r919" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfAmortizedCostAndFairValueOfInvestmentSecuritiesPortfolioD
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfFairValueOfInvestmentsSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Class", "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r536", "r537", "r538", "r539", "r540", "r541",
```

```
"r544", "r917" ] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis",
"presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfAmortizedCostAndFairValueOfInvestmentSecuritiesPortfolioD
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfFairValueOfInvestmentsSecuritiesDetail" ], "lang": { "en-us":
{ "role": { "terseLabel": "Asset Class", "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r536", "r537", "r538", "r539", "r540",
"r541", "r544", "r917" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueByFairValueHierarchyLevelAxis", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfFairValueOfInvestmentsSecuritiesDetail" ], "lang": { "en-us":
{ "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy
and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r384", "r407", "r408", "r409", "r410", "r411", "r412", "r530", "r532", "r533",
"r534", "r535", "r542", "r543", "r545", "r605", "r606", "r607", "r896", "r897", "r901", "r902", "r903", "r914", "r919" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec
], "lang": { "en-us": { "role": { "terseLabel": "Liability Class", "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r536",
"r537", "r538", "r539", "r540", "r541", "r544" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfFairValueOfInvestmentsSecuritiesDetail" ], "lang": { "en-us":
{ "role": { "terseLabel": "Level 1 [Member]", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or
liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r384", "r407", "r412", "r532", "r543", "r605", "r901", "r902", "r903", "r914" ] },
"us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member",
"presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfFairValueOfInvestmentsSecuritiesDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "Level 2 [Member]", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included
within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active
markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r384", "r407", "r412", "r532", "r533", "r543", "r606", "r896",
"r897", "r901", "r902", "r903", "r914" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueInputsLevel3Member", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfFairValueOfInvestmentsSecuritiesDetail" ], "lang": { "en-us":
{ "role": { "terseLabel": "Level 3 [Member]", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption
about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r384", "r407", "r408", "r409", "r410", "r411", "r412", "r532", "r533", "r534", "r535",
"r543", "r607", "r896", "r897", "r901", "r902", "r903", "r914", "r919" ] }, "us-
gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec
], "lang": { "en-us": { "role": { "terseLabel": "Fair Value by Liability Class", "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities
measured and disclosed at fair value." } } }, "auth_ref": [ "r536", "r537", "r538", "r539", "r540", "r541", "r544" ] }, "us-
gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]", "label": "Fair Value,
Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table.
These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r536", "r537",
"r538", "r539", "r540", "r541" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]", "label": "Fair Value, Liabilities
Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument liability measured at fair
value on recurring basis using unobservable input." } } }, "auth_ref": [ "r536", "r537", "r538", "r539", "r540", "r541", "r544" ] }, "us-
gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities
Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Summary of Changes in Fair Value and Other Adjustments of Assets and
Liabilities", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning
and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or
losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses
included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed
separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } },
"auth_ref": [ "r536", "r541", "r544" ] }, "rkda_FairValueMeasurementInitialRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930",
"localname": "FairValueMeasurementInitialRecognition", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
], "lang": { "en-us": { "role": { "terseLabel": "Initial recognition", "label": "Fair Value Measurement Initial Recognition", "documentation": "Fair Value Measurement Initial
Recognition." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value", "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability,
Period Increase (Decrease), Total", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
"documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption
about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r1147", "r1150" ] }, "us-
gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Fair Value, Measurement with Unobservable Inputs
Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect
the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r536", "r544" ] }, "us-
gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfFairValueOfInvestmentsSecuritiesDetail" ], "lang": { "en-us":
{ "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to
valuation techniques to measure fair value." } } }, "auth_ref": [ "r384", "r407", "r408", "r409", "r410", "r411", "r412", "r530", "r532", "r533", "r534", "r535", "r542", "r543",
"r545", "r605", "r606", "r607", "r896", "r897", "r901", "r902", "r903", "r914", "r919" ] }, "rkda_FairValueOfCommonStockAndPreFundedWarrants": { "xbrltype":
"monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "FairValueOfCommonStockAndPreFundedWarrants", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Fair value of
common stock and pre-funded warrants.", "label": "Fair Value of Common Stock and Pre-funded Warrants", "terseLabel": "Fair value of common stock and pre-funded
warrants" } } }, "auth_ref": [] }, "rkda_FairValueOfPromissoryNoteReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"FairValueOfPromissoryNoteReceivable", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of
promissory note receivable.", "label": "Fair Value of Promissory Note Receivable", "terseLabel": "Fair value of promissory note receivable" } } }, "auth_ref": [] },
"rkda_February122020ServiceAndPerformanceWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"February122020ServiceAndPerformanceWarrantsMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "February 12, 2020 Service and Performance Warrants [Member]", "label": "February122020 Service And Performance Warrants [Member]", "documentation":
"February 12, 2020 service and performance warrants." } } }, "auth_ref": [] }, "rkda_February32020ServiceAndPerformanceWarrantsMember": { "xbrltype":
"domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "February32020ServiceAndPerformanceWarrantsMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "February 3, 2020 Service and Performance Warrants [Member]", "label": "February32020 Service And Performance Warrants [Member]", "documentation":
"February 3, 2020 service and performance warrants." } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfAmortizedCostAndFairValueOfInvestmentSecuritiesPortfolioD
], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } }
}, "auth_ref": [ "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295",
"r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r327", "r328", "r329", "r330", "r331", "r332", "r334", "r335", "r385", "r399", "r516", "r546",
"r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r619", "r620", "r621", "r622", "r623", "r624", "r625",
"r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r699", "r893", "r914", "r917", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r930", "r1050", "r1051",
"r1052", "r1053", "r1054", "r1055", "r1056", "r1089", "r1090", "r1091", "r1092", "r1141", "r1144", "r1145", "r1146", "r1148", "r1151" ] },
"rkda_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
```

```
"FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationOfIntellectualPropertyAndCustomerListsDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite Lived Intangible Assets Amortization Expense After Year Four", "documentation": "Finite lived intangible assets
amortization expense after year four." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationOfIntellectualPropertyAndCustomerListsDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "2023", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets,
excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim
and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r354", "r876", "r895" ] }, "us-
gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationOfIntellectualPropertyAndCustomerListsDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "2022 (excluding the nine months ended September 30, 2022)", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of
Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be
recognized in remainder of current fiscal year." } } }, "auth_ref": [ "r1205" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationOfIntellectualPropertyAndCustomerListsDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets,
excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes
interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r354", "r876", "r895" ]
}, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationOfIntellectualPropertyAndCustomerListsDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets,
excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim
and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r354", "r876", "r895" ] }, "us-
gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationOfIntellectualPropertyAndCustomerListsDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets,
excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes
interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r354", "r876", "r895" ]
}, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationOfIntellectualPropertyAndCustomerListsDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-
Lived Intangible Assets by Major Class", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived
intangible assets." } } }, "auth_ref": [ "r347", "r348", "r349", "r350", "r352", "r353", "r355", "r356", "r636", "r643", "r876" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems":
{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationOfIntellectualPropertyAndCustomerListsDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Finite Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent
financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
} } }, "auth_ref": [ "r347", "r353", "r355", "r356", "r357", "r636", "r876", "r895" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationOfIntellectualPropertyAndCustomerListsDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-
Lived Intangible Assets, Major Class Name", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible
asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their
nature or by their use in the operations of a company." } } }, "auth_ref": [ "r347", "r348", "r349", "r350", "r352", "r353", "r355", "r356", "r876" ] }, "us-
gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr":
"debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationOfIntellectualPropertyAndCustomerListsDetail" ], "lang": {
"en-us": { "role": { "totalLabel": "Finite-Lived Intangible Assets, Net, Total", "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance", "periodStartLabel":
"Finite-Lived Intangible Assets, Net, Beginning Balance", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding
financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r636", "r1095" ] }, "rkda_FirstOfferingPeriodEndDate": { "xbrltype":
"dateItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "FirstOfferingPeriodEndDate", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "First offering period, end date", "label": "First Offering Period End Date", "documentation": "First offering period end date." } } }, "auth_ref": []
}, "rkda_FirstOfferingPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "FirstOfferingPeriodStartDate", "presentation":
[ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "First offering period, start date", "label": "First Offering Period Start Date", "documentation": "First offering period start date." } } }, "auth_ref":
[] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone
Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r970", "r980",
"r990", "r1022" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone
Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r970", "r980", "r990",
"r1022" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone
Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r970", "r980",
"r990", "r1022" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone
Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r970", "r980", "r990", "r1022" ]
}, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r970",
"r980", "r990", "r1022" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet
Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet
Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r1003" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Furniture and fixtures [Member]", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no
permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-
gaap_GainLossOnDispositionOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets", "crdr":
"credit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": {
"role": { "negatedLabel": "Gain on sale of property and equipment", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and
Timber Property", "negatedTerseLabel": "Gain on disposal of property and equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and
equipment assets, excluding oil and gas property and timber property." } } }, "auth_ref": [ "r1069", "r1097", "r1098" ] }, "us-gaap_GainLossOnDispositionOfIntangibleAssets":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfIntangibleAssets", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCollaborativeArrangementsAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": {
"label": "Gain (Loss) on Disposition of Intangible Assets", "negatedLabel": "Gain on sale of intangible assets", "terseLabel": "Gain on sale of collaborative arrangements",
"negatedTerseLabel": "Gain on sale of RS durum wheat trait", "documentation": "Amount of gain (loss) on sale or disposal of intangible assets." } } }, "auth_ref": [ "r1069" ] },
"rkda_GainLossOnPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "GainLossOnPrivatePlacement", "crdr":
"credit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": {
"documentation": "Gain (loss) on private placement.", "label": "Gain (Loss) on Private Placement", "terseLabel": "Valuation loss on March 2023 PIPE", "negatedLabel":
"Valuation loss on March 2023 PIPE" } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "GainLossOnSaleOfBusiness", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Disposition of
Business", "terseLabel": "Loss on sale of brand", "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being
conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant." } } },
"auth_ref": [ "r501", "r1069" ] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on
sale of property and equipment", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment,
Total", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } },
"auth_ref": [ "r10" ] }, "rkda_GoodwheatMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "GoodwheatMember",
"presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationNoncashItemsOfDiscontinuedOperationsDetails",
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationSummaryOfMajorClassesOfLineItemsConstitutingNetLossFromDiscon
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessSummaryOfMajorClassesOfLineItemsConstitutingTheBalanceSheetOnDiscontinuedOperations
```

"http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableAdditionalInformationDetails",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": {
"documentation": "GoodWheat [Member]", "label": "GoodWheat [Member]", "terseLabel": "GoodWheat" } } }, "auth_ref": [] }, "us-
gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": {
"terseLabel": "Impairment of property and equipment", "label": "Impairment, Long-Lived Asset, Held-for-Use", "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use,
Total", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for
disposal by means other than sale)." } } }, "auth_ref": ["r10", "r30", "r114", "r915"] }, "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": {
"totalLabel": "Net loss from continuing operations before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
"documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense
(benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r91", "r137", "r142", "r679", "r693", "r888", "r890", "r1079", "r1080", "r1081",
"r1082", "r1083"] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": {
"totalLabel": "Net loss from continuing operations", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling
Interest", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": [
"r125", "r142", "r197", "r208", "r218", "r312", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r483", "r494", "r529", "r549", "r693", "r888", "r1079",
"r1080", "r1081", "r1082", "r1083", "r1104"] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": {
"terseLabel": "Basic net loss per share attributable to common stockholders from continuing operations", "label": "Income (Loss) from Continuing Operations, Per Basic
Share", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } }
}, "auth_ref": ["r92", "r138", "r192", "r208", "r213", "r214", "r216", "r217", "r218", "r229", "r232", "r233", "r483", "r494", "r529", "r678", "r1168"] }, "us-
gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": {
"terseLabel": "Diluted net loss per share attributable to common stockholders from continuing operations", "label": "Income (Loss) from Continuing Operations, Per Diluted
Share", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit
outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive
potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r92", "r192", "r208", "r213", "r214", "r216", "r217", "r218", "r229", "r232",
"r233", "r234", "r494", "r529", "r678", "r1168"] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": {
"totalLabel": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total", "label": "Income (Loss) from
Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss from discontinued operations", "documentation":
"Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income
(loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments
to a prior period gain (loss) on disposal." } } }, "auth_ref": ["r57", "r58", "r59", "r60", "r61", "r71", "r164", "r471", "r694"] }, "us-
gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationSummaryOfMajorClassesOfLineItemsConstitutingNetLossFromDiscon
], "lang": { "en-us": { "role": { "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "terseLabel": "Net loss from discontinued
operations", "totalLabel": "Net loss from discontinued operations", "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the
parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-
down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": ["r57", "r58", "r59", "r60", "r61", "r67", "r71", "r125"] }, "us-
gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": {
"terseLabel": "Basic net loss per share attributable to common stockholders from discontinued operations", "totalLabel": "Income (Loss) from Discontinued Operations and
Disposal of Discontinued Operations, Net of Tax, Per Basic Share, Total", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net
of Tax, Per Basic Share", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain
(loss) from the disposal of the discontinued operation." } } }, "auth_ref": ["r93", "r192", "r230", "r232", "r233", "r1166", "r1168"] }, "us-
gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": {
"terseLabel": "Diluted net loss per share attributable to common stockholders from discontinued operations", "totalLabel": "Income (Loss) from Discontinued Operations and
Disposal of Discontinued Operations, Net of Tax, Per Diluted Share, Total", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations,
Net of Tax, Per Diluted Share", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation
and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": ["r127", "r230", "r232", "r233"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } },
"auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
"presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationNoncashItemsOfDiscontinuedOperationsDetails",
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationSummaryOfMajorClassesOfLineItemsConstitutingNetLossFromDiscon
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessSummaryOfMajorClassesOfLineItemsConstitutingTheBalanceSheetOnDiscontinuedOperations
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableAdditionalInformationDetails",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": {
"label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": ["r904", "r905"] }, "us-
gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
"presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationNoncashItemsOfDiscontinuedOperationsDetails",
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationSummaryOfMajorClassesOfLineItemsConstitutingNetLossFromDiscon
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessSummaryOfMajorClassesOfLineItemsConstitutingTheBalanceSheetOnDiscontinuedOperations
], "lang": { "en-us": { "role": { "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members
defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-
gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
"presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationNoncashItemsOfDiscontinuedOperationsDetails",
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationSummaryOfMajorClassesOfLineItemsConstitutingNetLossFromDiscon
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessSummaryOfMajorClassesOfLineItemsConstitutingTheBalanceSheetOnDiscontinuedOperations
], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group,
Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant
component." } } }, "auth_ref": ["r12", "r18", "r21", "r53", "r62", "r63", "r64", "r65", "r66", "r70", "r72", "r73", "r116"] }, "us-gaap_IncomeStatementLocationAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasesDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail"], "lang": { "en-
us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of
income where disaggregated amount has been reported." } } }, "auth_ref": ["r360", "r362", "r364", "r537", "r541", "r544", "r724", "r726", "r812", "r876", "r918", "r1170"] },
"us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain",
"presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasesDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail"], "lang": { "en-
us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income
where disaggregated amount has been reported." } } }, "auth_ref": ["r362", "r364", "r537", "r541", "r544", "r724", "r726", "r812", "r876", "r918", "r1170"] }, "us-
gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": {
"role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxes"
], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } },
"auth_ref": ["r198", "r452", "r455", "r456", "r457", "r458", "r460", "r461", "r468", "r470", "r472", "r473", "r747", "r910"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": {
"totalLabel": "Income Tax Expense (Benefit), Total", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax provision", "documentation": "Amount of current
income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r145", "r151", "r222", "r223", "r239", "r252",
"r264", "r454", "r455", "r469", "r704", "r910"] }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationNoncashItemsOfDiscontinuedOperationsDetails"], "lang": { "en-us":

{ "role": { "label": "Increase (Decrease) in Accounts and Other Receivables", "negatedLabel": "Accounts receivable and other receivables", "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables." } } }, "auth_ref": ["r9"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationNoncashItemsOfDiscontinuedOperationsDetails", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total", "terseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r9"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable and other receivables", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r9"] }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDueToRelatedParties", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Due to Related Parties, Total", "verboseLabel": "Amounts due to related parties", "label": "Increase (Decrease) in Due to Related Parties", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence." } } }, "auth_ref": ["r9"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationNoncashItemsOfDiscontinuedOperationsDetails", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Inventories, Total", "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r9"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationNoncashItemsOfDiscontinuedOperationsDetails", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r1049", "r1068"] }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Current Liabilities", "terseLabel": "Other current liabilities", "documentation": "Amount of increase (decrease) in current liabilities classified as other." } } }, "auth_ref": ["r1068"] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Noncurrent Assets", "terseLabel": "Other noncurrent assets", "negatedLabel": "Other noncurrent assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": ["r1068"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationNoncashItemsOfDiscontinuedOperationsDetails", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total", "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r9"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r970", "r980", "r990", "r1014", "r1022", "r1026", "r1034"] }, "rkda_InducementStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "InducementStockOptionMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Inducement Stock Option [Member]", "label": "Inducement Stock Option [Member]", "documentation": "Inducement stock option." } } }, "auth_ref": [] }, "rkda_IndustrialSeedInnovationsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "IndustrialSeedInnovationsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Industrial Seed Innovations [Member]", "label": "Industrial Seed Innovations [Member]", "documentation": "Industrial seed innovations." } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r1032"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r962", "r1038"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r962", "r1038"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r962", "r1038"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "totalLabel": "Total intangible asset, Net Carrying Amount", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r347", "r1095", "r1096"] }, "rkda_IntellectualPropertyAndCustomerListsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "IntellectualPropertyAndCustomerListsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationOfIntellectualPropertyAndCustomerListsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Intellectual Property and Customer Lists [Member]", "label": "Intellectual Property And Customer Lists [Member]", "documentation": "Intellectual property and customer lists." } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableAdditionalInformationDetails", "http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "totalLabel": "Interest Income (Expense), Net, Total", "label": "Interest Income (Expense), Operating", "verboseLabel": "Accrued interest", "documentation": "Amount of interest income (expense) classified as operating." } } }, "auth_ref": ["r675", "r1080"] }, "rkda_InventoryCurrentAndNonCurrentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "InventoryCurrentAndNonCurrentNet", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInventorySummaryOfInventoriesDetail"], "lang": { "en-us": { "role": { "totalLabel": "Inventories", "label": "Inventory Current And Non Current Net", "documentation": "Inventory current and non current net." } } }, "auth_ref": [] }, "us-gaap_InventoryCurrentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryCurrentTable", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInventoryAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Inventory, Current [Table]", "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInventory"], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": ["r336"] }, "rkda_InventoryFinishedGoodsCurrentAndNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "InventoryFinishedGoodsCurrentAndNonCurrent", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInventorySummaryOfInventoriesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory Finished Goods Current And Non Current", "documentation": "Inventory finished goods current and non-current." } } }, "auth_ref": [] }, "rkda_InventoryGoodsInProcessCurrentAndNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "InventoryGoodsInProcessCurrentAndNonCurrent", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInventorySummaryOfInventoriesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Goods in process", "label": "Inventory Goods In Process Current And Non Current", "documentation": "Inventory goods ion process current and non current." } } }, "auth_ref": [] }, "us-gaap_InventoryLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryLineItems", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInventoryAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Inventory [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Inventories - current", "totalLabel": "Inventory, Net, Total", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r177", "r881", "r929"] }, "us-gaap_InventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNoncurrent", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Inventories -

noncurrent", "totalLabel": "Inventory, Noncurrent, Total", "label": "Inventory, Noncurrent", "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle." } } }, "auth_ref": ["r1059"] }, "rkda_InventoryRawMaterialsCurrentAndNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "InventoryRawMaterialsCurrentAndNonCurrent", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInventorySummaryOfInventoriesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory Raw Materials Current And Non Current", "documentation": "Inventory raw materials current and non-current." } } }, "auth_ref": [] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInventoryAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Inventory Write-down", "terseLabel": "Inventories written down", "verboseLabel": "Write-down of inventories", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": ["r337"] }, "us-gaap_InvestmentIncomeAmortizationOfDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeAmortizationOfDiscount", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Investment Income, Amortization of Discount", "terseLabel": "Amortization of discount", "documentation": "Amount of accretion of purchase discount on nonoperating securities." } } }, "auth_ref": ["r98"] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeAxis", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfAmortizedCostAndFairValueOfInvestmentSecuritiesPortfolioD "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfFairValueOfInvestmentsSecuritiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Investment Type", "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": ["r765", "r767", "r768", "r770", "r772", "r835", "r838", "r840", "r844", "r845", "r846", "r851", "r852", "r853", "r854", "r855", "r949"] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeCategorizationMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfAmortizedCostAndFairValueOfInvestmentSecuritiesPortfolioD "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfFairValueOfInvestmentsSecuritiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": ["r765", "r767", "r768", "r770", "r772", "r835", "r838", "r840", "r844", "r845", "r846", "r851", "r852", "r853", "r854", "r855", "r949"] }, "us-gaap_InvestmentTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeExtensibleEnumeration", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfFairValueOfInvestmentsSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Investment, Type [Extensible Enumeration]", "documentation": "Indicates type of investment. Includes, but is not limited to, common stock, preferred stock, convertible security, fixed income security, government security, option purchased, warrant, loan participation and assignment, commercial paper, bankers' acceptance, certificates of deposit, short-term security, repurchase agreement, and other investment company." } } }, "auth_ref": ["r765", "r770", "r836", "r838", "r839", "r840", "r841", "r845", "r847", "r851"] }, "rkda_InvestmentsAndFairValueInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "InvestmentsAndFairValueInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Investments And Fair Value Instruments [Abstract]", "documentation": "Investments and fair value instruments." } } }, "auth_ref": [] }, "rkda_InvestmentsAndFairValueOfInstrumentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "InvestmentsAndFairValueOfInstrumentsDisclosureTextBlock", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstruments"], "lang": { "en-us": { "role": { "terseLabel": "Investments and Fair Value Instruments", "label": "Investments And Fair Value Of Instruments Disclosure [Text Block]", "documentation": "Investments and fair value of instruments disclosure." } } }, "auth_ref": [] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfFairValueOfInvestmentsSecuritiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Investments, Fair Value Disclosure", "totalLabel": "Investments, Fair Value Disclosure, Total", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": ["r1142", "r1143", "r1148"] }, "rkda_IssuanceAndOfferingCostsAllocatedToLiabilityClassifiedOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "IssuanceAndOfferingCostsAllocatedToLiabilityClassifiedOptions", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "documentation": "Issuance and offering costs allocated to liability classified options.", "label": "Issuance and Offering Costs Allocated to Liability Classified Options", "negatedLabel": "Issuance and offering costs allocated to liability classified options", "terseLabel": "Issuance and offering costs allocated to liability classified options" } } }, "auth_ref": [] }, "rkda_IssuanceCostsAllocatedToLiabilityPreferredOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "IssuanceCostsAllocatedToLiabilityPreferredOptions", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Issuance costs allocated to liability preferred options.", "label": "Issuance Costs Allocated to Liability Preferred Options", "terseLabel": "Issuance costs allocated to liability preferred options" } } }, "auth_ref": [] }, "rkda_JanuaryTwoThousandAndTwentyOneOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "JanuaryTwoThousandAndTwentyOneOfferingMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe "http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec], "lang": { "en-us": { "role": { "terseLabel": "January 2021 Offering [Member]", "label": "January Two Thousand And Twenty One Offering [Member]", "documentation": "January two thousand and twenty one offering." } } }, "auth_ref": [] }, "rkda_JanuaryTwoThousandAndTwentyOnePIPEMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "JanuaryTwoThousandAndTwentyOnePIPEMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "January 2021 PIPE [Member]", "label": "January Two Thousand And Twenty One P I P E [Member]", "documentation": "January two thousand and twenty one PIPE." } } }, "auth_ref": [] }, "rkda_JanuaryTwoThousandTwentyOnePlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "JanuaryTwoThousandTwentyOnePlacementAgentWarrantsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail"], "lang": { "en-us": { "role": { "terseLabel": "January 2021 Placement Agent Warrants [Member]", "label": "January Two Thousand Twenty One Placement Agent Warrants [Member]", "documentation": "January two thousand twenty one placement agent warrants." } } }, "auth_ref": [] }, "rkda_JanuaryTwoThousandTwentyOneServiceAndPerformanceWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "JanuaryTwoThousandTwentyOneServiceAndPerformanceWarrantsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail", "http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockParentheticalDetail"], "lang": { "en-us": { "role": { "terseLabel": "January 2021 Service and Performance Warrants [Member]", "label": "January Two Thousand Twenty One Service And Performance Warrants [Member]", "documentation": "January two thousand twenty one service and performance warrants." } } }, "auth_ref": [] }, "rkda_JanuaryTwoThousandTwentyOneWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "JanuaryTwoThousandTwentyOneWarrantsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail"], "lang": { "en-us": { "role": { "terseLabel": "January 2021 Warrants [Member]", "label": "January Two Thousand Twenty One Warrants [Member]", "documentation": "January two thousand twenty one warrants." } } }, "auth_ref": [] }, "rkda_JanuaryTwoThousandTwentyOneWarrantsPrivatePlacementOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "JanuaryTwoThousandTwentyOneWarrantsPrivatePlacementOfferingMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail"], "lang": { "en-us": { "role": { "documentation": "January two thousand twenty one warrants private placement offering.", "label": "January Two Thousand Twenty One Warrants Private Placement Offering [Member]", "terseLabel": "January 2021 Warrants [Member]" } } }, "auth_ref": [] }, "rkda_JohnSperlingFoundationMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "JohnSperlingFoundationMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "John Sperling Foundation [Member]", "label": "John Sperling Foundation [Member]", "documentation": "John sperling foundation." } } }, "auth_ref": [] }, "rkda_July2019ServiceAndPerformanceWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "July2019ServiceAndPerformanceWarrantsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail"], "lang": { "en-us": { "role": { "terseLabel": "July 2019 Service and Performance Warrants [Member]", "label": "July2019 Service And Performance Warrants [Member]", "documentation": "July 2019 service and performance warrants." } } }, "auth_ref": [] }, "rkda_July2020PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "July2020PlacementAgentWarrantsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail"], "lang": { "en-us": { "role": { "terseLabel": "July 2020 Placement Agent Warrants [Member]", "label": "July2020 Placement Agent Warrants [Member]", "documentation": "July 2020 placement agent warrants." } } }, "auth_ref": [] }, "rkda_July2020WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "July2020WarrantsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail"], "lang": { "en-us": { "role": { "terseLabel": "July 2020 Warrants [Member]", "label": "July2020 Warrants [Member]", "documentation": "July 2020 warrants." } } }, "auth_ref": [] }, "rkda_JulyTwoThousandAndTwentyWarrantsTransactionMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "JulyTwoThousandAndTwentyWarrantsTransactionMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "July 2020 Warrants Transaction [Member]", "label": "July Two Thousand And Twenty Warrants Transaction Member", "documentation": "July two thousand and twenty warrants transaction." } } }, "auth_ref": [] }, "rkda_JulyTwoThousandTwentyWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "JulyTwoThousandTwentyWarrantsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "July 2020 Warrants [Member]", "label": "July Two Thousand Twenty Warrants [Member]", "documentation": "July two thousand twenty warrants." } } }, "auth_ref": [] }, "rkda_June2019PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "June2019PlacementAgentWarrantsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail"], "lang": { "en-us": { "role": { "terseLabel": "June 2019 Placement Agent Warrants [Member]", "label": "June2019 Placement Agent Warrants [Member]", "documentation": "June 2019 placement agent warrants." } } }, "auth_ref": [] }, "rkda_JuneTwoThousandAndNineteenOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "JuneTwoThousandAndNineteenOfferingMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe "http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec], "lang": { "en-us": { "role": { "terseLabel": "June 2019 Offering [Member]", "label": "June Two Thousand And Nineteen Offering [Member]", "documentation": "June two

thousand and nineteen offering." } } }, "auth_ref": [] }, "rkda_JuneTwoThousandEighteenPlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "JuneTwoThousandEighteenPlacementAgentWarrantsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail"], "lang": { "en-us": { "role": { "terseLabel": "June 2018 Placement Agent Warrants [Member]", "label": "June Two Thousand Eighteen Placement Agent Warrants [Member]", "documentation": "June two thousand eighteen placement agent warrants." } } }, "auth_ref": [] }, "rkda_JuneTwoThousandEighteenWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "JuneTwoThousandEighteenWarrantsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "June 2018 Warrants [Member]", "label": "June Two Thousand Eighteen Warrants [Member]", "documentation": "June two thousand eighteen warrants." } } }, "auth_ref": [] }, "rkda_JuneTwoThousandNineteenWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "JuneTwoThousandNineteenWarrantsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail"], "lang": { "en-us": { "role": { "terseLabel": "June 2019 Warrants [Member]", "label": "June Two Thousand Nineteen Warrants [Member]", "documentation": "June 2019 warrants." } } }, "auth_ref": [] }, "rkda_LaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "LaboratoryEquipmentMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"], "lang": { "en-us": { "role": { "terseLabel": "Laboratory equipment [Member]", "label": "Laboratory Equipment [Member]", "documentation": "Laboratory equipment." } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasesDetail"], "lang": { "en-us": { "role": { "negatedTotalLabel": "Net lease cost", "totalLabel": "Net lease cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": ["r572", "r927"] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostAbstract", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Lease Cost", "label": "Lease, Cost [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements [Member]", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": ["r113", "r580"] }, "rkda_LegacyVenturesHawaiiLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "LegacyVenturesHawaiiLLCMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureConsolidatedJointVentureAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Legacy Ventures Hawaii, LLC [Member]", "label": "Legacy Ventures Hawaii L L C [Member]", "documentation": "Legacy Ventures Hawaii, LLC." } } }, "auth_ref": [] }, "us-gaap_LesseeDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Lessee Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Lessee Lease Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r570", "r581"] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Lessee Lease Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": ["r570", "r581"] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Existence of option to extend", "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "documentation": "Indicates (true false) whether lessee has option to extend operating lease." } } }, "auth_ref": ["r571"] }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseOptionToExtend", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Lease option to extend, description", "label": "Lessee, Operating Lease, Option to Extend", "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } }, "auth_ref": ["r571"] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Option to extend lease, term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r1154"] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Operating leases, term of contract", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r1154"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeases"], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r565"] }, "us-gaap_LessorOperatingLeaseAssumptionsAndJudgmentsValueOfUnderlyingAssetAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeaseAssumptionsAndJudgmentsValueOfUnderlyingAssetAmount", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Lessor, Operating Lease, Assumptions and Judgments, Value of Underlying Asset, Amount", "terseLabel": "Recognition of additional right-of-use asset and lease liability", "documentation": "Amount lessor expects from underlying asset following end of operating lease term." } } }, "auth_ref": ["r928"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r20", "r74", "r75", "r76", "r77", "r78", "r79", "r80", "r197", "r312", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r498", "r502", "r503", "r549", "r781", "r887", "r957", "r1104", "r1157", "r1158"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r88", "r134", "r689", "r929", "r1071", "r1094", "r1153"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r76", "r166", "r197", "r312", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r498", "r502", "r503", "r549", "r929", "r1104", "r1157", "r1158"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessSummaryOfMajorClassesOfLineItemsConstitutingTheBalanceSheetOnDiscontinuedOperations"], "lang": { "en-us": { "role": { "terseLabel": "Discontinued operations, liabilities", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": ["r3", "r53", "r69", "r115", "r163", "r164"] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessSummaryOfMajorClassesOfLineItemsConstitutingTheBalanceSheetOnDiscontinuedOperations"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Disposal Group, Including Discontinued Operation, Liabilities, Current, Total", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "terseLabel": "Current liabilities of discontinued operations - GoodWheat", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r3", "r53", "r69", "r112", "r115", "r163", "r164"] }, "us-gaap_LicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicenseMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "License", "label": "License [Member]", "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark." } } }, "auth_ref": ["r1108"] }, "rkda_LiquidityCapitalResourcesAndGoingConcernPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "LiquidityCapitalResourcesAndGoingConcernPolicyPolicyTextBlock", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Liquidity, Capital Resources, and Going Concern", "label": "Liquidity Capital Resources And Going Concern Policy Policy [Text Block]", "documentation": "Liquidity capital resources and going concern." } } }, "auth_ref": [] }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivable"], "lang": { "en-us": { "role": { "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "terseLabel": "Note Receivable", "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses." } } }, "auth_ref": ["r559", "r1085"] }, "us-gaap_LoansReceivableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansReceivableFairValueDisclosure", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"], "lang": { "en-us": { "role": {

"label": "Loans Receivable, Fair Value Disclosure", "terseLabel": "Estimated fair value of loan receivable", "documentation": "Fair value portion of loan receivable, including, but not limited to, mortgage loans held for investment, finance receivables held for investment, policy loans on insurance contracts." } } }, "auth_ref": ["r1152"] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"], "lang": { "en-us": { "role": { "terseLabel": "Machinery and equipment [Member]", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "rkda_March2018PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "March2018PlacementAgentWarrantsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail", "http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockParentheticalDetail"], "lang": { "en-us": { "role": { "terseLabel": "March 2018 Placement Agent Warrants [Member]", "label": "March2018 Placement Agent Warrants [Member]", "documentation": "March 2018 placement agent warrants." } } }, "auth_ref": [] }, "rkda_March2020ServiceAndPerformanceWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "March2020ServiceAndPerformanceWarrantsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail", "http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockParentheticalDetail"], "lang": { "en-us": { "role": { "terseLabel": "March 2020 Service and Performance Warrants [Member]", "label": "March2020 Service And Performance Warrants [Member]", "documentation": "March 2020 service and performance warrants." } } }, "auth_ref": [] }, "rkda_March2023AndAugust2022OptionsAndPlacementAgentOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "March2023AndAugust2022OptionsAndPlacementAgentOptionsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfKeyTermsAndActivityOfLiabilityClassifiedPreferredInvestmentOptionsDetail"], "lang": { "en-us": { "role": { "documentation": "March 2023 and August 2022 Options And Placement Agent Options.", "label": "March 2023 and August 2022 Options And Placement Agent Options [Member]", "terseLabel": "March 2023, August 2022 Options and Placement Agent Options [Member]" } } }, "auth_ref": [] }, "rkda_MarchTwoThousandAndEighteenPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "MarchTwoThousandAndEighteenPurchaseAgreementMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe], "lang": { "en-us": { "role": { "terseLabel": "March 2018 Purchase Agreement [Member]", "label": "March Two Thousand And Eighteen Purchase Agreement [Member]", "documentation": "March 2018 purchase agreement." } } }, "auth_ref": [] }, "rkda_MarchTwoThousandAndTwentyThreeOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "MarchTwoThousandAndTwentyThreeOfferingMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "March 2023 Offering [Member]", "label": "March Two Thousand And Twenty Three Offering Member", "documentation": "March two thousand and twenty three offering member" } } }, "auth_ref": [] }, "rkda_MarchTwoThousandAndTwentyThreePIPEMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "MarchTwoThousandAndTwentyThreePIPEMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "documentation": "March two thousand and twenty three P I P E.", "label": "March Two Thousand And Twenty Three P I P E [Member]", "terseLabel": "March 2023 PIPE [Member]" } } }, "auth_ref": [] }, "rkda_MarchTwoThousandEighteenOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "MarchTwoThousandEighteenOfferingMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec], "lang": { "en-us": { "role": { "terseLabel": "March 2018 Offering [Member]", "label": "March Two Thousand Eighteen Offering [Member]", "documentation": "March two thousand eighteen offering." } } }, "auth_ref": [] }, "rkda_MarchTwoThousandEighteenPIPEMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "MarchTwoThousandEighteenPIPEMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "March 2018 PIPE [Member]", "label": "March Two Thousand Eighteen P I P E Member", "documentation": "March two thousand eighteen P I P E." } } }, "auth_ref": [] }, "rkda_MarchTwoThousandEighteenWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "MarchTwoThousandEighteenWarrantsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail", "http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockParentheticalDetail"], "lang": { "en-us": { "role": { "terseLabel": "March 2018 Warrants [Member]", "label": "March Two Thousand Eighteen Warrants [Member]", "documentation": "March 2018 warrants." } } }, "auth_ref": [] }, "rkda_MarchTwoThousandTwentyThreeOptionsAndMarchTwoThousandTwentyThreePlacementAgentOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "MarchTwoThousandTwentyThreeOptionsAndMarchTwoThousandTwentyThreePlacementAgentOptionsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "March two thousand twenty three options and march two thousand twenty three placement agent options.", "label": "March Two Thousand Twenty Three Options And March Two Thousand Twenty Three Placement Agent Options [Member]", "terseLabel": "March 2023 Options and March 2023 Placement Agent Options [Member]" } } }, "auth_ref": [] }, "rkda_MarchTwoThousandTwentyThreeOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "MarchTwoThousandTwentyThreeOptionsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "March two thousand twenty three options.", "label": "March Two Thousand Twenty Three Options [Member]", "terseLabel": "March 2023 Options [Member]" } } }, "auth_ref": [] }, "rkda_MarchTwoThousandTwentyThreeOptionsSeriesAAndMarchTwoThousandTwentyThreePlacementAgentOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "MarchTwoThousandTwentyThreeOptionsSeriesAAndMarchTwoThousandTwentyThreePlacementAgentOptionsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec], "lang": { "en-us": { "role": { "documentation": "March two thousand twenty three options series A and march two thousand twenty three placement agent options.", "label": "March Two Thousand Twenty Three Options Series A and March Two Thousand Twenty Three Placement Agent Options [Member]", "terseLabel": "March 2023 Options - Series A & March 2023 Placement Agent Options [Member]" } } }, "auth_ref": [] }, "rkda_MarchTwoThousandTwentyThreeOptionsSeriesAMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "MarchTwoThousandTwentyThreeOptionsSeriesAMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe "http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfKeyTermsAndActivityOfLiabilityClassifiedPreferredInvestmentOptionsDetail"], "lang": { "en-us": { "role": { "documentation": "March two thousand twenty three options series A.", "label": "March Two Thousand Twenty Three Options Series A [Member]", "terseLabel": "March 2023 Options - Series A [Member]" } } }, "auth_ref": [] }, "rkda_MarchTwoThousandTwentyThreeOptionsSeriesBMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "MarchTwoThousandTwentyThreeOptionsSeriesBMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe "http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec "http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfKeyTermsAndActivityOfLiabilityClassifiedPreferredInvestmentOptionsDetail"], "lang": { "en-us": { "role": { "documentation": "March two thousand twenty three options series B.", "label": "March Two Thousand Twenty Three Options Series B [Member]", "terseLabel": "March 2023 Options - Series B [Member]" } } }, "auth_ref": [] }, "rkda_MarchTwoThousandTwentyThreePlacementAgentOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "MarchTwoThousandTwentyThreePlacementAgentOptionsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe "http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfKeyTermsAndActivityOfLiabilityClassifiedPreferredInvestmentOptionsDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "March Two Thousand Twenty Three Placement Agent Options.", "label": "March Two Thousand Twenty Three Placement Agent Options [Member]", "terseLabel": "March 2023 Placement Agent Options [Member]" } } }, "auth_ref": [] }, "rkda_MarchTwoThousandTwentyThreePreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "MarchTwoThousandTwentyThreePreFundedWarrantsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "documentation": "March Two Thousand Twenty Three Pre Funded Warrants.", "label": "March Two Thousand Twenty Three Pre Funded Warrants [Member]", "terseLabel": "March 2023 Pre-Funded Warrants [Member]" } } }, "auth_ref": [] }, "rkda_MarchTwoThousandTwentyThreePrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "MarchTwoThousandTwentyThreePrivatePlacementMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "March two thousand twenty three private placement.", "label": "March Two Thousand Twenty Three Private Placement [Member]", "terseLabel": "March 2023 Private Placement [Member]" } } }, "auth_ref": [] }, "rkda_MarchTwoThousandTwentyThreeSecuritiesPurchasePurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "MarchTwoThousandTwentyThreeSecuritiesPurchasePurchaseAgreementMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "March two thousand twenty three securities purchase purchase agreement.", "label": "March Two Thousand Twenty Three Securities Purchase Purchase Agreement [Member]", "terseLabel": "March 2023 Purchase Agreement [Member]" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Maximum [Member]", "terseLabel": "Maximum [Member]", "label": "Maximum [Member]" } } }, "auth_ref": ["r369", "r370", "r371", "r372", "r414", "r450", "r535", "r634", "r723", "r725", "r739", "r773", "r774", "r837", "r839", "r842", "r843", "r847", "r874", "r875", "r892", "r898", "r906", "r919", "r920", "r924", "r925", "r940", "r1106", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164"] }, "rkda_May2020PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "May2020PlacementAgentWarrantsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail"], "lang": { "en-us": { "role": { "terseLabel": "May 2020 Placement Agent Warrants [Member]", "label": "May2020 Placement Agent Warrants [Member]", "documentation": "May 2020 placement agent warrants." } } }, "auth_ref": [] }, "rkda_May2020WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "May2020WarrantsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail"], "lang": { "en-us": { "role": { "terseLabel": "May 2020 Warrants [Member]", "label": "May2020 Warrants [Member]", "documentation": "May 2020 warrants." } } }, "auth_ref": [] }, "rkda_May2020WarrantsPrivatePlacementOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "May2020WarrantsPrivatePlacementOfferingMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail"], "lang": { "en-us": { "role": {

```
"documentation": "May 2020 warrants private placement offering.", "label": "May 2020 Warrants Private Placement Offering [Member]", "terseLabel": "May 2020 Warrants [Member]" } } }, "auth_ref": [] }, "rkda_MayTwoThousandAndTwentyWarrantTransactionMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "MayTwoThousandAndTwentyWarrantTransactionMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "May 2020 Warrant Transaction [Member]", "label": "May Two Thousand And Twenty Warrant Transaction [Member]", "documentation": "May two thousand and twenty warrant transaction." } } }, "auth_ref": [] }, "rkda_MayTwoThousandTwentyWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "MayTwoThousandTwentyWarrantsMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "May 2020 Warrants [Member]", "label": "May Two Thousand Twenty Warrants [Member]", "documentation": "May two thousand twenty warrants." } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r1006" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1006" ] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec
], "lang": { "en-us": { "role": { "terseLabel": "Expected Dividend Yield [Member]", "label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": [ "r1144", "r1145", "r1146" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedTermMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec
], "lang": { "en-us": { "role": { "terseLabel": "Remaining Term [Member]", "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r1144", "r1145", "r1146" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec
], "lang": { "en-us": { "role": { "verboseLabel": "Expected Volatility [Member]", "terseLabel": "Expected Volatility [Member]", "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r919", "r1144", "r1145", "r1146" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec
], "lang": { "en-us": { "role": { "verboseLabel": "Risk-Free Interest Rate [Member]", "terseLabel": "Risk-Free Interest Rate [Member]", "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r1144", "r1145", "r1146" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec
], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r533", "r534", "r535", "r919" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec
], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r533", "r534", "r535", "r919" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]" } } }, "auth_ref": [ "r369", "r370", "r371", "r372", "r414", "r450", "r535", "r634", "r723", "r725", "r739", "r773", "r774", "r837", "r839", "r842", "r843", "r847", "r874", "r875", "r892", "r898", "r906", "r919", "r920", "r924", "r940", "r1106", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "periodEndLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance", "periodStartLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance", "totalLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Total", "terseLabel": "Non-controlling interest", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r87", "r133", "r197", "r312", "r373", "r375", "r376", "r377", "r380", "r381", "r549", "r688", "r785" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r1025" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfAmortizedCostAndFairValueOfInvestmentSecuritiesPortfolioD
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfFairValueOfInvestmentsSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Money Market Funds [Member]", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r1109" ] }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate, Type of Property", "label": "Real Estate, Type of Property [Axis]" } } }, "auth_ref": [ "r863", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873" ] }, "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate", "label": "Real Estate [Domain]" } } }, "auth_ref": [ "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r1033" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r1007" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r194" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r194" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "terseLabel": "Net cash used in operations", "label": "Net Cash Provided by (Used in) Operating Activities", "negatedLabel": "Net cash used in operations", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r104", "r105", "r106" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationNoncashItemsOfDiscontinuedOperationsDetails",
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Operating activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "totalLabel": "Net loss attributable to common stockholders", "negatedLabel": "Net loss attributable to common stockholders", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r96", "r106", "r139", "r164", "r182", "r185", "r189", "r197", "r208", "r213", "r214", "r216", "r217", "r218", "r222", "r223", "r231", "r312", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r483", "r494", "r529", "r549", "r697", "r803", "r825", "r826", "r955", "r1104" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

```
"NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": {
"negatedLabel": "Net loss attributable to noncontrolling interest", "terseLabel": "Net loss attributable to non-controlling interest", "totalLabel": "Net Income (Loss)
Attributable to Noncontrolling Interest, Total", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss)
attributable to noncontrolling interest." } } }, "auth_ref": [ "r47", "r126", "r182", "r185", "r218", "r222", "r223", "r696", "r1065" ] }, "us-
gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRecentAccountingPronouncements" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting
Pronouncements", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "documentation": "The entire disclosure for change in accounting
principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } },
"auth_ref": [ "r152", "r161", "r206", "r207", "r210", "r211", "r224", "r225", "r272", "r318", "r319", "r481", "r482", "r484", "r494", "r513", "r525", "r583", "r589", "r590", "r640",
"r641", "r642", "r733", "r734", "r735", "r736", "r738" ] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": {
"role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r1006" ] }, "ecd_NonNeosMember": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ],
"lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r970", "r980", "r990", "r1014", "r1022" ] },
"ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
"terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r997" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } },
"auth_ref": [ "r996" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation":
[ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r1014" ] },
"ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule
10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r1033" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule
10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r1033" ] }, "us-
gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NoncashInvestingAndFinancingItemsAbstract", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"NONCASH INVESTING AND FINANCING ACTIVITIES:", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation":
[ "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "Non-Controlling Interest [Member]", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets)
in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r44", "r403",
"r1074", "r1075", "r1076", "r1077", "r1201" ] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NonrelatedPartyMember", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-
us": { "role": { "label": "Nonrelated Party [Member]", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r1072", "r1073" ] },
"rkda_NoteReceivableBifurcatedDerivativesMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"NoteReceivableBifurcatedDerivativesMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
], "lang": { "en-us": { "role": { "documentation": "Note Receivable Bifurcated Derivatives.", "label": "Note Receivable Bifurcated Derivatives [Member]", "verboseLabel": "Note
Receivable Bifurcated Derivatives [Member]" } } }, "auth_ref": [] }, "rkda_NoteReceivableRecognizedFromSaleOfGoodWheat": { "xbrltype": "monetaryItemType", "nsuri":
"http://arcadiabio.com/20240930", "localname": "NoteReceivableRecognizedFromSaleOfGoodWheat", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation":
"Note receivable recognized from sale of good wheat.", "label": "Note Receivable Recognized From Sale Of Good Wheat", "terseLabel": "Note receivable recognized from sale of
GoodWheat" } } }, "auth_ref": [] }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NotesAndLoansReceivableNetCurrent", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Financing
Receivable, after Allowance for Credit Loss, Current, Total", "label": "Financing Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Note receivable - current",
"verboseLabel": "Current note receivable", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net
investment in lease." } } }, "auth_ref": [ "r674", "r1087" ] }, "us-gaap_NotesAndLoansReceivableNetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NotesAndLoansReceivableNetNoncurrent", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Financing
Receivable, after Allowance for Credit Loss, Noncurrent, Total", "label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent", "terseLabel": "Note receivable -
noncurrent", "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent." } } }, "auth_ref": [] },
"rkda_NumberOfAnnualInstallmentOfCommonStockSharesPayable": { "xbrltype": "integerItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"NumberOfAnnualInstallmentOfCommonStockSharesPayable", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel":
"Number of annual installment of common stock shares payable", "terseLabel": "Number of annual installment of common stock shares payable", "label": "Number Of Annual
Installment Of Common Stock Shares Payable", "documentation": "Number of annual installment of common stock, shares payable." } } }, "auth_ref": [] },
"rkda_NumberOfEquityIncentivePlans": { "xbrltype": "integerItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "NumberOfEquityIncentivePlans",
"presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "terseLabel": "Number of equity incentive plans", "label": "Number Of Equity Incentive Plans", "documentation": "Number of equity incentive
plans." } } }, "auth_ref": [] }, "rkda_NumberOfIndividualsAppointed": { "xbrltype": "integerItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"NumberOfIndividualsAppointed", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureConsolidatedJointVentureAdditionalInformationDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "Number of individuals appointed", "label": "Number Of Individuals Appointed", "documentation": "Number of individuals
appointed." } } }, "auth_ref": [] }, "rkda_NumberOfInstallmentBecomeDueWithinTwelveMonthsAsFullAmountContingentConsiderationIncludedInOtherNoncurrentLiabilities":
{ "xbrltype": "integerItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"NumberOfInstallmentBecomeDueWithinTwelveMonthsAsFullAmountContingentConsiderationIncludedInOtherNoncurrentLiabilities", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Number of installment become due within 12 months as full amount contingent consideration included in other noncurrent liabilities", "label": "Number Of Installment
Become Due Within Twelve Months As Full Amount Contingent Consideration Included In Other Noncurrent Liabilities", "documentation": "Number of installment become
due within twelve months as full amount contingent consideration included in other noncurrent liabilities." } } }, "auth_ref": [] }, "rkda_NumberOfLeaseAmendments": {
"xbrltype": "integerItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "NumberOfLeaseAmendments", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number
of lease amendments", "label": "Number Of Lease Amendments", "documentation": "Number of lease amendments." } } }, "auth_ref": [] },
"rkda_NumberOfTechnologyDevelopmentPrograms": { "xbrltype": "integerItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"NumberOfTechnologyDevelopmentPrograms", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
"Number of technology development programs.", "label": "Number Of Technology Development Programs", "terseLabel": "Number of development programs" } } }, "auth_ref":
[] }, "rkda_NumberOfTechnologyDevelopmentProgramsCeased": { "xbrltype": "integerItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"NumberOfTechnologyDevelopmentProgramsCeased", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
"Number of technology development programs ceased.", "label": "Number Of Technology Development Programs Ceased", "terseLabel": "Number of development programs
ceased" } } }, "auth_ref": [] }, "rkda_OctoberTwoThousandAndTwentyTwoServiceAndPerformanceWarrantsMember": { "xbrltype": "domainItemType", "nsuri":
"http://arcadiabio.com/20240930", "localname": "OctoberTwoThousandAndTwentyTwoServiceAndPerformanceWarrantsMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail" ], "lang": { "en-us": { "role": {
"documentation": "October Two Thousand and Twenty Two Service And Performance Warrants [Member]", "label": "October Two Thousand and Twenty Two Service And
Performance Warrants [Member]", "terseLabel": "October 2022 Service and Performance Warrants [Member]" } } }, "auth_ref": [] }, "rkda_OfferingClosingPeriod": {
"xbrltype": "dateItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "OfferingClosingPeriod", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Offering closing
period", "label": "Offering Closing Period", "documentation": "Offering closing period." } } }, "auth_ref": [] }, "srt_OfficeBuildingMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/srt/2024", "localname": "OfficeBuildingMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Office Space [Member]",
"label": "Office Building [Member]" } } }, "auth_ref": [ "r1203", "r1204" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": {
"totalLabel": "Loss from continuing operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from
operating revenues." } } }, "auth_ref": [ "r142", "r888", "r1079", "r1080", "r1081", "r1082", "r1083" ] }, "us-gaap_OperatingIncomeLossAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLossAbstract", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "Operating expenses :", "label": "Operating Income (Loss) [Abstract]" } } }, "auth_ref": [] }, "rkda_OperatingLeaseAssets": { "xbrltype": "monetaryItemType",
"nsuri": "http://arcadiabio.com/20240930", "localname": "OperatingLeaseAssets", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasesDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total leased assets", "label":
"Operating Lease Assets", "documentation": "Operating lease assets." } } }, "auth_ref": [] }, "rkda_OperatingLeaseAssetsAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://arcadiabio.com/20240930", "localname": "OperatingLeaseAssetsAbstract", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Operating Lease
Assets [Abstract]", "documentation": "Operating lease assets." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasesDetail" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Operating lease cost",
"terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over
```

remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r573", "r927"] }, "rkda_OperatingLeaseLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "OperatingLeaseLiabilitiesAbstract", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Operating Lease Liabilities [Abstract]", "documentation": "Operating lease liabilities." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Decrease in operating lease liability", "totalLabel": "Total leased liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r568"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasesDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liability \u2014 current", "terseLabel": "Current - Operating", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r568"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasesDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liability \u2014 noncurrent", "terseLabel": "Noncurrent - Operating", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r568"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Lease payments", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r569", "r576"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasesDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Right of use asset", "terseLabel": "Operating lease assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r567"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Lease amortization", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r1069"] }, "rkda_OperatingLeaseTermAndDiscountRateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "OperatingLeaseTermAndDiscountRateAbstract", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Lease Term and Discount Rate", "label": "Operating Lease Term And Discount Rate [Abstract]", "documentation": "Operating lease term and discount rate." } } }, "auth_ref": [] }, "rkda_OperatingLeaseTermExpirationMonthAndYear": { "xbrltype": "gYearMonthItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "OperatingLeaseTermExpirationMonthAndYear", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Operating lease term expiration month and year.", "label": "Operating Lease Term Expiration Month and Year", "terseLabel": "Operating lease term, expiration" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r579", "r927"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term (years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r578", "r927"] }, "rkda_OptionAmendmentAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "OptionAmendmentAgreementsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Option amendment agreements.", "label": "Option Amendment Agreements [Member]", "terseLabel": "Option Amendment Agreements [Member]" } } }, "auth_ref": [] }, "us-gaap_OptionIndexedToIssuersEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityLineItems", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfKeyTermsAndActivityOfLiabilityClassifiedPreferredInvestmentOptionsDetail"], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OptionIndexedToIssuersEquityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityTable", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfKeyTermsAndActivityOfLiabilityClassifiedPreferredInvestmentOptionsDetail"], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity [Table]", "documentation": "Disclosure of information about option contract issued and indexed to equity, classified as liability. Includes, but is not limited to, strike price, number of shares, indexed share, and settlement date." } } }, "auth_ref": ["r34", "r48", "r49", "r129"] }, "rkda_OptionsExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "OptionsExpirationPeriod", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Options expiration period.", "label": "Options expiration period" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "rkda_OrganizationPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "OrganizationPolicyPolicyTextBlock", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Organization", "label": "Organization Policy Policy [Text Block]", "documentation": "Organization policy." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Other Assets, Noncurrent, Total", "terseLabel": "Other noncurrent assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r170"] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax, Total", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax", "terseLabel": "Change in unrealized gains on available-for-sale securities", "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r179", "r180"] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total", "terseLabel": "Change in unrealized gains on available-for-sale securities", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r179", "r180", "r181", "r698"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income", "terseLabel": "Other comprehensive income", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": ["r14", "r19", "r183", "r186", "r190", "r218", "r550", "r551", "r556", "r676", "r698", "r1063", "r1064"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Reclassification adjustment for gains on available-for-sale securities included in net loss", "label": "OCI, Debt Securities, Available-for-Sale, Transfer from Held-to-Maturity, Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r1062"] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains on available-for-sale securities", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r179", "r181", "r306"] }, "us-gaap_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncome", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCollaborativeArrangementsAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Other Income", "terseLabel": "Other income", "verboseLabel": "other income", "documentation": "Amount of revenue and income classified as other." } } }, "auth_ref": ["r703", "r805", "r848", "r849", "r850"] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",

```
"localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Other current liabilities", "terseLabel": "Amounts due to related parties", "verboseLabel": "Royalty fees due", "totalLabel": "Other Liabilities, Current, Total", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r75", "r929" ] }, "us-gaap_OtherLiabilitiesNoncurrent": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Other Liabilities, Noncurrent, Total", "verboseLabel": "Other noncurrent liability", "terseLabel": "Other noncurrent liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r78" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Other income , net", "totalLabel": "Other Nonoperating Income (Expense), Total", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other (expense) income, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r99" ] },
"ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r1006" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r968", "r978", "r988", "r1020" ] },
"ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt",
"presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel":
"Compensation Amount" } } }, "auth_ref": [ "r971", "r981", "r991", "r1023" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": {
"label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r971", "r981", "r991", "r1023" ] }, "ecd_PayVsPerformanceDisclosureLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r995" ] }, "rkda_PaymentForAssetSaleTransaction": { "xbrltype":
"monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "PaymentForAssetSaleTransaction", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Payment for asset sale transaction.", "label": "Payment for asset sale transaction" } } }, "auth_ref": [] },
"rkda_PaymentForSaleOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"PaymentForSaleOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation":
"Payment for sale of disposal group, including discontinued operation.", "label": "Payment For Sale Of Disposal Group, Including Discontinued Operation", "negatedLabel":
"Cash paid related to sale of GoodWheat" } } }, "auth_ref": [] }, "rkda_PaymentToAquirePromissoryNote": { "xbrltype": "monetaryItemType", "nsuri":
"http://arcadiabio.com/20240930", "localname": "PaymentToAquirePromissoryNote", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Payment to aquire promissory note.", "label": "Payment To Aquire Promissory Note", "terseLabel": "Payment to aquire promissory note" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRent": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRent", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Rent payments", "label": "Payments for Rent", "documentation": "Cash payments to lessor's for use of assets under operating leases." } } }, "auth_ref": [ "r8" ] },
"rkda_PaymentsForTerminationFees": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "PaymentsForTerminationFees", "crdr":
"credit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
"Payments for termination fees.", "label": "Payments for Termination Fees", "terseLabel": "Early termination fees" } } }, "auth_ref": [] }, "rkda_PaymentsOfOfferingCosts": {
"xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "PaymentsOfOfferingCosts", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Payments Of Offering Costs", "documentation": "Payments of offering costs.", "negatedLabel": "Payments of offering costs relating to March 2023 PIPE" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr":
"credit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"verboseLabel": "Offering costs", "terseLabel": "Additional offering costs", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r27" ] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel":
"Payments to Acquire Investments, Total", "label": "Payments to Acquire Investments", "negatedLabel": "Purchases of investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r102" ] }, "us-
gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel":
"Payments to Acquire Property, Plant, and Equipment, Total", "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r103" ] },
"ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation":
[ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote"
} } }, "auth_ref": [ "r1005" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder
Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r1005" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": {
"en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r997" ] },
"ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r1014" ] }, "ecd_PeoName": {
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r1007" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r996" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [
"r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128",
"r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PlanNameDomain", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1110",
"r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129",
"r1130", "r1131", "r1132", "r1133", "r1134", "r1135" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior
Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r998" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r1042" ] }, "ecd_PnsnBnftsAdjFnTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [
"r997" ] }, "rkda_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "PreFundedWarrantsMember",
"presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Pre
Funded Warrants [Member]", "documentation": "Pre-funded warrants." } } }, "auth_ref": [] }, "rkda_PreferredInvestmentOptionsLiabilityExercisePricePerShare": { "xbrltype":
"perShareItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "PreferredInvestmentOptionsLiabilityExercisePricePerShare", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfKeyTermsAndActivityOfLiabilityClassifiedPreferredInvestmentOptionsDetail" ],
"lang": { "en-us": { "role": { "label": "Preferred Investment Options Liability Exercise Price Per Share", "documentation": "Preferred investment options liability exercise price
per share.", "terseLabel": "Exercise Price Per Share" } } }, "auth_ref": [] }, "rkda_PreferredInvestmentOptionsLiabilityIssuanceMonthAndYear": { "xbrltype":
"gYearMonthItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "PreferredInvestmentOptionsLiabilityIssuanceMonthAndYear", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfKeyTermsAndActivityOfLiabilityClassifiedPreferredInvestmentOptionsDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "Issuance Date", "label": "Preferred Investment Options Liability Issuance Month And Year", "documentation": "Preferred investment
options liability issuance month and year" } } }, "auth_ref": [] }, "rkda_PreferredInvestmentOptionsLiabilityMeasuredRemainingTerm": { "xbrltype": "durationItemType",
"nsuri": "http://arcadiabio.com/20240930", "localname": "PreferredInvestmentOptionsLiabilityMeasuredRemainingTerm", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec
], "lang": { "en-us": { "role": { "terseLabel": "Remaining term (in years)", "label": "Preferred Investment Options Liability Measured Remaining Term", "documentation":
"Preferred investment options liability measured remaining term." } } }, "auth_ref": [] }, "rkda_PreferredInvestmentOptionsLiabilityMember": { "xbrltype": "domainItemType",
"nsuri": "http://arcadiabio.com/20240930", "localname": "PreferredInvestmentOptionsLiabilityMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
], "lang": { "en-us": { "role": { "terseLabel": "Preferred Investment Options Liability [Member]", "label": "Preferred Investment Options Liability [Member]", "documentation":
"Preferred investment options liability." } } }, "auth_ref": [] }, "rkda_PreferredInvestmentOptionsLiabilityOutstanding": { "xbrltype": "sharesItemType", "nsuri":
"http://arcadiabio.com/20240930", "localname": "PreferredInvestmentOptionsLiabilityOutstanding", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfKeyTermsAndActivityOfLiabilityClassifiedPreferredInvestmentOptionsDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "Outstanding", "label": "Preferred Investment Options Liability Outstanding", "documentation": "Preferred investment options
liability outstanding." } } }, "auth_ref": [] }, "rkda_PreferredInvestmentOptionsLiabilityOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri":
"http://arcadiabio.com/20240930", "localname": "PreferredInvestmentOptionsLiabilityOutstandingMeasurementInput", "presentation": [
```

```
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec
], "lang": { "en-us": { "role": { "terseLabel": "Preferred investment options liability, measurement input", "label": "Preferred Investment Options Liability Outstanding
Measurement Input", "documentation": "Preferred investment options liability outstanding measurement input." } } }, "auth_ref": [] },
"rkda_PreferredInvestmentOptionsLiabilityTerm": { "xbrltype": "durationItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"PreferredInvestmentOptionsLiabilityTerm", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfKeyTermsAndActivityOfLiabilityClassifiedPreferredInvestmentOptionsDetail" ],
"lang": { "en-us": { "role": { "verboseLabel": "Remaining term (in years)", "terseLabel": "Term", "label": "Preferred Investment Options Liability Term", "documentation":
"Preferred investment options liability term." } } }, "auth_ref": [] }, "rkda_PreferredInvestmentOptionsMember": { "xbrltype": "domainItemType", "nsuri":
"http://arcadiabio.com/20240930", "localname": "PreferredInvestmentOptionsMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureNetLossPerShareSummaryOfSecuritiesNotIncludedInDilutedPerShareCalculationsDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred
Investment Options [Member]", "label": "Preferred Investment Options [Member]", "documentation": "Preferred investment options." } } }, "auth_ref": [] }, "us-
gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid
expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for
costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle,
if longer." } } }, "auth_ref": [ "r1061" ] }, "rkda_PresidentAndChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930",
"localname": "PresidentAndChiefExecutiveOfficerMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "Stanley Jacot, Jr. [Member]", "label": "President and Chief Executive Officer [Member]", "documentation": "President and Chief Executive Officer
[Member]" } } }, "auth_ref": [] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "lang": { "en-us": { "role": { "label":
"Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications", "documentation": "Disclosure of accounting policy for reclassification
affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref":
[ "r1057" ] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember",
"presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
], "lang": { "en-us": { "role": { "terseLabel": "Purchase Agreement [Member]", "label": "Private Placement [Member]", "documentation": "A private placement is a direct
offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": []
}, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Divestiture of
Businesses", "terseLabel": "Net consideration from sale of brand", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the
company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": [ "r26" ] }, "us-
gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from
issuance, aggregate offering prices", "label": "Proceeds from Issuance Initial Public Offering", "documentation": "The cash inflow associated with the amount received from
entity's first offering of stock to the public." } } }, "auth_ref": [ "r6" ] }, "rkda_ProceedsFromIssuanceOfCommonStockAndWarrantsGross": { "xbrltype": "monetaryItemType",
"nsuri": "http://arcadiabio.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsGross", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from
issuance of common stock and warrants gross", "label": "Proceeds From Issuance Of Common Stock And Warrants Gross", "documentation": "Proceeds from issuance of
common stock and warrants gross." } } }, "auth_ref": [] }, "rkda_ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndPreferredInvestmentOptions": { "xbrltype":
"monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockPreFundedWarrantsAndPreferredInvestmentOptions",
"crdr": "debit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Proceeds
from Issuance of Common Stock Pre-funded Warrants and Preferred Investment Options", "documentation": "Proceeds from issuance of common stock pre-funded warrants
and preferred investment options.", "terseLabel": "Proceeds from issuance of common stock, pre-funded warrants and preferred investment options from March 2023 PIPE" }
} }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromSaleOfEquityMethodInvestments", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Proceeds from sale of Verdeca - earn-out received", "label": "Proceeds from Sale of Equity Method Investments", "documentation": "The cash inflow associated with the sale
of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and
exercises significant influence." } } }, "auth_ref": [ "r26" ] }, "rkda_ProceedsFromSaleOfEquityMethodInvestmentsInAccountsAndOtherReceivable": { "xbrltype":
"monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "ProceedsFromSaleOfEquityMethodInvestmentsInAccountsAndOtherReceivable", "crdr": "debit",
"presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "Proceeds from sale of Verdeca in accounts receivable and other receivables", "verboseLabel": "Payment received on accounts and other
receivable", "label": "Proceeds From Sale Of Equity Method Investments In Accounts And Other Receivable", "documentation": "Proceeds from sale of equity method
investments in accounts and other receivable." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfIntangibleAssets", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCollaborativeArrangementsAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Proceeds
from Sale of Intangible Assets", "terseLabel": "Proceeds from sale of RS durum wheat trait", "documentation": "The cash inflow from disposal of asset without physical form
usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r101" ] }, "us-gaap_ProceedsFromSaleOfOtherInvestments": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfOtherInvestments", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Proceeds
from Sale of Other Investments", "terseLabel": "Proceeds from sale of investments", "documentation": "Amount of cash inflow from the sale of investments classified as other."
} } }, "auth_ref": [ "r1048" ] }, "rkda_ProceedsFromSaleOfPropertyAndEquipmentInAccountsReceivableAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri":
"http://arcadiabio.com/20240930", "localname": "ProceedsFromSaleOfPropertyAndEquipmentInAccountsReceivableAndOtherReceivables", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationNoncashItemsOfDiscontinuedOperationsDetails" ], "lang": { "en-us":
{ "role": { "terseLabel": "Proceeds from sale of property and equipment in accounts receivable and other receivables", "label": "Proceeds From Sale Of Property And
Equipment In Accounts Receivable And Other Receivables", "documentation": "Proceeds from sale of property and equipment in accounts receivable and other receivables." }
} }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationNoncashItemsOfDiscontinuedOperationsDetails",
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Proceeds from sale of property and equipment", "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total", "label": "Proceeds from Sale of Property, Plant,
and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services
and not intended for resale." } } }, "auth_ref": [ "r101" ] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ProceedsFromStockPlans", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Proceeds from ESPP purchases", "label": "Proceeds from Stock Plans", "documentation": "The cash inflow associated with the amount received from the stock plan during the
period." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember",
"presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationSummaryOfMajorClassesOfLineItemsConstitutingNetLossFromDiscon
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "Product", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r899" ] },
"srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationSummaryOfMajorClassesOfLineItemsConstitutingNetLossFromDiscon
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "Product and Service", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r267", "r635", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r877",
"r899", "r939", "r940", "r941", "r944", "r946", "r1102", "r1103", "r1107", "r1169", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180",
"r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1198", "r1199" ] },
"srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationSummaryOfMajorClassesOfLineItemsConstitutingNetLossFromDiscon
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "Product and Service", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r267", "r635", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r877",
"r899", "r939", "r940", "r941", "r944", "r946", "r1102", "r1103", "r1107", "r1169", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180",
"r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1198", "r1199" ] }, "us-
gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": {
"totalLabel": "Net loss", "label": "Net losses", "verboseLabel": "Net (loss) income", "terseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period,
net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r164", "r182", "r185", "r193", "r197", "r208", "r218", "r222", "r223",
"r312", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r483", "r494", "r496", "r499", "r500", "r529", "r549", "r679", "r695", "r752", "r803", "r825",
"r826", "r911", "r912", "r956", "r1065", "r1104" ] }, "rkda_PromissoryNoteCurrentAndNonCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://arcadiabio.com/20240930", "localname": "PromissoryNoteCurrentAndNonCurrent", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Promissory note,
current and non current.", "label": "Promissory Note, Current And Non Current", "terseLabel": "Promissory note, current and non current." } } }, "auth_ref": [] },
```

```
"rkda_PromissoryNoteInterestDescription": { "xbrltype": "stringItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "PromissoryNoteInterestDescription",
"presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation":
"Promissory note interest description.", "label": "Promissory Note Interest Description", "terseLabel": "Promissory note interest description" } } }, "auth_ref": [] },
"rkda_PromissoryNotePrincipalReceviableEachYear": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"PromissoryNotePrincipalReceviableEachYear", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Promissory note
principal receviable each year.", "label": "Promissory Note Principal Receviable Each Year", "terseLabel": "Promissory note principal receviable each year" } } }, "auth_ref": [] },
"rkda_PromissoryNoteReceivedFromAssetSale": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"PromissoryNoteReceivedFromAssetSale", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Promissory note received from asset sale.", "label": "Promissory note received from asset sale" } } }, "auth_ref": [] }, "rkda_PromissoryNoteTerm": {
"xbrltype": "durationItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "PromissoryNoteTerm", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Promissory note
term.", "label": "Promissory Note Term", "terseLabel": "Promissory note term" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and
Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Long-Lived Tangible Asset", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce
goods and services and not intended for resale." } } }, "auth_ref": [ "r11", "r580" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment, Net",
"label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business
and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r110", "r148",
"r149", "r150" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" ], "lang": { "en-us": { "role": {
"periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "totalLabel":
"Property, Plant and Equipment, Gross, Total", "terseLabel": "Property and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount
before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are
not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r113", "r168", "r692" ] }, "us-
gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems",
"presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Property Plant And Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts
included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [
"r580" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "periodEndLabel": "Property,
Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "totalLabel": "Property and equipment, net",
"terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and
amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to,
land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r11", "r580", "r680", "r692", "r929" ] },
"rkda_PropertyPlantAndEquipmentNetIncludingDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"PropertyPlantAndEquipmentNetIncludingDiscontinuedOperations", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" ], "lang": { "en-us": { "role": {
"documentation": "Property, plant and equipment, net including discontinued operations.", "label": "Property, Plant and Equipment, Net Including Discontinued Operations",
"totalLabel": "Property and equipment, net" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Long-Lived Tangible Asset", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal
conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and
equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r113", "r580" ] },
"ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r995" ] },
"ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure,
Table" } } }, "auth_ref": [ "r995" ] }, "rkda_RadianceBeautyLicensingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930",
"localname": "RadianceBeautyLicensingAgreementMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInventoryAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
"Radiance beauty licensing agreement.", "label": "Radiance Beauty Licensing Agreement [Member]", "terseLabel": "Radiance Beauty Licensing Agreement [Member]" } } },
"auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r369", "r370", "r371", "r372", "r406", "r414", "r442",
"r443", "r444", "r450", "r535", "r608", "r617", "r634", "r723", "r725", "r739", "r773", "r774", "r837", "r839", "r842", "r843", "r847", "r874", "r875", "r892", "r898", "r906",
"r919", "r920", "r924", "r925", "r940", "r949", "r1100", "r1106", "r1145", "r1160", "r1161", "r1162", "r1163", "r1164" ] }, "srt_RangeMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r369", "r370", "r371", "r372", "r406", "r414", "r442",
"r443", "r444", "r450", "r535", "r608", "r617", "r634", "r723", "r725", "r739", "r773", "r774", "r837", "r839", "r842", "r843", "r847", "r874", "r875", "r892", "r898", "r906",
"r919", "r920", "r924", "r925", "r940", "r949", "r1100", "r1106", "r1145", "r1160", "r1161", "r1162", "r1163", "r1164" ] }, "us-gaap_ReceivableWithImputedInterestDiscount": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivableWithImputedInterestDiscount", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"label": "Receivable with Imputed Interest, Discount", "terseLabel": "Loan receivable, discount", "documentation": "Disclosure of the unamortized amount of the discount on
the note or receivable which is deducted from the face amount of the receivable or loan. The discount or premium is the difference between the present value and the face
amount." } } }, "auth_ref": [ "r558", "r559", "r560", "r926" ] }, "us-gaap_ReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Receivables [Abstract]" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of
Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r963", "r973",
"r983", "r1015" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain",
"presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party",
"label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for
which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that
may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r273", "r413", "r594", "r595", "r683",
"r690", "r776", "r777", "r778", "r779", "r780", "r800", "r802", "r834" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RelatedPartyMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Related Party
[Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust
for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r199", "r200", "r594", "r595", "r596", "r597", "r683",
"r690", "r776", "r777", "r778", "r779", "r780", "r800", "r802", "r834" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Related
Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These
concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r273", "r808", "r809",
"r812" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
```

```
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r273", "r413", "r594", "r595", "r683", "r690", "r776", "r777", "r778", "r779", "r780", "r800", "r802", "r834", "r1156" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related-Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r591", "r592", "r593", "r595", "r598", "r748", "r749", "r750", "r810", "r811", "r812", "r831", "r833" ] }, "rkda_RemainingContingentLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "RemainingContingentLiability", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Remaining contingent liability", "label": "Remaining Contingent Liability", "terseLabel": "Remaining contingent" } } }, "auth_ref": [] },
"srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableAdditionalInformationDetails",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureConsolidatedJointVentureAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r201", "r202", "r383", "r389", "r597", "r618", "r681", "r883", "r884" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ],
"lang": { "en-us": { "role": { "totalLabel": "Research and Development Expense, Total", "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [
"r451", "r876", "r890", "r1165" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "R&D Expenses [Member]", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementAxis", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "auth_ref": [ "r159", "r203", "r204", "r205", "r208", "r209", "r213", "r214", "r215", "r216", "r219", "r220", "r221", "r222", "r223", "r224", "r238", "r320", "r321", "r479", "r480", "r483", "r484", "r493", "r494", "r522", "r527", "r528", "r529", "r562", "r564", "r587", "r588", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r740", "r1084" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r964", "r974", "r984", "r1016" ] },
"ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" }
} }, "auth_ref": [ "r965", "r975", "r985", "r1017" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": {
"en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r972", "r982", "r992", "r1024" ] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementDomain", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]" } } }, "auth_ref": [ "r159", "r203", "r204", "r205", "r208", "r209", "r213", "r214", "r215", "r216", "r219", "r220", "r221", "r222", "r223", "r224", "r238", "r320", "r321", "r479", "r480", "r483", "r484", "r493", "r494", "r522", "r527", "r528", "r529", "r562", "r564", "r587", "r588", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r740", "r1084" ] }, "us-gaap_RestructuringAndRelatedActivitiesDescription": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDescription", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Restructuring activities, description", "label": "Restructuring and Related Activities, Description", "documentation": "Description of a specific restructuring plan and related activities including the facts and circumstances leading to the restructuring or decision to exit an activity, and the expected completion date. This concept and related items would be utilized for each plan if multiple exit plans have been implemented in the period." } } }, "auth_ref": [ "r33", "r117" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit",
"crdr": "credit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r85", "r120", "r687", "r733", "r738", "r746", "r784", "r929" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "Accumulated Deficit [Member]", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [
"r158", "r203", "r204", "r205", "r209", "r218", "r221", "r223", "r317", "r325", "r359", "r462", "r463", "r478", "r479", "r480", "r484", "r493", "r494", "r507", "r510", "r511", "r515", "r527", "r563", "r566", "r729", "r731", "r753", "r1201" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": {
"totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total", "terseLabel": "Total revenues", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "verboseLabel": "License revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r140", "r141", "r239", "r245", "r246", "r259", "r264", "r267", "r268", "r270", "r404", "r405", "r635" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "Revenues:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "rkda_ReverseStockSplitPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "ReverseStockSplitPolicyPolicyTextBlock", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies" ], "lang": { "en-us": { "role": { "documentation":
"Reverse stock split policy policy text block.", "label": "Reverse Stock Split Policy [Policy Text Block]", "terseLabel": "Reverse Stock Split" } } }, "auth_ref": [] },
"srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
], "lang": { "en-us": { "role": { "terseLabel": "Reclassification upon Adoption [Member]", "label": "Revision of Prior Period, Accounting Standards Update, Adjustment [Member]" } } }, "auth_ref": [ "r159", "r208", "r209", "r216", "r224", "r320", "r321", "r479", "r480", "r483", "r484", "r493", "r494", "r522", "r529", "r562", "r587", "r588", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Right of use assets obtained in exchange for new operating lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r577", "r927" ] }, "us-gaap_RoyaltyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "Royalty", "label": "Royalty [Member]", "documentation": "Money for usage-based right to asset." } } }, "auth_ref": [ "r1108" ] },
"rkda_RoyaltyPaymentsDuePercentageOfNetRevenueAsDefinedInAgreements": { "xbrltype": "percentItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"RoyaltyPaymentsDuePercentageOfNetRevenueAsDefinedInAgreements", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Royalty payments due, percentage of net revenue as defined in the In-Licensing agreements", "label": "Royalty Payments Due Percentage Of Net Revenue As Defined In Agreements", "documentation": "Royalty Payments Due, Percentage Of Net Revenue As Defined In Agreements" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r1033" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r1033" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRecu
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfKeyTermsAndActivityOfLiabilityClassifiedPreferredInvestmentOptionsDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Accounts and Financing Receivables [Table]", "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss." } } }, "auth_ref": [ "r83", "r89", "r274", "r1088" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureNetLossPerShareSummaryOfSecuritiesNotIncludedInDilutedPerShareCalculationsDetail" ], "lang": { "en-us": {
"role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic
```

earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r29"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureNetLossPerShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Securities Not Included in Diluted per Share Calculations", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r29"] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfAmortizedCostAndFairValueOfInvestmentSecuritiesPortfolioD], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Available For Sale Securities [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287"] }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCollaborativeArrangementsAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r495"] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationTables"], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Summary of Major Classes of Line Items Constituting Discontinued Operations", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r12", "r18", "r21", "r53", "r62", "r63", "r64", "r65", "r66", "r70", "r72", "r73", "r116"] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureConsolidatedJointVentureAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": ["r308", "r309", "r311", "r474", "r1045", "r1046", "r1047", "r1136", "r1137", "r1138", "r1139"] }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureConsolidatedJointVentureAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Equity Method Investments [Line Items]", "label": "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r197", "r308", "r309", "r311", "r312", "r549"] }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureConsolidatedJointVentureAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Equity Method Investments [Table]", "label": "Equity Method Investment [Table]", "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets." } } }, "auth_ref": ["r164", "r197", "r308", "r309", "r311", "r312", "r549"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureIntangibleAssetsNetScheduleOfFutureAmortizationOfIntellectualPropertyAndCustomerListsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": ["r347", "r353", "r355", "r356", "r357", "r636", "r876", "r895"] }, "rkda_ScheduleOfInventoryCurrentAndNonCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "ScheduleOfInventoryCurrentAndNonCurrentTableTextBlock", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInventoryTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Inventories", "label": "Schedule Of Inventory Current And Non Current Table [Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. Includes current and non-current inventory balances." } } }, "auth_ref": [] }, "rkda_ScheduleOfKeyTermsAndActivityOfPreferredInvestmentOptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "ScheduleOfKeyTermsAndActivityOfPreferredInvestmentOptionsTableTextBlock", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Key Terms and Activity of Liability Classified Preferred Investment Options", "label": "Schedule Of Key Terms And Activity Of Preferred Investment Options [Table Text Block]", "documentation": "Schedule of key terms and activity of preferred investment options." } } }, "auth_ref": [] }, "rkda_ScheduleOfOperatingLeaseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "ScheduleOfOperatingLeaseTableTextBlock", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Leases", "label": "Schedule Of Operating Lease Table [Text Block]", "documentation": "Schedule of operating lease." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Property Plant And Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r11", "r580"] }, "rkda_ScheduleOfPropertyPlantAndEquipmentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "ScheduleOfPropertyPlantAndEquipmentTableTextBlock", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Property and Equipment, Net", "label": "Schedule Of Property Plant And Equipment Table [Text Block]", "documentation": "Schedule of property plant and equipment." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]", "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": ["r50", "r51", "r808", "r809", "r812"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramWeightedAverageFairValueAssumptionOfStockO], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r416", "r418", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Activity Under Stock Incentive Plans", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r16", "r17", "r122"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramTables"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Fair Value Assumption of Stock Option Awards", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r123"] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Warrants Issued to Purchase Common Stock", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r35"] }, "us-gaap_SecuritiesFinancingTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuritiesFinancingTransactionAxis", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Securities Financing Transaction [Axis]", "documentation": "Information by type of securities financing transactions, including, but not limited to those measured at fair value or cost." } } }, "auth_ref": ["r130"] }, "us-gaap_SecuritiesFinancingTransactionTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuritiesFinancingTransactionTypeDomain", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label":

"Securities Financing Transaction [Domain]", "documentation": "Measurement of financing transaction securities held." } } }, "auth_ref": ["r130"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r958"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r960"] }, "us-gaap_SegmentDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDiscontinuedOperationsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationNoncashItemsOfDiscontinuedOperationsDetails", "http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationSummaryOfMajorClassesOfLineItemsConstitutingNetLossFromDiscon "http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessSummaryOfMajorClassesOfLineItemsConstitutingTheBalanceSheetOnDiscontinuedOperations "http://arcadiabio.com/20240930/taxonomy/role/DisclosureNoteReceivableAdditionalInformationDetails", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Discontinued Operations [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, classified as held-for-sale or disposed of by sale or by means other than sale, and business and nonprofit activity on acquisition and upon joint venture formation, classified as held-for-sale." } } }, "auth_ref": ["r7", "r54", "r55", "r56"] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationNoncashItemsOfDiscontinuedOperationsDetails", "http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationSummaryOfMajorClassesOfLineItemsConstitutingNetLossFromDiscon "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r140", "r141", "r142", "r143", "r239", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r270", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r357", "r365", "r366", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r889", "r890", "r891", "r894", "r943", "r1169", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1198", "r1199"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Domain]" } } }, "auth_ref": ["r268", "r269", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r766", "r769", "r771", "r838", "r840", "r845", "r851", "r863", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r878", "r900", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r942", "r949", "r1107", "r1169", "r1171", "r1172", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1198", "r1199"] }, "rkda_SellingGeneralAndAdministrativeAndResearchAndDevelopmentExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "SellingGeneralAndAdministrativeAndResearchAndDevelopmentExpensesMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasesDetail"], "lang": { "en-us": { "role": { "terseLabel": "SG&A and R&D Expenses [Member]", "label": "Selling General And Administrative And Research And Development Expenses [Member]", "documentation": "Selling, general and administrative and research and development expenses." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Selling, General and Administrative Expense, Total", "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r97"] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasesDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel": "SG&A Expenses [Member]", "terseLabel": "Selling, General and Administrative Expenses [Member]", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "rkda_SeparationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "SeparationAgreementMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Separation agreement.", "label": "Separation Agreement [Member]", "terseLabel": "Separation Agreement [Member]" } } }, "auth_ref": [] }, "rkda_September2019PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "September2019PlacementAgentWarrantsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail"], "lang": { "en-us": { "role": { "terseLabel": "September 2019 Placement Agent Warrants [Member]", "label": "September2019 Placement Agent Warrants [Member]", "documentation": "September 2019 placement agent warrants." } } }, "auth_ref": [] }, "rkda_SeptemberTwoThousandAndNineteenOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "SeptemberTwoThousandAndNineteenOfferingMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe "http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec], "lang": { "en-us": { "role": { "terseLabel": "September 2019 Offering [Member]", "label": "September Two Thousand And Nineteen Offering [Member]", "documentation": "September two thousand and nineteen offering." } } }, "auth_ref": [] }, "rkda_SeptemberTwoThousandNineteenWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "SeptemberTwoThousandNineteenWarrantsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail"], "lang": { "en-us": { "role": { "terseLabel": "September 2019 Warrants [Member]", "label": "September Two Thousand Nineteen Warrants [Member]", "documentation": "September 2019 warrants." } } }, "auth_ref": [] }, "rkda_SeptemberTwoThousandNineteenWarrantsPrivatePlacementOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "SeptemberTwoThousandNineteenWarrantsPrivatePlacementOfferingMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail"], "lang": { "en-us": { "role": { "documentation": "September two thousand nineteen warrants private placement offering.", "label": "September Two Thousand Nineteen Warrants Private Placement Offering [Member]", "terseLabel": "September 2019 Warrants [Member]" } } }, "auth_ref": [] }, "rkda_SeriesAAndBPreferredInvestmentOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "SeriesAAndBPreferredInvestmentOptionsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Series A and B preferred investment options.", "label": "Series A and B Preferred Investment Options [Member]", "terseLabel": "Series A and B Preferred Investment Options [Member]" } } }, "auth_ref": [] }, "rkda_SeriesAPreferredInvestmentOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "SeriesAPreferredInvestmentOptionsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Series A preferred investment options.", "label": "Series A Preferred Investment Options [Member]", "terseLabel": "Series A Preferred Investment Options [Member]" } } }, "auth_ref": [] }, "rkda_SeriesBPreferredInvestmentOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "SeriesBPreferredInvestmentOptionsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Series B preferred investment options.", "label": "Series B Preferred Investment Options [Member]", "terseLabel": "Series B Preferred Investment Options [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total", "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r9"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Options vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r907"] }, "rkda_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiredOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpiredOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramSummaryOfActivityUnderStockIncentivePlansDet], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award expired outstanding intrinsic value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Expired Outstanding Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Options Expired" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramWeightedAverageFairValueAssumptionOfStockOp], "lang": { "en-us": { "role": { "terseLabel": "Dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r443"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramWeightedAverageFairValueAssumptionOfStockOp], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously

compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r442"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramWeightedAverageFairValueAssumptionOfStockOp], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r444"] }, "rkda_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsValue": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsValue", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Fair value assumptions, value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Value", "documentation": "Share-based compensation arrangement by share-based payment award, fair value assumptions, value." } } }, "auth_ref": [] }, "rkda_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramSummaryOfActivityUnderStockIncentivePlansDet], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, forfeiture, intrinsic value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Forfeiture, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Options Forfeited" } } }, "auth_ref": [] }, "rkda_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramSummaryOfActivityUnderStockIncentivePlansDet], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Options Granted", "label": "Share Based Compensation Arrangement By Share Based Payment Award Grants Outstanding Intrinsic Value", "documentation": "Share based compensation arrangement by share based payment award grants outstanding intrinsic value." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramWeightedAverageFairValueAssumptionOfStockOp], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r416", "r418", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Percentage in payroll deductions to acquire shares of common stock", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan." } } }, "auth_ref": ["r36"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee", "terseLabel": "Number of shares awarded o individual employee", "documentation": "The highest quantity of shares an employee can purchase under the plan per period." } } }, "auth_ref": ["r36"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Additional shares authorized for issuance under the plan", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Common stock available for future grant", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r36"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramSummaryOfActivityUnderStockIncentivePlansDet], "lang": { "en-us": { "role": { "terseLabel": "Shares Subject to Outstanding, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r425"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramSummaryOfActivityUnderStockIncentivePlansDet], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price Per Share, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r425"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramSummaryOfActivityUnderStockIncentivePlansDet], "lang": { "en-us": { "role": { "negatedLabel": "Shares Subject to Outstanding, Options Expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": ["r430"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramSummaryOfActivityUnderStockIncentivePlansDet], "lang": { "en-us": { "role": { "negatedLabel": "Shares Subject to Outstanding, Options Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r429"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramSummaryOfActivityUnderStockIncentivePlansDet], "lang": { "en-us": { "role": { "verboseLabel": "Shares Subject to Outstanding, Options Granted", "terseLabel": "Shares Subject to Outstanding, Options granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r427"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramSummaryOfActivityUnderStockIncentivePlansDet], "lang": { "en-us": { "role": { "periodEndLabel": "Aggregate Intrinsic Value, Ending Balance", "periodStartLabel": "Aggregate Intrinsic Value, Beginning Balance", "terseLabel": "Aggregate Intrinsic Value, Outstanding Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r36"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramSummaryOfActivityUnderStockIncentivePlansDet], "lang": { "en-us": { "role": { "terseLabel": "Total number of options outstanding", "periodStartLabel": "Shares Subject to Outstanding, Beginning Balance", "periodEndLabel": "Shares Subject to Outstanding, Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r423", "r424"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramSummaryOfActivityUnderStockIncentivePlansDet], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted-Average Exercise Price Per Share, Outstanding Beginning Balance", "periodEndLabel": "Weighted Average Exercise Price Per Share, Outstanding Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r423", "r424"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramSummaryOfActivityUnderStockIncentivePlansDet], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based

Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r439"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramSummaryOfActivityUnderStockIncentivePlansDet], "lang": { "en-us": { "role": { "terseLabel": "Shares Subject to Outstanding, Vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r439"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramSummaryOfActivityUnderStockIncentivePlansDet], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price Per Share, Vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r439"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Terms under the plan", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award", "documentation": "Description of terms of award under share-based payment arrangement." } } }, "auth_ref": ["r37"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramWeightedAverageFairValueAssumptionOfStockOp "http://xbrl.sec.ec/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramSummaryOfActivityUnderStockIncentivePlansDet], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price Per Share, Options expired", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": ["r430"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramSummaryOfActivityUnderStockIncentivePlansDet], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price Per Share, Options forfeited", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r429"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramSummaryOfActivityUnderStockIncentivePlansDet], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price Per Share, Options granted", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r427"] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Stock price", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r908"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramWeightedAverageFairValueAssumptionOfStockOp], "lang": { "en-us": { "role": { "verboseLabel": "Expected term", "terseLabel": "Expected term (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r441"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramSummaryOfActivityUnderStockIncentivePlansDet], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r36"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Employees are able to purchase company's common stock on first trading day of offering period, percentage", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Exercise price", "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "periodStartLabel": "Stockholders Equity, Beginning Balance, Shares", "periodEndLabel": "Stockholders Equity, Ending Balance, Shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments", "totalLabel": "Short-Term Investments, Total", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": ["r135", "r136", "r1060"] }, "us-gaap_ShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestmentsMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfAmortizedCostAndFairValueOfInvestmentSecuritiesPortfolioD "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfFairValueOfInvestmentsSecuritiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Short-term Investments [Member]", "label": "Short-Term Investments [Member]", "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet." } } }, "auth_ref": ["r853", "r854", "r855", "r879"] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasesDetail"], "lang": { "en-us": { "role": { "negatedLabel": "Short term lease cost", "terseLabel": "Short term lease cost", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": ["r574", "r927"] }, "rkda_ShortTermLeaseCostAndCostReclassifications": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "ShortTermLeaseCostAndCostReclassifications", "crdr": "debit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasesDetail"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Short term lease cost", "terseLabel": "Short term lease cost", "label": "Short Term Lease Cost And Cost Reclassifications", "documentation": "Short term lease cost and cost (reclassifications)." } } }, "auth_ref": [] }, "rkda_SoftwareAndComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "SoftwareAndComputerEquipmentMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail"], "lang": { "en-us": { "role": { "terseLabel": "Software and computer equipment [Member]", "label": "Software And Computer Equipment [Member]", "documentation": "Software and computer equipment." } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationNoncashItemsOfDiscontinuedOperationsDetails", "http://arcadiabio.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationSummaryOfMajorClassesOfLineItemsConstitutingNetLossFromDiscon "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": ["r140", "r141", "r142", "r143", "r162", "r239", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r270",

"r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r357", "r361", "r365", "r366", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r889", "r890", "r891", "r894", "r943", "r1169", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1198", "r1199"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r155", "r172", "r173", "r174", "r197", "r229", "r230", "r232", "r234", "r241", "r242", "r312", "r373", "r375", "r376", "r377", "r380", "r381", "r387", "r388", "r391", "r394", "r401", "r549", "r742", "r743", "r744", "r745", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r783", "r804", "r827", "r856", "r857", "r858", "r859", "r860", "r1044", "r1070", "r1078"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital [Member]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r14", "r82", "r86", "r87", "r158", "r187", "r188", "r189", "r203", "r204", "r205", "r209", "r218", "r221", "r223", "r240", "r317", "r325", "r359", "r403", "r462", "r463", "r478", "r479", "r480", "r484", "r493", "r494", "r507", "r509", "r510", "r511", "r512", "r515", "r527", "r550", "r552", "r553", "r554", "r555", "r556", "r563", "r566", "r588", "r698", "r729", "r730", "r731", "r753", "r827"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Axis]" } } }, "auth_ref": ["r268", "r269", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r766", "r769", "r771", "r838", "r840", "r845", "r851", "r863", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r878", "r900", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r942", "r949", "r1107", "r1169", "r1171", "r1172", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1198", "r1199"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r203", "r204", "r205", "r240", "r566", "r635", "r741", "r764", "r775", "r776", "r777", "r778", "r779", "r780", "r783", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r796", "r797", "r798", "r799", "r800", "r802", "r806", "r807", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r827", "r950"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r203", "r204", "r205", "r240", "r273", "r566", "r635", "r741", "r764", "r775", "r776", "r777", "r778", "r779", "r780", "r783", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r796", "r797", "r798", "r799", "r800", "r802", "r806", "r807", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r827", "r950"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r967", "r977", "r987", "r1019"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of shares related to employee stock purchase plan, Shares", "terseLabel": "Issuance of common stock pursuant to employee stock purchase plan", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": ["r14", "r81", "r82", "r120"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Shares of common stock issued", "terseLabel": "Issuance of shares, Shares", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r14", "r81", "r82", "r120", "r742", "r827", "r857"] }, "rkda_StockIssuedDuringPeriodSharesRelatedToExerciseOfOptions": { "xbrltype": "sharesItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "StockIssuedDuringPeriodSharesRelatedToExerciseOfOptions", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfKeyTermsAndActivityOfLiabilityClassifiedPreferredInvestmentOptionsDetail"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period Shares Related To Exercise Of Options", "documentation": "Stock issued during period shares related to exercise of options.", "terseLabel": "Exercised during the period" } } }, "auth_ref": [] }, "rkda_StockIssuedDuringPeriodSharesRelatedToExerciseOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "StockIssuedDuringPeriodSharesRelatedToExerciseOfWarrants", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Exercised during the period", "verboseLabel": "Issuance of shares related to Pre-Funded Warrants exercise", "label": "Stock Issued During Period Shares Related To Exercise Of Warrants", "documentation": "Stock issued during period shares related to exercise of warrants." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Reverse Stock Splits", "terseLabel": "Issuance of shares related to reverse stock split", "verboseLabel": "Additional shares of common stock of reverse stock split", "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": ["r14"] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares related to employee stock purchase plan", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": ["r14", "r81", "r82", "r120"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r14", "r81", "r82", "r120", "r753", "r827", "r857", "r956"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "periodEndLabel": "Stockholders' Equity Attributable to Parent, Ending Balance", "periodStartLabel": "Stockholders' Equity Attributable to Parent, Beginning Balance", "label": "Equity, Attributable to Parent", "totalLabel": "Total stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r82", "r86", "r87", "r109", "r785", "r801", "r828", "r829", "r929", "r957", "r1071", "r1094", "r1153", "r1201"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodStartLabel": "Stockholders Equity, Beginning Balance", "periodEndLabel": "Stockholders Equity, Ending Balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r44", "r45", "r46", "r158", "r159", "r188", "r203", "r204", "r205", "r209", "r218", "r221", "r317", "r325", "r359", "r403", "r462", "r463", "r478", "r479", "r480", "r484", "r493", "r494", "r507", "r509", "r510", "r511", "r512", "r515", "r527", "r550", "r552", "r556", "r564", "r588", "r730", "r731", "r751", "r785", "r801", "r828", "r829", "r861", "r956", "r1071", "r1094", "r1153", "r1201"] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancing"], "lang": { "en-us": { "role": { "terseLabel": "Equity Financing", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r119", "r196", "r386", "r388", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r400", "r403", "r517", "r830", "r832", "r862"] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityReverseStockSplit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Reverse Stock Split", "terseLabel": "Reverse stock split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": ["r121"] }, "us-

gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubleaseIncome", "crdr": "credit", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasesDetail"], "lang": { "en-us": { "role": { "label": "Sublease Income", "negatedLabel": "Sublease income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": ["r575", "r927"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r557", "r600"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r557", "r600"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r557", "r600"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureSubsequentEvents"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r599", "r601"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfPreferredInvestmentOptionLiabilitiesMeasuredAndRecordedOnRec
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfKeyTermsAndActivityOfLiabilityClassifiedPreferredInvestmentOptionsDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "rkda_SummaryOfAmortizedCostAndFairValueOfInvestmentSecuritiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "SummaryOfAmortizedCostAndFairValueOfInvestmentSecuritiesTableTextBlock", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Amortized Cost and Fair Value of Investment Securities Portfolio", "label": "Summary Of Amortized Cost And Fair Value Of Investment Securities Table [Text Block]", "documentation": "Summary of amortized cost and fair value of investment securities." } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r1013"] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual", "label": "Title and Position [Axis]" } } }, "auth_ref": ["r1086", "r1155"] },
"srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual", "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r1005"] },
"ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r1012"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r1032"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r1034"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfAmortizedCostAndFairValueOfInvestmentSecuritiesPortfolioD
], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r385", "r399", "r516", "r546", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r699", "r914", "r917", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r930", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1089", "r1090", "r1091", "r1092", "r1141", "r1144", "r1145", "r1146", "r1148", "r1151"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r1035"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r1036"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r1036"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r1034"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r1034"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r1037"] },
"ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r1035"] }, "rkda_TwoThousandFifteenOmnibusEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "TwoThousandFifteenOmnibusEquityIncentivePlanMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "2015 Omnibus Equity Incentive Plan [Member]", "label": "Two Thousand Fifteen Omnibus Equity Incentive Plan [Member]", "documentation": "Two thousand fifteen omnibus equity incentive plan." } } }, "auth_ref": [] }, "rkda_TwoThousandSixStockIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "TwoThousandSixStockIncentivePlanMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "2006 Stock Incentive Plan [Member]", "label": "Two Thousand Six Stock Incentive Plan [Member]", "documentation": "Two thousand six stock incentive plan." } } }, "auth_ref": [] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfAdoptionMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureInvestmentsAndFairValueInstrumentsSummaryOfChangesInFairValueAndOtherAdjustmentsOfAssetsAndLiabilitiesDe
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": ["r156", "r157", "r158", "r159", "r160", "r161", "r208", "r209", "r210", "r212", "r224", "r271", "r272", "r314", "r315", "r316", "r317", "r320", "r321", "r322", "r323", "r324", "r325", "r358", "r359", "r363", "r462", "r463", "r464", "r465", "r466", "r475", "r476", "r477", "r478", "r479", "r480", "r482", "r483", "r484", "r486", "r487", "r488", "r490", "r491", "r492", "r493", "r494", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r514", "r515", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r526", "r527", "r528", "r529", "r547", "r548", "r562", "r563", "r564", "r582", "r584", "r585", "r586", "r587", "r588", "r637", "r638", "r639", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738"] },
"us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCollaborativeArrangementsAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInventoryAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAndEmployeeStockPurchaseProgramAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": {
"terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
"documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } },
"auth_ref": ["r495"] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

```
"USTreasurySecuritiesMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfAmortizedCostAndFairValueOfInvestmentSecuritiesPortfolioD
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsSummaryOfFairValueOfInvestmentsSecuritiesDetail" ], "lang": { "en-us":
{ "role": { "terseLabel": "Treasury Bills [Member]", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities
issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities
- one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r885",
"r901", "r903", "r914", "r1167" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market
Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r1031" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "periodEndLabel": "Unrecognized Tax
Benefits, Ending Balance", "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance", "terseLabel": "Uncertain tax positions", "label": "Unrecognized Tax Benefits",
"documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r453", "r459", "r909" ] }, "us-gaap_VehiclesMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "VehiclesMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Vehicles [Member]", "label": "Vehicles [Member]", "documentation": "Equipment used primarily for road transportation." } } }, "auth_ref": [] },
"rkda_VerdecaLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "VerdecaLLCMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Verdeca LLC [Member]", "label": "Verdeca L L C [Member]", "documentation": "Verdeca LLC." } } }, "auth_ref": [] },
"ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date
Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } }
}, "auth_ref": [ "r1001" ] }, "rkda_WarrantAndRightsOutstandingTerm": { "xbrltype": "stringItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"WarrantAndRightsOutstandingTerm", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Term", "label": "Warrant and Rights Outstanding Term", "documentation": "Warrant and rights outstanding term." } } }, "auth_ref": [] },
"rkda_WarrantExpirationMonthAndYear": { "xbrltype": "gYearMonthItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "WarrantExpirationMonthAndYear",
"presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockParentheticalDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "Warrant expiration month and year", "label": "Warrant Expiration Month and Year", "documentation": "Warrant expiration month
and year." } } }, "auth_ref": [] }, "rkda_WarrantLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "WarrantLiabilities",
"crdr": "credit", "presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureInvestmentsAndFairValueInstrumentsAdditionalInformationDetail" ], "lang":
{ "en-us": { "role": { "terseLabel": "Warrant liabilities", "label": "Warrant Liabilities", "documentation": "Warrant liabilities." } } }, "auth_ref": [] }, "us-gaap_WarrantMember":
{ "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureNetLossPerShareSummaryOfSecuritiesNotIncludedInDilutedPerShareCalculationsDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrants to
Purchase Common Stock [Member]", "terseLabel": "Warrants [Member]", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase
shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r947", "r948", "r951", "r952", "r953", "r954"
] }, "rkda_WarrantModificationIncludedInValuationLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://arcadiabio.com/20240930", "localname":
"WarrantModificationIncludedInValuationLoss", "crdr": "credit", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail",
"http://arcadiabio.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation":
"Warrant modification included in valuation loss.", "label": "Warrant Modification Included In Valuation Loss", "terseLabel": "Warrant modification included in valuation loss",
"verboseLabel": "Warrant and option modifications included in Valuation loss on March 2023 PIPE" } } }, "auth_ref": [] }, "rkda_WarrantsAndOptionsDisclosureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "WarrantsAndOptionsDisclosureTextBlock", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptions" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants and Options", "label": "Warrants And
Options Disclosure [Text Block]", "documentation": "Warrants and options disclosure." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsNoteDisclosureAbstract", "lang": { "en-us": { "role": { "label":
"Warrants and Rights Note Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockDetail" ], "lang": { "en-us": { "role": {
"verboseLabel": "Term", "terseLabel": "Remaining term (in years)", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and
expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event
certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1144",
"r1145", "r1146" ] }, "rkda_WarrantsExpirationDate": { "xbrltype": "dateItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "WarrantsExpirationDate",
"presentation": [ "http://arcadiabio.com/20240930/taxonomy/role/DisclosureWarrantsAndOptionsSummaryOfWarrantsIssuedToPurchaseCommonStockParentheticalDetail" ],
"lang": { "en-us": { "role": { "documentation": "Warrants expiration date.", "label": "Warrants Expiration Date", "terseLabel": "Warrants expiration date" } } }, "auth_ref": [] },
"rkda_WarrantsExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://arcadiabio.com/20240930", "localname": "WarrantsExpirationPeriod", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/Role_DisclosureEquityFinancingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants
expiration period", "label": "Warrants Expiration Period", "documentation": "Warrants expiration period." } } }, "auth_ref": [] }, "us-
gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": {
"totalLabel": "Weighted average number of common shares outstanding - diluted", "label": "Weighted average shares - Diluted", "terseLabel": "Weighted average shares -
Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined
based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r228", "r234" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": {
"label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted-average number of shares used in per share calculations:" } } },
"auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://arcadiabio.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": {
"verboseLabel": "Weighted average number of common shares outstanding", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "label": "Weighted
average shares - Basic", "terseLabel": "Weighted average shares - Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable
shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been
outstanding to the total time in that period." } } }, "auth_ref": [ "r227", "r234" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and
Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r999" ] } } } },
"std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6", "SubTopic": "10",
"Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-6" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "25", "Paragraph": "7", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479405/805-10-25-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r3": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" },
"r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "SubTopic": "10", "Topic": "360",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-11" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "1D", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1D" }, "r8": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10",
"Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-
28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic":
"360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-
1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)",
"SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r14": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r16": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10",
"Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r19": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r22": { "role":
```

"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-3" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "55", "Paragraph": "63", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-63" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1A" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1C" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting

Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482309/360-10-15-4" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-9" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 5.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479836/810-10-S99-5" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "323", "Publisher": "FASB", "URI": "https://asc.fasb.org/323/tableOfContent" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r159": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r222": { "role":
```

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":
```

```
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
```

"Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher":

```
"FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r419":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-
10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r423": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r424": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r425": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r426": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r427": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r428": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r429": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r430": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r431": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r432": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r433": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r434": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r435": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r436": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r437": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r438": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r439": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r440": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r441": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r442": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r443": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r444": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r445": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r446": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r447": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r448": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r451": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting
Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r455": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r458": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-
50-17" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-
10-65-8" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r465": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477349/740-270-45-3" }, "r472": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name":
"Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r475": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-
65-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r479": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r480": { "role":
```

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-
50-3" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r545": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-
65-13" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r549": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r552": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-
45-20" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r556": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r558":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-
30-45-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479832/842-10-65-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-
10-65-5" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r564": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8",
"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r565": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/842-20/tableOfContent" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" },
"r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph":
"1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r568": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r571": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r572": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-
50-4" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r576": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r577": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r578": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r579": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r580": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-
65-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r584": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-
10-65-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r588": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r589": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards
Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-
50-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r595": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r598": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting
Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-
50-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r603": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r604": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r605": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r606": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r607": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r608": { "role":
```

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name":

"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-
45-3" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-
50-2" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r832": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-
45-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r836":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r837": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r838": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r839": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r840": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r841": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r842": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r843": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r844": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r845": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r846": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D",
"Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D" }, "r847": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r848": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column E)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r849": { "role":
```

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r878": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "SubTopic": "320", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r880": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r881": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r882": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r883": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r884": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r885": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r886": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r887": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r888": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r889": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r890": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r891": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r892": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r893": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r894": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r895": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r896": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r897": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r898": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r899": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r900": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r901": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r902": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r903": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r904": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r905": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r906": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r907": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r908": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r909": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r910": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r911": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r912": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r913": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
```

```
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r914": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r915": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r916": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r917": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r918": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r919": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r920": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r921": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r922": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r923": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r924": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r925": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r926": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r927": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r928": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3" }, "r929": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r930": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r931": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r932": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r933": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r934": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r935": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r936": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r937": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r938": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r939": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r940": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r941": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r942": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r943": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r944": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r945": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r946": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r947": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r948": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r949": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r950": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r951": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r952": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r953": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r954": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r955": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r956": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r957": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r966": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r967": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r968": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r969": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r970": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r971": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r972": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r973": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r974": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r975": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r976": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r977": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r978": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r979": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r980": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r981": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r982": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r983": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r984": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r985": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r986": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r987": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r988": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r989": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r990": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r991": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r992": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r993": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r994": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r995": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
```

```
"Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r996": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r997": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r998": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r999": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r1000": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r1001": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r1002": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r1003": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r1004": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r1005": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r1006": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r1007": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r1008": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r1009": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r1010": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r1011": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r1012": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r1013": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1014": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1015": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1016": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1017": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1018": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1019": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1020": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1021": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1022": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1023": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1024": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1025": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1026": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1027": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1028": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1029": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1030": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1031": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1032": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1033": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1034": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1035": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1036": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1037": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1038": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1039": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1040": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r1041": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r1042": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r1043": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1044": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r1045": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1046": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1047": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1074": { "role":
```

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/310-10/tableOfContent" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1131": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1132": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1133": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",

"Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1156": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1157": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1158": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1159": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1160": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1161": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1162": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1163": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1164": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1165": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1166": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r1167": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r1168": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1169": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1170": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1171": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1172": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1173": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1174": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1179": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1180": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1181": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1186": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1194": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B",

*"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1197": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r1198": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1199": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1200": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1201": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1202": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1203": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r1204": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1205": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } }
ZIP 77 0000950170-24-125613-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-125613-xbrl.zip M4$L#!!0 ("(;%GN,T&$4UL" "28)P 1 66>BR/NE=G?-,E31FQFJ8'#M/C.?]HK,C 2M MLB4?20;\[R="QF ;"@26K)2A5R_*MEZ]M[@]#PX>/"__+?__Y/_WM/P/<^^71X]_O_4ZO[QW4Y>05 M_3)9U*/9XG1.]_[+X6__]=[CZ=%D2O?^IX/G3^[]JNGQS1=WH-[+Y?+DY_N MWW_]^O6/K4^FBIG1Z9*OM?BQSH[OWP-X>_*'E+GUM=G(VG[QXN;SW7^L_O2??XFM/IW1T1&?W'DVF M.*T3/+IW>'5_\:W67^\=W!T=. ^Y?&UQ[SDM:/Z*VH_G)WVVY/?![V2Z^/L/ MEV[!M?UQ-G\Q7^><[[^18WXX/^BG-V5^U";OC15?5T<:I<+]\P^O'+K\Z*'^ M_-#EY4,G5V[@]W\M'V/K_`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}UV9ECA_!SQGM;E["KM#BX)ZV'"-7TTJ M\9^>T7R50V?#L#WXO"WR44,T'JH++'NM=4;$.H,JNGG3; K-[BOY#NEDN?JR M43I_2UY.14RE=E")%+C$-,72OB&O]MF#.4T*DV"'F^\K;&11UB=7OR=]Y>_ M?1\9%<([KT%$()9=PTYMJ3):C$E9 LUF@RNUP88I+2U^QMM MUXK4<(G+&_BR[^FY>X?W2NQ-267=1@A*%6-VBGU8J6R18DC4VH'W606KLR6B MT0BZ?NQM2K=IE;84'>U&]RP5WEJ:A;S7D)*N8+/1 4VLGH:-H]^]7W_AI-|- MN-%#ZZQE&?G[H9DJ\LD[9AN(A2CL%ZVZ"X]*&5CRU MZH/->5BUO0G_0.\+L,U6.9BU71I<#2,@:6(*&AG28J^Y1=O2L)(W6O9Q.PAH MO6ZA,2FT"5$R6W!N#Q8+6EYR;"\,^??#/^8K=_OL?27?_O!)B"Y[!UD*HU=- M'<7&!!6]:]T7K<>UH3<.<=!-5.0,RWGQW11 M'U-0M8./U;$(RB'!O[1<]2>2PCF@+K&P M24Q*6A^EPU:FEP% K>>22LC'#EDT^F_X45:<;2]A0.D).UF%",\^S/\.\I/M)\O3N62!'TW>R$_[@TE#9Z@B[4#.)W!%&8G;&="MND)M1%N&%;(U,_;>RM.F MG)1OI 3S1APJM0,;4R-1H9=0HZZ27T!5H4AO>>U)E9)DL%(9E4/74B/G!F'6MEZ]QI4+.N]EH_N[@O=$ED)&QE26L3.X7!H4!E+0L#MLRNN0AL7,PW3_7B*- MV2!IUIKS,B9IAJH&N>LAJD2L9DV#*,W"+BOIX=]V>RK9[(N]02-; 4)23$6;Q8PYQB<M;HS[ABV>^(8; -9M]%TK8, 0I)U6=D$O*E6OO+RWG][CH&^>)%.6.S@V M<9#($- ^(CK$K0,N1N7^=4J'/A$ZV)0.UF%",\^S/\.UI

U&WE,CH45MJ"6R,309D-G:0BX(>L6DLFDK9^H[8#9C7W=≈,?WT/VR]2T, B M>-L#,GC&]1^*.X!I)_U]9VF]Y-MXWID&($IY."+]/':V/QSC?*

*M;V"%T=>293^F9VR06%9A]3IK:*T]D:$$N2K^Q_96DF6?U0UK/V]2D+B;2N0= MX%NKR%)4!GH7"T%L>E)GWT4GYWU3QI@^;!W!FG"WV=3>>;Y[.B(D>O%D-=] MZ?JS.L72=0$=.CN2.B09$*K 6NP4+>8\[E*KT4IQKLN;6U_>PJ;DS2;E@H[@ M;3/@7 S_7@B[ESZY@CI8],/6V%W+D3V97<[6O6U!6U?BZ$\!MN>8+;$/2+(1*K7$U"O)(:9J!+68M;2CH3!W6 MC]B#B1DC4-C;T$VU4*MFE*MME"1,!I]*+R7WZ..P78'?2]4G?A5(7FDO=A'ULQ=M9TME:;KD0=M]BJ.U8'W(V= MJ4U5V=A@4S61SRC+I5VN!9(IQ)Y Q-Y49%;?.OK^XEB.WMC#!X*-6S5)R9SC;0L0U,2"9K(JV&*U/\PH#B6F1E4+*,*3=@Y\)"EQQ@(&1='S-B*

MTZ7@WL:0MAX#W$YMA(VU5NV[*+X&3LZ=K48(03F=0[$Q#AN)'ZHT:/!BG+6? MX]L8TVU3L\E; ZU) JI9!?@]#V>74'+B

M3I,$<9J'G&NV$))5';W75;>L1RIW%L%]E8TH5=Y[MEJX=^%TX-Z1[TUY'X?M MW98N@&M-/>)DXW#R9H4:'T^K7,J5J/OIWO DX[EFBH7>FA3\APIH@PS/\=99 M&?F9Q^M>W-C#EV]TBPI8*-EQ<46F4I<"C0IJE;4O..R6LJ&,RI?K[V?S2:5_ MSHYPN;) MVG=;G_ERCC27ETIB<7;!R/C=XC].WNXF@]6I3+=Z6%)9@^,I)-C_V MK*

3V[ENB']DJH0IZ'Z+UW[MU/\3GFXLK$;9:6=$X9+_$;4NRPC" (1_)AUC" MN+/S/A?]^X0UO]5A_9NTY-2RC'Z';)AGRHI*)*%H]1=ME1#4<-&9H>"KONS*

M566CPDZYI83B^"APQ7C(G?]QK03F'5A5G&3#E#&D "5[MJRI&4_NPY?3?=V>|O24Q-4_[@3SFB_,PW?O;.3UL&O%V=HC9G M>YS.;/.S9JAOZKF/ED/-4%-#7ZQ!'"]\][

IWA8YO#7 ;+L_693-\UDJGCFW MRTILU@.DZ!GCH+7>IYSCN).[!M1)>lO-.$ XW!EI-HT.HS!J<(F!=VG> V$, M#57T*@Z;HDVM7OCZ1"+1F+SSD*E7B"RI-*

;1B@Q^N!V)O8@(C M"&&QSI10H986SOV7I-%()KJEKG6-85AMO/'.VIO:R(WU.WLF|!$Q4&TD67'O M(+%_;ZYTK+7)OGA8.<=MY$[F #X>3-BGA;WM7P7CZUE\TN9C-

6L2D5C:C)5(,,2;2L,%&!#S(_D50WV]\N MO<]:Y&+&+S M$4H0,485]M"#\K"]=ZBVJG4:F7;N(6T"7@>CE2\E D7?&5Z;##DSVM8I45A$\4[-SN M1,3-T%,(HW;#^^;]>7.7-7L M-R>#[6JDF07!!.O&891-14P7:4H&5?]PS5Y?Q'2%26AE#O#*,,N[>VMZI8W _MFRG<#1YK<06A&"E"%141M855O?6C;>Z2G6K0&^UP>NB6^MNAKT\0VME*B2M MB!TEAG*9:@?E72PA-*

&/&W2$\[#C371C_FXF<@]09!"2*IZ5 ,$ M^G?4(66#D+LI,9-WQ0Y;)#UPO&T(RC;;B0&E"]Z+N";(S1?PNE>7..N0QBT? MV4-*

*\N2,JL^M7I*T(FXR*JE7P)%SEV@S^>R]9Z?)]CXLWKA$MX/%@I:7 M:/9ND"D[O6=,NS]I*$I\Q1\:"I!.4G@D8%.KEMK*X]TTW;QVT MC>6(QAOEL(WA(S?*

C4"45FYOBT%1+2;!,@B$;0I*R!*H\Z8C U@:=+R+77;(^ M7^03KWU37SXB6FKDZI+;'S3?[F:,36K9XG6MK&530B4EJ7H]T*O!YJ**KJJAQ; MQ]%X^-*

*N>:!9*T+:QKD$O2[!U9XH9C&!2;SH6WW(=+OTV"L5VE$HK3!GG.NBJ M'5/,(B!*Z[=G+$,F1N6&M1/?\.3&VP]\[(@IJRHJD85"),U@#(Q2S 5";BYZ MA4WY8>M5OV3*SZ4&]_FE#_?&.;VN5]F$A#ZRQG!HH"C^20=E4K-=6OI&)=,G M)&/%CS=S0QZLSEJS!"[9P)6]R%[Y E&;DC>>E?I3@ 9 :/5\EZ5ITW-9 FDL!.;*HLHY;D^0^ZI09!1+=%8+'98R[5"7,[LFKD*

MDNHF0'2MR-BRPL25=N::@ _%V5B')>[G&VC.)3;[FVXG6T.T1P@ID"N\N> 0=@V*, MD@)D3(X= A[&LPC=&W8TQ%U=2+1]YVF;=V%M@BDJ 3XHMD@T16K"Z*]N,MI-F MM[ZG449.H\1-*

85NE++10M-)]F(S\$9=$7]J.OONH?*O#=E^/.UW/;#!'T O3 M"#N<#T"@UJ%@,M M:ANT4GU<\[/ Z$WF<[IE%+6"DSV#5QV),J, C<4;7: MLAUO3,5G&]N>T NL9 _D\G.V4]'QY^+*

[&RU? MSBZMH?CPKT37[NZ ;<'DA%GIQ>Q+;_&&>$)G4(EQPAIXXQIA-\$3447#T-]! MK$5F95"#W&3%9Z'@T$?,>=ADQMXEO3\[\0%=&?&F^L27OOUO(ST>5>J:"H(J

M+H&S579RBS:C$IY9\,JQ3A^7V<;')[.V417^GXG0B1'DTDN6]6NSN"]-U8E M/UPG\5X0:%.![VJA[.+ M-H?[&WMMW@9PW: 31Z%"3]IDK8MM?3C/X"^?Y:P(_'C;3L_1S5:'96S):EE4*

MR2K/B$*QY"EKH?A:P6OE>C&]IG$K1P<,CQVNM77]P?>MZVLKJ!UL78\NURZ; MXFI,$5QBO)V<:!B+.2#227NK35:8^O1W30Z#]6N&,$;Z<]2(4]WLHZ]MQL*

M+]&F88M?]J25=TL&RA6&YA)"1,]HX?^RJZ;-;1U)VNCG]_Z$YKIN78$DZY] MH=P=06OQ.%Y;5(OR],S]HJA5/&.08&.1Q/[UM^H 7%&*)'@ @>E<- D<);:*

M\LDGL[(R<0ZO2(P$*))'A4/VF]Z>,6]4OBWZ(B7S%$6% =O' (6B 7MB .# MO5(V38E=7UOJO/SYODNS,JIOZ,/[OOE]C@_Z;LD^4 1@&$R7MI8Q2PK!0Y(< M(!2'Q+V%*

8O3O"%I=S6DQL:(JBYRU&UN8.CPHD M.)]8;G1IDF0.>\,<08O8ICF2!L>US2+[?CA(71V2Y3(W^:0!4)KQ- =1?SN:W MXWX+9A2.!SU_<'(Z"Q908Q0F[.D$<&6-

*;MON29YLG64I@ZB"R@Q*Q$H7]M9 M6]M=Y\=QVIX?UB[\UZ"?]+17WWMP:I%16?J9[_4QJ[4.!(F8U'U.!ASUR:PF MTH/QA"+K;;+HUI:N;7RUY^?)O"FUXU+G*

*M_1)H8N(T_DG"#P5!E%3:1KN,FV M+M6>G^=D;"Y#JH5"('3>H4E4/&D=A@ SCH)'5]DU+E^Y?K1M'6;4H*B0HZ"\ MH,"RZT6"+U&O-?*

2<2.6G_UV2]G#AWKTY]NDK\ #5CZD.>QV!-WZD V3= L1 MR91Q.>>SSHF<"'#$&=O&2/1!^4Q7[M\$<YX6T1=/BZ=5D^BOODW5$/$M#J8'"% \6 M$%)&:\N"QVO+]?

*MJ.H:5**1EC,4L4L+)%>=Y\E$-1Y+P#@]S*F@:GW/^'>Q M5L(S,7TGD506 Y?< E,T@-6)9<1$,&S@7K/U*[^]A*(V#WKGAWR0;?]B ,?O MYEM],KDO*OS!;_K1AW[^*PQ]*

<&;I9S;2W8\;_Z^0[XWIUKEI%]/Y^]/3Y=[U!&8Z.CLV55S7-#5W\<^;NSQ^^#OW!2=V_[;&S>|=/U MUG]_-;/OF-T[W_QK>ST';V>>^@#1_^6I[T?#CX/ MS]!$'_*

M@CH)IK<]H" 3A,%OR"PAW9YW7^9B&$#.?>:=I<Q\%Z^N/*0T -'V$%2V4,8 M#T[W\"X_'5=^,+&]\/+4^$Q%IU^?TQOPMFGX7

MS4G=.]O[F!K5+T+7ZL/@Z0DSB^T@_%X<)*NS>(.IE=_[N_U0ASG1HU.3?^\ M.5^/DSQ!^L2%O=-A@*]#R\)7>]+;WJ:^W'OWNQ'D.#+OW\CO_X-RS0 MRY]_RJ[*HW!Z?*

0R6T+>\),/P9N_#CP=OC]K]=Z^K-_]ZC_WW_WZIGIU M^/OO!T='!X?O-GUDR((C[X_]H_||>/?KQ|-W.]7K5Q5!G.F[QF+6IRRZ>PS] MY0(F9IUL#RE$NG6&3><#V,#3:-"K?74^1K-

[ALUXY/:<.\;W Q8,<#<^[X- MD:ZWAQ]^K\Z[?]4CVWAVZDG2=_U!OR$VM6NTZMM/C"GNE92@@|YUK)@ [8,% M:O.^7XB::QIBFC)#R%FIA\10XA(#<;Q? C"VIRM)T"03BG+J4:

(O:CZ)O-X M'^]IUP,WR6PW.^+78T Q@K]?+=KP_*W9Y=-5"3ST<3F:KW! MV Z^+;@:'C8:=R]]+9EX>0^,M AVBS;T__S]C T/']I\^.U_]@]OWA]^^%B] M_^/#T1_[[SY6'P^KQ-*

*P^)GI685H=?[@P_\'_6!V^K3[^YYO["JF[('3[KS[F MK[&F;//U\:(C^G8PK,;'H?KG^2]MIIZ7*F1/T'V:>D'QHPCI)#H';\^D3,$EO.;F MHM9L1='.D]8BF! 851:BH*

*Z8IP2T,@0D,0X9(RVBI*V1>%N/G.G]3QKBM^F3 MT7H,7'D:KN@\6AQ^6PPY:IE//EPHKB51.$3#!)WY '8:TRG5.5>XL MPB):%%HS)?*&6>.!6R9!;'DE-(R!;0)C^/AA]W10<,+GIDRK-*

+ N6HC:+T< M7$\E0^,+D3QG0W$X.+E5 R_2TJ;[/KC!-&!C+V^Z#7MU/[31A^]6?VLDC]5X ML$ZM6:>Y2&?B"LAT!V1R'H1ZE#?MJ[=U+U1):2:*O[B]3>=/L^.?.3/NR'N.,$

8I]:+KZAW=DIV+E]7V\D7D MODW>,T1""ZJC=0:H2]8NTS@72A$,G'1&&B8HU]H=D?@0/C>GL?K<',?7JEC< MV_FI!G%_Z(RO3?5+/1BY.O1=&.U4!WVWVYJUVPV8_N'--

^/&59ZX-A"KRZFL MS@Z,@TNQVGYJNY7]7A4O3INW&=W>L_+ELM:0,ISDYRQL4GCW[(FS&0\.) ^Y MW)2T-G++|^70,V>#R3@[_EOP+Z>OP@CMIGF;W>!R&-GI*.R-PJE)-*

D6X/L/- MLU_D]Z<&#,_? J4>U=,C/'OG]\\N2E?YB\%I7L;>=WW+ Y(;-NMD&N%O+U _MM/]/_\T'WYLU2PRJ9GP6RF?:"HRV&$P?^XU/R% <,14WVS4ES "JL#M-

NUD4,:"8$"$)%4$G.!Y)/V% *.T?'@2"X(W8HVRB9W2A8XQ0@)IE$--%P_^1MCNG4?C3?#F:QP[-3X[T1\:OF3&% 7&). MU2-F[3L2+Y]3X.7:$9@[64DCM]5@6 UR0N3KYKA%HBE7!

[WE?N[M1"16V]GZ*F U?1Y^-OWZ7\W?/[8)"QNT YV/^P>[5:S0K[#G^WPI[]=E WJ MW6#WUM%Y3H6;AG4=(#E:C;TT.3$^2I",@P2="V IYCD5Q#!F43N0O,],*=? MG/[OM[H?*

*\!*715(U]#I*B# \]WXS ?M4Z;*:<7V7^O8I,#$HJ]U-#,?G0NA* M@"6< T4&]X UP=HN:PK($[?@:)+NK@CF#U"(;#0\/>\QR:G2@13^4OZN=&) MG@@,VN13M-*

*0Q3*CT03UYD /:1+Q*OQX./PZ^+I5,FF3,C-9X_6L;6#@'?U_K_ZM#'*EC=5DA/RS*1Z '=0ST8= MU.;0MMGT9E?B^V$2P_K4]*HWWX*;Y"-7U6%, ["V,MI74IO5>Y07_7=[:_I_]*

M8=L6='7I>?Z/?U,$RY>C:AQZX?1XT]5O['S=ZKZ/"5$99*D)4#R8:_Z85DA M@U$XK1$8+Q.!XX&]@:!YQ8YHIE4\BECD^=\IS@L/<^K^IUVD76,F<^)7A= M-Y$[M-]S-

*8:4[7)*5W:@Y)[NZDW>WGK4"9)%>WI90ZD:-NHJ#(,O3B?#T23O MF(X'$'&>W]\9[9?=OW?7_IB_4UA\H/],,:@'&>W]\9[9?=OW?7_IB_^=O>/L@7NN?<]WS%"=-M&*

MR)5\!UOB&IJ'L1V^N>.NQ,B=^F2L&2EH+%T<_CZ&KDK_)1X$YTW(!5/A@/R:?P(E8 =)H%C MXC##3S4<9N3C#!/; %)[:VQ:LFO!G^8RI7(])C<8C3Q'#)W/%=$(F"]E6!$

*MH":P**)A3YW<&49.(;*]F?WP?U_OEWFI8UZ-8M(K9L'8-)N,.0LF2 %1>&X(M8E2*)|>,GPOMFQER-P&ROR]EQI,L],\;!;_VWQ|\ MW/^M^GW_P_]|\[%%A^?&VD6=-*

(ESWD&78W7L6>6.@_NS.LDI-KX>AR9P)YN_MP\N8XA_PCJ6O&56QB7#V?1ZZ-3H>) #F\ /P8V/S?AFV[^,ZZW,39S>/.O#CSN5Z?Q!S+MHTWBG+ZW_YMZ

MD]O+DTWY5;,GM/42FH:T332C,:51I4W9Z/=N\ZS/7S&]D]Q*+C6%L05CM@ M)%+0*GA A+"(A;=&/=G'.=WJ>S49#E,'I\=]LW(;F_'"Q^&?M$C)RQCI_Q) M37K::<56\Z*

\0]^KZMW@V4> ;4X6I\5"=(;NA%HG]7B<<"[T$GH-[_U,^'IG M54CD[ZQIBF[DW-=?0O7:C,WT@-!-!+]\QE7_Z(=)NI(A/CMK,NE-0_F,X&/U M0U::\F5%*-F=73$^<D>IR>8TGSE9-

*IY/&WP!TV'CM,F:-[%Y\=;41U;<\[T%8B:G-Z7Y;[,NGC#ML,*Z)A)[2U@I^=310+]71S M;I9+*1B(14+:3,(8/>8<)GD+9CDIYH[=[@YUO22B1$^C8Y#&'^G@L[2;9U?*

*MD@VICI[&7#5RBE%2C))BE!2V7KI9C))BE!2CI/#53>"K99*W8)*79)2,+G8[M/@U.\I';PZ8Y3:&L7+0D)R,8AN-T6RY8^-M@5 R78K@\9H#(*

*M&BOYS>:YRZ/P+:#_)G>_PUW;IG=B,ZOS'[MI++LRHBLB8HL)M)&8TDQ?\O< MKJ75VZ1T.EX,J[?)KG4\Z*6'C9IS>?)E]>:?DWI\5LS=8NX^8H#HL^ORLD]7 MNKEFW2S[=&6?*

*KM@GF\'ANK>%4R9Y"R9Y^1:+,Z/C3W%M+]'#,)[GC1QI[@:IFO M*Q;*8P-(:LV+Q9*Z>::=:-8*,5"*1;*9G]3<5V[!'7,LE:,,E/M5#Z@%W*B8?1H/ M[LOGL H+Y5UN2Z[P]8BT#L5,*6;*(P:*

((M+V9*Z>::=:.8*<5,*6;*9A"W MPF"7D*>.E#QUG5D7U_/4D4_IT>;S;+/%UR,W&8V2-?(I?=H[&]6CU>R]_'[1 MB%D8V*AZ?=&6YD34_]P]>1/7[1]AM"TJG*^YD,837HWSU,5*

Z@80(_)^*'? MG2T4"ZAT<\VZ62R@8@$5"V@S"%YANDNP@&BQ@#IS+IY:0/33/R79[^U@,IY^-|,_PICZ4(_^ M+/9-L6]>DQA"/3L7/9-Z>::=:/8-\6^*?:-9M"WPF.78-*

*^P8M]T9EU_W0Z'+C@LQFQHO,TS6L;<^;]Q:N+O5+LE6*O/!^19X7(;SRU+41^_MXXC\:DA-TZ*'5#1_;X;CZN"@:LM2#$*[B5_%_A)%\+/=@>%[FO_I#T\|#1- M]I>Z_C08?*

JHOZ]>@@,>CH_#L#]X?&EA?X7]/8;]E6BU%4=?-W_O!)?]6_Y15,G]?2E MQ4XI=D@AQ[!+]DJQ4X]=4NR4;>&CK=HI^\50ZO3GIVC< M>#!)33/!35,+XP^A::TW]=1<)-

*A/5Z%R?+'E4941[D1.3G3M,1? M=31M1QVF1P3^&(?|Y6P3IE@XQ<(I%DZA_]6;Q<(I%DZQ<([%LS5,MDT+I^1M MZLZZN)FWR8=H$DC5HR48J04(Z6[I'U+NEF,E&*D%"-E,SA8(:-*

+,%)$,5(ZLRZN M&RGB4_AV7-MZO)=E#>S=Q6KI%@ECQ@@BM98@V\VB5T>/V\!ITOW2_=+]S??*

*M@,VD1NW*B"Q)C5ZXAOA=K]$U*R!SP8M'Z5,S7E5PT=';IK^_V/_[QXNB1RYWS|I7(],QK]|<6]^1R@/_#A M_)*

*[4KOSUK%G_@CI)X[<]H"]C+WP#7P^#;Z0TS<+DI/_2UZ/3GCG;R]^^/#4^ MY[>^Z/0NKZX8N)>]!9YNCGG](4S'[F^3]^4#*S-M?]C(\P M&IOA>,],QH.7U[|(HSG|N)G>];*

(Q,75IS_2^FK/1RQ<_72R$V9//YZY9VBBTW3\JBE90T8[S&_W(A%;FQZ?6[1,B_W&Q0>X-1 MU?ZO+V;9[E/C4U-&P>??1H->[?'SS M>X5W_|^KPW>OW[P[>O.Z2K|='?YV\/I\M-*

>@D?L?4[O>'KUS>7_?]8/^WZNAC M^N#W-^|^/MW UF=!N<:DZ$SOC;5+_&?.Y.K0=V&T4QWTW>[CQT0\?4B:E7_'MDK>FEY9|^#0Z#N%

[;MM5CMZK\Z96K\Z;ND;K/8U:]95+78BQ^M^*-O)CZ]S/^X08/PL#Y/+\U/WJQ'Z;7N[E$XZ%?CX\%D9/H^R7GXYI+IN!H=_MFV&HDI29!<:F5<7_7.-2W>AW8T3<(&R-

*[F\8V8PM=I)?SZU/G>N9T%/9&X=0D0SE<-Z6:1[^XZ9+X4H]J6_?]\=G> M^?VW>.VG;Q-R5__E*HN;=7!*XWZZXZY$<<0"=RUP"]GE!%WYM\@S%NE?A[KW M':^52M)@C?OS\WPZ7N8B5]L_K6Z)_1=I[`]PK:0+>U88ECZZ;L M_P>DK2,LK68K,.MVOM:FNV45=W):.]7=ORN\59N]SZWP[G0]3X;#]%ME&CVW M5R!B:V1FRR"BK.*

*(MG=9.=7=QR^Z!.NUJ1$+SQ%L;?K\ 7=W':)YS]<%H>>>$, M[2E&,SIN*L&X_$LN5O/%]-)7]]J""P[8!B+.+8_L#]:KN]<7P%W] /<6YW0] MX.8)"__G^EN:QO[;H6D"]YHHB;>?G$B*

M:I[R;?PAQ_B^^D2-")Y8'M%[!8P+!X:",)RRBAFB&G]HNJ;D]3@R0@^&W.Z ME\5NO^_S_]Y%%-^O7T+7]\^N/H=5)X:1[24^B+ MR@=7GYC>Z*\O(/TUS='QUQ?UM_%>?W("?*

M"$#NG_MLG+ MO3U!+LA5D*L;R"45090$! X[BPP!U3"11C11"'3B%S$[F$B($:$P%1H8&9 M=-1Z1YE;4":;TN(24[D$CNI\5N.7(O[? H5?IQ<'1T/AF-(@'!2U?TO830^*

*M*3RX[^)5E,A5)8(C?H\6U,[0YH;&E53=>J:1;R?*!R(QR/ MCL8L'&N-NELXUM, -@A&'0T)8#5-'$L8"EI% 4@]9+PA%%/1"L#.H&6_[YM4*

MXY<0,WH7QNW"C%)DRRE7@:MMG\J.PI55BF).#3@5#!D"=AH;?1!N-2*11/G M7%8+L:,.5PA5'V[Y6W8|5F4A9@]'?SP8UNG]__%OBF#RLG+3U5ST2*=EK.B1*

*M]W[$*%>9(@@XQ008$P&,4XGV4ART(5XIVPKM9>WLZ0UVF*WE&^YNBBHM.U3 MV5%4$)$$]T#]DAHOM1(,$9B\-((IRF2(NHVV.U24$EN.2]5;8Z5;7.TQ[[J*

*MX]#SS;,%**W7HBG0Z2'+W;P*TTR>Y0YID7_"O,!SD^6\L MTBU7) 6VMGTJ.PI;'BMNHC5@K,YGL@#?SD*7MP- &YC^E0"IUG<#\8XBV^Y**6"U[5/94; BV'HEG06E \O*

MHT$9Y,%P]1/!E9';5ACPDL"IV.K%Z?MRNBN->SUN;SZSY>I2_KON3D-CN;9A6![Z,W?UU,/#_. ZF M^'P7EL'[ZT|LA)0N.-F/]K(1)66DHF<"OZ1)!+ @F6@(K> 3(S!.&UL1.W% M4-*

S8>CSHN]XDUT-]?46^#\ %NUU"+9>8'^4A)4BZ+#T%@M4=A\JG16$8^W! MB$3$6;0(M#$>)'-&>66D1[2]N(UGA$[\@XDN:+E>7F_2DD5 -M$B^#@8FUYQ M<&^3N5U\1M?*

R4V@1K>,:'#8R'XDQH&5TH)6/R MOD&PE1^$R7-D8[4A2@KNI2 3V]%RVY/D+-VO MO=YP]Z18C.R*'I\U.1BYBLQISIG9)!4L*]#3,E-4P#5RRGE GL>$WX)"POQ$ M-

&WDP'DDU@\'6^E?LRVO+WOF?YXO^ ??G(M<> ^>W>4D]44!]NZ>RHR'EC8B, M80+!,YL/"T>P//%4;KB@,E!]9$M1%'TL']65N96W$REZZXW6]D>\)LO$A#U. MJ)B,PM2/6I1*

IT6E('K<<+,T9Q*R!(<,NM$H"7%@)F.T3!O FTEVF&V,=?_M_%LPH] (W6'\8Q0:)T9;%0ZW/E]F@:EMG\].PA2F3A&-)&!B&#!L]@0(@1N M-$]4U"(IV^"]IX*

*IJ8N#M3A8VTO3F]91R>^?#6)35,*U_Z,8RLX Q%<=E\$ M]ID+-R2+K0U8)-!9ONQ";]@]VV=\&I+DY2QZ; N6Z*##8Q*B4 H/OB M4A3 M83MUA&'I ")&*

6,H5:CVHG(>7T"Bs#NV0TW-1FT:#O0OC-]FYR+R M$="O=;_W\"/-=(EG'+]\B L>=68]X\'7&B&C68)CR)*A#2&Q"MC!.,P,CAZ M(N7<-L]BA+3@47&4K@$'O3,5;O&6;HGL% 5P+

*<$D8I))12%XF5/L6 /:<@0T M"$21)YSI5KRE=R>8;-U%07>TV'8G1<&K;9_*CN*5PYY$&BTXXR0PK)H*3P0*

*MS8RQ.CBG6R&LR\.KLMU3/*IMR4B3I^X*=2T'_K=!7HI&N*H13*2"6"= N2B M*>6S"T.!L\Y3HA7'LI6,ME=R0K:]R;8ENN D_;/I4=A2<<<44@\TX)!W@(C M)$$-*

\02P=$HH+3#SK51P>!H\%00]/M4G^%1O\,^2B+9D5RS9%9>E4;RC6$EC M0#M,$WF-&"RR#(R3FE;12MO! \(]MB.[1XI9Z1SN16+%A9L+)@Y5WQ5IC+ MH#

*!)G@$IKA),,DI4(Z<0T8QI.:< XNP[Y5CY2V[7FR9";HZ Y?%V?RTU++% MP]RF()%=DB7)#R8Y&.495='U='7'76/S[TG32[0/14:U$*LZH"$R!*

*M",0D5/,.DMUO05]EJ()OR;O8/1+*T-1D0<)RN HBD=C&++6B# M1-(CW IA]+A[TZG(Q'8]//*0*?OBAW]0<.'93N5.E1IR$U_TOHG940@$Z?V"TOF5Q[*1*

M&.8E1$0L,)= ^:(HI>$&H0='99^H(!O;XL%[^'\3VYXWH6#/MD]E1[&' M>VF$]@2XR64/#/%@D!;@/=$",R8]9RTD1H;()Q987QRLLSG8][[.'\ST]E-3

*M^]3TRIG3>FQZ12=T6L2*3KB6)0%9$;2-H!!1.4M"-I9%0A?KI2?*>*WGG(B+ M|-%+<7N?I.V@_VHJ:U=415M'N!3;T5AON1XI>+7M4]E1O H.6RNE@(@1!R9E M+FJ;V"Q7T6/!=*

(@5C8]5HI7'!?>6P(+5L1[G9N<3'IYT[ID:3"NJ#T[27<>A M/Z] A*KNI[]#T2F=%>B4ZYMQ2;%0:A50*++R5R< ,/3#XHELND+HG$(K)TO MB%Z3R>55<$[:.3NM\%H]"Z,#^-*

\ZVMK&%XVW.&%>#:]JGI' 99!47W -! MB0>SF##+*I51*79Q*.](QQ$$#2'2B"P6%HP@6HOB?-,MT++/X2QJ?O!OS'# M?MW /+]"[:^G4/!PA39*PYU^N\ G(]F.PDO,/+ZFN1"N+Y&*

[5L./!7D+\A;D M?4;DY4XYQW+(;,)+8$+F:I:* G514;<&=A?DO0-Y M5^]:+X7>IT?^;CT>7_1BIZW]XMNZ]H.\)9HAFZN\QWR*@X]D2I %+]L U$1O#

M52N'4;]HWC3B%EK]I=HHKKO<#3=D]E1^],HS&5<0-Q-I'C @XNEBVI"?"SS\=!4//UVBX?!:1B:\7H,X*L+]'YU%;V/*

M+EI;#>"41[+:&YUV(Q=$O2IC^M:NI0]9ITIYEHE?B['YX8]SG?SC!@W"P_H\ MO30 >2_GBJS=W:-PT$\$93 9I>61L"!*U8WA=K9W?0]M#OOF=8SO*]+_@_W7$?WB4+W+3*

+6A7$H(N_RWRC-]9^J>WM5B10,YX3WZSOZ<^FZP MWFT8I]2I[+>@ZBW(K9;*>)?@8GV,^]BMS]VL>+6XIWCUHZ(BGFW6%^%V=VI; M'@1]#[']Y/?*

*O^/]C>)A_OK9=X66RX/B0=8AY$L\E/DYVGR\Z[N% _%YXAI;6*FW M'W3H5%M=:-X4Y!]54&@RQR/#8P];6LX%MT8?C!&/0I,/X4OH3\)HKTV? M],8<";AP2I-[G-*

+K$=Z^LJV&+>MN6<6=G-8MZVY9Q9V#W!IO[2)HD(UM7L=(L"DD& -5Z M%3P8 M[8*3-P\?,\(=,C$)YX"LY2#(8@#BXPXD(ZT,W7V&I\ &^'@Y-7Z6&Y$?^H MQ\>O)]/4\3?!\|VV6(

*M7F+&Y(OC|<<*CCT[CA'G];P0$X:L$XX)L>UV92E< MMRHYG6^URZE'BC)9=0S;FDGQ;9@>0C:@!-D,D%,!6*+*D&Q[#(YZH]B+ M.C'DFWI(.V\%)2:I("23],!K$(<+%%I6J0V)(9GTT-*

-F.AL(DN!J 1^OA\ M,2H8N5Z1]Z0EIS#91?PM);9<':\KNBK3N^UE/W%:^4QN?,NYFA5%Q.W-CB" MX5R#)9[2Q,R9M7-%U3V5'XL@%9K1%+[(O)9+4S!)H[#=HY8YTV>5O])GS%*

*M=!4B4H-Q/-VCK$W@)P($Z92RGG]$UNC44(E2+?!5IK*C\$5E\,G\LXEN20Y, M^ 1%EC' C&.&M6*.V9OPY7GT!%$"2DB?@U,=:(8"8%8C508'N,ZP9>0VVX\ MEH1=BTK-K'!*

*< W,5OIWFL-,2NNO[5P/G"R)-D]ZF+**RRHNJWB+IG7+NEM6 M<2>GM5/=+:F[5F6HO!],QM4@EA"(J;#HBO?K6@A$Ds%X(7.L7 3&40!KM8#(M$5+444;5W+&-14(@LI =QE\'*

S ;[NC,/Q2NS Z&O1\;UN%B)(M=U85E-KV MJ>PH2D5IG)7<0T09I8A!8$.D8)V1G'BN..%M1#HL':44+N$,!:.V>RH[BE%8 M(>DCY>!L5#GI5@2+A0-L @_&LL]:2.

*<8>D8178P%06E"DIM]51V%*4HYM3B M@"%]EE@122AE?++WD-*1&Y=H$I\+NEHD:F$%][I6VXY2)/7)6]GR$'(HF*$[MKDS?IU7Z)?0&IR?IJZ(.BU@17=>19N"0#*

(GA)LJJD6<)DP6UEGLD MM&GGN-14V)+B>'TI:F^F441MD5RVY;2I6V2V3V5'44HZIZSA" RQ.?$>28@3 MB)"D(M6N1"I:^=4U/)1"O."4@6EMGHJ.XI2""/97#@6+;#D?5@HO"*

*&2(R M6=52NM#.X;?EHQ1;8D*3+B M@E*=FH[T+N) +'BU"8N\X%5GIG+C\>]'\|%8*OX%Q#GV3N=T)OE(2)0) M VP Y%T0(2BM0VS#-*

;E4)MW4NZDX>D4!#ZLS./2/0LW:$X+%CX-NS0VB#,5 M(0I%@$47P21;$F0B8-0PSSB:LS47<5@6@]K;FKLL2Z+B86!V"=QA_& 0__U9_"7ZJ12'XS]/S;P?"/1;?"BCXI:%6F(5O-

)D[?]4&)]JVV?RHZB%?/>&,C M."8,L,@23XI8 @_$)(./^B#FN-4BOL7"K=;:LUB"(A<3JJ/0Z]7]SSO5Y] / M0]-K?(K&I\OKT3AGBO\2BCI95-9*L>2M+);LN6!".P1CR!H'>W))E; MM*

*[1$C!0[?"R?[4.X;KK#:Q/$)N#DY!%^N'Z M9Y3&- UV;XB9%"5-5@']9[3 H#K!8 >&:>%Y^"%8L""%@G'(.HL>+.B"\| M*U[8E0 @7>:N5 ' H % #L'@,9RK*07X+7RP*RFH(W*

0&7Z6R(:Q9MN&!7 M X1'"%P L +C6N-ID)]DK!(HS&5=VLU)=-DA@BG9Y;IH<:0GR"(R(.DFI,PY8GS)B *#/G$.7TBJ!9I\|@3QT/GM%6?'VK M@:EN!2<6F"HP56!JEG],*

*<"2%A\B23I/F\'35RV>KT]_-T-W7!%$:/7^X/V:HA4Z+3E%*UP+ ^4L6,S(> M):LZ<&!.4M"*I%PGW3-!G+)ZKN#&8WR!PS^]V?O5U/T<\GW8?S^LOYAQ>-]+ M3/>S0L-A!*

MLENNO)4>&B[QA-/A?'5L^]!#5?>K:.IA]<7T)]$:Q"0')R>#_(!^[/Z:H9# MTQ\W!=0'IU,/9&ULW:O'=2FCLU%"5K32T]2(PIIX30@8G3S*XOB/]33N]_UA(XN_78IB6WM4*

*MM%L9&0NK+OA5\&NZ:V*Y#I0A< &[A$4]@L$^P5D,.M>< --8^W2OYW/@E4(D% M*OBUW5/94?QR1&ML@X6@' =FK ;$AV3#C&+]!/8S"5Z>;37\KGQB^F29*'@ MUW9/94?*

*QBP2LF38:HF)OSR6B4QA9$I&ACAC.]DGO3*N!7]Q'2VV_7!;"7-< M.(A:#0Q?1>[5

*5@V7G<[FS04=+Y?S<5PMFSKE MU[,7LVGSH?/99%+_Y*1Y_+A8[]DXV0R\)1:Q7E=L2ZQW$-:+GM?@CTDHR5<: MB\V 0,4!N39)1I>XYUL#"(1H" Y!*VLK]:D"T6L/5IDB=,R\2-5]UA.N"C[N MB?](^KI@VZ%27Z=SK($+[3FK^I%%5N4D#Q"XBV!E9IY+8="'Z\1:4B[*!@;> M5AY6(E1BM5*#EM%+%K-1&!Z;6&^7GQ56'3G>]Z&?5&=#5-M;]CWTT=\064XY M@A3 Z15#:-0V@I($44'"N7.'%7"=5 MR^J,/09@436=HXH"9WV HEUVVHG*TAU1F%RZ/K$KJ4NBV=[2](&)$(5":YF M9MQ),Q 5(>]@($3TI0BNM-S:>Y;!8!910LFY$[$V"2IW%C!12R6YJLK4/S81 M?IW_V!%7 T]A7E8UU?\V3WS[|2$7]Y>N^ANB0=2/_N]GXJ?:FZ=YVOI?/U'> `MNUM _^MYN;IU /ZWT\* [V&PFHYNZPW;*ZE,D5S|>L1,9/P<;9:UK? @/G'S4=Q MQKYG_W7Y@IZDEW"^P"<+/ _SL,3+I["FX]N_]>#&.XTFEKR>7K_]2 M1= _ZXZ3\WEC9?-Z'YJDT%W=QH_5!? _CQNQ|N>![U_D)>8[XUI[<7M=# _"T?W0 M _=#]T/TT+[`?"W6(^]FY&OQ+'O.V)>+?#% N%<@!9><=A,#]@M"!A-QU>32 _M^>_ OS'=?O , [']>MYM?3GW@[QNLQ|H^BC&K>:U)@] MT[HI?W,W2LL<\6C=][L 5 I-][_^]SI;^8366&M>=)Y^WA5A^&5Y>;M- @#)R!|P"SMTBMW<93"Z*++BR85BP'H@NB"Z*++BR85BP'HHO. MT\5A4VNWX(MKEKGA"?[Y\N$]8.)>LLU#QJD%AX43Q*B#0XL0QF?WN&[DV M?R2=.ERVK9T4 _=U<)/) T)<3%S<,BXFZ4;2C>B"Z*(-ZX/HHBT+IA7+@>BB M\W1!D=Z-D9ZQB5D1&5AI"BCM! 1N$3@[+)9)R/G&VCQ(-BO3:$ND=NA/ CD47 MK2^K^"E,UCW0PW+T:YBGMR)CT:""4D.CRK^J.+OXCBA#SY%@U";G*"H8#C M/H/73E=_PB*S6Q5 .1D6L@[@;!"@$N?USZ."7)U,QNRS=EN)PTU7|Y>KY6(9 MIGD\?7/_V>#:'FD[\ (]HJVNV/9V N!/O%]WXZ^0BY2VX:|83.6B*H+C,KC#T2]E<,2Q4V1+6/2+5#V? 23K=*)U0B>11.Q#%2U#*(GAK"VAIG+FD;91)\L&,MT7)FACWU|8&8SJ1V$]5'QW/IE]1*P?-$O _FN<_M W,AI*M?SU?S]#6L<0'^"=,-3"ZN+5%6TMJR[M>YVR]7$I5`>$N15.4ZG56@6E+_W5 _:Y;)Q5 UW,SU;SQD6M&W=MRH)>;?#[M>O;\ IXORS\O$'OO,B&AV9&3\ZPWI>5/U$:VI0PFF9I@/%#;$HP'8VI"<7]M M2S >C*D)QOVU+<%X,*8F&/?7M@3CP9B:8-Q?VQ*,#[N'>L=F! [2'^NT]U#G6 M![# ^CFS]. 1XGPR7O8-E<2XM%^Z|Y%CCEYY[B#9F$ Y[L$9;D (IE7Q@5F^ MU3(!C2S!9 %)" 7*,@:1EP0I"*/1"97YE^M[;MXR76-T_3=G#4+WL%-J:).4 M^QLVS;:DVG(AV17I& B(6E8B5@[;VI" M<7]M2S >C*D)QE29M&ME4D+#N(P:F @%E#&J:<&F00?FK0G&];0U!5I8V9 M3>@;[T!QX\ EST#*4-#*X+W::L%VG/|QM5B^]Y>R>#T[SGG<7$.8G(9Q/ID^ M#>?C99BLRY36XOGI%>W\"G];C1?U1L|P_GZ<<%/2] K3[,UT_2[_"),5[]LG MD?=4T40\2+9MFVU)S@S&U 3C_MJ68#P84Q.,^VM;@O%@3$TPIN3"KLF%K$)F M6EA@B Q4L@6<$0:,+$I8HQ+[K9EC$4.4ED?0PGE0+"MPTC!(600K(/""4HN M=!,K=%+W(3:A_SZMSVA2+S"/WH3Q=#&J> SOPWC2|/2&ND)A41?O:(%I-:|K M'!?DLLAE=<6VI#P'8VI"<7]M2S >C*D)QOOVU+<%X,*8F&/?7M@3CP9B:8$SI MW%W3N9K)*

(+F/$#,J4)PE\#88,)A*9+HHF\7U=&XJ21AK&5CM(]@BFBY6/H!& M:[5!A4R8Z^G3-/L'?XR6RR.+Q-9/_F9V&"9Y^R M6)^3P"]P^;*\#A_VE+85?-A96Z((LFT;;4N]93"F)AB3:ME5M43F"PK&03+4 MH)!+B,PA>,\QN,0*R[U9A;ML0I-J:14DZ,#S0^PUUT4[&]^7.;F< ;F<6)<< MSC]=Z_?Z?#E:S";C/+HT4A<0N*/UOWWSK5@?+5*?7WEBFP(:)ON\8%IQ'(@N MB"Z(+K]P8%]Q'(@N.D\7G940GT6UTB3N>S>CE-QFQ/63 G MY.'28,2,Q(S$C"2DB"Z(+H@N^B&D;L$7ZURQSPQ/|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|&DX'R_#9%W9MA;/3Z]HYU?XVV]\#=ZAO/WXX2;F/5$IMF; MZ?I=UN'COBJT#368(\XDV[;.MB1G!F-]@G% ;4LP'HRI"<;]M2W!>#"F)AO7WU[8$8FF#<7]LZC =:H(QI7-W3>?&E%BT1D+) M18,RH4#@N4#*11EGLN'-T_ IG-UD4K%$$ A,Z!3-/L'3:CAX\O$UD_S^9G88)GG[)8GY/ +W#YLKP. M' 8U;LT,.VM+=$>V;:-M2;4.QM0$8U(M.ZL6+H)$&$G<3*]E59"@ \\/L== <%^UH4A6(;2F.RSPNF%S_Y MPESQO "])C]GC8*@DP G6-!:>,4*OYZ?.YW/ZN4TV;A]CS451]H3BTFZD70CNB"Z:,/Z(+IHRX)IQ7(@NN@\75"D=V.DQQ7F8 I"EL*" M"C5@"YX%D%]:E%-TS&P-SMVE$H,BO;9$>H<^\+]CT47KRRI^"I(U|:P?)WA M^1+?19R/)#L:"28D.3T[]/BOHU+D1&E*I8!%HN@T&?P12 8&Z/.-G/+\G67 M$IC/TG(.R*LC4;IZH%@P0LI"NB!$Y,5N32Y9SU%_N5HNEF&:Q],W>YBRSCD[MDG+@/GQ9)HFJX;+3F?SYH*.E\OY.*Z639WRZ|F+V;3YT/EL_M,JE_L2M"FBAB^O+$N;:PGG#]J-(V41]7Q=L M.U3]ZW2.U5;YI[+W8%,QE20S \|L_:>*DC,N1;)I*!=:?\EM\, "*KZ()HH 3_M"H&Y@,)S1,[,8Q/K+?.SQAUYUZN0FNILB&I[2[4')L-B=%%:GUCO4X+3,R^ANLA@*ZD6OG12' Q6=#.]"U+4#7*W1*8#"5:]"44B-W MY)<20]X4UIG)H0HZK$Y]78"DTO7)W8E<4DTVUN:/70UDU$I\L0K_2G>])4Q MX#7SE0A9I3-ILHUZ:^/&U9|'$2&M9:BV'+Q4&2)'D4H1AHEV:]QP?21[KRAP M]\XR]; -$U]_>\C%_1E"W^2P;Y_^U0^\[7T_SNW=22/M2+-GB*.0TNQ=_>2/ M%2VCZ6Q97[BM7U[^L! M1-]?>W1Y_'Z4)F%1T74>WB!,9QDOKZ#>< _/KBUO^S[KOSX3S' M-;R>U(>Q>C?],8\7YY/P\4GSVQ_/0VXHX$]QX'ASGQ?2U=9L?-,VEQN7CY0>N M7PHXS3^>SQ;K^49/YC@)R_% [_#',/C1/L[|GDT|UB!]N2=Q_NI8O'BXL?32]CU*I9AOGP25LO9CW_\17VLFQ^OI;RI6PREWMN3 M,/DI?%S|^-T/GU;$Q3M?&G$-H+7!KBR"+6/NUV9[9=$'8Z//[FDO)_V^,5]L M/GL?S^!XGD(>A]%/X]DBC7&:<'$TJAK@.M/&_KO+AOSZS MX+]26+S]5VG' WSZB;V?7F7OLR]%SX]TB9|>W&A61D_KLQO|/)G]OG@4"[?B M@?SY[Y?.]R|=>@BNW^?-GS;O *293#A.-S^%DVE5(K/5(DSS8H<'T4V.:VYN M+:VO.>[UD\2UA[UP=LVU-+ZO7OIZMET51[-5%3GC#YA_W'P49^O[]E^7+ZAV MG(3S|3Y9X'F85\Q=/H-U +EY[^^N'UAX/UZ,XWA2Z|GEZ_ TE&$]<=I^[WY MKZMN^>(V-W|YAQM>Q:|W;H=7[? 2^[T6# -)7:^EG?N'?@DEMSW/LUTRB4N M#Q@DWR'6ET+S6_^^SOSW==O\TX'#A -ZKLX_QM;Q=88:?1K M_>?;Q>AY%63YCT>;=ELMMSDQUX8'N:+O^5#MSHI".AW?^>/AC M=Y.X-5T+)E3/#$834Q!3$%/L@RGN="9]$$RQ<^>#_8>/CUUQ<'GI\|K^C MGW|Y^<^ST<^O7OXZ>GGZ -7QZY.7?QL=/WU|\H^3UR?/SYX,.K(4WX@L6\$O M#Y8NH+OM]-W2N[|W;8H9|$I3WB T4K=]H##MKR4;;:5EIPO:6;8\YI@#VZ8! M1W0!?--;/#FA=8D2G=@ZBEZ88DQ8#R%I"\K%"$X:!+3)N:BE9VRKH/V07>F\ M57V]R:2R="')+(LLVD]5R);& #C %;.:Y8R6^K,$:BXYY6=!M#5/-NF3!I !G M;&Y>D\ KAL"S4[)($W0#T>6G!]Q*8DM*4MU#W\|GMJ[+A:?8_U5&D]P-+T0 M[++CWZ|F_E,<;2@P\K(A_@'=+]IKW=_N0 M \5Y4\&\8V+G:K'L^GVNOG$'1HH_71NF;[#QF26.YZ/W8;+"IBH^S=Z|FS4? M.$Q_'OT>YO.P78[*-%?7NA:HDVW85^E6QTHIL]ZU]:U]Z#@[\;@CQ>IM'$1 MO.4:R&DEP&.HY*:*"IDY8|S6_(:[9.KF_\|AR0;^)1.? *_C_T6#_97FZ1O[Z M'/0 -[@_GN:7:]3_\AGT>SKAK#P%AY1*ZY:1B42[0Z*(,<;L$KA8-"AE$\3$ M(V3E%;.:T>%6VXB[9-!:0:+ZR/>KQ7>+9^!0W+!Y^">+Q6HS-*>)"4K!>9-M M2[/%?H6/F[X,XS+&RR""(H?N0)@3N_0VMXI%:1P(LV M;=U< <>"A1BR=3XZ:Y#?6]M?0K3Q/!< ?=K@\ @2G]!GE[|HX]-/V-PX]1U= MT_HL,/P'YI,K$5/[XY=:!P)2]?VU;; <)3NJFCZ\!EES5W1A5U=VZ&3D)%+?% MLYC.O77W(Q@<<=@)#LF$S"'"7'T9P-X%EV*3>FOWO^M!?PSR|7<^H')V>G#XG M.=UCE)&ON=G7Y.*\5B% 5A)!1;S",.! <#VE;'K8SR7<6TW\+XVE3(/5R M>CH?OZ_.Y712+[FI2;EGR11)9I+,9%NBL7]Q9QWW+E?R"AZ4T0@^,_[%VQBX MB]G$K5E"=Y;,|Z.Q[:&31\R:83,9Y:(? 1AH_P_HG;;Q6QZ2">PPH5IV>7AP_7V'O5W.G+\O<'$'B\6N#R^@L3G M\'Z;00G[|@D))-)I-M!\=K/'*IM7; $'WE]*!FLUB) M)6D).H8]N2L#@B _.@4C,L,!1R[5TMB/3-\OB7Z#.WMUU*HCG6^'K-[7:WA4 MUQMI]8Z";&!.[,!NAI>L36[ZSU]!5:MG_UY*"3$(A2Q5A^'S8;3Z&HDO/@&1 MFC9V9\63).^O;4F2W\B5V20=A%40LI6@2G!57D<&V7 ? L^4^R:W6W?N1Y'OD MRNT<>][Z?%$"O?42_%,I^7GX^*F./*0T7^'GK#H)\LY CEQ8=UQ80)D"5N\5 M-);]CF2 F#5"$E8<9#U[_))M*FO!#R?I' MC13>;0*%O,+1A$RB9/427 M"O!B5&^78_;_^,H2W>1U MF"3Q/P3Q3T1-!<08I.-SU^,<14/#'6HPZML!1SH,X\#T34!YTG MWCNB?LA|!K>?H,9U+Z9Y@>)|I8G3^>S],&/^Z>/?*U!<\9S' MG\AB|Z<8CA2G (<'"_)]XNIN<[6.TF%@"[0I329*&/|.:&!)19FD$AGWD_R M>%S-^1$ 9./ WT'UHPS ;(LRO\| R^.S QW|_O+?YZ-?G[U\M?1R8M /#[I M?? +B;Z/CIZ]/_G'R^N3Y&4VR_-IM]M7?T]WV\&YI5??^;@^=[FMUCNI> ;AG M"3$O1F4^>S=:.5/4VFI71^<7,\G5S$;R<6DYYO!Y7 5'EV\V1E\A<,&85\/KT M0(GFS+I- 8S DK7CFN%>#O5=@O'GBL6$"L67Y?0"B*>3,%T>3 /S2RSNJ?:M M1HW#+GPC4ass:!?9=HB4%ITOF&. 8G.E) ^\E1%4X:,D2CP8SQ[TTR'YX2ALZHQVZ MG+?

5*F_O2O@?.*\K*XPN&N...,RG,%LM+X:V8R91W&,LD0?YRG&0]!.:[L'Y MX$"%4 5N$1R\--:@UIR[XGBQE.L/ Z*R[>SW$Q%6RP;]T'>KSNQYDD1]]>V MG>;S@-+ [$!WX5#0HIFN07Y0"F8/4*#5SEAU&$>^5S[:+1DVONO90:OAQ!?'X M\P(EZ=MCU)"K^$KRQ&?+DI_ I>>@T D(6DO@T7 4V449PF&D[_HD|/Y]A#C2 M;."GH$GVDFV'R&6>*Q941I"&Y4W3-6>3@2*F"%F9M6!$L'IX3**WRG_>T"Y M^^ILE%?SU;O1FD]XKV;E?[?M 1A3'42?X4. ^XF9?X83/7F(;4)HY1]XB,HFR%9; MY!P]NKW,/IGV%2? 399B^&3?-^OB?=VU_;=IK+I1N $?6 (7LT@6!8OWFR@X M_W<.3T[#QR;!\O-LOG% S|:+\UE%^-\]'9Z?3--DE>,IRO,%V<] M9].]Y9=[IK/I@#T1:=^(],!49X3@/%@$B2F PE# "R\A,&%""-H7LT5U=Q'< MCT-U),,L ;R?|/-JGMZ&1?UT.G]'KJ-CKJ/3&MQ@\)9+"5F@!Q6UIY=-]33< MFQNMD\;(M#%B!!E13>!TTBV!2TB8&QCR:@ZCT;E4HMK/%8>MD76!E.U%E!ZBRT()?0"\ MS!H,UP]4<09B4@&$B5&%W!#K5LOPO#$I9%1_MYT/.P#BYQ/.N?=6_4=WNA!V:>Z-0@[B3N+.? H89/4I7L%3-K2BN'<0J*"'(M4K0*P:1TR(D7!V+FVTV\4$?2'W"7MIT4_1A;$C3PX@\|#+WX^>7'\XBD-O*#1 M_'2W;;Q;6M6|OUN]L]U'FX?Q8K$*T[0^ZY9F(]|-FH^8I7|? C9HW*O7Q81|| M'N;S,%TNUM6X?XWS'R[,9IA[-SALY=_%1OX9Y>CL23,C1 MZE+,Y MY CHB@"%Z,&GZ"&B$9Y;=%FD/YX#N7+]^N0"XR_+TS7"SQ[G\|QY56Z_WD! M[N-I/KW$\ >=IE<;!'=@XY|@T0FW3;8=).5YZ[FRP!.0]4R!Y\]A I-"MI: MJ35>ISR#*]JH W#;S!Q*KCD9[!0]XJTXH)0>EE+M-FSSO-%O4GZTX5S3^7,]+5 X(2.9F;G4Q@UDEG'&2^UM4> MP8EF9IWRR9L<)4M;QS'NK]LO./FRO+Q Y-,&D*2/N[^\21_WU|:TBWPZ,99L M2<;@0+(20.58B3%Z#.0"8I8%HG9" M5!FN1)-X\E-C'E)SB#IAU M'A2K7V+B 2PK1NFH5+#I@(>V#L>;^DA3#$"%Z8=4]76MU5M2X&@\W2C\IN)\ M_4W3!/]I7;341]Y+&UVM4OZT37RCW_)185')@DU5ZBNI/+BF7%,X+Y36W"'? M2QN(QFDU_WO^&=&O<+&SZN4V-/'L@BX^#39X M_B&]#=,W^'HL\7DIF.[0$O5V!Y;%D78'=(*/S=C45IIXF'CX47F826361H08 MFKP+"QQ<9@Z*%\%95-F%K;S++O%#MWF8LR,F)1$Q5=C?=_3CET*,T44Y[BAB MO91ILZO03*59+WH*/R@Y1LFQ76M1K8_"%@DB1@;*!_>+[/|$_F[? M_LY)Y0-Z!M(*52,'7KU8\!FT2U%57O+>;IU-D,%@%E%"R=E!TB95?V<*F*BE MDEPQXY7T/_)T\|G)PC5/A@!RLWO?Z[,^G MII\|_7YB]?'OXR>G9P]_>7EV=|?/3\;O?QY!*DG|NCDQ<\O7_UZ_/KDY0OI M@?V5V^RK6Z>[[>'=_G_VWK2YC21)&_R^OR)-[_1.E1F#'6=&A#0S9BK5T7]W MJE1;4G?O[I>V.,7L I%L)"") _>O7(S)QD" I'@ !D%$S39% 'G&X/WZ$'X6] MG_QL[^V,>^92|==WOV:A]_;7O_WP_D/N O'K]Z4G1$&.,MNG.]M'U4]>MB4. M[IZ'4RN='Q9-&U)KD3:ZA=FS$3PE-W0P' /<>KRD-PEN=W#LCCM-;TA^]K ME6O|O_Y2"M=NP<=#CVER\OAV9D?A&7M;KUZ'9~^O)51K:X-$P3B/N%84&6<) M"M02PI31*]RU#;QS)=R5PNI#Q?2W&3_^M+_-X>)U0HQ78_]VP]WXT,KFGLC M21V4_[4<9!5P+>"ZB;(HAC!F&4%>:P!*CVND7,!(*RZIE%28>NTPZ\[5='<% MKNMA<8^7|7_(Z%]BXN['8D,GEFQ1]'9'==KZ)L*T!B-DQQ+HH+)PHP)02L&DX@XL!1N2 *3(&E(CX93"8"TP)>L'6Q<# M,/RR @9+0;< @I\!!XH54;R(8D44$#TP$*7>TU0'N*;$(^XL@&CM:V1"<,J& M3'C@#8BM@VBZVTZ*-ET!PRD9PCBONQTN]IB5*.S*P+E>FZD'KCV:EIQKV! M$(:J$XE(]S$,L.W#-<?M!W8_WY!X4X^6,'/(T]W8" 58"[!NHB"C4'4MP480*A7UJKE#RB=TQ11*;SW M-=Y$(;!'|];B?"F'#(]9[=M.0S4)+C2?3-IU^+7].(8!^]X98 <4FZR*G]K6 M_TDF&FQ#8H(*R)L$R*,@^BRG@HD, =Q1%.Y+R8XBMBZ:#G6AK&'V ;9S97X M^_<%>_^^X.[+$ M&61 T4>66$>)BC]L=UF]BRWP.$!:%/\'*?[P:]J8 .LV"?S6:N6E=]_XNMO. M>MN36V+$'?IV.),?LF'P3?C43.&44S~9/K2S*;MJXM?P++V'^=] M4BU|$V%N+\WHLSGO7KWX(BAB?/-SS$4-ZP%2)8V|S-[MEAHM#R2_87DS[W MFV;;D=_$&KR>..,;4WW7M)UKPMB%[JAZ.W:7D>86"U(_G$VS_I-A\A_3]A\+ M8/S'*C#^8PZ, ^[& O\Y!_"]U=AHFC1N,C@ V!Z@K"DGC!>*4U\@8 MYI!QC$:GG*)\(QU@OYMU(-"ZJOO0N4F3P\!?C_UWIFNZ=_&W2>A@)#E4ZO.\ MY[M1Z_YX4<&EY@R>,9W,0C^&7*#KJ?2V_ |'V8'%X(H*<8?1O+B:]IB,+C"L$ V$(,X$189;AX27E.%@DF'V8)_@ MN\E' [9KGLEQ@+SNO/]IY'07=BA0>@',[((;^TO2JE\T41N&&F;6@D7OS#$_ ().SW-Z MV;OX=C$O((D=[5'S[W9L%N1X85W^YR%ZU,/&M;U=QKKVS&L.&RP"XI)XD)+W M#FPV$A551(BUX_Y[[O*%[?U_@YGLPXY3F,G^;7>2CZ>F&:>8",#W:5>=!./_ M-0.C/$P2_%3?F]'((" :$G_?&ZF)U6RL]-"@F+=QMBX4.6A|9=_:G]Q^]ZX MB4EHTAY5;P 38SL9-^:X^@ 8-$!0!JE)>]R8P8P3HXA"D1@@P. 84M[5\"<5 M-554P 9MB !_7YE2DQ)=869OVMEX.CG_%:[="?U]'T;FLYF$;:!K>VX\H9Y MSPGR3&#$;8A(6^T1-K4)MC:1XH%B03'MT"N\^20|# MYP|3*.P&FN:5:HC8.^(2Q#X*VWL@D^D/_]>LR76&DI8VC_^U<_-IU#]?^W(M^%4___RF^N9%^OW%MXEM2'C'G]< 0.VL&YU?7* A13" Q?//)@U0"NQA>NCG="((DN^D M 2YIIFF6\/CD5LI!5M.323N#(;9'IEBKO&E="/X(UAK$:AYLA+' LV#Q?9.\ M4/G#^>OZU5X|!VZ:5F#0A'&7MBCO1'MN1E-8/GC*

*^L'(ML\4=L<9[WH:) 51 MHG-^<=\ZL!CS!XMCV _S?Q'!7E5VDM>SK5[;%DCDQ[3V;U?6 @U@,AA#+Y9? M SOU23733#[.3UDIZW\CP<*I\UWT%6!$BD=*

(M:E3N9U$E:F1H9+&E30O)IP M6:QOHK6WFB K\P$["TC73B,',E)81HUQ:X&S%RK%K]:/7Z\7_V9UT:X]/\O M')Z+K[7P.);7GI[O0$N!JT-SU M0WY>?,JOY=,D!& GT4^ O(.5[$.;%*

*[^ !Q;TL\GLM(?; 05A ME4?M^.,4AE&=@4T"XBAQ[S1\,M7KCY/F?2\ X '#IR^^/:[^.D[2)>]#F)PN M-F6!G4?5W$,R"4-VG0N3[%N58U^R]$DY>.FNW]^O# ^NB#=.'WL)#]@XH0"5MU*9.%(RT&53?Z!:&U0[QY6(BF[1+P,%V.&^QMZ@H#7HO5)Z9*@'K/&"2\&) M]DIE]&2A^2[15+;;;OQCUD9-LPV=RPQQ\;. ^H#[Z_/PKT;+ER3IL6#M$$X4.XY*

MC)L3@11,#X7@#!,15'UK-C'7WR:M]G>+8.&MC1-?HRQ@+^]P\.D(.6>;V?F M/-?0S#'G-0>MTZ?#=)UW5

MY/;@VH%&&!.DQ6=M,@!9@$C3HP'9(%!3"8YZ*17%=N%,GA5],DBP"0]O5UT M/>D[V %?@SZ)@P&YNI/FK-?TGIMX>'N-J9*# MY.0KL$U.VA$HV^WG!,;=S((RT1@P%^9 _?6?*

*_ACI;Z"P@IH]{^#?"C"7'X->U8LGOZU.^/ MZ1%N6:WIO3&?SIM?S7OV >;NM=*C9.@DFH<7C/MO*MQZ1"B847VU?]_.1M7[ML\0GRQO??/<]:L9QE@@7MM* 4_Q*

*&CELR/F@WP[FSOS9#BCT(YA8_8 !IOYF M9]/I\I$?_O(&19" Z=D5H/0DF3EADC$HB=#TRPSLNU.PS7IS;_[D%;/E:# L_M$Y^%&%- %?!(-SM+SUMP+QA^YYD/S/1D%%*TP#=*

9Z/^ZF1]O5@N1)Y+E\3V MZU'77BB(E5EG!O\!RFU/GL+>"+YL@G8M7 -WA"]P:Y??T(^_ [L/ ,18^.#C M!&AK?F/7@]2'$V!2>/LQ& ?5_YZ-,H'2B[I+/K_/PP$.!]99!%9-F;WQ-*

*=IE7]+IA9LMM@998TW)_%O+AT45[#E8&PHVIY(-/O2AI8D@]=(CYX M2_B25*23E/*3?+AI4RXO[7ZND 91[TM#N8^_)&(=*'5PQ[#,&>3!8@FB@%<*

M^O.L(P_O4LD4_&P ^TQ1,[.\6K\U\51>R=;\B"GBC5<17@Y)E ME]//(@)\)$^?OBB[W^V\U$Y5+"D^/QIU7?^N _M[;I_E ^F:2XB ?5.DQK3XU4'S%&=A-,S2QZE M5=$)<

*__@"C^V-[\]I4+Y_!_E,2Z39A_I?R!L0SR_F,8AVGCX).S%';=*G%D M5.M1IEM=@I6[4U?;;(@ ;.59#)-+C)IGE_Q"F;W?N6F;5)Y>%LXE6+IF6-?3 MV71FDC#,RYYUCLI-*

*%QA(WX,=C)+.@9PPR703Z(0%N5O =109^:>OR2! MPK_ZO>D5E4P+WS5@$$S2[@[7YPN'1ZRX,;/+,@S; 3*S/;N'>FLO=:*B<,6"19EWZ>WX?R<@*

*M'K!N0W8EP5<;KCW(U.#AKGW_" &V(K/>;1; /M?ON-S0 =[<;QZ/4KUW%*6E MX(Y&("*68H\I9(2'\">R QG1:HOM)2G.71)B !N;U(BF/Q*

*84&QVUBX!T(#4#)\2^"Y/ M=E)3D*0.?!ST:*;YPE;2G/ 13 'DI9O.@0^(.EF<;[U.B/L#[-]=STU1SH M>V=%7-]F^4@HGPV!F\ (^KCZOM>2>TMD@:D+U,UO^<]N>$^.O[CF31F*

EQK^ MJM-S ,S9<)2*CQ+.SE68=T$6N+):IS]:4:?EA+%=+6$>"DQG74!11@)\)W!<[ZW]>[\&B6 >P,/2(/X.TOT-J,LMD,0/7X;3 MC^3B@__W'\R7=1Y:*

<@[^:]DEFNAHGYBG%]BIQVV!HQYY%[I UO60C..0!7 M$1&7%"/CL$-$!5[!*PR8.6N5>@D/!EN!:@8S(-RR&C,$;:;62,"B\Y1_ 1SGDK#@0).*(4X4 < A-6(8IQ1=Q$%[7R8_"]@4TSD#*

*M%5X!R1H@/Q$X8HQX[W&L@]RH,JX?-UQ-C=W;\6OGDG,\Z9;ODJ=PJ0WAMKC((QC&%. MM28J>[*W!.@FM] \W#-&>C@[^*;!5/?,L/@9QVQR5IYJ8<&5B*

*MRN"DG6|%^OK"9CP'JTQ_T+*22'ZOW/'JQ("8L2&,DT?[S/0.SOS@B<^.]SXD MKL?-J)]SY;(G/^"D]\,YEPX|%T<2?QWG@>2@WJ5I^M/KU[\MSI[2EI]=+G(YSQ _#XXL :RC_S@_[?*

*08*OR%2:*PWWNW5'KB>_M9*]2>G!{UHR'**CE643O*[NP/?29E$(Z22H@K4%^SUEU)_V]TLY*I/2DQ' M9DD2C9)*,)OT9Q=KU_KLLAX#\'>=F9\X5=$TDOGNU?*

#K!&L$QU .A&?PRCX<<2*R[?/J[2]DA MU [S$/@W2K+ST\>'\P0P^G:8@-G@YZVLD\'5YRYIE&O^):/OR[>KORTU& 8 M_H-XL+&EOH-AU2_8;Y0#F]863%4;IDN?

\L8_KB8>FS5PSW"6B.#]=^YB;O M+(6HF'14/F]FFT/.0CCPTG3+=\06Y<' $_S(053]D$>]",C#7D@ZR7&P_]^%0 M/5X/HF;UE#))]^#?\VT.FUA'!VL=V]A,9XF?2O'E$@IL8,DSS&?

_5%I=C^ .!X'V)'NJ!]BB,F11 MAWFEW6FR1FC#ZI#G&6PV&=Q=OIC4K,2;V:0@,YZXR7E.US>@CG19)<.+&+# M_S^024ZP.! 6VN5@6K\I)G2W)?B$'+

2H[WZW(,T'@Z:4>C1(^KIY]K>DKU.JOZ M<,GEE(\55:F[$%?0W.C=NE]73T)MH;XMQC/7_5;5O>.DA%]\Y(4I=OTH4YST MZOR&X^ %^1#UT58S?3 M\TN:8]^5?*

*FVLR[U9M;G2XLS2] <^O3BTR\|(]^WJ^37.*2E(H%%0+]L-@R*V0B&FX,[8?|S#\+_=03/'\T#8+*GXH:G;BJ[*TX0C>7|!MQ)$X2BYS@!'$O F*"^U18(GA&;5VOEQ&]3T6?WT#R*

M37[+\N_WD,W910>RUPLWQ4]FE-90D;EQ>L>PY8^6;(+SI;I* "J"6VNL#9 M]VB:M)SI%YHLUJN()X.'9G?AH'4F!UC2\#.GGZWXD7M=PX >O@"H07Y/+NW*

M_/,5G]B/]S]YPV:3/J)MLLRUS.!S.=QX.:ND ;UD"JZH(TWYQ&G#V5%P$\QZ#[D/7C:Z9_"^ _99NM184Z"MPSP MS=O49@7, ^J1 +@9OB(X\+R6&'7G Z44/C'I0N[H_OX,M-*

!2E.JK,)A7K,I+ M5N4UVRT0/IS20LV<=%2A6I" .&<66>HDPH08++WEGHM-2-^\9">P.[" _6GX M&OGM05!Q2N"X2JNRK9GX!]]@Z2=S(.Y)5&]OI@%=.&6C$WYQ[.'ENC9>/@-*

Q:QV M D=$K%&("^^1IH8A:[24A)FPX/DV@6T>9LYK8_-[/7^/HY[#7@N9O_VT?&K M039O?_WQ:V%?^H@0M4^!-BM1ULMP_U60]3Z'[%##*: 1:[J@)LW1-' ;_N+$

M(T%:!V!PK0XN%[0 %YX9RZ@DM+_LC-LK&#F82\;YM[5G%X>Q@)]0]XGZ\X M'#WWZO?\^/H:/ND/H: RCCZVWE=C[]BN#3)6]M2WU""E98T4P93)0%3!S: `G M=],[?FY

*_@)UG+\Q9TGA^7V>)_5Z['|J852??M"DJL-0H_9HZN%C(5"LO+V6U M6,O^ #XO9S6LYW.PF==B'AX8^I.\;!7'=GA26L7*I@"LN13,;SX]&YG!GY;< MCJ.A;&P6]7U%KKF?*

*KH,ONCB()/AZU?^^6O:@CV-QL)5=%M/SU//CJB_]E7Z< M]=K Y>.3?F9#!:T52W-9G6I>,VIP;]+,?]89;F>M(.U&@N77^-S6K-SL]-9 M7^3 YP.9K SL3NCL7;0OXCH:X==["3)3!T_! M](X^1?N*VB'#ZHA]@+-",_> RNN)*+W]^L%,TEEK]WIY,] W&W/[\)T2 F _M?2VL5_+CO=(WAL#>HS[L:A% E6C\$TQTB%]DM+F@S=1920(0HZQ11-PF%X_D*

*M&GFN:V\=LXZN%5"^#VVF'#,0[.F2'Y;;\7KZ9BB]\K=4>65CU; T7M)D=I). MIB@=;P-R+Z+O"T%>(,A@"(N4,Z F#6#)@TE^/AH/+?WRI\6^AP0N9@Y1A1SU&,55 XR*DSN)1(,55[;F*

MPK&U/@SWH<'<#@=0|>?6C+MESLVO8?JFWZ>-I8/MHY#N3YEN6[]K7?=,%3=S MB:U"O!^6[7@B5*F2X5"PYME&[B!S%,F$HX*$$&\A):Y00S%"V$3), M8 D:|MM0M/JI|*

["SKP=#^?!XX^O%P&DFR93>W!&[FZ/,>N">OH=;W.BL635#Q)6R-((UW0C@:PXE.--0(C%,<1:"L6MI$K!NQXHLG_MJ7B2K]TSA#6FWCMD94T0-X8#/7F!-%,Q@#7#

<"V+)VE#=5R^YC2R8=2$3_F$ M-B>4I>JK0]6 OB+EFH3/]5>OQMK(\.I$_#FC;Y8ZV35#*-=I"/W34Q4XUYSE MD]'\Z)6TRFXH,""!BE!$U-QFRZ6FTU

M$&C651/3)"LNU41/'3/2=;Z=V6EE[!#6O!9RUI]#KT8JA]X2W(7#[SYCZLK# M<] F19E7"\@5#);5%X;$S9PU.<2-+>8(0W+MZ3"[IKM0'/HY)NKJ;NGYCQ%*

*MNO^1HX9,KB2\#*2*LQ0M/S^^]P$V%$CIBF/\RT\]T4KZO/Q%7[=YR%-K5Y_M:Y8"^E0J&=*WC,H/FU=V6[EX>,WGG&\U;"F8C;K9S>:IL\+DNR?#123DE)[6.J)9]SCKN9&]9IR,?*

MK;B> U?: M4169 M6$NU2M(NIRK!T]7MSH.:#CUI2:E^-E&[1] M9(!_3W+8WOA\B5CSVB7]1LPKGHR2YVER>]&]PDTU59;C^;9<;<+D;LZW(UX M$-*

*&*Z2(8(C3Y!KPU".M**51$5W7#VHON](4:Y'5L[P/=I\)%UT+=NN M=/!X;F1SN7A=7TL#5*%N|MY _?X-;(9]17 Y8#2+H7"@KQ>33]=UI#(8GDU MC'5(![DFD?K?*

*87*R(LM+L5A>"F9Z\,-A>+:,>]MO!,>"F]K<-9=BN>|:M#8ZK,Y#(I0G_YQM8/#MI_O.H M,^,.@37?Q.O2D%0M>_G@N.[7FB]3S+K]=@OVVM\OZP]*#\I8T2ZN(@RB_FG\E'*

*M,#+S<)+=9K3[0"3I/I7"-\(/7[+.5<5YJO M1*YIUS_[Q7(4,(R%'$@:8^\G2CE_RH5+X5J_6* |:DZ/%=5_6L7I8>]H]4/_Y MQKO),:WWK2>^$=9*[>"UNY@I/2;XF4RUI.I&7_M??YY.KL:*

*(06%3_(?6N#\^ M@D =>S1(G9C_NUKJ? 9XZI7&E[WJF#ZX%EX^1(0SHP&Q.Y1_#K%C^O$+MRD M^-Q!W9OZL@1K2P#TE+[/I]@W+L?"*I@;B6?*

*3*AO_U5P%NF)R5RR@VM#Z/1BSO5BX.T5[/)RY]G;*A=MVQ&W9]?W&3$+AMCM2 MUD&I$)M:UTT=GUZWZ- D)BSMK$M'/=|^2:C;#)+1@F27UF\]B*Y VB-IY]M$*

ME\)#C\A#:UEVA86#KYA';QP79%<17(5'B]2:[]8Z*OV;#XBW!>#=B .F&]# MF*]SE-D6/.*/?EC\.-!U)=%O< [YV'A _=,+G, ^E"UT]^BY_I(=+J3&*

M$\7SF71[^">_Q4]PTK4%8BM:&=]9W$%B4V M+W+=X^>$M3:,#7<"M<>,MUF/<[M=]7"2GK]9"V3Y%[=Z;;YXB :,"4P1 M8<8@+F3]F\L8E3*8&KI(EDK11V$]'7 "FF?

*Z]GCE'\@HT>4:..:84(P0<45> M^#+KX.:D@SD<7% OY=I"+^Q"H1?VM>*6UY@&M>U1M8'C%3M:&"8*&?B'F)Q3H=$_PZ3-O&/HH2^ M*F!A *M.XD7.A.*

[O/JAN@'<\>JO#V>M\F=:,Q-/2P& M"IQ7]:X=X>WW\FO-@CU%MKKGMCY1,>0"Y0%KBVH/TH0[2Y"6H+P+/(UFGAI? M]T=V9,\Y]OQK]@4)BC8]K2W!8EB&XDV4 LZ-*

*5/2(FZM0YI*B90+)&B* MO;X"V[;K2=X,MJWW7C@BE!1XPX ?/$-/<"&$)P^($L?(O$OM[1SBD0ED>23(MJUI1I8(-MGYD=VY1]O:6*8]RIR2W]8EBF\=*

*<.*T)LE@EH[3&R&CCD27"UT$+ M[MS9'? MR M!OQ$)92.AA/B,8HDM2?'@8-PDAY)]]7#C$7OU@/;MNMJG?/];R,S3I7)?YBS M_]_MT'-MYT*K<%*!U$((!5*O[N,L"/;&U:"*

[UQ1^$(M,ZF>A+ V:1HGU%9"Z M70_OUB!UO0,YX0532[AP"1/!6PX/"ZHN!ZN;.%/Z>L'4 ^*]>V|\G8K&/B5Q5F/FE:0:.1EK MQ 6WR'(;$156,26]T7CM??V$1'WK8=1D+3$/1?

*L+=B[0>S%(BC] M9;KX)BDS.D0'E%/N+;^,"UJN.N8]>+"GN<QW%14V *CSPM&B>$,%%&&I$K] MJ % 52DFSF@<.65U[3C959AV@=%=;K-.3U0VREIIPBE'BM,:<><44L%*

[I#%54<+_ ME-](+8Z^8=:[> <9>?BEHV^D]T.4E06N"UP7N-YE/H_FW@L@(LYF#(\,H!> M9I%CP6+"N"5X(]IXW<$U/ZKQ?A['HE>,+Y@ -=*VV6H(Y,U\BZ$ MY'JRR-3:H!*

4CHS4WT"-%,!^-(S?IV#+9P:P124O<%W@>]MP;;SD)#&)@C M0*^72',5D+++B,BH5YAMXG2AP/53=.OK3QONIIW?]3SBZ4/[$YYA:55;)EWH*

M^KEM\7.?]'/R+A5.),N"/ +,^C@,T=E^$),N0#B**L1F&10A1E-:[P2!;CK3!58:HB=P]+%!9Y M5,NQ5):Z>97GW92K,W.>VB?GW@K&N8),BD4F[LZ(N,#15K6&E,IG*

*R/761JC@&]1#P>NQ?]P"PXD4Z MM.9 3RSEM.!LP=F"LW?"61Y-S9Q!*EB*N+ 8:1L$"L)Y9HW BJSC[':K4&T= M9]=28P2^;RIC =I2FZI PC M%ZD[*O!31>;B A>@*

9P7U2$5AD17&U[6K'1:/7<6[X.S> MXVRI;K7%ZE:CC<5E[??*E03-D]!YN(*3LNB(YPY[83D"^T3TC2!"P(Z!N2&L MEO]OPT:\(O9*E>=A9F@6S"V87S-XE9EM'6:"IM;*H$;>:

*(V.93^GUU@D:.1=K ME< OX^]_7,S>H$> _@'8I=55*7168/VR8KU6DE!B,6 RIP05-/=IJCB+FNL:, M8<[K39P=%-7\F:!\4=N',P-J&^4IDD= _^\75QX"?*

*F]J).'O^31;O3'M2)X^= CC^#Q;ZR/M3J@X9:] M+7M;IK, ^1G-66V=A[\:^]-NS*A]Y*]SY+$=+H B17 .2[#(^B?!*^7?[A33 MN;.SF$W&C W4MO[O]\%,'T)&MPE5W(>%*T5$"*

*[OMEMV^: UY]<9,0F&WIU>O M_HF)S;($]ZH;NU LMD,2*6M2UJ3P4:&9LB:%CPK-E#79HS4I?%1HI]S)(+1 M\S 7RQ*4)2A,42BB+$%ABD(190D*4Q2*V, !UX:C9-9G ?!],*'#Q.A[-*

L+5A4C%M.W# ^=!4(5GGA// M_)K2:0K+%)8I+%'$3.&9PC-%S.PC/16KL4#35]#!:RUZ#[*]#2P1>&+ M-;Y@A2*7Q2^*/*B\$7ABR(O"E\4OBCRHO!%X8LB+PI?*

%+XH]\+P1>&+(B_V MB&@.J@;7IM9UV\WWOGD[KJ8G[:PS8]]]^R3QW89WIQ-,GA20[=,L)!KV[^;?SZ@'^-ODI;/W+2:A$]A/+ME+?/!7HVML=&MFRWNG_0> MV,WT?@W-#

],AZ3?S)=G0\ZYN<$]P,%(*CJ0V#'",'+*U-D@943M5$X,MOMS@ M5&O&N8H^< ':*?#M%PZ4O_D?6]^QQ>OC<=5)+ MIX- D7**N @:\$]9)$*,FGE6UY1=QC]+O?+<:L2)]P$S"4;&*

<(NBL%HXCT MY#'Q[T;88Q@ 0=S;)<7N-O3C2YPMU&X4X!VDH#"]@#T$':(]4\13HIS6M M);'V,MPQP>[<'4/.$0Z8QR2R<#$2RD9K=91"KO6SWQW<25K@KL#=H6YT@;O-

*MPIW4/C+)4 @.X ZT-#!2>8V$4(8Q&A7V[C+<<49M--XC&D6R:AD8MLP*I*W4 M3 7CJ']D[W=<\0)W!>X.=:,+W&T6[H1F7&$#BAUAB*MHD=*4(R^)9YO&ZYFZ M#'?*

*8*ZT"UDB"CH>X-0%@1UBH99&"EMC4>|*[F+S)7CT[S!I$\DK2NBK@G8% M[0YUHPO:;13MJ':D=B(@S(5$G!N"C 2[M 8-+GC)B<;U&MIA0EGP!K$8P)8U*

MQ^,0T!>,$1&3Z(?:}E"]H5M#O4C2YHM]F#VF H5C(B+L$YB88K9(S"R GX ME 81O=-K!Q4.*RZY1,YI0#NN)3)!&*1P,(9Z)6N'BVY7T*Z/9Z)6N'BVY7T*Z/4&[/4,[B,F + MGB-G:*

*[!DA79(26*0K"-6ACI0_<)EM!,L)FN5@A'+ 2$]PTASP!BK(Q,RL"!]J MLT>Z'2MPMYS>/4,FYZ4#2LD>LZ;MIM6;9R'3'8E9O*9L5&1(:LR)(H:E&)K MD2"U!(W94Y*

G):6FD%8Q9 :UG?OVY$OJO,^,D%1G9_)1A|FVCU.8+B+E@@K- HQUH@KKY"B M5B-OI-|X.@^XBBQV' NP!3G*2S3,XI, M8 01&[$(+FA:Q\LX"A]1(L!6UD0G:QZG,S,G$<&"*"8M(!;?*

*0QQE3S&FL^!H MP=&"HW2'O5I&3C2U[*8&[/#H.#(NM,S+*7!D@:S9H@ALBHA4)$,] T,?QF:*[(*X]=)'4@?O=G0.L!!45I+#!Z M^#M>8'0CB4"1.TP)0:Y6R6VH*

*<*DD*@.SEO&'%QS5CF7KK C(=)!=??HR3\ M&;15S-D V*EV#GM%;2Q*8T&[9XMVCW3T;1FEQH24&F01KZU!%EN.@N<44^D, MMFQ!I\3K0**5R-*

*?)U>B#0.H)@2A1DG%,,&R#*3V'4GIW"5R4L]4#Y]DBKC;@D/),U]2DR5!/$>2V1BL$@ M(;4.E,.:4 &0L-3)'][<+:^A9|/78 _!DDF+>KZ/?%#4\V>RT8<)>(_DTS4Q M.@F:.0E.*

(.YD1)H;C!P-&(#568O-0R)3'QM ;U> ^F);H]H!5,+IFX%4[6P MU-'HD*NY2.=D 2DLTXE9, +R6@BS5@;Y+E&]^XFI_$G61BZ86C"U8.KN,170 M46&'DP?9$-?*

V0!7I/&&FRT/$]V5GST+A&K^XFIY @75"VH6E#UV:'J-57Z M*)=$"(9([E;%HZ-(N3H@@S&CDH>V5HHPEWB5XN[\^GR00&\9[+13PGPB,?& M>0;*GA8&*

<2PM4@SPKU:4<26L4W$M>N N(:<%)XN'O3 >R8;_90 SWNI6&H(M!"L:ZBD$6-'PKUE3HD6?(X\15UGS.(=2AGI7,V]1ES[U>_0/?|<+N&X" M#+&VO*X%038"']'(M'#+<.L1C!*

*V=*R[QVMG4-B-)-P>&-Q_1/\5(TN+#*-!7 MH,_VP4F,:X*U22WS(N+*$-#I2X"O()+?SB 7A(C:4\?C>B/,+09H%N@]1(XHT/=,-OHI01\FE',J(]1 M@Z[G]$7*^QIAPJ0,@BBU'IN^S5#-*

GV'$[19]GFNKO+[,!H!51]5'\,8B'F4 MHS2-A\N;;I](^U,HH9]X"P+Y!4FBP$?B]-IU;6CQE?S?3L@WKOGOG]#0Y> M7CU.N<@U)G:1@0"32-*

N>8T4P1$%3CQ3.@0AU6.&>PXH\E./(2#Y7E] D[^^ MG(5Q%S8=],G8UBN2W$"Q?? _9KL'](96K"\8/FA8KF46 M>:\1B2.%7E"#M M$4]#YO0(\X+F!FY90?."Y@7-*

*GRF:7^,9L999R@1B-'6$ M\4$BFT-=1)"**HPU6SOEW698\Z;1=\=GO7N*N"44I@!M =]#5IN=QL(2)I%0 MUB"N8HVTD ITY]K7E&OAE7S,H.S=],UJZYEY>XK@16;&U\%,*L*

*2!'/<&]J.5Z M*D[:T;O*C^QFV=$>2)_IV9D=AEP+T=HSX\UN6I%SEH@@O"'^&Z?G&3VP2.S+ ^,$0Z8QR2R<#$2RD9K=91"KO6SWQW<25K@KL#=H6YT@;O-*

*MPIW4/C+)4 @.X ZT-#!2>8V$4(8Q&A7V[C+<<49M--XC&D6R:AD8MLP*I*W4 M3 7CJ']D[W=<\0)W!>X.=:,+W&T6[H1F7&$#BAUAB*MHD=*4(R^)9YO&ZYFZ M#'?

|8B185&V&!FN.>1L[6S^[J.@1D3$68U(!Q%!G%&%+6!]R% MMI3:G0(9DZP V0,4W]OV3S@8E'P V_S8C)ON)/C[8]OZHOD^F'6^;KH?#'/=*
M<]/OY+QX2K&1EEKPA2],4FQ51848!,IEY;Z'%#M0|> MVWS:1N4#O@^59/9@'7Y;;1;S()0CN/-"QYB-UU$3%GODK2"(@ZA!EGB')%64 M&RC5(YC))OM/E\(\5VDF|$CSF_7R(+/;[I MXV;@J&.QFH"CU:. ^_O'GJX_E-M_X2$E&ZPR[+UD$3SY-XG$FN,%$B4-/C'CL MM**G0#Z%/YX/?SQRXM"!4T])%'JH8_-]&Z>?4Z&09, ^X]O1LE@IK?KWQZ<&L MS:*
*[("G9.#B7B_D$^?EG7KF9^(14%1EP)B0PW D7M18# _\UZOU=NB7L489.K# M31GB5C.D=*7(6&?A.ZVI"[?V,_XT:;M-===&FFI1("?)^_]ZE!< V&=+A*0^2*
M!R0,]RDZ4:2>60QYJK$2L8X*F\L IB4V@F&.B%,$<&,!RNK@D(.+K54UCMCN M!, 8UP7 ']#ZEE2AY?K^8MQ),PZ32[[\(C&>#0|50;$](C0P6)6(R%%1%PX MCA3G*
*AGF=;11*B;7PMAY\,;5U'"%)0*1P5M>@'0N+0@Q>&ZNZQ3"03)$ZU.L78K5IEPA MZYA&,6 OC8BF]CL2$[2(B0);94N?/FPI[ZQT-4>4Z-3N17FD:K#1@^|>"^]H M5?6:]*
*[8VQ((&BXS"(*5LGW0VQWFZ&6WY\O41,4H>Z NY3[8*#:A$3I8Q)*6-R7T<*MQ;3.N63U* A8R1|1MHA@ZGRRA)EY9HC)6!<2<U2K0G-5)*
*<<21I(($1B8U?"Z60*M#@&%P>G4-4;'ID(:2Q+$ZA@EQE2Y\^8S#^Y5_=I M"_/\=_Z@B)#BQ2E>G*_2S3?WK!5U-[%F.1.4>9<**WE0R!5&UN& N).2U5SP*
*M!S87FXNUUTMT^'X%',#W44B_@*1[O8(1UTK!C:GN2FQ9 .ZI_^AVZ6G?%I N M(%U >D| FFBG'5,>1<*R\0V>'O0#'2^^^|76W7I!;S(P>8@7W5;.\"E _PK@+U6?3*
M5?]QE2/B#B_KK&HEH2D MW)^(%-86:>TB8!F+)#FC+P+0ZHJL \X29O#74.8()GXMT#S^3F=+PE^)CB07((C'FE$G.&(M&4U8@HS3D@T9KV:]A?14|PH H)(4??.(N?-;|7QAOVAP
*M\P00.OT8MU4'1E>7FONC7>FKKN*D/>3,*[@V>9CZ \YRTF]W;O 1E14 G_<'G1.9L99.;T!U7'X (KMFTBP,YE5Q)|.OD3 M;Z:A:K(]WFAH=*
*X7A2XY.OQ1];F9GC3CRO7M&(?)'57M.#\| INV3C/5Y =*A M6([ML@8FX>#Y)R&D>ZY0.DS;62 L#FA9W&C0M+) 3M;$*%#59;^8T/?/%7X M?FPG[X$!?F[''W\& M$>9_ -*
,WD;V8T"\|NVC ^1\X+LFYA/,F>'KWRA]|:8|A6F= |.YY#V$]XQ3+0?8U\R'<.W>D;UQ M=8A>*A2\!Q(F,2+K0)FM#1,X8B5Q5.M&B1'"Z8@BH6"Z!\! I8A$1#)KK"3,
*MB'"A]^+W6;"9T4])CKT=N]',PVHF,N\5B^#?S=6*MXOE6C9]O#F(Y/8*

*I] MXX@59 ;ZZ<) E1?HK0M)Y*X3G!F-+L#Y-;H C/=3T\XZD/&7]).D 8(JQ<4 MN6O:^J:.GYF# OO%&:@T:-SZ,)_*BPL-0?^=0S2^O$3L51R%+\@WDY!7.G4G*
MG)V.7R4|9V3.7Z9O7YT9GXAA)=BFZ1=L"$OI/ CGK)LV3ZS^PGPK F7W%=!5 MDY^=EQ)@=+4'WL+' ^66CGKR /?OPQHI/8R0U(4M|/LSSS?N9!'H,PR^&8 M8D#=%
*BJ[RIY\0M8UO[CO,]|M(^),+>79O39G'=#,\'5+9]O8CX;R!NV0@1K MF[G9/3O0LXA5QKJF+:Y-R8^U2@ZBB'@,R4.*4U%888@3H%O$M3I9=VZ+FU]Q M=|-*
<:0A@=J&"O(MOQ]UT,LM??+U-=+4 |M?3VP[]''^1V^ZMWHXEON^RV ?; M9P_6887>LJ!*%%=EDJM6*&Z/!GP@AN,]9]U?FE[ULIG"*-RUZ_#ZDVE&N8\Q M:! H&2[5REX>QB(]C!*
*(^K&CX*I9$=|).I@C$XVG5K!)W5Z6J]_12_A=6+OM! M\C?D5?+A=,':)X!^%.L3+[7>GI@D8)'/*

*Y\!Y0%1=CGE_8C'O5 M&EY\7/UU#->-8#%]]=$TXYZ304)TH1]#DU5|^+897T@ [-^16O)-PDD8=R#Z MT[7M*0P0=LV=)*?4)(!RYZ;#E;;P4>7;VO%@1W53$$*I5EZ8Y-X(\E67=5Y0*
*M?YO;^ZE@"7^Z:OS)?OLXSO/+7KS%;&]^-FA4T[YH7QKBTE.Z;$2XG'5ZV06] M>T69N@.IOKA:<^"&I)G%E$M&6@!Q"-#O4 *XT"=5Q*$|(,UA >S4Z"-|W=Q*
M^[X/_DW;32\K$7/B?!\[TS2N.7A8V8W0,P>]X:8%[>44(=IE4O#_#*Y'55&D6VZP83*XTG M65PP_"R=P"1O9T/?F5?IZS0^OG^:7P\D-#)G77@YA^3Y,N38Q?[1+ZY*,/G4 M=*
(UM1@#.+^?/N"X9/K]5X&.F;M/.?OU6^|WVWZF"B.E__=|S'WO:U, MMTSW,?[E6PT=6-]C:OP["X9:KOH, \@U>.V%MHWWR=PG72]EMK..A"9W:U2 MMO=E.3:=)@'+F[[|Q?*
TQ/:8/NNL#)K>ERW0&\:0]]#S]6R/8?N2; M/Z[\>39+A3]I+?W&4ZY4/23WMYQ..5'T4WD
MX+%/9I2"MUX6\"C@4;9</H9;.\SG'*AZ">]O<]PRH6BG_3V/KDIET+TCVWB M_-*.P_D\E2?"HI9>LX?8RFXW]9+W W\V7OD"|YIYJRBB@"R(&Z^1C5$@IB.) M'@NF?+R<)&4"D=*
(+AZ3F'"%9UTA%+A)' 5PI$RY4/1SV-YG..5"T4]Z>Y_AE M%/^GM?7)3+B$9CVWH?("5 MZF;3\|HVHU$)Q|APO]ZK:@ SMVX
*MZ0M&E[H^]TOSN=O+LEM|$3MF1=;B=%'JYCSC;O00\P95W68P#W9B252EY1R") M$ETN! ?OA #IHZ%":H7?#>I?.Y4B\QORC/B.5 $<5QF4EUQP*HBP|EE]Q_*(MV2?U'5]CF?*
*W;K"IP5N"LP'D?X'0BVI02*9'K"H0Q%KQB'@21'"*D66PZ#0[>- M >G&K'=!G]31O/*

*Y]QM]+->L=0M$EF+?.]&?<@]/2]:>FJ1[RH_57XV)C^UR'<5H"I]Q&@6N3[V3,;O*24 M;'?FRQ]26-;XIEV-;U[SI-0|*77*E;-? 'E?X)0K1Q\]T>5_@E"M''S1Y#V[* M-*
*:WT8X.%:HWO"AXO%#PJ1[]P\K[*5>./FCROL 15XX^:/(>W)1K0NE:XWOW M(.B&9G>M|%0MK]:)!|{6$55 !N))%,!)M$ A*\C9'@UWYP29W)R((/0#+PM M:?*
*ZXD."X+;>!L@_9B.P)?];L'N+(,ED+KE4HVW625BC;()0%R92P5(&FBH$@ MFH.SRH,GB7O#HPUND$%O8U!6:WQ7<*O@5L%M6^!&+.&!F@0|)P2W$ 380"10*
M)X+BS"B=!K>VMP|N^Y@ HX);!;<;CL%;EX1G;,)D):HB*K#)8*!T%(D2C1 MQ#]Z+7"K)N?&@:L&8SQ63&J-[WHX|J(/1RI'OW#ROL 15XX^:/*^P"E7CCYH M\A[*

*J762YZ#uN^Z M$RTKQFUR"IR.$H3/'@OW!G1F4?(07.#QF>NTD%KCNYX95*2L2+DYI!1),B9= MA"B,!Y%(!!/Q-Z**
*(]I(:FI+=&E(^:6$60BMX5O"LX%G!Q:/4S(,*1*G86;%S5[!S%ZJPO" 0#<1'CV@))!%22@-R M<(8%L#JJ*CGBL5M@>C&+'/*1 7(6NS[Z7S%M=CW$VU*M3C82RT.YE-BUDD'*
MD2@/PA$-GN>(?]H@@Y",9!1=(1.V<*[^"# NY6@RIS:EK0'G(?N4 M*Y96+*U8^[*PE'L6 TVET"S)($)"7+2HB48AG3-1FT@'WI'M8^G^NY@KE%8H MK5#ZHJ!4)F8(B0EB$!2$L0
0U4FN!1[J2L=YPG;<%I1O3-X^(L!4G'UOM>[F MORQ.TVP4\.\X^K@CP'BM[R]V=^<%V4'/]@;F^?XD-> ^FI]CO>1-'L5G->'TD M]^AFXX"CJ>-240TJ6(<'%-*
*@F&)@@G&*14NY'N03XTZER#R"&-1^E0 QU6Y MRBVYX%2@^-L5V"Q:^.#<687=23/_E,;8PVFWGHUKFVF^D2F?9KY_I+/U(6*
MZ2IOB>,;.6'[GH0XEIQ_LT.7)3:P#LT]D=!\K9_M3'[EMH]9MT_6KKZ6C'P MRS/"YN?NIDDJ O"$"UY=ZPL]*6EF L%QS']^-I^/-5*
*MDU#M/"LR/UND9[=YMJD7Y,+L'SMF1Q">GZ1US&\O-LMR=KY+"-UO/[ASY.EX M//UT-;>=SB_ET99B4\2!['E^&7QV'LS]>+I3_I3=^= M)^5J=; MI[N?T_U*Z)IYAG1.-Z#X/I=@?*
*E%ES*FH=++#E@S6K^Z[\/O;[V,W.O MR45K>-.E_%,/;IQJ M%;8*'G7*E:-?"'E?X)0K1Q\]T>5_@E"M"S1Y#V[*M0K34YLX/T\GZ;S! OY_M\R;CHM9*3/M8K;G6):_2!?*
84!>$N9$B!,A!),;"$F!$F)P(\U(,:Y)'K9)6 M"CS!'\)E!CY8#T8IGYTWRGA__<9C<2^\G<3RW]\NG0P7]R!_&+5A/"T1X1M* MI\&,M";U4'E%LUTG;46S31:'2USF4##,1(+*
(Y"-8[1DXJ8).DE ;S74T"X%(M(3P!JP!P2@!5MPID,;P++2E6>4G1K,G3Z!6H:Q"686RG8(R$3,-4A'P,6@0 M)"4P)G!(,=CHGI#=5)1$":;3$IF 94(@E$4)-L:$:&B2=M8PIV.%L@IE%B-
*0I5XY^$>1]@5,N M\"W0Y'V!4ZX]G<53]4K. P^@PGHXC=O_[!?['(;:!>0PZ> MEHJ_!!P7'2AAG$?*5]D.C&'C7B:E(@.:- :A"89/,$ 0 ,!4\W8=>*KC>1(ML&/](-G*
*5N38)V)P%+2ECIMLS9?;<2X2)4V&9**.)UL''B6<216!L=H--'% M#9] [V==5K3SQH_&X\O@E#O\5WV++#W2P[&29\B=U'+_8ZN0Y,XX2G,$P9D%(MRQ&KHD19MUYH90S-*
*=I#L6R1.B"6@910@4O!@/]2(*B)P;RB1;)#L^|=+;\XV M?9%*;-D7>5!URBM"5H2L"/D5A"0N1AU= -W14-)Y\#Q)U(&D231X2;4?5+G) M3CB?$1R]0N4MR*ZLE@4=$[Z2F-*
*9&/05"/G,1Q#[/%1XK//XX/%)BM2(,B&,$ M!#5H8I*DP#1&1I1D$;TBYC[O6"4I M,"I9)(I:0@1T\A11M|,.)QXS$C@UCY3,L.BI0 M5[\"L0/FB@#(Z1,@4'"#$2@YZH8^V0R42A-*
4IB[R84H-!";-O0>K@L-WF "# M2 G64D55]":5-!P5"M05[\"L0'D@0.EY <3.SXOP*$(LE]WQ!\|F)2964YI8- MP@N<2I%Y#CE&@UJH"N"XRH &.1><"B+LP$%]=P\IU[S#^[G*
;.P#U K^ M8G=WGOH.>ITW,,_W)ZG)Q2G]L:OH/,W-'#^YO+O:M"DL9J/Y*'7^ZQ]26!9X MIEV!9]Y\2K/4N!:%:SR>?KIZU?5@F6'%]1W3WQ33[Q;SZ4K>RWA*Q7HY@4?D;4'R?*
BRV^].JD5-3RI->6[_),O_FYN_]5 MNC"6&]6E6L5T<^$GSP%=3R_)=S8#RN.O1W-L=RZWM_^4/3"68L*/NKYTT7K*
*M)K'|K@):+;M\4;Z5R6B&KZ@)59.XCJR*3!69*C+W$9FJ&%>1J2)S1Y'I@LJK MP#Q9?["V;/35YQZA6%GYE[SB]7\8C5C7N7HRM&5HRMY7^24*T0]NRK40 MPU,;.#!/)^F\)P?*
*[^3,/FXZ*V=V"'>K=UQPHVUEJE&[R3R]4PP2D-C'$#HEQ' MM893B)9&JA7SC TJR/-$G%>, C$D@,B6@#/>0V9),&(<4720$>JI:Y6*(\MD*
MK55:T6S725K1;),9JK7FJ=RK)S%Z$#HPL(Y[X,%S%Z1+4N7K:!8<]30' 3EZ M"*F""93 C0Q ,]ZGD.N1>0KE%4HJU#VA%!FJ" D^P!$1P["B"XSM -EO%5, MI!
8N0YESAG]6:%2@O2O)CTM>LR4)UT,)%*1+<*917**115'M*K4Q]+1M TR^C MR<(M^:5,&%=EU^;<];U129?)X22;,'8M"M:9^Y\@,HUI]0Z,]WR]'-8 NASQ MGU\#?*
Y/'Z3/$T2QUHH7K-EZ<3M[$47LV=N>OR[=OSER,.5KUP1&_C?+[JL'L5TB2^,9NV79V"U[,T1G1\3"ARG\O\L.EM\ Q2BYPI*=!%ZPY3\6B"PYB|V2RU6\RG;ZY^ M@>O:?|P1NK^]X#),*
*]K4;?W+G[9M7?[E@B67+*RIV/-Y1;(T+!M3<+-'V4Z8N MZ;.VC/?HZ&)C7P+O*G,ZBX**H" R6_+J:@TVF@")6"UBI":X02Q.)H(0IBVX M(/$=@SN\X0KY0 =CO.26$'%]7_|IZB;M+]-*
Y;M ,/7$QO) '7^4F;X;Z=1MVF MWOXP:L-X6O;\][C5]'^I^/-5DW"C/L-FYC/'[$W:\B]\90KW2]?>KYU4_ ' M<1/D5|=-6:SF'- G4T79S],PGA1T:&12(6Z^7I/CKV7=WJTO MV|U|L[JB-*
LNQ|:/3V+-?CT&(=PW+P_*3?+VC1O>]:J&:=I]B309M22?X_0?DL[8933YBD|/9*+5'W0HLQKTITCT\+S"' MK?S9'C=Q&P2V=C=Y,)]D<0,)B0!@>8:_"T,$)\,;@ L1SUPI1F:50Z$ '$E M-*
D=1#YX#IPIPS/56O.!7?>ON(@_X2+|.OD#6>C7_/VB1=6A;8<|=LE9Y&M' MO$?R"RZP9V"M3ZYM9GTMK'|@FR#;%+C"!V*:M/C!\PVM\':Y2NL*>Z,B-^_ MZXXEIRO9[_DV(-*
*K.T@D.&/6LGF_CHMC5W5PF2+3F%)LJ:1M4^["QX:W,HZ93 MTU('S,4EA)YT_(QD>1%;YX^3PFB3WG)]/HWF)]W:(PQ-VEXRC|JWL^#BR#5G M;G1]U]PY8"*L7(J1"IRC]&0ZXL#[:"*

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|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|$7+T:OY^^;8< M$#S&28= [&S_WIYK;$/JGV9\0X]RS_NWL?+\%KE8WPQ0 MKJ[O@UW:&?KF@;CZU9R$SV%OW:3IKLXD9D57+/L<;NQMISCL) R08+GWD@.G MO%1EY\7KPQ0X8T*VEE@N!N;]?6"@,Y]^6*Y BE_S^:_EMX2(:,W GJPVVC,;W MJ*A0G3%$N>*@5=)KC"L7VWDU;53FAZT]4LI[E7.%CNK2]3/\9]IO:HQK1U\7 M/+;LN:'14<'GKQPM-%7_+%1^(7Z;6:D_*;HIB[4Z+)/HQ<ZZ=[TO1[5?81SO'G;?

*L@V2+AEL\%9Q"A[Y&5K[^SWKPT"P@6!C0W<*P9(Q DB]C[1TO2^3 MP%CN]:U=(&\$P%"WV83+>_N%!RE[F1HP(&W+-G0G(,TTC53$L*PU)>@(!LDT M!0('W%]RAN>MYA[,OS9(V0;E (RB_X_E (S#8H?B_\$AF]PL9%,+8.DSG)S8 MG\%%#C;ZDG'6Q3P*^F 4,A@U,Z"I";(-!"4Y5YO+6H=,$F?H_RG@4@82UDR%LL5$ M'T(;H\ <0C0,K!F6ODHV0M!B:64=Y=] MU*XIPB@Y)P= MQ*@2&-,HJQ =D9YE0C5?6T^7HJCDFM8$)$N16Q"Q&,(]I[.-H/]0AXVF&W?H M0Z1F8K4%C#=>[*!<(6:L4 O7BM&@#?E#? 7"H//E@'3:BU!W:&3*9"ASD MY^WL; 9I&#(#Y<:&[A:XN6:O9 &]I'00*\-FB%8UB+K80#&5I.:MQ7IK?W1B M@!E9YUXU M@B\-N64N)<\Z^Z4LY50=ZHF? $V1AMS8@J=4/44.R(\^,W;F7;9[)N L %@ M8T-W"L!*30G%V 3K]@4DHR"GB&"C))5*9Y[NM^1V<[&5]P("T+=O0G8 T M6X+#(H9BK(/REV!?(B@8E.E6(499YSLP7QH@Y-M3L! 5/6OEO;?S@ ?CZ[^ M.QW@;RD[IX37U8)] ITWD"H6'"%][9EMKAF*;)UJIT&+$Z M^#Y2!R&Q,!][<&2,V"<9'P)ZGC.\/YKV#XP;&/[IST$:-T$97(<;:NE.X0,I> MC ?,VA0LOJB9A1&;2FS@0* 5TP2=+4#R=@C&:>?E1U]&<'\;-&!_YI9MZ$Y MFC%H:V:"4 ,#)C$4]L&;$#P<;&]&[#P<:&:[A5"95MR:CH+$*'\4VR&I)MD8I5S6V3I3;-Z_GN[M?0YD:_"!MRS9T-R MA%Q,H]TIS2'LP%]H@91L4 MWA_U_!^&]T>7", +=$XL7\2Z2;7%()LG:A&\M&1MS9H/T+](I2_#>;)"/4_FIW"'+6W MM4&(40P/RQ:R,PC5*TX@VRV,RF-CZ&1%0G[983(&LK .;B8.OMIHAN0)IR(6>C(4?+@$$14-"Z6X]DDG;D\BVMKU4)Q@K'4[[IE2GU8'\2 M5$RMQ!ILI?KD?F529IL#7@*^QH3L%?['6$)I3D&KOK12[!)*02;/(5M6ZG&:, M[-Y>W\'(7]8&#$C;L@W="4CST47O0P53E!-XZI-W@U: 43?6]*/!V3BE! ,@ M#4:V*6'^4<6 6MI I%'$O]N1?>5;<2E7",T+OTA E5!N!"BU2HJ4*L2S]B M3 EC!N%R IW-4*\X)3/6Y>U(FWKRXCL7IC_",SO$]NX0Q6B:<8F);9*]RBC M\\(C=_O4B[:*LQK^ZFLV6755* ;0% N478)8@<G+_>Q4B!*,M MZYI\T\. O T:. :!MRS9T)R#-Z\7I0PU-APK8.H$@F844&PO:A1QX7AP;FS%8 M;A"U ?#;"<|]F(F VA\|.-G+U(!;5NVH3L!;5&GDI$#9!*[$95"B,UY$,3 ME3 R;^*,DSV8>VUPLLV)^H B CNB N.8V*&(O /5^5 #M.)4GWZ)0(T5*/9% M9XU9V5D1H47KJBZ]BV;K*5#&0JR.@9+76%-K/K<1\1^:L*FEH-9)*!(I!FI.>T@JN@A5Y6U52T8;"/B/R+^ M+]\2&1' QYM:[5))+C@H+O?18(V -DK12Z8O[%4G2(8(2C3L,2F5[8QJ5!9^,C1,6BCV"W OY6Q0K MPUCMBDF$=32(W08-&)"V91NZ$Y#&/,J,86FL8^NC7"UD%11H&TVUN66C9\Q3 M&W(.36MP.O9FV820/">@$F)*5>>,8.& M(U"V 51#:LZ:RO-NF _F1!ND;(,"^Z.< X/ FC:/P+|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|.;5W"R M@5ZCM/ A8_[=G[$(]P_POW7Z_L5MNR)(44E8*>9(:,2R]6DFM"1+C0S6]NQ MR15K@+GG]H="0#XE0!^I>.\I^_(RPOV7"C$B ;M$, ^[2!>Y5&,%"5&2Z+5-[MJS*$:K35K%RH;5;@;X4/6-L\1(XH9"$KN3H%,(V4*YYBB30B_2/2 _*-DQ'I M?S0K)/E2X#G600\G=[W(|(4&YLZ&Z! MFQ(\B@H)O@#4=]/L,5U\|>)-2$&N!, < 2F)IW5BP3AM!A>5#*V&;"(@,A MU|$T=ALT8$#:EFWH3D :Y1R30P,I]^E*.O7I2]U!;MYGXL1Q MGKST8#ZT$>G?D$C J.Y?+>VKD].#PU6H_Q<^?7=0>"'BN9 3>)*](G]*N2O M_SBB_KL5|4 &M:O= ;*FK9IN9DP1O#/-*D/.IUF#IX[^)A,*M-][VGDR0&@< M>,XA"3,LGE](D?^5+>0LT8$#:EFWH M3D!:,V(.&]H0A*:)>6B$N34D"!A"JB56%VL3 >P7MF:24$QVCEF)*%=7^WV M'9SL96K @+0MV]"=@+2:R*?*#+5P >S=^F,R ?]D)=;*EV;MH_G01MA_0|+^ MH\|_7<^QG1_>LZ,.+[NT0N[E"'['1M7DYZ M$6\]Y][L1=;#*0|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|KNK#:-OF9;C\>GR6#L>9]40]+QY] M#6[/1GG^5=CQG? _H8?O0]W+K62S\R_#RMUY0M+\ZA2:'& QMV&UM^#H&:O9- MIZ#U^?#]FX;;K3#Q602H&(BD%70MNL3ZZGTSR13VTI^_(QW\ GS$8DL^0<-'< Y@#,+:"Y MM583DF4(O>4VNBK0FLD!UQ]%Z6+-:C87]BE4RH0(J;B>GY@SD/4,' I1=C8] MA4]!<]7GDMS@]M339GEO#E(/CCL@>T#VTW)<:@VCTAD4LH]*P? 4D@':XF6VBUD@![QK]^UOH$70$6K46%|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|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|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|VAGK1(!HUHLN-M1:(A0Y80MR!"=*4">M#*NN=+C7H\//L ^6 M(Z#UOG'#VAD(.#9TIX OY%";TQ:T]PXPH@<2Z +2UCC+B#;]6<&;2L7I;H[4 MAH'9>]DSSW:VK6:RRGM,PPW]IL5_X-F6;>A.X)G#X)(V 8()W:UB-"1#+&DKQ M)1>BX'%6@%M;386*AE9ZTLO03 P%&B&6S*MDDGI.9,$K-VS.@PP&V V-G2G MP*QD6UKC!*V%UK,Q(J2:/#3EFE5"T$R;6:7W]A4/4 ->4LA]-GB%@5.-=:;C5]@[-"P,?PL@URMD%Y J.9P&II7YV /E^>]7BH MN>PF|*T>+01V<3E E^92\QH,A0H80X88 X)VH54EEFFF65/C$-E&3TH8GG*] M@1X!!52@T2FN*A-Y?'G) =>T860'[!+IN"MMQNKH8F PO?T06]4@%VS")%Q! M4YK*\S:1CFJ*.10A&=T7%$]&%!'!).30C*ULPX-E! 3C:OF0&N 6-^/T0 J! M.*<:X?O',RQ*3 FC$TO"BF'14H7$R0(KBYX:%9=FCI+'0(=1XO L-L@ P+&A M.X-[M0434A:T4UR$%5FS:H0=*]J6@]Y89K@%A:F!R",P% M0(W&)W 0C^]+@6@#T0:B?5@6R\E7) TIAYZ/1!E(M0\4;8V98A C<.8!(5T# M,0/]W.RDIN:0)VK.@@DIN=T$6M->|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|/^&@Y/>.:+? E>'FVJB#\(2VY_IS>=^E= BH?^L.A MD.UO%KPLZ:0G;IR>KW. Y&MR?77VN=_BG_KSCNOXY()_?=IOJP27?'Q8'T+N MM-E?3&8*3 NZN+[F"SE7%W][>W)X)YY!:[%S^<"(O),@9#CUZ?I[<;#Q=Q.4"RF8A. &*[WQTL?(Z=3700CJ95^'L]^.[^2ESW!:\?1-%P>7 G_2O^MW MTSEEE/(7:"%_77S:?1)&?3_IO?]E^EU_| <)7U97:+?XZ>W103Y?+E:+^($N M7;N)O/7Z33:?L#S >O]X-*W]W61:%^]6]M ^KE=KWI=E;R'/(#3OY/3XW4'G M"")4TSM>=U[1J82PP>6T.1>D|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|4VOL7?C:SI3WCNWW4&FG4# M2W#I8*3309,/7OXP%EH@(NF& !\4,U["F/]$!KY'DM27 ("BXNNQVT?%$'/ MOV =YBDSWG:[GFZ!ZR1LM%D?O^O2>Z)6[,09UQ<"Z$B9:T"Y$V1(0)3K+3C05 M54!PKE? 9:=E8|%FIO#ZM8N3Z?,5]LT:TP(D *.H1^ =RQX*,#;?-=;S9%+GX M80B:17DNN!N!JLT8.GE!_: 5GD:42|*|HB[:P1- 01$:)20*$Y<6D)20H6 M(DE=ZL)->2@YWTC0^;<),E|EZ+ <8S5,7:W+>2,U(3$["RIZ[>S2LN@\34D@ M52/ C-X,6X@\;TUU!^"] 5@]X4;\>0P6,#)BE MXB]=P,S5[@=KH:0H5;ZWS+0/>TW=7_4H#-7_#7[-N4/MT=B_/)M(GR2< MIB3TI"1IE'HD"#CS$X <)M=;_5"?Q?'D7G-*|=-YKIYN!*AZ+C'1+EK=[VRH MG'@HUI>U\F5CN]?1E78!T,R+2AG;LL#^5]K,EDT!W3-=8/85:=/Q@%FLBIN M3/(CT(.[1, /\5.1>&OG4%H[^S&X]?Y;Y ,T9@]DGO&$^(F(8.-S#%^Y&8G" M+&'2RX0,UI(.'A7>'YQ8HAW%=K!9*N>=R)L9;2X=7VDQ\" .131/::+!V IL M_Z-=%>-"R$40O@?//G'3:%$CY[2C3S? F]A27SC\]J[N1\\ F2'E'QYBC]+TK MJ_'TW^ 2=34]AD7%9R;1=.AY0EZ>]@EEN\;4+(T#GK@!B22>PQGD'LE%*@CF ML.=AF#/|UT) H9"11\&H%%1P/(F8DM2'/P.:Y3X-4R;#M8S'.S.UL<9 4VC M[XUE^4M3M[<4Y+B: 15Q@3]HZL#W4WE$LP=GVH017L5. ^]!#'ZLA_Z>=BFA!)-- ,#Z M>1LD;IB'+/:R&C7[CYR7]DOUQ.;GVYS1[9'39 PX'M&DAY MH)2ZW&.$)AQ4SLP'?/*9)#$+@UC&>1!$?!6D>![[299FQ!-'@.,:A)B0-P2*5 M499E8)LRBF'FIXY3!T$Z\LBKW%V)I%A*>5&^3KGC+C1/3%:!#EVC9AX5$HGQ MSQ(2RQ2[LDM0244.YDSB1S3+8AY';YE;=R&F>WLIC&^BC^$#|2DA>/_V WXR M@KGN TC#Z=,.V 'IC(V>B7"193((P34@H&"-9GC&@22@]LSB@4D>1N%"5KB4;WU3(':=9::"^_/ M;+NE8:)FLFO$D2?"S6@L2.H!283&]T=MOVH@/Q@Q.%[M]BCRKSZ2^PD(I%>&$7]'J=8K^6!(1W-AK ,GICIUMKQ\RIQW+1'>"&9@V5.P M',PT.*8^C9D? 1E(689^M8Q0L*P)SR@5?NSSR,M7Z9])[]6<8>]NGX)&S/&H M^CPBTN,B!),]9T&Z^_IOP?';_AD_SOP$54D2A0F:/HSD,JBG H+>F MK;I)&-(|%I7!D)(O%'L[E06[U+]^5WI\0G' M_VIW.3",N8_5!X3%$C!09|ZA(?P322G@.)D#-UTKO$Z"+&81]T'H!S$)I0]Z M@9X ;/.SSPO#S@6/^PZF<>C+-PI*M]%%.34IWX< M^I3'KDC6^E@%TO4|'V"/)ZE/PCA-">5>1#*>2Q=TQ3SG>T >Z2B(XUTBCPV. MTS4\I%>X-Q5M;5#.-@)DW]MA*5-KT,'!825M80VG]$R0JN:B'R40$?YLEN4_MZ@2*K|^)\O6&K), ^_M>Q[7YE,1'BG3+EK:0]V-H]^Y\?P0$S/ZHB]+2F!5:M,=8GU+R?(/L*|Z;[71 M^B@3E3!W3,L+>MF>O/AQ3A+FR?TN]O9!:L<&5+*VF]O=M(?OA;;%=K0[FBU M-\]P=;X8GOMUD79:U!0]) MH@6CO)U-)IBSL%*N#U&2\6^/XMN;8(APW/1_ZLE#D.Z]56PZ8FG6NYAX/S M?28'9F26LA:=C.X"O3. Y4:KX@=,.FFK_I;[(XYOF8>[GUC0-SI3?8_7G.OI[BW M>4=^^,@C/? +3QWVA>Y3$=H[W> ^6]3H/;A!Z;CXA;QZ%-XWZ*=K&/>M;7|YW@ MAM.==O,DTOL9,<-V:%=&<'55:I[(\^-/I/)-'_3DPY?7?6H6[.^4|_;F4EGTL M^VR7??XP:CE1+/)*Z^;]<]_N7? WQ2>G1GZ0UYSO*1Y2/+1 .P]=E9(\[M&E(,\KI[FD]"Z;^^A?6W%MVN?LIR,&4Q=LEI=DWR74Y$?R3MPCY#+_M0-- QS,$:SL^T5*F=M%OWUS_*"1./[TIYQ",FGF#*.WGRZ<.>#;']LQQ=C^> " MNB3+A4]"Y]8D\V-&$B%C*[,XR;.UEW0=]H(NZ8CQ]GT]>=Y?">21!8GAF|/@>+YHRBYNF7>M0[/J-XH]=T#!M%Z6P[&)K,VPG%"2IZGP B+2E)(0S_|(7>X3WT_S1%"9^VFP M$UZ6#;CXY%Z6Q+5N%HN4=DL/ BG]D,DL3T(BO"0B@(QH3S,B9=2O8M4'DE;[7):1- +=MJS8AMLW*S!QM6G2%FQLQT#S3_RT4+C]0P[FAZF-V7S&CQ3 M\|24]D?+,,$R3BDI$PS!C)>2Y($"0RE]2GPE\[USR@L>!^'A#)>4K"*&:$!K$D M,8BN,/|"-\RV=U3U OXIE8RB:TXT?WCN>DH'B-7FGYTV;X.F6\3%*/?C/,.A MX9$/*GH4I23++>42DFW'ILR@*Q-HQ.T^,BT_M]_#]H_3[$_KVE:LL4%]@M$[Y M-5'"*).%!EN9$N))CE75(4I%QDN12L,#/61ZOM7[I8]!\F.R2$8S;HM\)YGEZO?XE6'>]2<4P9$0S_Z&KG'+Z>>T6L*\2(4PJ$0Y+LQSR3"'E0>R;(@ M(R%GE&1>GN+!V9'/7"^/*=L%2;;AX56%SGT%#E][_.H!#AW.TE$47GWPL/60 M6+3=*VW&*O[;+#T,_<#-XX0$H4?10Y(0/(:=!"+,(S^/9)\Z^P&73^XX"8]B

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|&PL^^]#\5'N3F&=XJS[3/W0* 5+NV%#OH%&>:+C.'G$BY\ M 1H$HU-X?M?,Q,WV[*CT_7T8Z-WGYS[S M^3WS_8O#AYS?-S*FTVLKT3=AXFVR|+\9M>^1> /:IUL"^T5BP".D:-PO36%; M4|Z8I7"U@#,O^,=KN#MOBG^,6EJUI_7E3MYG28"6\-? ? A&_N'YY;M7+_\DH MYJ9ZFE9P8&XEOT8;0U/P-_A[W#IO*P[*UE+4\,ZD=I-V\]NPFI;_[CMCRUY7_MKMZ'HK+\[@54WO;0F17"O9NV45DF(;TO A9P'="3:YD26_M) -.3^* (!'Y,21CG@[1)I\SD/IL2!)V5H7U#@4B12"Y6G,L"J%2Y)E<49D MP]*$I=*+A-A:|>4[6C2]RG*0U3)O3042Q,&?!%I6' ME=S+E?]8:MIU:K*8<0B[O%DUXIS[G-(,="$J24CS@-!4@IKCN1!(6>]$,T(E$:'"SR!2N)91EQLSR(&4]!19)6-;L(&, &8N'9Y,\Q%"674 M!4,217@DJ "3CN;Y3Q(WCP4%'&-)O NI5/*2>[P M$\YG%+10D#-9Z(4D=:/$B[D^OIV')- W:9]YG5A:E'=C3>Y2XYSI;- =D_C# M)CKAMPYH)NUDSQY;-D&PN,%ASO (X)]T(1^ D169[SLY10D5 MB?#=P.-!%N1B[116F?'495Y,1!1&)/0YP"1/ L!7GGI>'$,H<=,U/+RS]W8W\-J MBU99M.#X#'=YZ^"8TC!*LHB2V)4!@",+2.1%C'@\83GSI0<:X]8 !<.DTC0")9N!SLT"EU#NNL0+ MF112L"P-U[I./[E3%_D:&RWV?1:WJ:4'1\GS, #(ZN@6&"TPW@H8:PA\8M'P$'9Y^VC(?5>2o0SP M%X#*E^.A.1%H@#+D>2|27T;KL?\G=^=:=-&]H#0B7+B^"^#*, =.$KC>.= *&(0#?T4P[(1G-"4S=GOH@!YK;74,&BH>43BX9VEW<6#3V/ M@SHG(B*C"VY/"8IRQ(">[|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|'KM;|? PXZ^>^&R4$B-P\2|C0?V9ZEDUUA(]R$S"&60 M4#SH.0L\$C(\(B5(7>YC'MXX+G,72LV A3U/9'$8$7]H<^ R7,PU9\-/'< MQ_N]('|$ $9QYV3B;3%$*]DX-TB)V9I[-0VI%WB@ 04N9MVE+B:VAAEAS,^! M'ICOKP=][I(,^[Z"I1-?Z-<2].T7CF@9G<+573,3-TL1 MR/8]0^*#*!)K@R-$KX\#2B/80<@#,?#OZ=96!5//P8M)[C-%AHUR8:%K3Z;2\ MQ(M@N*+M "^0'8W-OD@"*!8/QP[DZ#A6L9RN)ACF,;^/G&DY:U4 M87%*&3! M:-4!<,U:?!S8]T4E&_'O&8RXO'1]QF:-'B$P< M,C@D C5C(>.,]6)Z -]$0 M,68Z.ML[OI1SZ>Q&/]\X/ &Y1U?? J2#@RK0>E.BZ6BQ6(M6@Y143%A0@?*A5K]+|$AXEQKE+2E.-)RT9]22[P M\:WS=U5?5",D2-[P"8]=$&+R92H_X0N/'1Z?:)-5XFFA9<[KS@6ORK'RE)]HVBX M\V]8@$[GY2$VZ'QA"T]//I .9V>10%@'Y]@67,1=<_$P?SKL"%N>+]W[]X M]^G5BQ^.8.'P'0-/*GSO7!2ETE\:+,H*(\S?=UAI4CAG]._^-=-9"YKEK'/4 M\L%#1C]M&+Y50U8+.1AXSP!3,Z@CY_',<(-XWR@AI?JKI= M\W4^N2T5${1[EKDDN%>H11<^%W+NFV--W=,066K8(P'"%]2'!-"$_Q5=[-!_^D= M5 0J'(<&2ZSH:FF1]T.7>_ #*W5]53NA^+,:VDEA*G0E;2XFB FGC@C9B7,^P M#@/?K(0%_CTKI@IZ>(,P SO=^@96-.;O #2=')X/\ 7_\.@#9I';Q>P-^4 MO+Q_+=']P3E2]2/&5C O.177\ [D\69Y&?<$YB+\%>_30BN1=3XKDBC;PPSQ,> M/LW]U]7BV.2E_SR!2GC_DN8KD@Y8Y(9$DJ2I!26/*

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|[%L'<76(G YZ*WZ\CU*7)L+ M/+6*!:"DX^%56.F0QJ"DIQS/L,)VT&%]X]H/%M?FB8#E#P)"98I=,B))\E1R M$E'IL<0+6QV2O5TLA.*:"TJA',11-*K9]X\PY>W+)SIYZU2@:*)BOF@PL63,GZO\9L%4M?Q P^E/Z'A? D5_5 U\3>C7_27YHQ[QS M1M|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|| V4P13F4_=1#!7/TI+-M!V88PO"\T*!Q/QBVG5- D0;F0J7X5DD?>Z: M41'T?@DPC8 + ;H'9YGT>YDC36:=$GJC>&BTMHT?%3U=5|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§"7L^: M1]SHQK^?OAD]QNXWU.+ '<$B7*D3/_[F*F"QM#6G+9GZW$]D3&0,=E:89"[0 M249)('.>!9(FW%OS@L4RCZ5/)?']*'"AX-A*)?6)#*@?Q!XHF.%:%/&.GC$DB*Z-X#M^EM/?1L|W4!'"-!3 '&0->6E%LWY=U=- [G>VT3UME711#[4]WN_<>)Z69D9?5*'YPC ZV/|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|(C@5LN4*KVH3FC=K/!"$H Q@;$/5=A8]U8 M*IBF\|/%$!M.H&6*I8G6(H!EFYJRL;9I3$0.;CT;@[]#8>K^;3]VVN#"%%55 MGVOT7KA\U8R=L]KF*"KY#-0R$#6? &G%>U+,6_<7#]5]$_N;/GS:@-O7L3/.YB5 "U@4M4U,|:5'APL!+& L^" MQ>?%W)3K7]=']D\USX*;.A#=QB]1.F#@CA0?<67KL)W-|U&3NQ3H0!QU8"]K M->X76-|_<)| XZ/@Q,D;M:2U\RJO@4K>X?* 'RP_9E|< 2\M?@:.0H%4"8WX MP#PF.0-V\|O@* & +TOX&S->4"N$9RM'2]PG(=S&D,?3%YA!TLPFFEI-$\'. ME'5U!CJ^4)$<0#/<^4Z<4^?565. <:OB!!YAO7_OPY/RNXO[*T OG>_+G/5& MSJN&45Y@=HGQ+/2FPR+Q\U5>OSZ?JP-%;VTS,)$SY+CQR>R)3?B:COOL M!FUX]$.')_9BHH+W@P)>=6,F01]=$7LI#EZ#00- ,BCG#H9I9M:!IF-@78K,A M0%BZ,47W$@RB:2[Q91J ZVNC:G,"7_&)X?M1-("404P#ABOK=I$G9?AG2/@K M/)9NF<<,+;3C8MJKE0?'<^^O4!_F:4|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|8T8K4#F1*T^>3>VQ^AK0IA9VZ?%TL'+@N3E M4VU<>)1$H(*G<9CY01(F?O1RV CM;R&F,*IROA8&-=627+,&B &@=|=S$!C MIWZQ[HO5Y[ZR(Q[BQ@"*_ :+3IWG"ESO.1X'%AS0U/N"927G_NP*#)#7TLP M&GACIXVV<-&H+06MX+<&5EXY9I5]HJ=6Z^ "2K*B?$C!0-<%BI*8 AFDNKZA2^O[%^T\O?M"F] 2XO)B6 M8NX7'3642OC:J(1_H$IX^Z5X[';+# ^"C?)ZS5#T' MM/O?=UU_I T K)XW8=4^K-;'?O3S|5MMF Q358[0^:UB TO^?O/0 A4&S,4> M]9&.D8-28<7<,*DLRF(::?O)&$YH+;9| M|(*B5"HU"<,Z.MT+W_Q^/EPPQ=KG)HT4%"6ND+EA?H(X)YZ;M&:M-SVFZD[M*YD[1_KALJ3G^,R^%T5?S3Z:?]*+,IV54QVM$]T*,=3ZK\4.ALJRI!PIHL3 MNLID 5$-NE,I[A ^W4..V!>^WS+*;WO@BS(P]D?4;5OS^_R+HQ9B3VC@,"Cl M?K\#B.G-=8 MQ.-0J(Q4M+VM)!+44A7SXG*PS?%9K\$,I Q=;!B,Q22D-R]^&*F(IJRKB\ED M5HGYK[J\:@)3[|"W!N.=BAI-<;#,2@Z3,@D"?;6,B:=[+ ^CM M#%T*.)C@*'JIX%U\+5B]DI"/K@6FAVGFVV(&C_(4HC?BP^M?,/.J'Q<,O7_MGY>;@6B)-XP"],PWM=OE #!!ZEU9V.*5CX(U?^8,HK!"U5-AC;U]7!T_H>2 MNHO4APXS7/LTI.'S32D 9AY-:C", !MNH$Q;:17L:O9TZ,W=>0D#YV'@M,// MW*LS./!ZW&+T4H@)YCN@CZ- @&,C'BQE*]K)HQSH)0^?&+FANA.-7^1^#S%=: MPCI4*D YS(U5]1Y"@ #>H?#\\P2&PYCEBN]QM.)1Q%(SL=PB22%. MRU#?[-5G##]@UQ H5,4)T2=7_'LFC$]202GR4EFB[Z$]>FAIC:()#U/!$TP% M,QX+&#BR4+$H472P1+<"A**8X&D,@E*E8QG/!0R]A"]|CR?RNLHDAXEVHI_] M!E6\KQS36>' P?UT*>8^<0"_T99C@ MOH 5]X[OWROOKHD"[0)=8*[C6)18*")5Y/",?;D^T75'KPK0;)O)2X^9B? MUUX=]BQ1]_J]4C6G]|E$Z[P1Z _J=14/C6@]|E$Z[P]K(9] 8I5;:(.0)N\PI-UV M]O_B -5Y8QX&1DO29U2G M[#I4;;R+FM]\Z- YIOP_F [/YUX?Y9KB\UIC4$9GF%?<"5W>A&_2HEXB?)C2 M556*@<XJ5 ^*'FK:3C= T_FS^@7F9HS7M+]^K+RL)F*F9P>']9L@H M%M'\)I#R%^%ZLG1PL@!E6B|57\RS1[>)+U5>S;93|+UA2L&]U\-IN<.N]I M-G74IH[0.\3^W[723+^QWDB_7-S@UXU_5>M@U(=IHRF&Q9-KM1D?-6MY8R M1Q3"KQ0_ZY#(O15)W%O$1>B>.V[S+RZO2UX[L1|=WUVN86E0QM9.EZ?_-B M4S*-;RT7;3KG;2*&&SBHA+A=H\AY Z9YIZ?KGCT8K)9QET4Q'/^9%S*H0NH//N6T W].X"_W? %A/>H>&[+\/!ZL+M2 M:4RG2]NX0 SG#>WHLU^G6X13=.OO9X>D-U^!/HVD>:8K<=-YZ[K[MAMT7\!. M"GU+!17'1@S\Y==7@[X3?VC;]S"-*

*A5]'WGEQE|N&Z_ZS*NV2G4YCT:8*S"| MCB7 BX8RJAJ.Z&,#YCG0O2D%DYIAGRFP:QMEN2WJ*'N[%NT5!HI_K9S[O9FJ MDR[/,#:O\@Y],,3@F;,I0]KV-*

%YB[:-9#UG.,/^SPPK#J3!MZ*N5ME58Q#R' MF7Y",(.E$30DP/'9FJ.JJ$7AB@VHYU]<"X^D,Z)11 MK9X".2N_DF#IBP|[QH>[_HTIWZ$ M2V\W#&FPBVL8,*

56];Q#P_SI*U"W83H:XP]%9X $N>Z[IUUA?1,[M8!-[_)] M0&G$!E<*A?8KE/ALM2&C)P*TO_TZQ8U]=MK_S=?B=:W9^]#THM5Y#_0AW3)E M?K03:C9SU6BI.99!QW99E^K5 ^6Z;10MPY4M M?'#WM3K#>G,M&T[8$)[#QO;-4W'SZM9 M59D!((QBVN>V.O=9BUZY:HWSQ6#A"DV:I(=B\,"F[_75!^E15AG7CE+DE%[G MH%*

[GR.*K$@;J65]A+!I'PK/Z9G]K3U/?/W5.V:.>7;S?B3LWY]!37:$]ZIV3 M6FO@<'FA2D#1\R&>]46ZC379K*>)R;2L+X70BJ5*XY3Z# >,M)GFW]H1E3?U MWR9Y1_NK,5VJT*?*

2+%Q5R(QC/%?&6&T8:&I7ACFZ=IQWT(AL^LPNI\]X-GUF MS^3*7?]BX, . D]2_56P4U-)6(56.-/+]CL'.N\^G]I[?[LU;W([%O+L3" MH%5M(Q[I]@C3O!%LEU?*

$H87#VY=:1\TP'=FOG/K/A: M]%T2FH;NUWD9#TZWK_6Q@<:JO4@!&=K^4AD@Z.'J:O9WOXS:"-%%"H(>< \L M0R6L;6>T;SY78RLZ79R),I&69)O$?$'4-)T M C@Z<:[(R-Z?]:H?*

D=YH,3#[42?'MU>C[:=*FL < @.T\A?#+&#N4_%:K4Z+>7G=*%"KLAQ3>Z52*Y+*/ M5+5[54Y0XX_$L::![$H]QALM)22_K67>LXF96=TSU>Y!YET2/-Z;$V*4I2=_&_AWCM?_W8-:OL*

M:Z(<*: 3UE"<-5C/3HQ0D.I_FX7"H+.RCK?@%QM KXB; MI%O"Z]V!KHW3ND4TI,,',CF@!OSEOU_$+ZZ?Z#P0U@=&IYVCI$>GUR^>8BGN MHN%I7D;@1RS;II%G2#O2>BP^ 0_^*

YY#M'>QLM)UA..&Q.>&DYX6IB ML;JHQ1>++_?"%_1^66RQ7'#P7!!8+K!<\)PG:B>WKY.S)+KGD[-VBB69>S&^ M%^X@YV]3 ?*

L>3P4;UI-6'9F&6;&@1TU%@V^F9"=#@\$LB4P8#75.R MVV#& 3#BJ4M!OJ53'7B;-//X61\K2ML&-.^\LJW-]5.=H\G;TG;3O:93=;2*

MM)WL,YNL)>EG/MG;6R2I%^.&QH>;'"9/],P3-P[\VUK[.)59/6?X8' M@S">@N?YCT(PW\@[?AXD<_JET4,BQ@6,2QB6,2PB&$1PR*&10R+&+=&#/>Y*

M8\6C>H_ND>_B;\E[Y. ^C]^A+W9FSF5=.NK5.I%WWSEHOO,UVL6J7Y>-#XF.; MY&+YV&[NOO.QS6VQ7&PW=]^YV.:VV/X MR09\MW2M9VNI>N#W.@#FZZEZP/9Z/V?*

KFT>]%C5>NZ58?EVG#]'CH$ MK,/GYF$8- #M5EL'KWM;C=+\|N):++:O(])||YYB(S=:,O%![.Y>\K% M\)OLVT4L P>B%<.B%;1A8X=6W.'B7)3U=:(*

(ZI5BZQ:9#=W MOYG8B^P^6R:VF[O73&R3O2T/V\W=;QZ.MU>N_MS]$S9[XFXD=BK*LJC.1LZ9 M]$1#2^6GH!PN+]H.T\;/;9-#VT[$MA.YPMTQ\D/ON;*

<4L&'QXCGC19!LSXUCT<*BA46+YXP6ONUNN",I+I:[H5.O=1VP?B2+ MW!:Y-^MY(S_;7]_$'05OJ^E9O+!XL26_+9@\4NIR;MMAOD/F>FUFWKR*:>./A=4Z/D$/(X?[*

JEN7H0^H8(O>6LO1EJ,M1$\M1P=QL,\[:?G9\K/E MYP$_'TCEQ^>)LUEM|WP>Q#-><Z1TT9.4;%Z8]N>]HEC+#3>V+<;[+6F8Z,\ MEHLM%__D62ZV7&PW=]^YV-*

WKN(#E8LO%EHM_2O:Z6YK-A'B*$SF[L6B,GV'D M5,)V@]TGEK'0:!M)6OW&,O&A,/%>ISI8)K9,;)GXI^_W^N@XF]|@N=ER|S # M\1#8V>8W;/>.5$676$[>-B:..5LS=|6:!<&S:*

[YD32F+%A8MME2/O[U#@"U:6+2P M:/&)[/WGV<&%=/!8W+&YL&3?"[97|[#=LV/R5K;]2/HC.*:_OYN'D0M:- M,$DN3D>_6O?17CEIK3?^%OT O/00'/)6^;(?%BJ1[G5>^RX?8[+8)?*

J_N'KT?PIDV!7G1%G5E_1'6=6Q= MQU>L6>I[_]_0C U2'X(^91'#(H9%#(L8%C$L8EC$[LA&<,BQJT1XJFGV-MN M++N9S6(]17OD7[5^=)NY8B-CEJ,/DJ-MYHKEYYW?*

9X$5K/!2"#\MMC#/=^;GFE\YKVMCS;_:)1ZR /E70Z$ VVZI"SWAS M]Y.3OT^M96/9><=WV;+SC2V;O>9F*Y,M$ULF_NG[/3^2RK8#V7T/Q2|US?\8*

M"VH/O;&);C;1[:K.3<^_G:PUH"QN6-S8>D)7&FXOQ&21PR*'18Z#0 YO%&[Q MM+X=!0[KY;%X8?%B.YI&LKUC 7<4+>>PQ14_I3+++H3WRNUH/^RTLM/@@3F^S*

MVI3EZ,/@:'!4Q7M|1K+E:.O1EJ,7*Y)%>YVE:[TX,4R!*BM4DLUD5L7<2VOYM5MRQB6,2P M*+%;)&,1PR*&10R+&!8Q+&)8Q+]9&V3ED?W&[%Z,JGQ#37[>UR70# VLV5+ M'.O!!*

[C]1;3I6Y=LUV'[!M^-T"B0627= M<&JLO/O:U]V497!RO#AW6$G;]K]?3.F9(%7-17\/C M_-L/Z#RDJ+KX>D^!$*

MEN(KX44C&';3.88%GTV]$UZTTY)>'N.O)U/*>5&=#1R2A1Z9<>'I+_Z:M5TA M+_L7JEN)J/C)M&X+]>Q&E+0KS@60VU>$YY7V](7I[_K26[+5+?@ >W ML&/^LL,!-*

L/\BSLWGGM%S>B+]BPJ&$9'F^Z8SKKZ9/D'6%?]M=IH[1]E$B9W M3,L++>MF>O/AQ3A+FR?TN*AI7.S:@@K7=W.ZF[2=/+?;G@>GRCC[C6\Q97XI/ M/BXZ>'F[.6P?*

X$FX\%=-.3'+1.(s[*R[_P@&|$<1PZ^,'TYNO7C,1HPI0W\UM7JKI9.A#,535%S>|%> M$SB| 3&NG/S2@37NWXZ_]^ZI'!'=]CY[;K-Z?[0W&V4B\IT;_]_>T"50 MRG>^%)YTX\?*

GC3'((/@I@4W5GC5=-;!<|KND GTLV@%;=A8+0F']2GKZ01^ M>FXK' R9O[DE98[4I:^1/*M+("E6GU4P M #XO<3+KA]H'],"!X0/IP 0 YK_STAB_XU>)X>G'67_O<2._F//BQ0S51K]'(*

MJ<3!]$&WY4+%&==27#U82DUND;(VO/$[+]%L"20Y112$!<3 M^!#DJG(5T*)QSFDY4RLXS,T##&E NG9J.>NI]NRH'E1%EVQ,#-W87+.<]O7 MJR;Z94FGV=).(HO,RDY!N$.=,Y

FBIL"X,O.\N]OZXM9:WX.(A)XZNUM2N MFQ7^UH_\4H<,"EG 9;#((()H:-8=>RIBI@N+:MEJZPJI4E8X7.!=%-U;/^TW9 M9DK; /3^TULUX%>$LQE(,OC2=SZ+,U"&\!3[IC8HV.!11S.

(JR*("]5.M!ZQO M2|63%\+M|>GCV3'"S3'@1D'#DW?^/\ MM OJQG'(,MY1ZL!$2V30+2'-$5PJG ^H/GMSI*GA&15;LO!)%2AHK-'L3$O8 M+/A";:IJR'+6&%4# JIHO1U'N'F6]U]&C6[N

E\57P4_TJSS7(7)?]C< +91TVHKC5L!6@,#HUT E3.EG MOU@M'CLOVD*KK\?]_9NJPM3KPN H2E\..=S,4|/XCU?X1ZG_ M.&^R4[K/E.+P<=[T.+=X1\$#O.C_MO>M7VTCV;Z?*

^_P5M;C).>EU;&/Y!8;I M7HLFI)M) FF@I^?>+UEEJ6S71);<)0EP _5W[RI)%L80OS"2M6-Z@!ZU?I] M;K^]ZIF5GH?/;A V#\CFK_Y]#(FS8UUF3>-AT;J =Y,XT :\|M->9^]%0E=

M1_^RK%C%H7DRZGS> UE-/U9?4UX<'2[']@31*;R!OF$G#DR60)93;$MZ2)3RM M+.2*$KXO0JR%+YCL(FPA*RB|%33)"L@*=IE0(JZHQ&*%IPXBE-(9=8R?*N5 M0\O?I /V|AS[&?

THX)X3,'%O" "CQD+AE_E ?'?CJ?QPY>4AXSO[J2Z.&>MA M1%[W4TV6MQ|M4F<*LR_JPK['8ELH%<)6OB|4(K; Q))*$[$[1BRI-!&|8\22 M2N\XL2]^,]@F!#OZO?B-

YYFD.U;n_)OK@^VSN=PP@FWDB#GMXAN!BGKF[MR6V3"[^];:-RV.@66>:TW3$9-!ETU] [&$PK@0R:#@H,^E4-VNIL[@PE,F/BQ"#

M$&.)V&OG3QLGL""P(+#8T'G7.X\6=$(MP0;!QL9A@W!C@?,EM]+RTMA0!JE1 M9Q S2S8/#URB15* ,+27BJ>&%)CW:RX5+9<>> ^ES(CDFXQ;9CJTWM+63%)-QB M6S&UM] .

ATEX!S]*9#XQXC45[)2-W-Z9WTFLBE_2ZE((N M&;FDUR41=/')I>T#MA7>G/I!B&?=436U@ D!ROLL*NM&Q6IV2-24OR7A%MJ.

MK4JW2W9.=DS"+;@=MS;72UH209.5[I!PBVG%A>YKHLT"'"T>N!*!X,H>,NXY

MS!&WPO7'(JA$:8H"61H!ZL+M*>05D5=$PBVV$;?;)&1@W7II4Y6 ,JEQWQX$W<%]E1(+^3>0/;@-QX$(J3FBB+9 M'(KPN#:]M0WN#=(?

O&5W"6RZ%)8]*9W("V)L,F2=UBXQ;1DFIO)HHL@9;+H MA5NGRF#.U';QJIE,\]&82X6-%IC'&"M_##1/=!.&^"N2U(]1-*LC>%UXORY] M+RT7KYNTN!:N*[U! MA0V$)Q1W=;]".W"

[#$+)?Y/.M4NH>;|[5R>KX+ ^6.$%X07 M&|*+=G-S+?*$%X07A!>[C!>MMD5H06A!:$%HL=6=17**%45I@Z&#)IG_Z 0(M2B,1'A%ML*Z;M/\F(2;@%-V*K MN;D2:DD$35:\P|

(MIA4W.R4X0IEZ'#:;;/@7=R.]"H:YN$@&_OW,E3UDC7]C MR;Z\ZE?I!H9.05#4EBR:+SFY<77*# MIIF9)CLF X5HO:'%;3F=,BI@6#28WTN%:OE;B3PCD&/;'XU_(!O?V-W7"GN MA?H

(7]L\A>2]Z0K0TFJOQ:*R@A/%UZIT6V2H,DK(N$6VHK;E6YG<\?RE$34 M9,<[+-QBVO&[=]6UP97GK^ZD4JZ1++KD%MTM@SE3 \5F-XD(@HA[MC"IB'Y? M*-

QZ"$A:TNP_M[K.=1HV<[O!# M014A!B'&AG8>;>[\]H$4NA%N$&YLN+RR^[!!7@:A!:%%_II;<@H7U #S&AFE M"Q&:Q3A/GUC#>]+O*Q%O$L)"?D]-+X7*U5)2?O$ME [+T$1(OA?

9!Fs%805U MLN0R.42=+ MWLE"N]$ I5LJE4]<*Q61DSR6T9^Q:*<'N^F319-'EL&CL6BFT M05,A&R8|)BZ5JAK9=W$A".#.#>A=V1)%]G$Q7KVB^]_V"E7@I(5!;(L@M#7

M:DHIB;#)&=IAX1;3DM^UNYNK_+[ZE$Y)"K+G'FB=> M/$?QI^\[?PX%#RE'08UNU.CV1%-&I;/];'&Q6]W(^R+D(.18.*]2Z6SPT!Y"

M#D(.0HY2($>CTCV@Q3B$%X07A!>+>1]:.X,HIVA!+2^OF4ZB_%"!,]^48U\B MM],]*$,G('E39-'EL&C+JEC-0I[X3B9-)DTF/>7(8<5]=TG49.V/ M1CY^P;>_#7T7-(.:6S9D9_9@;SW.?-

K2CF(GQ"1^TGF7(E;H47B6QB M:%$.-/+,@:?H_:)\])D#IF*Z&;=M/X*K#NO[BEGU^EOF[UGH |NF-SF1PM:K M<'B8)SW!1O"^8<"$Y\|SUV(GJ.#A7>,HA/<$89EMY4H$@BM[[%GB

']R+V!1 ^4!X$(2^'/'O%].K2KZ MSE/4+6\", ?#_QMNYK&R@&=IG;UJU.H,1N!*XJX3+PZP*QLP. W9UC1H=C=@= MJ];(0L5EB/>=^BH4M[S&;@!';OC ?-\%D1@,/H32M@8/3A+VD.9=?

T>5GBY $_94+@F&D@4_TVS@Z ^3|D7 M>N&:.N_(6V:[@&_[8WY0%0]WQ$);T :>#D6QM]5"> ^\/ZHVC_NNN*|Z$FC' MG5"/0$S1R#MV9#!V^>0(KQZ/N>/ N#)M)-)

((.ZL,'X3Q2$LC])/]@?K<+0 MC|=^(/6[-5R)W7<|^]1SO#.HS17<+|@0F =O9R?6]N.9C83>YF1!&/%_47+# MM)4E'KWT7% L'^NPB,>A?[QPPO 5_-G+6C3S\|+I0-

P1=^_X)#C>VT]5(GYS M(D6=5=$2RVC!(VEN5F@OW]VQ 0G-21PF\BD\7BX^FUP+O7RLP@:"$XJ[%8U1 MW('[91 JK0MEF4T6X<74OW\8EI;:UHO'I6,E@6] 429"%:.QZT\$/ QB.*>

MG1GAC+|F#\$GUMD>8 +@B)Z#8,ZZ [+QWSC8!7X$D1OBZ)%\5PRXF[ZSS'Y7 MO, 2!> ^/2F,4&W.Q'K+/!!>-P]AH^A X2/";WC0.=194.U,9 _=4;N4>HKR.(M*.3?

>A]W8YZVK:+L^^'O. 3PN48R"'PU :#R;\P?<=[;3!%T80 MA2!]CNSWX7FTGYE/IR_6;Y#>+?R,IA/4V"\:2[%FW93\^;Q5W=-\1:WP,L0 M#U]F!&ZG' ?

YDP'6BP$R7,R\",W4C!RC#U_2Y5/H&[6&* M>UN@MO;90.&M,!O;0CBF@H*W9XN/F4=GQ@:\!:=7#P9>)>[!#<>?I[B"H2'N M/,Z\S(QQV1)M>8'F- T/D%D

[1!LZ/KW5#H@@^SBD40.6JC^V#!=\IYT92BI M?/HJ$'+S(-#;D"3!#C$DU)[]@^) MZE]!7P*$&=:*5@V^L47&$2#+XTQ-WDK MW$GEZ0CV.<+P6C+XBXWK&2I9S

M'7"2QO^D!9%GR*(I>U%+6NBPNUUCSWHG_V']|A??F!3'CN.,]I=:Q4#JK^_MOYB>,VB`\V*@=I%.EGCO:F3[L9NZLP:V"76#FRTJG3Q_>X6'&&G.\N"[CIH?J3@&=*7SW?=393-^"!

[W'$S.5Y MT"FBK6DOTX??(|3H$*L&|-^!K\!G"R2|BBM4.I/-Z>G*Q$ $%8!]%L3,JK%? M394% 3S=>]/ &M^*|;T!X*(G7&^YG6K--8V@.W*#T-

26[[IL1NER^IS,N0J&GI<'AP;C,%_6&OA V1?!-'W@PB+GX\)69@"TS M GBABQG5V'?C=IR\J3"7Q]-FVGI68R>;]?-J1W@8;5Z%P[>BSUSD8RV_F 4>%F3I26#R:RIPN+]!

[76XY&$H&BW,V-Y#Q28 MH5CS4O)SAF*UEAR+U:XUT\'LO(N]1,NWCQI_ZGNV4%YQ^+(VUO:$*|&A!CV# M:%*#8E(5>=)BG[30YRSR#E0._P@?9$'4[TM;XFV .2,AS)-)WN*YDJ:1"J

MR*C6P(]0I+. ^,Q'IZU';28@*> MD##L'(OX1M!:,278$)88%Q)?5\]T'@,<*G1RM#NNOZ=7 ,A.S"#2\(?84Q@ M;"!|

(8\70PR2W%=#H8(:&,T((6>N$P3LQC+3$IBK@+F=&4&:X#Y9BZT%PHD*V_^!R>AE E"97TK.*[KG^G,[S:8()HA&|]W!A& MH5>7)Q-RHL:)[IEZK*[=^.]:F?9-W-F/_52T >S-

<*0II+W3Q1H_"N"AX,>C M5V?UUI(22%[,XP<9(QR420G%V1D<"R9K8.AX>]7E$YBLX?7WPCDVGSJHU^IO MD_M!65P^#L11(& N 28G+-"[=)A7[\UN6GHK VF,YNY'JK[6M6N-M

M-HT44VGR2/M//-6HM99_R%KA._7M?*;(Y#RS;2UFOYX^[VB><2RZ>TZ&QH= M%FT_HV5VG]T4<2^]^2SH E]Y;:^QEW^9KN)%/,47G8WZ1T M__P@N[.=2N2!

M.;3PI/"+*7PVA5AZ?:=IDU#D!5%DJ?.D=@)GL#RRFDHLU63Q_D]BTE56WFGUUJ6ICV_+";RYLU2L'EE5DH92!4'LR M:3+I[YAT]|(]:!19Z-MP=Y)L!+D[CTJ6Y//0$:!T!.C\^+/2?

+&3H')S!NC6 M%(:0@=!AE]"A66EW=_Z$8,I%;<|Y^W.F;RR(U-B-R$';M0.SZ+R|%\'CPTKS ML 1G9Y&_1F!!8+%VVLP"M-A4|A'GJ2+&\R.Z!M=WE#,'1>*N[BAPP|TN/OMZ:?

S9X[TNJ$=MO;P@@1*!TO= B;IC MJ8.<;(1LA#K(<|9!OOGI^=6SK$OQ]*+9)NQ=O$_8C\F^+WC^W-$F :DPN?=5 M5H_N5I: 7++:A1VA5J79 M|119UEOU@RA9MJ]:?4AWQ2<_B-

:BTEK4[^C+Y@+3G5F'2LA R$#(\',[TK9> M:IU3@=&!5]FOT^_B"OAB89X5A+VOA#^;L:@:-7I;J]Z?=>HM,NPZI2*A@0; M!!L;+#[6*_5F"?:VV$!J;LEEZ\5=8[P

<:^T)/|%5N#'J\WUH>3/-Y+M\MK| MTSGG43_@0[H>?['CN>]X,'.H]!]X@[<2P5C887*&:G)2]NR1W17F^5Y5-[_; M0V"7/MT0C]_%,;WI-BK "G/&*O# EOKXS0I[TZZG5_2YZ(R/?

("IOY/KS6XJ MN:Y;/ZW%)L^Z.Q\(+D+JO=2NZZ4\AMQ[\S)W/C0Z*N).:U3;.3W"A' M8RZ5/]\4?ALKY& X>7@^.QZ!JO!HV'X 9/?6AOIU_E@?

0IL]6A*9U^HV<2R5!R3CE=E#GAT9V!!]ZG&^Z=;C MA]B H]SQE-M@[=XENQ39.@'.VWS8/)8NIP23'?VN1]OOFW&;;#_#\TS>=Z2OQ9K0*H]#Z MJZ#-_I

#QCDI>9^YLH>;";E _L98L%!7M7^#? L89"R&68-TY"VS71X$/^V-^4!4/=\1B5Z#)>'E MV)#^UL7%^Z-J\|COBONJ(T$*R [<=B0:><-Z MJ-)X6(4'8<3_1\5|_ "|-7\60O:I#9Y'X@[XNX=

MGP3QWB)9F2=2U'ZTEEA&"QY)<[-"*Z;?/1C/C@\7?VGW73[?XKCOCI!F=>A< M7BSEPN/QI8$,<+\M,Q780CBQH|XR;K9F.KXO\?Z>|GO3IQ\]888YG2X;M?9T

M5GKZ,9S=%G,UIS.O]DK 2W>8Q@F@"[P9?.FOON_\J=^1O!Z&D;["3/56ZNF/ M(_T8)H+GB:XE-[GN@K7?$;AEM,W!D[LG7!=_/?!:]]=[OSW_$O)&'SK+:\

M;2\A<*.CI8S2S#Z7T?,5M*.8<|)K&)>7]:C_?)<9R3W7*&RD_.MN=J_WZ_^PEV=/+P>"E"C$\R4#836HY*XWM<2R<6W$6# M'_MP&SRN\0E\9\QD*]F+#!*35^#PII>9#^]% -

&I=IV# C@IINLHX$K&/&% M?VL #4Q|%1LNV);A3TX,2NH:.SLQB5L4SQ@[M7.=&;?_[QPVK(-CK3UV% 3)[0WN!.8_I)$03Q+ !_A38Y,9S%0T,@U,T^< MPH99D\%SIE+@>S-

/!R&P.K87H[K:VGI'>#_CXM;9L;V!M)2C3>T.BR>_GIO\ MJ3'<_-S M%+|&4"4RC('A/Y#>$+P,0V7DCPC_T\]Y-G: GC52-? M3D%"3CS*3B/L^

|9288<$^D"AJ7+|V4[0B8*.&364PPL8"&,]07, 1_)%C(M[U'+\,U8?@6AN_)OK9&ILJ151ZJV%;G:=D#5MH)%6W.J;=EEL%7+]K5:UMO4

M/N+5LK5&Y^#M,TMDUW=;F71^V@,FC+XVO_X5<72^M8SP%S?Y.9J[\^'CGM^< M?6;-HQ]^_ ^/DXN:\YN3F_%[G[.3B/8,_?-*)WS/P6!A:,_/KT_75[_<75V MS4Y^N?SCAGT^N?

IX=L.NSJ_EL0-OP"GX\HXJ,Z3\W_>#*+U%0E0OAM\>DK M<"M%GFR@=?3#Z>7%S=7EI^L<:;PVQ2]7EZ=G[U'E"Z/@&V:#V:0##?RL]|-8 MZ336*>Y?

4GUJC!\6MLG'G'IA=@[AM%XHWZ2(:9D3X8GC1-B^ <.7%; !1U\&-Z^ED<_;:1,28.]"EG,$@01GH(MFDZ_]:7A4H89.AN4?/'4'XVDR8NV9]EG88(X0RT2@R*7>|

M$1L2(R|^=2WN_9SF7|)90[SR!80KG:0!>],6..6P2 M3RA^FWM)$8CY'M YS3E4=)C/>P&$8,@1#,:5SB_I@:"2^+W_8)QV:THN,PF= M)X:GK6(D0I-

$6>#^;;HK:TLC8<+1)$$*1VF1AR0$*8?')O $E.4&\RDEF$ MCP\5#P)@-" P'& 3IH^5G9O#NZ W^58*))A@4_EQ&]3K3X05CM"0\0)S1%)E2H MH1SK*JP/MI.TRC_]/6,[3H=

(TW68CQ:N!/$XTPO#%$89YA3 U;2ROH2[U,#DTJRIZ?&;T=]+%@\!M+.29 MK"48Y"TR"'FG,W@.&_@PU!C40'3 &D1^--?XVVLE@@HYY_V2U!>\U5*EBH4Y MY=3VA.YISYQ>"7RZ%

.D:N2CQ2/0,X&F,7@T-3NQ4ZSXQCX$FV>8[MNZ"5;HE+-WHFUA[#.:;6 M /@27Y&A*F0D=94DM4MB0#<:HK0] 4#94T:9:F:,+#O+K&EE85H!>+>@^]C_

M\0FG[$>FK2OUIN"+GLEUFK*--N2I=6=N!CR^C0'5MQ]7*?XRMOUTSX]^4ALF MYH?!S7$Q>Z_-"CT!\"8?U!PF!OH8QCIA_T\T!E:,919KA(F>%#R@P7/S\/8B3J

MW!9ZCE^E .JKKYE@+A^3X)>3]QMV?@[QQ?&2 M^([^EE>B(Y/W/? ==BLW2*,:Q/7B&&/Q"!.UJJX#V)Z$\(/ M9:RHQC[H!@C,LF&;*?RK.^FP0P)BZ"#2F16\],A1DR-

SN1QI_U7G83 ?Q=4$ M'+%(F2ZZ7A3]!M, ^3MLX\5I4AC\:I*!M^^QKTX>4*XD]H/>9K"S]_L@\G MIS>75RN@6S$[&NK-L.PKA]_"H3'),:F6"IOX$0N&?N0Z

MV'(E^A'&4VEWC^YEBYO!XM9^$R%^P2S=>24I=9R#QD)>L"M06?:(/)$4-^)X M]L3SHC3&SR9Y/]8-_1/DUCQO:#C4-%*=V30:62V'NNCX$[_(L&7RKQ&QP]@ MX5^1A%\F"

(9QUB[N C/92S0XC)X#6\E>O)/$\R-/ %@+0*>]J2N 9TEJ'7=9 M $S.YGWCFQ R(R_ .?WW)(3*05HYS9$E-&L_O#_[M7RQSI_@6H_L7YY57& DJ2K"Z4LK>^ AD" +\O .JG]9P|*7FK

M]L/G\XLS@/D/.5+P,T#W3&=?:90[U.5R:6/QKC!JWLYELE-K=[OV0Q%SG3NF MU^\7K\7I%AU3RL)WAP]>#KMTYL ^;55OTG6K+Z=:KO69?5)O|S[%H]UJB MUVKNZ;

(@2.9*]'_:._W:LQO.09WWJIT#RZ]V&E:_>ECO]IK=KMUW1*/9M[BS MQSP^@A$*VSE"#<030W6L M7D,<]GM5QW(:U99H=ZN]=KM1[5L]YU <-)R^U5IWJ#!?KS#:[:LH-P-+#?(!

MO^:_FJ90S")EU%<<IM]Y*-Q$+/C\+A2=\V5$#]]Q M/!=N\)Q>>=V@JG.8I> M_O$;/ Z-V4)R+$Y)7(IAF@1Q<;@;^WH- M@;X$\TX/UP[H=?

OVTT]KMD[$J?/YY@!8VW7&FUCX,.Q(["T/'V*LR4?A1[M5L?F4U:]7JN_31X T;M\'(BCP&S>(1(>Z,-8S+OW9D|\P_7[>K>&R5'R_/&< MH]STYP[?9OYIM

]/X3CUC+/|)J;>4S!UOYBK7*,RL04SO<#M>Z6R+'ZGSO

MJ6>.+|2I;ZX]+WIRX7TYH(EJWBI3[K#6=>]A\U#L4^UFL8LF2@HR_9"TW,180'JY3!D^Q[&&N=/L@WS85>UG[W7[9EZ/3A- M/QN9?

LJC0]BX2TI#2K.H*+G5W(I>XB;:L[.]*+Z"*ZB"ZBB^@BNHBN MEZYPZ1ZN3?O2BT4H&VM=6SE$>8J35KUF_>\F?>WM=^EM2?DW3AAG0X6+,(9A M. Z.]O?O[NYJ@#;!K

_]V_T390]PD>5\X Z[V'1[R?:O5Z;9:S7T4%7"DUY%AA_C3N;71V/7U>9GLD]#;2N-V&M<"F,V313G]O6TZ-AS6/VX?U)4NDG$BQ!>

MKUO5YDL'SL%E4VDG,BWH1126;)+P05N\WFONX$+VHM)=(S"\82BT1/CUFQ:O' MG;GLJ2\Z<;LK-J*,*"/*B##BC"@CRHBRUUB60T6+ ^>F&QHI%BUR03F6,IY4Q M&CM3QOC,U3?

VD=_Q;\#A%2L8)5+;7)!*-0T2,=4T2BYF=#**2C9)F&H:NR5F MJFGD3#.HIDK4$65$&5%&E!%E1!E11I1136.M=$.3:AH[5-.H'S;JW4;NEF9< MF\VA|72'AX6*ZY![KIBP?

W+;#ROLGZI&U8I"D+I>M:*H5). J59!8J;U%T4B M=0T)'^P?4JFB5*26NE0Q_7BK5F_4L_]KXVBHDE&.+)11101940944:4$65$ M65X<<:ID?(^3YK]-

;^G$Q.OM+K7%\7>H981%R*:5ERC(V$*MX8N2GBW'W&5G M]*.\(1?=MGO2ULH);;.C@,V"DR!OZDWQFP+Y$*(NZ%+/39M3DNFC7K#3R7 M.AP*=LU5CWLBJ%]+8ZWBQ

]Q"@2(C16+%:^@9I0*(5*)5'"*52B50B=;O> M^;]?Z]2)Q1A7B(CPM8L)>=L:E^C**UWE,#JBE"@E2HE2HI0H)4JIK+&-LL:R M>T-06>.ERQJ-

[9FH@45+2BY7Q:ZRF%T1"E12I02I40I44J44M'B10(G]VI5SB^NJ5'1FT3Z M&A2>>UB38/_^Y>H3. _>"D'NV8.]],|+G:5=UK4$F?W>2OSL^#-?S0\;'8\$5 MW*%O/$=-

X[8^'^,#SG[(%W!>L+F40"O"0/SG9 / L:58>4$XXC'8GPV'Z MCNF DN\50PIY E[*,!&11"]12]02I41]84BE583*&417CN@A]$1I4UD

M44J4$]5$*5%*Y8P7*V=^YX\F[.P>K@:X@.+:'HH1 M9W_*<,C.DN+#)^E]Z_%@6O8(BL&F/"$CI8*(5"*52*52B50BM"D4KTAKRI" MJ0:B*T=TE/OF?@/T>

<04:XTI8E1C[*F2^QS[X:L2L>O5WUO>5OO\O MPW T'/ZDKY[= M#V5/AO"%I?1#\M =?'55=&815X0IL@=%?'@NUEXS,D<'8Y9.COBON'Y+_ MGR@(97^2?$W?40U"<&^/-

:%5?'EPA!TV9OO3&99,Q]RL-9O-M]_C4:BX%Z!S M?!2 5HIW]5KGX,?C\;1A11&#".C+,+?[=ZFWZWZ2@(%: E,#_ 1!9GH|IL0 M8_B@>YPPT'CR5Q#U_@.WXRZX>*,K>4^Z,IR8)WG(

O.R"GQ.L6 (K&80"?5$,@KI MV3Y\67&,I'H3ID1?*(&KV:4'+X68#0-0@?\]2CTCQ]> +Z:/VM!F]PE M[P-Q1]RJXY/@>&_ 58GXS8D4M8YKB66TX)$T-RNT8MK4=O T44HFG9_V O@+

M#R, N!65],X(L>>[SB9X"S_0$^#)]|%CP1=HWB6] WTA$Z+SH]P$:#<$C_5LX MKSWG;D- ' 5BS-%Y3)BAM%7I=^_-EKUN92"->WJ4/#^GIF4^U|;?2I$]IL]

M^_X3SUC+/|+\]L\TJX2Y7RW:#-K .O/+37G,O=W2ND5_ M2#^P)0:9086=>W9MT;KY]JR@41!-V67:UK6" M!9#MA? S(N_%M3^+<:IO!? MROD@:[2M(=!?)D=E(')9I<0QD6D"

(TYH';3'(0M\5SHL&4:Q^+ ?[+.;WRX_ MGURS?]:8]>EO)V3/T\'GGP^IWAC%P&!:"LF;11O/$_D M9ZZ^L8 \CG^#D1!T]:()$&W%I(V@ZSM+UW5RY((TN&=+[A8\.;+]@H:YN9&4 M-

CTF;-#VPJ-JJW;0ZKY-._%ULJ15:^,JGWSP@%8RE&'-D[+U[<^0VEB?Z_WX*7&_$K!U7L9QXD?A7[_Y\/W|;Q .W_?O/E_GAQ?W9U]5[;^6'211D*1DN^=Z--N_0\3$G?A9C!WZ/SIT4AH[^<

MO#_YT_&'#_^_'_??_^+^_?|VB[2[VG|8I^M;] M#D$O,G88XB# .W3IAT|H^DZ [L6H1^@[=+]'BR! =| M07_8CR (.^_^DC63LG36/_,4OO M911OSO'*R8+TK]]DX3\S)_!7/O;*
*(\@88UJ700/DSV8\P^8N7QL?I;HL3.22L MWM2'./@^BI_>D3^_@S_#R"?'[S\>?_P@>L;_>T[W/%E;['K'2?8HFU/Z"7;_M?XJ>W_$_TDY*A\;&A89D#0LS?*
_E(YWWR_OV'=_ _]\S4|(Z)QX(>_U_-)VG|\ M!W]^=!(LUP;[]9,@?RA.@OS12XMM.=4?WK$_]DW]ECF04YN2@R3G@,-L3], PUQ6'B/P;X&)KAF)[]Y/CD>
[GP29Q/:^4DC|0^65A^EER_,0XVVI# M_H??GI'_K-?_PWA.CI]C?;$X1.^37D4LGV.(] ,M8+,$Q M_(\E>3,?4^(?8/"RN?1LG|OQDU"G(6|)B$/TKZ3$*<&1O^A:=S:8|9KQ*3I MJQ+?*
*XC'|HW7X2!-X%^MRU+]O/;;"W&Y MP _]]T%>27ORJG[JC%_^FWX|%VZ*_8Y!S5-#_YWT^N[]'BH-W*0[V#D-_#Q MG>L$;A;09LX==='AW1_[G_PHY3/QW$7H78>]GNRLR7+RA*
*M_@&^>2Y[M]P_\A0I|B_\D?G=!#C!I2R/W|NS*1$ODL MP=XR__Z\S8FPEK(EN^;_()WYDU:.BK[,:A?/]W&;OR78K?T[^$]X9<*C6=1 MZ)'K%'OD!R)&^Q[YO7?]!/"TW]\Q3I,OH9-Y?*
@J2I-S3O;IWI/$'V&-)&($8 MSFDCE3CBU!$CCIZ5 WSWMNTMVYYK5M>82"PD",Q>%N#EBOW['>.'YRP3>[; MN&-+3^AGFZMTQXAUAXWF%%&T$K_\EE$E&M?;1FK\?*
*F^=F+1;X]0G#(_\F!MH M=1R#CWM^V871OGO[TGL>D/;|E']-EJOE5DC/Y%$^BS9DI=8@6S_CZRC);VY^*
*M*1B@VW%P_M3SX.1CPW62CT[%@\+X"":@GJ2WRT;#|_%QR*OQL6O7?]COU?CX MMI$V+P5#=T+7X?C1_)7P=HY&7PA_&G(A_*EKS_]UOPOA3V\;.4Z,5#_?^S1R M?U]'@8?CY.*?*
&5&XAXN2?>EU'(<_[W4%| /^#\2&?/OJS1R6,R=97P;1RQZV M@PXR'4?CI[V.!HR#Z$!O!V*0(5!>R>4I/0"(EMRZ?CQ+TZ0D5\G:9PU7XX]NG7LZ$^UWQZG
M23<5]")%BETWS:WE]II[Z7TI?,?2G<< E_7(S#2/>-% M'#OA4XL$V=RZ8_M.:K9/(8546F_:UW_[F.FM=]_XGSHVYZ-E8UB_MTWHOPG.*
MIL7CD\.GVMTHM^G8EC]5MH4;SB2%MPWJ)37\ZL#-0F6Z);5$)&?)H:9%Q^94 M+1V"|I7R.)6W#>K_!5$;|:E#39;+0X3RA!H5)MM$.TP:W";Q>Z;-"**TE/L_M;&]_L_TH=6QXU?*
1!J1S3<9 Z$-/=^%"L%1#(3[:V\$8HLR1MOC!^=KPR*E_M[!C$.M,(=$:T]|NF#)$9-QL_Y2&E1 P'TQ\FCU+#'K4T[|BRJHTDI\7]R0JU MMRWLIT?*
C%|SOMSB^7SMQ59$N_;ECBZI&#T >?:W.$:4DM0WAOG&##'K!2#0WCIQ MOGM,D7BN(K4TK=Q^Z;]6#5_<$K'E!12=;;UMW@ Q)GM,\#\SL@(7SXTZ=*51 MQV95+1\Y!*
*<1(O.V1$8_I;13XC:_:/G0Z=KIJ!GL047?BL'>W.C|GL,|^_@ MEN&*_CB<0,-(F]:I,\OV|(A[3TZ MMJ][Z&GQT;YMJ!%G;AVGH&HK&F-&?SLMH^Q^]1]X M?:/V??*
W7FFB:B@WP;:?,VBH6GD>G|00' -+R!EKOF@CW7$RJK:KX:KL,XF%:/ U/E;&:&LE/MOEJ-]F-^2$\,$5 VRN3W]34XTLYEU6OS=G)TG9RA M+|*
(>9#K.R+"DRK<7PZXG3UX#BTT4I_Y_@84Y2=7&[+5@5.YSZ]3|K;M3?%M5=[T23YYZOG>NLY2L?AJAKN|[G&FNZL1+VTWD|=(/0 M@-*
*P&^,5CF/LY7V8I_T:Q@OH\G_&#E#U"*T[[$:Q!QS=P>[$?OA$;2Q?$O@I M<-S?$W<=53AX^R*,?1%G:\@R3ZY"V0HB6=(UCA?>;QDG0D3$),&4F+*Q M]:9_]V-WG/.JI7^?<\ZGB?*
*Q0;4ZC=&"N2)DLE53I=.G?U:_@[0B/P#9I$0]K M_1O]>W8\# MZ?VVG4,L0BFY!:%,'I.-P0$FM^HRHT\S,^\Z++Z"=(*IVZ:.8'B$CDC8G:T MP?*
&UGZ3MMH$SXW47A=C63W2&"'^=)4D&?8>(I%< ?@J44@3+NH- M'EIH=AR1]O&Y-ENH8+:0+=CH*(WRA|$V 9Y&\G:&+)ZA0B$Q$P>]:H",TU4U M!^L\7>72:6^G3=-
I^T^|>|#Q!OY$*|:3)P,"IYG)<4?#D6G9]48?0X,%U\:0 M'2>R:KCM/I%D;HA.CC81TV/AV'R"*)|AF_?B39ZREG8Y5.K2/DC'0:R:@$1MQF+3# P)[=>TX0^U(MMF_/KAFLVZ2,7CO<);
<7]8[#T(:1FU1!##!:>?.SG/T&O50[_8YSU ?(MR@X*3&<9"I(S 4BA_ALT*WLJ4[HI:AI M! 8>>@OM0Z?UZ/SX?@B<\[_]_H'_>00)#K8F"'^OK"TY'-#S#]\0_U$].E\? MX^#[*YZYX?*
*L_?O.-MWCD!V>ZOE.(ZQBO9X>7EY7O9ZB1L%27AIYS% MT1;^0T=*1VZ3BO?=P?!PZ<1R]|%GT((YE7R!^5/!N/GPY^,/XY//E^> MZNGNS4ZB@1FE+#[*223PH,-1=NRG>%-*
*E(*EN >FM7)_"[YG4ZZGU#YE,=|1 M3V1[66L5,DBMBJVR&?_N.<=B",K*:,(FN>X7"'32Q>- ,B8YZE^9/$?OH"K4 MAKS_:_CBGS%(JG(:.IDW-^+T._]1S|Y_/,B=M[[Q\]GW/^G9]S_-*
Y.96]^+, M2=:70?2B]0:O-X"=?:4.SM?WI$PTL0E7W2.W*A-L#Y/X_?!0/BA'A? 7A0M M\CD2@F?0"F@9R_(9L 0H.O@D69W7/->|+YI!J:4=-K(%-6Q/YQBT"'U(63T=*
*M!C,;!IX3XS.QOZZ12X^T^", *4;S?L@P@-"=K3'"%4UIAIIGV4&>DX M-#QC'04>CA.6$F%*V>DQDL5;98!P,_"6V(.R1;XAL9Y\K*X;9=0_3ZZED/SH_MLET:R&H_8E-*
*(/O*Z?.1QO7(V:,4YK2+9W;U|R+X17]|NKZ?O9UIPFP8N![= M9*QRU(_W,)BE#CK6)?F|9/8)9EM*T1PX[8;>=K[C:@Y,_V^YN;_%M=\KRGC@ M#HT:P^JK(V-V'*
M2L7M9&S>$)72\,,^_H;N\|33\L+IIO2U\@BS\O>)\GH&7#Q%TE/H=/V8Z]=[_M>OUN+VYZT9J5KK?WI@TA:UTZWXNKNJY32;I#+XHN"G.7>O?;_TC32)S#=W< MUN[S?.M;|P],/?
\]!IV=1#"H')L!L6&/|:>0+?2=IR$DIY="]/&]_P"SDE?T M'H318]FY3Z8'T^]]]O*5TP>>]&$M=4]F[A8O?7>:]>'GOH#8>S,K^]>4YK[2H^"7S._ZA]F M-*
*TTDA$YCQA"BD\1/#*$/*VC.V8!|!)O$!:$"&VM-]H&WD&41^Z#M"(T:8;QU6 M3O)(D3.RY/C)<;:,;XRIS;N+KRFDE#\&^"+,-MP*3Y-1BDP5(#P]](#:=SA(M$_@-$$_H*
*E#F89AQTR_CK_S$YA_B)UC&:^<1]T > M@3M1N M_QT_'D^,_/ M=)IUU$Q.EPB>"=8IYRI)Q./4B?0//$*R?:)!|#TFOS$6\,0C:/_R&8 #25U M/X4.DDQQ5 R? KF6%$ L.7#D%IJ2?*
SMI5 .VT_,3@=_D7PC_19X_%-VSW$"V>R94,<[^,XGLGP,KKAM/EBHA@M@G2=C#'016^<#3XOP-"56"@U MTGPZB [G$G&$?F'P%=5##M0MFW!4Y;|IW\T&!M#,/4O)O<,^N7+B;
*<1$/3CL MRU7IEW6L#>BM]X@E<:H<+_*O_&B1?_Q?\OGZ+C[-_ , C'_'G FH@GW]CL\F^_MA7O\1/.E:T-@:GD8TE/WG2IL'-O!SHXP>7R< /SD3PR,M/9^[==SNFV0&?O5 MA&3PU*
H3|C^_ZM/\D!$Q%,RE=^;-F=O>EJ6(.'N]T_1\SL/^XQ[\D/.-/D' M_XB)GAECHJ1'"1&_X^_/8N\\I/2T7C*UY(&2U+^5?/LP9@O%>A)W98&U_SYLJ(@+)>ABN5)\1OQ(2B>)$G-1*
*MJT7O3TPS5Y^=?GE>R(OL SSQ1/Y'_%]U=Z@O;M-=KA58W(E D9$)RDA24R2 MC@L12FWJES[Z5]^K*U6XH%_?&0A/1(MLN[?;>TTG!5Y M=7;T7@>_&_?57WS%L>LG<'&5O'?*
\+_@V]KI!DTQG:?3#6||/SE=_DVVDMS1[ME)D =U6+B_'A)EM F?3@D_\9G31DF^H+\G+RM[EQJ692"1Z4Y+1;&!6SU. MF+/\?DN$B4:C=7?/:3^"9)FE1,L)/05^HN|T%MI--
*N5/CA^"W9CBV1(5PV<' MI:23MFLSS5W'CZ);|*M^3SI>MTTFIJ:^MQ>*_U=9=/<3QA MW=9Z-@CW>-'/-K>DM!M2:FWS(\AIYHP;'#IL+36M)CMVUT0TP9@O2/C$T]<[*
MS$=G29CIB6$*S?==3WD,BNKEP*/WJ[^NKS18"K@",EL@Q:<%X@3INLKQ@,)/T&*\/ SIIGK62P/42Y*?C6\S(UHO[7B'N-S>9HA3K=Y=4>VD37 12L[@=32# _C=!WQ9*
*^,&X,5>G28 M:(*N834?N_DOU#M%WZ%4)F-70$K0'6 N"YEP1X72#I-T__ZZWXOLB=SP MBLF9C/SP0E9W1WXG<@X63S'&I9K67G0FVZY"9D7K";QK.;$.51NPW:52=7::*
MD14/PA/Z"[_]^UN|Q1\@OA>,6)[_['N94V=%:6ZG^0O_6Q;LY:+NU6\ZW0G> M9REN\D"6EA>_N?UTA]^1$3KP8B]7RK?9&IS8H^-T|SX5H@99-3]>QC$4-7| M>]NF+J-XA7U*
*F%!,]D3R)-I\XKM4A:C[!(V.IWEMSHF.#E>"(@*P]W_HO;,? M(?|T*G(41H'O?&3)(IW]:4/ M:L-&6[J9RG;X%$5>+Y#C^[Z8[J5%0*+5T-@>KG5](:B$6%HT)_; M;|QUZ/\SPTF7-&Y\6*M!*
<6?D,60*.KAK_^)RU$%S>UF$&O=G,O4M87#:$S& M*K]46_7;8ANC=\(M.;ZNOZ4Q[_C9AU6[<-PU!'9U7Q5MGO_/"Y]*
*MFO=E+Y|JK;B3MPG$4IW"C4Y<'K_),R$[QI%LF).@UM,PH/>,4N*DFX?I0CI4 MF0$$IG\5-?@T^L2 ZQIF%!4YSZUWU+%2X(05[S]0WI.ZISFZ10LV(P!?K5X*
*MH>M;3W^,)4I9IM.:&H><;"&+*7/DVX-P;#?%WCF8+'"H@3.[5<(80&|&-_MM MC+>.IYUSX#4>A"YQ8MM"&OV#31YTK01)-]2JZ7!E|$%(N[3>A#(H M(0F;;3[I.\\E9[-*
;5]MM/46&+)W%,B;RPC/1@CIS9,O-IW7O,4G@/,NQ+>@C M60]N%SB-3H^]:,WX4CW%JZ@ 8G?QE9RP"97GQ/OJ.E ||VZ_XA6O:=W9$3Q*
MU=7[3+QMO\KM%=:WK5M9>R256#Q4@<)_(= -.7M#|\$>9/!U[1G8K?UU MWTO1*B6KAJD9E$:\QST2GGKTTAYP+J/"&<<04N=TI C0UY,J(O_KH\GY=IPL3 MK 37TDC4_O%I*
P@#.AH>CAR.IO;N3^".BOQ MY,!, U%=G\F5L2:B2).+?TAWTWD/,CZM4\?MVU5[2.)CRM$[TUT>9[)PW6R3 MT0#_3S%Y@;^$,78"D*:A/68FG^K+K8.B)4OH6?2,XX:[O?*
IW_?!NE8WNA>[6 MU6LZF=:)X367I1' P^_VB:^U:6>5_,T^N8>(U@]H4EE[=-1]O9#KUNO(F"HU MT7TU1[>.^SOXE;E,=^\XS[L:0/)V@@1\ TX6P.=_'V7!_99ZH"-O=P;:3 ZJ
MUW\=9$V@]- '42AF8.T5X^/W-#45#1O70 N48A:0WB;^LP "2=I>CFZ7&]_M"4QWQ_@NZ&NM$0W%-D;0L:D!'#+#>]%AUI;6[QV^S* L1??SU1TLDT=D#HD M/S_PA-*
*4&VFLB.F$2:4H4>NR)QUT1]\[ORG<;@=-Z=)P&5/.KJ3B)TP<^)=G2]D&?;PI SJ;S^NJ0"!*K2=/<.Y+ N==JL\|@[&* M%K<' 0,*5R+!T)3|S:N0/ 593^_=*%+V#EZN-*
LF0M_YX+5KH3@%5!;O!4XB3 M1E2DYK;323&YM-Q6?:W#TSJ4R]QL=1 "!74ZPG8W76=`S9]8FX>S[M-I;3^= MCHL?T_QJ]LF_;FDXI>.+5B4#W4S8@VBL2M4XUJO+
*;R974[@PPEICXL;$MBP M6*4X;BCT,)K<'/0V(@O8QI1SV+-&/[2#(3W 7O&A,[^X&>%]I.QT/3JY4[* MGR-:6B\'EE?,R[&?@(U.R1_8LU#]Z.%FD||\'&E,KVE1+A[FD\ABH@-9>/MC.*
*MZ!/F[7#6B-!%']/+('KI>K=:NUC5$VAY+1QOP8+18!)N;&9UHI]_Z_?D/|&[MW0D3R MV@@N:UP+3$6).X^>Y#P6C|\X2CSM/8*RWH'5UFDY%(]^A!QD'Y)I7*
*M"EMWU0KN[#:W^.5APH34S=@+7,[.[HH4-#KV ME-8(6O@9OD&*5 W2 YK=MT!@-2[N^8;IPB^QFOWBL#WP$X+-?U|BIC:T8 MTEUW.@>F&96?<$C>^("*"1NB&<$#"?*
*<&^07XU>-LU M49Y7#]7(%+-NEA(ZE.)WNU;V?K>=B/QH3JZ"/V(@>B,D7 M"3-3S.S5/U*C0:.FN@>IZ>5K]N2"?AF%U-/0[.-][S-A- E8$MTTXX@V'&L\ M-U.UBX-[D9@"?*
H' !UZU]L9@!PV8+\3A;3PEQ9M=S]:.V"]Q?+8C]]. M KHC /M'E/6[X6N# K4/HAVO/L3%.)$;\C'UJY_7^?EDNI2"'AVGNQ4RHK7],X/G\[D[G]2I]0PNM7ICP\57^(Z9(L/ROGDY
*MKG(&1V=|#?T#'5ZHI0KDEVU8;,Z=G_Q^23Y18; R45FZ||BZDU5"Y\59D[>@ M)5FEU&1"1^L+-SZ 3R6.0O*C*PM$G:UAC9.K4&U#@8.#IC*16D@;R08HI/:# M=[1W9D!G3Q/A2B?*
*O/ QY:-6J?AWU&!'EWJR(G(4XDlR%6\YD@*H%C2&@#>9N MK4,<$GK"2]1D7-V+EB753XIDEX%3+K]>_?O4%EQR#=U#G#YY/I(O6X^\#N0C M^O%]>T?I?GVG#*;)0IE&8(T.IS,C -*
IB!%Q30-KP_KHC;OF=1O,G%P'MBKV' M/=|B+NLY9(<3F2Z^)/ZG>W,%NON-V&P$Q,',$0&Y|)^ZPW2WF>Z2[&^1+'R MW#;=B-T=C6?4R'08(0G<4G-U#H:X3YK-4*
(3&I%7ZXKU*2NI7[!L#'(M"-T MIT$(W)O<(23-GN-MC%WF MUF/29+|^B=FSRK8>FX>K(&\9S?>MCC.E2[$Y7*%5*NG3G_-<9(< UR@S-WI?>%'1'9?&P&E]S*
M)@]BIYWR]9%9/,5.Q6DTH..TN0;D$8F$[L;>|WKG:L].AX6Z4>AC+36%ZG.59Q/VH3/HZ|^FAWED1M4]WW MD|X(OKOVLM+_R@3WFRTPEYM9;WZ>NE#>L[7>I
*,K_O[*X8(=^PMGLG5>8T+ M<$7[&A=T3^,0C)|X PY:[JH3[8\$ FW7"D;WQ)$5]|VZC03^NJTRBQJ&LXN MVIT'4LR|X6'.HH#,-^(I2OD9Z5]:90B%*7$DRNO2L6UM/>8 A\%D.*
4=LIF/ MYB[:(\:#'?GM^^XHLX:6TXDM7&%YB!;N/S,?BC-VUGIHZS+'Z'+#/SF]13"_5 MSDSJH50F=$:Q@&";:|9LZBQN7;X.R]+TMAW@GL,2QA&STZ'!::KR\R2\7O'*
MGY_NZ@FT""PF1[2'"JBO8?%(IP|^O?D(SCX:7D5\H|3/B182O9@:D]R<[Q" MKSLR;WIUG5*G]@EL 1]M 1*G(^IG*!6KB:+T@H=LR&=\|J1.O1;8V7Q*NS#*
M9;;Z$XIM9N!%9TY.48*DTX%>:CY=ZB84S<-0,B]W&E2A=#41->3H93Y],B,R M$#G#=;;@O93&S&\]!L KI:II9OE/'(10N?_RIR87!?!|@YOH|CN4FE].6$$ M3WVB>'_M?
*@@%^[$D367IY=]FD"C:@.;4+_.]M:/VW.FZR/AFI-2>G28TED"9 M< 24N&G[Z.@*7*BI<-.G+ PPUX.6-IPXD(ATCN5WQ5-"EIC^UGCQ=[!%+D1N1-O.YD;R=N^PKR;;4@@?*
BCL94|C)NCGVZZAYMJ=^ MY(!ZBR.MN3>R3K4Z[;F\W65-KDH)2@8-5,OGAT_@&?N.HH_@8U8=[QUUW"Z M<_NY^>/#3_QA ?,'CE=1O(&,NVZ3^3 "TT-;LTG6;\]-1&49[-*
&=2!XBEN(E M_PYWU$V4_AVG.38@\U:3]>&_@G9-9;8M3T+W+0"(E1 VC!-R6$6^30YR0"LP M)%'@LXC(6_*3NV/_VOHDIX7N=`C9CKOV0QSOU CJ5]6OK<=<$+.O81#8B+:B
M2LT])A;Q6N6Y PRQK@NH B^1"UG0.-XTW3<&!YS./E:?Q#/2|M9 5'?<7EO< M(Y?8H>(T"W5:KEI2XOC!464TM5;;>LW>5P-#^,KX(MT MQ-74=K'HON]29GL/%.]ZN"
*($TXXD9C8DM6HG?QTWN]"N;5+ARC0&[#D-+FY MFYK/$6CJY/WJ'_<%FE+Z3K@W.;1$XWXH3;;5+#HC]WSG>YPW BGN+&*C75 M-A,_=6D6;B;2YEAM%+E*
@1@'Q,)NHV7|:#R=A3%(?"X>Y+:KKHU:H: MV!71V=I%\]9T)%XW:T2_CA,+-#_C)Q#H/[<1"G$!)0DDCY'3&\BNJ5(I-)% MK)SU_6$0QY<6QH^_4IN\ OIR\"D^U)?(^[E8LD-*
*;H=XB;HW:DAWJWK-V=K' MJXNOV*7)'&0F1+.*&R&DVEK/#?ONB.5H*O7=.SD,7X"8J7]>6GIH/LCB-VU MOR5"]E/T"QD&WK&?G1?'|Z^OSUK.?GCK3/?*
E(XHQFEM$D5CVUQ1|(3F>" M,V-9%CLOR87A!"+$U=IXPU8U9&VU|#M9L M32/7I1VYSD%C3HM RB2+/
M:VA%\38TR.2!KS15K!GSMM1|!K&%O+P\/"Q0,5G41QC!OG0%84A,34Z/\ M@5S&=Q";4,"\E7|,^%^3)HEQ/UK3P;T ?,<*QSFX =FKY>K2#QTBJ#$;|(MV*
M3>"12^K_U/I6:AWB$.QT3)CIK(0UAJ)N\Q5YZO/'_=1?9;$+06GGF|JZB:+3 M$H31Q_.\/O NLU5'ITEE5=_SG7C'(NI9^$M+.DYC^\E8N"%:GY.LB?IT['O8 M.]U]2<#;P.!LR$>P
6I#69F!%)[:7.OPG7W!GY1)ZBF(NJK?)?CXI:5C+ -'N6)6FTP3'#%84#1&Y>\O^| M9DSH?2C-0%PO C-VU#DM99N?.@&$;]^O.0:S1UZ>5XD5["_3VYO)Q/GJ9.?[MJ^"M773CX3052*
*1%!7K7!SH.ZZL[EQMN4WB ?3(T?+=_9]VA2.[:)[<%<^CQ M> ^.S'Y#+/2)214@ZG+1$))/7N/-DQ%ZM'OD2FV(!HV#MCM6_O0\I/TI>8-!W; MO^"U[P8=!>U*C:9[X'! R#U]PB%9MX*
^"1L_].'H@#32[@#LV=F 7=]G<6\0 MIT)WGMQ%+A%:Z_ @^_71G@+65 -0NA-$4M=G,AEPH?X=.[7WV+ZDY@C]W5Q4 MH*/3I G/"O@] G &RF$;_FB?GE/@F_# _@&)^4A.;T-
QV#L'28!(;&N#4N[OV M>XII-QFY&I]BS!)..S[VSCZ6HUF8-'H1>N"|;XED;;;FYV$VT=5\|8P^T@= M@0F?;&IR&DIH-)MAJWNCM.!_(@H$:G'W5&44"K6@?U;:K0-S T@H/D[5Q)^*
*M+OU5BG&XW(3^8Y;4 ,4WJRM[4-&,XU*H)C4\46T8@8F-"Q"8#C:H>K.)]%*V M2-.8;$)*':(10Z(G+++!'LM42H8/^H98K:L6$T4-;-UHHCULC0S^2NY$AEX8) M>0/8A@F?'!*[S XUN*
*MJ.-R++4Y9"0I1+E=|-;QR?MWYFS|U GJ$1KO,(OH M$T"O3!90L%W;8GZ-#SLQ;%VYZL#RA>C*R=K?]QIYZEI9?KW-Q2;KX33GV*X*
MTLXS#)9Z/WQXP<$STS:317*9!0$[O5%O3O'G1EJ0(ZB45&Y6[8Y*6/"B4OQ M].9VDU,E<8X?PEC[0 @@XG_A2O MHAA77:4Z*-H#>P4(]:BIW=9L.P F$ M*
^5BZ8Q,:^F@O48,3PT$>WFR)A|]%%H2B!"A=],$\3>T]RQ[!]FUTC],O)W= M#L+<0(1Z2_1RJ<:CP;Q0I=;9XZ|W1FAVU):I]AB!E$\C1=IOTIR'=VMAS|\ M&!/^\,%&0A/D7.3H?*
*%WNC]Y]7U|EGB8K&+'Q[']\83_W]'#3KO.(9:=R8[R M.TO.=/6:36)5A_#9V-P]AID,8?R$HZ?8V:(J)4@8-I4N;YQHRE3U=@QU&0?ZT M4Q+A*8RKLTG.X"ZK#080#\LT1X0 MQ@]P?*
*&)KW!TM$EK0Y77|8WXF!*WL']38VGX?PTVY4E?:%=H3>,10/ M#U6FK3K=N0]A1]%V5XVNLC>N9?C"BZ\N36VNJ1GL5U]!B0 M6D#-*
*!Q.9B0FJ+B9JN.&IFXKETBU;GDPCXR9IB6D<;^%)AE/44M*E;I_I\8H4 M*_/>*$)2/A\ 7&1LW#GA7=$?R0EH79+N?IIO*WZA?(X\;3_(QDD?,=U0QV9 M ;VUYYS%X*\D%^-*
ILZ[8EG76O_ML!-<|/_G]DIP$@00+#^P@Z;6%@)ECU=\X V(+&]A.6PF&WC8>_0GE?6K-!!"T^5NZ^TT) M\2.B+]1:>N3G -.7@*
*B"&CXAY8A:32>LR12EB_Q<@.%:[[[ZME;%QL_.5W^3 MU<.)5?|^AZ"IVA2F/3.?9E C*U!_0@E[]IG,CE[(:SB$AHMD)W-!Z0],FV7BX*
M2JXVVSAB40:M^>YM/>96H(KAQ4/,1)PPH([I+?E|Y;J;J0RAU>D^\&8@:U# MT8WRPNP_^^3RB=WUKI_=HA>-Z?)5 3*6/,T4/S;'A(,LU%8+>G>_B4$_^I3H*
*MFWR]_<'0FK:A/P=H6&QZWB^<^]'B>OCT,44Z"G>1G$S/-J CO.\D?>L&5CN M/!ES$*HOP]\>G*\|8Z>)FZ;6A^R((CG<.5R@:BBNBO/ODK'E4*
MC&B+Y"HWM0KPT+5..RGKG5WG)^1N<-JT=U/ M-S0AN0(W8#^4PJXLD>YB]/&D,3(M^%?M41Y(03\(18M3O9=C?BB)&>5OROON M%HR]Y.4KP$- 6A'@ T44=4UXB-*
*J$H?'$[>-0.ARB6\(;M>%.-C2V=*UR#865 MZ0(O5S,04F/3Z=5HIFV!MMCJPV?Y7W&IE%H[Y+?>,294P^O.?]L]J[7+S# G M[I0$899D+X2L)GOC4#*
(STTD&:1=SFWS_\G%>#TY@.2#2GRW#6O%W'BSB,]6 MTSY/=^I?6MSF PB8@F16A)4;+=3L=@8A1)FD(7 M2_+XKV:4^'|:VAN8$!??*
*8$G07#!C047O.7;3QDR2=^"_Z0O:T*/7#!+K.V6+ MI$FXZ)=YJ;^;#6]774LFMM;?=(N-CA^ FSW.'DU|#F3MAL4ZQO:3>2*XK3 M)^<)4YR:E_PL+WQ/S?SK$S6BSB4(64TP?*
[$5&;JZX!4:LK<>4N4(!6^$6 M4V2ID0FS'/GU>XZO1HXY4;Q74;R!FZ#;## ^H_W1>DFCG!%T -H4V=@2^%]M7 M1X_IO>HT6S>Y!KRN>A3&/CUTH\/R.G @I?
*%B*S1&;A%0*I!,6+>8C@5XI. M6-(=+[[BV/433(&7#+F>1TYJOIO1:+;FC'^B#\@5]Y^86'F-,YCN5F;US)P M2H7$M")=B\^_J?5T]]5F2QX)!M5['85/M PF"ZGZ&0?>911_::S!VJ_OE#$*
*M_5 *'PLHA>U6TI%$C;KUF&6$%;*BVP'6E6Z_7GVW&=A6SJ* S#IB%7W5:X.Y M(-V&/ZNO-/T\?-H&TIUE3UE25KUN[|MS&_\JR*
MPP<78VIK.6D.#85%_C7V4[+5+VTA.Z6&_@@BO4P^A_IVG[6LVR9^[\Q'$YI MHAM;WTG6W($3>MQDG_OB^2$BZ"M6XH;IC/I+B=#XP.F_X__!D/9.9DAQ_ MCDPOI\$Z"'
=@J_4%HR6:-JV>6WJL">!O!-5E>^R:UF=Q+V8M++LO1>4>D- M1&83BML5B]?4?): FM<=L0[]^D[Z.2O?1JM'K;[M=.%X>2X!Q<)3P^=J2E[U M[J9=-
U.C@7G'::DM|F=;VNI^U/R!+XM.S.BH$=ZSY_22V@"MLKG']-+\?36AD&^-K4VUI/:-N3"K=U(\ M|D9F!EUKB@HIL,W-6M^OK[O?2K7Y(6=;-?,*8VL_04L@P)3!*
(W&@FDMS:UJ MP_=K' 1=Z6&%1I.ZHJNV,NH/V769VOOUG3XJ;00.BZP%0JM1^Q_,.H%[8YM M]5 _.%^O/+#V'3M3A[VG]?W$(*Q=/D$](OUXU8\5K.#B^S*FVE"K1;"MA]6# MPL-*
*1[_60N7#)Y!UL]),U-E<>SS*D,*LY0(T]:$]HRC]CG(MY$4JX;4BF*M5 MK1W06_>^,$'C,HIE@(\2O%*[[NT][1I%)) Z&T](%Z]IO/\,!R[,2/V(C&7 M&BQ=[T!C\SD93;IVIK6+8]-*
*<\&_M:!4^XQT_EL\CEUI4.=;B)?E-W:O:U-+P>1#@M<-.0DTQ_=BJ$#71)ZNIKJ%NC;=.B./Q MY$SVKYC.^_%]Y!?OZROT^*?YO2RQM:V<*4AR#+&$EGDU6)) MJW\^A/NZ*
$X_D8NDIOPJ_&CF 7ID NT$'>V\'[+F!%! 05K_'&&DIE!H#I< M=)=!]'?;;040# &1JQHHZ\(VM<;S3*O^Z*\FQUKNELY?G)"7N\:!(,H\#V'U*^):\'O";P3R6Z*
M2$8<==84UD+;DM!X36@$M^LH;(X^KS29S@%)9#H/JM22+S%_JRZ^@MC'DISA M?&9B>_(QF$TC,.7UU3R M:6LY?=0=#<3-\7;:04O;.TU8L"-UR-?
*GB4^R'9.JOO%T&BS%W|#Y$U' 0XT9_M8),NV)^ 5?_/:01X+ZMS.B.74$S.UH ITI AUZ/#00=*68MZFB;$23C%:"2! MSV!3(ZEQ7[6:3]=B4(^]EPB"Y^4B B !6\-',K=?=]@V<=N ?*
ZQ+,#?9D2 M<#@2$X7%$7D11.IQFZ\D@P-:0)98Y# 0^X%(-!.8A;6>Y5[R:HI%KO*8P*;@25[]9O"%TAO M-"*>]?K]\L83Q_YR[#!6-Z:6]=MF+"EM?PN@QP3']2FA8:M$F
*MV&5Q.#+4E'B)?HKIAD[@KST4$:%2[(L8I/.%%)?P@3?89")/*AWD$=2-:V3 M!LIVZP:1"6^R3;.F4_R[YNOSVB?ZG@=ZN;/U4R>XPTE$Q"[*Q? IHFB[H8OC MD"6;M*>]:"*
XF\S|DKU^6)Y^0^['4@'[\1/AW$HUWOWG8S>TN*/(2O6W& -^ M154-UME'D-']/4&LV3C"KJK E,D'O:[IGSQD!]%--,L!9R|ZHX^Y7^^96-1I M /%R]86#7-2(*;UL[#W(3*
*<32'7QUO')=\&E@];GJ+W/9*P 6#(UMQ8#6V]P M-PQ#KZX3[I$,U($:34R&@[(62,;(X\AQ_CL@09K*
M8J@)'W;RI4&@O6+H:CW9+1T,!!F=O/_PTYY@ET.ZSS)L3D2!6P^G,P<_)\PJUD%5#L";$&$'N?K1TZ$YB-ID[' VPR@F'Z/P/C;P M56FF7>X.<5U]=:&61Q_Y>SB9
*_'IW."OZ<,+#I[Q9_(YK5M*98TAJMN&RY M7.5ED^#,TTRRK+Z89*]^5I^(!S]E3GI1/OQ7/UU3LSG<9FM_^Q"Q5ZT1AF$H MA7G8-1J,2HHW0>27TB)>?>P70TEJCTJ*?9R<-*
*D,DM<4C[>NJ><8B^94(3(< MFX!9S67("*P7^32^;"$!?NCWX[?*F;K..,8"TB0D<]V8;&6)&AG#Q$ /, M,&B[^4TRO(H'8TYN"G;W%:59A-,>'3!N.NJ ^M0VC^C'_!L8==Y_KZK/F&*
MJ;29%.L!#!1%!(7^$4G]^^M&1>/R <#JJ@4;ZY;[L:UN\=8)P795!R.U##L MJ'KWU2V!6,_&&$+']1_+AF<-(4(>W92.#L!FXF_5<9Y#DM=FF7NV_!,-\,J M;KDH8F_EMJ'C=/ C^#%54

Y^ ?O5QR?5YLW;WWX M&>FR @RD^2%K[Z-;S)+6[L:TV-;X M10>3,?!N-(AB3=I__WYV2VULG" 0EK5&-VBQU>'=YO ()_=LCPF /*M;VIGG6M]WR5;N,-,KL&STXCN)D M5|>7^X>8GFZECD!K/&=+:]!U&K.PI2])JX;"7B)\-6-&"XM!YSL:2G!1LCCOA M^IMQ.SK- 9@05-K^4*5]40SWHCJ=S[;9076#TW:F^_6=KV"2="AZ.2Q4W5=;H4 M$W),:Y(?9+15[SR+/0C-]IOH.(^**F?B<| T^O10!:<[&CY%]UBT()0WMS|$ M0/!"M&)MQE63!5[K&-:D/VTRWRPE/3 91W&E'K@HD$K6_F^91^/X$P[E\@4P M'8(=7'$\%[(:F:>;^H2" <#$PDIP!C1$)BB2 AK%X1Y=I\-]+&:T-4 M\ C)XR!ET&DJ4B26>%0 M^50=2 .1@0/V7\['P%Z)"BR9.(:A>;;1#ML/:WL',\ ;$Q?2_K MJ\T6 "]IB)^2K]2$EZF=O&[.\3;&KB^ HWDZ0M_B,WN1F%YRH5!&R35^QL'' M5GM,6X^9Q*"4A$1I1:5_!%/JAU[!*3W(3'=MEW(@:1TA3@W]@](SSD6;+$;3:5;DG$#V-\@F#]%G M)P5Q;/<0- 0MJ0CP;H4]DV=&WP,EW1^B1UKU#N5Q^A)P5V41$9FI]D3D("];IP7,C<<^TX@ M'A.6(,; ,>H$.B]H(X@?)COERP4!3W($>=.0,1 91/S[,'GU>,D,5KM4X3E6 M]Q%Q:"1$M (41N$Q__?W1E^`],.0'<'KS&5]$7I0WE&C. :544<3)HBVE>X0P MX0S02 $?!E1E!$C"0B--'YX?!2.H.U&R3WQ[B1:PXAKZJ+>]\HC"3Z5A#_ M/E8Y801_F QP4DS\Q)D.*W>OQSTPR%4N"]/:(X)E7?FED#49;@28VX. MH(2 U+RG')1FB_[!Z!B3B7F43+F82YUCH^ZC=HE/A$FBU')-EJA+9\, M/8-83 >^/F?J@SK]\@6EE8-)()@%>5F0F >5=^1,T%7MO44;T>DHOWS%*U=Z MNHR=/:.'%LO$N,-$[8OB;907D01\D\(OQWR80!"6(RZ2/%#.^#?#!D E8E3Z M@H_G[E7P6CKEG.? 2/E+IK&9_C1U=0)5B$9BGF1]XLA+:F#/*Z*'[K4/^]Q^, MGK%W4Q<#06'N@I;QZ4M[),=$K8T#&,612A+E-(USQO0;$17 4Y?8*^*G/E2I M<:.GT!][(7)I<,|+<@?(D=!$"7%$]2.%/! (\WATTCV4-M3>OQK75/'V8@#*L MH\ C)XR!ET&DJ4B26>%0 M^50=2 .1@0/V7\['P%Z)"BR9.(:A>;;1#ML/:WL',\ ;$Q?2_K MJ\T6 "]IB)^2K]2$EZF=O&[.\3;&KB^ HWDZ0M_B,WN1F%YRH5!&R35^QL'' M5GM,6X^9Q*"4A$1I1:5_!%/JAU[!*3W(3'=MEW(@:1TA3@W]@](SSD6;+$;3:5;DG$#V-\@F#]%G M)P5Q;/<0- 0MJ0CP;H4]DV=&WP,EW1^B1UKU#N5Q^A)P5V41$9FI]D3D("];IP7,C<<^TX@ M'A.6(,; ,>H$.B]H(X@?)COERP4!3W($>=.0,1 91/S[,'GU>,D,5KM4X3E6 M]Q%Q:"1$M (41N$Q__?W1E^`],.0'<'KS&5]$7I0WE&C. :544<3)HBVE>X0P MX0S02 $?!E1E!$C"0B--'YX?!2.H.U&R3WQ[B1:PXAKZJ+>]\HC"3Z5A#_

RH/2:BO..,YN:8\W#)/X1TY$N:AV"(1"H0@MSRAHX!<(@|)*=*+PND/B/ +PJ1/7)&NM([&0X8#6#'OFD2_%P3S/(M1GU(XK8\6#0:B>P6;=\&/\->[\$'>Q.%%%5'8IL M,M4E6* [4FU3U2GBWUG)WQA>("2>',3N)Z-1"XM7HS+'>$_T!A%!\A-V&/B0T MJ5FVYP(L&%+2=DL*_)]SKPS?9+CPTXI2" 6=!P%F"GC,J'#6UT]8-$;E^ZU1 M4[@#3T"D*)F0S:OG;.9F3,]=8\1S8U#5]QJWR.R;:)1U6LRLBPS=MLS]NY?B);C+4 MRK]\^ORGLY*KN2+*!)Q0N2;3TTJKCQZ(X!+T,7Z_H"M9L\H*_W/I M:=#^,NB5P%[OC9Z-G.UCD=O:EV'W,(4/((%)1I>=R?V%KD*?'>MV+B"_LALXF&O439?S'KU|IQ%<*0Z/ .HQ"_+G *#P ')+L849D'WAF%GNQC(PT M$L\%+5WR_&KP[!5Z.4TFV<%S.GIB;BB\;0# C,<>%[D?4I%#T#>I6M+&2]\% MZM($.'Y*]9#7G/U3KX$1"OMED?"SM M%5 M*)\A:9+3SB.#J:UXZ6%Y+*,(=>+3,A;L" R;($*=6+8/ CPHUZPSJZ,' MMM.73)9=@W"U-R]D<"->QPG$$O91+(RR4GSY[B?K;,DS,,,51Q9OO"0VBM^ MVV>[>1 D 'G_K@-(_JES_T]B!))];]^(KR9S]_CDV"(31KW@=>? JG1R^_^Y8!?/Q:KS2@V-SR^H9M5L10\6N;D3!S6A:/@= M2]4U:!-/$;>DSXS"'*ORI>G:5%R'YIOR_+H_;U:JD3\HUEQH\1(/ K4M\|BL MBQ[OG348$VR:|>^)FI<)H6;4?)^7 83,8\FOC1$ROU1]$$]W|IW3@V-SR^H9M5L10\6N;D3!S6A:/@= M2]4U:!-/$;>DSXS"'*ORI>G:5%R'YIOR_+H_;U:JD3\HUEQH\1(/ K4M\|BL MBQ[OG348$VR:|>^)FI<)H6;4?)^7 GM>QTN,TJCQ3H*7[92_^5#Y"/@@X7@K/Z>MR^?/O\[D1TH=51W(<+0 MK,0\C,^UG&S>5|$=G5;T,)N'?[. MVWWY].63BM8H%^%6<8B#\,[[@LB63SI"]UH.7H;Q56;? EJQ=7"124A[21^HA_KB(NEORRF6=9PK<=.KN>XT>ZB1/P M@0G33[^8!]@!'\0234-0?MHR(0 ,$R9,L<"15,>/!L 'I-)]P#GP<7 ^!"$ MM!IP/#ZN)$]OM,DE,>==|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|%)OXNP;]6]2_+WR&=?[36O'_P,%K!GQ?Q"[UB/_ M^W-<>!!.Y0#KST8U"SPM3)SU .KI,0XL/:AM\\TTRP>B'5AXK5E2]5*MI:> MI) |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|^> M$]2H3)N_ATR5^SC["\UDNLH_Z>%5N4RT^'W95WI !$N<&3X(ME2=K"RG'&6&6//!N*3B$5B_^#"RV13W;^--TJH:8-R5OD%;$.?C-B9.9R;$G; M.G0Y3HU(#4=9/WMXGD>+5]$/_+*%FR<=+?)\3-8*$:^_2GRH!7Z3DCIU\KE M<3#HL$1'MZ@6XM'0S1V39%](& MGZF_BF(6O^XN^=N3Q6@S>4A@,.OT I3YOE5-\V2_3/=%@KPSR"7"WHB/W8WI M|AN1;SF3>6R9VZJOZ=,)W+'!TF*;U,7@^3N^* M\P['AY1)J+=8WO+>>L%-^8FH3\^',=]NZS]D9??E!&'PMR,.5H2EZX*FBV41 M,@5M!_#:3?-7NGPB0TBK+L#:+ZS **C*+P=S!$1%'. 8A)^2%%J[(CHXAVFT M4Q)A,HF58_ISR?&%4K#E*,./CY(3P0K"Y+-1D@,KJYU:TQ:H&!9E958NJ8^]5/() ^M6I+Z1'RBXL ^&.R1XW<5:73O(A&*VD?IE3 M.?]1WV2/>4A"HD*0]4<M7B^S#>]*2#%M M7DD+T4DA@;OB,C)RQH&/*:OVIAD/S?=VFJ[:?\|#\#P3!G^?I=BV> ^^H(N@RA M%E$4//:MLB7ID!UH?+\Y4]-(RZ>EX.9?WX>GB3Y?P,+B&F-)Q*>DK>52'IQ%*B"7B?'^F& M_V;%;TQ=|?0"0K)HL@'C#![S&ES'$-O4K6IM3'/5\'Y4CUL ,^:N@-_I[12M9 M1FJO?!H&B^@1;E*HY@0K)_T6Q2\I3=Y@P^&3L5AB[WRGW6 80]-_C@W]BBMB MN<,/R?_F),,Z",7:NE'E+ ^:`0/0'E1[^RG=`_WG7M34,ZC.BZ)\<:ZP+5Z// M'&HN4D.YBP,=X98C:L.BPA_!;=)395'8&VNCIP+V]9O]#*_U<3U?XW$MIU9Q M;_90 G1#HY429-;?H@?-IHAP7[=R*9U"^121&@?VTP/AO!?X\NIB$?+IY MN!I5)$\4C%YS_C(Y;XY;&>1M(GHB';_KIGO)@HRJ*Z],GS64C>_;!< M-GN[H \R <_FE35\KJ.ZHQH35T^'K9)N-4U^ZJ <->C(IL,IT(D0D)%_W><* M>]"/Q_/%]K!D[>6M@221BLPH+T[U,%26T)5,2 D[ZD7"GVA26(_YU1M"A$P7P-)9__B3]O M7+!]ZUV8L-OF0&9$#P6/&W,P,U+"+)D504ML%|:85I9F.8UQI&F][L94_BW4 M@!U%E'9]PMH67VTI+XAR*H#&!)984"Z>,8@/)Y,R/_ P]VGTBWS[DM) ;'E/ M5Q"FU,\TH6D1)#*;Z*P:)&B2>>[C>KH=X9DM2[@^]",U^(H-F=L=;4TN&;_$Q MJB09B,JX=TW? _^_^Y8]?/O_GG^W73AJ$5_7<*#%X9849#9B4!S$<&Y);C|-$ M14G+E/S7";'"REP4@R\L9;TI+ ^)%O'X)(YGP)H%B\|JYVBW<%^53^2R-[F8D MT<@T1IE;G9,ZKIE_9/|+OMH&OHVJR[=CH]3;8+N(Y-@VN|8V+ +"B9(0RV\I M12-+7UL^)P;6CFU*B6?##C4H,VV0=LC-^%4%AF2G5.C]VD|S&X)/E+'Y0#BN!N&HRR]7#K.7S M777D)G,TO/8[!G)",O%%!C!(S >2C6.H1IW M4'SQZ.KK0*S+C:JH83"P1.V7%$^$*,?)V,*-)4,@WPP6&6FR060,D#7!F: M+ D-NA:S.0?CBI49NIF"(7R-HQ\HN-Q"S.Z#,.S#DDD!U)]+'K]VVG -]U@_ MFG"?B6Z(Z(>(CF9B=:8S(CN3KC;1W8ES7\BWY+V _P)T;#Q#4Q/Z-I',XP%* M4NCMQ'DO7J+S(,"87]C>+9@7<##ZTH!_3R $PX8TJ,7-X7%7K6?6L@6,2*-4 M_ "GD#]R$G^U&S0G0E-%T^#]_)>39I+MY\]:C,5]G*$=|S;V(GY.^#3$U ZN M+1Z;E6YLI.LPXHHLU>+F5! U[>X,O%R|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|_KK.DH8^:3V^PV%?^(H(SB6BZ2J6R;*AP M2T(%"-AF&=DW;+DBID)R1[. C/Y^KXS?W,,+`D1BDR@!R"QTV6)%;G1+\Z<.7B>CHN\KBQJ&3Z3#+_0 M/7_G#AM7HGL14$EVXR[&8Y&5N2LX_%0?'X;=]B';G%1K\24'Q' ^BFA+:X&[MLK_3ET#QR/TH3!GOM:/G=N2'6QZB^,AU1XAHBK*^I=MEH&).=50E4(I"@>>3Y0P!C40RV$C,EPL0QZU*&OJ2@_ >3YNV,3(O,MY%SP7'QXR M2A!]TG&OLN3FN:U P5%Y+P:$ZB*XBMTT\DG@Y0=C$U;_F-FP@\ M*"NLQ(51:W'/-/W|)S%_M\'66QP M?,@N3H^C\IJ;Y\R0G#SY*W1 L <[Q|*@3#8MR;R$>$H"W 6+!S7),-?_/>IL2E7JL'>/;*GPM9D!-;8 M0&PC<6>>+)//H:;_^L=:+/ M*T5(68CL]=A5"H6I+VG]Z% E^%$%9DN5QIO?%>PO(OJ8$2 -YXLB?OJLU@Y< M6O$0ZJNCB!V$I_ @AZ)Y/R#I<=|NXS!4ONL6RS(*L.[#U?QN&S[0VYBXN MEB ;727,@U-A7R"65!IRWJXB/L*D3WR@&7.,_>^ZO.75BD)\HMAQ>I#_'893] MPQ_!7XE]"UQ@V!5R+5RGV1%17%H 6%/-W<41W=U[R=YI=;Z-@@#@4I$@$28(T MK64)#,,,FYP/=-P9.33]7M#"Y:C>E!9+B0S$1B',<1UO8<|$6RJ*VXA@KHT(MYCH1ADKU,>.=Q_C)L*04^3H1)DPGJEAA!DW;=3-^%0@\P9R+EBN-"@Q,@ X; M 9N09.,WFR[5%?%$7R32&&$*]U"5^?=GC3[YD1KYF5/) =(DY#=A>A8[.\C M+ %/I=RJ\|$IR?-8L'5,0V?]%%?TA<%:)7MGB]+A*#[6 /WFZZBGP(%<= M4$-KMU0A&(%=OC#VB!*YB?'3B,.9^TLC>X:0\RRZI>/WE@*VAX<=Y$ M<]]'_1:\H:!3Y66C>OJ7< !DR4=03@/E$B&>[-:LDX6^4M3K\A^,>^!,(]>B M<(OE@5F@A5,GD8\G$%9:,] Y@= [A4&@V8MQ$1(U!Q!2@H!X_L*"J;OB: M3290N;A06&@(+-RSLBPZ>QN$=3L$OHIJVU>/39A/\;CN\85ZP;+-Y&?@+7X MDHH ;Z+++7V.C02[GK745 ?D!|4%%% CE\)*UA,N;/T(!R%Z5+MX4FM4;,P MR(Z84 N,OFOZ!.XYS!T6.']IY<4(B1[B M3"5;$QPE'0!&H6ICH["&4'>\ENL>1KG4_V/R&]06Q MYS"]R_Q8RY^) WHNQ0C@- -5CP.H=*%4#ORM>&@>L\4I&Q,-ES,+X T]*%86T MJ AI7A32HDE(MAVGDTBK[%C-EY:GI>;KI67B@2|-WM55K7^]=] M;SCGA?:N(BTM%G0?C=]]#MX$#K$++=! @NH\PVLZW7"],8-GU2]K*;V3.B*=[MGA]K,#)D^!$NA3FUAAZVKXPL>IZ)*4J(J;R4H\<>?83@-0_ MT>0M]"D_^A]HLHR3->A-P\%BZ-2G3T3VA(> [T9=E](@Q&6<&SP66YQ^6Y=KT M1N0]-:9[8_!N#41#>O;IKV%)R.GQLL)0!:RK!A25 '$F3_S&R<[X3]:FT>Z$ MF-GK,[22-S.L3YU=B=829O1CY2;::/TEKY1]KG_?D+,!V9#KSL2% M%D1GQ!97N/)4B76P\R^7%""FL=CDG/%W(T+]QC][_X)Y:1HN0ZI2$'LN3%W> M'>WZLG=|5Z;$4_V#'4U#+!!?#T$E*([KD[0]'O76-,6B>I5U6.>F6'3/),_: M2L:M';G4]MZ#K)D/(0:R'T]!IT30;+I2G|<';@*L=_GHKVP MLE|A>O8|%T,T)_+"C"(7,T18"6!C",'3_]_":_B#+(=V(U[7E> Z&"P4JJ=0 M2_V HGT\:.!'1L!C*3#RZITF? IC2AX0__P:)@U3AKHHR0=)Y>N:,B$$*=50. M$XZDMQ$K*)VF?)65;$!$7D/V5X;LX<OZ+AXD8BM8R] M[_V+WL%'?(* [-@H'57@ >LZ_;<>V-AB|'"62[&._D"O@XCKHF%'KN)TBS! M-T_?#&--DN0T3XO-ULS!R$@6LU8;_A#&SI<+&_CZ/46@A9%':;?* NNX^1; MVNLHR#L \^A&I40K[]O&QFR-PB0K\SZ,RJI=:!'@6S6)!'I8PNPL-PUW3U426R7.BX|"CS+<&.)7 M<3X@B'586*@!!GC4SWH!:-4;<)"#<*GG,BN_-D+)[V(&?]=#"%:|2\[@50 ME-_P:[/HP;#@287Q%/4/B9WE-WUA5LU.[4,H325)I[(0FL2"+VCCWR*2)%MY M44G:(XL,]!9\^[I-LRJ Z/?X(:&0L$Z#X=SHHC-PK'[AJB8]$_0M^Y%'YY@5 MF*T%C.4_XYV1C\E_Z0Z1I(__:[LS5!JB>W1M 5GLA M?$'1!GKL($RPTO@E,1NXL8.,O[30&N9AW-74O)OD QQLM,T[CGD^7@)S0 Z7 M+88]9Y5Q!6]=|_Q571/L6W]W\1ED66K=SNH:&38>Z_\KUL8K -==W+ >-UIP M'@K.B@?;&8&54H)]IN_OO/7FST[L8*5]2]<0'-\Q"_VP-[!53I HBK:>TEU] M<3TDX9N742UV==\,7*.KH"A%JC29THVXOH2C,/:+\F:/NU7L2T@96[H6;9.] M&_M";P3.U';,5D(N5.IKBEV.X?C]5.7/Z]>0GZ&CY'=)XN0:?U0D(@T PNBY MM.%1S44_?B"'? 6%TLTP]M] LEY(P,A!;*5N2Z8'K1:BKSW*YB(&84>^P)B;L MI,8^>^^Y,:WG32Y363G)0CT(:X"4N+]6,>,'0"KBAH]EJ%)175+]W;_||R!#7H[YQ2E*QYE'H-G5D>-6XLXP'R%+[CW:$58- !_^Q^F_*?_4:M: MVSDYQF%0SE7AF(7),SX M0?>]#R0\$B)(Z2S@I-P??"%>2E(#^]=W3C'C$3D-+DHHQUK^"OM_ 2O!#-=<@D<.\ Y72 F(1@=GGDVAJH\S/G?F9C|'@07WCI M2L)31(%,3|Y1_W+(P)N(2YBFV4UDEGWH>4#[O'.%G@QG=*+3HPV@S0)>8"@' M 3& _?|.:$&]B"!](1'(Y_*]H][Y"Z[)7/Z/@N? 3P/S XO'$N^;OJD:.8A)!A M ;| D11^8'PI[&G5/"CY4+IZ]U=@VGSDRO75OK'K5]S=U7?5AV&^HK&Z?W:,ZD|<: MF(MO -C+3-71Q(N(>"63LV\@CTD3]^CV]*&85=;TFEJ;UIP=0_%2>!M,R9!P MA-U$ 7V'/%) (W==NC|N>(*N"-I'$8?D)\K]/%:J34SETBW;_R01*R363H]! M.&$3,V'4D7^$%$FS'LXS3=;ICD*@<&H<%,NX@GD#U%>$M/]!:V8[ZB7!TZ- M*;G,M+,+E7HD7$ST'G("9/R 6>Y3Y.D-<7H+2BFOV%$&:Z2OL,7;MB MS>OQS$@^HH\MOU*YKQJ4AAF)Z$<7@F&(G% (6F<0H92W<=H+YPW:"T^(%")L MAUC%IT -Q4E4<:8_@#$1GN"[+,%#IDEM<| ;"4C:BQ>.U|IK:;+C<5K@VG7 M=GZ6\#BB>2M 8"=E(.QE&%1041MK6&=#L* T)>$)%01G922RR8"FG#'-+0R M?Y9NUSKI $']?HD9)P. I>!\ZS>U$O;N39/\#4K$7"G]H 6-@DG&*&,%GP=[/:TH8[!Y MO&@W0* :DB.2GMNC9_8';*B59,',)IZUS>[L*&0X$RD:^_(7^6?%)1V77 M7'P-/%NKIB MT5%0.!8|L%X%B^0!2PB$A@5B 6B7]G_Q^"E-HCZ-]IOXJ"O^Q M';FBXD-"EY0_MLW;M#4&4]*&+:.H_#@)1'5LS07!<9,MPK><,|__^IF3O^)= M\\9Q0$='$W12ZG+S&>]$' G*613&0)'JGDG>M<7\WOSH?/;>;P)('E"QT8,% M*T-&;9&TM=#E@9ABT_*CP3M.Q-DXS'B9.52+]G#,$%@LIJ3@1#NP3XH?M8<5B.H6L)/5(-U"^-7H%?]VEVI4[FY5^U13)H+T MJ;#$)N5&8K]*W2)7+:0=3=>),6(VC(L1[\5^'A"EU1A5>Q5ZE:X2,R-KXS(. MH=,/)]6%D5%P4N-0DM&QU45Y0-)I0*2W&6AD-B03F7-C%RH*Z| ^:!;'SI'F M^UZL1@?E6N%&)[9"> <9CMURCS6#;*Q;I#O/.1@;'%D;'ZSC18-@&A"?I2TM MFDM^*^=HV'3+.S@EYM1IM>I**?)CS(Z-5GR6OWJ]2>YAF*UY$7Z&WT:*S&.(L\E&H0HU(AX,*,P!D_X&),%EF1N]HP MHT)4FD4#ZM/V)>6KC(_@ZFT 32 G1P0]BZ_MFIC!05:EIGM*#++2V&VOK]H(MBWDQD>[FX6ILR)E*],P#N>'_N](;/3,4OW(R:Z)GY15\2<'G-|$T0_';E!S) M"8[.6)ID__ -$7V%Y?:7Q:^)M5J'OL?Y6.Y/:20R>5<=MQ2IW*7?W-3^Q//87 MZB77_">|#'**)|$T"1 E2/4$&&%3\5"[QZ^P>""-AMW=G_]H9W>/Q%+S :UH MZX-9='!B_,V_<&F)S[$OVAU . Z'#LH)"E!(NQ"B@_"A%|_N5+FH+'\Y&78] M 5ZM&2 &|#<]TN2H:=@4O M!DD"-$^$E1((:[]M5)F541K[&P6-]9 MLR;6WX8\"P%S2D0;0T2>%!%]\AU23\2%R;V.O2@T,2N4DSZW$1RX9 M)$QRRH4|F)SZZ?%7N)G3+%Q@?7'3Y<^U1,9|/15L37.OY#N$MZ@/[3]47*)T MS5442)%=-($XDC-" 6-B::G:C?M">|J\).L@MA?Z&D8(R/2_PBOI QT!7??C MN19N/!/\&UHVYL-8T110BT32=^WPU2K2>]R-BLXP9522)0?-$V&#-')"_ L%1_8(74/8L MH=Y%/0#18>0*B!$@)*K(V8V!WOS:.^F"G[!A(/[A]7U9Z<2.05RDK%40T M ZP>>]P^:K$#BU5I0;?Z9O'WI^UFPS 6P6/YRWB8?%75&RQFU.>@PQDQNS3L M 383534J5;:B":R^A*XHWVEO-(>GFK]Y(4/+09S EC2"??4Z.*?+.*'-ZR2] MI[EB^>R]|WG)+"YN9@3C@?,AS(@>WAD?PAD,<$;^>F$DX;|F_&T(8S-V$]<8 MEQD4T?;>+;U/G!4O&TVROUF1%M0K4=]$BVP;<;V%8;#Z*Q=A"KG^7D&^'F'1 M1[>/;A4+?#L:&,M18-|\NCM^GG+=A7$M>&B>(#\|%&$\([#% M# ([]\).GL&2KQ@9K0,_M%-5X?*\T-PJ'*-9\026-(4^ M@V=UXQZ]Y K6N-+7+|\P < -(&TBGY^QCZ$:-KBF\W1ATB#E1!MA]39_]ON:(## MKWCF&4GK-U&6P ?MSR7@(ZD!?!1'*Y00*0OX-R'/TKTNY/6"\O)-N7I%(,W4^&XCY>]A7%^%7$W\ MA%%#+%5WOHZL&B^35B|) ;DM?S,) B#<*'GA;Q:Z|[:]!^7N713'Z%O9/W3LZ MO\S^BP4 \B%82, ($<_=M['OL815' U0G1EH$B5F ^.H[Y6IN.<+7[_[ECU\^?_FS M+9//L$P6+/C2!U&=|'^GO0PK3Q52G>58==;"SQ]IYG'5)E Z3W_]8N[SPV|+ M,/KXDBY#/117(WH8;ICR? PMBN3YHBPV5KO4<8P|30AO!?WI5CU+I:%E,9#_E M2F.S.M"1%7/K",S_2: ?H5U)A7P_|#&L^+[#|,I-;2VMS#V2U(>>P|R2/"?UQ M'GM)L%A>\E'X69RD%RLO3-9>-,"K)OE7\M_T+8S@,>?'WT.N'MM 8AF6(SEI M2!06I29+%%UK9| 04/.CH(D;Z3K\7P;@ZY,U-_WTLI$+I1YS'P/85<4"VM MYY8!]Q4H#,)B8B"N@& <>!"PG)RI!GT^!$S85$SK,3N\3:8]-7@W0TF=.HA<< MDV%ET_2)T<'H$$V%XETO^QT.+V6'@|(+I/S:8FG4-I8NN5ZI>>L-BW<4D#+Y M52S@&6*RD5VB"|*+=K]/X6]YM6/(K0^3- ,46/0P!!X>AGEN!<:$SN!/&*W M:J=:G(/B-3UD_4JBJ:')RGL0&6H4V+;DDJ6;#*_X(F[=/7^*@!E1)9;T5YET M1V1'_)/.6+%C)1V52U9FL))]KY2%R7'9N:^PKP9*2X5|>'#8!>G90%P9^+ M)8:*&@#E@V1CJ>0$;&IAE:3SH;AKSG'+I5,AO;8RR/S>_KS4/<WF^6N MO*N')W+A,1IL3ZAG8&?C;NAY$*#JYC%((3#R^2AZN(GX3)YNHE^CL,H^X5/ M5_D_KQ/D72=Y_.7UX?H&2*=_P9|DS?1^8>0'"*L(Y,X\@]M3X1%O!.E,*X MB0AV2W[Y0,(H'?V]5\BXGBB-3]'?T8ME7@=E;D3&]7*Q^!4 M+ORH%CV\53FG 2_WJZ>%[OP)/A)MZ%0S? MJTC/3LV]GR@+9$K1;1R]WG+M(!@.+NBAUBU 5((2% M-1966E*SX2!#;+\6L MK'S%6K'MILAT>[X+8I?4IK@;8#5I8K!R;?'!ER92]LXD6KKJRZJ)57-88F" M7*6H:2LA6"X)M&+BG=4+LU^]T-PJ^-=::.,HS"AN3*|N<"(AH)<)T[FH%H-CNA+0 M8H|4K(.!32!85>&2|UF-7SY]^4) ^H.\|=9_S/ %3-9QE*U20'?B8LR?RS]^ MFD&.UI<_? $"Y]$6%/9]AUR3OFV#G*3;4,2Y,8Q_2OW?&1 MKK?K 1R$@I 5IV"O03.IXT4UIC;D-UL\2S>)LP\]BB_!=?65_XP>+W@9P=- M(@%%,&K#U20+P64: '|\GA% ?EB *.;.%F6 MA" .;3/F*3.? 0*F:\/$[_ZS095T_9:KQ]65NQ5Q$|]T:UOW-,YY&UP(W>'+) M!B^\(] 5 *K1X'(+Z]P NL$5D3Y2#"E\CB6 /M7_^OT,#)):0 +L$K7#<;$] MK?):C W6:'5<@'7]0C5Y ? +0T+/KK>H#1N!T6(Y'T8RB^(2UKT1T2' M1/0H3A^ !Q9>8Y5Q0AJE),B4T2QAE=R$*)11"D7M1|(.:E>)6A5%Y8OS| MDZ,32*4=|A>:|N%#3*5]WCS'|",CL51G'EM)9A;C$88E]>#BL@6GWO^**2-(1 M-KNC=Y^@2GY0|_E@1PI+W(6QSH_M41N+5G$'!691SYITD9[4D]1/Q5LQ. MPSICB^6W5!B3:VS)O4QVN%@]@^BI/|"?N5+(]P B7IYE A0/KN)M!'2E]UB4-Y8/5NA?;;NXPR-HZ4B M+_5R]6<=&H'S.&8N_XQL?/-$7">72((" .3,N$TN)?&/(@0TD M@E/DO6 HYO3-P*XSXJ89?]MJ0-;G6)EJ@:4<[?4YAHBWAR1=?P.;G,_X$'1BXH1G07 MQ.9J):8' ^"$*HE. K#KS&R4@T*WMD_?!-R_$.>@$_RL5DTUS^M^.T/2V- M2.L!,B. ZAD4MC1CR*U='\,QQ4Q^CRHSVWY%9(;_DB29OH0]%Z[@*Q<_E-1S0 M@R7OX3D1T)[+&\]PD :4=BF^4<%QB>?U2&ZY!XD?/4F.J-P;DUDW0:WKF" M*AU23&H#$. 7H/(8N.RJTMXCU@,!Q7U0=.2CG!8 H@ MUT-MO=|G.0OQ0@3"6AJ'X.LBY5)^0%>^&+4'9#/-7/R&$&HW I MYU1S)Z@339YH^G;.F7&X+ 09., J8$Y=11F$W> <1O2(*T(A2ZAB>Z:B+YGA:*NEHS\N75, M@*9@P5X^NBV[/ Y<"=4!'[VPLQ3#)_6S'99>(Q&Y?#U%YSRRDW8\N):U(MFRXO611"YOWA@$@1(D3>[2(O2.6<([N9?0K&A**RYMP\#J+BG[]GS=|K>Z!T": 3$ M[/CQ8W&G?!-'(6| R@991".#U1E=+I:@9.9:'QCL0"_L"TQG= %/M*@4Q!C(M;L:UDHW!]%*?30872X)1F@8FH2)_M65< -:&EIL Q\1B#V\J1\5H F(>5P#_FEQ#\ MRLMS*#9\N! Q+>%7/I+0U)E=C(4NY8^0/'ID1DSD@!G1: H78RXG"1R>A#0] M?T@HG\^$&OG ,JIY(.APZ(6C0]IC7\,>XDK#]\V<33W5R%]PQ?/8@GY MOM&6WH6,?Q5'M+V8[Q%9CDJYYJ1HVW%.IER'-BCV?#&]\: .2" MT#)GV/]\^M=/GSYSI5)A>9^1S__^:?:I$_Y/(0UYVVP5)^$.:?!G\GGVXW_|MV^Q/__8)1?%Y]N6/_S[|\ G?*-NY+MVR8ZL8X2#!A92.:M=O-0QKIM^JE3GK;JG>&|-P2[5R M9L7KU) <;MI>1\3E@ _"2!W/#_G3B_Y3 1R7>E MIF8C#.#9X> /<9DN1P>DD_WM,F]1^,C M7[UO0[@1E9NB^N?EQUT&+*/%;41]T/C('M%',34^&XC<9]&!\@38=8-*\>C[-XN M>]@N3ME+6Y2^@"*2',,?Z[H"H[KK:TI M 4MHF"D;FD@@>J61'Q[M$C,HBD>Q2?.$V"E[A$R>?),P^0%#)C__VVC5]^KB MN^_#B$*H]?"Q_'^:-G:|&,.8P5/AP:7(? P0FZ^+Q<0*MA=M?TI=.,UK4'A,|W M+V18+%P4MY7YB)SE;Q&_?1BX1R%=4<50?OXB M,7"93!|J1R+12%4L*P+OKF"M,:+'/,&Y>UMO\34E16/=5_*H(!# ?&-9/QBA>+X1&7KQ3AQVZ.BYE?")T#|801G5G&6/>)02X4 MVU,/)%FA#"JSE9+A!*J.& 6"U%AWN-'(ML74>EB-@.*5$RR"@/BHBHGRXH M0D-4Q8CX<6T=|F55S ,85%0?3%)-*

*,6K.RDD=QK*211K@C@_0\A01L,1$2LHR%J"CYMUVMP MJB-HF($FJKM""/G3YE<=5|(?2,C1O&)7Z&;6G1'LC?S55N'(T?DO>U*5'/B< M:P39#O8NDY)H*J MU;BS03DRCY^],S61?:=BV.D)"JQM.[(?J<5@IDX%EW.F4?;LE>P86PYUAJZS MJF%3FKQ4K;("Z0'Z)!M%&"6$$55[D,R/9S908B,WS?X[W%5IT:4"QV;<|>?F%O^ MA<:NZ6O,S&%PL)#C#_PFW5$O2<<-++'%]=*(VY]=(]$=4ERH8Q1^+0JB?*S MIP6Z)@_.(VLED;2P3,9]$|UYB;\J9@AH9$G>9@7%\(8K8H"|23Q12=UVI8;Q M&68FKY5DD!Q-],.*H+3\C4Q?*)XM%9|IH>@2CD1"U/AYC!YS'XZ[':D:6 M3L<:NQBQF7+G1N*276&PHAP*Y['*1H.=&@D=O7;9I5EBW_@3R_8=D6HF<& MNXY%UW"^?=&7%9YOI3@UJQ>997FP@BCJCCCXF9+ _#NYJ]X(=CE19VDI,5'&2QK;\IF$@LFHN5B%=|K[]+:!J+I9+WGDR M0 F"S(L8W9&?/3_F:L_/R;]:,VJ/P5INM!?4!28#T">Z R) [,&E&JT9\!QA6 MQP=<)UZZ>DCB-SZHX'SW+07OA:Y6.P<@;Y']/4"@WL7\Z2=R?;OXJ8E/9;ETN8=">1-U16<;S]\$Z&(?S_I M N<]6@S0]L+9,1P#GE?5&'+# [E!C<1UZX#F3@LTAIC?FJRQ3"M"?28'053V7D.M]A#!PC.(RHZ9],.2=D^HXPS$WEB M+/@R'?706?=:?GPY'.:?M.V3<$\J0(BL /^.U:.R5_W@:O:(? .V2Q_ 81 M\&P'3P*X",;K'L6,1>|UX G&$/"$T(.0Y5_ &)L/1-6V%F/YH"(K1I[|\6LD M@-# A)T7%$U 53]+EV=;",O$F]I3,!OVD$/+U<[YO7'U+N|=|#5\#QGK!Q>G MRYHCC|*:?XI^$EB=C05G;R M(VP6OCU3P>KB)?/""*P>G.$5/%FNR_M\$'!?[!;VK=ZC*8EEWV"YI;)W=$A% M]'LC K %X >+(F*&=. $^Y;*S4 6AG"N3.&4[@U[.+Q'O\3OO/=PO5T7$W\? M:'*UWK!X1R=|>|N155.FP?2AAO>;D:NY7^_+>=,(= |^=+X@@_ M#+;|1*,C MBTA5INGZE+M9; C#'X/M->*%"7;1O*0> ^_PE D6AGLQ/HH Q+]X10 ,2Q" M84PHNUH;PEX3 KDIR$R#J11@5#ZJR KJ7H>U\^D4 _Y-+DDZ":A?B@BE03S M|*R)@EIA]$W\-WM3J- 8DL+Y;8AF$OD,&9=2 =|4Z8;%\4V:X_*L:UF(W,=;'P M1=Z5-$\@^ M^KP|^2@^JK1,$1O (K.43#"9Y.Q0+&%;XD(Q"H^\POGR)>\Z)?\U(0"77\8F53B M6DJS/WX5L123 @#1.DK[X48+[T1N<*>2INL\R'6)9#2|IY@#QU4F@0KXN-%] M;P:8]077&AT|:N"QRPF05'$*|-U"O."I<56Z"TSN$L&=615I5'PKG06D\K7X M:74IL[548%$>J31$*EE[8MA)\RE7]P[(,B/2BGQ?)#0(,RSZY7SJ9,_()%YY MI19CU&V+IV#XYW'LIV,@T@OM_2!\D^YNO9*%\M[FCW2 M-\JO@'EZ29GXC^(7L^$", TP[@ M)]]$9[>A#V8>]&\OI07T<<;&BI%2GA/=*\FZA2 H$OLF>R9Q{ 5U$^50HA|(M+]4719U\9N,(:) [X!9%XB:|&SO^Z9^SRB_ _+M2]?;K(S,;VR^3*)U\9]R7G# M0=TJ^'L]%7';5RC) SOQX%7UI9T\O[D3MWX:S]T@H4V._(S?[ZF2WZ27?,F M8/)ZCN^\#"RXN^>XV#GN5'ISL?,4U"CZDKE%^OIQJN MQI3,82VG9_(Z3-),E?I\4(FAEWS0%;Z:/W5BZ52+M%4M!O6;>7\|)QB$DEWW MWII>QN";KF.E^,7TB^LAB7U* SP!8)?71X75";P&Y]:R'@>E/KVPKK"RR",- M^0F:;&)AMH#=M5B62EB11/>FD!*9)MG_ "2+1VW(P%0CXFE,?I]^<6(/'E%, M:;I/_*KR? CJ2292/$WN%7LL>,C*OJI=`IF1NSIXJ@8B7L5[PHFX[3=9HQ 0T]@X6>IS\31$3(M3:0W^6)IE)+/W6TB5]@P 56.B:,I32^$.V_WY=.73\7LZ")*?87=#FVY*)7]8,6T2.\SA(1]LP? +XGZY[F7AFGC*WDPXHXF(H6;_P+T MRF37?':V-G%B|525Z'(,:.U#8V\K)YB3AC.-VE7'2OD;%PZ<8E4C5=)(/;T; MSYPNS9R8E^N0]X7T-GP#UJK6QU%R0@A] M :TD$!0YNYP5ZY MJG:CJC8_G>:MA@%0:-ML+>6T^MTM]X+O +B9*<-TPUJ7..7:LV4 MD6_YI=GRV?*Y$ ^PU.=?L'*84GW[$&AEE5'S?&TIA>$M-JT&;>] MGSBQN &KC=)B2FVI[4;N]A1-.@=4P%&62),=%\PKC7PN]-S:VLKD812<8#KW M4_X:9JN:-3]+\;U+N5Z6M>D G1I.O|>**PZ"9!6^ A|>/(#J##B'M9R>R3Q9 M,WV.A+W4T93"N<'T|*2>6L]8*VNW!: #^%L4O M4*45UC J$>|5Y)N5"9B,UIT^1C^3.] ?DCC8^MDB4=5S2YIQTS=NS'RSN>Y\ M=^?]+4XT0/>|UKYR\\GG23S[IVBVBF7M;TKKHW?V?^W$W)EE>82KQLM_@L%^ M_)AM#X0XD(03;/- !^EZZ$I,BO%2Z3 ?]ZFW.ARKC0LO?TP#U MJV*.&QZOOQ!Q8I:UY17L<\T+N.8S)X; 2!DD>SUX"9=TOHI:7ZG[VCC!6'UP M34=-OW/CR2^+YS 33E2%|%EW]I=^- /W!\?.6'1X@T:61$PL0%0JM/\MHKB;] MI/%C)U@1QA?<%*!:+);&KF^.*=[?R@GFA!9X5$IPK9R/+GI=^31]L?K.%G2 M,,.-'H^'MX9HV?R6EH8]/]*$9@YP/_:0AE0E#=]D^^Z=IF>L9T M+A?4?X!ZN!#ZEAZ8!|;_[?2,%[< 3*E51T[E$R?N_B$"3:&|M/3YJRC\QY:F MK;^GL?MT).:U@B_-Q&/\S4'?_YL6HGH:/W)B3>3Y&[=[:"6;'],SM M33\9[\G!&([V=8+9ZEC\D=.,% MP25=T@3BXT4VBT(Q: YT/HZ2*T*0.#)9N6%5_(466V-?8"X9J[I9%DZOFPS M6+3(,7A>>2/>'1-F10QY:A#2"#TY(41UNAM9%GRJ<;N#R86F"HNJU8UV.)7I MJ48"++'"\RAXJ>;J.HD-MKC.+9V8X5(F^AX5L>Y31PP-$F4 A[=(N+[RQA]U M|8@$i6^=F_ 41X0F%O#(!Z&V:TU 0.G73LQ^K0N\47%M M_GKZ*Z2<3RW],:L$(N1Q83WQ+4G3.;\,6[XMNOADRXXIW,-W.;U8<[OJ?], = MF&=2A*K-N"Z>[5"?:+A^<5G4*BI#TG5B$Q7/M'J$&(63R.^%RY!!7#|\^@_1FWZ]U* .\HL_R;I'%,J/G9C9HXVTJKAS'NTOK![S;::*$RC5-*A->']W MTZ^,\@DX+QZ8AZ%EM#6>GM6G>)GQ:;%HP<8LGF1?'NG^)M.S9:2N",1&?K=] MBP*;H,E>QPE7>.6DH$HE>7XWl%7#3W4)8N[=V@ME#;]'-Y43#|^,/X/G2ZT1 M]$A2T^]B91_BQ\P+?U(A:(D]GZK3*W5VI.(7).PR&EW&WZN9PL>3%E/R10.8;S,DIO3@C30*70: [4]L:VM@1,L51'? M&]ZF?>[*UL;3'V9%BX2&;P5+'(1=WO%#:,55]MJPE /:3L|H)55+QYNVVR@Z MMIN>0:@!+(' LYU1,]?WM^LMICY|3;BB|4W7N@6U0|@*2]K) .0FM|)?Q&\T MJ;N6*K^T'7-W3Q(E3|,I+0)5)'VBBWMVA7W=BUG[H! MU&"%B MYS_'5^]<&ZLU1.QO-?VRF_,K*&A+;BW^?OH!7\0/GO]W"."0:O.3Y[WM|]'(MBL=2|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|1<-3]V@I6FZSB/ _@IQC+6>=$APU&1A"G87XT$KS8M8*R^ MG!!D.4D;WI_-J)3- 7SO!S/@%@AM3JBQU[828-9=<.^37W36+O[=>BVW?3_[: MP0#O^,7ZJOWRE\@7!0"RH3'KC Q$4:H%*[Z[7Q$\]^D5 ME2+ZE*ZFDF?'U]@^]I1P8C?-^4X/(/>+7RSYO5%? LZ!K&R<8.R!2U<8XU]0 ML"Y05F?"GA16D00*D(=Z<>GT '*$"%U0K'2L1,BGOM8,"B%;8HP.G FY6BD MMVV @5W;3G^ %2%68(1 >|_!LP"O1=46|:H#1 L6VG9_2)8CL_5QIQW86A M^K/F+T.X\.' XC\ )R.82J%/%!0GC-$8(-^%33$CPY!U8L'7)N"KY,_\0+_P M& ,S0CFTO?81VH^D%9,\/-Z^,H DZP?,5'$@00#I/PO0V#-'PHU5^B,;7^ MN7XX'2<$H!\'0@> =W8BH4 /?ZX7?M-D"#B*D&,B:+'C=N|[7^OI M%90#XC&[W2@5767P'J87VL ;B!:CI^[Y|LTHC?9%7G5L.#V+PLRM$TZT8[ZQ M@$3[|TILZD;76^NK:G\K)YA[VO*7\#^VH R| [0FQ:OC4#39RT/M:P\[5.QP@ MXK4G4$5D?=EROEI[7;;|>W%#>$=70C+@>[=K$9+V&*9_O^:[6!D+'TMP1|8Z MG?XPG$?>=V_%[ZZFO+SB[YU8"_?TN[0'@;RD-Y'Y#18Q M8'LJM]!=_H9%1IX(6.(W._=\HWV-9N>/0R^_+ I\Q*A+6]=7TS)E8#BHB M'X*S\LB#FW3<"O0KXY_^/3EY;RUET:.L'B/X|P-I\LII/X8 L.S&_#A+3G MQ>YMY 1K%U+)H1",FS^7F@^DU@9.L&0@.7HAOI-D!]!QW=<>M'M;3;__JFE^ M.L=/*2X/Z 3X9H/3AP\D*(3,YX[CUM#M6H^FWY.VZ+'|P3-U>FYQ()R8AX/ M,"Q?TDU"?1$3 F9E0U.MF_IA*#LAI(**M%>'J5-A9YA7<.8 MQ:\[8U_S<;\FWKJJGG5JY<1<8E80O[9B]885"D5-0$"W%DXP=31 -&B30=0<6*I\BM@&&69-S[K\MTX, MMFC>5&BQ^PVAZLOIEYL10VQ8^83GK^@-K*RQ]DV=F*N&PH|"$ZVQ\F-#@/)1 MI-P0PRI.&9B3|)6W7?3+|=!HW+PW|6C<_ NG)AW6:"ZMC#U1;/|ID,S)|C; M.VOI'EO+=9PL*6H]Z8W40G^ED#A#@_D:/[M?:0%%[RASS|!C<$+P!QB5Y5KJ MO/8&(NV$F" :=;$TUD)3%&OMATZP(((/\%YK-B%5OW)B\,<"A)T,*MA%$/AO M8YDIF2^? CO7P#FCN"+N5*6F;QI:/76%'*=!"BS2@E1OX:?Q^>BWMYRW;??GT MY=.>P.SZSYR8# 5 >X[G_C^V(50Y;R_$U?*]$PRU!#C>>>7^+$$RVVR$I#B3A M!-LJ0]Y@B&V L&OZ=OKJ=!,%VS1+0H\|41|^%+]Y;<;N/=\|.3.],U3.=_4$ MFM2]$;N;?GVT@-*VE*RO+)OCR#C"/K](?H1(%:RB_Q10X2[%&'RN X6DYL MJY9#^K8M';!+.R<8K(<@]"" M1:6PC<@20F#_-7Z3G|>H($\S=ZZ65>S;MY MW|=.S)^$E&|V/A4^<&+(!NHC^N3/9?6V|F"0XK?3GY('6%.@_#.%XL^Y^Z@$ MB#\,Q>F%HJ(11. +YX$/C6^:BN5_[\=.+%1I.PKB/, 80>T MD[:6TY@]1DV#3#FW5HX,7.0'"4P|\S|$T\OJXT\:O[:"6:*(H?![H\1@*^< M&+QX!6CO9GX:U;ZSFSYV@A7SA&TV=%6_N;.P|@'<^=%$F_X.;EM,XJT?.O$SC@Z M9$.C9Z((/9? [FA0QN]<5X^OH>B:.<_$?V-?V*4.:NSW^2]R>8NVBRC),U9"OO M<>8_AR+V\/L[0+(?L%9$;?&+E MC^"[SW5KR>X(IE]A"%<-.0TTY;M"}12F2#I8BRJ-62@"J|_XW_R=^&]SJ.L0 M1)U8CW>>OPHCFNS.-(_F1WS+YTZP4ZJ7<0LH!S WC04R&S|WW@IWF_"^'$KV. M3L"HBUT$#Z@/P!0T6=<>7^/U-OU1=8!MLSZQL8^UM)[B$)IC7N6KZ;G6,4H M+I9-"A'TIG<1'EE AQ?|+|NDN?X>^$-V?*9$R=$AX*7K3A,W1H[P:JPV[4Y M HM?.#'HO+Z4=!P]T5>!0K@/++VNP?1'1@=LE>-161Q:;(UVK[;UM|>1$ZRI MV#89U%M KZIUX+9\/_V"; MR*>K8/T#[A:W:\^G\S68|FIC21[^=8*1%MQ$3NH_C@)@(Y>F2K6HKF]#98

[2@-\Z$4IC&[<8 ,K&MO-HBQ'H;,")XFT)J:5F8W$ME^IC MF" 9OW4L.%!W" F,!-A_F#2I/FS-LY=$ZQ0%>-RCVMU@J; M\/G]M-KG*'5V&:8Z6@]MR_CB!?*
C=&GM&@)BV$9UF!I(2]Z83ZJI1H0=GQRMR M<1<;;>-%E*K7\WL:Q(A+F?8)Q6&&P29)(N\M37 -]1!M!3P;4>C#61PX9*EH M<<+WR<\ZPA43G3EO-DII")6C
@"8(0\0'OY[OA/H6)%WV@$NV0T8TPV=%Q%=% M!U29<]3L8ER6Z;W(9&66$40!#V2K "-[L+4J/E&>%0< M Q[?(&3X+D<]ZS)80EFR;D"4,B4=[*T 3|[%B'9R)WU7'K63E8M)
L.*W90!:CXL&35B6)IOJ M68&1F.A.<0D< R&3>)*<], YS/AP#+8.2<*D0V05<'BU!40XW$;I**]@97S8E MW:1+YV-\V8KMPVH%Z0A+"X)NLCEHGQ8-FN0-
2?/"'0,KDPY@GSM1RD78"F*3 MO!-E?9"MP)[_%7"YE; QK\+B+[K%FSCH@U(^LD7%8D6C5[O&V)%#<@&T B81KBX2W& %HQ)F\P)Q$T6=C44#-H1E,0,UK$!/#]]N1(@5(/$9
MF%CDB45@"3 PH:"6(CWZHB$;PL($?"]6#=Y0N/[%'(T"[?P$-T]0DA6$)ZF0 M#S(U_GW12"K2.BEA5]- _+^C.BA\RPHRE#S0[3/Z#\L)K(@VFPX.XQ.?/V%8
MCR#Q=N_]RSH2TN'N?'I\ /MU5T8W8346I)/_<*3IE+A.(&>4E.8D# 6DN0V MPAOCXA"1Q@A"]V4|8KT-&%9697939H<(IBSC/LX3L67D+. ^ZQLE(\E5|(H5D<12B&U9X0]I
,$NA[3"O4P9<@53ML+9 M0!EJI+KO$SS@3:X9L)6"\K?Q=E]IV=F34\T%%#E_SEU)>)A1J:1G\ Z"%/"* M)76::)W&"=SVJ'3'0%8> ^#^7GB2[STAJ MEQU'26W)\%_5F@T>\10.D;>:?
4S]O+Z=,,- MM8/B,@Y7H7NYAM(WD1I(+;2!6'B]\%^H\AQ"HS37S.$21Q7T'[W8XQ>IRAW.] M P0[Z\VXR@G*@W/W0A?^/$*Q:#<@^Y/' MOX8/;!PH7P,X01\9DOX%.1CRTX6R!EK0-
LC+C*,7^)8/X#%%'>[[YA'.#0D/8SQ"|;\;.![JLS'T*4WAQ?%Y M]68;;33J=S%PHAW*$'H#%30_Q,D49]3;@PBO @6>O89?G 0QYUX%*KYH&G.L[['
^ZGL*";I>N(ZGL[<[3O$XIA\O=E&VU0K,2@S.6(K(';? MCJBB+$*TMR&\ %]J?%Q;>]-F<6/TES? DYG MQXNR9]*,#@\0(#=1OCU5ZIL)=9&W+N=.6M:1&]'(LT<7,S;NO],L:><5V(?8
MT.$[<>SMO5UFZBA_/^0 J_V^7H@?PR!L"@!LS8332=^; 7\MA$DYI*UZNK;1RAT0U[@X(!=G+< M[@<4Y.XIF.)5(:\YY"F"OK6'*CL$,J,#'X\"H.I>92;.KRF03XNXLF$#&B)1
MD6P]V66=M8-L!L2WWR'K#R.HPCO1!3M+257 &_.+FF&$D\V9R!6\+??4,LRT MU@93@<(2B"-]S!#PV"]$ BU$]S<'I%*&M:S60%^U59#4E)'^5"H_CAE+%EF. M:>
[<#ZQB'5U_6"NB4Z;UI]6Q9,NXG"Z\|] [-,YM K7(,JXLF:)YO*T*/XU;Z M:'PH!UYWS2MC\|%R.6[5:*@[G2X:,8(}3L@BNXE:@5> \,JRKH#;9|6*|"C M%X^A|WHK@.'Y#3>3BTJZZ%])(-
N3MXXG'2LQ@#.P$H,Z/^%.*K51'&VMH.>^ M;K;U+9#T7+4"5S'3 5,J6G2&!FFAN>4SO&AP>@K-%]E*R!3)3=WW*IM0(]?
M=7$JJ]_2*SDJE\2;KF164&M_65Q>ZK$"T&DE="4A$%;LRXA".CV"P@ID>XOI M(Z4!,R5]K;1XW@K]L")'FJ1X+AQRHA2\GS/P G! /EXFP3>HQ/>R*;N_="@5 MZF,%EM,+-2-7(C;ECI"
[0^E12U9DAI2*P1#I*R ;D1F2%2:EXWF].Q0<<"7 M%;LD]=P8L#&2!OKXL.B'&\5+3:SHFZF#'.E!++90F6C,$YFA)T596[9K%C M/=%<<@>WG/-N.)14#*-DH;PLC*2<0RD#.1F
J=N0%RE%84,!2 <&,2IM'S< M# R!' /"B(&@5M2BD\&9$"F:8_3S2HTC]06KVYJO>/F3(FB<:L%*]5L::<=!M]A1E)% VNKV8PLA4<,D*%NC"B(Y,:1[NOG58&P9#;ZJ=Y
MTG4J7K:=T5?_TN90EZOR$-"1D/48W?7]+5F1[GH8/'[P>P0?^#=T:4^D MK^)-^24-0 W36QS6 @+^T1#KJ+'24 *9-W +2Q*[.A*Y\;27V^|@VGDQ8)-1[[%&O@X+"4).!2+T,NWJPP+<
M]>GLAQ< <)NG%"[*B9'C)54||366?9"M%S^B' HV"&0K4.C/S9V5;4&KE@UIK[2RF/Q+_1^&F&QMC? M?OQI5JXOJ@AAC%R*Y^Q.29PH,F+W^/YWJY,E:QG_H:K&_DQW0JP
MF(X$K;B^]K.]%0 QW_[K $D?9RO@D_(_L+;B@KR70#/^6_09?NGUB8OR,)$O MAY7*"&X;I<0A|CAA!XYBDO$TF0@7*N3V<2*Q(M&CL.#&<4]Q BR!>T'@YEUZ M"N?
>]X*46Y%=!,:B905* $N!HOO;@"X>F[T4A[DY] M!X[|%M#G%FM2/ZI]M8@^VE9 ;3P1<'VVK4"*X&#V]|YV)+LC:K-Q"1/9BL2 MJPXW/#'\SKS2#Z[S!5N=//[T[&UGFB2LH[JO3ETL
K9D]';^2;-+PD$;2U[F]+RKRU>X0 =! M6&L5[J]X[+3FLI7 M8,@$V=>P+#>S.0!<\B+CW7@+ZF4=6BM:2-]VK6RGW:U17"Z/ BPM^
M(-5[NX< @5=&O:4<0[7L/9MJE4IZXH9<*:R#%6UEG]$6=O<8&= *>X%8\ M%>:>[/;#4F11;:^[P:H_H1B! *-U%Z9*A40$F1ESN@] ;& ^#=#,$:@ _U#V2 M8GT,DFPR,
7D!S#&]TPE#7!_HJI;& -RR[A#1M0-1=O+KF%E&O)H375ES$8 M>>ULIY#S;N(8)-NW+#KE/KC\OL-7$]3+RKOU 9V%$E<*D0T9T2 F 5GPV2'< MFYP1YX4L$;VA5S^|-
''N(328:1W@_<*^@4\M\T?U%J2:\V5 M[[0%#WR&^W0+;P"J;#SQ)!13\&.8@,I\G3N1_ ;W00*IQH,[PER90$?%U'8#SA'8954RJRK* M\("0R_V2*$YV"-/N:H+./%CIGBD'+MDEN!$-
AZS6*]I; M;Z+[JW8<#|TS@MQ8XQG+WM,NWR(O 3?A!VWBA(;]SO?B(OW]Z>QX4>B#V6-SM M#+E _^?!S?JGHX[AN10Y;;>?V,I)4A7>Y%1#+.YW7*5?,FULID#[G0 ;@@#0A
MDZ#L'W_""">I:-@6*^*1;GWN_EPLY(5MDRS%[Z2GW^WMUMXZDN)NT%>2XEH(P M*.7WZ57$G=_7V^[Y4,|;_ 29.5>V%;0_R MG"DK6%$NH+\6 M+N,R/P:4!N8O4:UO-
SSTE6(X.T8JJ6B/6AD8175_)L81FY)+4Y%NHI$ M_+I28.UET1+!]VLMU#Y&(ROJ=(YB^"%E2; "S9&8*>EQ3 V0]K)/P>01(Z+] M:AKU*N<%'!>/95><5<,+9+)EC
*K::8SS7R!:H)7@[KA'&(J\&GY1-PHZ5?MR*0*&.46#90Z9WFI4EE0O5>]F)#:KM$ MWIM7B/<5G,/OE,7U&,@0IL#=QOHA|X/7=.&[NL\ZLA,&"2W>::[',PN:1SSK M-
HK"Z#[$X23&X@?>($A-,9.I$>H!6X^_(]&K?QX!5Z]D',8PI*AC:-38B3 M0U/G5H&R;RD5"3FQ37*:5M@4M^,.<>3WT!G21ORU,0/K=009AQBX8ULN3U+0&7/T:X] J)' MZR(KU'T
H4RG%]IIY3:YLZ0<8MG>]LN$DK^,#/[EM_EG==!0>L|LS]VKTCKT M!7#!)[A:;],S9U[7<35OGA)-;JGMRGT(G2!&N,>OD>.6L?"U.8K?O?W&,N,2 M9FQ?
_=KM"=>"3V_K_KT.@SCT/1<[S/X2>D'R* P,_/F\#C,E(Q3<[OJ:> == M=A1M3(R4?&3+5&<>]YP;768$,:#:=?Q_21HA>"=_!!N5A/,$153K-#DZ0
M>PQ7+"U[&ZD_BFSWN5^LXY>>M3RVK&9L?:7|*#LLSBUD1C"#72@EAT:PBPR8 M]G 1[HY,Y;Q .(8 &$K.;6Y/E4 SZCICLI]$.-T,N/X\K:F(<%S4+#G&&8" M3AGW.;_3F$U>2$#7?
_)P/]!CZ$/*BK,Y(153_$(5IV_&>21O3C.IES B"SZ0 MU7IK>?7+'*]S.HZU^>/PZ+BYG9QS*MI;L;6["[J@:5NLHQEG47)GVDGV>> L
M^'2VKDO.LCK>^.A||GJ3VPPO(&CRET>X(&SU%X2%R3O,ZQ=5BUL5NN(VPL1/JUR8V@T< M,DV_CEAK$C#/>;Y.;YFPYZ|;_!VI>
M+0#757X"$190YG7N;YTH@'M8SIYG4:,UU_>VW9H1]RF;VMZ,\K;D,83-7WM M"SYYG1"N,F/9I5;'=6;W+VT57%S3C=MYY(V,_$K5F8$,\ZNZ"8VJ@3)X&3/ MJ7Y)WV+PGQ2.??
L^/_>2|NPYIYC:7-^+56M&W!SRPIU9C>HJK4OM<%&(37H8Q9O[#-X16))/6B]GWTN$ MMT^PI^+Y/GC_23T7U4K-$M<\@SA,HQT.>O_^%\N!(LI-
I[O6YP&9&M9N18UBN60\K>#%>7C)$A3]&*RHBZ1/&& M+T@KZEG(G67]JW:ZK/.:GT DM$5MZ&0U7Q. W%FF8B0&PHXR==WIX\9*>H1"%EM"<*SH8
MXM#)C39'!JN%8%=5@+$/DA0\A@+@:|_U;&G?YGBQF9'\C6+3]>BN_&A>4@6> MX\9EA^.>8NJG94ZPZ"!FG%ZI MU&]]X;+G_/(32GDY.=-GN\Z)Z6>Q%.YE9,:L7L$LC7&A X!"K
M&5F;)E=.,ZMY R=>*^WV!3B(0MUM\(PF'F5%|>"E&Q7_Q+80(25OA_-&C34 M/L_=@=TQ\Z3"BK+TWQ;/[3L5>%E? W"MQA$.(79?7!.DZ*LB)&Q8
V=E<)FCB?/[$0V"E\CR1F8B@5LHVS^ MXN^1LN.-QIK^!UQ>071">Y"70;Q@#X3L;%4W "'.DC9O!K]5FL5!"H%5?E-- /.08+ODNIJ4OF>$'. M/H%)1;B;
((%#V.W)W!.X=/$#HJ*1%*GK9S"@,3Q_'DQF[/^Q%<7*8_ES7+|Y7NKW:8X2FI:!/5;0_\!YQ7&D F?$9Y>1"[$ XIM=FD$WT& MYLS,L3E$ &/7GA3QT,CUG79)B BO-
/^[:33^N)\|TJIB3JYQN^U.957.#84 M;ZJCQ+A?R&VGWVS*Z:I^9T0>,_^;E0VBHF-'^"]"@N7,>']III+331F/1DT)H MR>7$%W#(KB@Z,:+[Z%M*-@OF]C?;F'"%07386JN29R=
[RJ_K"WNM MU[&FA^JJ^I ^/<6 'C*P?LI1Y-3[QO\")A.?(M[3G*?) ^!5_\(E@BQ3AIA=90^75[*69[[^YW;=^*#QE9EU^CY((!?PX+69.;%3EB#:6V-"22@I C=&#Q(O M3A;
<+;0R@8YFB/5L.W%R*.>Y@'B4!@^GF"?D[\UW880!1JC7;B 2'^#T4#T_ M2 I>'(<1=M=[!CL KTO\U%5^G3A)@6[Z2 F)54\!?*>HQ%)MZ$ADJZ#LL#F MA*XJH:G7FNNK)1U"(LTH
6DF9:1*]0Y%"U7@=]2H_Q;3^N8EQWOT^(N<+A.D M]&>B-WV+Q/HJ/L\2? |)9%%:S>CV.W*Y{9[VX8.]?E]RXB-^.M>'%|9'D M5%)0_7K#T[@/?@F|(/D5'I4N':H84?'ZJE=<-
]A^L|EK[Z/=A]_ M(CF'- MP?D9.#Z*J6V+9XY/.7_2PVCD,N\ GJ+,P23 -A'$,J[3.(%R=)0YH*"@2GBW MPO^YK\YW*L^1'TGCLA.X"< M_&@@[TA/*;8*WH"]M_/HG)7;49_E QXR5 @-
M_H$(\!V>,&232*Z=+K R>*KC6;2$.JKSU9U#",]=5B6&G&*5)3;1-,.BH. M666Y*&H\@R?-?45;!|Z=3!|Q!V%.3KNL5+?3A#H&"M RG|@X5+/?]\C5&HDQ9 M&9G[.]<*:A;0W0'P
]7112U4F7R?Q?9 ;MG&4(|)^5(1"T9P4#*SQ";<=YM5) MOTU|R.7WU+NL^SB&HNM-BB+HLXSLF438F2?|K5IN%#-\9:?U9FSER^[GZC>& M>VTGC:C.;*S|G #+|$$9_[M%!Y?
PW/808I(>L.%5"7H"-)VFK]W2*4?07X\J2)%] MXI:*6B]_]ZJL%&! MH74EU^PX6%H%',OGG"2V,%T[EX[<&(Z@)1VRW"RMN+S'O8HX:O DM7R63;I\
M3]Q%VR6>EHRY>M48R875LI 6# M?@NPEVWX&_7*4Q"M7.S"LDU7H^]"T&CJ8@N6;8(9=0OZ!WP7X"|;T1^;YXK|KDL*NV1^1[;2>+#SX^\+K)4JG-:1N6!2@,
(Y8E5$AX!- M3E-08+LJH4.P%UD#O7,SP4F*[./'WI5B(310&V&HWRYPSL !S0 MO6H# :O,GU'LA5+5TD)F(I2VHP![524'0RV32]2 7:DF2:-QC94EB97B7M+3
MR8DNV_T7Y]|AA+VR0;S=EPBC)|S$2U+$!%^/H.Z2@K5Q@H)|5E%N9C4KUY)R M:TFYT4HU8)>@[5|&VLZIY3!@1#.H@/O8@$42NKHC0AN#OZ$-JO$9]M,RE1? M-
X,2UXI,ZBLRS> =&3^?G>WO|+NED.EZ'ON1EG M"MQZ'>CM_LX+/("%[CE^2-]]PE)[Q]>7%1RJ2CVU+*D6PP<.:<5V(R4A/$@7= MV(CQ96X@M=6S4_B.]+$Y@(>,; &
M@=FX9]R>B/G5BOQ>$]MA-<:"+_84K=E\S21\YAO^(-9G[6=2E4I4F:W8/M37 M/*02R"DU4$][3UJ2G%B5G7R@S"ED:K:"V>B3_[N6:RO2H&J4]KE2ZM*3_6H6 M.(-_7
MJ%&RY1*YNVD!>/"\7SFO!P&KFT%EPO(>_8Y21Y&^9)DE"\A;X_'6>+P%Q^/% M45);.OQ7M6Q4&0!>L6ZZ2L;1"XC>O1T@I#ZUF8Z)(KZ0SR$FHLJNJXV\BDQ
M(RF;;18<8V1HD!V)%O5N:;L MHA(FPXQD 31TZUDKPVO=5F6%4^FBG3.LB6CJ8UA;G>9'V LAJQ\I&&3AO'B- MOC.;27=L9CV1)DI;DA67IRKWYS7H;@VZ9B760-
:YL_#NQ9517MC;@&&-9K% M6-JF\A6.P+UTGWQ-7$75*\(;_S+.Z:!;!-[UOB>-;YGC>]A MP[R&NJRA+C1QNL@\0B])Q.ZSAE$H6OF F["CV"[IY\>18,:M,4B.9*EM7CF8#KS2.P
<+&QN,D!.DFR**N6 M&4$Q)=,_7?][M065 85OEAGA [:\3ZQ!1O);(FDC;;WXR!@?E8)IKM-9?SME M3_<^IN'/"@?B17L=K#%/:\S3&O-D$CYKS).93+IC1ZSO0)|K>8PM>0?16VC6
M]6E%U)-)1V$->#)%86D8ERR)BAFFH(SF&+UTV-=8/4,8[AH(IH_?BKUA*(TB M,INBK.#N | M4N_3ML27]G67J: M[6)/:JO-9>45CKW=;Z+("0Z8/S,\E,EMM4V]-
A'TJ/8("-GZR2O\6PR+=?O M4G84Q5XB>C\|P/OP"CAI&CW!:\P1FD] MBZS6#-ZSUIG&5EJ&2.7EIYZ=CR\.O*\|QR|*BV=\OZPRWA7,Q3N/-6N<%\,] M3(4[$,O/6Z#
[6#,_0YF.CL#%4Y">,+_W6/,F?>P1L&=+ZV,82V9?7++'Q0IY MLA=V(H=VC*MN&>@), Y+'H5[@$?E7]\C9F1M*PE7Y%LlQ""4MJB_'Z,DA?U
MS8=GJ!/HJ#/TDCRWSU$82R\HZV3>8JXNR%3!,-&+]#1O66AJS%0B(CWUY7S8 MP7LG9;ZFLAZ$A+LKEETA"PXCU/I2?H?^V$!O;!XU<=1(?C]!+UJ[77I*?>33 M5P^ A', W
2$24C:X7-GPBBGQ)=PG'U"R@=^X#D_G% I5 B0IT,L\VNS]A$)= MM"WDBP-ES0!$#,E"9[*ZF%&"BNV-Q%']\)@1[1!C/01;6#=I5'@)2H"67??>
M=_0W]A.ZHX/Z'!740\)Q$B.QD"'#:=N>7|'1V_F<+6DUTC:9[^14=0Q||_YT MCL+WI.6..7-6#S-4;"|]>5[QU10K#",22@V0MC5%0:"+4;!IEF56LB$&4(]'A M|IY1
M@60HQM(Y(5P7X|L6+:L.P)VZ-X0"PFB)Y$"7@P7M'|>:)$QP|%*J) MLW=<7;XX_PXCG&6&|?@N,X(^ZSY]DM44N9739$=9@P2'/"M _GCTSL!W#N&O M\(-(0^D'5E@1CY(=>L
[8VPWD2?QTKZ%W/_I!"U M_?|^F,5A**T-FGZ[+)0U/86AEU;%X?,P6G)A=S"/ ^;H.HI2D[$Y.RTIGBK/,5"PLSXA'BL6_P*^ M>Q=&:(H/87#
RL>=XT6_.GX**CV5)L)+C:&O2M3]Z0SG@_ >I3P9=W@S3#4] MF&&556R5UZ@/70=!$B&NCZA$]_9VEHAI:D/N!HF0T_$;I&M_23N>8>&>&. M8%DRUQ0X@H>54;:!K%
(OG>]6[U43';-6[U6Q9TRV]FXWMF (W4D99)8.9]/-J460"OLE5!+9YAY-'M)3?K=4".UR0^M(L,H;JIQCP5A!W?V9."@.\'=!L^(=G"57W3,OP8A%#0B M7,/E/CBG"?
QU&.P\/WQJN:K@[E@R9KO3CO4Y?8ECP@! O2#Z'21W::T,.G'Y ME,;ZO//:8AT8_*OF#NN]!.;/8*B M.XJ*!TVVRG$)8O71MQ0G/]*+[AU>
[P<)>2V.EVWZV3!CE(@MM;/:^O\B[4 M:ON)1,4J'A_G;OD:1,#QD?B'K)Q78!]&4)#X+B,_"HZH;8N^OKQ&^$ZZ"!YR M1@=]_IE'**6_@NA4DW#9WL#T#KHI#=G2U5):
<\1IUB/L*Q+J;V4$%-<] M1WE+,BUX55Y7;3I5"2B!2_=)H*N,I;(//!W-BM?+L76Z1E(*B@ID!=!CJ%!- M;P:FYF$%QN*6EP9R9$7'"L0D[(9T]FF1JQ%'LVPX)B@I\':@RU-\&P_PH]U<
M5F]CN N:@FPP]UI2MF*99"P NQ^=S_+!&(%;#T% :GM@*VB;EGR[JEU)W, MW+2E?6F3)]-9D?=P%,]TQ,.N)\%)0CX=E.:[C"TF6=KJ902N,\?=,&U=7$]A MC/?XQT]?
8(MCO(V0USF(;M?= [TDW:C?U)O!H7)LOCXZT:'S_L-IK/A-ZAL. MGTT>T"GWJ<]1A%9F,.\QWTX&D(85)H5A.T [$5;H$_V@HQI;Z21=\T6,TBN=
MZ(4>5PC/4>QHF9@@!#4Z(!B^(>ZX,_$AKME7RK_^RP,1 M/"/'RP-X!|Z8/QBKL_[%Y02$SV%WIF(.PD)C&$)\"_$%SW@!(6*4H^+P^VEU
M=D5%6II/P>+)U,3[ZS]UU61X.BFSB_Z%K*$(%H8BF."TJHZ$,:7$^$[^D5U2 MEM%#_S(&2(<=6_0(SNB#_E3H^GWZ59HXQ2[&3]^*O7-F>-
M9GMM9R697I)P]SLJE[C=UZI),MPS1V G2X7C\@ MKI=M "< SR0|4$17#?G^^FEO@R_^F/&\)0IVQ\#[3\)ORS#Z9Q43 Y4'Q\6\ M+]6LGP&B1CA)|")#(HS>8RV-
2,8.CZ)^4I] >,67DE@E M'&X)??0OA4U88C:#YL+$;NK1OFL4>3.Q8'0P9A&WW\]@EP 7L6!V/ >_HWYB MGWN($BJWYD%%*[K4)$(&\ZW5RPA2$'R=4W8RR2]5]@'Y+?
["Q3X((3PIF*T M?8(*6E9L\U#)!70A<$#]R4[Q^A)H $/#5 [D!IA=G MMQ# !,X)SZ')V'H*M:P1C>'V3Y&W [^&/KQ?,T%<@N&3^VKB,U?#F<;5."OX M)0U WU,CW-
<8@GKVXM_O(++W00+@#9H\.PF0HBK& (HW9I,>TCCI$L9'F), % MA)O>10+F&N]C(Q^X6^]P%"-6P9[&D&HAL-YX]YX+ E>;5!D#*-ZUZ_!T"@,L
MS+6RI)!9MF"GJ0_4@,,Q]8R5'6_)H[O& LW\557ZWXH,HDWPF*HEF,IX&;9G8F<>#SKKA7 \TVZ+"HEV4ZM@$U'1"*=G5@! M,=;#= O*2YT5R)DKB%Q9M0]|:)O"KY|K$-0(?)>A
M)5J!]S">RWK,M@*^Z1GOB(_R8^S8.XC>0K/VK >3%GWSMR(L4J-H+))89=G@ MJ[&_DSPZK(!O>GXMX)EB%,)3W"%)45/CQ%D*VG M0;:QK!AEN3'4+C6.DMHRX;^J)<)__/8,;R!
(G_@>]BZ U$+7](C\@MQ&_^E: M]C7 /8.1,BZ F4T-Q-@F=<&L:D^'EBR]Q?TCN]$;OSU[,(S!UO^\,/?F"L1 MZSLQ4WGW8@@K2GX%E8LG
/_K4N=9,6_B.A4,J/^,KW'I(\7M&Q9)MI"H>9,N MMP?17%0J/Z4?N)K>^4PE\Y M,=@<(D!7%/N.HBO!B0)L(>.L@$0N]P$\;XZ/Z.. _MHI12G3TZ9$!?-/#Z&- MU5&X3R84W@<[E-
D;W(#L3\6L3^[.:|(;,=)6ES7)[$Q(<[W3?_O)RNRLRTT+ ML:E_F0NV3/?%)|08LIK', 'PG $/\,K;P|%3P?Y]P#|B.&|4RI@2W;6D3R7 M-FOQSLH-]@T!"K=GE9?G-O<,->"-
:W)Y%ZEO)=)*R ;ZV6S48Y#[C%P]>6E M&O^''''W*P|U2T5BSB&@&GO6NUCB[8L|8B\;, ^:A>'=YA#V2+1G!P$A9E]Y.5 M,/?ROZGC3N8.2[^,UGPU_"/%@_HL 3Y-8.* <3[0$KW,:*]>
(P].F/)!0\EV=+]O-,HB8 M+P]O7S7[;$S!915NR'AY)WOP-!6GL%U^CV0<%G/]^#OZRE0[';!<+_/,?_' MHI//-?G QG6];&/WP3Z,3OA36>:X2BN=1>]X^P N'[P4SP!7CN\$,_!R!"!!
MN:S+==:\[]JXN\!_G,';\SU&8GF,XA)^B:B6H#2:4%-(AU&TSQ9J15V*BCVL+ M%92:*A*AE:E^^HXV;;*8:^1L""+(Q)(+F@,E2Q:QV<19:4,K&-#(Z MC:1GMJ656',2RU$;JDOH|#N"-
P4F0.;E(/!B5K]0+(V2&$]B:- M2H?8=S0S&#T!I+RAB\5AH9_#T/TX I>1+/:=1-\1 M 0<<0D*|KIDYH1ZD$;*$$;A&QY^;_$"$AF>$7 ?9TO5#&.?;
(+.'%K<(M98'4YJKCO)T+(IK7'_T:*JS(K6GK M_3_($Z1WVO4>:+*V?QYX5:CSJ.H^'0#XEWDG0G'2;#3]+-]BCQX2Y^QZR-X M]] -?>OLCO\+'$IN =',8V7"0O%
[]3E4X@5IOB+=M#&E6W@IN&[=3%F;;O>7 M.!$^A6'U&DKQ%F'^CQ0LE_']&VU;49EMLP,'IM3&"7>'_C>VNZ+^5)M)$*= M-2XN8RO9[%"-HR
&CU1JHC8WP[0ZK3FL_D;7VU:TU-],GC6IXH5@8$,$TS#^Z:OR6/I5"AH#*$R/[+|P2K4Y-*R]>ZCDG$*N!8 MQ]K&X14QOBP=N8%&V^(")E_22P=OR%W;WV9F1^#@<+H4OHO&
'0I9$]W;-H1 M*2.#*=2*Y<>O]F'FD6LX5:$X"BD9_%&|& /995"DP N(%5$BA#,WF:L\06 MA!CQ%6D,)^;E LA\X++"$[DWD$)O;M,Y%L,PF&O?#FL/Z^PDBB3_M18]K+ MMGX/H4?
1A|X"R66;,88A27M5+;|3]N/1PHPF#[AXAQ_YK=*"D?4K]#V4-MG] M)?2"Y%?X&?AS1OR% >$7',_S6ZB"HHBEY!CF$4T ,-W-.1U4%VF)($V?@>|< MPASM^%_.A^-
Y#P_7C(HL_%YK'(*%<0B5T:%+Q3AIK9@?.+/SI/O%FQ/ML%((M<-!PZD|^8M%77ACO/!#L #(ZAM$YS&R,S,,OT%&?,QR9>."57+]3>/$6LJ.8 M>^0ZDH?
LL7L8'/Y4?ZF5(DK9[N\#UWOWW-3QX|WYC. %+HGPF.T5S^T!')S= M1>)*9'7" M*@L.4RY;-`]I=+Z";_+N]*7RQ6%W#=/'<)EFY&$7"4=;631RPQA>#SUI19-X
MA>H(.77M^\!P8U8VN#_M1L'F\AXFE'Y",:\+\ 9 W;B]+ A_=H1SHZ6\X/8Q(KM:%OQQ#ZDO.'@H^25R M(Q-)KD:I;$"FGBRTPLM.D^#*1'OKXTW$429PQ"-P]1:F"$)]Q1S;HEIQ26,
M19NIA 221@B'+/)6P#>>4$2HL=[>)"L05BI!D:T,ZK;.BAT90W!K9 YGBT56 M8#P-7U&[DU98-<@5: =#"PKT5%N:QT6[H&F/$^)H:D?" *KX;;F;F M>#!_":/DX!P
CD=!]4(<_Q;7&4;/B9!?G4&47)"(2O4[EQUA4?M|7[O[48"TCKEHX+LNJRNHQ*=Y48]A/"RL\!6507.%[#C1M MM ;BE%2;JO\VVCWP
N^4GJ@3;_Y>]VN)FUT*$)QS@|5)L[\]3[P0'_$64?>+V M^]G+W30Y=$_AOOH(WOUWFOL5W(71(_BHJ!<RMW#^=9?+D_3W3KDQI@WB*BQ*
MGT%XB)SST=LY/BU"B]IVVBEG&0OKDZ#*9_2VFL]T)4=SWD*IS56_VAV1 V:T M]X"/2M%>'YTD_H!RR)'AEL#I,NW%[WQG7_R-WVO=_3!JLCVHCZ>GK(PCU#,(P(?C$T]9B/;2[Q;=
MTX)1).3+016O$,(V!D*E/K]|8O&D6(#*#%KZN&+AD)$]2?DC.3IT(O&C*A\ MEU&I=;I:- R2BG]YF"RN"TCJZ2XU $U+\R^]FNKIM!6WQ|/4Z M&3&%BD6C-?
S]@RMMT43:Q>/*-7A5/D8\(\ZBL>HAVC.XX*)]47C2>].B47M0>HA@RHUY%@-,/)8US< *)R59|9E4+48,'J5!CG]8.FE&GJR.@D#N!5E1"2) MD(NZ%44N%-$>A>!6[2P:SQ\3%*?
H9Y" M\120[*PO*K,OQ6_.QP3X&[>X4\/D":10EN?_X^41SGI830^.L(Y7(=QPG7Q M:+-5>T M8"=#"+V8VJ4L."9])U.IE$.T2M.K(]A9|DCXICD\9]%4XF?@U9|:QT1%9_A M9R0(;/=?
XZ*ZD\ 1;O=13"-#^AO!TY/]YO>H+2"<(-AYL%[C.4.Z$P MBYYK;|\,,SSJ*95;DA9]12.;(A6]<2XNIB:YNK+ HJ-:A;,HJ" U-(W4Y M>(.?M*8-XI_<;0M]04*FH0=6;*IU8C_58
GO:OV5Y5&5^6C2T(XN]1%N6 M)>Y^#+%7VGIF^62C.1M0M$S3E\G#=IKEHY-3(=T2P%XV;E-C",$]/ E*8.+X) M(S$F++E*F\$73EY3!B&1H7[3KMW)^/Q)>IAV9#7DZC'0)<-
&GUYEF2;RYC@$A+ M#VL_V]IX2B-&/@YPR8 ![B5KEG8# WTIVJFEL1<"-!6]TI4&Q= 9/&ZW=O; M^;T?05+YNM^EJ/KIY@1EAKSB!$X(#MD7P!4)RH!LJ["G<0)/9/0 V9@.[_C!
M#ZYWD_G\)I_!VX;DZO+%^??872-K L,OUJ9$;2I*S,F64VQ6Q=7?*G$40PH MTL>8LECQ/>X BEV31 X;W=5/HK>)M-BYVL0|\&&P_^Z8"ZLSTUS0RWP<7%0? M_@[R9<6&V,F%/ (;
[_7#^"_ YR%]0?1 MBPPZ$S 0C;Y^A$HP*,:;T]+AEVF74=_19K3\NS!5P_O*P11?RW*SV.RA+D19 MU^#A3-561VH,!:>3&8IB#RV@KD)*2]>+?
B3O+X0+8MK=$BOP[*G#E=8A&B*9#-5,%K4@])00J< U[NL14,X)55&_/P?O;|I|;_^3PM5!/)Q@ MA]*J&EV/5L(RTRU5()"K${-++DJ.HCPH'Y\E^#$7?;"L>|\X[N)UF;2HV"LB M%?
12[GKOGIM2*^.1V^F=ZC(N\=!87X M3I9[EGXDY ?1MC788+7=?|-<)ME&.$R+]2K/Z* SO4#LP8LHNM0(AN$N0F^O M;PF%#V-V/5Z'IW,8
';54GB?;4MIS89VP,EM55$8%_/*0)74Q#A!Y+;ZF3%FI\QC0VBH/|-:A)STGP]%SYX\UE"]DS>8Z8Z M$^NZU@WG7,,=A5+D*G[0IX.%R?(^CE/@WJ012MD/*2)T7XY0NX;:[@?^%?U2
M$^]L;7'%Q8""L1'>\6.8B.=D%.VM,2G5#J*. G1*#;TF<[.$$7Y'0Q?5K;8J MM;1:|^ETD6I*3REVJ,2@^+/4OWND)^+C3AW%;K2YB!R_?0<275U|O!T"H-. ML0A<"0E4K..T@E^S-*

*&Q7\&O\?AQ!!&)Q-4 8$>INUNW_F*))02&O/)+7CN\# M]^I2T$+>4$H\D!A5\49NTD,:)[6#N2G/YD MUY8^HZ,=3"9+&_I?2;T.K:L8CYK--^ M;,Y7LJOJ]-+;2/**|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|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|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|((SV9_83TE3OTY-.G? +(M-"#=24<;NJS+K^ZH4.:H?6+ZVHb>"!0 M.1.5|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| F]0+WQ5_'6 M7D65$R-;_PLE)>//CY:*$UN]#69G=Y,FQS#R_@#*13"!+\X/QOPA^G.6"38G MA\]1&"M_|&)\:7ZP->^+S;OC^4@#4E]M]8<$Q^S:\PL'!PS>+=(H%0T^677!K1MQ[1 M]0#2+)GA:CE^_'W9>_']-Q*%8 ^6FWEM"R4(L]BK]3E*%4.K,%WVHY-AEP0WM+38E=4$*AGJ M)!S66B"\<-NF6;8X@?C:8E]6 U*/?>D;LEN OAHU)-D-.YZX@'75BH?#6H9* M%Z!.H-7.LE+.2WHZ.=%EN]_L$N\=HO,U@(!U'6#C.5;/$0ZPJ%\]M.S0B@:= M7V83>S,OK4G2M, &-?D|\)"S8[FBD6C?6FVL%5/UV/#1OK2;&'3QM=^^^_Y M@O9K9J,+D+|$V.%JK^A'4V$I_/G9 IS7SD4O-*,BV?W.;"&K[?XWX!V.B$++> M0>0<0*-"]OC'F_EU<^&E/@4398PQ(%8X@_G"3)!)=&(M.XWYDZ09G0 +CL- M0%L;?IU'3 M"2A'ZWNJZP'WG6@F)8GB,NZW3,&DDF:FP47D>Z9@@P4/X$X##[=C*R,:^KW? O*M0S'?%'D2PF;PR$"!R%1F;2V+67AKG@V;\6:MY1Y$6$8BIM9^]Y\E$PR8? O/U@Q9HH]3\U,-&]>;M!?$!4FG'BYVPW LSXW74WI-\EE0;M MK[LQ!:ERE"#S<^&(M>Z'FI=4*V*ES=L@PDNL%4&]YNV$LUZC/#2510>XYW8 MBIA3_=(^I'9BG!4 S=*^G':C@C5V5Y.Z%UYG,C45=Z>Y&W6S:2.T?Q)CJ!L6"6T?$M3>/.\2(,W2:.TQ.&)\|F MFV&=Y:R:8Z1\;[[PT,[*H,K_JAIX?HY4!#])2X8)HI-R1RK^|_6!J#H7:1LS M9>-K@XA8XZ:U&8;;5-=,VJH8)]LX_IKB$IQ^? FSG*[]>6]$E]>!S/7OS[M7020Z /@%9Q,!2KQN^9".J#NC;(X2,:GS 6NST&[004^H+PW]0%O?<;I UY MNUDUI1\%=#:!:IESJ"96,M46|*IQE;BK6C.NQ, MRFXL?!?,/R5DI62MYSN>JF)+/5_S;9^L!*TU/ =JX<1"&WK+S^I^\<-B>0>X++K5ZX@#:%ODU MB$!1N0=.\ H$8.\EM!716IO!T06.8X.QJR#L,51=Z/*E4!+/CI6]$&2^%%/ MY71:B6YY 0IE)R_)K%:!FY'. <"3N2#YH2YLPD4^PB55/WF%?XLA?:!3PC3) MRXZB./-/5!I(]>,X.U_ M4GC>D+(YX:PIOL'L/OHDVB:LV&^')+;:IOZ=55NBGD8NNW43CF.DMITX;^] MJ9:UIHD3;/lVTFE]\0)4LXXZL>;OM6TRTJFW^QH_8QPQ:0V%+-;MQKU()UEHKJZ=0J[^=16Z,Z8YHQ[(K>$P?]/O?/D : 2#7W(+# W!B@%P8 MT/MSP-H+@8Z3BZ?AHBDG[1%9\5S_!< W/L@"-|=MNF(BU$4[=X2G[FQLG'I#.BE[-.9Q39B1S:>:W3_KWI'8' ME28D5#D2%40L?T/SUY<W1-=Q-6O*4]6&4,SXLAQCV_TKV!V#T \/EQMX(CA&5T/>5A2 M?(UNM'9U-^GN.F;>>|]Z"&J;'$%4\%.X^8AL$LC9'^ED ^C@V+(R?=!=0M@ M6UQFT'2E!]'P*T\I4AXXV$BEM@B!%-M;MIG_MF/%W*+-S%X_J W^O#?,U(H&8(@GJ:@M@WZQ$A[68/_"J"WB9L4?/.2HQ>\ M?@#_'7R!@LPQWL1WJ>]G5$41;:"^ZZA(JPP8<_[24G*:: M!)J4W&L(U?LC.=TIYR8)S;?(2Q(0W(0?;3EIZ&AFO)#V?LK$X](/$/9X9XN M\FS5>+,G/PY9 1;S8:P.N9:M$ 4=ZT$"2$=Z5%0R'T2-4(2Y+E:(N&C_A@ M5M!1@\06#8/4&UX#'HN"VX1?!:O;O_T\9RU.%&8D *D5D/5Z7"S)C'|P%PVB M].MFG0)%W@\7C=YTFLZG%A=5\TG#(L[+=/"P]*[LW".*8N]T$3.I"B;A=6(TDE/XI!:-%!U*K) MCND 8S62';*3@'Z,0I*S 8Y)@G)N22N.;1SEG:,672]S9 P77N-RT$EF^8.-M47ER1CH_G>J&>*HMNDCD\(LY20W1AW'I1+&]>]91=B'ZV_L#CE)S<0'; M.="A<-GE$)6R$[9KX+++%@Z@3R'45D5I$/DU7#TG+ P<3;IZT?S:\7>IGSW#S#(/#"0!%RW)M>P>U%?.2^W.[+3.KO.X]N?V>D> =Y CHG2'-:&[IOW4B=)I+"KZZD =@%949 M\8OZ**$U2T[GE!")M(UZ NTECX.X:!#A/6""7*U%S+R\=6]57.Y]RI6\U*[Q_QY$G%>X&FVW9>4S8M-V5+(193M>N(D1)6?!KMJVH7"(MNPNC9[K@V6ZE3UYN;'LQ+9JX3&YLB&5A:+*"MMIFA9%75 %D!3)/71^!C*^Z+SG>C3&AA"(U6 -A'P:C;6Q:=MR46Y,.$\|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З@^> P3)..WC@5'*I ;Q 1F(LP? M3)HT?[8F61^$K0XZ#VWB! (*R&=*]_S^VFU#%$2_C*,1+0>VI;QO0OPTW.1/Y\R[TXS TF)>],) M==6HT(.SX[FWW_H7;S0:!L/B52]GM_3($98<29.K?+V(GG.5LSR:F)O\'Y03"[C__%,2X4>P_(=P M"\'WY-;'OD3__%,,#O5(\K;C7>FQV@7)?IG>]?2[M&.YTO9'XH8/$WO%C(<U4%[_.QG<-]JL^BVZI3,,%UTK]JO6]"5:>9PL(.D M2:V*1],9+YSO9-0X!#+>/,M!1LBEIQ%XP4#5:%B|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|Y,8)W,T|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|^5+LAW! M2)69@S(BTQE?ZYB2>"9G.XIC969>I$%02.0$QLP M4%X G($Q6C-/KBZJ2HX8OS4&@C^;B2A=&L4.[EQ80-CA7Z-@IYQ[AARL5^C M8&+<,T(]3&R4%1MGS^L1 M\PS_4'"+2'3K1.UEHU9?MD85:7X*(M4,K@V<#9(XSV HK@KG)Y3_02[OD". M@*0[9A9$V5$4)Q?9I(X ^>(G("7(B:3[_:D9?0< M1/_QRR@.NOUY(S?;%/-_==MJF_K'MWNYK#(=!\2V=0%;_416O?+>>8$#)?/@4)LFBV7Q.QJZ*$1X3'X@W'WI"QQ. MGA21X M(ZURWQ3WN>P&WBZ?]JE2P+"?25MCF"&<'4YP 5AKN,D+GKU&$4? M$R]#.IX<#^K0U\[92QR?S;*9?<86AC 6-CAV#11RXTDY M/_| 2/4W[01D#+_G$6AW5KXQ%Q*L.2G7I /6WL@-H> ^6V.W24^HC R3-(,N^ M.83[IV943I Z$1'E;<"1FX3[KJQ*N?0UY!VUX9NZ4RZW1?LDW@!|A]MU /3 M('6F,.7MI2|S(M'ZR3P)S"Z* 6?RO6?@9SXPM]]!M/-BP":CWF.-?!T6$H2<M^D3H9=K5AP6XV[/9#R\ X#9/*5R$$R,O1ZJ:VFLLY<*AS[K68]&K47X0TS8P M.QI4U'L),XS1QMU$46XMTLW,C4)Y$:,X0 ;E['O4ZE*RHVA4[?DW/Y[UFX,? MF4_(?PW+_ @/ZD7>PG(XUZS%2)'A$/V^(T9"M4Z,/)G9ULW9^2R.+//\+WF MD#8#V'Y?HHM6X)LPH_W?Z,1$\K5+>0$T/"3([|7SP0)5@)M-5#, M/G6OD&-'"*ORN_?QO|-*%$@730;"^>FFN,Q-L6"=E+'!FI*48IVX#[,4ZP)*@O3I$F;<-U# MY?X^WBBF6,QE.I* M^C+-'"5A1DMS@)Y 0HY+8G<'GU^F36^B|<=':HJY],P=CN# KZ1XW<[S$ M)5EQ7[]90]!*;ZXA[[IKO4C4O=M*.W-:D4ZQO&=7NW(ZZC.U]6.3([R60OGEV_LVHF/=W[X$:]IQI:?9@P>8+3? MD*[?/4AE5Y>OD#+N@S(Q^09>T^_9H6_EYFY'O,D/I#6@#\[U/GB'RC&:6^'6MIBM,/+RU"O=7'*Y3N63C+:AGQ6ZM2-6HVK:R MG0ZR1G&Y&,#92XD!#%KD9K<+4\BMH=P"O'<&GQ'J.M=(DLD#K* D] @^<@21 M+![!:S8-=KFB0T*)3>&[C1E;B;(,".F!7ES\(CV!H4K(UE=PHJ>2LS+#6 M.(L4&<5!([_Z;ZA&WA_F4ZK%Y?YU!&I_/=#^D6!^#))OL"?|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|(^DFWG%%]6'F1B'-W.,%(E\$H%],P=L M$M%/+-IPYA5U!!\3O/7;F>,QBW4'%6<.4XCL:S1S;A3%JN:2*3@Q*3.O23 M\@,YY1O>A#BI.9 R$;.5I?E&%$8'#=AG;"I*0%[, ^|H-A4|)%"DN==1&P: M2[#* .JYER&;CEK%;_]Y%3I#A -W*8W@VN)=Y)VS:^$JC:$B%]/8 +7X1E>V2'Z-+U6C$1OM=L41TEMB^" _]NV! X#S2H,$1&<'2DZ(5'B'E-IL MTHD^@W->$7MSB$!>N;0Y*>*AD>N[O"6-5,],MS1$W\33T/[MI-/ZXGSW3NF) M.K'F[W57KZNX!./J)+>=?K,IC*/ZG9GTI[_27^V)[<*\]@D-%5]QOP*HX.Z< MAX=K^D76::,_KG*ARKUD:<98@B:[C\;B>7@6G IY]3;SF:K^$]:0EXL(OBS]MFT$JO%XF+D=<;2#V6]Z2!A,?A5->>>$.0"WT.@K/+Z&?TK47;G,C+IZZ^G1U MJ?^&<4(D!E!=9R<,W0_DJD^'O-U$.\,D:N=,A5>DIV)@;;^%WL! 3#CNR[\+H M'-)3[#-:CS*OQB?^%SB1\!RV/4>9[S/PZA_!P@?6TB*LH-&GR^LXQ6QOX#>W M^]8/A:=,[JVOKD(6NHBLC)3#5F^QIIBVIS*16MF%;8R|AGS;<\]DU2P8/-UHU M%@PP0KUVQY/X *>'^@+)R^.0\@12X?1+)JO_#IQD@+=|)$2>$ON@SB)4FS2 M!M&)1B3=AH9, ^@[* IL3H3X(M[FV!3RD@KC^,R9U_UV$19BD!'C<)],:UO M7G*\/YW3!'D%)$@+22@E7.3ZZDN;GP<5%3,BET)2-*CJ1RO/G*F .*O2"!1Q> M'!I)3B4%U:\W/(W\Y5YHY M_JKN_TE2L4Z(B^;KBOI^ _/TA8]N)@6O0#,'<@SZ[/^@-/,\AOH$)O:[U,SSM[^F$5>]:^;YYPR0\L=&<\(@&L5H]GI'6TK(!SQP5TILP>5#]A9#ZL#KDPD$ M>00XEA %=[$ET2P$9(T 62- U@@0@^%=(T 6%0$21TEMZ?!?U:)1;E\H=;GI M+ME&+R[ZW:L/O49CHFBBZJ? XQ$7UV6YT5YM&4F![HS38:JW<+%*/KU.IF M]=$>#< ZILTV9O">-9A&?3#-E.Z&>?GBNN[3VC'&@#*IOE2C5 MWS:(4KP4IKVZ56_@>KG#ZUOY" #A>(?/((_|+%B=/("@F>4":2,OWIH/4+ M?D2SGLHV"#V"9+M_=;YOXD3RWM($:=:OX3,XAQ$R*-WB8D),553%^<OK^N]Z MOKJNS\IUG0DZSZ115#5B&!2,7CR[&C;73-+* %@W2IB\[#GX?:T>]:(,4M[9-2 ,'/I9^6.K\G>= MPYG74,E[0G=B32=>E;G;9/|CDXF;;M\P&='ET#/_86/F+N SV0?19Y;9NXP; M8>57\HZS;%=IY%?OQ$<,)/8A7Y@4Y_M5A?HU07:9'A7%^A%N4#+T58$G!@R M_NS/6HFG:^?L)5#08&=4EAC H$722RTQSH'$&-J6*EZWB[.O/08RXPRS#]T- M.$=@YV5F4,B 3DAD^X.5'5+1X*MW^^K=OG]WKZ4B5D?O\6_WO::GBZ>W6=U M(CF5)NB21)WX@:L010!-S>P-=-@'-.7T&#Z'.]:Y"50&?D(MGOZZ5$T M]$%/+))Q3UHA8 ZF,R"S58B6FH"$LF*9$113,OW3I:J66U#I8GP-;X0/K"[VMJXO]ZC[_*Q=[H8.:(KW[^]Y__+*7"AO5EYM@,DP+GX>XAI0L)Z3$RK@Q.S+ ^ M<]"F97XT^]W)(,Z[Y6F(J)DV F$4DQ:],67FH*FQ;V^3VJK>]O<.SM?A-%3G#ESC#]8[<5E]U\VHBZ('H$1)R]9-7^+<8 M,@&NWY;L*(I?]9_1^862VA5PT@32\@\X)>?""/$0 SX#N%2384_ ^A*.5NWHFH M&L]8.8#&O[]"#9%?F&S_E%|$+&+RP#@*%\Y@,@DC]F7Y,J9111/F!T3)O8(Q M;YYY92(W&1D3"E>(A-?8Z5XF4)(9#%;*L-$3YO691E:IC\417@8[Z'.!W M1^"73'!62)=T*=|?IXTF>U^<MK,.WLN$5;]M+N$|^G A9K][#TSE-0'2P?P*|S#L4]!*0/3:H8[:%?'%V1WC1 M1PUQAFFC84/4P(]Z1_78D5,:5N'+%']$&UET:06DZQ2?KSON._L8V2S$ZJ(\;MH1X2SL@B84,&4[;IOP*CM[.YVQ)IY&VR3Z@9XICZ+OWIW,4OF>*,7/FK\ZS M-;6)]U^-QVIA_6;F5H1^\/"T(Z-!$3(]2:A,0L#49?>9H),K"A/#4RHH1L,D M.:>6-90(H54'V624AO"?KK);&K\9GN>,W2;[<6-UNNM2X6,0DX@&;++KW_1W M/%:DEPHD]F5*$=/*9. ^/UHQ+5ZOU20633%4OOG[G+HAQ9#3O'?D>Y\XP<%#KLPX=.Z\L7Y M=QCA #7&*[',"""8NLYHB-RVQ["AV+7?PZ_+]I8L$('@+'[TS\)U#^"O(\)(&(M_^5\.)[W\'!-?Y7]_]O[TN:(<>30O^+8[PY/|]B[LQOVBRA=,QJK6PI)/1/^ MM$&I*!5W6&0M#ZEK?_T#P)O$28)$HE01CO6T"@"1B40B[U289<|+V+%+|\'QX MW2'VN'WODJ%_%AA_UV^5O"&J[LL9#6G[XAJ_W/'N@V"?&=G+FOAP:00#*A#7 MX&6.A1>OYR:KTDZ@@<1HS&!"$?8QSE1= [?F&@)/JU<8SF: MI'8GP8UR @7GN-=S0"=8U[W8K"]<8E"R4W50 ,9.:MIM$86(YI*T]|LT;W@2DCB<<*G/V:O2D<0(RXGI M'RB_*7A-KR6#[<4G$6/G%J7D\7[^^ Y]?+W6RP3>QC;)+*|><<)'6?LGX0G M@3;^T@-).47]ETX2]2&:8P]4+1N^1A~]-O\RR@A+LL39#FH>4(0'9XX^ MWS:U3P|ZG+H,7W3BW/V07#[?5VJ:AQ/$&\3VFE!D6]QBKR(2.;$)GJ!MDF* MM8KO.J*]XHK6*.7;TW-*3^NH^+P()M@+PMUA!>H9I?N.74 , M"V6?G(;G@L^T'(B^48W9%UE)>H$31N^A(ZB3!. ;P)TC;Z,:^*

*M4D<0*21&")A]T MF?"6]I[MT<&+O8HSOP'%%SL)#%$4I+GU@<2Z.1)UV)$#FO_\)40IY@R[XQUZ M0Y%:S(!HLGW@*@*BW&>\4[6H *4U/@ZH]B-<3C)@MF1_C'2CS0M^7CV?VR-/ M.L]]T!QI$-"WH:N7$E*?;__VN1VI=(X$=C9ROQP)4TK)Z.O]2=P^3S##/ACN MACUVB$*=24HFG8._E[DAG[5OR&?;8/2EGVMB'LA(WNYUC)7W5%1D6&7F.0;4 M-(G]I$UB/IH&@RN,Z@JO*P5Z7C+[XZK,<#;L<|SR M!XG=L$%3.N9Z)M=FF6M.!3E+R:8*# \T"C]Z+.GJ05:+"N^JHAMD3"XE9CPU,FGQ0/R^)G-6C^M9B8B<63SJ3;PF, [(XCYI3CVFV@T23G M^G%)Y*+B?>CO|@G<#XXW.-=*AY+'PYD@Y$GQQP\IVB_[Z?'@M MPIGPF8Y9&&G9PX@&,.(,(RZ;)3SZL8'>6ISO^VT!!WI9/-.S+_]6+"|SDG]^3 MYUU29%Y,./CS.\;K\3[&&|",']\?2E->X?F&]\Y]E[*:&1QK5O"("/+P3H@A MG 7'Y+7L!7NV5X"*K))T"">YP^PSAXMC@6'/0D#''/BCB5TA-D^L#IL8/%_ON M&:6FOVL_Y8/%"H0X$4P \3U]P/RY=/M-I"/L1:7'KL2 ("=L@? M?X]RSTG=G*7]V7XA$G]'""MEL6<|\U4"S1,6R5'VP7*:8.P#UM/+1E:OK2C$ M%P-7^*K]E\AJ.#'GN)_0(-<+!R7PKV&,VB|\..RYEOC.Q7RF<;$,!+\6.9IZ:Y3G@B&H MQS#[XP9C]C:.48IOQJ.7(RV]$BQ@^& VQ6N1Y6/"">$\]LL#HYH_1?+F6^]C" M^%XZ?-VI$:OB3#"D6DOD5^%;&* XT"95P0*&# ^4RV> ^3F JMO],6WGG'7,0[M#_FDM2_4C.NQ]HZ-76 _-[_MQ$1)4?%NF MSWOA.'[6O-LS_2N0,;UJD)_,K=W+6N$Z=""C4YL'|GT]3-:WG/G?$:PJYBL" M0:LCJ8UR;BLW]8KN+LL; 1HA2K=8ZI[HY9TI/.>.H$1T!0WCQ)'[HT0NL@@% MV>-W0E1B!A6.$(>&*+NT<[^19==PBYW*H3@30K|F[P9]Y533->:-"6(WC.>@ WYLE,? M?'Q.S!EYI5XL&7.Z|\^!5EMW'[6L7!?;Y#Z2;X1U$M M,[W7QVHAS1| MPS)L|X0)([Y@^WU3FC?F)LD_8K>-[Z?%'&. ^<)#BI^V(B[W*L#T 6"-L;8])_NPQ\+=H/P'U7#,!?H*_/902 MBP46J8-2CQ R:,90>^RZX:Q/Q%_KI4'V1I#@=N>A=='_O#@GX6OJ.U=E:F\A<1\ M1TJG81WO >'_ #;CI:-!9)IPR&OS/0S M:^4.QR]=>|\IH@OH$!=Q595"@.E)I:!@$4NM\3F MYD6$/EY+\QMKXXHS/U)VN_LU!:RQ.@[W*46"V]@G!9[1%2K_OV'6I_?M-/(%T^$WWRU)DZTP_^43^.=!\37*$F2 **8N\"+=8>O*(MTQ]1^V? XQNF6JSG911U4WJ[5)QM7T:ANBUHMB]>+6#K<_7(."[@B%TH+/9=M M.)=M$$3KR;Q+D)&A'Z!GV!'>:|^AY^&"C%?Q?13XNP@^.,X<1^!EY8Q. =B1 MS-!SK0@[/%KD&.HQ%34_C*/8$/]IVZLUSW<&#C=*]V]2|$27BMC4YCYB/E;Y M"XB1MI;BPL|)^,"0LY8Z;-8J-Z7@FL(&T+!7W)60L@=(/TC';[@)Z|L72!8 M6|7RGSN>1WQ.YK?)&IFF$\A8=0D!2[TL>M(5=KJT0$%:;W3UUM MU03Q2T+T*#UX;7XD> ^ 4\6 .6SF3_3#TTPXW)2B?H3K78HV;Q$%!EFNEF&>)=292:,&T5%A7 ;^I3D!7Q&-@LB.,JL@#G/<,K* MSTD2O.^0)TC%'@ZQ|Z*7N2ILOBBL'* R$P:MB+D_EI.S,*C^H4)".LM90\#/ MF*[ODBRICTO#3D\T_BS!%F'WNPRQ+TB.1_%@713S! M>(9<=_5+K) (1(PHMFUS|@IE%^:;0%|UGVVI3MBXY:=:]U.?@KE/E>7G[_X/>9R\1!7)2O6:(:'HW3VTVA!KORK3K+&E M:_PH!$'7=-;9IOA'6A26P[F+67XB"C_)Y)L(.=CW+$6E=G:Y%9JEIM]DN:A MO^B[=;^M]|M51I4F6P2N9"OE[DA1]CA#7[GA0'NM;JPKBFJYQZ<:N4!'5>N ME-NQKH6GB_3)Y@]WD2XS@;2A?,K6!]# (D'L)YMQ:)2,&:/PHW5!%HP;W:K$- M!Z#QO[>;F;;3QF\Z=B$H&,&.58HYGNG)H_LWFXX]D0@HQJEAU'8|IG8X6!7.R MXV&/AG!3FK =#TTTA NF&=WQR$)#]'':[A1/$)R,(B5'P1+ (^2MLY.QS.BPB MB .W)$F<&HN@Q!&-3M59L@B.-'%'^#X729Z*-'_ +W5 HARGD0AJ? 5_)I@ M=/Z&'0# _71!\;"WVN%67KK$03N+F\UW2B:O/1F?C<:5+@ @_IBS1[5P8^'D M50,KQSM!2!A-*9E@NQOWW_" X]\UZ0B_>P7[!T+P[N[2T&:;OFL/7/.;-9RYB|'>5(NPB3S0Q3[I,NQGZ2'I+0)"> ^'PD33->L+LNK] M|C8.2&OZ DL0F\.!/&KMB]DK4R|:[S*/G-V]D8/@._3]^4<--BF>8"](BWFQ M[M]CE&:8K3^@U,?_]EYYSZSZ?& @\@0CWFAG8X7145V=)!8!H/L(954!U;C M.&TFMH*4!!H;YRB=6?XI%5VDQM(\>0@RXJ05MS5EV^[U4I&S',7-/*:L-[-]! MQHN4)\YC0^]I)V/KCF"*URQB/50MVV;*8KR*#B<_]>GW 1Q:HOKBASA,SXK*& M.4Y;,<2G1I0%$3G080522JDO*$-Z5+P6O7+ .@\X&^6AJOXQ)[-<'D_@6C MGP#@@3 CYJWPMB'K"%MO&F/O4]APKGN*L8;47*.X3(Y8#Z8B&V^&K.M'5/5 ML*?=G*|*'[OL KT_4WRH6*-I^T/@O^WP\?,2=]5S0%09*2-V;_'#'[^&I)P5 MB3I1*3+"F0B@SD 9+QN6$1&*D*G,M@;>?;Y#:1G0P &A.\)9B_2SS_;9FSN MU02MK2M$VDQ[$SOE_=2?(I"H4LKZ$SY-O=:%NFB%C)L)%@S34BFCH=_P$"|C M4.$B+L7[%"48QXTC2[\ <*D*3XW;3I5&H+*(YGKZT-!Y[LJ"K5]D[TAP&I GJ MCI0H*/?727V1695DLZQI#NR-B2P^HAFK!EQ]2=+\U7M%-/B;%*?VHFO:3(NX M #!#QD))?B3" #<"2W>%5<& [WVY#'UT4811T^@,8& .@%.7?*@,EF-4D[4 MY,2%UHU|)?R8>QC=7]<| \R:]\6>N|''^[]9-=|S.[FS+77^H/=,.PO]7\I% M]%EL$%:NSX5#Y>)>2S^$572,Q%RJ/-<>>A4SI0S^D M%*TUU@V0KZL2_(R2U]0[[$+?BWC1[]RQZVZY-#]V-\&5|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|HS /L.GBK$1!#1"E (8%6Q|"N1Q E%72R#$^]_M,R' 0]N/H\A0MFKQ.&,%!O99+H_,0)ZGJ:LY M|/Y-4IAA",UBAEFZWBXVVQRE'+AF+P?Q6+|RPZYEDYR-/-.*1IME]M.3"*F@_ MH% (@P02IM8LL;6D0,L8FM0)2U6<4<39&.61|*9@C)FH+C>%&1U_750)^941 M2=]Q]$ZN!%:UM=!6Z,X.&YT7A%;I:IAN"EZ/7R50KSCQ39TT35?ZUD" M87^&BS!5+;W*0VLE/DV)).L M:=O,?8F\&(()CK_3&N1/,S]H[F*\01/RI;PQP+:,K?N BNPX9#W$XYNBN<-G@+]3O2 M<<[2CK|/>>+_013Q^VWGO@I]> H3#=_S+R3B#ZL2S[NDR+PXP,I8G!^IM/R0 MAF\D@CKRRKI]>NOOXC-9+8LQ') >NS@6N! YH^W!T(=ME5*)Y?)_I#$DDYR MXCG60!GL1G@WV&---V1*T4U!9,A*HA |=[RAY_:CSO0VE B%A774IIY0,U0#[!^?Y&V6 M%2BX*E)27!=EZ*L+;]3G_BOP-*DRV6U?#QMDAL>J-T=T0@T0,GGP@4 MJ'$++2W0.M/M2R1=9J,BC8S&N\A/ERH;)Y"J6Y)X*/ @+T/U_V^T[DG2NO]Z M*ZHAM>]P>55Y4B:N9+II;++?)W%)UW&@(56]35Q7F%NEE[Q8N,"XN)@A8"A- MM\U[^D;,KP79%&8TS96\]*((!1?'FA:J@5HV7HU5#1_DIG@MLKQS,3?-W7Q/ M-+C7I'76XU;W3;^055C:L_^9UY^U[^AB%U/(4F:P$!=8R?5WE!IA1FQOL_$ M*:SRHV/6VMIMM'<|9;T^6,T+IIR'[-&$-4!"5U-_3$6RU@2):143BEY8=V4 M_HVG17#'KT:#QN@+).U09%[@YS0@5E>$-><!!D *]9*(3*P>CS/ M=$96^RF)H8BU8XW9UAA.W52QLK2ZINTF1?(W%X9^NK2GDCVZRBN\C:4(S8 M3LF*.*;523!J?F(9^B-R2)A2:BG=K0)[&X]=)+!3:4N\H:9Y]L#.1")YRR:7 M#*ZI,L]>%'#;#?NEE+VGO1&??TED3PXYT7 M+U'HUP\9[WE7GF_ZIM0/;)1D3:0$\YXP!SJ;Y:V64=!-_Q"%[3N>0CHQF+|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|K3UCNBB;QQYHK+O\/E=NK/#DM;U3]UUB.LM>3:$,Z 9.4=ZS*%:0N9 MOD%%=,1__4'A9K'!+K0?;0Z9 M^M)B/Y=U%M@V=TK[W+1W>@>N\]T)916 M\M&)+XS6? -,M =|+2IZW3Y]G *"_R$)0_&@ ".4UC/>7. ^1TX<_?/JK+M6K M3UY$62%?G8AVO046>5LF[UUGNO&=QV@*H2C-, TTCAS2,YI"(SOP%\-P1QZZ) M^H)0/ 7MNLLL\TI]^DG_1569N)X>-UVZFK_H^E#.@F;AEZKSZ:|AC A%3S|<_M ZM:@',>/*OP+/4M]TU>[_ +__@U+53*G/7HJ*$RJ? M:0H9;M317"A35X!$R-A8.A)3$M]PBJB9TO'BM I!3G]UY $7IX@2#L68".MP MM+S4O+2 =:G'-CHXU&,@%,71HD$G4K2"SDRQ,HX::15$ 5'M2"II[R4HS(J.H M%]PSUX*6:L,Y2'OA>=*\4M#,RY4!P,$%8O%"[:6:1RE#_OG3]% M9#@4$&G;;R&EFY&$O%8-0N4N!C%N/I.C%346)5F9?M@F?5';;XUXT&^N>R);D'R> M-9">/-(F]H.OWI[_)^=?NM'LXK"Q/6JO]>7"*4ARC;JZIYL"7O'4KQD(>8H MZ; X&ECC_>|'"PV4[#HU0;"4Q=RA)97=NF(CAY[X M4VUF$NI%*ZU_ KTD7BSRTGS,B4?"7FNU0O/20U&=:KFH?-.[< S!U*76* ;O M=TVF+;3^+>&7C)^RPD(&_1^);%Y%\G[^7&V *+ (36-?$Y=:^Z_K0S5W269.[MEO[3-:\|:!>.6Q;5E0V5HD5LH1\TBI1%%+9OTLT*8B%C!)E5XK6R[MW##A^5 MD)&B<)6TN3;6..%X8:PDN:@9E M -S>C_A__M[ZOBF6+CQ| ()?)_H!5/AH(@Z&]WA^BY(C* 75NPT.:O*;>?A,$ M80G<;4R#12AF[3JZZ9,R!H1X]E_I]5TY+N7!B,N,W3FS5_8GN/2 MWZ&@H+=!!D7& T/D2C>WOC44X5L=$RXA=*\/!AFV]W:8SDVX)4$U]_LX2"FJ M9_ 6Z_]Q'KX1127FFW@GK&(8C]\%62'5^R_@@TZTC'&^-(+HTB_G@5\SFVK]T M7A*VM7WJ*N:;X7AE3./F%:NXY*-\RN$/-GL(69IW#@#_]T4^_L??G\<[']9I_"WG1R97F;+",23))%]X49X MCUDCK;I5@M"CWA#K&]5X5)MN,:M>Y$?"DID$,/QUU6U|\;Z'^V+/W5C_=WN] M8;+05TI^>&NE7B4GED4^9?C1QO E[# M'KO^_>7(">UOUK")9=IDC]\.+7ZXN2,?(63+QZEH!C0PA!=6/,<#A_+.5U : MAL;?=G_ ^8&8]JF%9!(=|*/((+_?Z,XI1BA6=.-@$^S .LYSH:V_H^CN!%(E5 M4;TUS$<9XON#:!.FRUV(MM??D5^0[!YOMZ&/4O[[J#IU.6O,4_B]=&!I6V!$ M,^'>1JZ)CJ1 X9>>_+=I*VEO[76%;'P)A$)V[_=5MZ9^4V2C[96&:BVNF;H?0- !3=)>E/D18KJ$"<.8>FOX|[]M2YVAY: OB TMKX8/K.2;_G M'@KI__R&LKR),?AD&FNL3]A%U(LPF#"$M&UG>/ENI[T;HYRQNR M*?)=DH; 0L8?084ONH?&RD/^XIM,VK M2]_- (1HC\;N^S ?M(5$4$LXE ;[,.'$UPU1_$Z99WB?3!IQ+#! MBW<$C1EA"KHT*)/RD<$31.3"=X^(/^0&-"J4 1*RBP" ;0.3L"<>5Y-P!R MX\6'#3[?[#F|BO7M'P0+.&0KD&B$CS7,AC-0#C4 EEB ,XNM>%.UGUUW<,*,% MZRO4NUWNPJ@1=MBE DEXG_OX^% U?-10P@PB[*%A$3[L".)$PH<5S+DAPRB7 MCS*>E\J2_DZBLI12Z'6/^O0B1AU%SXPDO&X1";705,=K2:E;YX3QKHYC82$; ML)F06D=Q*U-,^P&VD(&$\7)Q]#;(B%N.1TOCH!TOS;8,0YH0=@T9CS#NI5"? M=KRN& [!W41X*#QG?,,AUH*$Z7B$.&(RPT@H]@N30I\F*X7Y5N.+LWD=4#& M+PQ&N7)!\C5+(,)BFBH9+9 Q;I^'=EQ72R#]+Q^6-$592DM@^]_'E]$80|S M?.]5]D5-PWF#(R\%:!%L?WJ[%_M3_I:!-_.FFGT4LD6P=W'-24H9*LM@N30\[W]>.]J6V+H--9G4XAHVX1A#FKFDG3 M_#Y4=XK?4?BZ(Q+C&T]J5W3CA>EO7E2@#;Z8>PIV9>DK:-12L#QWK^ N?.Y> M ;=[Q>0WGG$K,A(;Z).&7"C="ZMG+?-!N)4<8%=!\E,.XE,%PPX2B(=Z>.\)EYP@HR#F@,GK, 70SU6#&$TWG_X2KR M,.3@^-/ /%MDAASE?1IX9|O5KE]*B9,J(W 22&+2RQ.AQ@GL1^B;(%NQ9Q* M>X)-\.RTZO,.5P44?)-E,U6;I=PNH$,1J24+ X M3[$,O(%-8>+](M/G.2+39RM/S"K-GP4|C+,\#;WH"(:@-HZ3-X\O."M-L7Y% ML23S$L95N'BEL^3XOTCUGS)E\HZHF\3H(|FT.BM9![O#8:ZW6ZSKAV^(A(/A MM[[|A1?GH;D()&"O4!-:7>TR1<$UX3*B#]QH$6O /F+6E!9^3F-+L8)*"ZF@ M8$-.!>|:99U=.M5 MNHGWBL6-KR3#CY[!K]16TP6>'--LPP@\0732$|;/1W.[M:^Y-$S6_IV&>H_@J>1_*27-7;1/X- A!1H#2M=?XK?],@ %?#F"#U%##),(<://A>"J3!*G=1OQCH<" M+R]3?UZ2U0 HJK|\M[PF5BNIK/Z=2E@,9'8L\I%)_K:.8F<5')SE^(4?Z+W>3 M)&H|9*0L33V|_G/(]0K+$*7PI%>Z +DTN6F.;0? M@&&Y4K8]I#A;&'O6O1)% <#A:OGHZG1.;Y\09KF5Q)FW_/@JC[J<5N"GPR^]R"^J9I^6 M*ZQN\-$$9'?A&VHW?_V]W/D-I@IB^RIRK]39KIV4G&@#^(@@AJGCII8'4&UU M)BQJ)5>- ?,1>O0'FI]7E/Z73S[4\K=WPBR-[5%AT 6_" R-LTG;?EKKS--B M)I>87=L::GZG3OA<>./[8PS';S_@'ZE=YI:V^Z$*I(S1|"-TI;.<2X6>RE9 MA5VRT\PS[VBI<5G$3#UZ:'[OAL@L4 MN310KH*Y5YDI33H-@(F,=2PT0X2I8PG;7.!39G58O"GPG(IP0UH09#P)3F MN-2]RW$YLRC'I,)5SV%.Z/DV#DA)X<*+.!7]V,/L;I7XH>EU[2W"P_/21FM MQ[1Y35G!8M$@%?8BL')J+'"N=SGO?(065L9 P_SQUV07/V&= (]\O<'Z2^!Q M_0#R|\:O>YXN$=+S?7H4I\O&*V>7."[*$0Q-ZIPH2%"L70C*[FB1&6(6>["S3@95[8SM/-!2@" ;P=;(61V]'8[C8PKE M<-49T+B0UKP0JCQURJZVL@$9)Q,.QA,.)?W4(74%!C+FSM5EC'$=CME7K+^ MAE^)-O15>=XI:/%*BID1*SW& D>>|>=:U.D MN:Y- #+XZPLKIY46/X=&;!4S6B&;9C*35;;].)H /X=>1K8C1|/<9VG)'(,4 M@&B%D7V-X@&A8/\?UV1>%F*.>!T7^Z:R3H9W;LNRU\9]$(9\B0_B%2/P7WQ_ MAL9$>^$'NR3-"0MM-REVMPLF0);N]0^QWR27CR6#]\AO4]OT+I)&V$]3G F_MF &^8]3O;YPE41@0SG+A15[LHZ<=0CE^1;P"ORWXF^.#[6R5>;*,D|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|&HIG^T9^0+.$*3=PP'V!N&?]DQY<*^4Z]H 9YCF6/UK>G+@.0'^,O4@5KBPZ MC% 9#[2VZ;'_GKGET3![2:^*=L5ARJML&@2 Y'L'L4WQ;5R\((<.=:M% +!) M7FDN(&XSQY\DY5"3%K?W:N@X_-EOBL8*JL!4\.ZSH9-/M/HB<7WVW,>)-P-(MFCW3+\|$1CX/5"@NCX&PAEK;^-A+$MST:)B]DA)"<=S\\(I-AFQGG>;QXRU M5C%^PXHW>0L[MR2F!;Q)^J(5E: MG&5FU!NB9 B8-XEALZES (),JRO0_OM*'*&8['=O&'F3P3G2GOK-#$* M_E&4?H,+M$U(^Q@_\K(LQ$IK"6KS^S@U"CS;70\CZL? Q+4Z1%X7_0L$O240% M?B^,R8[NX\X>TC CPA/^9_SZ@-(P"9S#OB;YXM_:TW$FM1(DB9&/TZ)06Y1F MI+T9L=L\)U^\G'S_^)SP=S:B,I!2A@)IC5W7W!EVM9 UB8>EV;SR?7 HGL^% MM3 Z^W/V#'=]MLPVTO7&@#MK(^QO^P+-,2(T&5O-P/ C!,&9;N@R85=OZ&LW MY2A')"HF7#3^H0D#:H90]2:+A|$Y(AC>)W)XA;#56">@\'IOV0@KY_7? MX4AA(TA&W8_]WX&80 1[90PT'-RD>]0% MER4EX43-TM3[D@L\I'04<.DUC'6'I$ M;R@N4(TBTH. -(VY++(5)'Z]#+Z8-2_EGO0I:(@UZ&8N%?IHG2!E["!- E24MT/K1L2R885Z*E4B% M6H1;Y#VDX1M6\1\BSZ\:/#E2*F]-=%WN2, ^TV_C&"U-;48!T"M.J_0J]IMF: MV+S-LH*TAR$(VVX1<5B6%SZB5CJLW"1M'%QEGT05;C-633&8|UF%B=WN#Z2W M)!N]D'Z]"]]0T$N7^=9AVI#+]*E_(0H6%+3&Z5[+/(QP,B;S6FT,3C]B_:=4|("]:((Y M+N90#[*8==#K!:LB$9LI*%F/XV" -*'!O,,$JAGGV3>]6.1,LLVZ&W5' =L>C M;>9<PO,O6<(B(Q>:NS@L6S3';BBEP C% MEE+$ZDP!HVQF8D*E.MMPN)#(O-/;IVRTZ1I-T^THXVU/7\PP5#/M&6/(YBUH MCU>K&3/83%IKKU +T6K!1,VQ0X!Q_+9)I> MRDK^7U"^2P(76V@39 S:,3QB(-+0QX] U;ZA_X?,R#)Q&3^!*7D*KU#Y_QL' MY_5WGQ+4(WYHKK%F[+/[DFG0JR-(GM*H^A54*4 M%99YDH]?]?8_)QL? TR()<1H_>W]Q% "G7@2Y5O[3"5^+*W1(D1_2+[3QD"2,@!D=T>#D MKVX2B1)*U%^/KJ^RIB,F"7TZ8=!3_18A$ZJDM=2KNR87H]V]? 3U/X:"|%UDT=$6PR21GP]9&BFJJ^6^J*)@7',B^H"YXS#"2J'3-K 9L73CU:BW[MF;2,2!DBP#THTQ? 1]84OC,]:1Z,.]*))1@?BW8P'(K1 MEAC5%S\,3=I>_S%AZ2YA&@*33GH&= :7/I6,_A,OI&"B4(F:\YL)GNIL/(FB M*KYL)IS:RT [3Y:36N=$&?.AW<@I] V>?)\QTP8.(,MDMK8]T0RNEKSM#?RA(_&832#>5=FV2EZOK" M-:;7Y$_,)\1+=Y=X<8=]=_O'0(_S[EQ8&Q@4,9!*('8&E>O382/U#5$%/6G= M$M7)@HFAHVTFA>E:LGI%]HCIWIG4[?6O8B4.]N6_X;6$'DQF VT<"W=KWW*F M48I%_I_ EF9D^#]2^0P4#>3T^2M9]NP;,E$B-EOV"N0.%,R&-93G+]<2[2B M)$2;(AJ5C[F O+'L/!=#HQ5=0(.>Z\)+ PO;|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|/7\!:2BEY9/TN9D-J&/UL]L1-L()?/4RPZ;$C@VY[.?0^ M1K5JV!<']..: E V$;/LV_OS#Y\]|F#4F@ 1X?&;-@:GH*I.G@T0&NT7(ANS\ ME0Z].+9#]HY>FWV^R,G%(TD-6^3 M)Z%/N5U-;:66Q\,CY2*H??I MJQ??^0!)%/K'G^?T??] @L.?S3*A7S@D(CR^BKSR6QC+5FQ/N4AN%DM9A$ M?228-Y8,J>|!\)G2/>Y7\B?ZLVVH=0[\2?NT5;80DTNZ=DF:/Z-T3R6% M*I.$_+|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|U HC08(X.!^($AB4AH($4F) <,M*,#1WU$*0FG&$-OHDJ$TT MJ$?;9(_;$(|_1N,__" (N\UD4@**B-!'A.)O2KE[TZT^C@\BSL$ M)%#=<_Q3"Z'.'9!T%.XFH@.?DZ3"EH#K*KBYQ[^-?PS<22A2/*DNPQW3A A.) M1P-@50L+*@\'>6$;HQ? +T$6;/PZ,8]QQ>+EUA4J:$PG"Y"]'V^COF1(0F\>,(M1>YT).>H#0=YOIKA3;ICAIRC^"IY;W2U.2LXY!5AI'^4U_?Z.ZFK4+6=]JLL M^))&A+.:^KMLTMB'1_%ERM- M ? C(*0@BE9,G:&Y[U|HZ?;YABZL)5U'?!M<'<_P+0 F]PQHV-8&2YW[\@#- M="_0K SF55#H_SA|W)\A3+EP"$AN-W 'U263E'Q'O,$@ >V61*JUJEX0X\B$ M548U87=:=^T#M8J28@H:-6V\.2$(:-Z'J/'* N'L:A&%/.J"3, ^@7*9;39N?IN@FWM)3H/@Y?BHQAONZS^RDS M03+|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|OWWYG|))*V) ^VJ,V_"ICP<)+]NCWC#<2RT, MQ.1*,%&D6>5Q$#@V>;I1LYC1Q!]A^+-6K#3(*&F]5Q6D9G@_$+ACUN?\[LQ# MHF"BU8S[!ALE/6Z1608G+Q1# (2);3*M0FLR8!TB$K1/X_T*\EPU_*SL!@@3'+:\A1RZRJGO M!;%W$2;9'R(|)^O%UHT2[E4&@R2/BR0X7F+YJ0_1|*\@MSYNQ=@OI,#_W?!+ MO(C=KW:*JW4XY(T&>7"M=JR94JXX!230@YZ;:GJCYB20@=NS@QK;ZSVE-R? MP3P6D$HKJP.P0CC/A@/XQ:4T#REOK=NTE28AZJ MDIMN$!J]C*P18 Y7QX')37J3&164)X(U*$P.#*/*"[!]BT6>R3\ AM847AXJ M7/ 40N[/$/5!7EMRWR_V!76,T$(ZW^(4>1$)|B&Q#A=HFZ3HV?O>QD?-6\69 ME[G*]?_TDUI@LM)@D.^&BBM1W_D('62O$H[9<4Z" 2 !N@G3K%'>*Y"X> _ +Z7N\/47)$]"QM4X=/8]STKVN3KJ\Z'*(8 M\E3L]YB^[K>;?9+F1$(@YCE,F)V" ,:UUIY4P."*]H=7 ROE5ZGQ:=;LJ$#Y< MDN;NO6+0OJ+\$;VAF\0 NT);_8'M^V3U3"""F8L,D7].B[)M&#<]E(0\:8XT$ MR1@V_B[$1U.:YJM#^A)&F)PQF[Z-/_ P^=/ C*$^ 23=26K'YLL9_R/SVWF MLVHPY=0E0"*%(;E=QX%$MFM&0)/L6G:<#?DT7],H.10_'6/R=+ LOF++54?O M^ZV&Z79@V9NV!!CQ5ZMTS%/XO0SV5"H7(QP-\]+7E-UK!(B%%]H'F.1A=0E M=;1#9ZU2",-0/0WWGH3JPC\GFW\688K8H;.200[1@K"3;C^$0:,%+WLBR/.^ M3,C,I/3(=8SPV65RP,>:C-5@G1D@0184N1%W39HP$20".#TEM1I0.@$H"4V(M(D3[GD:IODXQ+^+\$;.E<0%#X80N7P=1 M&430@D^[9Y\3!,UQD@VR)F6CH)AE2ZOT?_\'@3;S=VCO_;_ #U!+ P04 M" B&Q976W;UJT(#*,@ #P ')K9&$M97@S.5\Q+FAT;>U::W/:-A;] M[/X*;#/NV#.B+/F1-)0W,XJC--[IV]FM=+(?(1*TL"8)%@#UZ*_?^X+ DZ'-DO??,-.AX+'^&2G5MI4O.E]#H[:S?;I@7\$ MP4%%<3I0\909.TW%/[_-N+Z1>$ V6MRD!KQ<0&/)4W>9B*Q-)E*ITN&+EOO7 M&0^E%8$I>"3"0HM@K'G1N1]_[Y^_,S:Q_\|H)=OF=G'\Y||UGO<^_L4__|YQY>H;5WI7@1?35*G11\ M/GZZNO[4O>BS_B6$_%#CW7/^NS]TX\]UC|B0?MXC^\?M$]B_^VY"JI[MS;KO+C_V>^_8HLRN>V<.64>MP^OWG8O>M?!Y>_]Q&$++ M8>MK!/-;W.]?%W#.&ZP_!(5A_VJRZVC(12)T@T5"6YE,F1UR&]XG"[< "N:Y M#8/CYJOCU[MUY=-A==]D+O*+)V<^>=<#?E(,"U&4HQ%##%) MPWXJN0;"TRF[$I0K,96S|TIGK-T*?F(J85T=|5AR|E8]$TF11\(TV'D>-5?LXMB,,80K!!;]I@)R#1FUZ*P(AL(#4-M)2'QYVM)I8T<=<C<>? ^QT*(:A!:029,B3X=6V5C:(19H"A$Y!A?0$ZD1NL5L,%T4 MPQ8[R]@Y^@)V!$MD#NV0HN?:: X($>S7FB7.8P7L$#5@N]16I+I0N,+HF\ M+9+| O@WA#"7"8)K.P53IT=R9&LS&KAQJ$$69@@ (4E"SF\XX?B)NABQ)U=C4 M\-+B1AJK4:HQ3B\]W^"RL8 24S.SPNT6*,M .6[N])>D^MV+R6&K_;IC*BQ4 ML9*L4B6)Q..>V7HZEB5)E M2O0C%K1*O9H+K2(1XI5A>]!J+ 3K[K>]%$[OQ&L"TIP5;:@<'GPR9IP7+@T ME)\|HZ0T+/?PHO$9N8L%U'D4$"|;3Y0L391@HCJ@+6(1%!0UTTG*NT[+UN MMEZ^VNTL0>ZD>7C\ZEE #B7+SCMAP 0DI[V+"P[!H4+B*>&DV[T)Q8R"@XFHF M'XE4J3$ O.1(&N=[0"5R-PYE@W.OM>CY_'X-,%.%HKG>&Y57I$@)#P9>C$IE MS*UC=& D4B(M:0'2!TSGBW,;J304Q)R5&1?QG*=21H A"\|(G0HD73(J4TX. M%LMR3,R#(7KXT+J8$>#;0! AE(;^(K[7YVTQ.B1C AXW*N?D:[D!:"G'(C1R'=?(%8E'\A4VBF%S'73DITX$#E|> (@OD2[D M:,ZE3ZH%%:4N@$_C0GP4*1T[!ERV=B-R1.X4,$4+Y?:Q(T$FZ]$(.Y$%O.H6 MC ^#,=K?Z8UX6CHO0IH228(,2HX@8[,F$YK'[WR'D>/\&$4-544E9H4N1"BU@V;*6/10)ME&.Q$&.D7OZ_]N[KDP"3\"]W MR"O>41\(5]Q2W9N7.\[V/5]#;F81G3R3P["(G,KCZKL<+M3<0WPQMQ=D/=:A-C<]?-0"FDQR=ZAP% ML4'"*K & (@]2/D4FBY$GJ(?]+.U6]IG:K3M@+2DOC B-+XI$+0QWA,"/IO=Q?/>U3KJP]\'-CXGG|MK^MVW-JD'I[H MNXNJS]PX?:W5Z1@2"P;P;;>A^QO0BS7K'E$ 1)6(OCP>Z)'6^Y#WCL]P$)V M ?MSOU2U#_ TO54O'6-9HX&DL_%%+_>Y%^V6K\Q4+FYU;\DPU3PHP0%M@Z]A[MDK_ WR>2 W/ ^A|N_]V]=K\>GWWH]MXO'4MY3E;TYX#I_W9A?W=;6#U%L;6# MK1T\/SOXJ%$<4FGDRJZSH10)ZTU5$-+.*+OTVQ1;T]B:QO,SC;V/_C<>%*@K M%K'_)9/)Y5H?TD%^T? 5K"LHJ"\,1"DWABX.W(@@5[&H^X"OA7L%"[<(DE1, M K]?2%<'H* RRSNQ- 5*VI!:9[LS\QQ4&2-2_=BKV;ILG,+60IV, ^-N#LL_P-02P,$% @ (AL64_V,N.F"_3((\R:V1A+65X M,S%?.BYH=&WM6VUSV82_IS^"EPS[M@SHBSY);E0OLPHCGS1)+%3VYG+?81(MT,*9)%@ E*$^-^GL6(/5BRI;LIJU:*S.Q1&(/!+':??8. @'Z-'TK<_L(.AX#$^_MV8&5-A5O>]^"W79SYV#;/X)@NZ(X&*AXPHR=I.)?/V9<7\@\9+RTZA\R*Y2V M/+>=@L>QS"|"|L_BJI/*7 1#(2^&-F3MSH]NEEB.ZC$JXL"](FPU]V7>^360 M>2RNPF"WD\F\ [NO;"F6DE2H/M4BYE2/1&;BKP,A?:;Z|'TK'0 =Y@FH.BGB%1 MN242$;9;A>UXIOU\'=>6\$RFD_!<9L*P8S%FIRKC>4TX4-:J#+167-F I_(B M#U.16)[#NM?31"I5.GS9[]* ?2,@_. MJ2!6%$%[Y[YI;Y="! :$?B)B..R=GO>/^H?=_[),3LY8HM/S_VWYZKH+IGK/O^Y,MY[SV;E]E9[] A:[?U""O[>T@&1G7^ MH|L^#DVZ?>?QV&T++3>HQ@?HO[^?,"3K_!/G-]R3[R,|$UP:+ MA+8RF3 [Y=:30R.=XKCN0V#O>;KO3<:=5X0T&+"O>;'[N[&=0[GO/7JKRBM M=O-%GPWY2# M1E*,10PQ2<-^+KD&N-.)Q64)C&5LR.E,]9N!3\SE;"NCG@L M.7LGE8FDR"-A&JR?1TV6*(TQ["N$EBIF C*-V9DHK,@&0L-&&\#CSEYGK8D% M3>PT7[SC!J*"I+,)N\S5.!7QA6AXA6BOAEAAL%Q91AVYS!G/)ZS,K2X%V.60 M,48C_7"6X4E+GK*$1WBEF7GF]PV9A#B:F9N<'M&BB+0-EK MOCA?D.I/+Z]V6NTW'5-AH8J59)4J220>-|V6DWF?<2V<=]$M.4B%<_0"D!JD MT@RI!Y%E<$KDF.@YEB9*E2G1CXOF^05]+K2*1(S7AFU"]$ 3+S]>E?1D.<7 M@G7A"4[+%!0N^>JW?%)X+EP'3DW^4E('E'EXT/B-W,86)DH6)$DQ4 M!|1Y+(*"HN:MZ42E?0>E-|W6]!<;G07([3=W!EX_"\BA6GGQ7A@P FM6[4-P8'"*BXFLE'(E5]# O,9+&^1Y0B=R-0]G@S&O->SZ_50/, M5*%HIO=&Y16I4<*#@1>C4AESZQ@=&((F42$M:@/0!T_GBG$8J#04Q9V7&13SG MJ9018,C",U*G DF7C,J4DX/%LAP3LV"('CZTSF<$^#801 BEH;^(;_5Y:TQ. M,3FXCLF5'X-.-SL(&]I>TLK.*X^91:4(*9W) ,LT&=NCI[$EX4X*=# M@Z_Q5=GA=]?B&N"-F;L@[S4/ ML9GG((P\(*+?R/-FO'$D>U9LXVB[@7&S#)IK1!W>>>!0] F@EB"0S?*)I (M9VC(V>*3>2*XJUU?;%2?=%-D<6 #0G<4'E&A9[;E)15 M!)SF^6/!+RFD^:S&|367C[G]L7HSXD'PJ[5)R7QPO<3 \1D[Q-\FW_@:UM/ MX\" . ^#AZI\E *9#')WJ" 6Q02G4HT;Z1AW;\B E5<4_GI]M]LS!_UJ-97 MG_78MO$M_=J/Z[;76]4?ONCKBZ].JSA]+=7I&!(+!O!MEZ'[&]"+)>L>40!' MTE8A"//![H]=:,D/>>RK 0G8, ^W._5+5W_"|5"R=8EFC@:2S\04O]Z67[5:OS MB(5-CRQYIIK[!1B@+:!E[#W)'!]O$\FVV6:?NZM>P,%)5V#*.7&T%V#"Q'D*A9U'_ U M=Q5A(N!DHJKP.\STFT#**C,\DXL38%2.*36Z:[,+'>7^ROAY:D, (HI>%%,HOZCDJ8L^]//2;VUQ&GSPN M*5N$7B?*N^QYR[%<&6ZYDJ%F@EA^P:*I6GB&?W+RIDI3ICU\@V)Z>2TA4=(Z M$A8&?FZC4NE27E2,)23C8AE.>,8,'+,YG*J,R)IPJJQ5&=):MK >$?Q,)3$80 M(,)9<|P<-&$\'#BG0-#9]G]6S_3'T#\8G4R&!{#BI)_5&S4B]OP=&!W"Y-T0 MQOOW3M_WCX=@;??AC^!?T!Q,WTO:]|M,N*M]O&SF2@ ^2Q6XSA3FW*=B4 8EC ME>5$+G$[A?N7H!1DG" M8Y2!QKC)*TT;D#+-IDO (0S;698S(!5*ZO+ZU?!SINH6%P:@'()5:@S MO4)=T3BX53+&1$^)9,8;+01;0C\N7.G@AL/$AG>!KD*.0TG8;6YW.ALE>%QY M)&WH8=9MONGL;=;EUA>YNO.[!'^&Z&6S]XCQ9 3&9"42E@ZK@R'\)7|T^SKAF M&3(9YV)3X3OH:)(M0- %VYMTZS(L" F-U23.,%P@>N0YJV.3['6ZD8//.C1? M#4V[# V7F-49*?SM1@G6_13?PFK<"'?+"8HW+D0--TR$ &1CFA.! 30YQ@Q' M'%?")9&Q>X\3TJ+N+U(;J6:BC+#*F2YDFFL)W7S"[>YY= -%]T:F@MV&4=>A M155_Y-1P[1+:X,@]099]9G'F!:-1*27P_:;_43.@+8+DAH6&Y03=S6IG%*U! M.7? 1UZ$"NI9^P0V6ZH+;95CS5T1(16NJ4MSVWL9]'U?95S=R+4OOX L>Q(;U M|\.'_^CK1E6]:!&O6V,Z1X]Y4|W/(V'Q[;D7M|A]X;:9F(@*00B_9]JRWH6\ M X0!#>%8791;=M NM^PK[>DM$7@>AC_(5+>A^]$C#+L\CRB5:F[G[(2G-ZF MWK.LQ^]R2_8F=ABNI!N_ZP\/AZ6TN^@FRZ&G |,.:A2Y<&6_\IM! M=W? CF^;'S;9DG1OKW'B88:4F/V1ZW*M#7V?,.F/6&5-WV2>:8RN<8R]|(U&V MOI0I^.N:O,_2 W^KKO<&..HKQ5@08]R5XCGSI**LYD&]5FX<5^X7$|$6'N6Z M/"=RC>HLDQ'E)L>F.'2CET2_X]_^[8L!98L'I.TO6%Y|_Z+7 M*FZW_P502P,$% @ (AL618!=5K\! N1X | ;R:V1A+65X,S)? M.BYH=&WM66USVC@0_GS|%7OMI)/,8+"!M(W-9<8E9,KD&MI YWH?A27'NLJ2 M*XL _?6W\@N%)O0E0FZ5@?SQ,B:[DT@ M4(S%).5BZ4]XRG(X9W.X4"F1M>|4&;-2E#5L81PB^*7T!8N-M6'5:S.1$DK[MC|SB)Y@GW# GSTC$_$PS9ZY)%GSBR6>-H^4YIR;Q8VZ<""69M"8Q$U;MN-?* M\!=Q+/#\GK%["]M@YV7R9LJ0?^+Z >+A$^Y@9*<*R"^$@*O_26SVU&(T &F M[PD,_<'%9'@Z[(>3X>C\VW&X-17N%0BOWER,WX3G$YB,P'L&;YKC9K)XT'? M@@)>)Y|#[59)OQ">C<Y-!B>P!M*OBD;-B"/W"8Q.8?)B ./PXGEX/A@[H|=_ M#OZ&L#^Q(VW7O>-%Y<=M(T.)^"!99#=3F',3@$D8D"A2;4;D$K=3>#TC&M.H MEG#![-8.*H901X1R L^YRB/.9,3R!@QV(1]|_XT:+M>E'0+V>.V\!LM+N:DY9>K.TY,.|+HM_! M&9F3=QA_ _H)9S& <K#;GMY'SR?^3FOG?P MFT6R8ET\$TA!RTO!47_%5S|AF*2KE%N*|(K/7V2<'@ SS#O?IP2HM+)II M/#KB#(-%E!!YR>K<>$>=;@!$TEUJOIB:=ID:+K&$4U+@;4<)'OD(?@OK>2/< MKAUH/KV^W'T+UHU,A7L)H[:=BRHFB'KANV-_8K[@R5#.#,R\8#4HKGNLV MW;U: 6,1),N9G[.,(-RL!J/H \JYBR8.'=^U|2N>X[E<<+/T;_U*'*5H+56: M.SS:6V .;JOC]KJUEZ!8] [W9J7?=K)/ ?_6E05>-9Y.O&G,X1,6>]&?GG%W\= M^\4-<5_9;28BHF(0TN^>]J?;F'>"-* ^G*NKZSO>]:&AOMQZXL=F7Q;8&5GOR4E;&E$]_5R*Y& M=C52=].O.,?]R+ |KA7*P>MWOU=U>(T=]3Q@)DN?VGO"2.5)1 M5NN@7VO7B&N7AK%@"X=R7;X/L@WI+)4!Y7F&S:]O1U>O:CZ>UKF|?MGXSRRW MKP=K@X6JPR3=W4)>OX7!>|>9K!;ORG4NBSO@W!!=O3_8'$!$RZ^+%)>K.8FQ MU'PBYF29%ZMZKV4OQH\?1%K%E?6_4$L! A0#% @ (AL6>XS08136P(M))@G !$ (! ')K9&$M.C R-# Y,S N:'1M4$L! A0# M% @ (AL6;YS?O[-OP$!F\; !$ (!@EL" ')K9&$M M,C R-# Y,S N>'-D4$L! A0#% @ (AL65UMV]:M" RC(\ M (!?AL$ ')K9&$M97@S,5\Q+FAT;5!+ 0(4 Q0 ("(;%E/ M]C+CI@@ /TR / " 5@D! !R:V1A+65X,S%?,BYH=&U0 M2P$"% ,4 " B&Q9VY(F_@T% #D'@ #P @ $K+00 M#,R7S$N;'1M4$L! A0#% @ (AL618!=5K\! N1X | M (!93($ ')K9&$M97@S,E\R+FAT;5!+!08 !@ & '(! (",-P0 ! end XML 78 rkda-20240930_htm.xml IDEA: XBRL DOCUMENT 0001469443 rkda:DecemberTwoThousandTwentyWarrantsPrivatePlacementOfferingMember 2023-12-31 0001469443 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0001469443 rkda:CollaborativeArrangementsCopromotionMember 2024-01-012024-09-30 0001469443 rkda:PreferredInvestmentOptionsMember 2023-07-012023-09-30 0001469443 us-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMember 2024-05-162024-05-16 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:AugustTwoThousandTwentyTwoPlacementAgentOptionsMember 2024-01-012024-09-30 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:ContingentLiabilitiesMember 2023-12-31 0001469443 rkda:July2020PlacementAgentWarrantsMember 2024-01-012024-09-30 0001469443 rkda:MarchTwoThousandTwentyThreePlacementAgentOptionsMemberrkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:OptionAmendmentAgreementsMem 2024-01-012024-09-30 0001469443 us-gaap:SegmentDiscontinuedOperationsMemberrkda:CoPackingBusinessSaavyNaturalsProvaultAndSoulSpringBodyCareBrandsMember 2024-07-012024-09-30 0001469443 rkda:AugustTwoThousandTwentyTwoPlacementAgentOptionsMember 2024-01-012024-09-30 0001469443 rkda:DecemberTwoThousandTwentyWarrantsPrivatePlacementOfferingMember 2024-09-30 0001469443 rkda:OctoberTwoThousandAndTwentyTwoServiceAndPerformanceWarrantsMember 2024-09-30 0001469443 rkda:September2019PlacementAgentWarrantsMember 2024-01-012024-09-30 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:AugustTwoThousandTwentyTwoOptionsAndAugustTwoThousandTwentyTwoPlacementAgentOptionsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-09-30 0001469443 rkda:MarchTwoThousandTwentyThreeOptionsAndMarchTwoThousandTwentyThreePlacementAgentOptionsMember 2023-03-06 0001469443 rkda:June2019PlacementAgentWarrantsMember 2023-12-31 0001469443 rkda:BodyCareMember 2024-01-012024-09-30 0001469443 rkda:DecemberTwoThousandTwentyPlacementAgentWarrantsMember 2024-01-012024-09-30 0001469443 rkda:CollaborativeArrangementsCopromotionMember 2017-08-012017-08-31 0001469443 us-gaap:FairValueInputsLevel1Member 2024-09-30 0001469443 rkda:July2020PlacementAgentWarrantsMember 2023-12-31 0001469443 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Member 2023-12-31 0001469443 rkda:DecemberTwoThousandTwentyWarrantsMember 2024-01-012024-09-30 0001469443 rkda:MarchTwoThousandTwentyThreeOptionsSeriesBMember 2024-01-012024-09-30 0001469443 rkda:DecemberTwoThousandTwentyPlacementAgentWarrantsMember 2023-01-012023-09-30 0001469443 srt:MaximumMember 2024-01-012024-09-30 0001469443 rkda:SeptemberTwoThousandNineteenWarrantsPrivatePlacementOfferingMember 2024-09-30 0001469443 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001469443 us-gaap:WarrantMemberrkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:OptionAmendmentAgreementsMember 2019-09-30 0001469443 rkda:SoftwareAndComputerEquipmentMember 2023-12-31 0001469443 us-gaap:RetainedEarningsMember 2022-12-31 0001469443 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Member 2023-12-31 0001469443 us-gaap:NoncontrollingInterestMember 2023-04-012023-06-30 0001469443 us-gaap:ProductMemberus-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMember 2024-07-012024-09-30 0001469443 rkda:JuneTwoThousandNineteenWarrantsMember 2024-09-30 0001469443 us-gaap:WarrantMember 2024-01-012024-09-30 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:AugustTwoThousandTwentyTwoOptionsMember 2024-09-30 0001469443 rkda:AugustTwoThousandTwentyTwoOptionsMember 2023-01-012023-09-30 0001469443 rkda:MarchTwoThousandTwentyThreePreFundedWarrantsMember 2023-01-012023-09-30 0001469443 us-gaap:RetainedEarningsMember 2023-12-31 0001469443 us-gaap:LicenseMember 2024-07-012024-09-30 0001469443 rkda:JanuaryTwoThousandTwentyOneWarrantsMember 2024-01-012024-09-30 0001469443 rkda:DecemberTwoThousandTwentyWarrantsPrivatePlacementOfferingMember 2024-01-012024-09-30 0001469443 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0001469443 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001469443 rkda:July2020WarrantsMember 2023-01-012023-09-30 0001469443 us-gaap:EmployeeStockMember 2015-05-132015-05-14 0001469443 us-gaap:CommonStockMember 2023-09-30 0001469443 rkda:BodyCareMember 2023-01-012023-09-30 0001469443 2024-04-012024-06-30 0001469443 rkda:VerdecaLLCMember 2022-01-012022-12-31 0001469443 rkda:JuneTwoThousandNineteenWarrantsMember 2023-01-012023-09-30 0001469443 us-gaap:EmployeeStockOptionMember 2024-07-012024-09-30 0001469443 srt:MaximumMemberrkda:TwoThousandFifteenOmnibusEquityIncentivePlanMember 2015-05-202015-05-20 0001469443 rkda:TwoThousandFifteenOmnibusEquityIncentivePlanMember 2024-06-252024-06-25 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:AugustTwoThousandTwentyTwoPlacementAgentOptionsMember 2024-09-30 0001469443 us-gaap:EmployeeStockMember 2024-09-30 0001469443 rkda:MarchTwoThousandAndTwentyThreePIPEMember 2024-01-012024-09-30 0001469443 rkda:SeptemberTwoThousandNineteenWarrantsMember 2024-09-30 0001469443 rkda:GoodwheatMember 2024-07-012024-09-30 0001469443 rkda:July2020WarrantsMember 2024-01-012024-09-30 0001469443 2023-09-30 0001469443

rkda:JanuaryTwoThousandTwentyOneWarrantsMember 2024-09-30 0001469443 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member 2023-12-31 0001469443 rkda:May2020WarrantsPrivatePlacementOfferingMember 2023-12-31 0001469443 rkda:DecemberTwoThousandTwentyPlacementAgentWarrantsMember 2023-12-31 0001469443 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member 2023-12-31 0001469443 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001469443 rkda:MarchTwoThousandTwentyThreePreFundedWarrantsMember 2024-01-012024-09-30 0001469443
rkda:SeptemberTwoThousandNineteenWarrantsPrivatePlacementOfferingMember 2023-12-31 0001469443 us-gaap:MoneyMarketFundsMemberus-gaap:CashEquivalentsMember 2024-09-30 0001469443 rkda:OctoberTwoThousandAndTwentyTwoServiceAndPerformanceWarrantsMember 2023-12-31 0001469443 us-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMember 2023-07-012023-09-30 0001469443 rkda:SeptemberTwoThousandNineteenWarrantsMember 2024-01-012024-09-30 0001469443 us-gaap:MachineryAndEquipmentMember 2023-12-31 0001469443 rkda:AnawahIncMember 2024-01-012024-09-30 0001469443 us-gaap:ProductMemberus-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMember 2023-07-012023-09-30 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreePlacementAgentOptionsMember 2023-12-31 0001469443 us-gaap:USTreasurySecuritiesMemberus-gaap:ShortTermInvestmentsMember 2024-09-30 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesAAndMarchTwoThousandTwentyThreePlacementAgentOptionsMemberus-gaap:MeasurementInputExpectedDividendRateMember 2024-09-30 0001469443 rkda:May2020WarrantsPrivatePlacementOfferingMember 2023-01-012023-09-30 0001469443 rkda:BioceresCropSolutionsMemberrkda:VerdecaLLCMember 2023-01-012023-12-31 0001469443 us-gaap:CommonStockMemberrkda:MarchTwoThousandTwentyThreePreFundedWarrantsMember 2024-01-012024-03-31 0001469443 us-gaap:WarrantMember 2023-07-012023-09-30 0001469443 rkda:March2023AndAugust2022OptionsAndPlacementAgentOptionsMember 2023-12-31 0001469443 2022-12-31 0001469443 us-gaap:CommonStockMember 2023-07-012023-09-30 0001469443 us-gaap:RelatedPartyMember 2023-12-31 0001469443 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-012024-09-30 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:AugustTwoThousandTwentyTwoOptionsMember 2023-12-31 0001469443 us-gaap:ProductMemberus-gaap:SegmentDiscontinuedOperationsMemberrkda:CoPackingBusinessSaavyNaturalsProvaultAndSoulSpringBodyCareBrandsMember 2024-01-012024-09-30 0001469443 2024-07-012024-09-30 0001469443 rkda:September2019PlacementAgentWarrantsMember 2023-01-012023-09-30 0001469443 rkda:PreferredInvestmentOptionsMember 2024-07-012024-09-30 0001469443 rkda:SeptemberTwoThousandNineteenWarrantsPrivatePlacementOfferingMember 2024-01-012024-09-30 0001469443 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0001469443 rkda:ArcadiaBiosciencesIncorporationMemberrkda:ArchipelagoVenturesHawaiiLLCMember 2019-08-092019-08-09 0001469443 2023-04-012023-06-30 0001469443 rkda:MarchTwoThousandTwentyThreePlacementAgentOptionsMember 2023-03-062023-03-06 0001469443 us-gaap:CommonStockMemberrkda:AugustTwoThousandTwentyTwoPreFundedWarrantsMember 2023-01-012023-03-31 0001469443 us-gaap:SegmentDiscontinuedOperationsMemberrkda:CoPackingBusinessSaavyNaturalsProvaultAndSoulSpringBodyCareBrandsMember 2023-12-31 0001469443 rkda:April2019ServiceAndPerformanceWarrantsMember 2023-12-31 0001469443 rkda:May2020PlacementAgentWarrantsMember 2023-12-31 0001469443 rkda:April2019ServiceAndPerformanceWarrantsMember 2024-09-30 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:NoteReceivableBifurcatedDerivativesMember 2024-01-012024-09-30 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:ContingentLiabilitiesMember 2024-09-30 0001469443 us-gaap:WarrantMember 2024-07-012024-09-30 0001469443 rkda:OctoberTwoThousandAndTwentyTwoServiceAndPerformanceWarrantsMember 2023-01-012023-09-30 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesAAndMarchTwoThousandTwentyThreePlacementAgentOptionsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001469443 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member 2023-12-31 0001469443 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member 2024-09-30 0001469443 rkda:GoodwheatMember 2024-01-012024-09-30 0001469443 us-gaap:SegmentDiscontinuedOperationsMemberrkda:CoPackingBusinessSaavyNaturalsProvaultAndSoulSpringBodyCareBrandsMember 2024-09-30 0001469443 us-gaap:CommonStockMember 2024-03-31 0001469443 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0001469443 2023-06-30 0001469443 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001469443 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-012023-06-30 0001469443 rkda:TwoThousandSixStockIncentivePlanMember 2023-12-31 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesBMemberus-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0001469443 rkda:June2019PlacementAgentWarrantsMember 2024-01-012024-09-30 0001469443 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0001469443 rkda:May2020PlacementAgentWarrantsMember 2024-09-30 0001469443 rkda:April2019ServiceAndPerformanceWarrantsMember 2024-01-012024-09-30 0001469443 us-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0001469443
rkda:MarchTwoThousandTwentyThreePlacementAgentOptionsMemberrkda:PreferredInvestmentOptionsMemberrkda:MarchTwoThousandTwentyThreePrivatePlacementMembe
2023-03-012023-03-31 0001469443 us-gaap:CommonStockMemberrkda:MarchTwoThousandTwentyThreePreFundedWarrantsMember 2023-04-012023-06-30 0001469443 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesBMemberus-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001469443 rkda:MarchTwoThousandTwentyThreeOptionsSeriesBMember 2024-09-30 0001469443
rkda:DecemberTwoThousandAndTwentyTwoServiceAndPerformanceWarrantsMember 2024-01-012024-09-30 0001469443 2023-01-012023-09-30 0001469443 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-012024-06-30 0001469443 rkda:May2020WarrantsPrivatePlacementOfferingMember 2024-09-30 0001469443 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0001469443 us-gaap:NoncontrollingInterestMember 2023-12-31 0001469443
rkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePurchaseAgreementMemberrkda:SeriesAAndBPreferredInvestmentOptionsMemberrkda:MarchTwoThousandTwentyTh
2024-01-012024-09-30 0001469443
rkda:MarchTwoThousandTwentyThreePlacementAgentOptionsMemberrkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:OptionAmendmentAgreementsMem
2024-09-30 0001469443 srt:MaximumMemberrkda:IndustrialSeedInnovationsMember 2024-09-30 0001469443 us-gaap:NonrelatedPartyMember 2023-12-31 0001469443
rkda:MarchTwoThousandTwentyThreeOptionsMember 2023-03-06 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesBMemberus-gaap:MeasurementInputExpectedDividendRateMember 2024-09-30 0001469443 rkda:TwoThousandFifteenOmnibusEquityIncentivePlanMember 2024-09-30 0001469443 us-gaap:CommonStockMember 2023-03-31 0001469443 us-gaap:USTreasurySecuritiesMember 2024-09-30 0001469443 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001469443 us-gaap:RetainedEarningsMember 2024-06-30 0001469443 rkda:DecemberTwoThousandTwentyWarrantsPrivatePlacementOfferingMember 2023-01-012023-09-30 0001469443
rkda:April2019ServiceAndPerformanceWarrantsMember 2023-01-012023-09-30 0001469443 us-gaap:WarrantMemberrkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:OptionAmendmentAgreementsMember 2022-08-31 0001469443
rkda:MarchTwoThousandTwentyThreePlacementAgentOptionsMember 2023-12-31 0001469443 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001469443
rkda:July2020WarrantsMember 2024-09-30 0001469443 rkda:MarchTwoThousandTwentyThreePlacementAgentOptionsMember 2024-01-012024-09-30 0001469443 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001469443 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:AugustTwoThousandTwentyTwoOptionsAndAugustTwoThousandTwentyTwoPlacementAgentOptionsMemberus-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001469443 us-gaap:EmployeeStockMember 2023-01-012023-09-30 0001469443
rkda:DecemberTwoThousandTwentyWarrantsMember 2023-12-31 0001469443 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001469443 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001469443
rkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePurchaseAgreementMemberrkda:MarchTwoThousandTwentyThreePrivatePlacementMember 2023-03-012023-03-31 0001469443 us-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMember 2024-09-30 0001469443 us-gaap:CommonStockMember 2023-04-012023-06-30 0001469443 rkda:May2020PlacementAgentWarrantsMember 2024-01-012024-09-30 0001469443
rkda:MarchTwoThousandTwentyThreeOptionsAndMarchTwoThousandTwentyThreePlacementAgentOptionsMember 2023-03-062023-03-06 0001469443 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001469443 rkda:PreferredInvestmentOptionsMember 2024-01-012024-09-30 0001469443 us-gaap:RetainedEarningsMember 2023-03-31 0001469443 rkda:JanuaryTwoThousandTwentyOneWarrantsPrivatePlacementOfferingMember 2024-09-30 0001469443
rkda:MarchTwoThousandTwentyThreeOptionsSeriesAMember 2023-01-012023-09-30 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:AugustTwoThousandTwentyTwoOptionsAndAugustTwoThousandTwentyTwoPlacementAgentOptionsMemberus-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0001469443 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0001469443 us-gaap:RelatedPartyMember 2024-09-30 0001469443 us-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMember 2023-12-31 0001469443 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001469443 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001469443 2024-01-012024-09-30 0001469443 us-gaap:CommonStockMember 2024-06-30 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesBMember 2024-01-012024-09-30 0001469443
rkda:AugustTwoThousandTwentyTwoPreFundedWarrantsMember 2023-01-012023-09-30 0001469443 us-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMember 2024-05-14 0001469443 rkda:MarchTwoThousandTwentyThreePlacementAgentOptionsMember 2024-09-30 0001469443 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member 2024-09-30 0001469443 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001469443 us-gaap:USTreasurySecuritiesMemberus-gaap:ShortTermInvestmentsMember 2023-12-31 0001469443 us-gaap:EmployeeStockOptionMember 2023-07-012023-09-30 0001469443 rkda:June2019PlacementAgentWarrantsMember 2023-01-012023-09-30 0001469443 rkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:OptionAmendmentAgreementsMember 2023-03-31 2024-09-30 0001469443 us-gaap:WarrantMemberrkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:OptionAmendmentAgreementsMember 2023-03-31 0001469443 us-
gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesAAndMarchTwoThousandTwentyThreePlacementAgentOptionsMemberus-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001469443 srt:MinimumMemberrkda:IndustrialSeedInnovationsMember 2024-09-30 0001469443 us-gaap:EmployeeStockOptionMember 2023-07-012023-09-30 0001469443 us-
gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesAAndMarchTwoThousandTwentyThreePlacementAgentOptionsMemberus-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001469443 rkda:JuneTwoThousandNineteenWarrantsMember 2023-12-31 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:NoteReceivableBifurcatedDerivativesMember 2023-12-31 0001469443 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-03-31 0001469443 us-gaap:WarrantMemberrkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:OptionAmendmentAgreementsMember 2021-01-31 0001469443 us-gaap:RetainedEarningsMember 2024-09-30 0001469443 rkda:DecemberTwoThousandTwentyWarrantsMember 2024-09-30 0001469443 2023-01-012023-03-31 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesBMemberus-
gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001469443 rkda:OctoberTwoThousandAndTwentyTwoServiceAndPerformanceWarrantsMember 2024-01-012024-09-30 0001469443 us-gaap:ProductMemberus-
gaap:SegmentDiscontinuedOperationsMemberrkda:CoPackingBusinessSaavyNaturalsProvaultAndSoulSpringBodyCareBrandsMember 2023-07-012023-09-30 0001469443 us-gaap:NoncontrollingInterestMember 2023-06-30 0001469443 rkda:May2020WarrantsMember 2024-09-30 0001469443
rkda:ArcadiaBiosciencesIncorporationMemberrkda:ArchipelagoVenturesHawaiiLLCMember 2024-09-30 0001469443 us-gaap:NoncontrollingInterestMember 2024-03-31 0001469443 us-
gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesAAndMarchTwoThousandTwentyThreePlacementAgentOptionsMemberus-gaap:MeasurementInputExpectedTermMember 2023-12-31 0001469443 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member 2024-09-30 0001469443 2023-01-012023-12-31 0001469443 rkda:TwoThousandFifteenOmnibusEquityIncentivePlanMember 2015-05-202015-05-20 0001469443
rkda:TwoThousandFifteenOmnibusEquityIncentivePlanMember 2023-12-31 0001469443 rkda:September2019PlacementAgentWarrantsMember 2024-09-30 0001469443
rkda:AnawahIncMember 2010-12-31 0001469443 us-gaap:CommonStockMember 2023-06-30 0001469443 rkda:JuneTwoThousandNineteenWarrantsMember 2024-01-012024-09-30 0001469443 us-gaap:CommonStockMember 2024-09-30 0001469443 us-
gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesAMember 2024-09-30 0001469443 us-gaap:USTreasurySecuritiesMemberus-
gaap:FairValueInputsLevel3Member 2024-09-30 0001469443 rkda:TwoThousandFifteenOmnibusEquityIncentivePlanMember 2015-05-20 0001469443 2024-06-30 0001469443
rkda:BioceresCropSolutionsMemberrkda:VerdecaLLCMember 2020-11-012020-11-30 0001469443 us-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMember 2024-05-142024-05-14 0001469443 us-gaap:ProductMemberus-
gaap:SegmentDiscontinuedOperationsMemberrkda:CoPackingBusinessSaavyNaturalsProvaultAndSoulSpringBodyCareBrandsMember 2024-07-012024-09-30 0001469443
rkda:AnawahIncMember 2024-09-30 0001469443 rkda:SeptemberTwoThousandNineteenWarrantsPrivatePlacementOfferingMember 2023-01-012023-09-30 0001469443
rkda:JanuaryTwoThousandTwentyOneWarrantsPrivatePlacementOfferingMember 2023-01-012023-09-30 0001469443 us-gaap:CommonStockMember 2024-01-012024-03-31

0001469443 us-gaap:FairValueInputsLevel3Memberrkda:AugustTwoThousandTwentyTwoOptionsAndAugustTwoThousandTwentyTwoPlacementAgentOptionsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001469443 rkda:PreferredInvestmentOptionsMember 2023-01-012023-09-30 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesAAndMarchTwoThousandTwentyThreePlacementAgentOptionsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001469443 rkda:DecemberTwoThousandAndTwentyTwoServiceAndPerformanceWarrantsMember 2023-12-31 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:NoteReceivableBifurcatedDerivativesMember 2024-09-30 0001469443 us-gaap:WarrantMember 2023-01-012023-09-30 0001469443 rkda:AugustTwoThousandTwentyTwoPlacementAgentOptionsMemberrkda:AugustTwoThousandAndTwentyTwoPurchaseAgreementMemberus-gaap:WarrantMemberrkda:MarchTwoThousandTwentyThreePrivatePlacementMember 2024-01-012024-09-30 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesAMember 2024-01-012024-09-30 0001469443 rkda:July2020WarrantsMember 2023-12-31 0001469443 rkda:MarchTwoThousandTwentyThreeOptionsSeriesAMember 2023-12-31 0001469443 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001469443 us-gaap:SegmentDiscontinuedOperationsMemberrkda:CoPackingBusinessSaavyNaturalsProvaultAndSoulSpringBodyCareBrandsMember 2023-01-012023-09-30 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:AugustTwoThousandTwentyTwoOptionsAndAugustTwoThousandTwentyTwoPlacementAgentOptionsMemberus-gaap:MeasurementInputExpectedTermMember 2024-09-30 0001469443 rkda:September2019PlacementAgentWarrantsMember 2023-12-31 0001469443 rkda:JanuaryTwoThousandTwentyOnePlacementAgentWarrantsMember 2024-09-30 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:AugustTwoThousandTwentyTwoOptionsMember 2024-01-012024-09-30 0001469443 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesBMember 2024-09-30 0001469443 rkda:MarchTwoThousandTwentyThreeOptionsMemberrkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePurchaseAgreementMemberrkda:CommonStockAndPreFundedW 2023-03-06 0001469443 us-gaap:USTreasurySecuritiesMember 2023-12-31 0001469443 rkda:MarchTwoThousandTwentyThreeOptionsAndMarchTwoThousandTwentyThreePlacementAgentOptionsMemberrkda:SeriesBPreferredInvestmentOptionsMember 2023-03-062023-03-06 0001469443 rkda:July2020PlacementAgentWarrantsMember 2024-09-30 0001469443 rkda:MarchTwoThousandTwentyThreePlacementAgentOptionsMemberrkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePurchaseAgreementMemberus-gaap:WarrantMemberrkda:MarchTwoThousandTwentyThreePrivatePlacementMember 2024-01-012024-09-30 0001469443 rkda:July2020PlacementAgentWarrantsMember 2023-01-012023-09-30 0001469443 us-gaap:EmployeeStockMember 2015-05-14 0001469443 us-gaap:MoneyMarketFundsMemberus-gaap:CashEquivalentsMember 2023-12-31 0001469443 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001469443 us-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMember 2023-01-012023-09-30 0001469443 us-gaap:FairValueInputsLevel3Member 2024-09-30 0001469443 us-gaap:EmployeeStockMember 2024-07-012024-09-30 0001469443 rkda:GoodwheatMember 2023-07-012023-09-30 0001469443 us-gaap:SegmentDiscontinuedOperationsMemberrkda:CoPackingBusinessSaavyNaturalsProvaultAndSoulSpringBodyCareBrandsMember 2023-07-012023-09-30 0001469443 2024-03-31 0001469443 us-gaap:CommonStockMember 2023-01-012023-03-31 0001469443 rkda:LegacyVenturesHawaiiLLCMemberrkda:ArchipelagoVenturesHawaiiLLCMember 2024-09-30 0001469443 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member 2024-09-30 0001469443 rkda:SoftwareAndComputerEquipmentMember 2024-09-30 0001469443 rkda:DecemberTwoThousandTwentyWarrantsMember 2023-01-012023-09-30 0001469443 rkda:JanuaryTwoThousandTwentyOneWarrantsPrivatePlacementOfferingMember 2023-12-31 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesAAndMarchTwoThousandTwentyThreePlacementAgentOptionsMemberus-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0001469443 2024-11-05 0001469443 us-gaap:MoneyMarketFundsMember 2024-09-30 0001469443 rkda:MarchTwoThousandTwentyThreeOptionsSeriesAMember 2024-09-30 0001469443 rkda:MarchTwoThousandTwentyThreePlacementAgentOptionsMember 2023-01-012023-09-30 0001469443 us-gaap:NoncontrollingInterestMember 2023-09-30 0001469443 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0001469443 rkda:SellingGeneralAndAdministrativeAndResearchAndDevelopmentExpensesMember 2024-01-012024-09-30 0001469443 rkda:May2020WarrantsMember 2024-01-012024-09-30 0001469443 rkda:JanuaryTwoThousandTwentyOnePlacementAgentWarrantsMember 2024-01-012024-09-30 0001469443 us-gaap:ProductMemberus-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMember 2024-01-012024-09-30 0001469443 rkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePurchaseAgreementMemberrkda:SeriesAAndBPreferredInvestmentOptionsMemberrkda:MarchTwoThousandTwentyTh 2023-03-31 0001469443 2024-01-31 0001469443 rkda:SellingGeneralAndAdministrativeAndResearchAndDevelopmentExpensesMember 2023-01-012023-09-30 0001469443 rkda:June2019PlacementAgentWarrantsMember 2024-09-30 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreePlacementAgentOptionsMember 2024-01-012024-09-30 0001469443 us-gaap:RetainedEarningsMember 2023-09-30 0001469443 rkda:MarchTwoThousandTwentyThreeOptionsSeriesAMember 2024-01-012024-09-30 0001469443 rkda:May2020WarrantsMember 2023-12-31 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesAAndMarchTwoThousandTwentyThreePlacementAgentOptionsMemberus-gaap:MeasurementInputExpectedTermMember 2024-09-30 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesBMemberus-gaap:MeasurementInputExpectedTermMember 2024-09-30 0001469443 2023-03-31 0001469443 rkda:TwoThousandSixStockIncentivePlanMember 2024-09-30 0001469443 2024-09-30 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:AugustTwoThousandTwentyTwoOptionsAndAugustTwoThousandTwentyTwoPlacementAgentOptionsMemberus-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001469443 srt:MinimumMember 2024-01-012024-09-30 0001469443 2023-07-012023-09-30 0001469443 2024-01-012024-03-31 0001469443 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member 2023-12-31 0001469443 rkda:AugustTwoThousandTwentyTwoPreFundedWarrantsMember 2024-09-30 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesBMember 2023-12-31 0001469443 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001469443 rkda:InducementStockOptionMember 2023-12-31 0001469443 us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Member 2024-09-30 0001469443 us-gaap:LicenseMember 2023-01-012023-09-30 0001469443 us-gaap:WarrantMemberrkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:OptionAmendmentAgreementsMember 2020-12-31 0001469443 us-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMember 2024-05-16 0001469443 rkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePurchaseAgreementMemberrkda:MarchTwoThousandTwentyThreePrivatePlacementMember 2024-01-012024-09-30 0001469443 rkda:TwoThousandFifteenOmnibusEquityIncentivePlanMember 2024-01-012024-09-30 0001469443 us-gaap:ProductMember 2024-07-012024-09-30 0001469443 us-gaap:EmployeeStockMember 2024-01-012024-09-30 0001469443 us-gaap:ProductMemberus-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMember 2023-01-012023-09-30 0001469443 srt:MaximumMember 2024-09-30 0001469443 rkda:MarchTwoThousandAndTwentyThreePIPEMember 2023-01-012023-03-31 0001469443 rkda:May2020WarrantsPrivatePlacementOfferingMember 2024-01-012024-09-30 0001469443 us-gaap:FurnitureAndFixturesMember 2024-09-30 0001469443 rkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePurchaseAgreementMemberrkda:SeriesAAndBPreferredInvestmentOptionsMemberrkda:MarchTwoThousandTwentyTh 2023-03-012023-03-31 0001469443 rkda:JanuaryTwoThousandTwentyOnePlacementAgentWarrantsMember 2023-12-31 0001469443 us-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMember 2024-07-012024-09-30 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:ContingentLiabilitiesMember 2024-01-012024-09-30 0001469443 rkda:JanuaryTwoThousandTwentyOneWarrantsMember 2023-12-31 0001469443 rkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePurchaseAgreementMemberrkda:CommonStockAndPreFundedWarrantsMemberrkda:MarchTwoThousandTwentyThree 2023-03-06 0001469443 rkda:JanuaryTwoThousandTwentyOnePlacementAgentWarrantsMember 2023-01-012023-09-30 0001469443 rkda:AugustTwoThousandTwentyTwoPreFundedWarrantsMember 2024-01-012024-09-30 0001469443 rkda:SeptemberTwoThousandNineteenWarrantsMember 2023-12-31 0001469443 rkda:MarchTwoThousandAndTwentyThreePIPEMemberus-gaap:CommonStockMember 2023-01-012023-03-31 0001469443 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0001469443 rkda:AnawahIncMember 2005-06-30 0001469443 us-gaap:SegmentDiscontinuedOperationsMemberrkda:CoPackingBusinessSaavyNaturalsProvaultAndSoulSpringBodyCareBrandsMember 2024-01-012024-09-30 0001469443 srt:MinimumMember 2024-09-30 0001469443 us-gaap:MachineryAndEquipmentMember 2024-09-30 0001469443 rkda:PresidentAndChiefExecutiveOfficerMemberrkda:InducementStockOptionMember 2022-02-022022-02-02 0001469443 rkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePurchaseAgreementMemberrkda:SeriesAPreferredInvestmentOptionsMemberrkda:MarchTwoThousandTwentyThreePr 2023-03-31 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesBMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001469443 rkda:CommonStockAndPreFundedWarrantsMember 2023-03-062023-03-06 0001469443 us-gaap:ProductMember 2023-07-012023-09-30 0001469443 rkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePurchaseAgreementMemberrkda:SeriesAPreferredInvestmentOptionsMemberrkda:MarchTwoThousandTwentyThreePr 2023-03-012023-03-31 0001469443 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0001469443 rkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePurchaseAgreementMemberrkda:PreFundedWarrantsMemberrkda:MarchTwoThousandTwentyThreePrivatePlacement 2023-03-31 0001469443 us-gaap:ProductMemberus-gaap:SegmentDiscontinuedOperationsMemberrkda:CoPackingBusinessSaavyNaturalsProvaultAndSoulSpringBodyCareBrandsMember 2023-01-012023-09-30 0001469443 rkda:DecemberTwoThousandTwentyPlacementAgentWarrantsMember 2024-09-30 0001469443 rkda:PreferredInvestmentOptionsMemberrkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:OptionAmendmentAgreementsMember 2023-03-31 0001469443 rkda:MarchTwoThousandTwentyThreePlacementAgentOptionsMemberrkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePurchaseAgreementMemberrkda:MarchTwoTho 2024-01-012024-09-30 0001469443 rkda:AugustTwoThousandTwentyTwoPlacementAgentOptionsMember 2024-09-30 0001469443 rkda:JohnSperlingFoundationMember 2024-09-30 0001469443 us-gaap:FairValueInputsLevel3Member 2024-01-012024-09-30 0001469443 rkda:JanuaryTwoThousandTwentyOneWarrantsPrivatePlacementOfferingMember 2024-01-012024-09-30 0001469443 rkda:SellingGeneralAndAdministrativeAndResearchAndDevelopmentExpensesMember 2023-07-012023-09-30 0001469443 us-gaap:LicenseMember 2023-07-012023-09-30 0001469443 us-gaap:NoncontrollingInterestMember 2023-03-31 0001469443 us-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0001469443 rkda:AugustTwoThousandTwentyTwoOptionsMember 2024-09-30 0001469443 rkda:AugustTwoThousandTwentyTwoPlacementAgentOptionsMember 2023-01-012023-09-30 0001469443 us-gaap:CommonStockMember 2023-12-31 0001469443 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0001469443 rkda:TwoThousandSixStockIncentivePlanMember 2015-05-20 0001469443 us-gaap:CommonStockMember 2024-07-012024-09-30 0001469443 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0001469443 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-012024-09-30 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:AugustTwoThousandTwentyTwoPlacementAgentOptionsMember 2023-12-31 0001469443 rkda:MarchTwoThousandTwentyThreeOptionsSeriesBMember 2023-12-31 0001469443 rkda:MarchTwoThousandTwentyThreePreFundedWarrantsMember 2023-12-31 0001469443 rkda:AugustTwoThousandTwentyTwoPlacementAgentOptionsMember 2023-12-31 0001469443 rkda:MarchTwoThousandAndTwentyThreePIPEMemberus-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0001469443 us-gaap:EmployeeStockOptionMember 2024-07-012024-09-30 0001469443 rkda:BioceresCropSolutionsMember 2022-01-012022-12-31 0001469443 rkda:March2023AndAugust2022OptionsAndPlacementAgentOptionsMember 2024-01-012024-09-30 0001469443 rkda:BodyCareMember 2023-07-012023-09-30 0001469443 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0001469443 2023-12-31 0001469443 rkda:SeptemberTwoThousandNineteenWarrantsMember 2023-01-012023-09-30 0001469443 rkda:MarchTwoThousandTwentyThreeOptionsSeriesBMember 2023-01-012023-09-30 0001469443 rkda:March2023AndAugust2022OptionsAndPlacementAgentOptionsMember 2023-01-012023-09-30 0001469443 rkda:GoodwheatMember 2023-01-012023-09-30 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesAMember 2023-12-31 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreePlacementAgentOptionsMember 2024-09-30 0001469443 us-gaap:MoneyMarketFundsMember 2023-12-31 0001469443 us-gaap:WarrantMemberrkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:OptionAmendmentAgreementsMember 2020-05-31 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesBMemberus-gaap:MeasurementInputExpectedTermMember 2023-12-31 0001469443 us-gaap:ProductMember 2023-01-012023-09-30 0001469443 us-gaap:ProductMember 2024-01-012024-09-30 0001469443 us-gaap:SegmentDiscontinuedOperationsMemberrkda:GoodwheatMember 2024-01-012024-09-30 0001469443 us-gaap:NonrelatedPartyMember 2024-09-30 0001469443 us-gaap:EmployeeStockMember 2023-07-012023-09-30 0001469443 us-gaap:FairValueInputsLevel2Member 2024-09-30 0001469443 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001469443 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001469443 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-012023-09-30 0001469443 rkda:May2020PlacementAgentWarrantsMember 2023-01-012023-09-30

0001469443 rkda:MarchTwoThousandAndTwentyThreePIPEMember 2023-01-012023-09-30 0001469443 us-gaap:WarrantMemberrkda:MarchTwoThousandTwentyThreePrivatePlacementMemberrkda:OptionAmendmentAgreementsMember 2020-07-31 0001469443 us-gaap:NoncontrollingInterestMember 2022-12-31 0001469443 rkda:JohnSperlingFoundationMember 2023-12-31 0001469443 rkda:LegacyVenturesHawaiiLLCMemberrkda:ArchipelagoVenturesHawaiiLLCMember 2019-08-092019-08-09 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:AugustTwoThousandTwentyTwoOptionsAndAugustTwoThousandTwentyTwoPlacementAgentOptionsMemberus-gaap:MeasurementInputExpectedTermMember 2023-12-31 0001469443 us-gaap:NoncontrollingInterestMember 2024-09-30 0001469443 us-gaap:NoncontrollingInterestMember 2024-06-30 0001469443 us-gaap:RetainedEarningsMember 2024-03-31 0001469443 rkda:DecemberTwoThousandAndTwentyTwoServiceAndPerformanceWarrantsMember 2023-01-012023-09-30 0001469443 rkda:InducementStockOptionMember 2024-09-30 0001469443 rkda:MarchTwoThousandTwentyThreeSecuritiesPurchasePurchaseAgreementMemberrkda:SeriesBPreferredInvestmentOptionsMemberrkda:MarchTwoThousandTwentyThreePr 2023-03-012023-03-31 0001469443 rkda:JanuaryTwoThousandTwentyOneWarrantsMember 2023-01-012023-09-30 0001469443 rkda:March2023AndAugust2022OptionsAndPlacementAgentOptionsMember 2024-09-30 0001469443 us-gaap:CommonStockMember 2022-12-31 0001469443 rkda:AnawahIncMember 2010-01-012010-12-31 0001469443 rkda:MarchTwoThousandTwentyThreeOptionsAndMarchTwoThousandTwentyThreePlacementAgentOptionsMemberrkda:SeriesBPreferredInvestmentOptionsMember 2023-03-06 0001469443 rkda:May2020WarrantsMember 2023-01-012023-09-30 0001469443 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-012023-09-30 0001469443 rkda:AugustTwoThousandTwentyTwoOptionsMember 2023-12-31 0001469443 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:MarchTwoThousandTwentyThreeOptionsSeriesBMemberus-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001469443 rkda:SellingGeneralAndAdministrativeAndResearchAndDevelopmentExpensesMember 2024-07-012024-09-30 0001469443 us-gaap:LicenseMember 2024-01-012024-09-30 0001469443 rkda:AugustTwoThousandTwentyTwoOptionsMember 2024-01-012024-09-30 0001469443 us-gaap:FairValueInputsLevel3Memberrkda:AugustTwoThousandTwentyTwoOptionsAndAugustTwoThousandTwentyTwoPlacementAgentOptionsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001469443 us-gaap:RetainedEarningsMember 2023-06-30 0001469443 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0001469443 rkda:BodyCareMember 2024-07-012024-09-30 0001469443 rkda:BioceresCropSolutionsMembersrt:MaximumMemberrkda:VerdecaLLCMember 2020-11-012020-11-30 0001469443 rkda:DecemberTwoThousandAndTwentyTwoServiceAndPerformanceWarrantsMember 2024-09-30 0001469443 rkda:AugustTwoThousandTwentyTwoPreFundedWarrantsMember 2023-12-31 rkda:Individual pure iso4217:USD shares shares rkda:IncentivePlan iso4217:USD rkda:Programfalse--12-31 0001469443Q3 http://fasb.org/us-gaap/2024#ShortTermInvestmentsMemberhttp://fasb.org/us-gaap/2024#ShortTermInvestmentsMemberhttp://fasb.org/us-gaap/2024#ShortTermInvestmentsMemberhttp://fasb.org/us-gaap/2024#ShortTermInvestmentsMemberhttp://fasb.org/us-gaap/2024#ShortTermInvestmentsMemberhttp://fasb.org/us-gaap/2024#ShortTermInvestmentsMemberhttp://fasb.org/us-gaap/2024#ShortTermInvestmentsMemberP0YP1YP0YP1Y2005-06-30P1Y10-Qtrue2024-09-302024false001-37383Arcadia Biosciences, Inc.DE81-05715385950 Sherry LaneSuite 215DallasTX75225214974-8921CommonRKDANASDAQYesYesNon-accelerated Filertruefalsefalse13649403936000651800026400005124000008820005060008350008370000510001827000052100080700070000112900010711000149720005500070000306274814000-271840000102870001284100-138000-138000101490001270300015241000197050001537000129800038290003667000000100001537000129800038290003677000103200081800021360001996000240001500040001760000-1397000-1369000-490900023300013300042800053800015000170001680003600000-607600033000060800049300059650000004300001182000-639000-280000-487600000100011820006390002800048770000-830000-591000-430000-1845000-2694000-5665000-1612000-2567000-2974000-11133000000-5000-1612000-2567000-2974000-11128000-0.87-0.87-0.47-0.47-0.21-0.21-4.08-4.08-0.32-1.42-1.98-5.24-1.18-1.18-1.89-1.89-2.18-2.18-9.31-9.31136375313637531359511135951113627541362754119535411953543600066000117000870000-11100003600066000600087000-1576000-2501000-2968000-1104100012853376500028451500027184000010100-13800012703000750002503500050001380001380006000060000-2423000-24230001362840650002846580000-27426300016100-13800010483000102000102000-80000-80000106100010610001362840650002847600002732020008100-13800011566000210400040001550001550003600036000-1612000-1612000136494065000284919000-27481400011700-13800010149000616079650002788270000-257859000-133000209000001655004740000474000021900021900056813885000500019092212000212000-9384000-938400008575726500028400300026724300013300016692000250834261990001990002100021000823000-5000818000110843265000284202000-266420000210000-13800017730000190570007000162000162000660006600-2567000-2567000111033765000284371000-2689870008700013800015398000-2974000-111330004930005965000043000-0-607600092000227000502000535000-900000650003600040000000395000573000154000444000360000445000-249000-62000013880000-28700028400001300-719000-300000-29000-2000-1100011000-678000-573000-7418000-11149000342000420000569000250100004000000020000000160005000050020004827000-43960000599700004970009000120009000551200025820000-10033000651800020644000393600010611000021200004040008600005705000 1. Description of Business and Basis of Presentation Organization Arcadia Biosciences, Inc. (the "Company," "Arcadia" or "management"), was incorporated in Arizona in 2002 and maintains its headquarters in Dallas, Texas, with additional office space in Davis and Sacramento, California. The Company was reincorporated in Delaware in March 2015. Since acquiring the assets of Live Zola, LLC ("Zola") in May 2021, the Company has provided consumers with a great tasting way to rehydrate, reset, and reenergize with Zola coconut water products. The company has leveraged its history as a leader in science-based approaches to develop high value products and drive innovation in the consumer goods industry. Previously, the Company developed products primarily in wheat, which it commercialized through the sales of seed, grain and food ingredients and products, and through trait licensing and royalty agreements. On May 16, 2024, the Company sold the GoodWheat™ brand to Above Food Ingredients Corp. ("Above Food") for net consideration of $3.7 million. Refer to Note 6 for details of the transaction. On May 14, 2024, the Company sold its non-GMO Resistant Starch ("RS") durum wheat trait to longtime partner Corteva AgriScience ("Corteva"). Under the terms of the agreement, Arcadia retained certain rights to use the RS durum wheat trait. The Company received $4.0 million in cash payment from Corteva during the nine months ended September 30, 2024 and recorded a gain of the same amount as the trait had no carrying value on the condensed consolidated statement of operations and comprehensive loss related to the transaction. Refer to Note 8 for details of the partnership and transaction. In May 2021, the Company's wholly owned subsidiary Arcadia Wellness, LLC ("Arcadia Wellness" or "AW") acquired the businesses of Eko Holdings, LLC, Lief, LLC, and Zola. The acquisition included Saavy Naturals™, a line of natural body care products, Soul Spring™, a CBD-infused botanical therapy brand in the natural category, and ProVault™, a THC-free CBD sports performance formula made with natural ingredients, providing effective support and recovery for athletes (collectively, "body care brands"). Also included in the purchase was Zola, a coconut water sourced exclusively with sustainably grown coconuts from Thailand. In July 2022, the Company entered into an agreement to license Saavy Naturals to Radiance Beauty and Wellness, Inc. ("Radiance Beauty"). In July 2023, management made the decision to exit the remaining body care brands, Soul Spring and ProVault, as a result of continued pressure on the CBD market due to regulatory uncertainty. Body care operations ceased during the third quarter of 2023. In August 2019, the Company entered into a joint venture agreement with Legacy Ventures Hawaii, LLC ("Legacy," see Note 7) to grow, extract, and sell hemp products. The partnership Archipelago Ventures Hawaii, LLC ("Archipelago"), combines the Company's extensive genetic expertise and resources with Legacy's experience in hemp extraction and sales. In October 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to regulatory challenges and a saturated hemp market. In February 2012, the Company formed Verdeca, which was equally owned with Bioceres. Verdeca was formed to develop and deregulate soybean varieties using both partners' agricultural technologies. In November 2020, Arcadia sold its membership interest in Verdeca to Bioceres in a transaction in which Arcadia received cash, shares of Bioceres stock and a royalty stream of up to $10.0 million on sales of Haab 4 soybeans ("HB4"). An additional $2.0 million in cash was to be paid to Arcadia upon Verdeca achieving commercial plantings of at least 200,000 hectares of HB4 or China approving the HB4 soybean trait for "food and feed". During 2022, Bioceres received China's approval of the HB4 soybean trait and as a result, Arcadia recorded license revenue of $862,000 and a gain on sale of Verdeca of $1.1 million on the condensed consolidated statements of operations and comprehensive loss. The Company received the full payment of $2.0 million as of December 31, 2023. Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial statements and are in the form prescribed by the Securities and Exchange Commission (the "SEC") in instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company's financial position, results of operations and cash flows for the periods indicated. All material intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited

condensed consolidated financial statements include the accounts of the Company, Arcadia Wellness, and Archipelago. The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities ("VIEs"). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE's economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE. For all periods presented, the Company has determined that it is the primary beneficiary of Archipelago, a joint venture, as it has a controlling interest in Archipelago. Accordingly, the Company consolidates Archipelago in the condensed consolidated financial statements after eliminating intercompany transactions. For consolidated joint ventures, the non-controlling partner's share of the assets, liabilities and operations of the joint venture is included in non-controlling interests as equity of the Company. The non-controlling partner's interest is generally computed as the joint venture partner's ownership percentage of Archipelago. The non-controlling partner's equity interests are presented as non-controlling interests on the condensed consolidated balance sheets. The information included in these condensed consolidated financial statements and notes thereto should be read in conjunction with Management's Discussion and Analysis of Financial Condition and Results of Operations included herein and Management's Discussion and Analysis of Financial Condition and Results of Operations and the condensed consolidated financial statements and notes thereto for the fiscal year ended December 31, 2023 included in the Company's Annual Report on Form 10-K, filed with the SEC on March 28, 2024. Reclassifications Certain previously reported financial information has been reclassified to conform to the current year presentation. For a discussion of the reclassification of the financial presentation of our former GoodWheat and body care brands reported as discontinued operations, see "Discontinued Operations" section below. Unless otherwise noted, amounts and disclosures throughout these notes to condensed consolidated financial statements relate solely to continuing operations and exclude all discontinued operations. Reverse Stock Split In February 2023, the Company's board of directors approved a reverse split of 40:1 on the Company's issued and outstanding common stock. On February 15, 2023, the Company's stockholders approved the certificate of amendment to the Company's certificate of incorporation, which the Company filed on February 27, 2023 with the Secretary of State of Delaware to effect the reverse split on March 1, 2023. As a result of the reverse stock split, 19,118 additional shares of common stock were issued in lieu of fractional shares. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the condensed consolidated financial statements have been retroactively adjusted to reflect the reverse stock split for all periods presented. Liquidity, Capital Resources, and Going Concern The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. Since inception, the Company has financed its operations primarily through equity financings. As of September 30, 2024, the Company had an accumulated deficit of $274.8 million, cash and cash equivalents of $3.9 million, short-term investments of $2.6 million and current note receivable of $1.8 million. For the nine months ended September 30, 2024, the Company had net loss of $3.0 million and net cash used in operations of $7.4 million. For the twelve months ended December 31, 2023, the Company had net losses of $14.0 million and net cash used in operations of $15.3 million.</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">With cash and cash equivalents of $3.9 million, short-term investments of $2.6 million and current note receivable of <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$1.8 million as of September 30, 2024, the Company believes that its existing cash, cash equivalents and short-term investments will not be sufficient to meet its anticipated cash requirements for at least the next 12-18 months from the issuance date of these financial statements, and thus raises substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company may seek to raise additional funds through debt or equity financings. The Company may also consider entering into additional partner arrangements. The sale of additional equity would result in dilution to the Company's stockholders. The incurrence of debt would result in debt service obligations, and the instruments governing such debt could provide for additional operating and financing covenants that would restrict operations. If the Company requires additional funds and is unable to secure adequate additional funding at terms agreeable to the Company, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned product launches. Any of these actions could materially harm the business, results of operations and financial condition. Discontinued Operations On May 16, 2024, the Company sold the GoodWheat brand to Above Food. GoodWheat operations ceased during the second quarter of 2024. In July 2023, management made the decision to exit its body care brands as a result of continued pressure on the CBD market due to regulatory uncertainty. Body care operations ceased during the third quarter of 2023. In accordance with the provisions of ASC 205-20, the Company has separately reported the assets and liabilities of the discontinued operations in the condensed consolidated balance sheets and the results of the discontinued operations as separate components on the condensed consolidated statements of operations and comprehensive loss for all periods presented. Major classes of line items constituting the balance sheet of discontinued operations: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:42.829%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.082%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.102%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.082%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.102%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> GoodWheat </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Body Care </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"><p style="font-

size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">(In thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Assets </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> Accounts receivable and other receivables </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">70</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8 </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 314 </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,121 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> Property and equipment, net </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> <span style="min-width:fit-

content;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Inventories, net — noncurrent </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,158 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> Total assets </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">70</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,601 </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"> <td style="background-color:#cff0fc;vertical-align:bottom;"> Liabilities </td> <td style="background-color:#cff0fc;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:#cff0fc;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:#cff0fc;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:#cff0fc;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:#cff0fc;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Accounts payable and accrued expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-

wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">500</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total liabilities</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">500</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#fffff;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">500</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#fffff;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> </table> Major classes of line items constituting net loss from discontinued operations: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:27.746%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:5.681000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.981%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:5.681000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.981%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:5.681000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:5.681000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:5.881%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> GoodWheat </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Body Care </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="background-color:#fffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times

New Roman;margin-bottom:0;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> (In thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Product revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(76</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 300 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">372</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 484 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 373 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Cost of revenues </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (285 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (691 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (634 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (34 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (291 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,000 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> (Loss) Gain on sale of property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (24 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 36 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Selling, general and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (330 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,580 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2,040 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (4,551 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (86 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (651 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Net loss from discontinued operations </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(430</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (1,845 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,694</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(83</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (591 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> </table> The following table presents non-cash items of discontinued operations: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.829%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.082%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.102%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.082%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.102%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> GoodWheat </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Body Care </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> <span style="white-space:pre-

wrap;min-width:fit-content;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> (In thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Depreciation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">37</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 109 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Gain on disposal of property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(65</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (36 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Write-down of inventories </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 275 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Accounts receivable and other

receivables </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(78</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,975 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 250 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Prepaid expenses and other current assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(500</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 144 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Proceeds from sale of property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">342</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> There were no other operating or investing non-cash items for the nine months ended September 30, 2024 and 2023. Organization Arcadia Biosciences, Inc. (the "Company," "Arcadia" or "management"), was incorporated in Arizona in 2002 and maintains its headquarters in Dallas, Texas, with additional office space in Davis and Sacramento, California. The Company was reincorporated in Delaware in March 2015. Since acquiring the assets of Live Zola, LLC ("Zola") in May 2021, the Company has provided consumers with a great tasting way to rehydrate, reset, and reenergize with Zola coconut water products. The company has leveraged its history as a leader in science-based approaches to develop high value products and drive innovation in the consumer goods industry. Previously, the Company developed products primarily in wheat, which it commercialized through the sales of seed, grain and food ingredients and products, and through trait licensing and royalty agreements. On May 16, 2024, the Company sold the GoodWheat™ brand to Above Food Ingredients Corp. ("Above Food") for net consideration of $3.7 million. Refer to Note 6 for details of the transaction. On May 14, 2024, the Company sold its non-GMO Resistant Starch ("RS") durum wheat trait to longtime partner Corteva AgriScience ("Corteva"). Under the terms of the agreement, Arcadia retained certain rights to use the RS durum wheat trait. The Company received $4.0 million in cash payment from Corteva during the nine months ended September 30, 2024 and recorded a gain of the same amount as the trait had no carrying value on the condensed consolidated statement of operations and comprehensive loss related to the transaction. Refer to Note 8 for details of the partnership and transaction. In May 2021, the Company's wholly owned subsidiary Arcadia Wellness, LLC ("Arcadia Wellness" or "AW") acquired the businesses of Eko Holdings, LLC, Lief, LLC, and Zola. The acquisition included Saavy Naturals™, a line of natural body care products, Soul Spring™, a CBD-infused botanical therapy brand in the natural category, and ProVault™, a THC-free CBD sports performance formula made with natural ingredients, providing effective support and recovery for athletes (collectively, "body care brands"). Also included in the purchase was Zola, a coconut water sourced exclusively with sustainably grown coconuts from Thailand. In July 2022, the Company entered into an agreement to license Saavy Naturals to Radiance Beauty and Wellness, Inc. ("Radiance Beauty"). In July 2023, management made the decision to exit the remaining body care brands, Soul Spring and ProVault, as a result of continued pressure on the CBD market due to regulatory uncertainty. Body care operations ceased during the third quarter of 2023. In August 2019, the Company entered into a joint venture agreement with Legacy Ventures Hawaii, LLC ("Legacy," see Note 7) to grow, extract, and sell hemp products. The partnership Archipelago Ventures Hawaii, LLC ("Archipelago"), combines the Company's extensive genetic expertise and resources with Legacy's experience in hemp extraction and sales. In October 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to regulatory challenges and a saturated hemp market. In February 2012, the Company formed Verdeca, which was equally owned with Bioceres. Verdeca was formed to develop and deregulate soybean varieties using both partners' agricultural technologies. In November 2020, Arcadia sold its membership interest in Verdeca to Bioceres in a transaction in which Arcadia received cash, shares of Bioceres stock and a royalty stream of up to $10.0 million on sales of Haab 4 soybeans ("HB4"). An additional $2.0 million in cash was to be paid to Arcadia upon Verdeca achieving commercial plantings of at least 200,000 hectares of HB4 or China approving the HB4 soybean trait for "food and feed". During 2022, Bioceres received China's approval of the HB4 soybean trait and as a result, Arcadia recorded license revenue of $862,000 and a gain on sale of Verdeca of $1.1 million on the condensed consolidated statements of operations and comprehensive loss. The Company received the full payment of $2.0 million as of December 31, 2023. Arizona2002Delaware2015-033700000400000040000001000000020000008620001100000020000000 Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial statements and are in the form prescribed by the Securities and Exchange Commission (the "SEC") in instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company's financial position, results of operations and cash flows for the periods indicated. All material intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company, Arcadia Wellness, and Archipelago. The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities ("VIEs"). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE's economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE. For all periods presented, the Company has determined that it is the primary beneficiary of Archipelago, a joint venture, as it has a controlling interest in Archipelago. Accordingly, the Company consolidates Archipelago in the condensed consolidated financial statements after eliminating intercompany transactions. For consolidated joint ventures, the non-controlling partner's share of the assets, liabilities and operations of the joint venture is included in non-controlling interests as equity of the Company. The non-controlling partner's interest is generally computed as the joint venture partner's ownership percentage of Archipelago. The non-controlling partner's equity interests are presented as non-controlling interests on the condensed consolidated balance sheets. The information included in these condensed consolidated financial statements and notes thereto should be read in conjunction with Management's Discussion and Analysis of Financial Condition and Results of Operations included herein and Management's Discussion and Analysis of Financial Condition and Results of Operations and the condensed consolidated financial statements and notes thereto for the fiscal year ended December 31, 2023 included in the Company's Annual Report on Form 10-K, filed with the SEC on March 28, 2024. Reclassifications Certain previously reported financial information has been reclassified to conform to the current year presentation. For a discussion of the reclassification of the financial presentation of our former GoodWheat and body care brands reported as discontinued operations, see "Discontinued Operations" section below. Unless otherwise noted, amounts and disclosures throughout these notes to condensed consolidated financial statements relate solely to continuing operations and exclude all discontinued operations. Reverse Stock Split In February 2023, the Company's board of directors approved a reverse split of 40:1 on the Company's issued and outstanding common stock. On February 15, 2023, the Company's stockholders approved the certificate of amendment to the Company's certificate of incorporation, which the Company filed on February 27, 2023 with the Secretary of State of Delaware to effect the reverse split on March 1, 2023. As a result of the reverse stock split, 19,118 additional shares of common stock were issued in lieu of fractional shares. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the condensed consolidated financial statements have been retroactively adjusted to reflect the reverse stock split for all periods presented. In February 2023, the Company's board of directors approved a reverse split of 40:1 on the

Company's issued and outstanding common stock.19118 Liquidity, Capital Resources, and Going Concern The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. Since inception, the Company has financed its operations primarily through equity financings. As of September 30, 2024, the Company had an accumulated deficit of $274.8 million, cash and cash equivalents of $3.9 million, short-term investments of $2.6 million and current note receivable of $1.8 million. For the nine months ended September 30, 2024, the Company had net loss of $3.0 million and net cash used in operations of $7.4 million. For the twelve months ended December 31, 2023, the Company had net losses of $14.0 million and net cash used in operations of $15.3 million.</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">With cash and cash equivalents of $3.9 million, short-term investments of $2.6 million and current note receivable of <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$1.8 million as of September 30, 2024, the Company believes that its existing cash, cash equivalents and short-term investments will not be sufficient to meet its anticipated cash requirements for at least the next 12-18 months from the issuance date of these financial statements, and thus raises substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company may seek to raise additional funds through debt or equity financings. The Company may also consider entering into additional partner arrangements. The sale of additional equity would result in dilution to the Company's stockholders. The incurrence of debt would result in debt service obligations, and the instruments governing such debt could provide for additional operating and financing covenants that would restrict operations. If the Company requires additional funds and is unable to secure adequate additional funding at terms agreeable to the Company, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned product launches. Any of these actions could materially harm the business, results of operations and financial condition. -274800000390000026000001800000-3000000-7400000-14000000-153000003900000260000018000000 Discontinued Operations On May 16, 2024, the Company sold the GoodWheat brand to Above Food. GoodWheat operations ceased during the second quarter of 2024. In July 2023, management made the decision to exit its body care brands as a result of continued pressure on the CBD market due to regulatory uncertainty. Body care operations ceased during the third quarter of 2023. In accordance with the provisions of ASC 205-20, the Company has separately reported the assets and liabilities of the discontinued operations in the condensed consolidated balance sheets and the results of the discontinued operations as separate components on the condensed consolidated statements of operations and comprehensive loss for all periods presented. Major classes of line items constituting the balance sheet of discontinued operations: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.829%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.082%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.102%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.082%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.102%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> GoodWheat </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Body Care </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> (In thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Assets </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-

align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> Accounts receivable and other receivables </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">70</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8 </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Inventories, net — current </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,121 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> Property and equipment, net </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 314 </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Inventories, net — noncurrent </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,158 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-

space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> Total assets </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">70</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,601 </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"> <td style="background-color:#cff0fc;vertical-align:bottom;"> Liabilities </td> <td style="background-color:#cff0fc;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:#cff0fc;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:#cff0fc;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Accounts payable and accrued expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 500 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> Total liabilities </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:right;">500 </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Major classes of line items constituting net loss from discontinued operations: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:27.746%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:5.681000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.981%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:5.681000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.981%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:5.681000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:5.681000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:5.881%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> GoodWheat </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Body Care </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;">

 </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> (In thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Product revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(76</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 300 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">372</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 484 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:right;">373 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Cost of revenues </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (285 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (691 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (634 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 313 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (291 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (400 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,000 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (24 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 36 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Selling, general and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (330 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,580 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2,040 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (4,551 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Net loss from discontinued operations </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(430</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (1,845 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(2,694</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (5,665 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> (83 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (591 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> </table> The following table presents non-cash items of discontinued operations: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.829%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.082%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.102%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.082%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.102%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> GoodWheat </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Body Care </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> (In thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-

align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Depreciation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">37</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 109 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Gain on disposal of property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(65</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (36 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Write-down of inventories </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 275 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Accounts receivable and other receivables </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(78</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(99</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Inventories</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 575 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(1,975</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">250</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Prepaid expenses and other current assets</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Accounts payable and accrued expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(500</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 144 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Proceeds from sale of property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">342</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> There were no other operating or investing non-cash items for the nine months ended September 30, 2024 and 2023. Major classes of line items constituting the balance sheet of discontinued operations: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:42.829%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.082%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.082%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.102%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> GoodWheat </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:center;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Body Care </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> (In thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Assets </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> Accounts receivable and other receivables </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">70</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8 </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 314 </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-

align:bottom;text-align:left;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Inventories, net — noncurrent </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,158 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> Total assets </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">70</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,601 </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Accounts payable and accrued expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 500 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left,"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;word-break:break-word;"> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total liabilities</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000,"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right,">500</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">500</p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Major classes of line items constituting net loss from discontinued operations: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:27.746%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:5.681000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.981%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:5.681000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.981%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:5.681000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:5.681000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:5.881%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> GoodWheat </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Body Care </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left,"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom,"> </td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times

top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">300</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 372 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">484</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">37</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 373 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Cost of revenues </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (285 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (691 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (634 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (313 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (291 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (400 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,000 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> (Loss) Gain on sale of property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (24 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 36 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Selling, general and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (330 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,580 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2,040 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (4,551 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-

wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (86 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (651 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Net loss from discontinued operations </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(430</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (1,845 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(2,694</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (5,665 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (83 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (591 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> </table> The following table presents non-cash items of discontinued operations: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.829%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.082%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.102%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.082%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.102%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> GoodWheat </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Body Care </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;

Roman;margin-bottom:0;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> (In thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Depreciation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">37</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 109 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Gain on disposal of property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(65</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (36 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 275 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accounts receivable and other receivables</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (78 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (99 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Inventories </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">575</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,975 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 250 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Prepaid expenses and other current assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accounts payable and accrued expenses</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (500 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">144</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Proceeds from sale of property and equipment</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 342 </td> <td

style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">37</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> There were no other operating or investing non-cash items for the nine months ended September 30, 2024 and 2023. <700008000000112100000031400000031580000070000460100000050000000050000000-760003000003720004840000370000373000028500069100063400003400003130000-291000-400000-10000000000-2400011000650003600000000-330000-1580000-2040000-45510000-860000-651000-430000-1845000-2694000-56650000-830000-591000370001090000240006500036000000275000007800000099000-57500019750000-250000000-14000-500000144000050003420003700000 2. Recent Accounting Pronouncements In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) — Improvements to Reportable Segment Disclosures. The amendments in this update improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The new guidance is effective retrospectively for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this update on our segment disclosures. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) — Improvements to Income Tax Disclosures. The amendments in this update require additional income tax disclosures primarily related to the rate reconciliation and income taxes paid. The new guidance is effective either prospectively or retrospectively, for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this update on our income tax disclosures. 3. Inventory Inventory costs are tracked on a lot-identified basis and are included as cost of revenues when sold. Inventories are stated at the lower of cost or net realizable value. The Company makes adjustments to inventory when conditions indicate that the net realizable value may be less than cost due to physical deterioration, obsolescence, changes in price levels, or other factors. Additional adjustments to inventory are made for excess and slow-moving inventory on hand that is not expected to be sold within a reasonable timeframe to reduce the carrying amount to its estimated net realizable value. The write-downs to inventory are included in cost of revenues and are based upon estimates about future demand from the Company's customers and distributors and market conditions. The Company recorded a write-down of $154,000 related to hemp and GoodWheat seed during the three and nine months ended September 30, 2024. The Company recorded inventory write-downs of $252,000 and $444,000 related to packaging materials, hemp seed and GoodWheat during the three and nine months ended September 30, 2023, respectively. If there are significant changes in demand and market conditions, substantial future write-downs of inventory may be required, which would materially increase the Company's expenses in the period the write down is taken and materially affect the Company's operating results.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Inventories, net consist of the following (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.76%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Raw materials</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 450 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">373</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Finished goods</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">385</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">660</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Inventories</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 835 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-

wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,033 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 1540001540002520004444000 Inventories, net consist of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.76%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Raw materials </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">450</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 373 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Finished goods </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 385 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 660 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Inventories </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">835</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,033 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>4500003730003850006600008350001033000 4. Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:83.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:52.44%;box-sizing:content-box;"></td> <td style="width:2.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.599999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:19.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Software and computer equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">291</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 349 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Machinery and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:right;">34 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Furniture and fixtures </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 32 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 39 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Leasehold improvements </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,584 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,590 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Property and equipment, gross </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,907 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,012 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Less: accumulated depreciation and amortization </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,852 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,942 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Property and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">55</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 70 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Depreciation expense was $7,000 and $92,000 for thethree and nine months ended September 30, 2024, respectively. Depreciation expense was $89,000 and $227,000 for the three and nine months ended September 30, 2023, respectively. During the three and nine months ended September 30, 2024 and 2023, there were no sales of property and equipment from continuing operations. Property and equipment are considered assets held for sale when management approves and commits to a plan to dispose of a property or group of properties. The property and equipment held for sale prior to the sale date is separately presented, within current assets, on the condensed consolidated balance sheet as assets held for sale. Property and equipment related to Archipelago of $51,000 were classified as assets held for sale as of December 31, 2023. During the first quarter of 2024, the Company recorded an impairment of $36,000 related to these assets. During the second quarter of 2024, all Archipelago property and equipment previously held for sale were sold. Property and equipment, net consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:83.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:52.44%;box-sizing:content-box;"></td> <td style="width:2.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.599999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:19.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> <span style="color:#000000;white-

space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Software and computer equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">291</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 349 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Machinery and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 34 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Furniture and fixtures </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 32 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 39 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Leasehold improvements </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,584 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,590 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Property and equipment, gross </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,907 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,012 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Less: accumulated depreciation and amortization </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,852 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,942 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Property and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">55</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 70 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>291000034900003400032000390001584000159000019070002012000185200019420005500070000700092000890002270005100036000 5. Investments and Fair Value Instruments <span

style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Available-for-Sale Investments The Company classified short-term investments as “available-for-sale.” These short-term investments are free of trading restrictions. The investments are carried at fair value, based on quoted market prices or other readily available market information. Unrealized gains and losses are included in accumulated other comprehensive income, which is reflected as a separate component of stockholder’s equity in the condensed consolidated balance sheets. Gains and losses are recognized when realized in the condensed consolidated statements of operations and comprehensive loss. The following tables summarize the amortized cost and fair value of the investment securities portfolio at September 30, 2024 and December 31, 2023 and the corresponding amounts of unrealized gains and losses recognized in accumulated other comprehensive income: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.38%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> (Dollars in thousands) </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Gains </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Estimated
Fair Value </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> September 30, 2024 </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> Cash equivalents: </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Money market funds </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,770</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,770 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> Short-term investments: </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> <span

*style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Treasury bills </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,523 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 117 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,640 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total Assets at Fair Value </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,293</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 117 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,410 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> (Dollars in thousands) </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Estimated
Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> December 31, 2023 </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:*

color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Cash equivalents: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,925</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,925 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Short-term investments: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Treasury bills </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,023 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 101 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,124</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total Assets at Fair Value</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 9,948 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">101</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-

align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,049</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company did not have any investment categories that were in a continuous unrealized loss position for more than twelve months as of September 30, 2024.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Fair Value Measurement</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The fair value of the investment securities at September 30, 2024 were as follows:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Fair Value Measurements at September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">(Dollars in thousands)</p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Level 1</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Level 2</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Level 3</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Assets at Fair Value</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Money market funds</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,770 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,770</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Short-term investments:</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Treasury bills</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,640</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,640</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total Assets at Fair Value</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,410 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,410 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> The fair value of the investment securities at December 31, 2023 were as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value Measurements at December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> (Dollars in thousands) </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-

align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Assets at Fair Value </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,925</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,925 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Short-term investments: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Treasury bills </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,124 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td

style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,124 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total Assets at Fair Value </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,049</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2024 or 2023. The Company's financial instruments consist primarily of cash and cash equivalents, short-term investments, accounts receivable and other receivables, note receivable, accounts payable and accrued liabilities. For short-term investments, accounts receivable and other receivables, accounts payable and accrued liabilities, the carrying amounts of these financial instruments as of September 30, 2024 and December 31, 2023 were considered representative of their fair values due to their short term to maturity or repayment. Cash equivalents are carried at cost, which approximates their fair value. The note receivable is recorded at amortized cost. The amortized cost of the note receivable is considered approximate fair value due to its variable interest rate. The Company's Level 3 liabilities consist of a contingent liability resulting from the Anawah, Inc. ("Anawah") acquisition as described in Note 14, as well as preferred investment options related to the March 2023 Private Placement and August 2022 Registered Direct offerings described in Note 10. The contingent liability related to the Anawah acquisition was measured and recorded on a recurring basis as of September 30, 2024 and December 31, 2023, using unobservable inputs, namely the Company's ability and intent to pursue certain specific products developed using technology acquired in the purchase. A significant deviation in the Company's ability and/or intent to pursue the technology acquired in the purchase could result in a significantly lower (higher) fair value measurement. The preferred investment option liabilities were measured and recorded on a recurring basis using the Black-Scholes Model with the following assumptions as of September 30, 2024 and December 31, 2023:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:20.683%;box-sizing:content-box;"></td> <td style="width:1.279%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.372%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.279%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.508999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.279%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.372%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.279%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.508999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.279%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.372%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.279%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.508999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> March 2023 Options - Series A &
March 2023 Placement Agent Options </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> March 2023 Options - Series B </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> August 2022 Options & August 2022 Placement Agent Options </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,
2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,
2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> <span

style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Remaining term (in years) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.40 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.16 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.61 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.92 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.67 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Expected volatility </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 86.9 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 91.7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 78.7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 91.8 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 90.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:8pt;background-color:#eff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Risk-free interest rate </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.6 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.9 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.2 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.6 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Expected dividend yield </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table> The significant input used in the fair value measurement of the Company's Level 3 options liabilities is volatility. A significant increase (decrease) in volatility could result in a significantly higher (lower) fair value measurement. The following table sets forth the establishment of the Company's Level 3 assets and liabilities, as well as a summary of the changes in the fair value and other adjustments (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:17.477%;box-sizing:content-box;"></td> <td style="width:1.061%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.447999999999995%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.061%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.447999999999995%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.061%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.149999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.061%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.949%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.061%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.149999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.061%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.088%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.061%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.088%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.181%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.591999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="30" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:7pt;background-color:#fffffc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> (Dollars in thousands) </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> March 2023
Options - Series A </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> March 2023
Options - Series B </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> March 2023 Placement Agent Options </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> August 2022
Options </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> August 2022 Placement Agent Options </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Note Receivable Bifurcated Derivatives </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Contingent
Liabilities </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance as of December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,008 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">41</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 46 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">159</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,257 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:7pt;background-color:#fffffff;word-break:break-word;"> <td style="text-indent:8pt;white-space:pre-wrap;vertical-align:top;"> Initial recognition </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 250 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:8pt;white-space:pre-wrap;vertical-align:top;"> Change in fair value </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (378 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (41 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (19 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">

(53 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (493 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:7pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance as of September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">630</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">27</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 106 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 250 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,014 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following tables summarize the amortized cost and fair value of the investment securities portfolio at September 30, 2024 and December 31, 2023 and the corresponding amounts of unrealized gains and losses recognized in accumulated other comprehensive income: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> (Dollars in thousands) </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">

 </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Estimated
Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> September 30, 2024 </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;">

space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total Assets at Fair Value </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,293</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 117 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,410 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> (Dollars in thousands) </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Estimated
Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> December 31, 2023 </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Cash equivalents: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,925</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td>

<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,925</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Short-term investments:</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Treasury bills</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,023</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">101</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,124 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total Assets at Fair Value </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,948</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 101 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,049 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>27700000027700002523000117000026400005293000117000054100004925000004925000502300010100005124000994800001010000100490000 The fair value of the investment securities at September 30, 2024 were as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.38%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value Measurements at September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> (Dollars in thousands) </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Assets at Fair Value </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;">

solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,640 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total Assets at Fair Value </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,410</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,410 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> The fair value of the investment securities at December 31, 2023 were as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value Measurements at December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> (Dollars in thousands) </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:bottom;"> Assets at Fair Value </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Cash equivalents: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;">Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,925</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,925</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Short-term investments:</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Treasury bills</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,124</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,124</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total Assets at Fair Value</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,049 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,049 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>27700000027700002640000002640000541000000541000049250000049250005124000005124000100490000010049000 The preferred investment option liabilities were measured and recorded on a recurring basis using the Black-Scholes Model with the following assumptions as of September 30, 2024 and December 31, 2023:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:20.683%;box-sizing:content-box;"></td> <td style="width:1.279%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.372%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.279%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.508999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.279%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.372%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.279%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.508999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td>

<td style="width:1.279%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.372%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.279%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.5089999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> March 2023 Options - Series A &
March 2023 Placement Agent Options </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> March 2023 Options - Series B </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> August 2022 Options & August 2022 Placement Agent Options </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,
2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,
2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,
2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31,
2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Remaining term (in years) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.40 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.16 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.61 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.92 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.67 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Expected volatility </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 86.9 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 91.7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-

content;">78.7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 91.8 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 90.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Risk-free interest rate </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.6 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.9 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.2 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.6 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Expected dividend yield </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table>
P3Y4M24DP4Y1M28DP0Y7M9DP2Y11M1DP3Y8M1D86.991.7078.791.890.53.63.905.23.64000000 The following table sets forth the establishment of the Company's Level 3 assets and liabilities, as well as a summary of the changes in the fair value and other adjustments (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:17.477%;box-sizing:content-box;"></td> <td style="width:1.061%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.447999999999995%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.061%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.447999999999995%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.061%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.149999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.061%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.949%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.061%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.149999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.061%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.088%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.061%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.088%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.181%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.591999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="30" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> <span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-

content;">(Dollars in thousands) </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> March 2023
Options - Series A </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> March 2023
Options - Series B </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> March 2023 Placement Agent Options </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> August 2022
Options </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> August 2022
Placement Agent Options </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Note Receivable Bifurcated Derivatives </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Contingent
Liabilities </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance as of December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,008</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 41 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">46</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 159 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,257 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:7pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:8pt;white-space:pre-wrap;vertical-align:top;"> Initial recognition </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-

size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 250 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 250 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:7pt;background-color:#eff0fc;word-break:break-word;"> <td style="text-indent:8pt;white-space:pre-wrap;vertical-align:top;"> Change in fair value </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (378 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (41 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (19 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (53 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (493 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:7pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance as of September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">630</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">27</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 106 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1 </td> <td style="white-

space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">250</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,014 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>10080004100046000159000300002000000325700000000250000025000-378000-41000-19000-53000-200000-49300063000002700010600010002500002000000314000 6. Note Receivable On May 16, 2024, the Company sold the GoodWheat brand to Above Food for net consideration of $3.7 million. The assets sold consisted primarily of grain and finished goods inventories, formulations and trademarks. A loss of $1,500 was recognized in the condensed consolidated statements of operations and comprehensive loss during the nine months ended September 30, 2024, related to the sale. In connection with the transaction, Arcadia paid to Above Food $2.0 million and received a $6.0 million promissory note dated May 14, 2024. The promissory note has a term of three years and accrues interest at the Wall Street Journal prime rate. On each of the first, second and third anniversaries of the promissory note, accrued interest and $2.0 million of principal are payable to Arcadia. The promissory note contains contingent features, including an option that requires Above Food to cause its parent entity, Above Food Ingredients Inc. (“Parent Company”), to issue to the Company publicly traded stock of Parent Company in exchange for the cancellation of a portion of the principal of the promissory note, as well as default provisions. The Company accounted for the promissory note as a note receivable in accordance with ASC 310. The Company did not elect the fair value option and since the Company intends to and has the ability to hold the promissory note to maturity, it has been classified as held for investment and is reported on the condensed consolidated balance sheet at amortized cost. The first installment payment due in 2025 is classified as current and the remaining installment payments due in 2026 and 2027 are classified as noncurrent on the condensed consolidated balance sheet. The contingent features of the promissory note were evaluated for bifurcation in accordance with ASC 815. The contingent features requiring bifurcation had an estimated fair value of $250,000 as of the transaction date and as of September 30, 2024. The estimated fair value of the contingent features is reported in note receivable - noncurrent on the condensed consolidated balance sheet as of September 30, 2024. The promissory note was recorded at a discount of $545,000, which is being amortized over the term of the promissory note using the effective interest method. The Company recognized discount amortization of $60,000 and $89,000 in the condensed consolidated statements of operations and comprehensive loss during the three and nine months ended September 30, 2024, respectively. The Company recognized accrued interest of $126,000 and $193,000 in the condensed consolidated statements of operations and comprehensive loss during the three and nine months ended September 30, 2024, respectively. 3700000150020000006000000P3YWall Street Journal prime rate200000025000054500060000089000126000193000 7. Consolidated Joint Venture In 2019, the Company and Legacy Ventures Hawaii, LLC, a Nevada limited liability company (“Legacy”), formed Archipelago Ventures Hawaii, LLC, a Delaware limited liability company and entered into a Limited Liability Company Operating Agreement (the “Operating Agreement”). The Company and Legacy formed Archipelago to develop, extract and commercialize hemp-derived products from industrial hemp grown in Hawaii. Pursuant to the Operating Agreement, a joint operating committee consisting of two individuals appointed by the Company and two individuals appointed by Legacy will manage Archipelago. As of September 30, 2024, the Company and Legacy hold 50.75% and 49.25% interests in Archipelago, respectively, and have made capital contributions to Archipelago of $3.1 million and $3.0 million, respectively, as determined by the joint operating committee. The Operating Agreement includes indemnification rights, non-competition obligations, and certain rights and obligations in connection with the transfer of membership interests, including rights of first refusal. The Company consolidates Archipelago in the condensed consolidated financial statements after eliminating intercompany transactions. Legacy’s equity interests are presented as non-controlling interests on the condensed consolidated balance sheets. Refer to Note 1 for basis of presentation. In October 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to regulatory challenges and a saturated hemp market. 220.50750.49253100000030000000 8. Collaborative Arrangements In August 2017, the Company entered into a collaborative arrangement for the research, development and commercialization of our non-GMO RS durum wheat trait in North America. This collaborative arrangement was a contractual agreement with Corteva and involved a joint operating activity where both Arcadia and Corteva were active participants in the activities of the collaboration. Arcadia and Corteva participated in the research and development, and Arcadia had the primary responsibility for the intellectual property strategy while Corteva generally led the marketing and commercialization efforts. Both parties were exposed to significant risks and rewards of the collaboration and the agreement included both cost sharing and profit sharing. The activities were performed with no guarantee of either technological or commercial success. <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-

content;">The Company accounted for research and development (“R&D”) costs in accordance ASC 730, Research and Development, which states R&D costs must be charged to expense as incurred. Accordingly, internal R&D costs are expensed as incurred. Third-party R&D costs are expensed when the contracted work has been performed or as milestone results are achieved. On May 14, 2024, the Company sold its RS durum wheat trait to Corteva. Under the terms of the agreement, Arcadia retained certain rights to use the RS durum wheat trait. The Company received $4.0 million in cash payment from Corteva during the nine months ended September 30, 2024 and recorded a gain of the same amount as the trait had no carrying value on the condensed consolidated statement of operations and comprehensive loss related to the transaction. 2017-08400000040000000 9. Leases Operating Leases As of September 30, 2024, the Company leases office space in Dallas, TX, Davis and Sacramento, CA, as well as additional buildings, land and equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these short-term leases on a straight-line basis. The Company subleases the Davis office to third parties. Some leases (the Dallas and Davis offices, a warehouse, and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years. The exercise of lease renewal options is at the Company’s sole discretion. In January 2024, the Company exercised it’s option to renew the facility lease in American Falls, Idaho for one year through December 31, 2024. The lease renewal resulted in recognition of additional right-of-use asset and lease liability of $86,000 on the condensed consolidated balance sheet. The Company subsequently terminated the facility lease in American Falls, Idaho effective July 2024.</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company’s lease agreements do not contain any material variable lease payments, material residual value guarantees or material restrictive covenants. Leases consisted of the following (in thousands):</p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:28.806%;box-sizing:content-box;"></td><td style="width:1.66%;box-sizing:content-box;"></td><td style="width:29.646%;box-sizing:content-box;"></td><td style="width:1.38%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:16.563%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.38%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:16.563%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Leases</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Classification</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Assets</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating lease assets</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Right of use asset</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 306 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">792</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total leased assets</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 306 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 792 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> Liabilities </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td

style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Current - Operating </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> Operating lease liability- current </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">346</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 852 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Noncurrent - Operating </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> Operating lease liability- noncurrent </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 155 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total leased liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">346</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,007 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:20.6%;box-sizing:content-box;"></td> <td style="width:1.18%;box-sizing:content-box;"></td> <td style="width:21.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Lease Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Classification </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three
Months Ended
September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three
Months Ended
September 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine
Months Ended
 September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine
Months Ended
 September 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Operating lease cost </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> SG&A and R&D Expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">172</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 191 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span

style="color:#000000;white-space:pre-wrap;min-width:fit-content;">678 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">572</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Short term lease cost</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> SG&A Expenses</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Sublease income (1)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> SG&A and R&D Expenses</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(142</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(111</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(404</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(329</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Net lease cost</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">83</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 253 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> </table> <span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1) Sublease income is recorded as a reduction to lease expense. <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.629%;box-sizing:content-box;"></td> <td style="width:1.52%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:25.165000000000003%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.52%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:25.165000000000003%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Lease Term
and Discount Rate </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> <span style="white-space:pre-wrap;font-

family:'Calibri',sans-serif;min-width:fit-content;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted-average remaining
lease term (years) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted-average discount rate </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table> Some leases (the Dallas and Davis offices, a warehouse, and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years. The exercise of lease renewal options is at the Company's sole discretion. In January 2024, the Company exercised it's option to renew the facility lease in American Falls, Idaho for one year through December 31, 2024. The lease renewal resulted in recognition of additional right-of-use asset and lease liability of $86,000 on the condensed consolidated balance sheet. The Company subsequently terminated the facility lease in American Falls, Idaho effective July 2024.trueP6YP1Y86000000Leases consisted of the following (in thousands):<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:28.806%;box-sizing:content-box;"></td> <td style="width:1.66%;box-sizing:content-box;"></td> <td style="width:29.646%;box-sizing:content-box;"></td> <td style="width:1.38%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.563%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.38%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.563%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Leases</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Classification</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Assets</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating lease assets</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> Right of use asset</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 306 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">792</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total leased assets</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 306 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> <span style="color:#000000;white-

space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Current - Operating </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> $</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 346 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">852</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Noncurrent - Operating</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> Operating lease liability- noncurrent</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">155</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total leased liabilities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 346 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,007</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;min-width:fit-content;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:20.6%;box-sizing:content-box;"></td> <td style="width:1.18%;box-sizing:content-box;"></td> <td style="width:21.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Lease Cost</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Classification</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three
Months Ended
September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three
Months Ended
September 30, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine
Months Ended
 September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine
Months Ended
 September 30, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating lease cost</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> SG&A and R&D Expenses</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 172 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:right;">191 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">678</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 572 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Short term lease cost </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> 5G&A Expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Sublease income (1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> 5G&A and R&D Expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (142 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (111 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (404 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (329 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Net lease cost </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">33</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 83 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">284</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 253 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> </table> <span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1) Sublease income is recorded as a reduction to lease expense. <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.629%;box-sizing:content-box;"></td> <td style="width:1.52%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td

style="width:25.165000000000003%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.52%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:25.165000000000003%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Lease Term
and Discount Rate </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted-average remaining
 lease term (years) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0.7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted-average discount rate </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr>
</table>3060007920003060007920003460008520000155000346000100700017200019100067800057200030003000100001000014200011100040400032900033000830002840
style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">10. Equity Financing March 2023 Private Placement In March 2023, the Company issued in a private placement offering (the "March 2023 Private Placement") pursuant to a securities purchase agreement ("March 2023 Purchase Agreement") (i) 165,500 shares of its common stock, (ii) pre-funded common stock purchase warrants (the "March 2023 Pre-Funded Warrants") to purchase up to 500,834 shares of common stock, at an exercise price of $0.0001 per share, (iii) Series A preferred investment options (the "March 2023 Options - Series A") to purchase up to a total of 666,334 shares of common stock, at an exercise price of $9.00 per share, and (iv) Series B preferred investment options (the "March 2023 Options - Series B", and together with the March 2023 Options - Series A, the "March 2023 Options") to purchase up to a total of 666,334 shares of common stock, at an exercise price of $9.00 per share, and raised total gross proceeds of $6.0 million. The March 2023 Private Placement closed on March 6, 2023. The March 2023 Pre-Funded Warrants became exercisable upon issuance and were fully exercised as of September 30, 2024. The March 2023 Options - Series A are exercisable at any time at the option of the holder and expire 5 years from the date of issuance. The March 2023 Options - Series B were exercisable at any time at the option of the holder and expire 1.5 years from the date of issuance. As of September 30, 2024, the March 2023 Options - Series B expired. In connection with the March 2023 Private Placement, the Company entered into preferred investment option amendment agreements (the "Option Amendment Agreements") with certain investors. Under the Option Amendment Agreements, the Company agreed to amend certain existing warrants and preferred investment options to purchase up to a total of 178,132 shares of common stock that were previously issued to the investors in September 2019, May 2020, July 2020, December 2020, January 2021 and August 2022, with exercise prices of $300.80, $191.00, $154.00, $120.00, $125.20 and $37.35 per share, respectively (the "Existing Warrants"). Under the Option Amendment Agreements, the Company agreed to lower the exercise price of the Existing Warrants to $9.00 per share. In addition, the Company granted to a placement agent preferred investment options to purchase a total of 33,317 shares of Common Stock (the "March 2023 Placement Agent Options") that have an exercise price per share equal to $11.25 and a term of 5 years from the date of issuance. The re-pricing of the Existing Warrants resulted in an increase in fair value of $404,000, of which $185,000 of the increase in fair value was related to the August 2022 liability classified options. The increase in fair value related to the re-pricing of Existing Warrants was recognized in Valuation Loss on March 2023 PIPE on the condensed consolidated statements of operations and comprehensive loss. <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-

align:left;">The March 2023 Options and March 2023 Placement Agent Options are classified as liabilities within Level 3 due to certain early settlement provisions that preclude them from equity classification. The Company utilized the Black-Scholes Model on March 6, 2023 with the following assumptions for the Series A Investment Options: volatility of 128.55%, stock price of $7.61 and risk-free rate of 4.27%. The following assumptions were utilized for the Series B Investment Options: volatility of 103.33%, stock price of $7.61 and risk-free rate of 4.97%. The estimated fair value of the liability classified March 2023 Options issued was $6.6 million. The estimated fair value of the common stock option liabilities was subsequently remeasured at September 30, 2024 with the changes recorded on the Company's condensed consolidated statements of operations and comprehensive loss. The estimated fair value of the common stock issued and March 2023 Pre-Funded Warrants was $5.1 million. The total estimated fair value of the common stock issued, March 2023 Pre-Funded Warrants and March 2023 Options as of March 6, 2023 exceeded the gross proceeds of the March 2023 Private Placement by $5.7 million and this amount was recognized in Valuation Loss on March 2023 PIPE on the condensed consolidated statements of operations and comprehensive loss. The March 2023 Placement Agent Options were issued for services performed by the placement agent as part of the March 2023 Private Placement and were treated as offering costs. The value of the March 2023 Placement Agent Options was determined to be $212,000, calculated using the Black-Scholes Model. The Company incurred additional offering costs totaling $548,000 that consist of direct incremental legal, advisory, accounting and filing fees relating to the March 2023 Private Placement. A total of $430,000 was allocated to the common stock option liabilities and expensed while the remaining $330,000 was allocated to the common stock and March 2023 Pre-Funded Warrants and offset to additional paid in capital.
1655005008340.0001666334966633496663349660000P5YP1Y6M178132300.8191154120125.237.3593331711.25P5Y4040001850001.28557.610.04271.03337.610.049766000005style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">11. Warrants and Options Equity Classified Common Stock Warrants The Company issued the following warrants to purchase shares of its common stock, which are outstanding as of September 30, 2024 and December 31, 2023, respectively. These warrants are exercisable any time at the option of the holder until their expiration date. <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:26.155%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:8.318%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:5.379%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:8.118%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:8.538%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:8.538%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:8.538%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.418%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Issuance Date </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Term </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Exercise
Price Per
Share </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Exercised
during the
Year Ended
December 31,
2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Outstanding at
December 31,
2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Exercised
during the
Nine Months Ended
September 30,
2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Outstanding at
September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> March 2023 Pre-Funded Warrants </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> March 2023 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> perpetual </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (425,834 </td><td style="white-space:nowrap;vertical-align:bottom;">) </td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 75,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (75,000 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> December 2022 Service and Performance Warrants (1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> December 2022 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11.20</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">October 2022 Service and Performance Warrants (1)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">October 2022</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5 years</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> August 2022 Pre-Funded Warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> August 2022 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> perpetual </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (56,813 </td> <td style="white-space:nowrap;vertical-align:bottom;">)

</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> January 2021 Placement Agent Warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> January 2021 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">159.60</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,846</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,846</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">December 2020 Warrants (2)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 2020</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5.5 years</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,367 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> December 2020 Warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> December 2020 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 120.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-

wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 49,100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 49,100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> December 2020 Placement Agent Warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> December 2020 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 152.80 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,274 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,036 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 198.80 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-

wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 802 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 802 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> May 2020 Warrants (2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> May 2020 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9.00</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,946</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,946</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">May 2020 Warrants</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">May 2020</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5 years</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 191.20 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24,863 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24,863 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> May 2020 Placement Agent Warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> May 2020 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 245.20 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-

wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,741 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,741 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> September 2019 Placement Agent Warrants (3) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> September 2019 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">379.20</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,649</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">June 2019 Placement Agent Warrants (3)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 2019</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5 years</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 251.60 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,862 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> April 2019 Service and Performance Warrants (1)(3) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> April 2019 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 247.20 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-

wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,629 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> January 2021 Warrants (2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> January 2021 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9.00</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,831</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,831</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">January 2021 Warrants</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">January 2021</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5.5 years</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 125.20 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 90,629 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 90,629 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> September 2019 Warrants (2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> September 2019 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-

wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,892 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,892 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> September 2019 Warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> September 2019 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">300.80</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,594</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">June 2019 Warrants</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 2019</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5.5 years</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 200.00 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 10,896 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 10,896 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double

#000000;text-align:center;"> (482,647 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 341,957 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (75,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 259,817 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> (1) The Company issued service and performance warrants (“Service and Performance Warrants”) in connection with professional services agreements with non-affiliated third party entities. (2) These warrants were repriced as part of the March 2023 Private Placement offering. (3) These warrants expired during the nine months ended September 30, 2024. Liability Classified Preferred Investment Options The preferred investment options issued in connection with the March 2023 Private Placement and August 2022 Registered Direct offerings contain certain early settlement provisions that preclude them from equity classification and therefore were accounted for as liabilities at the date of issuance and are adjusted to fair value at each balance sheet date. The change in fair value of the options liabilities is recorded as change in fair value of common stock warrant and option liabilities in the condensed consolidated statements of operations and comprehensive loss. The key terms and activity of the liability classified preferred investment options are summarized as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:23.615%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:8.858%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:5.699%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:8.878%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.079%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.318%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.318%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.138%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Issuance Date </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Term </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Exercise
Price Per
Share </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Exercised
during the
Year Ended
December 31,
2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Outstanding at
December 31,
2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Exercised
during the
Nine
Months Ended
September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Outstanding at
September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> March 2023 Options - Series A </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> March 2023 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 years </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9.00 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 666,334 </td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 666,334 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> March 2023 Options - Series B (2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> March 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9.00</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">666,334</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">33,317</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">33,317</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">August 2022 Options (1)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">August 2022</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5 years</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 118,063 </td> <td style="white-space:nowrap;vertical-align:bottom;">

</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 118,063 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"> August 2022 Placement Agent Options </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> August 2022 </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 52.80 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,904 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,904 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,489,952 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 823,618 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> (1) These options were repriced as part of the March 2023 Private Placement offering. (2) These warrants expired during the nine months ended September 30, 2024. The Company issued the following warrants to purchase shares of its common stock, which are outstanding as of September 30, 2024 and December 31, 2023, respectively. These warrants are exercisable any time at the option of the holder until their expiration date. <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:26.155%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.318%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:5.379%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.118%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.538%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.538%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.538%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.418%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6.5pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:center;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Issuance Date </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Term </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Exercise
Price Per
Share </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Exercised
during the
Year Ended
December 31,
2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Outstanding at
December 31,
2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Exercised
during the
Nine Months Ended
September 30,
2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Outstanding at
September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> March 2023 Pre-Funded Warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> March 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> perpetual </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(425,834</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">75,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(75,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">December 2022 Service and Performance Warrants (1)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 2022</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5 years</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11.20 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> October 2022 Service and Performance Warrants (1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-

space:pre-wrap;vertical-align:bottom;text-align:left;"> October 2022 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16.00</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">August 2022 Pre-Funded Warrants</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">August 2022</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">perpetual</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (56,813 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> January 2021 Placement Agent Warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> January 2021 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 159.60 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,846 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,846 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,846 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> December 2020 Warrants (2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-

align:bottom;text-align:left;"> December 2020 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9.00</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16,367</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16,367</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">December 2020 Warrants</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 2020</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5.5 years</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 120.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 49,100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 49,100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> December 2020 Placement Agent Warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> December 2020 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 152.80 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,274 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> July 2020 Warrants (2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">July 2020 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9.00</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16,036</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16,036</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">July 2020 Placement Agent Warrants</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">July 2020</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5.5 years</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 198.80 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 802 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 802 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> May 2020 Warrants (2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> May 2020 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,946 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,946 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> May 2020 Warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">May 2020 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">191.20</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">24,863</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">May 2020 Placement Agent Warrants</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">May 2020</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5 years</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 245.20 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,741 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,649 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 379.20 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> June 2019 Placement Agent Warrants (3) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 2019 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">251.60</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,862</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">April 2019 Service and Performance Warrants (1)(3)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">April 2019</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5 years</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 247.20 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,629 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> January 2021 Warrants (2) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> January 2021 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,831 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,831 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> January 2021 Warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">January 2021 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">125.20</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">90,629</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">90,629</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">September 2019 Warrants (2)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 2019</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5.5 years</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,892 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,892 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> September 2019 Warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> September 2019 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 300.80 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,594 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,594 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"> June 2019 Warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-

space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 2019 </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5.5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 200.00 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 10,896 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 10,896 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (482,647 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 341,957 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 75,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 259,817 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> (1) The Company issued service and performance warrants (“Service and Performance Warrants”) in connection with professional services agreements with non-affiliated third party entities. (2) These warrants were repriced as part of the March 2023 Private Placement offering. (3) These warrants expired during the nine months ended September 30, 2024. 2023-03perpetual0-42583475000-75000020222-12P5Y11.201000010002022-10P5Y160100001000202 2-08perpetual0-568130002021-01P5Y6M159.600984609846202020-12P5Y6M901636701636720 20-12P5Y6M120.000491000491002020-12P5Y152.800327403274202020-07P5Y6M9.000160360160362020-07P5Y6M198.800802080220 20-05P5Y909946099462020-05P5Y191.200248630248632020-05P5Y245.200174101741741 2019-09P5Y379.200164900201 9-06P5Y251.600186200201 9-04P5Y247.200362900202 1-01P5Y6M907831078312021-01P5Y6M125.209062909062920 19-09P5Y6M909892098922019-09P5Y6M300.806594065942019-06P5Y6M200010896010896-482647341957-75000259817The key terms and activity of the liability classified preferred investment options are summarized as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:23.615%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.958%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:5.699%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.878%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.079%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.318%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.318%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.138%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Issuance Date </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Term </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:6.5pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Exercise
Price Per
Share </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Exercised
during the
Year Ended
December 31,
2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Outstanding at
December 31,
2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Exercised
during the
Nine
Months Ended
September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Outstanding at
September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> March 2023 Options - Series A </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> March 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9.00</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">666,334</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">666,334</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">March 2023 Options - Series B (2)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">March 2023</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.5 years</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 666,334 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:right;">11,25 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33,317 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33,317 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> August 2022 Options (1) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> August 2022 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9.00</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">118,063</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">118,063</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">August 2022 Placement Agent Options</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">August 2022</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5 years</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 52.80 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,904 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,904 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,489,952 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 823,618 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> (1) These options were repriced as part of the March 2023 Private Placement offering. (2) These warrants expired during the nine months ended September 30, 2024. 2023-03P5Y906663340666334202 3-03P1Y6M906663340020 23-03P5Y11.2503331703331 72022-08P5Y901180630118063202 2-08P5Y52.805904059404148995208236 18 12. Stock-Based Compensation and Employee Stock Purchase Program Stock Incentive Plans The Company has two equity incentive plans: the 2006 Stock Plan (“2006 Plan”) and the 2015 Omnibus Equity Incentive Plan (“2015 Plan”). In 2006, the Company adopted the 2006 Plan, which provided for the granting of stock options to executives, employees, and other service providers under terms and provisions established by the Board of Directors. The Company granted non-statutory stock options (“NSOs”) under the 2006 Plan until May 2015, when it was terminated as to future awards, although it continues to govern the terms of options that remain outstanding and were issued under the 2006 Plan. The 2015 Plan became effective upon the Company’s IPO in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 3,860 shares of common stock reserved for future issuance, which included 259 that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan.The maximum number of shares that may be awarded to any individual employee, including our directors and officers, during any calendar year was 9,375 shares. The 2015 Plan provides for the grant of incentive stock options (“ISOs”), NSOs, restricted stock awards, stock units, stock appreciation rights, and other forms of equity compensation, all of which may be granted to employees, officers, non-employee directors, and consultants. The exercise price for ISOs and NSOs will be granted at a price per share not less than the fair value of our common stock at the date of grant. Options granted generally vest over a four-year period; however, there might be alternative vesting schedules, as approved by the Board. Options granted, once vested, are generally exercisable for up to 10 years, after grant to the extent vested. On June 25, 2024, the shareholders approved an amendment to the Company’s 2015 Plan that increased the number of shares of common stock that may be issued under the 2015 Plan by 200,000 shares and increased the maximum number of shares of common stock issuable to employees, including our officers and directors, in any fiscal year from 9,375 shares to 50,000 shares. On February 2, 2022, former president and chief executive officer of the Company, Stanley Jacot, Jr. was hired. The Company granted Mr. Jacot an inducement stock option to purchase 7,902 shares of the Company’s common stock pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The Company filed a registration statement on Form S-8 to register the issuance of shares upon exercise of this inducement stock option. The inducement options grants were issued outside of the 2015 Plan, but are subject to the terms and conditions of the 2015 Plan. As of September 30, 2024, a total of 338,248 shares of common stock were reserved for issuance under the 2015 Plan, of which 127,725 shares of common stock are available for future grant. As of September 30, 2024, a total of 102 and 210,523 options are outstanding under the 2006 and 2015 Plans, respectively. As of December 31, 2023, a total of 102 and 71,609 options were outstanding under the 2006 and 2015 Plans, respectively. A total of 6,949 and 8,366 inducement options were outstanding as of September 30, 2024 and December 31, 2023, respectively. The following is a summary of stock option information and weighted average exercise prices under the Company’s stock incentive plans (in thousands, except share data and price per share): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:81.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.672%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.242%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.28%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.762%;box-sizing:content-box;"></td> <td style="width:1%;box-

sizing:content-box;"></td> <td style="width:1.28%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.762%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Shares
Subject to
Outstanding
Options </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Weighted-
Average
Exercise
Price Per
Share </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Aggregate
Intrinsic
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding — Balance at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 80,078 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">85.30</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Options granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 158,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.71 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Options forfeited </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (7,927 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 19.08 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">397</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Options expired</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(12,576</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">170.08</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Outstanding — Balance at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">217,575</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 22.83 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td

style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,140</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Vested and expected to vest — September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">198,542</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24.68 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,778</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Exercisable — September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,515</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 84.37 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> Aggregate intrinsic value represents the difference between the exercise price of the options and the estimated fair value of the Company's common stock determined by its Board of Directors for each of the respective periods. As of September 30, 2024, there was $524,000 of unrecognized compensation cost related to unvested stock-based compensation grants that will be recognized over the weighted-average remaining recognition period of 1.4 years. In determining the fair value of the stock-based awards, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. Expected Term—The expected term is the estimated period of time outstanding for stock options granted and was estimated based on a simplified method allowed by the SEC, and defines the term as the average of the contractual term of the options and the weighted-average vesting period for all open employee awards. Expected Volatility—The historical volatility data was computed using the daily closing prices for the Company's shares during the equivalent period of the calculated expected term of the stock-based awards. Risk-Free Interest Rate—The risk-free interest rate is based on the interest rate of U.S. Treasuries of comparable maturities on the date the options were granted. Expected Dividend—The expected dividend yield is based on the Company's expectation of future dividend payouts to common stockholders. The fair value of stock option awards was estimated at the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumption: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.11%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.422%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.402%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.422%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.642%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> <span style="white-space:pre-wrap;font-

family:'Calibri',sans-serif;min-width:fit-content;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Expected term (years) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8.04 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.06 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Expected volatility </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 101.31 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 101.31 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 124 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Risk-free interest rate </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.77 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.61 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Dividend yield </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> The Company recognized $155,000 and $395,000 of compensation expense for stock options awards during the <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-

width:fit-content;">three and nine months ended September 30, 2024, respectively. The Company recognized $162,000 and $573,000 of compensation expense for stock options awards during the three and nine months ended September 30, 2023, respectively. Employee Stock Purchase Plan The Company's 2015 Employee Stock Purchase Plan ("ESPP") became effective on May 14, 2015. The ESPP allows eligible employees to purchase shares of the Company's common stock at a discount of up to 15% of their eligible compensation through payroll deductions, subject to any plan limitations. After the first offering period, which began on May 14, 2015 and ended on February 1, 2016, the ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company's common stock on the first trading day of the offering period or on the last day of the offering period. As of September 30, 2024, the number of shares of common stock reserved for future issuance under the ESPP is 3,209. The ESPP provides for automatic annual increases in the shares available for purchase beginning on January 1, 2016. As of September 30, 2024, 8,073 shares had been issued under the ESPP. The Company recorded $2,000 and $6,000 of ESPP related compensation expense during the three and nine months ended September 30, 2024, respectively. The Company recorded $7,000 and $12,000 of ESPP related compensation expense during the three and nine months ended September 30, 2023, respectively.</p>2The 2015 Plan became effective upon the Company's IPO in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 3,860 shares of common stock reserved for future issuance, which included 259 that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan.38602599375P4YP10Y200000937550000790233824812772510221052310271609694983666<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following is a summary of stock option information and weighted average exercise prices under the Company's stock incentive plans (in thousands, except share data and price per share):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:81.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:57.672%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.242%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.28%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.762%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.28%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.762%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Shares
Subject to
Outstanding
Options</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Weighted-
Average
Exercise
Price Per
Share</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Aggregate
Intrinsic
Value</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Outstanding — Balance at December 31, 2023</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">80,078</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 85.30 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Options granted </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 158,000 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.71 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Options forfeited </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:right;">(7,927 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 19.08 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">397</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Options expired</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(12,576</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">170.08</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Outstanding — Balance at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">217,575</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 22.83 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,140</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Vested and expected to vest — September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">198,542</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24.68 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,778</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Exercisable — September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,515</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 84.37 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr>
</table>8007885.3001580002.710792719.083970001257617O.08021757522.833140000198542246827780005051584.370524000P1Y4M24D The fair value of stock option awards was estimated at the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumption: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.11%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.422%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.642%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.402%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.422%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.642%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Expected term (years) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8.04 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8.04 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.06 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Expected volatility </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 101.31 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 101.31 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 101.31 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 124 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Risk-free interest rate </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.77 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.77 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.61 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Dividend yield </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr></table>P8Y14DP8Y14DP7Y21D1.013101.01311.240.037700.03770.03610000155000395000162000573000 0.152015-05-142016-02-01P6M0.85320980732000600070001 2000 13. Income Taxes Income tax expense during interim periods is based on applying an estimated annual effective income tax rate to year-to-date income, plus any significant unusual or infrequently occurring items that are recorded in the interim period. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in various jurisdictions, permanent and temporary differences, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, additional information becomes known, or as the tax environment changes. The interim financial statement provision for income taxes is different from the amounts computed by applying the United States federal statutory income tax rate of 21%. The Company's effective tax rate was 0.00% for each of the three and nine months ended September 30, 2024 and 2023. The difference between the effective tax rate and the federal statutory rate of 21% was primarily due to the full valuation allowance recorded on the Company's net deferred tax assets. During the nine months ended September 30, 2024, there were no material changes to the Company's uncertain tax positions. In February 2023, the Company received notification from the Internal Revenue Service ("IRS") that our Archipelago joint venture was selected for audit for the 2021 tax year. The Company received the IRS Notice of Proposed Partnership Adjustment during the third quarter of 2024 and accepted the adjustments. The Company is now awaiting the IRS Final Partnership Adjustment ("FPA"). Reception of the FPA will start a 45-day clock on making the push out election, to push the audit adjustments to the partners. Upon conclusion of the audit, Arcadia expects to adjust their balance of available tax net operating losses and have no penalties or interest due. The Company is currently not under audit for state purposes. 0.2100000.210 14. Commitments and Contingencies Leases The Company leases office and warehouse space and equipment under operating lease agreements having initial lease terms ranging from one to five years, including certain renewal options available to the Company at market rates. The Company also leases land for field trials on a short-term basis. See Note 9. Legal Matters From time to time, in the ordinary course of business, the Company may become involved in certain legal proceedings. The Company currently is not a party to any material litigation or other material legal proceedings. Contingent Liability Related to the Anawah Acquisition In June 2005, the Company completed its agreement and plan of merger and reorganization with Anawah, to purchase the Anawah's food and agricultural research company through a non-cash stock purchase. Pursuant to the merger with Anawah, and in accordance with the ASC 805 - Business Combinations, the Company incurred a contingent liability not to exceed $5.0 million. This liability represents amounts to be paid to Anawah's previous stockholders for cash collected on revenue recognized by the Company upon commercial sale of certain specific products developed using technology acquired in the purchase. During 2010, the Company ceased activities relating to three of the six Anawah product programs thus, the contingent liability was reduced to $3.0 million. During 2016, one of the programs previously accrued for was abandoned and another program previously abandoned was reactivated. During 2019, the Company determined that one of the technologies was no longer active and decided to abandon the previously accrued program. As of September 30, 2024, the Company continues to pursue or are otherwise liable for a total of two development programs using this technology and believes that the contingent liability is probable. As a result, $2.0 million remains on the condensed consolidated balance sheet as an other noncurrent liability. Contracts The Company has entered into contract research agreements with unrelated parties that require the Company to pay certain funding commitments. The initial terms of these agreements range from one to three years in duration and in certain cases are cancelable. The Company licenses certain technologies via executed agreements ("In-Licensing Agreements") that are used to develop and advance the Company's own technologies. The Company has entered into various In-Licensing Agreements with related and unrelated parties that require the Company to pay certain license fees, royalties, and/or milestone fees. In addition, certain royalty payments ranging from 2% to 15% of net revenue amounts as defined in the In-Licensing Agreements are or will be due. The Company could be adversely affected by certain actions by the government as it relates to government contract revenue received in prior years. Government agencies, such as the Defense Contract Audit Agency routinely audit and investigate government contractors. These agencies review a contractor's performance under its agreements; cost structure; and compliance with applicable laws, regulations and standards. The agencies also review the adequacy of, and a contractor's compliance with, its internal control systems and policies, including the contractor's purchasing, property, estimating, compensation and management information systems. While the Company's management anticipates no adverse result from an audit, should any costs be found to be improperly allocated to a government agreement, such costs will not be reimbursed, or if already reimbursed, may need to be refunded. If an audit uncovers improper or illegal activities, civil and criminal penalties and administrative sanctions, including termination of contracts, forfeiture of profits, suspension of payments or fines, and suspension or prohibition from doing business with the government could occur. In addition, serious reputational harm or significant adverse financial effects could occur if allegations of impropriety were made against the Company. P5Y500000036300000020000 0P3Y0.020.15 15. Net Loss per

Share Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per share attributable to common stockholders is computed giving effect to all potentially dilutive common shares, including common stock issuable upon exercise of stock options and warrants. Dilutive securities are not included in the computation of net loss per share when the impact would be anti-dilutive. Securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows (in shares): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.052%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.478%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.478%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.478%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.518%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> For the Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Options to purchase common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 217,575 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 84,058 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Warrants to purchase common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 259,817 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 266,957 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 259,817 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 266,957 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Preferred investment options </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 823,618 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,489,952 </td> <td style="white-

space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 823,618 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,489,952 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,301,010 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,840,967 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,301,010 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,840,967 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> Securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows (in shares): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"> <td style="width:42.052%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.478%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.478%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.478%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.518%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> For the Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Options to purchase common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 217,575 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 84,058 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Warrants to purchase common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-

align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 259,817 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 266,957 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 259,817 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 266,957 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Preferred investment options </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 823,618 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,489,952 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 823,618 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,489,952 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,301,010 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,840,967 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,301,010 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,840,967 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>21757584058217575840582598172669572598172669578236181489952823618148995213010101840967130101018409672130101018409677p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">16. Related-Party Transactions The Company's related parties include Moral Compass Corporation ("MCC") and the John Sperling Foundation ("JSF"). The rights to the intellectual property owned by Blue Horse Labs, Inc. ("BHL") were assigned to its sole shareholder, the John Sperling Revocable Trust ("JSRT") due to BHL's dissolution and then subsequently to the JSF. The JSF is deemed a related party of the Company because MCC, one of the Company's largest stockholder, and the JSF share common officers and directors. JSF receives a single digit royalty from the Company when revenue has been collected on product sales or for license payments from third parties that involve certain intellectual property developed under research funding originally from BHL. Royalty fees due to JSF were $30,000 and <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$58,000 as of September 30, 2024 and December 31, 2023, respectively, and are included in the condensed consolidated balance sheets as amounts due to related parties. 3000058000falsefalsefalsefalse"